european journal of pharmacology

an international journal

ELSEVIER

Master Author and Key word Indexes, Volumes 209–228, 1992

(EJP Molecular Pharmacology Section, Volumes 225–227, and EJP Environmental Toxicology and Pharmacology Section, Volume 228, incorporated)

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1992

European Journal of Pharmacology

Author and Key word Indexes, 1992
Volumes 209–228
(EJP Molecular Pharmacology Section, Volumes 225–227, and EJP Environmental Toxicology and Pharmacology Section, Volume 228, incorporated)

ELSEVIER SCIENCE PUBLISHERS B.V.— AMSTERDAM — LONDON — NEW YORK — TOKYO

© 1993 Elsevier Science Publishers B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V., Copyright and Permissions Department, P.O. Box 521, 1000 AM Amsterdam, The Netherlands.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

This journal is printed on acid-free paper.

US mailing notice – European Journal of Pharmacology (ISSN 0014-2999) is published 3 times/month by Elsevier Science Publishers (Molenwerf 1, Postbus 211, 1000 AE Amsterdam, Netherlands). Annual subscription price in the USA US$ 3766.50 (subject to change), including air speed delivery. Second class postage paid at Jamaica, NY 11431.
USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003.
Airfreight and mailing in the USA by Publications Expediting.

Printed in The Netherlands

Author index
volumes 209–228
1992

Master author index to volumes 209–228

Aaronson, P.I., see Smirnov, S.V. (217) 105
Aasen, A., see Waelbroeck, M. (227) 33
Abadie, P., Baron, J.C., Bisserbe, J.C., Boulenger, J.P., Rioux, P., Travère, J.M., Barré, L., Petit-Taboué, M.C. and Zarifian, E.
Central benzodiazepine receptors in human brain: estimation of regional B_{max} and K_D values with positron emission tomography (213) 107
Abbondi, M., see Basilico, L. (222) 241
Abbracchio, M.P., Fogliatto, G., Paoletti, A.M., Rovati, G.E. and Cattabeni, F.
Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A_1 but not A_2 receptors (227) 317
Abdel-Latif, A.A., Yousufzai, S.Y.K., De, S. and Tachado, S.D.
Carbachol stimulates adenylate cyclase and phospholipase C and muscle contraction-relaxation in a reciprocal manner in dog iris sphincter smooth muscle (226) 351
Abdel-Rahman, A.-R.A., see Zhang, X. (222) 81
Abdelrahman, A. and Pang, C.C.Y.
Calcitonin gene-related peptide is a venous dilator in conscious rats (217) 185
Abdul-Ghaffar, T., see Canfield, P. (216) 293
Abe, A. and Karaki, H.
Mechanisms underlying the inhibitory effect of dibutyryl cyclic AMP in vascular smooth muscle (211) 305
Abe, K., see Hara, H. (221) 193
Abe, K., see Watanabe, Y. (223) 179
Abe, T., see Tokumaru, H. (227) 363
Abe, Y., see Masumura, H. (210) 163
Abe, Y., see Nishiyama, A. (218) 311
Abebe, W. and MacLeod, K.M.
Augmented inositol phosphate production in mesenteric arteries from diabetic rats (225) 29
Aberdeen, J., see Stewart-Lee, A.L. (216) 167
Abete, P. and Vassalle, M.
Role of intracellular Na^+ activity in the negative inotropy of strophanthidin in cardiac Purkinje fibers (211) 399
Abiko, Y., see Nasa, Y. (213) 171
Abraham, S.T. and Rice, P.J.
Protein kinase C-mediated contractile response of the rat vas deferens (218) 243
Abraham, W.M., Ahmed, A., Cortes, A., Sielczak, M.W., Hinz, W., Bouska, J., Lanni, C. and Bell, R.L.
The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep (217) 119
Abrahams, T.P. and Schofield, G.G.
Norepinephrine-induced Ca^{2+} current inhibition in adult rat sympathetic neurons does not require protein kinase C activation (227) 189
Accomazzo, M.R., see Viganò, T. (219) 159
Aceves, J., see Montaño, J.-A.A. (218) 335
Achike, F.I., Dai, S. and Ogle, C.W.
Blood pH and the actions of nifedipine on cardiac excitation–contraction coupling (219) 369
Ackerman, J.M. and White, F.J.
Decreased activity of rat A10 dopamine neurons following withdrawal from repeated cocaine (218) 171
Acosta, G.B., see Otero Losada, M.E. (224) 21
Acuña Castroviejo, D., Del Aguila, C.M., Fernández, B., Gomar, M.D. and Castillo, J.L.
Characterization of ouabain high-affinity binding to rat cerebral cortex. Modulation by melatonin (226) 59
Adams, F., see Boix, F. (216) 103
Adams, L.M., see Wasterlain, C.G. (212) 275
Addae, J.I., see Connick, J.H. (214) 169
Advenier, C., see Candenas, M.-L. (210) 291
Advenier, C., see Candenas, M.-L. (219) 473
Advenier, C., see Devillier, P. (214) 67
Advenier, C., see Martin, C.A.E. (224) 137
Agata, N., Tanaka, H. and Shigenobu, K.
Effect of Mn^{2+} on neonatal and adult rat heart: initial depression and late augmentation of contractile force (222) 223
Aghajanian, G.K., see Kogan, J.H. (211) 47
Agoston, S., see Henning, R.H. (216) 73
Ahlborg, U.G., Brouwer, A., Fingerhut, M.A., Jacobson, J.L., Jacobson, S.W., Kennedy, S.W., Kettrup, A.A.F., Koeman, J.H., Poiger, H., Rappe, C., Safe, S.H., Seegal, R.F., Tuomisto, J. and Van den Berg, M.
Impact of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls on human and environmental health, with special emphasis on application of the toxic equivalency factor concept (228) 179
Ahlenius, S. and Wijkström, A.
Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat (222) 69
Ahlenius, S., see Fernández-Guasti, A. (210) 121
Ahmad, S., see Pasyk, E. (212) 209
Ahmed, A., see Abraham, W.M. (217) 119
Ahrén, B., see Karlsson, S. (213) 145
Ahrén, B., see Lindskog, S. (210) 183
Aida, K., see Tawata, M. (212) 87
Aihara, K., see Matsumoto, Y. (213) 167
Aikawa, J., see Namiki, A. (227) 339
Aikawa, T., see Itabashi, S. (218) 187
Aikawa, T., see Morikawa, M. (217) 31
Akaoka, H., see Chergui, K. (219) 169
Akera, T., see Temma, K. (220) 63
Aki, Y., see Nishiyama, A. (218) 311
Akil, H., see Mansour, A. (227) 205
Akiyama, K., see Ujike, H. (211) 323
Akiyoshi, J., see Lesch, K.P. (227) 233
Aktories, K., see Koch, G. (226) 87

Alam, A.M. and Starr, M.S.
Dopaminergic modulation of pilocarpine-induced motor seizures in the rat: the role of hippocampal dopamine D_1 receptors (222) 227
Alamo, C., see Iglesias, V. (211) 35
Alasuzoff, I., see Porter, R.H.P. (225) 195
Albertini, P., see Chiamulera, C. (216) 335
Albus, U., see Englert, H.C. (210) 69
Aldana, I., see Frechilla, D. (219) 409
Aleixandre, A., Pintado, A. and Puerro, M.
α_2-Adrenoceptor-mediated contractions in the rabbit aorta treated with BAY K 8644 (221) 129
Aleppo, G., see Sortino, M.A. (226) 273
Alesiani, M., see Moroni, F. (218) 145
Alfaro, M.J., see Martín, M.I. (224) 77
Alguacil, L.F., see Iglesias, V. (211) 35
Alick Paterson, I., see Li, X.-M. (210) 189
Allard, M., see Gicquel, S. (222) 61
Allescher, H.-D., Sattler, D., Piller, C., Schusdziarra, V. and Classen, M.
Ascending neural pathways in the rat ileum in vitro – effect of capsaicin and involvement of nitric oxide (217) 153
Allgaier, C., see Jackisch, R. (226) 245
Almegård, B., Stjernschantz, J. and Bill, A.
Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists (211) 183
Almotrefi, A.A. and Dzimiri, N.
Effects of β-adrenoceptor blockers on mitochondrial ATPase activity in guinea pig heart preparations (215) 231
Alonso, R., see Chaudieu, I. (220) 203
Altavilla, D., see Squadrito, F. (210) 107
Altavilla, D., see Zingarelli, B. (222) 13
Altieri, P., see Ghiggeri, G.M. (228) 77
Alvarez, T., see Frechilla, D. (219) 409
Aly, M.H.M., see Mohamed, A.S. (227) 181
Amalric, M., Heurteaux, C., Nieoullon, A. and Lazdunski, M.
Behavioral effects of modulators of ATP-sensitive K^+ channels in the rat dorsal pallidum (217) 71
Amano, H., see Mino, N. (221) 77
Amar, C., see Martinat, C. (228) 63
Ambrosio, C., see Barbaccia, M.L. (219) 485
Amerini, S., Rubino, A., Mantelli, L., Filippi, S. and Ledda, F.
The inhibitory effect of opioid and α_2-adrenoceptor agonists on cardiac sensory neurones is pertussis toxin-insensitive (216) 445
Amerini, S., see Mantelli, L. (213) 79
Amorim, C.Z., Cordeiro, R.S.B. and Vargaftig, B.B.
Interference of antihistamines and anti-allergic drugs with antigen-induced paw edema in boosted and unboosted mice (216) 429
Amorim, C.Z., Martins, M.A., Cordeiro, R.S.B. and Vargaftig, B.B.
Differential inhibition by the PAF receptor antagonist, WEB 2170, of allergic inflammation in single sensitized and boosted mice (211) 29
Andersen, K.E., see Suzdak, P.D. (224) 189
Andersen, P.H., Grønvald, F.C., Hohlweg, R., Hansen, L.B., Guddal, E., Braestrup, C. and Nielsen, E.B.
NNC-112 [1], NNC-687 and NNC-756 [1], new selective and highly potent dopamine D_1 receptor antagonists (219) 45
Andersen, P.H., see Nielsen, E.B. (219) 35
Andersson, S.E. and Le Greves, P.
Ruthenium red and capsaicin induce a neurogenic inflammatory response in the rabbit eye: effects of ω-conotoxin GVIA and tetrodotoxin (209) 175
Andersson, S.E.
Glibenclamide and L-N^G-nitro-arginine methyl ester modulate the ocular and hypotensive effects of calcitonin gene-related peptide (224) 89
Andre, P., Ferrat, T., Steinman, M. and Olpe, H.-R.
Increased acetylcholine and quisqualate responsiveness after blockade of $GABA_B$ receptors (218) 137
Andrews, N., Zharkovsky, A. and File, S.E.
Acute handling stress downregulates benzodiazepine receptors: reversal by diazepam (210) 247
Andrews, N., see File, S.E. (218) 9
Andrieux, M., see Sokoloff, P. (225) 331
Anestis, D.K., see Gruetter, C.A. (217) 109
Angelucci, F., see Negri, L. (209) 163
Angus, J.A., see Deckert, V. (221) 17
Annies, R., see Gerdes, C. (220) 91
Ansari, M.S., see Kessler, R.M. (223) 105
Antoine, M.-H., Berkenboom, G., Fang, Z.-Y., Fontaine, J., Herchuelz, A. and Lebrun, P.
Mechanical and ionic response of rat aorta to diazoxide (216) 299
Anzai, K., see Tokumaru, H. (227) 363
Aoki, K., see Okamiya, Y. (222) 99
Appenheimer, M., see Ko, Y. (227) 215
Araie, E., see Miwa, K. (214) 127
Arakawa, H., Tokuyama, K., Yokoyama, T., Mochizuki, H., Morikawa, A., Kuroume, T. and Barnes, P.J.
Effect of maturation on histamine-induced airflow obstruction and airway microvascular leakage in guinea pig airways (215) 51
Arakawa, M., see Suzuki, S. (227) 395
Araki, N. and Takagi, K.
Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig tracheal smooth muscle (216) 113
Arborelius, L., see Nomikos, G.G. (216) 373
Arch, J.R.S., see Foster, K.A. (222) 143
Arenas, C., see Sánchez-Pozo, A. (228) 29
Argiolas, A., see Melis, M.R. (220) 43
Århem, P., see Veintemilla, F. (218) 59
Århem, P., see Westlind-Danielsson, A. (224) 57
Ari, G. and Finberg, J.P.M.
Effects of clorgyline on the release of noradrenaline from rat vas deferens (219) 89
Arisawa, M., see Kuwahara, T. (221) 99
Arleth, A., see Ohlstein, E.H. (225) 347
Arlinghaus, L., Mehdi, S. and Lee, K.S.
Improved posthypoxic recovery with a membrane-permeable calpain inhibitor (209) 123
Arneklo-Nobin, B., see Bodelsson, M. (219) 455
Arnt, J., Hyttel, J. and Sánchez, C.
Partial and full dopamine D_1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro (213) 259
Arnt, J., Lembøl, H.L., Meier, E. and Pedersen, H.
Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and O-Me-THPO in rats: evidence for involvement of different muscarinic receptor subtypes (218) 159
Arnt, J., see Sánchez, C. (211) 9
Arteche, E., see Candenas, M.-L. (219) 473
Arvola, P., Pörsti, I., Vuorinen, P., Huhtala, H., Metsä-Ketelä, T. and Vapaatalo, H.
L-Cysteine augments the vasorelaxation induced by sodium nitrite and SIN-1 but not that due to acetylcholine (214) 289
Asano, M., see Shibasaki, M. (215) 271
Asano, M., see Suzuki, Y. (219) 401
Asano, T., see Sako, K. (209) 39
Asano, T., see Satoh, S.-i. (220) 243
Ashby, Jr., C.R., see Minabe, Y. (209) 143
Ashby, Jr., C.R., see Minabe, Y. (209) 151
Ashida, S., see Masumura, H. (210) 163
Assreuy, J., see Rodrigues, M.S. (216) 357
Astolfi, M., see Patacchini, R. (215) 93
Aubert, I., Cécyre, D., Gauthier, S. and Quirion, R.
Characterization and autoradiographic distribution of [^{3}H]AF-

DX 384 binding to putative muscarinic M_2 receptors in the rat brain (217) 173
Auguet, M., Delaflotte, S., Chabrier, P.-E. and Braquet, P.
The vasoconstrictor action of big endothelin-1 is phosphoramidon-sensitive in rabbit saphenous artery, but not in saphenous vein (224) 101
Aulakh, C.S., see Lesch, K.P. (227) 109
Aulakh, C.S., see Lesch, K.P. (227) 233
Ault, B., see Martin, D. (219) 59
Azmitia, E.C., see Berger, U.V. (215) 153

Baamonde, A., Daugé, V., Ruiz-Gayo, M., Fulga, I.G., Turcaud, S., Fournié-Zaluski, M.-C. and Roques, B.P.
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D_1 receptor stimulation (216) 157
Baba, A., see Nakano, Y. (219) 339
Babycos, C.R., see Nossaman, B.D. (213) 1
Bachus, S.E., see Kaneda, H. (212) 43
Backhauß, C. and Krieglstein, J.
Extract of kava (*Piper methysticum*) and its methysticin constituents protect brain tissue against ischemic damage in rodents (215) 265
Badhri, P., see Beubler, E. (219) 445
Badia, A., see Bosch, F. (222) 163
Baganoff, M.P., see Davies, M.S. (227) 51
Bagdy, G., Sved, A.F., Murphy, D.L. and Szemeredi, K.
Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists (210) 285
Bagetta, G., Iannone, M., Scorsa, A.M. and Nisticò, G.
Tacrine-induced seizures and brain damage in LiCl-treated rats can be prevented by N^{ω}-nitro-L-arginine methyl ester (213) 301
Baidan, L.V., Fertel, R.H. and Wood, J.D.
Effects of brain-gut related peptides on cAMP levels in myenteric ganglia of guinea-pig small intestine (225) 21
Baissat, J., see Leboeuf, J. (216) 183
Baker, A.J. and Fuller, R.W.
Effect of cyclic adenosine monophosphate, 5′-(N-ethylcarboxyamido)-adenosine and methylxanthines on the release of thromboxane and lysosomal enzymes from human alveolar macrophages and peripheral blood monocytes in vitro (211) 157
Baker, R., see Freedman, S.B. (215) 135
Bakich, V., see McIntosh, C.H.S. (223) 117
Balcells, E., Suarez, J. and Rubio, R.
Functional role of intravascular coronary endothelial adenosine receptors (210) 1
Ball, S.G., see Bryson, S.E. (225) 1
Ball, S.G., see Bryson, S.E. (225) 119
Ball, S.G., see Hall, A.S. (226) 253
Ball, S.G., see Wintersgill, H.P. (227) 283
Ballati, L., Evangelista, S., Maggi, C.A. and Manzini, S.
Effects of selective tachykinin receptor antagonists on capsaicin- and tachykinin-induced bronchospasm in anaesthetized guinea-pigs (214) 215
Ballesta, J.J. and Orts, A.
Interaction of opioid drugs with human platelet α_2-adrenoceptors (227) 349
Balmforth, A.J., see Bryson, S.E. (225) 1
Balmforth, A.J., see Bryson, S.E. (225) 119
Balmforth, A.J., see Hall, A.S. (226) 253
Balmforth, A.J., see Wintersgill, H.P. (227) 283
Balster, R.L., Grech, D.M. and Bobelis, D.J.
Drug discrimination analysis of ethanol as an N-methyl-D-aspartate receptor antagonist (222) 39
Bamforth, K.J., Dalgliesh, K. and Coughtrie, M.W.H.
Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity? (228) 15
Banerji, S., Habibuddin, M. and Pal, S.P.
Antiulcer and gastric secretory activity of N-phthaloyl γ-aminobutyric acid (219) 211
Bang, L. and Nielsen-Kudsk, J.E.
Smooth muscle relaxation and inhibition of responses to pinacidil and cromakalim induced by phentolamine in guinea-pig isolated trachea (211) 235
Bank, P.A., Yao, E.F., Phelps, C.L., Harper, P.A. and Denison, M.S.
Species-specific binding of transformed Ah receptor to a dioxin responsive transcriptional enhancer (228) 85
Banks, R.J.A., see Dourish, C.T. (211) 113
Baños, J.-E., see Bosch, F. (222) 163
Bapna, J.S., see Ramaswamy, S. (220) 147
Baquer, N.Z., see Saxena, A.K. (216) 123
Baraban, J.M., see Bhat, R.V. (227) 447
Barajas-López, C. and Huizinga, J.D.
Ouabain-induced excitation of colonic smooth muscle due to block of K^+ conductance by intracellular Na^+ ions (221) 51
Barbaccia, M.L., Roscetti, G., Trabucchi, M., Ambrosio, C. and Massotti, M.
Cyclic AMP-dependent increase of steroidogenesis in brain cortical minces (219) 485
Barbier, A.J. and Lefebvre, R.A.
Effect of 3-isobutyl-1-methylxanthine and zaprinast on non-adrenergic non-cholinergic relaxation in the rat gastric fundus (210) 315
Barbier, A.J.M. and Lefebvre, R.A.
Effect of LY 83583 on relaxation induced by non-adrenergic non-cholinergic nerve stimulation and exogenous nitric oxide in the rat gastric fundus (219) 331
Barker, J.L., see Cruciani, R.A. (226) 287
Barnard, E.A., see Zaman, S.H. (225) 321
Barnes, N.M., Cheng, C.H.K., Costall, B., Ge, J., Kelly, M.E. and Naylor, R.J.
Profiles of interaction of R(+)/S(−)-zacopride and anxiolytic agents in a mouse model (218) 91
Barnes, N.M., Costall, B., Ge, J., Kelly, M.E. and Naylor, R.J.
The interaction of R(+)- and S(−)-zacopride with PCPA to modify rodent aversive behaviour (218) 15
Barnes, N.M., see Jones, D.N.C. (215) 63
Barnes, P.J., see Arakawa, H. (215) 51
Barnes, P.J., see Belvisi, M.G. (210) 221
Barnes, P.J., see Belvisi, M.G. (215) 341
Barnes, P.J., see Kuo, H.-P. (215) 297
Barnes, P.J., see Kuo, H.-P. (221) 385
Barnes, P.J., see Sakamoto, T. (213) 367
Barnett, A., see McQuade, R.D. (215) 29
Baron, B.M., see Boeijinga, P.H. (219) 9
Baron, B.M., see Lambert, L.E. (216) 131
Baron, J.C., see Abadie, P. (213) 107
Barr, G.A. and Wang, S.
Tolerance and withdrawal to chronic morphine treatment in the week-old rat pup (215) 35
Barrachina, M.D., see Martinez-Cuesta, M.A. (218) 351
Barradas, M.A., see Gill, J.K. (214) 269
Barré, L., see Abadie, P. (213) 107
Barrett, J.E. and Gleeson, S.
Discriminative stimulus effects of 8-OH-DPAT in pigeons: antagonism studies with the putative 5-HT_{1A} receptor antagonists BMY 7378 and NAN-190 (217) 163
Barrett, R.J., Droppleman, D.A. and Wright, K.F.
N-0861 selectively antagonizes adenosine A_1 receptors in vivo (216) 9
Barrigón, S., see Salinas, P. (209) 105
Bartfai, T., see Lindskog, S. (210) 183

Barthelemy, C., see Zongazo, M.A. (209) 45
Bârzu, T., Desmoulière, A., Herbert, J.M., Level, M., Herault, J.P., Petitou, M., Lormeau, J.-C., Gabbiani, G. and Pascal, M.
O-Acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase α-smooth muscle actin expression in cultured arterial smooth muscle cells (219) 225
Basdevant, A., see Laferrère, B. (215) 23
Basile, A.S., Paul, I.A. and De Costa, B.
Differential effects of cytochrome P-450 induction on ligand binding to σ receptors (227) 95
Basilico, L., Abbondi, M., Fumagalli, A., Parolaro, D., Gori, E. and Giagnoni, G.
Influence of pertussis toxin on thermic responses to morphine and neurotensin in rats (222) 241
Basilico, L., Parolaro, D., Rubino, T., Gori, E. and Giagnoni, G.
Influence of ω-conotoxin on morphine analgesia and withdrawal syndrome in rats (218) 75
Bast, A., see Jansen, F.P. (217) 203
Bast, A., see Leurs, R. (225) 137
Bast, A., see Voss, H.-P. (227) 403
Batchelor, A.M., see East, S.J. (209) 119
Bauco, P., see Rompré, P.-P. (211) 295
Baudrie, V. and Chaouloff, F.
Mechanisms involved in the hyperglycemic effect of the 5-HT_{1C}/5-HT_2 receptor agonist, DOI (213) 41
Baudrie, V., see Chaouloff, F. (214) 101
Baudrie, V., see Zamfir, O. (219) 261
Bäumert, H.G., see Lambrecht, G. (217) 217
Baxter, G.S. and Clarke, D.E.
Benzimidazolone derivatives act as 5-HT_4 receptor ligands in rat oesophagus (212) 225
Baxter, G.S., see Ford, A.P.D.W. (211) 117
Baylor, L.M., see Mungan, Z. (214) 53
Bazan, E., Campbell, A.K. and Rapoport, R.M.
Protein kinase C activity in blood vessels from normotensive and spontaneously hypertensive rats (227) 343
Beal, M.F., see Vécsei, L. (220) 259
Beart, P.M., see Loiacono, R.E. (216) 331
Beatch, G.N., see Igwemezie, L.N. (210) 271
Beer, M.S., Stanton, J.A., Bevan, Y., Chauhan, N.S. and Middlemiss, D.N.
An investigation of the 5-HT_{1D} receptor binding affinity of 5-hydroxytryptamine, 5-carboxyamidotryptamine and sumatriptan in the central nervous system of seven species (213) 193
Beil, W., Staar, U. and Sewing, K.-Fr.
Pantoprazole: a novel H^+/K^+-ATPase inhibitor with an improved pH stability (218) 265
Beinborn, M., see Hennies, S. (218) 303
Beleta, J., see Fernández, A.G. (222) 257
Bélichard, P., see Pruneau, D. (211) 329
Bell, R.L., see Abraham, W.M. (217) 119
Bell, R.L., see Kessler, R.M. (223) 105
Belloni, P.A., see Viganò, T. (219) 159
Belvisi, M.G., Miura, M., Stretton, D. and Barnes, P.J.
Capsazepine as a selective antagonist of capsaicin-induced activation of C-fibres in guinea-pig bronchi (215) 341
Belvisi, M.G., Stretton, C.D., Yacoub, M. and Barnes, P.J.
Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans (210) 221
Bemis, K.G., see Sommers, C.D. (216) 87
Benavides, J., see Claustre, Y. (225) 37
Benishin, C., see Hu, P.-S. (209) 87
Bennett, T., see Gardiner, S.M. (213) 449
Berdeu, D., see Petit, P. (221) 359
Berga, P., see Fernández, A.G. (222) 257
Berger, U.V., Gu, X.F. and Azmitia, E.C.
The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine (215) 153
Bergmann, J.S., see Johnson, K.M. (227) 411
Berkenboom, G., see Antoine, M.-H. (216) 299
Bernad, N., see Galas, M.C. (226) 35
Bernad, N., see Maletínská, L. (222) 233
Bernat, A., see Herbert, J.M. (216) 175
Bernedo, E., see Frechilla, D. (219) 409
Berridge, T.L., Doxey, J.C. and Roach, A.G.
Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats (213) 213
Berridge, T.L., Doxey, J.C., Roach, A.G. and Smith, C.F.C.
Selectivity profile of the α_2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat (213) 205
Berrino, L., see Maione, S. (219) 477
Berry, J.L., see Small, R.C. (219) 81
Bertacco, S., see Muccioli, G. (227) 293
Bertelli, R., see Ghiggeri, G.M. (228) 77
Berthelot, P., see Ong, J. (218) 343
Berthelot, P., see Ong, J. (221) 145
Bertilsson, I.-L., see Bodelsson, M. (219) 455
Bertolini, A., see Poggioli, R. (213) 87
Bertrand, C., see Da Silva, A. (212) 97
Bertrand, G., Gross, R., Petit, P., Loubatières-Mariani, M.-M. and Ribes, G.
Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats (214) 159
Berzetei-Gurske, I.P. and Toll, L.
The μ-opioid activity of κ-opioid receptor agonist compounds in the guinea pig ileum (212) 283
Besançon, R., see Sokoloff, P. (225) 331
Besse, D., Weil-Fugazza, J., Lombard, M.-C., Butler, S.H. and Besson, J.-M.
Monoarthritis induces complex changes in μ-, δ- and κ-opioid binding sites in the superficial dorsal horn of the rat spinal cord (223) 123
Besson, J.-M., see Besse, D. (223) 123
Besson, J.-M., see Kayser, V. (224) 83
Bettini, E., see Spreafico, E. (227) 353
Beubler, E., Badhri, P. and Schirgi-Degen, A.
5-HT receptor antagonists and heat-stable *Escherichia coli* enterotoxin-induced effects in the rat (219) 445
Beusenberg, F.D., Van Amsterdam, J.G.C., Hoogsteden, H.C., Hekking, P.R.M., Brouwers, J.W., Schermers, H.P. and Bonta, I.L.
Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and β-sympathicomimetics (228) 57
Bevan, J.A., see Henrion, D. (224) 13
Bevan, J.A., see Oriowo, M.A. (216) 415
Bevan, R.D., see Oriowo, M.A. (216) 415
Bevan, Y., see Beer, M.S. (213) 193
Bhat, R.V. and Baraban, J.M.
High basal expression of *zif268* in cortex is dependent on intact noradrenergic system (227) 447
Bhatia, S., see Makujina, S.R. (221) 243
Biagi, M., see Brown, M.C.S. (227) 163
Biancardi, E., see Sher, E. (216) 407
Bianchetti, A., see Simiand, J. (219) 193
Bianchi, M., Mantegazza, P. and Panerai, A.E.
Effects of two different reversible monoamine oxidase-A inhibitors on nociceptive thresholds in the rat (219) 113
Bidlack, J.M., Saripalli, L.D. and Lawrence, D.M.P.
κ-Opioid binding sites on a murine lymphoma cell line (227) 257
Bidzseranova, A., Gueron, J., Tóth, G., Penke, B. and Telegdy, G.
Effect of atrial natriuretic peptide on apomorphine-induced

stereotyped cage-climbing behavior in mice (211) 411
Bieck, P.R., Duhl, D.M., Eiring, A., Gillespie, D.D., Manier, D.H. and Sulser, F.
Dose-dependent down-regulation of β-adrenoceptors by isoproterenol in rat C_6 glioma cells (225) 171
Biegon, A., Mathis, C.A. and Budinger, T.F.
Quantitative in vitro and ex vivo autoradiography of the α_2-adrenoceptor antagonist [^{3}H]atipamezole (224) 27
Biegon, A., see Mathis, C.A. (210) 103
Biggio, G., see Sanna, E. (216) 457
Bilder, G.E., see Merkel, L.A. (222) 175
Bill, A., see Almegård, B. (211) 183
Bill, D.J., Fletcher, A., Glenn, B.D. and Knight, M.
Behavioural studies on WAY100289, a novel 5-HT$_3$ receptor antagonist, in two animal models of anxiety (218) 327
Billings, B., see Duttaroy, A. (221) 211
Billman, G.E.
The calcium channel antagonist, flunarizine, protects against ventricular fibrillation (212) 231
Bilsky, E.J., see Menkens, K. (219) 345
Bing, B., see Sauro, M.D. (225) 351
Biscardi, R., see Wilson, M.A. (215) 99
Bischoff, C. and Tiedtke, P.I.
Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks (213) 269
Bisserbe, J.C., see Abadie, P. (213) 107
Bitar, K.G. and Coy, D.H.
Identification and initial characterization of a putative neuromedin B-type receptor from rat urinary bladder membranes (219) 117
Bitran, J.A., see Manji, H.K. (227) 275
Black, C.K., see Schmidt, C.J. (220) 151
Blackburn, K.J., see Gwilt, M. (215) 137
Blair, R.W., Chandler, M.J., Bolser, D.C. and Foreman, R.D.
Intracardiac phenylbiguanide causes excitation of spinal neurons by activation of cardiac sympathetic afferents (216) 119
Blanksma, P.K., see Van Waarde, A. (222) 107
Blarer, S., see Small, R.C. (219) 81
Blier, P. and Bouchard, C.
Effect of repeated electroconvulsive shocks on serotonergic neurons (211) 365
Blier, P., see Curet, O. (221) 59
Blin, N., see Sugasawa, T. (216) 207
Bluthé, R.-M., Dantzer, R. and Kelley, K.W.
Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor α in mice (209) 281
Bo, X. and Burnstock, G.
Species differences in characteristics and distribution of [^{3}H]α,β-methylene ATP binding sites in urinary bladder and urethra of rat, guinea-pig and rabbit (216) 59
Boada, J., see Candenas, M.-L. (219) 473
Boadle-Biber, M.C., see Corley, K.C. (213) 417
Bobbitt, J.L., see Sommers, C.D. (216) 87
Bobelis, D.J., see Balster, R.L. (222) 39
Bobillier, P., see Lepetit, P. (209) 207
Bockaert, J., see Manzoni, O. (225) 357
Bodanszky, M., Sharaf, H., Roy, J.B. and Said, S.I.
Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate (216) 311
Boddeke, E.W.G.M., Enz, A. and Shapiro, G.
SDZ ENS 163, a selective muscarinic M$_1$ receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices (222) 21
Boddeke, H.W.G.M., see Pombo-Villar, E. (226) 317
Bodelsson, M., Törnebrandt, K., Bertilsson, I.-L. and Arneklo-Nobin, B.
Heterogeneity of contractile 5-HT receptors in human hand veins (219) 455
Boeijinga, P.H., Galvan, M., Baron, B.M., Dudley, M.W., Siegel, B.W. and Slone, A.L.
Characterization of the novel 5-HT$_3$ antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells (219) 9
Boer, R., see Eltze, M. (224) 125
Boeynaems, J.-M., see Coquette, A. (226) 1
Bohn, H., Martorana, P.A. and Schönafinger, K.
Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs (220) 71
Boireau, A., see Fajolles, C. (216) 53
Boix, F., Mattioli, R., Adams, F., Huston, J.P. and Schwarting, R.K.W.
Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens (216) 103
Boja, J.W., see Rostène, W. (218) 175
Boje, K.M. and Skolnick, P.
Nitric oxide does not mediate the neurotrophic effects of excitatory amino acids in cultured cerebellar granule neurons (212) 151
Boksa, P., see Chaudieu, I. (220) 203
Bolser, D.C., see Blair, R.W. (216) 119
Bolzon, B.J., see Small, D.L. (210) 131
Bonagamba, L.G.H., see Machado, B.H. (221) 179
Bonanno, G., see Raiteri, M. (213) 17
Bonaventure, N., see Jardon, B. (210) 201
Bond, A. and Boot, J.R.
The effect of calcium channel modulators on blood pressure and pressor responses to noradrenaline in the guinea-pig (218) 179
Bond, A., see Boot, J.R. (219) 123
Bond, E.F., Heitkemper, M.M. and Gruver, M.K.
Mediation of thyrotropin-releasing hormone induced gastric motility increases in developing rats (217) 127
Bonhomme, E., see Simonet, S. (216) 135
Bonhomme, G., see Laferrère, B. (215) 23
Boniotti, A., see Mapp, C.E. (228) 103
Bonnet, J.-J., see Vaugeois, J.-M. (210) 77
Bonta, I.L., see Beusenberg, F.D. (228) 57
Booij, J., see Stoof, J.C. (213) 439
Boot, J.R. and Bond, A.
The effect of Ca^{2+} channel modulators on vagally induced bronchoconstriction in the guinea-pig (219) 123
Boot, J.R., see Bond, A. (218) 179
Booth, R.F.G., see Lad, N. (223) 163
Borges, R., see Candenas, M.-L. (219) 473
Bormann, J., see Müller, W.E.G. (226) 209
Borrell, J., see Cambronero, J.C. (219) 75
Borsini, F., see Prisco, S. (214) 13
Borsini, F., see Volonté, M. (213) 163
Bortolotto, Z.A. and Collingridge, G.L.
Activation of glutamate metabotropic receptors induces long-term potentiation (214) 297
Bortot, L., see Cutrufo, C. (222) 1
Bosch, F., Morales, M., Badia, A. and Baños, J.-E.
Effects of velnacrine, tacrine and physostigmine on tetanic twitch responses at the rat neuromuscular junction (222) 163
Boschetto, P., see Crescioli, S. (228) 45
Bost, J.G.P.J., see Marjorie, (217) 49
Bott, A., Eltze, M. and Illes, P.
External ATP antagonizes the effect of potassium channel openers in guinea-pig ventricular papillary muscle (213) 141
Bottlaender, M., see Varastet, M. (213) 275
Bou, J., see Fernández, A.G. (222) 257
Bouchard, C., see Blier, P. (211) 365

Bouchelet de Vendegies, I., see Kidd, E. (211) 133
Boucher, M., Chapuy, E. and Duchêne-Marullaz, P.
Membrane stabilizing activity and β-adrenoceptor antagonist-induced bradycardia in conscious dogs (211) 343
Bouhassira, D., Villanueva, L. and Le Bars, D.
Effects of systemic morphine on diffuse noxious inhibitory controls: role of the periaqueductal grey (216) 149
Boulenger, J.P., see Abadie, P. (213) 107
Boulton, A.A., see Li, X.-M. (210) 189
Bouska, J., see Abraham, W.M. (217) 119
Bousquet, P., see Suaud-Chagny, M.F. (213) 305
Bousquet, P., see Tibiriça, E. (209) 213
Bouysset, F., see Vayssettes-Courchay, C. (211) 243
Bouzoukis, J., see Wrathall, J.R. (218) 273
Boyet, S., see Schroeder, H. (220) 217
Bozza, P.T., see Castro-Faria-Neto, H.C. (213) 183
Bozza, P.T., see Martins, M.A. (220) 55
Brabec, V., see Jurásková, V. (221) 107
Brabec, V., see Vrána, O. (226) 5
Bradford, H.F., see Cotterell, K.L. (214) 285
Braestrup, C., see Andersen, P.H. (219) 45
Braida, C., see Holzmann, S. (215) 1
Braida, D., see Sala, M. (217) 37
Brain, S.D., see Hughes, S.R. (219) 481
Branch, R.A., see Sabra, R. (226) 79
Brands, J., see Stam, N.J. (227) 153
Braquet, P., see Auguet, M. (224) 101
Braquet, P., see Pons, F. (217) 65
Brazell, C., see Hatfield, R.H. (216) 1
Bredt, D.S., see Breslow, M.J. (210) 105
Breipohl, G., see Rhaleb, N.-E. (210) 115
Breslow, M.J., Tobin, J.R., Bredt, D.S., Ferris, C.D., Snyder, S.H. and Traystman, R.J.
Role of nitric oxide in adrenal medullary vasodilation during catecholamine secretion (210) 105
Brien, J.F., see Liu, Z. (211) 129
Briggs, R.S.J., see Porter, R.H.P. (225) 195
Briggs, R.S.J., see Porter, R.H.P. (227) 83
Briner, V.A., see Pfeilschifter, J. (225) 57
Britvić, S., see Kurelec, B. (228) 51
Broadley, K.J., see Herepath, M.L. (215) 209
Broccardo, M. and Improta, G.
Antidiarrheal and colonic antipropulsive effects of spinal and supraspinal administration of the natural δ opioid receptor agonist, [D-Ala^2]deltorphin II, in the rat (218) 69
Brodde, O.-E., see Van Waarde, A. (222) 107
Broekhoven, M.H., see Linthorst, A.C.E. (219) 23
Broqua, P., see Chaouloff, F. (214) 101
Broqua, P., see Zamfir, O. (219) 261
Brørs, O., see Stokke, M. (227) 379
Brouillet, E., see Varastet, M. (213) 275
Brouwer, A., see Ahlborg, U.G. (228) 179
Brouwers, J.W., see Beusenberg, F.D. (228) 57
Brown, J.F., Hanson, P.J. and Whittle, B.J.R.
Nitric oxide donors increase mucus gel thickness in rat stomach (223) 103
Brown, M.C.S., Biagi, M., Renzetti, A.R., Rovero, P., Criscuoli, M. and Mizrahi, J.
[^{125}I]His-neurokinin A binds selectively to NK_2 receptors of the B-type in rat small intestine smooth muscle membranes (227) 163
Brownfield, M.S., see Levy, A.D. (221) 121
Brozius, M.M., see Leurs, R. (225) 137
Bruinvels, A.T., Landwehrmeyer, B., Moskowitz, M.A. and Hoyer, D.
Evidence for the presence of 5-HT_{1B} receptor messenger RNA in neurons of the rat trigeminal ganglia (227) 357
Brunden, M.N., see Cimini, M.G. (222) 93
Brune, K., see Zeilhofer, H.U. (213) 155
Brunet, J.-L., see Chergui, K. (219) 169
Brus, R., see Kostrzewa, R.M. (209) 157
Bryan, H., see Ohlstein, E.H. (225) 347
Bryson, S.E., Drew, G.M., Hall, A.S., Ball, S.G. and Balmforth, A.J.
Characterization of the dopamine receptor expressed by rat glomerular mesangial cells in culture (225) 1
Bryson, S.E., Warburton, P., Wintersgill, H.P., Drew, G.M., Michel, A.D., Ball, S.G. and Balmforth, A.J.
Induction of the angiotensin AT_2 receptor subtype expression by differentiation of the neuroblastoma × glioma hybrid, NG-108-15 (225) 119
Bryson, S.E., see Hall, A.S. (226) 253
Bryson, S.E., see Wintersgill, H.P. (227) 283
Brzozowski, T., see Konturek, S.J. (211) 277
Buck, S.H., see Henderson, A.K. (225) 175
Buckland, P.R., see O'Donovan, M.C. (226) 335
Buckley, T.L., Van de Velde, M.J., Henricks, P.A.J., Engels, F. and Nijkamp, F.P.
13-Hydroxyoctadecadienoic acid attenuates oedema formation induced by leukotriene B_4 in vivo in rabbit skin (218) 369
Buckley, T.L., see Hughes, S.R. (219) 481
Buckner, C.K., see Kusner, E.J. (210) 299
Buda, M., see Chergui, K. (219) 169
Budai, D., Wilcox, G.L. and Larson, A.A.
Modulation of N-methyl-D-aspartate and (R,S)-α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) responses of spinal nociceptive neurons by a N-terminal fragment of substance P (216) 441
Budinger, T.F., see Biegon, A. (224) 27
Budohoski, L., see Challiss, R.A.J. (226) 121
Bui, J.D., Kimura, B. and Phillips, M.I.
Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood–brain barrier (219) 147
Buisson-Defferier, S. and Van den Buuse, M.
Cardiovascular effects of the 5-HT_{1A} receptor ligand, MDL 73005EF, in conscious spontaneously hypertensive rats (223) 133
Bulloch, J.M. and McGrath, J.C.
The effect of ethanol on responses of the isolated rabbit ileocolic artery (211) 1
Bult, H., see Jorens, P.G. (212) 113
Bult, H., see Jorens, P.G. (224) 7
Bungardt, E., Buschauer, A., Moser, U., Schunack, W., Lambrecht, G. and Mutschler, E.
Histamine H_1 receptors mediate vasodilation in guinea-pig ileum resistance vessels: characterization with computer-assisted videomicroscopy and new selective agonists (221) 91
Bungardt, E., Vockert, E., Feifel, R., Moser, U., Tacke, R., Mutschler, E., Lambrecht, G. and Surprenant, A.
Characterization of muscarinic receptors mediating vasodilation in guinea-pig ileum submucosal arterioles by the use of computer-assisted videomicroscopy (213) 53
Bungardt, E., see Lambrecht, G. (217) 217
Bunker, C.F., see Hanson, G.R. (218) 287
Burbach, J.P.H. and Meijer, O.C.
The structure of neuropeptide receptors (227) 1
Burges, R.A., see Gwilt, M. (215) 137
Burin, L., see Golombek, D.A. (210) 253
Burnstock, G., see Bo, X. (216) 59
Burnstock, G., see Rubino, A. (220) 95
Burnstock, G., see Stewart-Lee, A.L. (216) 167
Buschauer, A., see Bungardt, E. (221) 91
Bush, L., see Hanson, G.R. (218) 287
Bussolino, F., see Zingarelli, B. (222) 13
Bustamante, D., see Miranda, H.F. (217) 137
Butler, S.H., see Besse, D. (223) 123

Cadieux, A., see T-Benchekroun, M. (216) 421
Cadoni, C. and Gee, K.W.
Complex interactions between the steroid derivative RU 5135 and the $GABA_A$-receptor complex (227) 147
Cai, N.-s., see Kiss, B. (209) 109
Cai, R.-Z., see Jaworek, J. (214) 239
Cai, Z. and McCaslin, P.P.
Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca^{2+} levels in neuronal culture (219) 53
Calabresi, M., see Salvati, P. (221) 267
Calapai, G., see Squadrito, F. (210) 107
Calcaterra, P., see Sala, M. (217) 37
Calder, J.A., Schachter, M. and Sever, P.S.
Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels (220) 19
Calenco-Choukroun, G., Daugé, V., Gacel, G. and Roques, B.P.
Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a μ-opioid receptor agonist (209) 267
Calixto, J.B., see Duarte, D.F.P. (215) 75
Callaway, C.W. and Geyer, M.A.
Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat (214) 45
Callaway, J.K. and King, R.G.
Effects of inhaled α_2-adrenoceptor and $GABA_B$ receptor agonists on citric acid-induced cough and tidal volume changes in guinea pigs (220) 187
Calleja, J.M., see Gil-Longo, J. (221) 1
Camacho, F., see Dunn, R.W. (214) 207
Camarasa, J., see Escubedo, E. (225) 15
Cambronero, J.C., Rivas, F.J., Borrell, J. and Guaza, C.
Release of corticotropin-releasing factor from superfused rat hypothalami induced by interleukin-1 is not dependent on adrenergic mechanism (219) 75
Cameron, H., see Watanabe, Y. (222) 157
Campbell, A.K., see Bazan, E. (227) 343
Campbell, B.J., Dimaline, R., Dockray, G.J. and Hughes, J.
Inhibition of food intake by omeprazole in the chicken (209) 231
Campo, G.M., see Squadrito, F. (210) 107
Campo, G.M., see Zingarelli, B. (222) 13
Campos, M., see Gil-Longo, J. (221) 1
Camus, J., see Waelbroeck, M. (227) 33
Candenas, M.-L., Naline, E., Sarria, B. and Advenier, C.
Effect of epithelium removal and of enkephalin inhibition on the bronchoconstrictor response to three endothelins of the human isolated bronchus (210) 291
Candenas, M.-L., Norte, M., González, R., Arteche, E., Fernández, J.J., Borges, R., Boada, J., Advenier, C. and Martín, J.D.
Inhibitory and contractile effects of okadaic acid on rat uterine muscle (219) 473
Candenas, M.-L., see Devillier, P. (214) 67
Candido, J., see Duttaroy, A. (221) 211
Canela, E.I., see Casadó, V. (225) 7
Canfield, P. and Abdul-Ghaffar, T.
Stimulation of bicarbonate secretion by atypical β-receptor agonists in rat cecum in vitro (216) 293
Cannizzaro, C., see Flugy, A. (214) 233
Cannizzaro, G., see Flugy, A. (214) 233
Canonico, P.L., see Sortino, M.A. (226) 273
Caporali, M.G., Scotti de Carolis, A. and Popoli, P.
N-Ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits (223) 15
Caputi, A.P., see Squadrito, F. (210) 107
Caputi, A.P., see Zingarelli, B. (222) 13
Caramelo, C., see Gómez-Garre, D. (224) 167
Caratozzolo, O., see Pinna, C. (214) 143
Carayon, A., see Zongazo, M.A. (209) 45
Carbone, E., see Sher, E. (216) 407
Carbonell, L., see Mármol, F. (226) 93
Cardinali, D.P., see Golombek, D.A. (210) 253
Caricati-Neto, A., Sette, M. and Jurkiewicz, A.
Increased density of α-adrenoceptors in vas deferens of spontaneously hypertensive rats (SHR), indicated by functional and receptor binding studies (218) 51
Carli, M., Tranchina, S. and Samanin, R.
8-Hydroxy-2-(di-n-propylamino)tetralin, a $5\text{-}HT_{1A}$ receptor agonist, impairs performance in a passive avoidance task (211) 227
Carr, L.A., Khristen Basham, J., York, B.K. and Rowell, P.P.
Inhibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components (215) 285
Carruba, M.O., see Nisoli, E. (216) 81
Casadó, V., Mallol, J., Canela, E.I., Franco, R. and Lluis, C.
Modulation of adenosine agonist $[^3H]N^6$-(R)-phenylisopropyladenosine binding to pig brain cortical membranes by changes of membrane fluidity and of medium physicochemical characteristics (225) 7
Cascalheira, J.F. and Sebastião, A.M.
Adenine nucleotide analogues, including γ-phosphate-substituted analogues, are metabolised extracellularly in innervated frog sartorius muscle (222) 49
Case, C.L., Ravin, R.R., Holani, R., Gillette, P.C. and Hewett, K.W.
The developmental electrophysiologic effects of moricizine HCl on the canine cardiac purkinje fiber (218) 213
Casolini, P., see Sigala, S. (211) 351
Casteels, R., see Missiaen, L. (227) 391
Castiella, E., see Frechilla, D. (219) 409
Castillo, J.L., see Acuña Castroviejo, D. (226) 59
Castro-Faria-Neto, H.C., Bozza, P.T., Silva, A.R., Silva, P.M.R., Lima, M.C.R., Martins, M.A., Cordeiro, R.S.B. and Vargaftig, B.B.
Interference of azelastine with anaphylaxis induced by ovalbumin challenge in actively sensitized rats (213) 183
Castro, M., see Mota-Filipe, H. (213) 227
Castro Faria Neto, H.C., see Martins, M.A. (220) 55
Cattabeni, F., see Abbracchio, M.P. (227) 317
Cauvin, C., see Tejerina, T. (219) 279
Cayla, J., see Varastet, M. (213) 275
Cecconi, R., see Tramontana, M. (212) 137
Ceci, A., see Prisco, S. (214) 13
Ceci, A., see Volonté, M. (213) 163
Cécyre, D., see Aubert, I. (217) 173
Cenarruzabeitia, E., see Frechilla, D. (219) 409
Cercós, A., see Ivorra, M.D. (219) 303
Cerletti, C., see Evangelista, V. (216) 401
Chabrier, P.-E., see Auguet, M. (224) 101
Chaki, S. and Inagami, T.
A newly found angiotensin II receptor subtype mediates cyclic GMP formation in differentiated Neuro-2A cells (225) 355
Challiss, R.A.J., Richards, S.J. and Budohoski, L.
Characterization of the adenosine receptor modulating insulin action in rat skeletal muscle (226) 121
Chamienia, A.L. and Johns, E.J.
The influence of changes in perfusion pressure and angiotensin II on the renal excretory responses to atrial natriuretic peptides (218) 319
Chan-Yeung, M., see Howard, S. (227) 123
Chanal, S., see Fayard, J.-M. (216) 127
Chand, N., Harrison, J.E., Rooney, S., Pillar, J., Jakubicki, R., Nolan, K., Diamantis, W. and Duane Sofia, R.

Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach (211) 121
Chandler, M.J., see Blair, R.W. (216) 119
Chang, C.-H., Yu, Z.-N. and Song, D.-L.
Formycin triphosphate as a probe for the ATP binding site involved in the activation of guanylate cyclase (227) 229
Chang, C.C., see Chiou, L.C. (216) 199
Chang, J.-H., see Huang, H.-C. (211) 359
Chang, J.-H., see Huang, H.-C. (217) 143
Chaouloff, F., Baudrie, V., Layeillon, C. and Broqua, P.
The 5-HT_2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane increases brain tryptophan levels in the rat (214) 101
Chaouloff, F., see Baudrie, V. (213) 41
Chaouloff, F., see Zamfir, O. (219) 261
Chapman, R.W., see Hey, J.A. (211) 421
Chapman, V. and Dickenson, A.H.
The spinal and peripheral roles of bradykinin and prostaglandins in nociceptive processing in the rat (219) 427
Chapuy, E., see Boucher, M. (211) 343
Charléty, P.J., see Chergui, K. (219) 169
Chatelain, P., see Manning, A. (220) 249
Chaudieu, I., Alonso, R., Mount, H., Quirion, R. and Boksa, P.
Effects of L- and N-type Ca^{2+} channel antagonists on excitatory amino acid-evoked dopamine release (220) 203
Chauhan, N.S., see Beer, M.S. (213) 193
Chavoix, C., see Varastet, M. (213) 275
Chen, C.-C.
Differentiation of renal Na^+-K^+-ATPase in control and streptozotocin-induced diabetic mice by G-protein acting toxins and phorbol esters (225) 275
Chen, C.-C., see Huang, H.-C. (217) 143
Chen, C.-F., see Chiou, W.-F. (215) 277
Chen, G. and Cheung, D.W.
Pharmacological distinction of the hyperpolarization response to caffeine and acetylcholine in guinea-pig coronary endothelial cells (223) 33
Chen, G., see Manji, H.K. (227) 275
Chen, G., see Suh, S.H. (219) 377
Chen, S.-Y., see Wang, Y.-X. (222) 219
Chen, X.-H. and Han, J.-S.
All three types of opioid receptors in the spinal cord are important for 2/15 Hz electroacupuncture analgesia (211) 203
Cheng, C.H.K., see Barnes, N.M. (218) 91
Cheng, D.Y. and Gruetter, C.A.
Chronic estrogen alters contractile responsiveness to angiotensin II and norepinephrine in female rat aorta (215) 171
Cheng, J., Roques, B.P., Gacel, G.A., Huang, E. and Pasternak, G.W.
κ_3 Opiate receptor binding in the mouse and rat (226) 15
Chergui, K., Akaoka, H., Brunet, J.-L., Charléty, P.J., Saunier, C.F., Buda, M., Privat, A., Vignon, J., Kamenka, J.-M. and Chouvet, G.
Inhibition of locus coeruleus neurons by the phencyclidine analog, N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine: evidence for potent indirect adrenoceptor agonist properties (219) 169
Cheung, D.W., see Chen, G. (223) 33
Cheung, D.W., see Small, D.L. (210) 131
Chevillard, C., see Diochot, S. (227) 427
Chiamulera, C., Albertini, P., Valerio, E. and Reggiani, A.
Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia (216) 335
Chiasson, B.J., Hooper, M.L., Murphy, P.R. and Robertson, H.A.
Antisense oligonucleotide eliminates in vivo expression of c-*fos* in mammalian brain (227) 451
Chiavaroli, C., Vacher, P. and Schlegel, W.
Modulation of Ca^{2+} influx by protein phosphorylation in single intact clonal pituitary cells (227) 173
Chiba, S. and Tsukada, M.
Potent antagonistic action of OPC-31260, a vasopressin V_2 receptor antagonist, on [Arg^8]vasopressin-induced vasoconstriction in isolated simian femoral arteries (221) 393
Chiba, S., see Iwatsuki, K. (209) 63
Chiba, S., see Iwatsuki, K. (218) 237
Chiba, S., see Takei, M. (219) 15
Chignard, M., see Nahori, M.-A. (228) 213
Chin, J.P.F. and Pennefather, J.N.
Classification of the β-adrenoceptor subtype in the rat portal vein: effect of altered thyroid hormone levels (212) 201
Chin, M., see Tawata, M. (212) 87
Chiou, L.C. and Chang, C.C.
Antagonism by β-eudesmol of neostigmine-induced neuromuscular failure in mouse diaphragms (216) 199
Chiou, W.-F., Chou, C.-J., Shum, A.Y.-C. and Chen, C.-F.
The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action (215) 277
Chipkin, R.E., see Tedford, C.E. (211) 169
Chitano, P., see Mapp, C.E. (228) 103
Chiu, A.T., see Leung, K.H. (227) 63
Chiyotani, A., see Tamaoki, J. (220) 87
Choiniere, D., see Wrathall, J.R. (218) 273
Chou, C.-J., see Chiou, W.-F. (215) 277
Chouvet, G., see Chergui, K. (219) 169
Chrapusta, S.J., Karoum, F., Egan, M.F. and Wyatt, R.J.
γ-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions (222) 129
Christ, D.D., see Reilly, T.M. (226) 179
Christ, D.D., see Wong, P.C. (220) 267
Christakos, S., see Walters, M.R. (213) 309
Christofi, F.L., Tack, J. and Wood, J.D.
Suppression of nicotinic synaptic transmission by adenosine in myenteric ganglia of the guinea-pig gastric antrum (216) 17
Christophe, J., see Delporte, C. (224) 183
Christophe, J., see Delporte, C. (227) 247
Christophe, J., see Waelbroeck, M. (227) 33
Chu, S.-H., see Huang, H.-C. (211) 359
Chuang, D.-M., see Lesch, K.P. (227) 233
Chugun, A., see Temma, K. (220) 63
Chun, M., see Sun, L. (226) 367
Chung, K.F., see Sakamoto, T. (213) 367
Chyu, K.-Y., Guth, P.H. and Ross, G.
Effect of N^{ω}-nitro-L-arginine methyl ester on arterial pressure and on vasodilator and vasoconstrictor responses: influence of initial vascular tone (212) 159
Ciaccia, A., see Crescioli, S. (228) 45
Ciaccia, A., see Mapp, C.E. (228) 103
Cimini, M.G., Brunden, M.N. and Gibson, J.K.
Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium (222) 93
Ciuffi, M., see Moroni, F. (218) 145
Civelli, O., see Mansour, A. (227) 205
Civelli, O., see Seeman, P. (227) 139
Clanton, J.A., see Kessler, R.M. (223) 105
Clark, D., see Overton, P. (213) 165
Clark, M.A., Korte, A., Myers, J. and Egan, R.W.
High affinity histamine H_3 receptors regulate ACTH release by AtT-20 cells (210) 31
Clarke, D.E., see Baxter, G.S. (212) 225
Clarke, D.E., see Ford, A.P.D.W. (211) 117
Classen, M., see Allescher, H.-D. (217) 153
Claustre, Y., Eudeline, B., Benavides, J. and Scatton, B.

5-HT_{1C} receptors mediate phosphoinositide turnover activation in the immature rat hippocampus (225) 37
Clement, H.-W., Gemsa, D. and Wesemann, W.
The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltammetry (217) 43
Clement, M.E., see Ramage, A.G. (219) 165
Clementi, F., see Sher, E. (216) 407
Clingan, C.A., see Delay-Goyet, P. (222) 213
Cockerham, S.L., see Silbaugh, S.A. (223) 57
Codd, E.E. and Shank, R.P.
1,3-Di(2-[5-^{3}H]tolyl)guanidine labels more than one site in rat forebrain (217) 149
Coffin, V.L., see McQuade, R.D. (215) 29
Cohen, M.L., Schenck, K., Nelson, D. and Robertson, D.W.
Sumatriptan and 5-benzyloxytryptamine: contractility of two 5-HT_{1D} receptor ligands in canine saphenous veins (211) 43
Cohen, M.L., see Killam, A.L. (218) 295
Coker, S.J., see Ellis, A.M. (219) 97
Colado, M.I., see Martín, M.I. (224) 77
Collingridge, G.L., see Bortolotto, Z.A. (214) 297
Collins, K.A., see Tseng, L.F. (214) 59
Collins, P., see Jiang, C. (211) 163
Collu, M., see Diana, M. (211) 415
Cometta-Morini, C., see Maguire, P. (213) 219
Concas, A., see Sanna, E. (216) 457
Connaughton, S., see Smith, K. (211) 251
Connell, T.A., see Zhou, L.-W. (218) 219
Connelly, C.D., see Raffa, R.B. (217) 221
Connick, J.H., Addae, J.I., Nicholson, C.D. and Stone, T.W.
The σ ligand 1,3-di-o-tolylguanidine depresses amino acid-induced excitation non-selectively in rat brain (214) 169
Conroy, D.M., Samhoun, M.M. and Piper, P.J.
Vasoactive intestinal peptide and helodermin inhibit the release of cyclo-oxygenase products induced by leukotriene D_4 and bradykinin from guinea-pig perfused lung (218) 43
Constanti, A. and Libri, V.
Trans-ACPD induces a slow post-stimulus inward tail current (I_{ADP}) in guinea-pig olfactory cortex neurones in vitro (214) 105
Constanti, A., see Libri, V. (212) 253
Coppes, R.P., see Remie, R. (211) 257
Coquette, A., Boeynaems, J.-M. and Vray, B.
Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis (226) 1
Corbett, R., see Dunn, R.W. (214) 207
Cordeiro, R.S.B., see Amorim, C.Z. (211) 29
Cordeiro, R.S.B., see Amorim, C.Z. (216) 429
Cordeiro, R.S.B., see Castro-Faria-Neto, H.C. (213) 183
Cordeiro, R.S.B., see Martins, M.A. (220) 55
Cordeiro, R.S.B., see Pasquale, C.P. (223) 9
Cordi, A., see Randle, J.C.R. (215) 237
Coric, P., see Noble, F. (223) 91
Corley, K.C., Singh, V.B., Phan, T.-H. and Boadle-Biber, M.C.
Effect of gepirone on increases in tryptophan hydroxylase in response to sound stress (213) 417
Cornfeldt, M.L., see Dunn, R.W. (214) 207
Cortes, A., see Abraham, W.M. (217) 119
Cortes, D., see Ivorra, M.D. (219) 303
Cortesini, C., see Gentilini, G. (217) 9
Cortijo, J., Gonzalez, M., Ortiz, J.L. and Morcillo, E.J.
Effects of Na^+ transport inhibitors on guinea-pig tracheal responses to spasmogens (221) 43
Costa, T., see Ogino, Y. (225) 299
Costall, B., see Barnes, N.M. (218) 15
Costall, B., see Barnes, N.M. (218) 91
Costall, B., see Jones, D.N.C. (215) 63
Costentin, J., see Dubuc, I. (219) 327
Costentin, J., see Vaugeois, J.-M. (210) 77
Cotterell, K.L., Croucher, M.J. and Bradford, H.F.
Weak anticonvulsant activity of CGP 37849 and CGP 39551 against kindled seizures following systemic administration (214) 285
Cottrell, G.A., see Van Hartesveldt, C. (214) 27
Coughtrie, M.W.H., see Bamforth, K.J. (228) 15
Coulombe, Jr., R.A., see Hsieh, G.-C. (228) 107
Couture, R., see Décarie, A. (213) 125
Couture, R., see Hasséssian, H. (227) 103
Couture, R., see Lopes, P. (210) 137
Cowburn, R.F., see Porter, R.H.P. (225) 195
Cowen, P.J., see Gartside, S.E. (221) 27
Coy, D.H., see Bitar, K.G. (219) 117
Coy, D.H., see Mungan, Z. (214) 53
Crabbe, J.C.
Antagonism of ethanol withdrawal convulsions in Withdrawal Seizure Prone mice by diazepam and abecarnil (221) 85
Crescioli, S., De Marzo, N., Boschetto, P., Spinazzi, A., Plebani, M., Mapp, C.E., Fabbri, L.M. and Ciaccia, A.
Theophylline inhibits late asthmatic reactions induced by toluene diisocyanate in sensitised subjects (228) 45
Crill, W., see Greene, C. (226) 279
Criscione, L., see Rubino, A. (212) 237
Criscuoli, M., see Brown, M.C.S. (227) 163
Crivellari, M.T., see Viganò, T. (219) 159
Crompton, M.R., see Lowther, S. (222) 137
Crosby, Jr., G., see Tedford, C.E. (211) 169
Croucher, M.J., see Cotterell, K.L. (214) 285
Crouzel, C., see Varastet, M. (213) 275
Cruciani, R.A., Barker, J.L., Durell, S.R., Raghunathan, G., Guy, H.R., Zasloff, M. and Stanley, E.F.
Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes (226) 287
Csoka, K., see Larsson, R. (228) 237
Cuccheddu, T., see Sanna, E. (216) 457
Cuenca, E., see Iglesias, V. (211) 35
Cuffí, M.L., see Mármol, F. (226) 93
Culbertson, C.T., see Deutsch, H.M. (220) 173
Culman, J., see Itoi, K. (219) 435
Cumiskey, W.R., see Silver, P.J. (212) 143
Curet, O., De Montigny, C. and Blier, P.
Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain (221) 59
Currie, J., see Penn, A. (228) 155
Currie, M.G., see Kato, J. (225) 113
Cutrufo, C., Bortot, L., Giachetti, A. and Manzini, S.
Differential effects of various xanthines on pentylenetetrazole-induced seizures in rats: an EEG and behavioural study (222) 1
Czachura, J.F., see Rasmussen, K. (209) 135
Czarnobilski, K., see Konturek, S.J. (211) 277

Dahlgren, I.L., see Klint, T. (212) 241
Dai, S., see Achike, F.I. (219) 369
Dale, J., see Kaneda, H. (212) 43
Dalgliesh, K., see Bamforth, K.J. (228) 15
Dalsgaard, C.-J., see Xu, X.-J. (216) 337
Daly, J.W., see Murata, M. (227) 43
Daly, S.A. and Waddington, J.L.
Two directions of dopamine D_1/D_2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D_1 receptor antagonists (213) 251
Damas, J. and Remacle-Volon, G.
Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat (211) 81
Damase-Michel, C., see Montastruc, P. (213) 159
D'Amato, M., see Preziosi, P. (221) 343

Daniel, E.E., see Pasyk, E. (212) 209
Daniel, E.E., see Shimamoto, H. (216) 225
Daniels, D.C., see Watanabe, Y. (222) 157
Dannals, R.F., see Lever, J.R. (216) 459
Dansette, P.M., see Martinat, C. (228) 63
Dantzer, R., see Bluthé, R.-M. (209) 281
Dapper, J., see Müller, W.E.G. (226) 209
D'Aquila, P.S., Sias, A., Gessa, G.L. and Serra, G.
The NMDA receptor antagonist MK-801 prevents imipramine-induced supersensitivity to quinpirole (224) 199
Darles, G., see Graham, D. (226) 373
Darlington, C.L., see Sansom, A.J. (220) 123
Darlison, M.G., see Zaman, S.H. (225) 321
Darrow, E., Strahlendorf, J.C. and Strahlendorf, H.K.
Extracellular magnesium concentration alters Purkinje cell responsiveness to serotonin and analogues (209) 19
Das, B., see Libri, V. (212) 253
Da Silva, A., Dhuy, J., Waeldelé, F., Bertrand, C. and Landry, Y.
Endopeptidase 24.15 modulates bradykinin-induced contraction in guinea-pig trachea (212) 97
Daugé, V., see Baamonde, A. (216) 157
Daugé, V., see Calenco-Choukroun, G. (209) 267
Davies, B.T. and Wellman, P.J.
Effects on ingestive behavior in rats of the α_1-adrenoceptor agonist cirazoline (210) 11
Davies, M.F., see Maguire, P.A. (214) 85
Davies, M.F., see Maguire, P.A. (226) 233
Davies, M.S., Baganoff, M.P., Grishin, E.V., Lanthorn, T.H., Volkova, T.M., Watson, G.B. and Wiegand, R.C.
Polyamine spider toxins are potent un-competitive antagonists of rat cortex excitatory amino acid receptors (227) 51
Davis, J.M., see Pandey, G.N. (226) 303
Dawes, E., see Ikeda, H. (210) 53
De, S., see Abdel-Latif, A.A. (226) 351
Debaert, M., see Ong, J. (218) 343
Debaert, M., see Ong, J. (221) 145
De Beer, E.L., Finkle, H., Voest, E.E., Van Heijst, B.G.V. and Schiereck, P.
Doxorubicin interacts directly with skinned single skeletal muscle fibres (214) 97
De Brito Sánchez, M.G., see Golombek, D.A. (210) 253
Décarie, A. and Couture, R.
Characterization of the peripheral action of neuropeptide K on the rat cardiovascular system (213) 125
De Ceballos, M.L., see Taylor, M.D. (219) 183
Deckert, V. and Angus, J.A.
Evidence that 5-HT_2 receptors predominantly mediate the contraction of the rat basilar artery to 5-hydroxytryptamine (221) 17
De Costa, B., see Basile, A.S. (227) 95
De Costa, B., see Reith, M.E.A. (227) 417
DeFeo, P.A., see Zinkand, W.C. (212) 129
De Gaetano, G., see Evangelista, V. (216) 401
De Haan, L.H.J., see Zwijsen, R.M.L. (228) 115
DeHaas, C.J., see Kusner, E.J. (210) 299
DeHaven-Hudkins, D.L., Fleissner, L.C. and Ford-Rice, F.Y.
Characterization of the binding of [^{3}H](+)-pentazocine to σ recognition sites in guinea pig brain (227) 371
De Jong, W., see Linthorst, A.C.E. (219) 23
De Jong, W., see Petty, M.A. (210) 85
Delaflotte, S., see Auguet, M. (224) 101
Del Aguila, C.M., see Acuña Castroviejo, D. (226) 59
Delarge, J., see Masereel, B. (219) 385
Delay-Goyet, P., Franco-Cereceda, A., Gonsalves, S.F., Clingan, C.A., Lowe III, J.A. and Lundberg, J.M.
CP-96,345 antagonism of NK_1 receptors and smoke-induced protein extravasation in relation to its cardiovascular effects (222) 213
Del Bianco, E., see Tramontana, M. (212) 137
Del Carmine, R., see Preziosi, P. (221) 343
Dellweg, H., see Theis, J.G.W. (226) 149
Del Monte, F., see Harding, S.E. (223) 39
Delporte, C., Poloczek, P., Tastenoy, M., Winand, J. and Christophe, J.
Atrial natriuretic peptide binds to ANP-R_1 receptors in neuroblastoma cells or is degraded extracellularly at the Ser-Phe bond (227) 247
Delporte, C., Winand, J., Poloczek, P., Von Geldern, T. and Christophe, J.
Discovery of a potent atrial natriuretic peptide antagonist for ANP_A receptors in the human neuroblastoma NB-OK-1 cell line (224) 183
Del Prado, M., see Hey, J.A. (211) 421
Del Río, J., see Pérez-Otaño, I. (217) 211
Delton, I., see Gharib, A. (225) 359
DeLuca, A.W., see Valliere, J.E. (226) 191
De Marzo, N., see Crescioli, S. (228) 45
Demchyshyn, L., see Miller, K.J. (227) 99
De Montigny, C., see Curet, O. (221) 59
De Moraes, S., see Tabach, R. (216) 449
De Natale, G., see Desole, M.S. (219) 67
Den Hertog, A., see Henning, R.H. (216) 73
Den Hertog, A., see Van der Zee, L. (215) 317
Denison, M.S., see Bank, P.A. (228) 85
Denoroy, L., see Petit, J.-M. (212) 79
De Paermentier, F., see Lowther, S. (222) 137
De Paulis, T., see Kessler, R.M. (223) 105
De Potter, W., see Jimenez Del Rio, M. (225) 225
De Sarro, A., see De Sarro, G. (215) 221
De Sarro, G. and De Sarro, A.
Anticonvulsant activity of competitive antagonists of NMDA receptor in genetically epilepsy-prone rats (215) 221
De Simoni, M.G., see Gemma, C. (209) 139
De Smedt, H., see Missiaen, L. (227) 391
Desmoulière, A., see Bârzu, T. (219) 225
Desole, M.S., Miele, M., Enrico, P., Esposito, G., Fresu, L., De Natale, G. and Miele, E.
Effects of cortical ablation on apomorphine- and scopolamine-induced changes in dopamine turnover and ascorbic acid catabolism in the rat striatum (219) 67
Deutsch, H.M., Schweri, M.M., Culbertson, C.T. and Zalkow, L.H.
Synthesis and pharmacology of irreversible affinity labels as potential cocaine antagonists: aryl 1,4-dialkylpiperazines related to GBR-12783 (220) 173
Devillier, P., Candenas, M.-L., Naline, E. and Advenier, C.
Influence of benzodiazepines on the response of the guinea-pig isolated trachea to the contractile action of adenosine (214) 67
Devilliers, G., see Mouillac, B. (225) 179
Devlin, T.M., see Von Lubitz, D.K.J.E. (216) 37
Devlin, T.M., see Von Lubitz, D.K.J.E. (219) 153
Devreese, A.-M., see Jorens, P.G. (212) 113
De Vries, J., see Hempenius, R.A. (228) 207
De Vriese, A., see Lefebvre, R.A. (221) 235
De Weille, J.R., see Szewczyk, A. (216) 323
De Weille, J.R., see Szewczyk, A. (226) 175
De Witte, P., see Nijs, G. (218) 199
De Witte, P., see Van Hoestenberghe, A. (212) 121
Dhasmana, K.M., Villalón, C.M., Zhu, Y.N., Tadipatri, S. and Saxena, P.R.
Role of 5-HT_1-like receptors in the increase in intragastric pressure induced by 5-hydroxytryptamine in the rat (213) 293
Dho, L., see Salvati, P. (221) 267
Dhuy, J., see Da Silva, A. (212) 97
Diamantis, W., see Chand, N. (211) 121
Diamond, J., see Langlands, J.M. (227) 131

Diana, M., Collu, M., Mura, A. and Gessa, G.L.
Haloperidol-induced vacuous chewing in rats: suppression by α-methyl-tyrosine (211) 415
Diana, M., Pistis, M., Muntoni, A., Rossetti, Z.L. and Gessa, G.
Marked decrease of A10 dopamine neuronal firing during ethanol withdrawal syndrome in rats (221) 403
Diaz, B.L., see Pasquale, C.P. (223) 9
Di Carlo, R., see Muccioli, G. (227) 293
Dickenson, A.H., see Chapman, V. (219) 427
Dickenson, A.H., see Kalso, E.A. (216) 97
Dickenson, A.H., see Sullivan, A.F. (215) 127
Dickinson, K.E.J., Frizzell, R.A. and Sekar, M.C.
Activation of T84 cell chloride channels by carbachol involves a phosphoinositide-coupled muscarinic M_3 receptor (225) 291
Dijcks, F.A., see Fernhout, B.J.H. (213) 313
Dijkema, R., see Stam, N.J. (227) 153
Diksic, M., see Takada, A. (228) 131
Dimaline, R., see Campbell, B.J. (209) 231
Diochot, S., Vittet, D., Mathieu, M.-N., Launay, J.-M. and Chevillard, C.
Effects of endothelins on the human megakaryoblastic cell line MEG-01 (227) 427
Di Rosa, M., see Ialenti, A. (211) 177
Do Cao, T., see Martinat, C. (228) 63
Docherty, J.R., see Smith, K. (211) 251
Docherty, J.R., see Smith, K. (219) 203
Dockray, G.J., see Campbell, B.J. (209) 231
D'Ocon, P., see Ivorra, M.D. (219) 303
Doehmer, J., see Wölfel, C. (228) 95
Doménech, T., see Fernández, A.G. (222) 257
Domeney, A.M., see Jones, D.N.C. (215) 63
Done, C., Silverstone, P. and Sharp, T.
Effect of naloxone-precipitated morphine withdrawal on noradrenaline release in rat hippocampus in vivo (215) 333
Donigi-Gale, D., see Hogaboam, C.M. (216) 315
Donin, L., see Patrini, G. (210) 259
Donnell, D., see Voss, H.-P. (227) 403
Douglas, F.L., see Makujina, S.R. (221) 243
Douglas, S.A., Elliott, J.D. and Ohlstein, E.H.
Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses (221) 315
Doulut, S., see Dubuc, I. (219) 327
Dourish, C.T., Duggan, J.A. and Banks, R.J.A.
Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT_1 receptor antagonist DuP 753 but not by the selective AT_2 receptor antagonist WL 19 (211) 113
Dourish, C.T., see Williams, A.R. (219) 105
Downie, J.W., see Espey, M.J. (221) 167
Downing, S.J., see Piper, I. (219) 347
Doxey, J.C., see Berridge, T.L. (213) 205
Doxey, J.C., see Berridge, T.L. (213) 213
Drapeau, G., see Rollandy, I. (209) 95
Dresse, A., see Verbanck, P.M.P. (211) 15
Drew, G.M., see Bryson, S.E. (225) 1
Drew, G.M., see Bryson, S.E. (225) 119
Droogmans, G., see Missiaen, L. (227) 391
Droppleman, D.A., see Barrett, R.J. (216) 9
Drown, D.B., see Jayasekara, S. (228) 37
Drugan, R.C., see Holmes, P.V. (226) 189
Drukarch, B., see Stoof, J.C. (213) 439
Du, X.-J. and Riemersma, R.A.
Effects of presynaptic α-adrenoceptors and neuronal reuptake on noradrenaline overflow and cardiac response (211) 221
Du, Z.-Y. and Woodman, O.L.
The effect of hypercholesterolaemia and atherosclerosis on α-adrenoceptor-mediated vasoconstriction in conscious rabbits and rabbit aorta (211) 149
Du, Z.-Y., Dusting, G.J. and Woodman, O.L.
Baroreceptor reflexes and vascular reactivity during inhibition of nitric oxide synthesis in conscious rabbits (214) 21
Duan, J. and Karmazyn, M.
Protective effects of amiloride on the ischemic reperfused rat heart. Relation to mitochondrial function (210) 149
Duane Sofia, R., see Chand, N. (211) 121
Duarte, D.F.P., Sant'Ana, A.E.G. and Calixto, J.B.
Analysis of the vasorelaxant action of jatrophone in the isolated aorta of the rat: influence of potassium channel blockers (215) 75
Duarte, I.D.G. and Ferreira, S.H.
The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP pathway (221) 171
Duarte, I.D.G., Santos, I.R., Lorenzetti, B.B. and Ferreira, S.H.
Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide–cGMP pathway (217) 225
Dubner, R., see Ren, K. (219) 235
Dubuc, I., Costentin, J., Doulut, S., Rodriguez, M., Martinez, J. and Kitabgi, P.
JMV 449: a pseudopeptide analogue of neurotensin-(8–13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse (219) 327
Duchêne-Marullaz, P., see Boucher, M. (211) 343
Duckles, S.P., see Li, Y. (210) 23
Dudley, M.W., see Boeijinga, P.H. (219) 9
Duffy, R.A., see McQuade, R.D. (215) 29
Duggan, J.A., see Dourish, C.T. (211) 113
Duhl, D.M., see Bieck, P.R. (225) 171
Dumont, I., see Schroeder, H. (220) 217
Dumont, M. and Lemaire, S.
Interaction of 1,3-di(2-[5-^{3}H]tolyl)guanidine with σ_2 binding sites in rat heart membrane preparations (209) 245
Duncia, J.V., see Reilly, T.M. (226) 179
Dunn, R.W., Flanagan, D.M., Martin, L.L., Kerman, L.L., Woods, A.T., Camacho, F., Wilmot, C.A., Cornfeldt, M.L., Effland, R.C., Wood, P.L. and Corbett, R.
Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents (214) 207
Duque, D.F., see Golombek, D.A. (210) 253
Durante, W., see Schini, V.B. (216) 379
Durcan, M.J. and Morgan, P.F.
Opioid receptor mediation of the hypothermic response to caffeine (224) 151
Durell, S.R., see Cruciani, R.A. (226) 287
Durieux, C., Ruiz-Gayo, M. and Roques, B.P.
In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCK_B agonist [^{3}H]pBC 264 (209) 185
Durlach-Misteli, C. and Van Ree, J.M.
Dopamine and melatonin in the nucleus accumbens may be implicated in the mode of action of antidepressant drugs (217) 15
Düsing, R., see Ko, Y. (227) 215
Dusting, G.J., see Du, Z.-Y. (214) 21
Duttaroy, A., Billings, B., Candido, J. and Yoburn, B.C.
Chronic d-amphetamine inhibits opioid receptor antagonist-induced supersensitivity (221) 211
Dyatlova, N., see Jurásková, V. (221) 107
Dykstra, C., see Meller, S.T. (214) 93
Dziki, M., Hönack, D. and Löscher, W.
Kindled rats are more sensitive than non-kindled rats to the behavioural effects of combined treatment with MK-801 and valproate (222) 273
Dzimiri, N., see Almotrefi, A.A. (215) 231

East, S.J. and Garthwaite, J.
Actions of a metabotropic glutamate receptor agonist in immature and adult rat cerebellum (219) 395
East, S.J., Batchelor, A.M. and Garthwaite, J.
Selective blockade of N-methyl-D-aspartate receptor function by the nitric oxide donor, nitroprusside (209) 119
Ebinger, G., see Jimenez Del Rio, M. (225) 225
Edvinsson, L., see Heilig, M. (209) 27
Edvinsson, L., see Potter, E.K. (221) 307
Effland, R.C., see Dunn, R.W. (214) 207
Egan, M.F., see Chrapusta, S.J. (222) 129
Egan, R.W., see Clark, M.A. (210) 31
Egan, R.W., see Hey, J.A. (211) 421
Egido, J., see Gómez-Garre, D. (224) 167
Eglen, R.M., see Ford, A.P.D.W. (211) 117
Eglen, R.M., see Ford, A.P.D.W. (225) 105
Eglezos, A., Giuliani, S., Viti, G. and Maggi, C.A.
Direct evidence that capsaicin-induced plasma protein extravasation is mediated through tachykinin NK_1 receptors (209) 277
Eguchi, S., Hirata, Y., Imai, T., Kanno, K., Ohta, K., Emori, T. and Marumo, F.
Effects of three distinct natriuretic peptides on receptor binding and guanylate cyclase activities in rat glioma cells (225) 79
Eiger, S., see Lameh, J. (227) 19
Eigyo, M., Katsuura, G., Shintaku, H., Shinohara, S., Katoh, A., Shiomi, T. and Matsushita, A.
Systemic administration of a cholecystokinin analogue, ceruletide, protects against ischemia-induced neurodegeneration in gerbils (214) 149
Eigyo, M., Katsuura, G., Shintaku, H., Shinohara, S., Katoh, A., Shiomi, T. and Matsushita, A.
Systemic administration of a cholecystokinin analogue, ceruletide, protects against ischemia-induced neurodegeneration in gerbils (219) 487
Eiring, A., see Bieck, P.R. (225) 171
Eison, M.S., see Pick, C.G. (211) 375
El-Fakahany, E.E., see Mohamed, A.S. (227) 181
Elayan, H., Kennedy, B. and Ziegler, M.G.
Propranolol reduces rat dopamine-β-hydroxylase activity and catecholamine levels (212) 259
Elayan, I., Gibb, J.W., Hanson, G.R., Foltz, R.L., Lim, H.K. and Johnson, M.
Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine (221) 281
Elinder, F., see Veintemilla, F. (218) 59
Elinder, F., see Westlind-Danielsson, A. (224) 57
Elizondo, E., see Schini, V.B. (216) 379
Elliot, M., see Jansen, K.L.R. (214) 281
Elliott, G.R., Van de Meent, D. and Van Dijk, J.
Interleukin-1α-stimulated fibroblast eicosanoid synthesis is not mediated by interleukin-6 (214) 253
Elliott, J.D., see Douglas, S.A. (221) 315
Elliott, J.D., see Ohlstein, E.H. (225) 347
Elliott, P.J., see Overton, P. (213) 165
Ellis, A.M. and Coker, S.J.
Contribution of antiplatelet activity to the effects of 5-HT_2 receptor antagonists on reperfusion-induced arrhythmias in anaesthetized rats (219) 97
Ellis, P.M., see Gartside, S.E. (221) 27
Elsinga, P.H., see Van Waarde, A. (222) 107
Eltze, M. and Boer, R.
The adrenoceptor agonist, SDZ NVI 085, discriminates between α_{1A}- and α_{1B}-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat (224) 125
Eltze, M., Mutschler, E. and Lambrecht, G.
Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M_1, M_2 and M_3 (211) 283
Eltze, M., see Bott, A. (213) 141
Elwood, W., see Sakamoto, T. (213) 367
Emeis, J.J., see Tranquille, N. (213) 285
Emonds-Alt, X., see Martin, C.A.E. (224) 137
Emori, T., see Eguchi, S. (225) 79
Emri, Z., see Juhász, G. (209) 131
Enas, J.D., see Mathis, C.A. (210) 103
Endo, Y., see Hattori, Y. (213) 147
Endoh, M., Takanashi, M. and Norota, I.
Effect of (+)-niguldipine on myocardial α_1-adrenoceptors in the rabbit (223) 143
Endoh, M., Takanashi, M. and Norota, I.
Effects of vasopressin on phosphoinositide hydrolysis and myocardial contractility (218) 355
Endoh, M., see Kawanami, T. (216) 385
Enero, M.A., see Ricci, D. (212) 195
Engels, F., see Buckley, T.L. (218) 369
Engler, M.B.
Effects of omega-3, omega-6 and omega-9 fatty acids on vascular smooth muscle tone (215) 325
Englert, H.C., Wirth, K., Gehring, D., Fürst, U., Albus, U., Scholz, W., Rosenkranz, B. and Schölkens, B.A.
Airway pharmacology of the potassium channel opener, HOE 234, in guinea pigs: in vitro and in vivo studies (210) 69
Enrico, P., see Desole, M.S. (219) 67
Entzeroth, M., see Zhang, J. (218) 35
Enz, A., see Boddeke, E.W.G.M. (222) 21
Epelbaum, J., see Fosset, M. (220) 273
Erdö, S.L., see Kiss, B. (209) 109
Ericson, H. and Ross, S.B.
Subchronic treatment of rats with remoxipride fails to modify σ binding sites in the brain (226) 157
Ericsson, G., see Westlind-Danielsson, A. (224) 57
Eriksson, E., see Nilsson, C. (218) 205
Errol, C., see Hall, A.S. (226) 253
Ertan, A., see Mungan, Z. (214) 53
Esbenshade, T.A., see Han, C. (226) 141
Escalante, A.L., see Fernández-Guasti, A. (210) 121
Escanero, J., see Gómez-Garre, D. (224) 167
Escubedo, E., Pallas, M., Nuñez, C. and Camarasa, J.
Effects of Ro 5-4864 and PK 11195 in rat duodenum and vas deferens (225) 15
Espey, M.J., Downie, J.W. and Fine, A.
Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats (221) 167
Esplugues, J.V., see Martinez-Cuesta, M.A. (218) 351
Esposito, E., see Prisco, S. (214) 13
Esposito, G., see Desole, M.S. (219) 67
Estañ, L.À., see Rubio, E. (212) 31
Eudeline, B., see Claustre, Y. (225) 37
Eurin, J., see Zongazo, M.A. (209) 45
Evangelista, S., see Ballati, L. (214) 215
Evangelista, V., Piccardoni, P., Maugeri, N., De Gaetano, G. and Cerletti, C.
Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G (216) 401
Evans, R.G., Hayes, I.P. and Ludbrook, J.
Effects of α-adrenoceptor antagonists and clonidine on the haemodynamic response to acute hypovolaemia in conscious rabbits (216) 265
Eyssen, H., see Van Hoestenberghe, A. (212) 121

Fabbri, L.M., see Crescioli, S. (228) 45
Fabbri, L.M., see Mapp, C.E. (228) 103

Facci, L., see Moroni, F. (218) 145
Faccioli, L.H., see Ferreira, S.H. (217) 207
Facheris, L., see Speciale, C. (214) 107
Fadayel, G.M., see Schmidt, C.J. (220) 151
Fadayel, G.M., see Schmidt, C.J. (223) 65
Fadda, E., see Moroni, F. (218) 145
Fadda, E., see Siliprandi, R. (219) 173
Fajolles, C., Boireau, A., Ponchant, M. and Laduron, P.M.
[^{3}H]RP 62203, a ligand of choice to label in vivo brain 5-HT_2 receptors (216) 53
Fang, Z.-Y., see Antoine, M.-H. (216) 299
Fanidi, A., see Fayard, J.-M. (216) 127
Fariello, R.G., see Speciale, C. (214) 107
Fauchère, J.-L., see Simonet, S. (216) 135
Faunce, D.M., see Sawutz, D.G. (227) 309
Fauq, A.H., see Reynolds, I.J. (226) 53
Fayard, J.-M., Chanal, S., Fanidi, A., Pageaux, J.-F., Lagarde, M. and Laugier, C.
In vivo inhibition of basal and estrogen-induced phospholipase A_2 activities by the triphenylethylene antiestrogen, tamoxifen, in immature quail oviduct (216) 127
Fedele, E., see Raiteri, M. (213) 17
Fedorov, N.B., Screbitsky, V.G. and Reymann, K.G.
Effects of philanthotoxin-343 on CA1 pyramidal neurons of rat hippocampus in vitro (228) 201
Feifel, R., see Bungardt, E. (213) 53
Fekete, I., see Molnár, L. (209) 81
Feldman, J., see Tibiriça, E. (209) 213
Fernandes, A.C., Filipe, P.M. and Manso, C.F.
Protective effects of a 21-aminosteroid against copper-induced erythrocyte and plasma lipid peroxidation (220) 211
Fernandes, L.B., Preuss, J.M.H. and Goldie, R.G.
Epithelial modulation of the relaxant activity of atriopeptides in rat and guinea-pig tracheal smooth muscle (212) 187
Fernández, A.G., Puig, J., Beleta, J., Doménech, T., Bou, J., Berga, P., Gristwood, R.W. and Roberts, D.J.
Pancopride, a potent and long-acting 5-HT_3 receptor antagonist, is orally effective against anticancer drug-evoked emesis (222) 257
Fernández-Alfonso, M.S., Sánchez-Ferrer, C.F. and Marín, J.
Sodium pump activation by 5-hydroxytryptamine in human placental veins (221) 185
Fernández, B., see Acuña Castroviejo, D. (226) 59
Fernandez, E., see Miranda, H.F. (217) 137
Fernández-Guasti, A., Escalante, A.L., Ahlenius, S., Hillegaart, V. and Larsson, K.
Stimulation of 5-HT_{1A} and 5-HT_{1B} receptors in brain regions and its effects on male rat sexual behaviour (210) 121
Fernández, J.J., see Candenas, M.-L. (219) 473
Fernhout, B.J.H., Dijcks, F.A., Moolenaar, W.H. and Ruigt, G.S.F.
Lysophosphatidic acid induces inward currents in *Xenopus laevis* oocytes; evidence for an extracellular site of action (213) 313
Ferrandi, M., see Masereel, B. (219) 385
Ferrari, F., Pelloni, F. and Giuliani, D.
B-HT 920 stimulates feeding and antagonizes anorexia induced by ACTH and immobilisation (210) 17
Ferrari, F., Pelloni, F. and Giuliani, D.
Suppressive effect of the dopamine D_2 receptor agonist B-HT 920 on rat grooming (216) 345
Ferrari, F., see Revel, L. (216) 217
Ferrari, M.D., see Saxena, P.R. (220) 79
Ferrari, P., see Masereel, B. (219) 385
Ferrat, T., see Andre, P. (218) 137
Ferreira, S.H., Lorenzetti, B.B. and Faccioli, L.H.
Blockade of hyperalgesia and neurogenic oedema by topical application of nitroglycerin (217) 207
Ferreira, S.H., see Duarte, I.D.G. (217) 225
Ferreira, S.H., see Duarte, I.D.G. (221) 171
Ferris, C.D., see Breslow, M.J. (210) 105
Fertel, R.H., see Baidan, L.V. (225) 21
Fetzer, C., see Walters, M.R. (213) 309
Feuerstein, G., see Yue, T.-L. (214) 277
Fibiger, H.C., see Robertson, G.S. (219) 323
Fiekers, J.F., see Heppner, T.J. (213) 427
File, S.E., Andrews, N., Wu, P.Y., Zharkovsky, A. and Zangrossi, Jr., H.
Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience (218) 9
File, S.E., see Andrews, N. (210) 247
Filep, J.G., Földes-Filep, É., Rousseau, A., Fournier, A., Sirois, P. and Yano, M.
Endothelin-1 enhances vascular permeability in the rat heart through the ET_A receptor (219) 343
Filep, J.G., Rousseau, A., Fournier, A. and Sirois, P.
Structure-activity relationship of analogues of endothelin-1: dissociation of hypotensive and pressor actions (220) 263
Filep, J.G., see Sirois, M.G. (214) 119
Filipe, P.M., see Fernandes, A.C. (220) 211
Filippi, S., see Amerini, S. (216) 445
Finberg, J.P.M., see Ari, G. (219) 89
Fine, A., see Espey, M.J. (221) 167
Fingerhut, M.A., see Ahlborg, U.G. (228) 179
Fink-Jensen, A., Suzdak, P.D., Swedberg, M.D.B., Judge, M.E., Hansen, L. and Nielsen, P.G.
The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats (220) 197
Finkle, H., see De Beer, E.L. (214) 97
Fischette, C.T., see Walters, M.R. (213) 309
Fisher, A., see Segal, M. (220) 103
Flanagan, D.M., see Dunn, R.W. (214) 207
Fleisch, J.H., see Silbaugh, S.A. (223) 57
Fleissner, L.C., see DeHaven-Hudkins, D.L. (227) 371
Fleming, I., see Schuller, F. (212) 93
Fletcher, A., see Bill, D.J. (218) 327
Fletcher, P.J., see Kish, S.J. (209) 101
Flood, J.F., Morley, J.E. and Lanthorn, T.H.
Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor (221) 249
Flouquet, N., see Ong, J. (218) 343
Flouquet, N., see Ong, J. (221) 145
Flugy, A., Gagliano, M., Cannizzaro, C., Novara, V. and Cannizzaro, G.
Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats (214) 233
Foegh, M.L., see Huang, H.-C. (211) 359
Fogliatto, G., see Abbracchio, M.P. (227) 317
Foignant, N., see Sugasawa, T. (216) 207
Folco, G.C., see Viganò, T. (219) 159
Földes-Filep, É., see Filep, J.G. (219) 343
Folger, W.H., Halushka, P.V., Wilcox, C.S. and Guzman, N.J.
Characterization of rat glomerular thromboxane A_2 receptors: comparison to rat platelets (227) 71
Folkerts, G., Van Esch, B., Janssen, M. and Nijkamp, F.P.
Virus-induced airway hyperresponsiveness in guinea pigs in vivo: study of broncho-alveolar cell number and activity (228) 219
Folkerts, G., Verheyen, A. and Nijkamp, F.P.
Viral infection in guinea pigs induces a sustained non-specific airway hyperresponsiveness and morphological changes of the respiratory tract (228) 121
Foltz, R.L., see Elayan, I. (221) 281
Font, M., see Frechilla, D. (219) 409
Fontaine, J., see Antoine, M.-H. (216) 299
Ford, A.P.D.W., Baxter, G.S., Eglen, R.M. and Clarke, D.E.

5-Hydroxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT_4 receptors (211) 117
Ford, A.P.D.W., Eglen, R.M. and Whiting, R.L.
Analysis of muscarinic cholinoceptors mediating phosphoinositide hydrolysis in guinea pig cardiac muscle (225) 105
Ford-Rice, F.Y., see DeHaven-Hudkins, D.L. (227) 371
Foreman, R.D., see Blair, R.W. (216) 119
Forn, J., see Mármol, F. (226) 93
Forray, C., see Mohamed, A.S. (227) 181
Förstermann, U., Schmidt, H.H.H.W., Kohlhaas, K.L. and Murad, F.
Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-β (225) 161
Förstermann, U., see Klabunde, R.E. (223) 1
Fosset, M., Epelbaum, J. and Lazdunski, M.
Antidiabetic sulfonylureas antagonize somatostatin inhibition of prolactin secretion in vitro (220) 273
Foster, K.A., Arch, J.R.S., Newson, P.N., Shaw, D. and Taylor, S.G.
Effect of Rb^+ on cromakalim-induced relaxation and ion fluxes in guinea pig trachea (222) 143
Foster, R.W., see Small, R.C. (219) 81
Fournié-Zaluski, M.-C., see Baamonde, A. (216) 157
Fournié-Zaluski, M.-C., see Noble, F. (223) 83
Fournié-Zaluski, M.-C., see Noble, F. (223) 91
Fournier, A., see Filep, J.G. (219) 343
Fournier, A., see Filep, J.G. (220) 263
Fournier, A., see Sirois, M.G. (214) 119
Fournier, A., see T-Benchekroun, M. (216) 421
Fragoso-Veloz, J. and Tapia, R.
NMDA receptor antagonists protect against seizures and wet-dog shakes induced by 4-aminopyridine (221) 275
Franchi-Micheli, S., see Gentilini, G. (217) 9
Franco-Cereceda, A. and Lundberg, J.M.
Capsazepine inhibits low pH- and lactic acid-evoked release of calcitonin gene-related peptide from sensory nerves in guinea-pig heart (221) 183
Franco-Cereceda, A., see Delay-Goyet, P. (222) 213
Franco-Cereceda, A., see Lou, Y.-P. (210) 173
Franco, R., see Casadó, V. (225) 7
Frank, H., see Wölfel, C. (228) 95
Franklin, P.H., see Roth, J.E. (215) 293
Frechilla, D., Bernedo, E., Castiella, E., Lasheras, B., Cenarruzabeitia, E., Monge, A., Aldana, I., Alvarez, T., Losa, M.J. and Font, M.
Antihypertensive and vasodilator effect of A-80b, a new pyridazino indole derivative (219) 409
Frederiksen, K., see Suzdak, P.D. (224) 189
Fredholm, B.B., see Hu, P.-S. (209) 87
Fredholm, B.B., see Kontny, E. (227) 333
Fredow, G., see Löscher, W. (213) 31
Freedman, S.B., Patel, S., Harley, E.A., Iversen, L.L., Baker, R., Showell, G.A., Saunders, J., McKnight, A., Newberry, N., Scholey, K. and Hargreaves, R.
L-687,306: a functionally selective and potent muscarinic M_1 receptor agonist (215) 135
French, E.D.
Competitive NMDA receptor antagonists attenuate phencyclidine-induced excitations of A10 dopamine neurons (217) 1
French, J.F., see Lambert, L.E. (216) 131
Fresu, L., see Desole, M.S. (219) 67
Frew, R., see Lundy, P.M. (225) 51
Frewin, D.B., see Jonsson, J.R. (211) 263
Friebe, T., see Lambrecht, G. (217) 217
Friedman, E., see Undie, A.S. (226) 297
Frizzell, R.A., see Dickinson, K.E.J. (225) 291
Frodsham, G. and Jones, R.B.
Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle (211) 383
Frost, J.J., see Lever, J.R. (216) 459
Fückel, D. and Petzinger, E.
Interaction of sulfonylureas with the transport of bile acids into hepatocytes (213) 393
Fückel, D., see Petzinger, E. (213) 381
Fuji, K., see Nabeshima, T. (223) 109
Fujii, T., see Morimoto, H. (224) 1
Fujii, T., see Murai, M. (217) 23
Fujii, T., see Ueda, M. (219) 271
Fujimori, K., see Inoue, K. (215) 321
Fujimoto, J.M., see Suh, H.H. (213) 337
Fujimoto, M., Mihara, S.-i., Shigeri, Y. and Itazaki, K.
Possible implication of peptidase activity in different potency of angiotensins II and III for displacing [^{125}I]angiotensin II binding in pig aorta (215) 259
Fujimoto, M., see Niwa, M. (225) 281
Fujinami, H., see Komabayashi, T. (225) 209
Fujishima, M., see Sadoshima, S. (224) 109
Fujita, K., see Kobayashi, A. (215) 43
Fujita, Y., see Renming, X. (223) 185
Fukazawa, M., see Namiki, A. (227) 339
Fukuchi, S., see Mizuno, K. (215) 305
Fukuda, H., see Yamazaki, J. (220) 237
Fukushima, Y., see Kawabata, A. (218) 153
Fukutake, K., see Notsu, T. (220) 35
Fukuzaki, A., Suga, O., Karibe, H., Miyauchi, Y., Gokita, T. and Uchida, M.K.
Ca^{2+}-independent contraction of uterine smooth muscle induced by vanadate and its inhibition by Ca^{2+} (220) 99
Fukuzumi, Y., see Kawabata, A. (218) 153
Fulga, I.G., see Baamonde, A. (216) 157
Fuller, R.W., see Baker, A.J. (211) 157
Fumagalli, A., see Basilico, L. (222) 241
Furman, B.L., see Guc, M.O. (224) 63
Furspan, P.B.
WAY 120,491 activates ATP-sensitive potassium channels in rat tail artery (223) 201
Fürst, U., see Englert, H.C. (210) 69
Furuhama, K., see Sugawara, T. (228) 147
Furukawa, Y., see Takei, M. (219) 15
Fusamoto, H., see Kawano, S. (211) 55
Fuxe, K., see Hedlund, P.B. (224) 203

Gaál, L., see Molnár, P. (215) 17
Gabbiani, G., see Bârzu, T. (219) 225
Gacel, G., see Calenco-Choukroun, G. (209) 267
Gacel, G., see Pick, C.G. (220) 275
Gacel, G.A., see Cheng, J. (226) 15
Gacel, G.A., see Tive, L.A. (216) 249
Gackenheimer, S.L., see Gehlert, D.R. (211) 189
Gaer, J.A.R., see Knock, G.A. (219) 415
Gagliano, M., see Flugy, A. (214) 233
Gähwiler, B.H., see Gerber, U. (221) 401
Galas, M.-C., see Maletínská, L. (222) 233
Galas, M.C., Bernad, N. and Martinez, J.
Pharmacological studies on CCK_B receptors in guinea pig synaptoneurosomes (226) 35
Gale, K., see Meloni, R. (209) 113
Gale, K., see Peterson, C.J. (221) 151
Gallager, D.W., see Primus, R.J. (226) 21
Gallagher, J.P., see Zheng, F. (211) 281
Galli, A., see Moroni, F. (218) 145
Galvan, M., see Boeijinga, P.H. (219) 9
Garant, D., Sperber, E. and Moshé, S.

The density of $GABA_B$ binding sites in the substantia nigra is greater in rat pups than in adults (214) 75
Garaschuk, O.V., Kovalchuk, Y.N. and Krishtal, O.A.
Trans-ACPD selectively inhibits excitability of hippocampal CA1 neurones (212) 305
Garattini, S., see Grignaschi, G. (211) 137
Garaulet, J.V., Laorden, M.L. and Milanés, M.V.
Influence of temperature on the effects of μ-, δ- and κ-opioid receptor agonists in the guinea-pig ileum myenteric plexus (223) 19
García-Barrado, M.J., Reverte, M. and Moratinos, J.
Role of Ca^{2+} channel blockers in insulin secretion resulting from α_1- and β-adrenoceptor stimulation in the rabbit (219) 461
García-Sáinz, J.A., Macías-Silva, M., Olivares-Reyes, A. and Romero-Avila, M.T.
Histamine activates phosphorylase and inositol phosphate production in guinea pig hepatocytes (227) 325
García-Sáinz, J.A., Romero-Avila, M.T., Olivares-Reyes, J.A. and Macías-Silva, M.
Guinea pig hepatocyte α_{1A}-adrenoceptors: characterization, signal transduction and regulation (227) 239
Gardiner, S.M., Kemp, P.A., Bennett, T., Palmer, R.M.J. and Moncada, S.
Nitric oxide synthase inhibitors cause sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats (213) 449
Garg, A., see Kurelec, B. (228) 51
Garrick, T., Yang, H., Trauner, M., Livingston, E. and Taché, Y.
Thyrotropin-releasing hormone analog injected into the raphe pallidus and obscurus increases gastric contractility in rats (223) 75
Garthwaite, J., see East, S.J. (209) 119
Garthwaite, J., see East, S.J. (219) 395
Gartside, S.E., Ellis, P.M., Sharp, T. and Cowen, P.J.
Selective $5\text{-}HT_{1A}$ and $5\text{-}HT_2$ receptor-mediated adrenocorticotropin release in the rat: effect of repeated antidepressant treatments (221) 27
Gauthier, C. and Soustre, H.
Forskolin effects on slow inward current and phasic tension of frog atrial fibres: modulation by adenosine and phosphodiesterase inhibitors (225) 129
Gauthier, S., see Aubert, I. (217) 173
Gay, N., see Lepetit, P. (209) 207
Gayet, J., see Ginefri-Gayet, M. (217) 85
Ge, J., see Barnes, N.M. (218) 15
Ge, J., see Barnes, N.M. (218) 91
Gebhart, G.F., see Meller, S.T. (214) 93
Geboes, K., see Nijs, G. (218) 199
Geboes, K., see Van Hoestenberghe, A. (212) 121
Gee, K.W., see Cadoni, C. (227) 147
Gehlert, D.R., Gackenheimer, S.L., Seeman, P. and Schaus, J.
Autoradiographic localization of [^{3}H]quinpirole binding to dopamine D_2 and D_3 receptors in rat brain (211) 189
Gehring, D., see Englert, H.C. (210) 69
Geisslinger, G., see Zeilhofer, H.U. (213) 155
Gemma, C., Ghezzi, P. and De Simoni, M.G.
Activation of the hypothalamic serotoninergic system by central interleukin-1 (209) 139
Gemsa, D., see Clement, H.-W. (217) 43
Gentilini, G., Franchi-Micheli, S., Pantalone, D., Cortesini, C. and Zilletti, L.
$GABA_B$ receptor-mediated mechanisms in human intestine in vitro (217) 9
Geppetti, P., see Tramontana, M. (212) 137
Geraci, A., see Mulè, F. (212) 215
Gerakakis, A., see Sinzinger, H. (219) 129
Gerber, U. and Gähwiler, B.H.
4C3HPG (RS-4-carboxy-3-hydroxyphenylglycine), a weak agonist at metabotropic glutamate receptors, occludes the action of trans-ACPD in hippocampus (221) 401
Gerdes, C., Richter, A., Annies, R. and Löscher, W.
Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs (220) 91
Gerlach, M., Riederer, P. and Youdim, M.B.H.
The molecular pharmacology of L-deprenyl (226) 97
Gertner, S.B., see McLeod, R.L. (209) 141
Gessa, G., see Diana, M. (221) 403
Gessa, G.L., see D'Aquila, P.S. (224) 199
Gessa, G.L., see Diana, M. (211) 415
Gessa, G.L., see Rossetti, Z.L. (221) 227
Gessner, G.W., see Jarvis, M.F. (219) 319
Gewecke, M., see Wedemeyer, S. (223) 173
Geyer, M.A., see Callaway, C.W. (214) 45
Gharib, A., Delton, I., Lagarde, M. and Sarda, N.
Evidence for adenosine A_{2b} receptors in the rat pineal gland (225) 359
Ghezzi, P., see Gemma, C. (209) 139
Ghiggeri, G.M., Bertelli, R., Ginevri, F., Oleggini, R., Altieri, P., Trivelli, A. and Gusmano, R.
Multiple mechanisms for doxorubicin cytotoxicity on glomerular epithelial cells 'in vitro' (228) 77
Giachetti, A., see Cutrufo, C. (222) 1
Giagnoni, G., see Basilico, L. (218) 75
Giagnoni, G., see Basilico, L. (222) 241
Gião-T.-Rico, J.M., see Mota-Filipe, H. (213) 227
Gião-T. Rico, J.M., see Macara, B. (218) 27
Gibb, J.W., see Elayan, I. (221) 281
Gibb, J.W., see Hanson, G.R. (218) 287
Gibson, J.K., see Cimini, M.G. (222) 93
Gicquel, S., Mazarguil, H., Allard, M., Simonnet, G. and Zajac, J.-M.
Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects (222) 61
Gies, J.-P., see Haddad, E.-B. (211) 273
Giesen-Crouse, E., see Morain, P. (220) 11
Gil-Longo, J., Orallo, F., Verde, I., Campos, M. and Calleja, J.M.
Role of the endothelial system in BAY K 8644 enantiomer and nifedipine vasomodulator action in rat aorta (221) 1
Gill, J.K., Stansby, G., Shukla, N., Hamilton, G., Barradas, M.A. and Jeremy, J.Y.
5-Hydroxytryptamine stimulates $^{45}Ca^{2+}$ uptake by human umbilical vein endothelial cells in culture: mediation by $5\text{-}HT_2$ receptor subtypes (214) 269
Gill, R., see Hatfield, R.H. (216) 1
Gillespie, D.D., see Bieck, P.R. (225) 171
Gillette, P.C., see Case, C.L. (218) 213
Ginefri-Gayet, M. and Gayet, J.
Involvement of serotonin receptors in methionine sulfoximine-induced hypothermia in the rat (217) 85
Ginevri, F., see Ghiggeri, G.M. (228) 77
Giridhar, J., Peoples, R.W. and Isom, G.E.
Modulation of hypothalamic norepinephrine release by atrial natriuretic peptide: involvement of cyclic GMP (213) 317
Giros, B., see Sokoloff, P. (225) 331
Giuliani, D., see Ferrari, F. (210) 17
Giuliani, D., see Ferrari, F. (216) 345
Giuliani, S., see Eglezos, A. (209) 277
Glaser, T., see Greuel, J.M. (211) 211
Gleeson, S., see Barrett, J.E. (217) 163
Glenert, U.
Effects of chronic anethole trithione and amitriptyline treatment on rat parotid gland signalling (226) 43
Glenn, B.D., see Bill, D.J. (218) 327
Glennon, R.A., see Young, R. (212) 117
Glick, S.D., see Maisonneuve, I.M. (212) 263

Gobert, J., see Gower, A.J. (222) 193
Goicoechea, C., see Martín, M.I. (224) 77
Gokita, T., see Fukuzaki, A. (220) 99
Gokita, T., see Ishine, T. (219) 285
Gold, P.E., see Hall, J.L. (221) 365
Goldberg, S.R., see Schindler, C.W. (213) 99
Goldie, R.G., see Fernandes, L.B. (212) 187
Goldie, R.G., see Preuss, J.M.H. (228) 3
Goldie, R.G., see Rigby, P.J. (228) 141
Goldstein, M., see Tsuda, K. (216) 319
Golombek, D.A., Duque, D.F., De Brito Sánchez, M.G., Burin, L. and Cardinali, D.P.
Time-dependent anticonvulsant activity of melatonin in hamsters (210) 253
Gomar, M.D., see Acuña Castroviejo, D. (226) 59
Gómez-Garre, D., Guerra, M., González, E., López-Farré, A., Riesco, A., Caramelo, C., Escanero, J. and Egido, J.
Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor (224) 167
Gomi, Y., see Morikawa, K. (213) 409
Gomibuchi, T., see Mizuno, K. (215) 305
Gommeren, W., see Schotte, A. (218) 373
Gonalons, N., see Simiand, J. (219) 193
Gonon, F., see Suaud-Chagny, M.F. (213) 305
Gonon, F., see Tibiriça, E. (209) 213
Gonsalves, S.F., see Delay-Goyet, P. (222) 213
González, A.M. and Pazos, A.
Affinity changes in muscarinic acetylcholine receptors in the rat brain following acute immobilization stress: an autoradiographic study (214) 261
González, A.M. and Pazos, A.
Modification of muscarinic acetylcholine receptors in the rat brain following chronic immobilization stress: an autoradiographic study (223) 25
González, E., see Gómez-Garre, D. (224) 167
Gonzalez, F., see Wölfel, C. (228) 95
Gonzalez, M., see Cortijo, J. (221) 43
González, R., see Candenas, M.-L. (219) 473
Goodman, L., see Kaneda, H. (212) 43
Goodson, Jr., T., see Silbaugh, S.A. (223) 57
Gordon, L., see Rutherford, R.A.D. (212) 1
Görg, A., see Ko, Y. (227) 215
Gori, E., see Basilico, L. (218) 75
Gori, E., see Basilico, L. (222) 241
Gori, E., see Patrini, G. (210) 259
Gori, E., see Sala, M. (217) 37
Goromaru, T., see Hashimoto, K. (228) 171
Goshima, Y., see Nakamura, S. (222) 75
Goto, S., see Miura, T. (221) 333
Gould, E., see Watanabe, Y. (222) 157
Gower, A.J., Noyer, M., Verloes, R., Gobert, J. and Wülfert, E.
ucb L059, a novel anti-convulsant drug: pharmacological profile in animals (222) 193
Gozlan, H., see Kidd, E. (211) 133
Gozlan, H., see Martin, P. (212) 73
Grabowski, J., see Silverman, P.B. (212) 165
Gradin, K., Qadri, F., Nomikos, G.G., Hillegaart, V. and Svensson, T.H.
Substance P injection into the dorsal raphe increases blood pressure and serotonin release in hippocampus of conscious rats (218) 363
Graham, D., Darles, G. and Langer, S.Z.
The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studies (226) 373
Grahame-Smith, D.G., see Newberry, N.R. (219) 135
Grahame-Smith, D.G., see Newberry, N.R. (221) 157
Graier, W.F., Schmidt, K. and Kukovetz, W.R.
Is the bradykinin-induced Ca^{2+} influx and the formation of endothelium-derived relaxing factor mediated by a G protein? (225) 43
Grange, E., see Lepetit, P. (209) 207
Gratton, A., see Rompré, P.-P. (211) 295
Gray, D.W. and Marshall, I.
Nitric oxide synthesis inhibitors attenuate calcitonin gene-related peptide endothelium-dependent vasorelaxation in rat aorta (212) 37
Gray, G.A., see Schuller, F. (212) 93
Grech, D.M., see Balster, R.L. (222) 39
Greene, C., Schwindt, P. and Crill, W.
Metabotropic receptor mediated afterdepolarization in neocortical neurons (226) 279
Greenwood, B. and Mandel, K.G.
Effect of mebeverine hydrochloride on jejunal motility and epithelial transport in the anesthetized ferret (211) 143
Greim, H., see Wölfel, C. (228) 95
Greuel, J.M. and Glaser, T.
The putative 5-HT_{1A} receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro (211) 211
Griesbacher, T. and Lembeck, F.
Analysis of the antagonistic actions of HOE 140 and other novel bradykinin analogues on the guinea-pig ileum (211) 393
Grignaschi, G. and Samanin, R.
Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat (212) 287
Grignaschi, G., Neill, J.C., Petrini, A., Garattini, S. and Samanin, R.
Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats (211) 137
Grimm, U., see Lambrecht, G. (217) 217
Grisar, J.M., see Petty, M.A. (210) 85
Grishin, E.V., see Davies, M.S. (227) 51
Gristwood, R.W., see Fernández, A.G. (222) 257
Grønvald, F.C., see Andersen, P.H. (219) 45
Groß, R., see Theis, J.G.W. (226) 149
Gross, R., see Bertrand, G. (214) 159
Gross, R., see Hillaire-Buys, D. (218) 359
Grossman, W., see Qiu, Z. (214) 293
Groten, J.P., Luten, J.B. and Van Bladeren, P.J.
Dietary iron lowers the intestinal uptake of cadmium-metallothionein in rats (228) 23
Gruetter, C.A., Lemke, S.M., Anestis, D.K., Szarek, J.L. and Valentovic, M.A.
Potentiation of 5-hydroxytryptamine-induced contraction in rat aorta by chlorpheniramine, citalopram and fluoxetine (217) 109
Gruetter, C.A., see Cheng, D.Y. (215) 171
Grundemar, L. and Högestätt, E.D.
Unmasking the vasoconstrictor response to neuropeptide Y and its interaction with vasodilating agents in vitro (221) 71
Gruver, M.K., see Bond, E.F. (217) 127
Gu, X.F., see Berger, U.V. (215) 153
Guan, H.-c., see Seeman, P. (227) 139
Guaza, C., see Cambronero, J.C. (219) 75
Guc, M.O., Furman, B.L. and Parratt, J.R.
Modification of α-adrenoceptor-mediated pressor responses by N^G-nitro-L-arginine methyl ester and vasopressin in endotoxin-treated pithed rats (224) 63
Guddal, E., see Andersen, P.H. (219) 45
Gueron, J., see Bidzseranova, A. (211) 411
Guerra, M., see Gómez-Garre, D. (224) 167
Guet, T., see Randle, J.C.R. (215) 237
Gui-Hua, C. and Woolverton, W.L.
Antagonism of quinpirole by (+)-AJ 76: possible involvement of D_3 receptors (209) 285

Guilbaud, G., see Kayser, V. (224) 83
Guillemain, I., see Rollandy, I. (209) 95
Guillemette, G., see Tousignant, C. (225) 235
Guillon, G., see Mouillac, B. (225) 179
Guitard, J., see Simiand, J. (219) 193
Gullikson, G.W., see Moummi, C. (216) 47
Gundlach, A.L., see King, P.R. (218) 101
Gupta, R.C., see Kurelec, B. (228) 51
Gusmano, R., see Ghiggeri, G.M. (228) 77
Gusovsky, F.
Endothelin-elicited stimulation of phospholipase C is mediated by guanine nucleotide binding protein(s) (225) 339
Gusovsky, F., see Manji, H.K. (227) 275
Gusovsky, F., see Murata, M. (227) 43
Gustafsson, L.E., see Persson, M.G. (224) 99
Gustafsson, T., see Potter, E.K. (221) 307
Guth, P.H., see Chyu, K.-Y. (212) 159
Guy-Grand, B., see Laferrère, B. (215) 23
Guy, H.R., see Cruciani, R.A. (226) 287
Guzman, N.J., see Folger, W.H. (227) 71
Gwilt, M., Blackburn, K.J., Burges, R.A., Higgins, A.J., Milne, A.A. and Solca, A.M.
Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs (215) 137
Gwilt, M., Henderson, C.G., Orme, J. and Rourke, J.D.
Effects of drugs on ventricular fibrillation and ischaemic K^+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro (220) 231
Gyévai, A., see Horváth, G. (225) 305

Haapalinna, A., see Jäkälä, P. (221) 351
Habermann, B., see Koch, G. (226) 87
Habibuddin, M., see Banerji, S. (219) 211
Haddad, E.-B. and Gies, J.-P.
Neuraminidase reduces the number of super-high-affinity [^{3}H]oxotremorine-M binding sites in lung (211) 273
Haga, H., see Mizuno, K. (215) 305
Hagan, R.M., see Overton, P. (213) 165
Hagelin, E.M., see Stokke, M. (227) 379
Hajj-ali, A.F. and Zimmerman, B.G.
Nitric oxide participation in renal hemodynamic effect of angiotensin converting enzyme inhibitor lisinopril (212) 279
Håkanson, R., see Wang, Z.-Y. (213) 235
Håkanson, R., see Wang, Z.-y. (216) 327
Haldeman, B., see Thomsen, C. (227) 361
Hales, T.G. and Lambert, J.J.
Modulation of $GABA_A$ and glycine receptors by chlormethiazole (210) 239
Hall, A.S., Errol, C., Bryson, S.E., Ball, S.G. and Balmforth, A.J.
Thiol group identification at or near the agonist binding site of the vascular dopamine receptor (226) 253
Hall, A.S., see Bryson, S.E. (225) 1
Hall, J.L. and Gold, P.E.
Plasma glucose levels predict the disrupting effects of adrenoceptor antagonists on enhancement of memory storage (221) 365
Halushka, P.V., see Folger, W.H. (227) 71
Hamada, T., see Kamisaki, Y. (217) 57
Hamahashi, T., see Kamisaki, Y. (217) 57
Hamilton, G., see Gill, J.K. (214) 269
Hammer, Jr., R.P., Seatriz, J.V. and Ricalde, A.R.
Regional dependence of morphine-induced μ-opiate receptor down-regulation in perinatal rat brain (209) 253
Hammerland, L.G., Olivera, B.M. and Yoshikami, D.
Conantokin-G selectively inhibits N-methyl-D-aspartate-induced currents in *Xenopus* oocytes injected with mouse brain mRNA (226) 239
Hammond, D.L., see Stapelfeld, A. (214) 273
Hamon, M., see Kidd, E. (211) 133
Hampson, D.R., Huang, X.-p., Wells, J.W., Walter, J.A. and Wright, J.L.C.
Interaction of domoic acid and several derivatives with kainic acid and AMPA binding sites in rat brain (218) 1
Han, C., Esbenshade, T.A. and Minneman, K.P.
Subtypes of α_1-adrenoceptors in DDT_1 MF-2 and BC3H-1 clonal cell lines (226) 141
Han, J.-S., see Chen, X.-H. (211) 203
Hanani, M. and Wood, J.D.
Corticotropin-releasing hormone excites myenteric neurons in the guinea-pig small intestine (211) 23
Hankins, M., see Ikeda, H. (210) 53
Hanrahan, S.M., see Mathis, C.A. (210) 103
Hansen, L., see Fink-Jensen, A. (220) 197
Hansen, L.B., see Andersen, P.H. (219) 45
Hanson, G.R., Bunker, C.F., Johnson, M., Bush, L. and Gibb, J.W.
Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse (218) 287
Hanson, G.R., see Elayan, I. (221) 281
Hanson, P.J., see Brown, J.F. (223) 103
Hara, H., Onodera, H., Kawagoe, J.-i. and Kogure, K.
Failure of basic fibroblast growth factor to prevent postischemic neuronal damage in the rat (209) 195
Hara, H., Sukamoto, T., Ohtaka, H., Abe, K., Tatumi, Y., Saito, Y., Suzuki, A. and Tsukamoto, G.
Effects of baicalein and α-tocopherol on lipid peroxidation, free radical scavenging activity and 12-O-tetradecanoylphorbol acetate-induced ear edema (221) 193
Harada, J., Ueda, H., Iso, Y. and Satoh, M.
Affinity cross-linked δ-opioid receptor in NG108-15 cells is low molecular weight (25 kDa) and coupled to GTP-binding proteins (227) 301
Harada, K., see Iwamoto, T. (224) 71
Harada, T., see Satoh, S.-i. (220) 243
Harding, S.E., Jones, S.M., Vescovo, G., Del Monte, F. and Poole-Wilson, P.A.
Reduced contractile responses to forskolin and a cyclic AMP analogue in myocytes from failing human ventricle (223) 39
Hargreaves, R., see Freedman, S.B. (215) 135
Hargrove, H., see Zinkand, W.C. (212) 129
Harhammer, R., Schäfer, U., Henklein, P., Ott, T. and Repke, H.
CCK-8-related C-terminal tetrapeptides: affinities for central CCK_B and peripheral CCK_A receptors (209) 263
Harley, E.A., see Freedman, S.B. (215) 135
Harms, J., see Woodward, J.J. (210) 265
Harms, L., see Tschöpl, M. (213) 71
Harper, P.A., see Bank, P.A. (228) 85
Harper, R.K., see Ni, H. (224) 157
Harper, R.M., see Ni, H. (224) 157
Harris, A.L., see Silver, P.J. (212) 143
Harris, B., Moody, E. and Skolnick, P.
Isoflurane anesthesia is stereoselective (217) 215
Harrison, J.E., see Chand, N. (211) 121
Harrison, N.L., see Lovinger, D.M. (211) 337
Harsing, Jr., L.G., Sershen, H., Toth, E., Hashim, A., Ramacci, M.T. and Lajtha, A.
Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study (218) 117
Hartmann, M. and Schrader, J.
Protein kinase C phosphorylates a 15 kDa protein but not phospholamban in intact rat cardiac myocytes (226) 225
Harvey, R.J., see Zaman, S.H. (225) 321
Hashim, A., see Harsing, Jr., L.G. (218) 117
Hashimoto, K., Maeda, H. and Goromaru, T.
Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine (228) 171

Hashimoto, M., Hashimoto, T. and Kuriyama, K.
Protective effect of WEB 1881 FU on AF64A (ethylcholine aziridinium ion)-induced impairment of hippocampal cholinergic neurons and learning acquisition (209) 9
Hashimoto, S., Kigoshi, S. and Muramatsu, I.
Neurogenic responses of urethra isolated from the dog (213) 117
Hashimoto, S., see Morikawa, K. (213) 409
Hashimoto, T., see Hashimoto, M. (209) 9
Hashimoto, Y., see Koga, Y. (220) 141
Hassédssian, H., Prat, A. and Couture, R.
Anaesthetic doses of pentobarbital antagonize phosphatidylinositol hydrolysis induced by substance P or carbachol in the spinal cord and cerebral cortex of the rat (227) 103
Hata, F., see Kanada, A. (216) 287
Hatfield, R.H., Gill, R. and Brazell, C.
The dose–response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model (216) 1
Hattori, H., see Wasterlain, C.G. (212) 275
Hattori, K., see Shinozuka, K. (222) 113
Hattori, Y., Nagashima, M., Endo, Y. and Kanno, M.
Glibenclamide does not block arterial relaxation caused by vasoactive intestinal polypeptide (213) 147
Hay, D.W.P. and Wadsworth, R.M.
Effects of methoxamine and barium on $^{45}Ca^{2+}$ fluxes in the rat vas deferens (225) 313
Haycock, D., see Sawutz, D.G. (227) 309
Hayes, I.P., see Evans, R.G. (216) 265
He, H., see Nishiyama, A. (218) 311
Head, R.J., see Jonsson, J.R. (211) 263
Healy, D.P., see Ye, M.-Q. (227) 79
Hedlund, P.B., Yanaihara, N. and Fuxe, K.
Evidence for specific N-terminal galanin fragment binding sites in the rat brain (224) 203
Hegedüs, K., see Molnár, L. (209) 81
Heilbronn, E., see Järlebark, L. (225) 75
Heilig, M., Edvinsson, L. and Wahlestedt, C.
Effects of intracerebroventricular D-myo-inositol-1,2,6-trisphosphate (PP56), a proposed neuropeptide Y (NPY) antagonist, on locomotor activity, food intake, central effects of NPY and NPY-receptor binding (209) 27
Heiligers, J.P.C., see Saxena, P.R. (220) 79
Heinrich-Hirsch, B., see Wölfel, C. (228) 95
Heitkemper, M.M., see Bond, E.F. (217) 127
Hekking, P.R.M., see Beusenberg, F.D. (228) 57
Helgren, M.C., see Klabunde, R.E. (223) 1
Hempenius, R.A., De Vries, J. and Rietjens, I.M.C.M.
Molecular orbital study on the glutathione-dependent detoxication of ozonides (228) 207
Henderson, A.K., Yamamura, H.I., Maggi, C.A., Buck, S.H., Van Giersbergen, P.L.M. and Roeske, W.R.
Demonstration of a neurokinin A receptor subtype in transfected fibroblasts (225) 175
Henderson, C.G., see Gwilt, M. (220) 231
Henke, S., see Rhaleb, N.-E. (210) 115
Henklein, P., see Harhammer, R. (209) 263
Henlin, J.-M., see Rubino, A. (212) 237
Hennies, S., Beinborn, M. and Sewing, K.-F.
Gastric prostaglandin E_2 receptors are the common antisecretory target of mucosal prostanoids (218) 303
Henning, R.H., Nelemans, A., Scaf, A.H.J., Van Eekeren, J., Agoston, S. and Den Hertog, A.
Suramin reverses non-depolarizing neuromuscular blockade in rat diaphragm (216) 73
Henricks, P.A.J., see Buckley, T.L. (218) 369
Henrion, D., Laher, I., Laporte, R. and Bevan, J.A.
Further evidence from an elastic artery that angiotensin II amplifies noradrenaline-induced contraction through activation of protein kinase C (224) 13
Henry, J.L., see Hong, Y. (216) 257
Henry, P.J., see Preuss, J.M.H. (228) 3
Heppner, T.J. and Fiekers, J.F.
Compound 48/80 blocks transmission and increases the excitability of ganglion neurons (213) 427
Herault, J.P., see Bârzu, T. (219) 225
Herbert, J.M., Laplace, M.-C., Bernat, A., Salel, V. and Maffrand, J.P.
Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen (216) 175
Herbert, J.M., see Bârzu, T. (219) 225
Herchuelz, A., see Antoine, M.-H. (216) 299
Herepath, M.L. and Broadley, K.J.
Resistance of β_2-adrenoceptor-mediated responses of lung strips to desensitization by long-term agonist exposure – comparison with atrial β_1-adrenoceptor-mediated responses (215) 209
Herman, A.G., see Jorens, P.G. (212) 113
Herman, A.G., see Jorens, P.G. (224) 7
Herrero, M.T., see Pérez-Otaño, I. (217) 211
Herron, D.K., see Silbaugh, S.A. (223) 57
Hertting, G., see Jackisch, R. (226) 245
Hess, H.-J., see Nagahisa, A. (217) 191
Heurteaux, C., see Amalric, M. (217) 71
Heuzé-Joubert, I., Mennecier, P., Simonet, S., Laubie, M. and Verbeuren, T.J.
Effect of vasodilators, including nitric oxide, on the release of cGMP and cAMP in the isolated perfused rat kidney (220) 161
Hewett, K.W., see Case, C.L. (218) 213
Hey, J.A., Del Prado, M., Egan, R.W., Kreutner, W. and Chapman, R.W.
(R)-α-Methylhistamine augments neural, cholinergic bronchospasm in guinea pigs by histamine H_1 receptor activation (211) 421
Hey, J.A., see McLeod, R.L. (209) 141
Heym, J., see Schmidt, A.W. (215) 351
Heym, J., see Schmidt, A.W. (219) 490
Hidaka, H., see Satoh, S.-i. (220) 243
Hietala, J., see Lappalainen, J. (210) 195
Higgins, A.J., see Gwilt, M. (215) 137
Hildebrandt, C., see Lambrecht, G. (217) 217
Hilf, G. and Jakobs, K.H.
Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes (225) 245
Hill, J.L., see Lesch, K.P. (227) 109
Hill, J.L., see Lesch, K.P. (227) 233
Hill, R.G., see Longmore, J. (222) 167
Hill, S.J., see Iredale, P.A. (226) 163
Hillaire-Buys, D., Gross, R., Roye, M., Ribes, G. and Loubatières-Mariani, M.-M.
Adrenergic inhibition of insulin secretion involves pertussis toxin-sensitive and -insensitive mechanisms (218) 359
Hillegaart, V., see Fernández-Guasti, A. (210) 121
Hillegaart, V., see Gradin, K. (218) 363
Himeno, A., Niwa, M., Nakao, K., Suga, S.-i., Yamashita, K., Kataoka, Y., Nakane, Y., Imura, H. and Taniyama, K.
C-type natriuretic peptide-22 differentiates between natriuretic peptide receptors in rat choroid plexus and subfornical organ (215) 337
Himeno, A., see Niwa, M. (225) 281
Hinz, W., see Abraham, W.M. (217) 119
Hiramatsu, M., Koide, T., Ishihara, S.-i., Shiotani, T., Kameyama, T. and Nabeshima, T.
Involvement of the cholinergic system in the effects of nefira-

cetam (DM-9384) on carbon monoxide (CO)-induced acute and delayed amnesia (216) 279
Hiramatsu, M., see Nabeshima, T. (223) 109
Hiraoka, M., see Nitta, J.-i. (214) 191
Hirata, Y., see Eguchi, S. (225) 79
Hirata, Y., see Namiki, A. (227) 339
Hirose, T., see Inoue, M. (221) 135
Hirshman, C.A., see Koga, Y. (220) 141
Hisa, H., Tomura, Y., Yamagata, T. and Satoh, S.
Atrial natriuretic peptide suppresses renal vasoconstriction induced by angiotensin II and norepinephrine in dogs (222) 265
Hisayama, T., see Moritoki, H. (210) 61
Hishikawa, K., Nakaki, T., Suzuki, H., Saruta, T. and Kato, R.
Transmural pressure inhibits nitric oxide release from human endothelial cells (215) 329
Hitosugi, H., see Kamei, J. (224) 39
Hjorth, S. and Tao, R.
The putative 5-HT_{1B} receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969 (209) 249
Hjorth, S.
(−)-Penbutolol as a blocker of central 5-HT_{1A} receptor-mediated responses (222) 121
Hlaváček, J., see Maletínská, L. (222) 233
Hmaidan, Y., see Rossetti, Z.L. (221) 227
Hobara, T., see Ogino, K. (212) 9
Hobara, T., see Ogino, K. (219) 493
Hofman, G., see Van Oosterhout, A.J.M. (209) 237
Hogaboam, C.M., Donigi-Gale, D., Shoupe, T.S. and Wallace, J.L.
PF-5901 inhibits gastrointestinal platelet-activating factor synthesis in vivo (216) 315
Högberg, T., see Marcusson, J.O. (215) 191
Högestätt, E.D., see Grundemar, L. (221) 71
Hohlweg, R., see Andersen, P.H. (219) 45
Holani, R., see Case, C.L. (218) 213
Hollingsworth, M., see Piper, I. (219) 347
Holmes, P.V. and Drugan, R.C.
Angiotensin II rapidly modulates the renal peripheral benzodiazepine receptor (226) 189
Holopainen, I., Rau, C. and Wojcik, W.J.
Proposed antagonists at $GABA_B$ receptors that inhibit adenylyl cyclase in cerebellar granule cell cultures of rat (227) 225
Holtzman, S.G., see Jones, D.N.C. (215) 345
Holtzman, S.G., see Jones, D.N.C. (221) 161
Holycross, B.J. and Jackson, E.K.
Effects of chronic treatment with caffeine on kidney responses to angiotensin II (219) 361
Holzmann, S., Kukovetz, W.R., Braida, C. and Pöch, G.
Pharmacological interaction experiments differentiate between glibenclamide-sensitive K^+ channels and cyclic GMP as components of vasodilation by nicorandil (215) 1
Hönack, D., see Dziki, M. (222) 273
Hönack, D., see Löscher, W. (215) 199
Hong, A., see Lundy, P.M. (225) 51
Hong, Y. and Henry, J.L.
NMDA receptor antagonists block cardiovascular responses to intrathecal administration of D-baclofen in the rat (216) 257
Honscha, W., Ottallah, M., Schenk, A., Schuh, K. and Petzinger, E.
Separation and purification by two-dimensional gel electrophoresis of a 52–54 kDa bumetanide binding protein from rat liver plasma membranes (226) 215
Hood, J.S., see Nossaman, B.D. (213) 1
Hoogsteden, H.C., see Beusenberg, F.D. (228) 57
Hooper, M.L., see Chiasson, B.J. (227) 451
Hoque, A.N.E., see Nasa, Y. (213) 171
Horacek, J., see Lefebvre, R.A. (214) 1
Horii, A., see Okakura, K. (213) 189
Horikawa, Y., see Kawai, M. (211) 195
Horisaka, K., see Yamada, J. (216) 307
Horiuchi, A., see Iwatsuki, K. (209) 63
Horn, P.T. and Kohli, J.D.
Studies on the location of catecholamine receptors in canine sympathetic ganglia (224) 103
Horowski, R., see Lange, K.W. (212) 247
Horton, R.W., see Lowther, S. (222) 137
Horváth, G., Gyévai, A., Rappay, G., Makara, G.B. and Nagy, I.
Influence of oligopeptide aldehydes on intracellular Ca^{2+} concentration in rat pituitary cells (225) 305
Hosoki, R., see Yanagisawa, M. (220) 111
Houck, W.T., see Sawutz, D.G. (227) 309
Hough, C.J., see Lesch, K.P. (227) 233
Hough, L.B. and Nalwalk, J.W.
Inhibition of morphine antinociception by centrally administered histamine H_2 receptor antagonists (215) 69
Howard, J.L., see Pollard, G.T. (221) 297
Howard, P.G., MacLeod, B.A. and Walker, M.J.A.
Quinacainol, a new antiarrhythmic with Class I antiarrhythmic actions in the rat (219) 1
Howard, S., Chan-Yeung, M., Martin, L., Phaneuf, S. and Salari, H.
Polyphosphoinositide hydrolysis and protein kinase C activation in guinea pig tracheal smooth muscle cells in culture by leukotriene D_4 involve a pertussis toxin sensitive G-protein (227) 123
Howbert, J.J., see Rasmussen, K. (209) 135
Hoyer, D., see Bruinvels, A.T. (227) 357
Hsieh, G.-C., Sharma, R.P., Parker, R.D.R. and Coulombe, Jr., R.A.
Immunological and neurobiochemical alterations induced by repeated oral exposure of phenol in mice (228) 107
Hsieh, S.-T., see Tsujino, T. (226) 69
Hu, P.-S., Benishin, C. and Fredholm, B.B.
Comparison of the effects of four dendrotoxin peptides, 4-aminopyridine and tetraethylammonium on the electrically evoked [^{3}H]noradrenaline release from rat hippocampus (209) 87
Huang, E., see Cheng, J. (226) 15
Huang, F.Y., see Tseng, L.F. (215) 309
Huang, H.-C., Chang, J.-H., Tung, S.-F., Wu, R.-T., Foegh, M.L. and Chu, S.-H.
Immunosuppressive effect of emodin, a free radical generator (211) 359
Huang, H.-C., Huang, Y.-L., Chang, J.-H., Chen, C.-C. and Lee, Y.-T.
Possible mechanism of immunosuppressive effect of scoparone (6,7-dimethoxycoumarin) (217) 143
Huang, H.-C., Jan, T.-R. and Yeh, S.-F.
Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation (221) 381
Huang, H.-C., Lee, C.-R., Weng, Y.-I., Lee, M.-C. and Lee, Y.-T.
Vasodilator effect of scoparone (6,7-dimethoxycoumarin) from a Chinese herb (218) 123
Huang, H.Y., see Jackisch, R. (226) 245
Huang, T.-F., see Ko, F.-N. (218) 129
Huang, T.-F., see Ko, F.-N. (219) 29
Huang, X.-p., see Hampson, D.R. (218) 1
Huang, Y.-L., see Huang, H.-C. (217) 143
Huang, Z., see Matsubara, T. (224) 145
Hubert, G.W., see Robertson, G.S. (219) 323
Hudson, G.M., Marquis, K.L., Stamidis, H. and Young, G.A.
Cholecystokinin octapeptide alters morphine-induced effects on EEG power spectra both quantitatively and qualitatively (221) 217
Huggler, E., see Krause, K.-H. (227) 221
Hughes, J., see Campbell, B.J. (209) 231

Hughes, S.R., Buckley, T.L. and Brain, S.D.
Olvanil: more potent than capsaicin at stimulating the efferent function of sensory nerves (219) 481
Huhtala, H., see Arvola, P. (214) 289
Huizinga, J.D., see Barajas-López, C. (221) 51
Humphreys, T.M., see Schmidt, C.J. (220) 151
Huston, J.P., see Boix, F. (216) 103
Huwiler, A., see Pfeilschifter, J. (225) 57
Hylden, J.L.K., see Ren, K. (219) 235
Hyttel, J., see Arnt, J. (213) 259

Ialenti, A., Ianaro, A., Moncada, S. and Di Rosa, M.
Modulation of acute inflammation by endogenous nitric oxide (211) 177
Ianaro, A., see Ialenti, A. (211) 177
Iannone, M., see Bagetta, G. (213) 301
Ibayashi, S., see Sadoshima, S. (224) 109
Ibrahim, I.N., see Nossaman, B.D. (213) 1
Ichihara, K., Nabeshima, T. and Kameyama, T.
Effects of dopamine receptor agonists on passive avoidance learning in mice: interaction of dopamine D_1 and D_2 receptors (213) 243
Ichihara, K., see Nasa, Y. (213) 171
Ichihara, K., see Okumura, K. (215) 253
Iglesias, V., Alguacil, L.F., Alamo, C. and Cuenca, E.
Effects of yohimbine on morphine analgesia and physical dependence in the rat (211) 35
Igwemezie, L.N., Beatch, G.N., McErlane, K.M. and Walker, M.J.A.
Mexiletine's antifibrillatory actions are limited by the occurrence of convulsions in conscious animals (210) 271
Iino, T., Katsura, M. and Kuriyama, K.
Protective effect of vinconate on ischemia-induced neuronal damage in the rat hippocampus (224) 117
IJzerman, A.P., see Van der Bent, A. (226) 327
Ikeda, H., Dawes, E. and Hankins, M.
Spontaneous firing level distinguishes the effects of NMDA and non-NMDA receptor antagonists on the ganglion cells in the cat retina (210) 53
Ikeda, K., see Yoshida, M. (222) 205
Ikegaki, I., see Satoh, S.-i. (220) 243
Ikegami, K., see Matsumoto, Y. (213) 167
Ikemoto, F., see Mino, N. (221) 77
Ikemoto, Y., Yoshida, A. and Oda, M.
Blockade by trifluoperazine of a Ca^{2+}-activated K^+ channel in rat hippocampal pyramidal neurons (216) 191
Illes, P., see Bott, A. (213) 141
Illes, P., see Tschöpl, M. (213) 71
Imai, T., see Eguchi, S. (225) 79
Imaizumi, A., Lefort, J., Leduc, D., Lellouch-Tubiana, A. and Vargaftig, B.B.
Pertussis toxin induces bronchopulmonary hyperresponsiveness in guinea-pigs while antagonizing the effects of formyl-L-methionyl-L-leucyl-L-phenylalanine (212) 177
Imhoff, V., see Rollandy, I. (209) 95
Imperato, A., Mele, A., Scrocco, M.G. and Puglisi-Allegra, S.
Chronic cocaine alters limbic extracellular dopamine. Neurochemical basis for addiction (212) 299
Imperato, A., see Sigala, S. (211) 351
Impicciatore, M., see Revel, L. (216) 217
Improta, G., see Broccardo, M. (218) 69
Imura, H., see Himeno, A. (215) 337
Imura, N., see Tanaka, T. (228) 9
Inagaki, C., see Inoue, M. (221) 135
Inagaki, N., see Miura, T. (221) 333
Inagami, T., see Chaki, S. (225) 355
Inagami, T., see Morishita, Y. (225) 203
Inomata, H., Ji, J.J. and Utagawa, A.
Possible involvement of Ca^{2+}-related inward current in P_2-purinoceptor-mediated depolarization of the guinea-pig vas deferens (217) 93
Inostroza, H., see Pérez, H. (213) 435
Inoue, K., Nakazawa, K., Watano, T., Ohara-Imaizumi, M., Fujimori, K. and Takanaka, A.
Dopamine receptor agonists and antagonists enhance ATP-activated currents (215) 321
Inoue, M., Hirose, T., Yasukura, T. and Inagaki, C.
Ethacrynic acid-induced convulsions and brain neurotransmitters in mice (221) 135
Inui, J., see Itoh, H. (218) 347
Inui, J., see Matsumoto, Y. (213) 167
Inukai, T., see Shimomura, Y. (209) 15
Ioculano, M., see Squadrito, F. (210) 107
Ioculano, M., see Zingarelli, B. (222) 13
Iorio, L.C., see Tedford, C.E. (211) 169
Iredale, P.A., Martin, K.F., Hill, S.J. and Kendall, D.A.
Agonist-induced changes in $[Ca^{2+}]_i$ in N1E-115 cells: differential effects of bradykinin and carbachol (226) 163
Irie, K., see Masumura, H. (210) 163
Irie, K., see Muraki, T. (226) 311
Isaac, L., see Pandey, G.N. (226) 303
Ishihara, K., see Renming, X. (223) 185
Ishihara, M., see Yamamoto, S. (227) 113
Ishihara, S.-i., see Hiramatsu, M. (216) 279
Ishihara, T., see Kawai, M. (211) 195
Ishii, A., see Miki, I. (227) 199
Ishii, T., see Kai, H. (220) 181
Ishii, T., see Kanada, A. (216) 287
Ishii, Y. and Sumi, T.
Amitriptyline inhibits striatal efflux of neurotransmitters via blockade of voltage-dependent Na^+ channels (221) 377
Ishikawa, H., see Notsu, T. (220) 35
Ishikawa, K., see Mino, N. (221) 77
Ishikawa, M., see Namiki, A. (227) 339
Ishine, T., Miyauchi, Y., Gokita, T., Matsuo, K. and Uchida, M.K.
Ca^{2+}-dependent inhibition of Ca^{2+}-independent contraction in uterine smooth muscle (219) 285
Ishiyama, H., see Ogino, K. (212) 9
Ishiyama, H., see Ogino, K. (219) 493
Ishizaki, R., see Kojima, S.-i. (224) 45
Iso, Y., see Harada, J. (227) 301
Isohama, Y., see Kai, H. (212) 101
Isohama, Y., see Kai, H. (220) 181
Isom, G.E., see Giridhar, J. (213) 317
Itabashi, S., Aikawa, T., Sekizawa, K., Sasaki, H. and Takishima, T.
Evidence that an atypical β-adrenoceptor mediates the prejunctional inhibition of non-adrenergic non-cholinergic contraction in guinea-pig bronchi (218) 187
Itazaki, K., see Fujimoto, M. (215) 259
Ito, T., see Yoshida, N. (216) 435
Ito, Y., see Morikawa, K. (213) 409
Itoh, H., Sato, Y., Taniguchi, K., Nakagawa, H., Inui, J. and Takeuchi, J.
Differences between vasorelaxant responses of the canine and human mesenteric arteries and veins to amrinone (218) 347
Itoh, T., see Kamisaki, Y. (217) 57
Itoh, T., see Suzuki, S. (217) 97
Itoh, T., see Takao, Y. (215) 245
Itoi, K., Tschöpe, C., Jost, N., Culman, J., Lebrun, C., Stauss, B. and Unger, T.
Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats (219) 435
Itskovitz, H.D., see Stier Jr., C.T. (210) 217
Iversen, L.L., see Freedman, S.B. (215) 135

Ivorra, M.D., Cercós, A., Zafra-Polo, M.C., Perez-Prieto, J., Sáez, J., Cortes, D. and D'Ocon, P.
Selective chiral inhibition of Ca^{2+} entry promoted by bisbenzyltetrahydroisoquinolines in rat uterus (219) 303
Ivy Carroll, F., see Rostène, W. (218) 175
Iwamoto, T., Harada, K., Nakajima, F. and Sukamoto, T.
Effects of ouabain on muscle tension and intracellular Ca^{2+} level in guinea-pig aorta (224) 71
Iwamoto, Y., see Kamei, J. (224) 39
Iwao, H., see Nishiyama, A. (218) 311
Iwatsuki, K., Horiuchi, A., Ren, L.-M. and Chiba, S.
Effects of the cyclic nucleotide phosphodiesterase inhibitors, rolipram, 3-isobutyl-1-methylxanthine, amrinone and zaprinast, on pancreatic exocrine secretion in dogs (209) 63
Iwatsuki, K., Ren, L.-M. and Chiba, S.
Effects of YM435, a novel dopamine D_1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs (218) 237
Izawa, T., see Komabayashi, T. (225) 209
Izumi, Y., see Ogino, K. (212) 9
Izumi, Y., see Ogino, K. (219) 493

Jackisch, R., Huang, H.Y., Rensing, H., Lauth, D., Allgaier, C. and Hertting, G.
α_2-Adrenoceptor mediated inhibition of exocytotic noradrenaline release in the absence of extracellular Ca^{2+} (226) 245
Jackson, D.M., Pollard, C.E. and Roberts, S.M.
The effect of nedocromil sodium on the isolated rabbit vagus nerve (221) 175
Jackson, E.K., see Holycross, B.J. (219) 361
Jackson, H.C. and Nutt, D.J.
Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice (221) 199
Jackson, H.C., Ramsay, E. and Nutt, D.J.
Effect of the cyclopyrrolones suriclone and RP 59037 on body temperature in mice (216) 23
Jacobson, A.E., see Reith, M.E.A. (227) 417
Jacobson, J.L., see Ahlborg, U.G. (228) 179
Jacobson, S.W., see Ahlborg, U.G. (228) 179
Jähnig, P., see Lange, K.W. (212) 247
Jäkälä, P., Viitamaa, T., Sirviö, J., Riekkinen, Jr., P., Salonen, J., Haapalinna, A., Virtanen, R. and Riekkinen, P.
Continuous α_2-adrenoceptor blockade by atipamezole decreases neocortical high-voltage spindle activity in rats (221) 351
Jakobs, K.H., see Hilf, G. (225) 245
Jakubicki, R., see Chand, N. (211) 121
Jan, T.-R., see Huang, H.-C. (221) 381
Jancar, S., see Tavares de Lima, W. (213) 63
Jansen, F.P., Rademaker, B., Bast, A. and Timmerman, H.
The first radiolabeled histamine H_3 receptor antagonist, [^{125}I]iodophenpropit: saturable and reversible binding to rat cortex membranes (217) 203
Jansen, K.L.R., Elliot, M. and Leslie, R.A.
σ Receptors in rat brain and testes show similar reductions in response to chronic haloperidol (214) 281
Jansen, W., see Leurs, R. (225) 137
Janssen, M., see Folkerts, G. (228) 219
Janssen, P.F.M., see Schotte, A. (218) 373
Jard, S., see Mouillac, B. (225) 179
Jardon, B., Bonaventure, N. and Scherrer, E.
Possible involvement of cholinergic and glycinergic amacrine cells in the inhibition exerted by the ON retinal channel on the OFF retinal channel (210) 201
Järlebark, L. and Heilbronn, E.
Tetrahydroaminoacridine and related compounds interfere with fura-2 and indo-1 (225) 75
Jarrott, B., see King, P.R. (218) 101
Jarvis, M.F., Gessner, G.W. and Ly, C.Q.
The angiotensin hexapeptide 3–8 fragment potently inhibits [^{125}I]angiotensin II binding to non-AT_1 or -AT_2 recognition sites in bovine adrenal cortex (219) 319
Jauzac, P., see Polastron, J. (226) 133
Jaworek, J., Konturek, P.K., Konturek, S.J., Cai, R.-Z. and Schally, A.V.
Actions of novel bombesin receptor antagonists on pancreatic secretion in rats (214) 239
Jayasekara, S., Sharma, R.P. and Drown, D.B.
Effects of N-ethyl,N-nitrosourea on monoamine concentrations and metabolizing enzymes in mouse brain regions (228) 37
Jenner, P., see Lange, K.W. (212) 247
Jenner, P., see Taylor, M.D. (219) 183
Jeremy, J.Y., see Gill, J.K. (214) 269
Ji, J.J., see Inomata, H. (217) 93
Jiang, C., Sarrel, P.M., Lindsay, D.C., Poole-Wilson, P.A. and Collins, P.
Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro (211) 163
Jiang, H., see Yamamoto, S. (227) 113
Jimenez Del Rio, M., Pinxteren, J., De Potter, W., Ebinger, G. and Vauquelin, G.
Serotonin-binding proteins in the bovine cerebral cortex: interaction with serotonin and catecholamines (225) 225
Johns, E.J., see Chamienia, A.L. (218) 319
Johnson, K.M., Bergmann, J.S. and Kozikowski, A.P.
Cocaine and dopamine differentially protect [^{3}H]mazindol binding sites from alkylation by N-ethylmaleimide (227) 411
Johnson, K.M., see Lonart, G. (220) 271
Johnson, M., see Elayan, I. (221) 281
Johnson, M., see Hanson, G.R. (218) 287
Jokela, R., see Strömbom, J. (214) 165
Jones, D.N.C. and Holtzman, S.G.
Effects of naloxone infusion upon spontaneous and amphetamine-induced activity (221) 161
Jones, D.N.C. and Holtzman, S.G.
Long term κ-opioid receptor blockade following nor-binaltorphimine (215) 345
Jones, D.N.C., Barnes, N.M., Costall, B., Domeney, A.M., Kilpatrick, G.J., Naylor, R.J. and Tyers, M.B.
The distribution of 5-HT_3 recognition sites in the marmoset brain (215) 63
Jones, R.B., see Frodsham, G. (211) 383
Jones, S.M., see Harding, S.E. (223) 39
Jonsson, B., see Larsson, R. (228) 237
Jonsson, J.R., Head, R.J. and Frewin, D.B.
Effect of α_1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat (211) 263
Jorens, P.G., Rosseneu, M., Devreese, A.-M., Bult, H., Marescau, B. and Herman, A.G.
Diminished capacity to release metabolites of nitric oxide synthase in macrophages loaded with oxidized low-density lipoproteins (212) 113
Jorens, P.G., Van Overveld, F.J., Vermeire, P.A., Bult, H. and Herman, A.G.
Synergism between interleukin-1β and interferon-γ, an inducer of nitric oxide synthase, in rat lung fibroblasts (224) 7
Jost, N., see Itoi, K. (219) 435
Jouvet, M., see Petit, J.-M. (212) 79
Joyce, J.N., see Murray, A.M. (227) 443
Judge, M.E., see Fink-Jensen, A. (220) 197
Juhász, G., Kékesi, K.A., Emri, Z., Ujszászi, J., Krogsgaard–Larsen, P. and Schousboe, A.
Sleep promoting effect of a putative glial γ-aminobutyric acid uptake blocker applied in the thalamus of cats (209) 131
Jukic, D., see Rhaleb, N.-E. (210) 115
Jukic, D., see Tousignant, C. (225) 235

Julou-Schaeffer, G., see Schneider, F. (211) 269
Junien, J.L., see Yoneda, M. (223) 197
Junquero, D.C., see Schini, V.B. (216) 379
Juorio, A.V., see Li, X.-M. (210) 189
Jurásková, V., Dyatlova, N. and Brabec, V.
Interferon inducer, polyriboguanylic · polyribocytidylic acid, inhibits experimental hepatic metastases in mice (221) 107
Jurkiewicz, A., see Caricati-Neto, A. (218) 51
Just, I., see Koch, G. (226) 87

Kadowitz, P.J., see Nossaman, B.D. (213) 1
Kagami-ishi, Y., Shibata, S. and Watanabe, S.
Neuroprotective effect of 5-HT_3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices (224) 51
Kai, H., Isohama, Y., Takaki, K., Oda, Y., Murahara, K., Takahama, K. and Miyata, T.
Both β_1- and β_2-adrenoceptors are involved in mediating phosphatidylcholine secretion in rat type II pneumocyte cultures (212) 101
Kai, H., Makise, K., Matsumoto, S., Ishii, T., Takahama, K., Isohama, Y. and Miyata, T.
The influence of neuraminidase treatment on tracheal smooth muscle contraction (220) 181
Kajikuri, J., see Suzuki, S. (217) 97
Kalbfleisch, J., see Kostrzewa, R.M. (209) 157
Kalenak, A., see Von Lubitz, D.K.J.E. (216) 37
Kalso, E.A., Sullivan, A.F., McQuay, H.J. and Dickenson, A.H.
Spinal antinociception by Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr, a selective δ-opioid receptor agonist (216) 97
Kalso, E.A., see Sullivan, A.F. (215) 127
Kamada, T., see Kawano, S. (211) 55
Kamal, J., see Maguire, P. (213) 219
Kamei, J. and Kasuya, Y.
Antitussive effects of Ca^{2+} channel antagonists (212) 61
Kamei, J. and Kasuya, Y.
The effect of hydrochlorothiazide on the enhanced coughing associated with treatment with enalapril (213) 137
Kamei, J., Iwamoto, Y., Kawashima, N., Hitosugi, H., Misawa, M. and Kasuya, Y.
Involvement of haloperidol-sensitive σ-sites in antitussive effects (224) 39
Kamei, J., Kawashima, N. and Kasuya, Y.
Naloxone-induced analgesia in diabetic mice (210) 339
Kamenka, J.-M., see Chergui, K. (219) 169
Kameyama, T., see Hiramatsu, M. (216) 279
Kameyama, T., see Ichihara, K. (213) 243
Kameyama, T., see Nabeshima, T. (223) 109
Kameyama, T., see Toyoshi, T. (213) 25
Kameyama, T., see Ukai, M. (222) 7
Kameyama, T., see Yoshida, S. (214) 247
Kamisaki, Y., Hamahashi, T., Hamada, T., Maeda, K. and Itoh, T.
Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions (217) 57
Kamisaki, Y., see Takao, Y. (215) 245
Kanada, A., Hata, F., Suthamnatpong, N., Maehara, T., Ishii, T., Takeuchi, T. and Yagasaki, O.
Key roles of nitric oxide and cyclic GMP in nonadrenergic and noncholinergic inhibition in rat ileum (216) 287
Kanai, Y., see Nagahisa, A. (217) 191
Kane, K., see McIntosh, M. (210) 37
Kane, K., see McIntosh, M. (210) 45
Kaneda, H., Shirakawa, O., Dale, J., Goodman, L., Bachus, S.E. and Tamminga, C.A.
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats (212) 43
Kanno, K., see Eguchi, S. (225) 79
Kanno, M., see Hattori, Y. (213) 147
Kanno, M., see Shida, S. (212) 267
Karaki, H., see Abe, A. (211) 305
Karaki, H., see Kim, B.K. (223) 157
Karaki, H., see Sakata, K. (221) 9
Karaki, H., see Sanagi, M. (222) 247
Karanian, J., see Morgan, P.F. (225) 217
Karibe, H., see Fukuzaki, A. (220) 99
Karlsson, S. and Ahrén, B.
CCK-8-stimulated insulin secretion in vivo is mediated by CCK_A receptors (213) 145
Karlsson, U., see Näsström, J. (212) 21
Karmazyn, M., see Duan, J. (210) 149
Karoum, F., see Chrapusta, S.J. (222) 129
Kase, H., see Miki, I. (227) 199
Kase, H., see Morishita, Y. (225) 203
Kashimoto, T., see Mikami, M. (210) 91
Kasuya, Y., see Kamei, J. (210) 339
Kasuya, Y., see Kamei, J. (212) 61
Kasuya, Y., see Kamei, J. (213) 137
Kasuya, Y., see Kamei, J. (224) 39
Kataoka, Y., see Himeno, A. (215) 337
Kataoka, Y., see Niwa, M. (225) 281
Kato, H., see Morikawa, K. (213) 409
Kato, J. and Currie, M.G.
Suppression of atrial natriuretic peptide (ANP) receptor recovery from homologous down-regulation by 8-bromo-cGMP in endothelial cells (225) 113
Kato, K., see Shinkawa, T. (219) 217
Kato, M., see Sugawara, T. (228) 147
Kato, R., see Hishikawa, K. (215) 329
Kato, R., see Nakaki, T. (219) 311
Kato, R., see Yamamoto, S. (227) 113
Kato, S., see Yoshida, N. (216) 435
Katoh, A., see Eigyo, M. (214) 149
Katoh, A., see Eigyo, M. (219) 487
Katsura, M., see Iino, T. (224) 117
Katsuura, G., see Eigyo, M. (214) 149
Katsuura, G., see Eigyo, M. (219) 487
Katz, J.L., see Schindler, C.W. (213) 99
Kauffman, G., see Saperas, E. (209) 1
Kawabata, A., Fukuzumi, Y., Fukushima, Y. and Takagi, H.
Antinociceptive effect of L-arginine on the carrageenin-induced hyperalgesia of the rat: possible involvement of central opioidergic systems (218) 153
Kawagoe, J.-i., see Hara, H. (209) 195
Kawaguchi, T., see Niwa, M. (225) 281
Kawai, M., Horikawa, Y., Ishihara, T., Shimamoto, K. and Ohfune, Y.
2-(Carboxycyclopropyl)glycines: binding, neurotoxicity and induction of intracellular free Ca^{2+} increase (211) 195
Kawanami, T., Morinobu, S., Totsuka, S. and Endoh, M.
Influence of stress and antidepressant treatment on 5-HT-stimulated phosphoinositide hydrolysis in rat brain (216) 385
Kawano, S., Tanimura, H., Sato, N., Tsuji, S., Takei, Y., Ogihara, T., Nagano, K., Fusamoto, H. and Kamada, T.
Effects of proton pump inhibitor on gastric mucosa hemodynamics and tissue oxygenation in anesthetized rats (211) 55
Kawase, T. and Van Breemen, C.
Aluminum fluoride induces a reversible Ca^{2+} sensitization in α-toxin-permeabilized vascular smooth muscle (214) 39
Kawashima, N., see Kamei, J. (210) 339
Kawashima, N., see Kamei, J. (224) 39
Kayser, V., Besson, J.-M. and Guilbaud, G.
Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat (224) 83

Keane, P.E., see Simiand, J. (219) 193
Keiler, A., see Sinzinger, H. (219) 129
Keilhoff, G. and Wolf, G.
Memantine prevents quinolinic acid-induced hippocampal damage (219) 451
Kékesi, K.A., see Juhász, G. (209) 131
Kelley, K.W., see Bluthé, R.-M. (209) 281
Kelly, M.E., see Barnes, N.M. (218) 15
Kelly, M.E., see Barnes, N.M. (218) 91
Kemp, P.A., see Gardiner, S.M. (213) 449
Kendall, D.A., see Iredale, P.A. (226) 163
Kennedy, B., see Elayan, H. (212) 259
Kennedy, R.H., see Ruch, S. (216) 393
Kennedy, S.W., see Ahlborg, U.G. (228) 179
Kerman, L.L., see Dunn, R.W. (214) 207
Kerr, D.I.B., see Ong, J. (218) 343
Kerr, D.I.B., see Ong, J. (221) 145
Kessler, R.M., Mason, N.S., Votaw, J.R., De Paulis, T., Clanton, J.A., Ansari, M.S., Schmidt, D.E., Manning, R.G. and Bell, R.L.
Visualization of extrastriatal dopamine D_2 receptors in the human brain (223) 105
Kettrup, A.A.F., see Ahlborg, U.G. (228) 179
Khatter, J.C. and Navaratnam, S.
Enhancement in myocardial inotropic response to BAY K 8644 with advancing age (216) 351
Khristen Basham, J., see Carr, L.A. (215) 285
Khuenl-Brady, K.S., Mair, P. and Koller, J.
Antagonism of vecuronium by one of its metabolites in vitro (222) 153
Kidd, E., Bouchelet de Vendegies, I., Levy, J.-C., Hamon, M. and Gozlan, H.
The potent 5-HT_3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system (211) 133
Kigoshi, S., see Hashimoto, S. (213) 117
Kikuchi de Beltrán, K., Koshikawa, N., Saigusa, T., Watanabe, K., Koshida, Y. and Kobayashi, M.
Cholinergic/dopaminergic interaction in the rat striatum assessed from drug-induced repetitive oral movements (214) 181
Kikuchi de Beltrán, K., see Koshikawa, N. (209) 75
Kilbourn, M.R., Sherman, P.S. and Pisani, T.
Repeated reserpine administration reduces in vivo [^{18}F]GBR 13119 binding to the dopamine uptake site (216) 109
Killam, A.L. and Cohen, M.L.
Presence of β- but not α-adrenoceptors in the rat jugular vein: autoradiographical evidence (218) 295
Killingsworth, C.R. and Robinson, N.E.
The role of muscarinic M_1 and M_2 receptors in airway constriction in the cat (210) 231
Kilpatrick, G.J., see Jones, D.N.C. (215) 63
Kim, B.K., Mitsui, M. and Karaki, H.
The long-term inhibitory effect of a Ca^{2+} channel blocker, nisoldipine, on cytosolic Ca^{2+} and contraction in vascular smooth muscle (223) 157
Kim, Y.S., see Molenaar, P. (209) 257
Kimber, N.D., see Klabunde, R.E. (223) 1
Kimura, B., see Bui, J.D. (219) 147
Kimura, I., see Yamada, J. (216) 307
Kinbara, K., see Yoshida, S. (214) 247
Kindgen-Milles, D. and Klement, W.
Pain and inflammation evoked in human skin by bradykinin receptor antagonists (218) 183
King, A., see Miller, K.J. (227) 99
King, K.A., see Tabrizchi, R. (219) 141
King, P.R., Gundlach, A.L., Jarrott, B. and Louis, W.J.
α_2-Adrenoceptor and catecholamine-insensitive binding sites for [^{3}H]rilmenidine in membranes from rat cerebral cortex (218) 101
King, R.G., see Callaway, J.K. (220) 187
Kinter, C.M., see Lever, J.R. (216) 459
Kirino, Y., see Tokumaru, H. (227) 363
Kisara, K., see Sakurada, S. (211) 75
Kiseleva, V.I., see Vrána, O. (226) 5
Kish, S.J., Wilson, J.M. and Fletcher, P.J.
The polyamine synthesis inhibitor α-difluoromethylornithine is neuroprotective against N-methyl-D-aspartate-induced brain damage in vivo (209) 101
Kishimoto, T., see Okamiya, Y. (222) 99
Kiss, B., Cai, N.-s. and Erdö, S.L.
Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies (209) 109
Kitabgi, P., see Dubuc, I. (219) 327
Kitamori, S., see Tsuji, K. (210) 213
Kiyomoto, H., see Nishiyama, A. (218) 311
Klabunde, R.E., Kimber, N.D., Kuk, J.E., Helgren, M.C. and Förstermann, U.
N^G-Methyl-L-arginine decreases contractility, cGMP and cAMP in isoproterenol-stimulated rat hearts in vitro (223) 1
Klee, A., Schmid-Schönbein, G.W. and Seiffge, D.
Effects of platelet activating factor on rat platelets in vivo (209) 223
Klement, W., see Kindgen-Milles, D. (218) 183
Klint, T., Dahlgren, I.L. and Larsson, K.
The selective 5-HT_2 receptor antagonist amperozide attenuates 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane-induced inhibition of male rat sexual behavior (212) 241
Knight, M., see Bill, D.J. (218) 327
Knock, G.A., Wharton, J., Gaer, J.A.R., Yacoub, M.H., Taylor, K.M. and Polak, J.M.
Regional distribution and regulation of [^{125}I]calcitonin gene-related peptide binding sites in coronary arteries (219) 415
Knolle, J., see Rhaleb, N.-E. (210) 115
Knutsen, L.J.S., see Suzdak, P.D. (224) 189
Ko, F.-N., Wu, T.-S., Liou, M.-J., Huang, T.-F. and Teng, C.-M.
PAF antagonism in vitro and in vivo by aglafoline from *Aglaia elliptifolia* Merr (218) 129
Ko, F.-N., Wu, T.-S., Liou, M.-J., Huang, T.-F. and Teng, C.-M.
Vasorelaxation of rat thoracic aorta caused by osthole isolated from *Angelica pubescens* (219) 29
Ko, Y., Görg, A., Appenheimer, M., Wieczorek, A.J., Düsing, R., Vetter, H. and Sachinidis, A.
Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells (227) 215
Kobayashi, A., Fujita, K. and Nakazawa, K.
In rat brain amoxapine enhances dopamine metabolism: pharmacokinetic variations of the effect (215) 43
Kobayashi, H., see Ogino, K. (212) 9
Kobayashi, H., see Ogino, K. (219) 493
Kobayashi, I., see Shimizu, H. (222) 279
Kobayashi, I., see Shimomura, Y. (209) 15
Kobayashi, M., see Kikuchi de Beltrán, K. (214) 181
Kobayashi, M., see Koshikawa, N. (209) 75
Kobayashi, M., see Mino, N. (221) 77
Kobayashi, S., see Shimomura, Y. (209) 15
Kobayashi, Y., see Shinozuka, K. (222) 113
Koch, G., Habermann, B., Mohr, C., Just, I. and Aktories, K.
ADP-ribosylation of rho proteins is inhibited by melittin, mast cell degranulating peptide and compound 48/80 (226) 87
Koda, A., see Miura, T. (221) 333
Kodama, K., see Shibata, S. (221) 113
Kodama, K., see Shibata, S. (221) 255
Koekkoek-Van den Herik, I., see Van de Heijning, B.J.M. (209) 199
Koeman, J.H., see Ahlborg, U.G. (228) 179

Koga, Y., Satoh, S., Sodeyama, N., Hashimoto, Y., Yanagisawa, T. and Hirshman, C.A.
Role of acetylcholinesterase in airway epithelium-mediated inhibition of acetylcholine-induced contraction of guinea-pig isolated trachea (220) 141
Kogan, J.H., Nestler, E.J. and Aghajanian, G.K.
Elevated basal firing rates and enhanced responses to 8-Br-cAMP in locus coeruleus neurons in brain slices from opiate-dependent rats (211) 47
Kogo, H., Takasaki, K., Takeo, S., Watanabe, G., Taya, K. and Sasamoto, S.
Indomethacin inhibits the secretion of inhibin and oestradiol-17β stimulated by pregnant mare serum gonadotrophin in the immature female rat (221) 289
Kogo, H., Takasaki, K., Yatabe, Y., Nishikawa, M., Takeo, S. and Tamura, K.
Inhibitory and stimulatory actions of danazol in rat ovarian and uterine tissues (211) 69
Kogure, K., see Hara, H. (209) 195
Kohlhaas, K.L., see Förstermann, U. (225) 161
Kohli, J.D., see Horn, P.T. (224) 103
Koide, T., see Hiramatsu, M. (216) 279
Koide, T., see Sugawa, M. (215) 57
Kojima, C., see Satoh, M. (221) 35
Kojima, S.-i., Ishizaki, R. and Shimo, Y.
Investigation into the 5-hydroxytryptamine-induced relaxation of the circular smooth muscle of guinea-pig stomach fundus (224) 45
Kolesnikov, Y.A., Pick, C.G. and Pasternak, G.W.
N^G-Nitro-L-arginine prevents morphine tolerance (221) 399
Koller, J., see Khuenl-Brady, K.S. (222) 153
Komabayashi, T., Yakata, A., Izawa, T., Fujinami, H., Suda, K. and Tsuboi, M.
Mechanism of carbachol-stimulated diacylglycerol formation in rat parotid acinar cells (225) 209
Komajda, M., see Zongazo, M.A. (209) 45
Kondo, H., see Temma, K. (220) 63
Kondo, Y., see Tada, S. (227) 25
Kondo, Y., see Tomura, H. (226) 363
Konno, K., see Tamaoki, J. (220) 87
Kontny, E., Kvanta, A. and Fredholm, B.B.
Activation of protein kinase C and elevation of cAMP interact synergistically to raise c-Fos and AP-1 activity in Jurkat cells (227) 333
Konturek, P.K., see Jaworek, J. (214) 239
Konturek, S.J., Brzozowski, T., Majka, J. and Czarnobilski, K.
Role of nitric oxide and prostaglandins in sucralfate-induced gastroprotection (211) 277
Konturek, S.J., see Jaworek, J. (214) 239
Korpi, E.R., Lüddens, H. and Seeburg, P.H.
$GABA_A$ antagonists reveal binding sites for [^{35}S]TBPS in cerebellar granular cell layer (211) 427
Korpi, E.R., Uusi-Oukari, M. and Wegelius, K.
Substrate specificity of diazepam-insensitive cerebellar [^{3}H]Ro 15-4513 binding sites (213) 323
Korte, A., see Clark, M.A. (210) 31
Koshida, Y., see Kikuchi de Beltrán, K. (214) 181
Koshikawa, N., Kikuchi de Beltrán, K., Saigusa, T., Kobayashi, M. and Stephenson, J.D.
Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats (209) 75
Koshikawa, N., see Kikuchi de Beltrán, K. (214) 181
Koss, M.C.
Comparison of peripheral and central nervous system sympatholytic actions of prazosin using the cat nictitating membrane (211) 61
Koster, A.S., see Redegeld, F.A.M. (228) 229
Kostrzewa, R.M., Brus, R. and Kalbfleisch, J.
Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats (209) 157
Kovalchuk, Y.N., see Garaschuk, O.V. (212) 305
Kowatch, M.A., see Villalobos-Molina, R. (226) 129
Kozikowski, A.P., see Johnson, K.M. (227) 411
Kozikowski, A.P., see Reynolds, I.J. (226) 53
Kramer, V., see Miranda, H.F. (217) 137
Krause, K.-H., Van Delden, C., Huggler, E., Monod, A. and Lew, D.P.
Differential effects on neutrophil activation of staurosporin and its protein kinase C-selective derivative cgp 41231 (227) 221
Krča, S., see Kurelec, B. (228) 51
Krell, R.D., see Kusner, E.J. (210) 299
Kreutner, W., see Hey, J.A. (211) 421
Krieglstein, J., see Backhauß, C. (215) 265
Krishtal, O.A., see Garaschuk, O.V. (212) 305
Kristensen, J., see Larsson, R. (228) 237
Kristensen, P., see Thomsen, C. (227) 361
Krogsgaard–Larsen, P., see Juhász, G. (209) 131
Kubota, Y., see Tsujino, T. (226) 69
Kudoh, T., see Kuwahara, T. (221) 99
Kuhar, M.J., see Rostène, W. (218) 175
Kuk, J.E., see Klabunde, R.E. (223) 1
Kukovetz, W.R., see Graier, W.F. (225) 43
Kukovetz, W.R., see Holzmann, S. (215) 1
Kume, S., see Tawata, M. (212) 87
Kunihara, M., Ohyama, M. and Nakano, M.
Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective κ-opioid receptor agonist (214) 111
Kunitada, S., see Masumura, H. (210) 163
Kunos, G., see Varga, K. (214) 223
Kuo, H.-P., Liu, S. and Barnes, P.J.
The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways (221) 385
Kuo, H.-P., Rohde, J.A.L., Barnes, P.J. and Rogers, D.F.
K^+ channel activator inhibition of neurogenic goblet cell secretion in guinea pig trachea (215) 297
Kupsch, A., see Pérez-Otaño, I. (217) 211
Kuraishi, Y., see Ueda, M. (219) 271
Kurelec, B., Garg, A., Krča, S., Britvić, S., Lucić, D. and Gupta, R.C.
DNA adducts in carp exposed to artificial diesel-2 oil slicks (228) 51
Kurihara, M., see Niwa, M. (225) 281
Kuriyama, K., see Hashimoto, M. (209) 9
Kuriyama, K., see Iino, T. (224) 117
Kurose, Y., Yano, H. and Miyazaki, A.
Effect of the β-adrenoceptor antagonist, propranolol, on feeding induced by noradrenaline and muscimol in rats kept at high and temperate-ambient temperatures (211) 39
Kuroume, T., see Arakawa, H. (215) 51
Kusner, E.J., Buckner, C.K., DeHaas, C.J., Lengel, D.J., Marks, R.L. and Krell, R.D.
Tachykinin-induced dyspnea in conscious guinea pigs (210) 299
Kuwabara, A., see Shimomura, Y. (209) 15
Kuwahara, T., Kudoh, T., Nagase, H., Takamiya, M., Nakano, A., Ohtsuka, T., Yoshizaki, H. and Arisawa, M.
Tetronothiodin, a novel CCK_B receptor ligand, antagonizes cholecystokinin-induced Ca^{2+} mobilization in a pituitary cell line (221) 99
Kvanta, A., see Kontny, E. (227) 333
Kwan, C.-Y., see Shimamoto, H. (216) 225

Lad, N., Williams, T.J. and Booth, R.F.G.
Neutrophil infiltration into the ischaemic/reperfused rabbit isolated myocardium: effect of PF-5901 and cycloheximide (223) 163

Laduron, P.M., see Fajolles, C. (216) 53
Laferrère, B., Leroy, F., Bonhomme, G., Le Gall, A., Basdevant, A. and Guy-Grand, B.
Effects of bombesin, of a new bombesin agonist (BIM187) and a new antagonist (BIM189) on food intake in rats, in relation to cholecystokinin (215) 23
Lagarde, M., see Fayard, J.-M. (216) 127
Lagarde, M., see Gharib, A. (225) 359
Lagente, V., see Pons, F. (217) 65
Laher, I., see Henrion, D. (224) 13
Lai, C.-S., see Yen, M.-H. (221) 261
Lajtha, A., see Harsing, Jr., L.G. (218) 117
Lambert, J.J., see Hales, T.G. (210) 239
Lambert, L.E., French, J.F., Whitten, J.P., Baron, B.M. and McDonald, I.A.
Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis (216) 131
Lambert, N.A., see Lovinger, D.M. (211) 337
Lambrecht, G., Friebe, T., Grimm, U., Windscheif, U., Bungardt, E., Hildebrandt, C., Bäumert, H.G., Spatz-Kümbel, G. and Mutschler, E.
PPADS, a novel functionally selective antagonist of P_2 purinoceptor-mediated responses (217) 217
Lambrecht, G., see Bungardt, E. (213) 53
Lambrecht, G., see Bungardt, E. (221) 91
Lambrecht, G., see Eltze, M. (211) 283
Lambrecht, G., see Waelbroeck, M. (227) 33
Lameh, J., Eiger, S. and Sadée, W.
Interaction among μ-opioid receptors and α_2-adrenoceptors on SH-SY5Y human neuroblastoma cells (227) 19
Land, T., see Lindskog, S. (210) 183
Landry, Y., see Da Silva, A. (212) 97
Landwehrmeyer, B., see Bruinvels, A.T. (227) 357
Lane, K.E., see Silverman, P.B. (212) 165
Lang, D. and Lewis, M.J.
The effects of flosequinan on endothelin-1-induced changes in inositol 1,4,5-trisphosphate levels and protein kinase C activity in rat aorta (226) 259
Lang, F., see Wöll, E. (212) 105
Lange, K.W., Löschmann, P.-A., Wachtel, H., Horowski, R., Jähnig, P., Jenner, P. and Marsden, C.D.
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets (212) 247
Langel, Ü., see Lindskog, S. (210) 183
Langer, S.Z., see Graham, D. (226) 373
Langlands, J.M. and Diamond, J.
Translocation of protein kinase C in bovine tracheal smooth muscle strips: the effect of methacholine and isoprenaline (227) 131
Langlois, X., see Simiand, J. (219) 193
Lanni, C., see Abraham, W.M. (217) 119
Lanthorn, T.H., see Davies, M.S. (227) 51
Lanthorn, T.H., see Flood, J.F. (221) 249
Laorden, M.L., see Garaulet, J.V. (223) 19
Laplace, M.-C., see Herbert, J.M. (216) 175
Laporte, R., see Henrion, D. (224) 13
Lappalainen, J., Hietala, J., Pohjalainen, T. and Syvälahti, E.
Regulation of dopamine D_1 receptors by chronic administration of structurally different D_1 receptor antagonists: a quantitative autoradiographic study (210) 195
Lappe, R.W., see Merkel, L.A. (216) 29
Lark, L.A. and Weyhenmeyer, J.A.
The antihypertensive effect of acute intracerebroventricular administration of captopril in Dahl salt-sensitive rats (222) 33
Larson, A.A., see Budai, D. (216) 441
Larson, A.A., see Mousseau, D.D. (217) 197
Larsson, K., see Fernández-Guasti, A. (210) 121
Larsson, K., see Klint, T. (212) 241
Larsson, R., Jonsson, B., Csoka, K., Kristensen, J., Nilsson, K. and Nygren, P.
Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia (228) 237
Lasheras, B., see Frechilla, D. (219) 409
Laubie, M., see Heuzé-Joubert, I. (220) 161
Laubie, M., see Simonet, S. (216) 135
Laubie, M., see Vayssettes-Courchay, C. (211) 243
Laugier, C., see Fayard, J.-M. (216) 127
Launay, J.-M., see Diochot, S. (227) 427
Lauth, D., see Jackisch, R. (226) 245
Law, S., see McIntosh, C.H.S. (223) 117
Lawrence, D.M.P., see Bidlack, J.M. (227) 257
Layeillon, C., see Chaouloff, F. (214) 101
Lazdunski, M., see Amalric, M. (217) 71
Lazdunski, M., see Fosset, M. (220) 273
Lazdunski, M., see Szewczyk, A. (216) 323
Lazdunski, M., see Szewczyk, A. (226) 175
Le Bars, D., see Bouhassira, D. (216) 149
Leboeuf, J., Baissat, J. and Massingham, R.
Protective effect of bepridil against veratrine-induced contracture in rat atria (216) 183
Lebrun, C., see Itoi, K. (219) 435
Lebrun, P., see Antoine, M.-H. (216) 299
Leclaire, J., see Martinat, C. (228) 63
Ledda, F., see Amerini, S. (216) 445
Ledda, F., see Mantelli, L. (213) 79
Leduc, D., see Imaizumi, A. (212) 177
Lee, C.-R., see Huang, H.-C. (218) 123
Lee, C.Y., see Lin, W.-W. (219) 355
Lee, K.S., see Arlinghaus, L. (209) 123
Lee, M.-C., see Huang, H.-C. (218) 123
Lee, N.M., see Takemori, A.E. (221) 223
Lee, Y.-T., see Huang, H.-C. (217) 143
Lee, Y.-T., see Huang, H.-C. (218) 123
Leenders, P.J.A., see Marjorie, (217) 49
Lefebvre, R.A. and Horacek, J.
Relaxant effects of BRL 38227 and pinacidil on the rat gastric fundus (214) 1
Lefebvre, R.A., De Vriese, A. and Smits, G.J.M.
Influence of vasoactive intestinal polypeptide and N^G-nitro-L-arginine methyl ester on cholinergic neurotransmission in the rat gastric fundus (221) 235
Lefebvre, R.A., see Barbier, A.J. (210) 315
Lefebvre, R.A., see Barbier, A.J.M. (219) 331
Lefebvre, R.A., see Smits, G.J.M. (223) 97
Lefer, A.M., see Siegfried, M.R. (212) 171
Lefort, J., see Imaizumi, A. (212) 177
Lefort, J., see Pretolani, M. (216) 141
Le Fur, G., see Simiand, J. (219) 193
Le Gall, A., see Laferrère, B. (215) 23
Legrand, J.C., see Zongazo, M.A. (209) 45
Le Greves, P., see Andersson, S.E. (209) 175
Lehmann, J., see Mathis, C. (220) 107
Leidig, A., see Wermelskirchen, D. (219) 253
Lellouch-Tubiana, A., see Imaizumi, A. (212) 177
Lemaire, S., see Dumont, M. (209) 245
Lembeck, F., see Griesbacher, T. (211) 393
Lembøl, H.L., see Arnt, J. (218) 159
Lemke, S.M., see Gruetter, C.A. (217) 109
Lemli, J., see Nijs, G. (218) 199
Lemli, J., see Van Hoestenberghe, A. (212) 121
Lengel, D.J., see Kusner, E.J. (210) 299
Leone, M.P., see Sala, M. (217) 37
Lepagnol, J.M., see Randle, J.C.R. (215) 237

Lepetit, P., Touret, M., Grange, E., Gay, N. and Bobillier, P.
Inhibition of methionine incorporation into brain proteins after the systemic administration of p-chlorophenylalanine and L-5-hydroxytryptophan (209) 207
Leroy, F., see Laferrère, B. (215) 23
Lesch, K.P., Aulakh, C.S., Wolozin, B.L., Hill, J.L. and Murphy, D.L.
3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid decreases NMDA receptor mRNA (227) 109
Lesch, K.P., Hough, C.J., Aulakh, C.S., Wolozin, B.L., Tolliver, T.J., Hill, J.L., Akiyoshi, J., Chuang, D.-M. and Murphy, D.L.
Fluoxetine modulates G protein α_s, α_q, and α_{12} subunit mRNA expression in rat brain (227) 233
Leslie, R.A., see Jansen, K.L.R. (214) 281
Leslie, R.A., see Newberry, N.R. (219) 135
Leslie, R.A., see Newberry, N.R. (221) 157
Leung, K.H., Roscoe, W.A., Smith, R.D., Timmermans, P.B.M.W.M. and Chiu, A.T.
Characterization of biochemical responses of angiotensin II (AT_2) binding sites in the rat pheochromocytoma PC12W cells (227) 63
Leurs, R., Brozius, M.M., Jansen, W., Bast, A. and Timmerman, H.
Desensitization of histamine H_1 receptor-mediated cyclic GMP production in guinea-pig lung (225) 137
Lévai, G., see Mészáros, J. (210) 333
Level, M., see Bârzu, T. (219) 225
Lever, J.R., Scheffel, U., Kinter, C.M., Ravert, H.T., Dannals, R.F., Wagner, Jr., H.N. and Frost, J.J.
In vivo binding of N1′-([^{11}C]methyl)naltrindole to δ-opioid receptors in mouse brain (216) 459
Levy, A.D., Li, Q., Sanz, M.C.A., Rittenhouse, P.A., Brownfield, M.S. and Van de Kar, L.D.
Repeated cocaine modifies the neuroendocrine responses to the 5-HT_{1C}/5-HT_2 receptor agonist DOI (221) 121
Levy, J.-C., see Kidd, E. (211) 133
Lew, D.P., see Krause, K.-H. (227) 221
Lewis, M.J., see Lang, D. (226) 259
Lewis, S.A., see Underwood, S.L. (210) 97
Leysen, J.E., see Schotte, A. (218) 373
Leyva, J., see Maione, S. (219) 477
Li, G., see Sher, E. (216) 407
Li, Q., see Levy, A.D. (221) 121
Li, X.-M., Juorio, A.V., Alick Paterson, I. and Boulton, A.A.
Absence of 2-phenylethylamine binding after monoamine oxidase inhibition in rat brain (210) 189
Li, Y. and Duckles, S.P.
Effect of endothelium on the actions of sympathetic and sensory nerves in the perfused rat mesentery (210) 23
Libri, V., Das, B. and Constanti, A.
Ganglionic nicotinic receptor agonists exhibit anti-muscarinic effects in guinea-pig olfactory cortical brain slices (212) 253
Libri, V., see Constanti, A. (214) 105
Lie, K.I., see Van Waarde, A. (222) 107
Lignon, M.-F., see Maletínská, L. (222) 233
Lim, H.K., see Elayan, I. (221) 281
Lima, M.C.R., see Castro-Faria-Neto, H.C. (213) 183
Lima, M.C.R., see Pasquale, C.P. (223) 9
Limon, I., see Tesson, F. (219) 335
Lin, L. and Nasjletti, A.
Prostanoid-mediated vascular contraction in normotensive and hypertensive rats (220) 49
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (219) 153
Lin, R.C.S., see Von Lubitz, D.K.J.E. (216) 37
Lin, W.-W. and Lee, C.Y.
Intestinal relaxation by endothelin isopeptides: involvement of Ca^{2+}-activated K^+ channels (219) 355
Lindsay, D.C., see Jiang, C. (211) 163
Lindskog, S., Ahrén, B., Land, T., Langel, Ü. and Bartfai, T.
The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion (210) 183
Linnoila, M., see Morgan, P.F. (225) 217
Linthorst, A.C.E., Broekhoven, M.H., De Jong, W., Van Wimersma Greidanus, T.B. and Versteeg, D.H.G.
Effect of SCH 23390 and quinpirole on novelty-induced grooming behaviour in spontaneously hypertensive rats and Wistar-Kyoto rats (219) 23
Liou, M.-J., see Ko, F.-N. (218) 129
Liou, M.-J., see Ko, F.-N. (219) 29
Lipartiti, M., see Siliprandi, R. (219) 173
Liu, C., see Safrany, S.T. (226) 265
Liu, C.-F., see Tao, P.-L. (215) 301
Liu, S., see Kuo, H.-P. (221) 385
Liu, Y., see Von Euler, G. (227) 449
Liu, Y.J.
Effect of extracellular calcium concentration on angiotensin AT_1 receptor-mediated smooth muscle contraction and antagonism in rabbit aorta (223) 205
Liu, Z., Brien, J.F., Marks, G.S., McLaughlin, B.E. and Nakatsu, K.
Carbon monoxide does not inhibit glyceryl trinitrate biotransformation by or relaxation of aorta (211) 129
Livingston, E., see Garrick, T. (223) 75
Lluis, C., see Casadó, V. (225) 7
Lodge, D., see Palmer, A.J. (221) 205
Loew, G., see Maguire, P. (213) 219
Loew, G.H., see Maguire, P.A. (214) 85
Loew, G.H., see Maguire, P.A. (226) 233
Loh, H.H., see Takemori, A.E. (221) 223
Lohse, M.J., see Ungerer, M. (226) 381
Loiacono, R.E. and Beart, P.M.
Hippocampal lesions induced by microinjection of the nitric oxide donor nitroprusside (216) 331
Lomasney, J.W., see Schwinn, D.A. (227) 433
Lombard, M.-C., see Besse, D. (223) 123
Lombardi, G., see Moroni, F. (218) 145
Lonart, G., Wang, J. and Johnson, K.M.
Nitric oxide induces neurotransmitter release from hippocampal slices (220) 271
Longmore, J. and Hill, R.G.
Characterisation of NK receptors in guinea-pig urinary bladder smooth muscle: use of selective antagonists (222) 167
Lopes, P. and Couture, R.
Cardiovascular responses elicited by intrathecal kinins in the conscious rat (210) 137
Lopez-Belmonte, J., see Whittle, B.J.R. (218) 339
López-Farré, A., see Gómez-Garre, D. (224) 167
Lopez-Garcia, P., see Martinat, C. (228) 63
Lorenzetti, B.B., see Duarte, I.D.G. (217) 225
Lorenzetti, B.B., see Ferreira, S.H. (217) 207
Lormeau, J.-C., see Bârzu, T. (219) 225
Losa, M.J., see Frechilla, D. (219) 409
Löscher, W. and Fredow, G.
Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters (213) 31
Löscher, W. and Hönack, D.
The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems (215) 199
Löscher, W., see Dziki, M. (222) 273
Löscher, W., see Gerdes, C. (220) 91
Löscher, W., see Rundfeldt, C. (213) 351
Löschmann, P.-A., see Lange, K.W. (212) 247
Lou, Y.-P., Franco-Cereceda, A. and Lundberg, J.M.
Variable α_2-adrenoceptor-mediated inhibition of bronchocon-

striction and peptide release upon activation of pulmonary afferents (210) 173
Loubatières-Mariani, M.-M., see Bertrand, G. (214) 159
Loubatières-Mariani, M.-M., see Hillaire-Buys, D. (218) 359
Loubatières-Mariani, M.-M., see Petit, P. (221) 359
Louis, W.J., see King, P.R. (218) 101
Lovinger, D.M., Harrison, N.L. and Lambert, N.A.
The actions of 3-aminopropanephosphinic acid at $GABA_B$ receptors in rat hippocampus (211) 337
Lowe, V., see Noronha-Blob, L. (211) 97
Lowe III, J.A., see Delay-Goyet, P. (222) 213
Lowe III, J.A., see Nagahisa, A. (217) 191
Lowther, S., De Paermentier, F., Crompton, M.R. and Horton, R.W.
The distribution of $5\text{-}HT_{1D}$ and $5\text{-}HT_{1E}$ binding sites in human brain (222) 137
Lucić, D., see Kurelec, B. (228) 51
Ludbrook, J., see Evans, R.G. (216) 265
Lüddens, H., see Korpi, E.R. (211) 427
Lugnier, C., see Muller, B. (225) 263
Lundberg, J.M., see Delay-Goyet, P. (222) 213
Lundberg, J.M., see Franco-Cereceda, A. (221) 183
Lundberg, J.M., see Lou, Y.-P. (210) 173
Lundberg, J.M., see Pernow, J. (222) 171
Lundy, P.M., Hong, A. and Frew, R.
Inhibition of a dihydropyridine, ω-conotoxin insensitive Ca^{2+} channel in rat synaptosomes by venom of the spider *Hololena curta* (225) 51
Luomala, K., see Sjöholm, B. (215) 109
Lupattelli, G., see Sinzinger, H. (219) 129
Luquin, M.R., see Pérez-Otaño, I. (217) 211
Luten, J.B., see Groten, J.P. (228) 23
Luyten, W.H.L.M., see Schotte, A. (218) 373
Ly, C.Q., see Jarvis, M.F. (219) 319

Ma, X.-l., see Siegfried, M.R. (212) 171
Maayani, S., see Wiener, H.L. (220) 131
Mabley, J., Wayman, C.P. and Wilson, J.F.
Endogenous γ-aminobutyric acid tonically inhibits release of α-melanocyte-stimulating hormone from rat hypothalamic slices (209) 127
Macara, B. and Gião-T. Rico, J.M.
Effect of Ca^{2+} modulators on acetylcholine-induced phasic and tonic contractions and A23187-induced contractions in ileal longitudinal muscle and IP_3 production (218) 27
Macdonald, A.G., Ramsey, R.L., Shelton, C.J. and Usherwood, P.N.R.
Single channel analysis of ketamine interaction with a quisqualate receptor (210) 223
MacDonald, J.F., see Reynolds, J.N. (224) 173
Machado, B.H. and Bonagamba, L.G.H.
Microinjection of S-nitrosocysteine into the nucleus tractus solitarii of conscious rats decreases arterial pressure but L-glutamate does not (221) 179
Machida, J., see Yoshida, M. (222) 205
Machii, K., see Namiki, A. (227) 339
Macías-Silva, M., see García-Sáinz, J.A. (227) 239
Macías-Silva, M., see García-Sáinz, J.A. (227) 325
MacLeod, B.A., see Howard, P.G. (219) 1
MacLeod, K.M., see Abebe, W. (225) 29
Maeda, H., see Hashimoto, K. (228) 171
Maeda, K., see Kamisaki, Y. (217) 57
Maeda, Y., see Murai, M. (217) 23
Maehara, T., see Kanada, A. (216) 287
Maelicke, A., see Šoskić, V. (226) 109
Maffrand, J.P., see Herbert, J.M. (216) 175
Maggi, A., see Spreafico, E. (227) 353
Maggi, C.A., see Ballati, L. (214) 215
Maggi, C.A., see Eglezos, A. (209) 277
Maggi, C.A., see Henderson, A.K. (225) 175
Maggi, C.A., see Patacchini, R. (215) 93
Maggi, C.A., see Tramontana, M. (212) 137
Maguire, P., Tsai, N., Kamal, J., Cometta-Morini, C., Upton, C. and Loew, G.
Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors (213) 219
Maguire, P.A., Davies, M.F., Villar, H.O. and Loew, G.H.
Evidence for more than two central benzodiazepine receptors in rat spinal cord (214) 85
Maguire, P.A., Villar, H.O., Davies, M.F. and Loew, G.H.
Thermodynamic analysis of binding to the cerebellar type I benzodiazepine receptor (226) 233
Maigret, C., see Van Wimersma Greidanus, T.B. (209) 57
Maione, S., Berrino, L., Vitagliano, S., Leyva, J. and Rossi, F.
Pregnenolone sulfate increases the convulsant potency of N-methyl-D-aspartate in mice (219) 477
Mair, P., see Khuenl-Brady, K.S. (222) 153
Mais, D.E., True, T.A. and Martinelli, M.J.
Characterization by photoaffinity labelling of the human platelet thromboxane A_2/prostaglandin H_2 receptor: evidence for N-linked glycosylation (227) 267
Maisonneuve, I.M. and Glick, S.D.
Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior (212) 263
Maistre, G., see Zongazo, M.A. (209) 45
Majewski, H., see Mian, M.A. (213) 47
Majka, J., see Konturek, S.J. (211) 277
Makara, G.B., see Horváth, G. (225) 305
Makise, K., see Kai, H. (220) 181
Makovec, F., see Revel, L. (216) 217
Maksay, G.
Modification of benzodiazepine receptors supports the distinctive role of histidine residues (227) 57
Makujina, S.R., Sabouni, M.H., Bhatia, S., Douglas, F.L. and Mustafa, S.J.
Vasodilatory effects of adenosine A_2 receptor agonists CGS 21680 and CGS 22492 in human vasculature (221) 243
Malenkova, I.V., see Vedernikov, Y.P. (211) 313
Malenkova, I.V., see Vedernikov, Y.P. (212) 125
Maletínská, L., Lignon, M.-F., Galas, M.-C., Bernad, N., Pírková, J., Hlaváček, J., Slaninová, J. and Martinez, J.
Pharmacological characterization of new cholecystokinin analogues (222) 233
Mallard, N., Marshall, R., Sithers, A. and Spriggs, B.
Suramin: a selective inhibitor of purinergic neurotransmission in the rat isolated vas deferens (220) 1
Mallol, J., see Casadó, V. (225) 7
Mandel, K.G., see Greenwood, B. (211) 143
Manev, H., see Siliprandi, R. (219) 173
Manier, D.H., see Bieck, P.R. (225) 171
Manji, H.K., Chen, G., Bitran, J.A., Gusovsky, F. and Potter, W.Z.
Idazoxan down-regulates β-adrenoceptors on C6 glioma cells in vitro (227) 275
Manning, A., Mouton, J. and Chatelain, P.
Fantofarone (SR 33557): effect on post-ischaemic functional recovery in perfused rat hearts (220) 249
Manning, R.G., see Kessler, R.M. (223) 105
Manso, C.F., see Fernandes, A.C. (220) 211
Mansour, A., Meng, F., Meador-Woodruff, J.H., Taylor, L.P., Civelli, O. and Akil, H.
Site-directed mutagenesis of the human dopamine D_2 receptor (227) 205
Mansuy, D., see Martinat, C. (228) 63
Mantegazza, P., see Bianchi, M. (219) 113
Manteghetti, M., see Petit, P. (221) 359

Mantelli, L., Amerini, S., Rubino, A. and Ledda, F.
Effects of thromboxane agonists on cardiac adrenergic neurotransmission (213) 79
Mantelli, L., see Amerini, S. (216) 445
Manzini, S., see Ballati, L. (214) 215
Manzini, S., see Cutrufo, C. (222) 1
Manzoni, O., Prezeau, L., Sladeczek, F. and Bockaert, J.
Trans-ACPD inhibits cAMP formation via a pertussis toxin-sensitive G-protein (225) 357
Mao, Y.-K., see Pasyk, E. (212) 209
Mapp, C.E., Boniotti, A., Papi, A., Chitano, P., Fabbri, L.M. and Ciaccia, A.
The products of the reaction between toluene diisocyanate and water contract isolated guinea pig bronchi (228) 103
Mapp, C.E., see Crescioli, S. (228) 45
Marchi, M., see Raiteri, M. (213) 17
Marcusson, J.O., Norinder, U., Högberg, T. and Ross, S.B.
Inhibition of [^{3}H]paroxetine binding by various serotonin uptake inhibitors: structure–activity relationships (215) 191
Marescau, B., see Jorens, P.G. (212) 113
Marín, J., see Fernández-Alfonso, M.S. (221) 185
Marjorie, , Nelissen-Vrancken, H.J.M.G., Leenders, P.J.A., Bost, J.G.P.J., Struijker-Boudier, H.A.J. and Smits, J.F.M.
Comparison of angiotensin-converting enzyme inhibitors in the rat in perfused hindlimbs and in vivo (217) 49
Marks, G.S., see Liu, Z. (211) 129
Marks, R.L., see Kusner, E.J. (210) 299
Mármol, F., Carbonell, L., Cuffí, M.L. and Forn, J.
Demonstration of inhibition of cyclic AMP accumulation in brain by very low concentrations of lithium in the presence of α-adrenoceptor blockade (226) 93
Marquis, K.L., see Hudson, G.M. (221) 217
Marsden, C.D., see Lange, K.W. (212) 247
Marsden, C.D., see Taylor, M.D. (219) 183
Marshall, I., see Gray, D.W. (212) 37
Marshall, R., see Mallard, N. (220) 1
Martin, C.A.E., Naline, E., Emonds-Alt, X. and Advenier, C.
Influence of (±)-CP-96,345 and SR 48968 on electrical field stimulation of the isolated guinea-pig main bronchus (224) 137
Martin, D. and Swartzwelder, H.S.
Ethanol inhibits release of excitatory amino acids from slices of hippocampal area CA1 (219) 469
Martin, D., Ault, B. and Nadler, J.V.
NMDA receptor-mediated depolarizing action of proline on CA1 pyramidal cells (219) 59
Martin-Iverson, M.T. and Yamada, N.
Synergistic behavioural effects of dopamine D_1 and D_2 receptor agonists are determined by circadian rhythms (215) 119
Martín, J.D., see Candenas, M.-L. (219) 473
Martin, J.R.
Pressor response to posterior hypothalamic administration of carbachol is mediated by muscarinic M_3 receptor (215) 83
Martin, K.F., see Iredale, P.A. (226) 163
Martin, L., see Howard, S. (227) 123
Martin, L.L., see Dunn, R.W. (214) 207
Martín, M.I., Goicoechea, C., Colado, M.I. and Alfaro, M.J.
Analgesic effect of salmon-calcitonin administered by two routes. Effect on morphine analgesia (224) 77
Martin, P., Gozlan, H. and Puech, A.J.
5-HT_3 receptor antagonists reverse helpless behaviour in rats (212) 73
Martin, P., see Simiand, J. (219) 193
Martin, P.L.
Evidence that adenosine receptors in the dog left atrium are not of the typical A_1 or A_2 adenosine receptor subtypes (214) 199
Martin, P.L.
Relative agonist potencies of C^2-substituted analogues of adenosine: evidence for adenosine A_{2B} receptors in the guinea pig aorta (216) 235
Martinat, C., Amar, C., Dansette, P.M., Leclaire, J., Lopez-Garcia, P., Do Cao, T., Nam N'Guyen, H. and Mansuy, D.
In vitro metabolism of isaxonine phosphate: formation of two metabolites, 5-hydroxyisaxonine and 2-aminopyrimidine, and covalent binding to microsomal proteins (228) 63
Martinelli, M.J., see Mais, D.E. (227) 267
Martinez-Cuesta, M.A., Barrachina, M.D., Piqué, J.M., Whittle, B.J.R. and Esplugues, J.V.
The role of nitric oxide and platelet-activating factor in the inhibition by endotoxin of pentagastrin-stimulated gastric acid secretion (218) 351
Martínez-Fong, D., see Montaño, J.-A.A. (218) 335
Martinez, J., see Dubuc, I. (219) 327
Martinez, J., see Galas, M.C. (226) 35
Martinez, J., see Maletínská, L. (222) 233
Martinez-Mir, I., see Rubio, E. (212) 31
Martinez, R.P., see Raffa, R.B. (215) 357
Martinez, R.P., see Raffa, R.B. (216) 453
Martinez, R.P., see Raffa, R.B. (217) 221
Martins, M.A., Pasquale, C.P., Bozza, P.T., Silva, P.M.R., Castro Faria Neto, H.C. and Cordeiro, R.S.B.
Homologous tachyphylaxis to bradykinin and its interference with allergic pleurisy in actively sensitized rats (220) 55
Martins, M.A., see Amorim, C.Z. (211) 29
Martins, M.A., see Castro-Faria-Neto, H.C. (213) 183
Martins, M.A., see Pasquale, C.P. (223) 9
Martire, M., see Preziosi, P. (221) 343
Martorana, P.A., see Bohn, H. (220) 71
Martres, M.-P., see Sokoloff, P. (225) 331
Marumo, F., see Eguchi, S. (225) 79
Marumo, F., see Nitta, J.-i. (214) 191
Masereel, B., Ferrari, P., Ferrandi, M., Pirotte, B., Schynts, M., Parenti, P. and Delarge, J.
Na^+,$2Cl^-$,K^+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives (219) 385
Mason, N.S., see Kessler, R.M. (223) 105
Mason, S.L. and Reynolds, G.P.
Clozapine has sub-micromolar affinity for 5-HT_{1A} receptors in human brain tissue (221) 397
Massi, P., see Patrini, G. (210) 259
Massingham, R., see Leboeuf, J. (216) 183
Masson, F., see Zongazo, M.A. (209) 45
Massotte, L., see Verbanck, P.M.P. (211) 15
Massotti, M., see Barbaccia, M.L. (219) 485
Masumura, H., Kunitada, S., Irie, K., Ashida, S. and Abe, Y.
A thromboxane A_2 synthetase inhibitor retards hypertensive rat diabetic nephropathy (210) 163
Masumura, H., see Nishiyama, A. (218) 311
Masuyama, Y., see Tsuda, K. (216) 319
Masuzawa-Ito, K., see Suzuki, Y. (219) 401
Mathieu, M.-N., see Diochot, S. (227) 427
Mathis, C., Lehmann, J. and Ungerer, A.
The selective protein kinase C inhibitor, NPC 15437, induces specific deficits in memory retention in mice (220) 107
Mathis, C.A., Biegon, A., Taylor, S.E., Enas, J.D. and Hanrahan, S.M.
[^{125}I]5-Iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex (210) 103
Mathis, C.A., see Biegon, A. (224) 27
Matsubara, T., Moskowitz, M.A. and Huang, Z.
UK-14,304, R(−)-α-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms (224) 145
Matsuda, A., see Morimoto, H. (224) 1
Matsuda, T., see Nakano, Y. (219) 339

Matsuda, Y., see Morishita, Y. (225) 203
Matsumoto, S., see Kai, H. (220) 181
Matsumoto, Y., Ochi, H., Aihara, K., Inui, J. and Ikegami, K.
Effects of Y-20811, a thromboxane A_2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs (213) 167
Matsuo, K., see Ishine, T. (219) 285
Matsushita, A., see Eigyo, M. (214) 149
Matsushita, A., see Eigyo, M. (219) 487
Matsuzaki, M., see Sugasawa, T. (216) 207
Mattioli, R., see Boix, F. (216) 103
Maugeri, N., see Evangelista, V. (216) 401
May, B., see Walters, M.R. (213) 309
May, T.
Striatal dopamine D_1-like receptors have higher affinity for dopamine in ethanol-treated rats (215) 313
Mazarguil, H., see Gicquel, S. (222) 61
Mazière, B., see Varastet, M. (213) 275
Mazière, M., see Varastet, M. (213) 275
McAllister, K.H.
N-Methyl-D-aspartate receptor antagonists and channel blockers have different effects upon a spinal seizure model in mice (211) 105
McCabe, R.T., see Von Lubitz, D.K.J.E. (219) 153
McCall, R.B., see Ramage, A.G. (219) 165
McCaslin, P.P. and Yu, X.Z.
Cyanide selectively augments kainate- but not NMDA-induced release of glutamate and taurine (228) 73
McCaslin, P.P., see Cai, Z. (219) 53
McDonald, I.A., see Lambert, L.E. (216) 131
McDonald, J.W. and Schoepp, D.D.
The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates N-methyl-D-aspartate-induced brain injury (215) 353
McDonough, J.R., see Mele, P.C. (218) 229
McErlane, K.M., see Igwemezie, L.N. (210) 271
McEwen, B.S., see Watanabe, Y. (222) 157
McGrath, J.C., see Bulloch, J.M. (211) 1
McGuffin, P., see O'Donovan, M.C. (226) 335
McIntosh, C.H.S., Law, S. and Bakich, V.
Chronic naltrexone treatment of rats: effects on gastrointestinal opioid peptide content (223) 117
McIntosh, M., Kane, K. and Parratt, J.
Effects of selective opioid receptor agonists and antagonists during myocardial ischaemia (210) 37
McIntosh, M., Kane, K. and Parratt, J.
The electrophysiological effects of opioid receptor-selective antagonists on sheep Purkinje fibres (210) 45
McKenna, P.J., see Yue, T.-L. (214) 277
McKenzie, R.J., see Von Lubitz, D.K.J.E. (216) 37
McKenzie, R.J., see Von Lubitz, D.K.J.E. (219) 153
McKnight, A., see Freedman, S.B. (215) 135
McLaughlin, B.E., see Liu, Z. (211) 129
McLean, D.B., see Mele, P.C. (218) 229
McLean, S., see Schmidt, A.W. (215) 351
McLean, S., see Schmidt, A.W. (219) 490
McLees, A., see Sneddon, P. (214) 7
McLeod, J.D. and Piper, P.J.
Effect of removing the endothelium on the vascular responses induced by leukotrienes C_4 and D_4 in guinea-pig isolated heart (212) 67
McLeod, R.L., Gertner, S.B. and Hey, J.A.
Modulation of cardiovascular function by central histamine H_3 receptors in conscious guinea pigs (209) 141
McMahon, T.J., see Nossaman, B.D. (213) 1
McMillan, D.E.
Effects of drugs on behavior before and during chronic diazepam administration (215) 145
McNaughton, N., see Panickar, K.S. (210) 307
McQuade, R.D., Duffy, R.A., Coffin, V.L. and Barnett, A.
In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity (215) 29
McQuay, H.J., see Kalso, E.A. (216) 97
McQuay, H.J., see Sullivan, A.F. (215) 127
Meador-Woodruff, J.H., see Mansour, A. (227) 205
Meeder, J.G., see Van Waarde, A. (222) 107
Mehdi, S., see Arlinghaus, L. (209) 123
Meier, E., see Arnt, J. (218) 159
Meijer, O.C., see Burbach, J.P.H. (227) 1
Meldrum, B.S., see Smith, S.E. (211) 109
Meldrum, B.S., see Smith, S.E. (213) 133
Mele, A., see Imperato, A. (212) 299
Mele, P.C., McDonough, J.R., McLean, D.B. and O'Halloran, K.P.
Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F (218) 229
Melis, M.R., Stancampiano, R. and Argiolas, A.
Effect of excitatory amino acid receptor antagonists on apomorphine-, oxytocin- and ACTH-induced penile erection and yawning in male rats (220) 43
Meller, S.T., Dykstra, C. and Gebhart, G.F.
Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex (214) 93
Meloni, R. and Gale, K.
Cocaine-induced turning behavior in rats with 6-hydroxydopamine lesions: effect of transplants of fetal substantia nigra (209) 113
Meltzer, H.Y., Zhang, Y. and Stockmeier, C.A.
Effect of amperozide on rat cortical 5-HT_2 and striatal and limbic dopamine D_2 receptor occupancy: implications for antipsychotic action (216) 67
Memo, M., see Nisoli, E. (216) 81
Memo, M., see Pizzi, M. (209) 169
Mencia-Huerta, J.M., see Pons, F. (217) 65
Meng, F., see Mansour, A. (227) 205
Mengod, G., see Pombo-Villar, E. (226) 317
Menkens, K., Bilsky, E.J., Wild, K.D., Portoghese, P.S., Reid, L.D. and Porreca, F.
Cocaine place preference is blocked by the δ-opioid receptor antagonist, naltrindole (219) 345
Mennecier, P., see Heuzé-Joubert, I. (220) 161
Merkel, L.A. and Bilder, G.E.
Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits (222) 175
Merkel, L.A., Rivera, L.M., Perrone, M.H. and Lappe, R.W.
In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor (216) 29
Mermet, C., see Suaud-Chagny, M.F. (213) 305
Mermet, C., see Tibiriça, E. (209) 213
Merriweather, C., see Pfeilschifter, J. (225) 57
Messing, M.W.J., see Struijker Boudier, H.A.J. (218) 191
Mészáros, J. and Lévai, G.
Catecholamine-induced cardiac hypertrophy uncouples β-adrenoceptors from slow calcium channels (210) 333
Mészáros, J.
Sodium-pump injury and arrhythmogenic transient depolarizations in catecholamine-induced cardiac hypertrophy (210) 325
Metsä-Ketelä, T., see Arvola, P. (214) 289
Meulemans, A.L. and Schuurkes, J.A.J.
Is the action of cisapride on the guinea-pig ileum mediated via 5-HT_4 receptors? (212) 51
Meunier, J.-C., see Polastron, J. (226) 133

Meuse, A.J., see Qiu, Z. (214) 293
Meyer, M.E., see Van Hartesveldt, C. (214) 27
Mian, M.A., Majewski, H. and Rand, M.J.
An inhibitory effect of isoprenaline on stimulation-induced noradrenaline release from rat atria (213) 47
Miasiro, N. and Paiva, A.C.M.
Effects of endothelin-3 on the isolated guinea-pig ileum: role of Na^+ ions and endothelin receptor subtypes (214) 133
Michel, A.D., see Bryson, S.E. (225) 119
Michiaki, T., see Takao, A. (217) 101
Middlemiss, D.N., see Beer, M.S. (213) 193
Miele, E., see Desole, M.S. (219) 67
Miele, M., see Desole, M.S. (219) 67
Mierau, J. and Schingnitz, G.
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D_2 receptor agonist (215) 161
Mihara, S.-i., see Fujimoto, M. (215) 259
Mihic, S.J., Van Berckel, B.N.M., O'Dowd, B.F., Nguyen, T. and Wu, P.H.
Effects of sedatives on GABA-mediated chloride flux into cerebral cortical microsacs prepared from emotional and non-emotional mice (218) 283
Mikami, M., Tachikawa, E. and Kashimoto, T.
Effects of gentamicin on catecholamine levels in the striatum, hypothalamus, adrenal gland and vas deferens (210) 91
Miki, I., Kase, H. and Ishii, A.
Differences in activities of thromboxane A_2 receptor antagonists in smooth muscle cells (227) 199
Milanés, M.V., see Garaulet, J.V. (223) 19
Millan, M.J.
Evidence that an α_{2A}-adrenoceptor subtype mediates antinociception in mice (215) 355
Miller, K.J., King, A., Demchyshyn, L., Niznik, H. and Teitler, M.
Agonist activity of sumatriptan and metergoline at the human 5-$HT_{1D\beta}$ receptor: further evidence for a role of the 5-HT_{1D} receptor in the action of sumatriptan (227) 99
Milne, A.A., see Gwilt, M. (215) 137
Minabe, Y., Ashby, Jr., C.R. and Wang, R.Y.
The effect of acute and chronic LY 277359, a selective 5-HT_3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons (209) 151
Minabe, Y., Ashby, Jr., C.R., Schwartz, J.E. and Wang, R.Y.
The 5-HT_3 receptor antagonists LY 277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells (209) 143
Minneman, K.P., see Han, C. (226) 141
Mino, N., Kobayashi, M., Nakajima, A., Amano, H., Shimamoto, K., Ishikawa, K., Watanabe, K., Nishikibe, M., Yano, M. and Ikemoto, F.
Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats (221) 77
Miranda, H.F., Bustamante, D., Kramer, V., Pelissier, T., Saavedra, H., Paeile, C., Fernandez, E. and Pinardi, G.
Antinociceptive effects of Ca^{2+} channel blockers (217) 137
Misawa, M., see Kamei, J. (224) 39
Misawa, M., see Suzuki, T. (213) 91
Mishra, R.K., see Srivastava, L.K. (225) 143
Missale, C., see Sigala, S. (211) 351
Missiaen, L., De Smedt, H., Droogmans, G. and Casteels, R.
2,5-Di-(tert-butyl)-1,4-benzohydroquinone and cyclopiazonic acid decrease the Ca^{2+} permeability of endoplasmic reticulum (227) 391
Misu, Y., see Nakamura, S. (222) 75
Mitsui, M., see Kim, B.K. (223) 157
Mitsui, M., see Sanagi, M. (222) 247
Mitsui, Y., see Tada, S. (227) 25
Mitsuka, S., see Takada, A. (228) 131
Miura, M., see Belvisi, M.G. (215) 341
Miura, T., Inagaki, N., Goto, S., Yoshida, K., Nagai, H. and Koda, A.
Leukotriene receptors in the skin of rats differ from those of mouse skin or rat stomach strip (221) 333
Miwa, K., Miyagi, Y., Araie, E. and Sasayama, S.
Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes (214) 127
Miyagi, Y., see Miwa, K. (214) 127
Miyajima, T., see Tsujino, T. (226) 69
Miyake, H., see Morimoto, H. (224) 1
Miyamae, T., see Nakamura, S. (222) 75
Miyamori, I., see Takeda, Y. (213) 445
Miyamoto, A., see Villalobos-Molina, R. (226) 129
Miyata, T., see Kai, H. (212) 101
Miyata, T., see Kai, H. (220) 181
Miyauchi, Y., see Fukuzaki, A. (220) 99
Miyauchi, Y., see Ishine, T. (219) 285
Miyazaki, A., see Kurose, Y. (211) 39
Mizota, M., see Notsu, T. (220) 35
Mizota, M., see Shinkawa, T. (219) 217
Mizrahi, J., see Brown, M.C.S. (227) 163
Mizuno, K., Niimura, S., Tani, M., Haga, H., Gomibuchi, T., Sanada, H. and Fukuchi, S.
Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats (215) 305
Mocaër, E., see Schroeder, H. (220) 217
Mochizuki, H., see Arakawa, H. (215) 51
Mochizuki, T., see Okakura, K. (213) 189
Modin, A., see Pernow, J. (222) 171
Moerlein, S.M. and Perlmutter, J.S.
Binding of 5-(2′-[^{18}F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography (218) 109
Mohamed, A.S., Forray, C., Aly, M.H.M. and El-Fakahany, E.E.
Lack of intrinsic activity and significant subtype selectivity of SR 95639A at muscarinic receptors (227) 181
Mohr, C., see Koch, G. (226) 87
Moison, R.M.W., see Redegeld, F.A.M. (228) 229
Molenaar, P., Roberts, S.J., Kim, Y.S., Pak, H.S., Sainz, R.D. and Summers, R.J.
Localization and characterization of two propranolol resistant (−)[^{125}I]cyanopindolol binding sites in rat skeletal muscle (209) 257
Mollace, V., Prosdocimi, M. and Nisticó, G.
Cloricromene synergizes with antiplatelet drugs and nitric oxide-like factor derived from rat peritoneal polymorphonuclear cells (222) 181
Molnár, L., Hegedüs, K. and Fekete, I.
Difference between the cerebrovascular effect of purinergic Co-ATP and that of the cholinesterase inhibitor, physostigmine, in vivo (209) 81
Molnár, P. and Gaál, L.
Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo (215) 17
Momiyama, T., see Renming, X. (223) 185
Monassier, L., see Tibiriça, E. (209) 213
Moncada, S., see Gardiner, S.M. (213) 449
Moncada, S., see Ialenti, A. (211) 177
Moncada, S., see Whittle, B.J.R. (218) 339
Monge, A., see Frechilla, D. (219) 409
Monod, A., see Krause, K.-H. (227) 221
Monopoli, A., see Viganò, T. (219) 159
Montaño, J.-A.A., Martínez-Fong, D. and Aceves, J.
$GABA_B$ receptor activation partially inhibits N-methyl-D-aspartate-mediated tyrosine hydroxylase stimulation in rat striatal slices (218) 335
Montastruc, J.-L., see Montastruc, P. (213) 159

Montastruc, P., Damase-Michel, C., Tavernier, G., Tran, M.-A. and Montastruc, J.-L.
Release of neuropeptide Y and noradrenaline during afferent nerve stimulation (213) 159
Moody, E., see Harris, B. (217) 215
Moolenaar, W.H., see Fernhout, B.J.H. (213) 313
Morain, P., Peglion, J.-L. and Giesen-Crouse, E.
Ca^{2+} channel inhibition in a rat osteoblast-like cell line, UMR 106, by a new dihydropyridine derivative, S11568 (220) 11
Morales, M., see Bosch, F. (222) 163
Morales-Olivas, F.J., see Rubio, E. (212) 31
Moratinos, J., see García-Barrado, M.J. (219) 461
Morcillo, E.J., see Cortijo, J. (221) 43
Mordvintcev, P.I., see Vedernikov, Y.P. (211) 313
Mordvintcev, P.I., see Vedernikov, Y.P. (212) 125
Morency, M.A., see Srivastava, L.K. (225) 143
Morgan, J.P., see Qiu, Z. (214) 293
Morgan, P.F., Nadi, N.S., Karanian, J. and Linnoila, M.
Mapping rat brain structures activated during ethanol withdrawal: role of glutamate and NMDA receptors (225) 217
Morgan, P.F., see Durcan, M.J. (224) 151
Mori, F., see Moroni, F. (218) 145
Mori, M., see Shimizu, H. (222) 279
Mori, M., see Uehara, Y. (220) 119
Morikawa, A., see Arakawa, H. (215) 51
Morikawa, K., Hashimoto, S., Yamauchi, T., Kato, H., Ito, Y. and Gomi, Y.
Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex (213) 409
Morikawa, M., Aikawa, T., Sekizawa, K., Ohrui, T., Sasaki, H. and Takishima, T.
Inhibitory actions of prostaglandin E_1 on neurogenic plasma extravasation in rat airways (217) 31
Morimoto, H., Yamashita, M., Matsuda, A., Miyake, H. and Fujii, T.
Effects of FR 113680 and FK 224, novel tachykinin receptor antagonists, on cigarette smoke-induced rat tracheal plasma extravasation (224) 1
Morimoto, H., see Murai, M. (217) 23
Morin, D., Sapena, R., Zini, R. and Tillement, J.-P.
Serotonin enhances the β-adrenergic response in rat brain cortical slices (225) 273
Morinobu, S., see Kawanami, T. (216) 385
Morishita, Y., Sano, T., Kase, H., Yamada, K., Inagami, T. and Matsuda, Y.
HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors (225) 203
Moritoki, H., Yoshikawa, T., Hisayama, T. and Takeuchi, S.
Possible mechanisms of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide (210) 61
Morley, J.E., see Flood, J.F. (221) 249
Moroi, M., see Namiki, A. (227) 339
Moroni, F., Alesiani, M., Facci, L., Fadda, E., Skaper, S.D., Galli, A., Lombardi, G., Mori, F., Ciuffi, M., Natalini, B. and Pellicciari, R.
Thiokynurenates prevent excitotoxic neuronal death in vitro and in vivo by acting as glycine antagonists and as inhibitors of lipid peroxidation (218) 145
Morooka, S., see Sugasawa, T. (216) 207
Mos, J., Olivier, B., Poth, M. and Van Aken, H.
The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino)tetralin on resident intruder aggression in the rat (212) 295
Moscoso, G., see Rutherford, R.A.D. (212) 1
Moser, P.C.
The effect of 5-HT_3 receptor antagonists on the discriminative stimulus effects of amphetamine (212) 271
Moser, U., see Bungardt, E. (213) 53
Moser, U., see Bungardt, E. (221) 91
Moshé, S., see Garant, D. (214) 75
Moskowitz, M.A., see Bruinvels, A.T. (227) 357
Moskowitz, M.A., see Matsubara, T. (224) 145
Mota-Filipe, H., Castro, M. and Gião-T.-Rico, J.M.
Effect of DL-propranolol on nitric oxide production in perfused rat hindquarters (213) 227
Mouillac, B., Devilliers, G., Jard, S. and Guillon, G.
Pharmacological characterization of inositol 1,4,5,-trisphosphate binding sites: relation to Ca^{2+} release (225) 179
Moummi, C., Yang, D.-C. and Gullikson, G.W.
5-HT_4 receptor activation induces relaxation and associated cAMP generation in rat esophagus (216) 47
Mount, H., see Chaudieu, I. (220) 203
Mousseau, D.D., Sun, X. and Larson, A.A.
Identification of a novel receptor mediating substance P-induced behavior in the mouse (217) 197
Mouton, J., see Manning, A. (220) 249
Muccioli, G., Scordamaglia, A., Bertacco, S. and Di Carlo, R.
Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats (227) 293
Mulè, F., Postorino, A., Geraci, A. and Serio, R.
Neurotensin: dual effect on the motor activity of rat duodenum (212) 215
Muller, B., Stoclet, J.-C. and Lugnier, C.
Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles (225) 263
Müller, S. and Nigam, S.
Arachidonic acid release and platelet-activating factor formation by staurosporine in human neutrophils challenged with n-formyl peptide (218) 251
Müller, W.E.G., Schröder, H.C., Ushijima, H., Dapper, J. and Bormann, J.
gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine (226) 209
Mulvihill, E., see Thomsen, C. (227) 361
Mungan, Z., Ozmen, V., Ertan, A., Coy, D.H., Baylor, L.M., Rice, J.C. and Rossowski, W.J.
Structural requirements for galanin inhibition of pentagastrin-stimulated gastric acid secretion in conscious rats (214) 53
Muntoni, A., see Diana, M. (221) 403
Mura, A., see Diana, M. (211) 415
Murad, F., see Förstermann, U. (225) 161
Murahara, K., see Kai, H. (212) 101
Murai, M., Morimoto, H., Maeda, Y. and Fujii, T.
Effects of the tripeptide substance P antagonist, FR113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs (217) 23
Murakami, K., see Shibasaki, M. (215) 271
Muraki, T., Irie, K., Uchida, Y. and Nomoto, T.
Developmental changes in the effect of atrial natriuretic peptide on tissue cyclic GMP content and particulate guanylate cyclase activity of aorta, kidney and lung of rats (226) 311
Muramatsu, I., see Hashimoto, S. (213) 117
Murata, M., Gusovsky, F., Yasumoto, T. and Daly, J.W.
Selective stimulation of Ca^{2+} flux in cells by maitotoxin (227) 43
Murphy, D.L., see Bagdy, G. (210) 285
Murphy, D.L., see Lesch, K.P. (227) 109
Murphy, D.L., see Lesch, K.P. (227) 233
Murphy, P.R., see Chiasson, B.J. (227) 451
Murray, A.M., Ryoo, H. and Joyce, J.N.
Visualization of dopamine D_3-like receptors in human brain with [^{125}I]epidepride (227) 443
Murray, J.M., see Wiener, H.L. (220) 131

Murray, T.F., see Roth, J.E. (215) 293
Mustafa, S.J., see Makujina, S.R. (221) 243
Mutschler, E., see Bungardt, E. (213) 53
Mutschler, E., see Bungardt, E. (221) 91
Mutschler, E., see Eltze, M. (211) 283
Mutschler, E., see Lambrecht, G. (217) 217
Mutschler, E., see Waelbroeck, M. (227) 33
Myers, J., see Clark, M.A. (210) 31

Nabeshima, T., Hiramatsu, M., Niwa, K., Fuji, K. and Kameyama, T.
Effect of naftidrofuryl oxalate on 5-HT_2 receptors in mouse brain: evaluation based on quantitative autoradiography and head-twitch response (223) 109
Nabeshima, T., see Hiramatsu, M. (216) 279
Nabeshima, T., see Ichihara, K. (213) 243
Nabeshima, T., see Yoshida, S. (214) 247
Nadi, N.S., see Morgan, P.F. (225) 217
Nadler, J.V., see Martin, D. (219) 59
Nagahisa, A., Kanai, Y., Suga, O., Taniguchi, K., Tsuchiya, M., Lowe III, J.A. and Hess, H.-J.
Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist (217) 191
Nagai, H., see Miura, T. (221) 333
Nagano, K., see Kawano, S. (211) 55
Naganuma, A., see Tanaka, T. (228) 9
Nagao, T., see Yamazaki, J. (220) 237
Nagasaka, M., see Okumura, K. (215) 253
Nagase, H., see Kuwahara, T. (221) 99
Nagase, H., see Portoghese, P.S. (218) 195
Nagase, H., see Suzuki, T. (213) 91
Nagashima, M., see Hattori, Y. (213) 147
Nagata, M. and Osumi, Y.
Central noradrenergic inhibition of gastric motility in rats (223) 153
Nagy, I., see Horváth, G. (225) 305
Nahori, M.-A., Renesto, P., Vargaftig, B.B. and Chignard, M.
Activation and damage of cultured airway epithelial cells by human elastase and cathepsin G (228) 213
Nahorski, S.R., see Safrany, S.T. (226) 265
Nakagawa, H., see Itoh, H. (218) 347
Nakajima, A., see Mino, N. (221) 77
Nakajima, F., see Iwamoto, T. (224) 71
Nakajima, H., see Shinkawa, T. (219) 217
Nakajima, M., see Tsujino, T. (226) 69
Nakaki, T., Otsuka, Y., Nakayama, M. and Kato, R.
Endothelium-accelerated hyporesponsiveness of norepinephrine-elicited contraction of rat aorta in the presence of bacterial lipopolysaccharide (219) 311
Nakaki, T., see Hishikawa, K. (215) 329
Nakamura, S., Goshima, Y., Yue, J.-L., Miyamae, T. and Misu, Y.
Transmitter-like 3,4-dihydroxyphenylalanine is tonically released by nicotine in striata of conscious rats (222) 75
Nakane, H., see Sadoshima, S. (224) 109
Nakane, Y., see Himeno, A. (215) 337
Nakano, A., see Kuwahara, T. (221) 99
Nakano, M., see Kunihara, M. (214) 111
Nakano, Y., Matsuda, T., Takuma, K., Yoshikawa, T. and Baba, A.
Sex difference for tolerance of 5-HT_{1A} receptor-mediated temperature and corticosterone responses in mice (219) 339
Nakao, K., see Himeno, A. (215) 337
Nakashima, M., see Takiguchi, Y. (215) 289
Nakatsu, K., see Liu, Z. (211) 129
Nakaya, H., see Shida, S. (212) 267
Nakayama, M., see Nakaki, T. (219) 311
Nakayama, S., see Takaki, M. (211) 125
Nakazawa, K., see Inoue, K. (215) 321
Nakazawa, K., see Kobayashi, A. (215) 43
Naline, E., see Candenas, M.-L. (210) 291
Naline, E., see Devillier, P. (214) 67
Naline, E., see Martin, C.A.E. (224) 137
Nalwalk, J.W., see Hough, L.B. (215) 69
Namiki, A., Hirata, Y., Fukazawa, M., Ishikawa, M., Moroi, M., Aikawa, J., Yamaguchi, T. and Machii, K.
Granulocyte-colony stimulating factor stimulates immunoreactive endothelin-1 release from cultured bovine endothelial cells (227) 339
Namiki, M., see Tsuji, K. (210) 213
Nam N'Guyen, H., see Martinat, C. (228) 63
Nanry, K.P., see Pollard, G.T. (221) 297
Narita, M., see Suzuki, T. (213) 91
Narita, M., see Takei, M. (219) 15
Nasa, Y., Hoque, A.N.E., Ichihara, K. and Abiko, Y.
Cardioprotective effect of pindolol in ischemic-reperfused isolated rat hearts (213) 171
Nasjletti, A., see Lin, L. (220) 49
Näsström, J., Karlsson, U. and Post, C.
Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice (212) 21
Natalini, B., see Moroni, F. (218) 145
Navaratnam, S., see Khatter, J.C. (216) 351
Navarra, P., see Preziosi, P. (221) 343
Naylor, R.J., see Barnes, N.M. (218) 15
Naylor, R.J., see Barnes, N.M. (218) 91
Naylor, R.J., see Jones, D.N.C. (215) 63
Nebel, U., see Wermelskirchen, D. (219) 253
Negri, L., Noviello, V. and Angelucci, F.
Behavioural effects of deltorphins in rats (209) 163
Nehlig, A., see Schroeder, H. (220) 217
Neill, J.C., see Grignaschi, G. (211) 137
Nelemans, A., see Henning, R.H. (216) 73
Nelemans, A., see Van der Zee, L. (215) 317
Nelissen-Vrancken, H.J.M.G., see Marjorie, (217) 49
Nelson, D., see Cohen, M.L. (211) 43
Nestler, E.J., see Kogan, J.H. (211) 47
Neuhaus, R. and Reber, B.F.X.
Inhibition of membrane currents and rises of intracellular Ca^{2+} in PC12 cells by CGS 9343B, a calmodulin inhibitor (226) 183
Newberry, N., see Freedman, S.B. (215) 135
Newberry, N.R., Sprosen, T.S., Watkins, C.J., Leslie, R.A. and Grahame-Smith, D.G.
AS-5370 potently antagonizes 5-HT_3 receptor-mediated responses on NG108-15 cells and on the rat vagus (219) 135
Newberry, N.R., Watkins, C.J., Reynolds, D.J.M., Leslie, R.A. and Grahame-Smith, D.G.
Pharmacology of the 5-hydroxytryptamine-induced depolarization of the ferret vagus nerve in vitro (221) 157
Newberry, N.R.
5-HT_{1A} receptors activate a potassium conductance in rat ventromedial hypothalamic neurones (210) 209
Newman, M.E.
Serotonin inhibits adenylate cyclase in human platelet membranes (226) 281
Newson, P.N., see Foster, K.A. (222) 143
Nguyen, T., see Mihic, S.J. (218) 283
Ni, H., Zhang, J., Harper, R.K. and Harper, R.M.
Discharge dependencies of amygdala central nucleus neurons to the cardiac and respiratory cycle following local cocaine administration (224) 157
Nicholls, D.G., see Pocock, J.M. (226) 343
Nicholson, C.D., see Connick, J.H. (214) 169
Nicosia, S., see Viganò, T. (219) 159
Nieduzak, T.R., see Schmidt, C.J. (220) 151
Nielsen, E.B. and Andersen, P.H.
Dopamine receptor occupancy in vivo: behavioral correlates using

NNC-112, NNC-687 and NNC-756, new selective dopamine D_1 receptor antagonists (219) 35
Nielsen, E.B., see Andersen, P.H. (219) 45
Nielsen, E.B., see Suzdak, P.D. (224) 189
Nielsen-Kudsk, J.E. and Thirstrup, S.
Antidiabetic sulfonylureas relax isolated rabbit coronary arteries (209) 273
Nielsen-Kudsk, J.E., see Bang, L. (211) 235
Nielsen-Kudsk, J.E., see Thirstrup, S. (215) 177
Nielsen, P.G., see Fink-Jensen, A. (220) 197
Nieoullon, A., see Amalric, M. (217) 71
Nigam, S., see Müller, S. (218) 251
Niho, T., see Notsu, T. (220) 35
Niimi, N., Noso, N. and Yamamoto, S.
The effect of histamine on cultured endothelial cells. A study of the mechanism of increased vascular permeability (221) 325
Niimura, S., see Mizuno, K. (215) 305
Nijkamp, F.P., see Buckley, T.L. (218) 369
Nijkamp, F.P., see Folkerts, G. (228) 121
Nijkamp, F.P., see Folkerts, G. (228) 219
Nijkamp, F.P., see Van Oosterhout, A.J.M. (209) 237
Nijs, G., De Witte, P., Geboes, K. and Lemli, J.
Influence of rhein anthrone and rhein on small intestine transit rate in rats: evidence of prostaglandin mediation (218) 199
Nijs, G., see Van Hoestenberghe, A. (212) 121
Nilsson, C. and Eriksson, E.
Partial dopamine D_2 receptor agonists antagonize prolactin-regulating D_2 receptors in a transfected clonal cell line (GH_4ZR_7) (218) 205
Nilsson, K., see Larsson, R. (228) 237
Nishi, K., see Yoshida, M. (222) 205
Nishi, S., see Yokoo, H. (222) 43
Nishijima, K., see Shinkawa, T. (219) 217
Nishikawa, K., see Yamamoto, S. (227) 113
Nishikawa, M., see Kogo, H. (211) 69
Nishikawa, M., see Okamura, T. (220) 27
Nishikibe, M., see Mino, N. (221) 77
Nishiyama, A., Tamaki, T., Masumura, H., He, H., Kiyomoto, H., Aki, Y., Yamamoto, A., Iwao, H. and Abe, Y.
Effects of semotiadil fumarate (SD-3211) on renal hemodynamics and function in dogs (218) 311
Nisoli, E., Tonello, C., Memo, M., Pizzi, M., Spano, P.F., Reina, G. and Carruba, M.O.
Tolerance to hypoactivity and sensitization to hyperactivity after chronic treatment with a presynaptic dose of lisuride in rats (216) 81
Nisticó, G., see Mollace, V. (222) 181
Nisticò, G., see Bagetta, G. (213) 301
Nitta, J.-i., Sunami, A., Marumo, F. and Hiraoka, M.
States and sites of actions of flecainide on guinea-pig cardiac sodium channels (214) 191
Niwa, K., see Nabeshima, T. (223) 109
Niwa, M., Kawaguchi, T., Himeno, A., Fujimoto, M., Kurihara, M., Yamashita, K., Kataoka, Y., Shigematsu, K. and Taniyama, K.
Specific binding sites for ^{125}I-endothelin-1 in the porcine and human spinal cord (225) 281
Niwa, M., see Himeno, A. (215) 337
Niznik, H., see Miller, K.J. (227) 99
Niznik, H.B., see Seeman, P. (227) 139
Noble, F., Coric, P., Fournié-Zaluski, M.-C. and Roques, B.P.
Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101 (223) 91
Noble, F., Turcaud, S., Fournié-Zaluski, M.-C. and Roques, B.P.
Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine (223) 83
Noé, E., see Zongazo, M.A. (209) 45
Noguchi, T., see Tawata, M. (212) 87
Nolan, K., see Chand, N. (211) 121
Nomikos, G.G., Arborelius, L. and Svensson, T.H.
The novel 5-HT_{1A} receptor antagonist (S)-UH-301 prevents (R)-8-OH-DPAT-induced decrease in interstitial concentrations of serotonin in the rat hippocampus (216) 373
Nomikos, G.G., see Gradin, K. (218) 363
Nomoto, T., see Muraki, T. (226) 311
Noordhoek, J., see Redegeld, F.A.M. (228) 229
Nörenberg, W., see Tschöpl, M. (213) 71
Norinder, U., see Marcusson, J.O. (215) 191
Noronha-Blob, L., Sturm, B. and Lowe, V.
Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate (211) 97
Norota, I., see Endoh, M. (218) 355
Norota, I., see Endoh, M. (223) 143
Norte, M., see Candenas, M.-L. (219) 473
Noso, N., see Niimi, N. (221) 325
Nossaman, B.D., McMahon, T.J., Ragheb, M.S., Ibrahim, I.N., Babycos, C.R., Hood, J.S. and Kadowitz, P.J.
Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban (213) 1
Notsu, T., Ohhashi, K., Tanaka, I., Ishikawa, H., Niho, T., Fukutake, K. and Mizota, M.
5-Hydroxydecanoate inhibits ATP-sensitive K^+ channel currents in guinea-pig single ventricular myocytes (220) 35
Novara, V., see Flugy, A. (214) 233
Noviello, V., see Negri, L. (209) 163
Nowak, G., see Pilc, A. (212) 109
Noyer, M., see Gower, A.J. (222) 193
Nuñez, C., see Escubedo, E. (225) 15
Nutt, D.J., see Jackson, H.C. (216) 23
Nutt, D.J., see Jackson, H.C. (221) 199
Nygren, P., see Larsson, R. (228) 237

Obermaier-Skrobranek, B., see Ungerer, M. (226) 381
Obeso, J.A., see Pérez-Otaño, I. (217) 211
Ochi, H., see Matsumoto, Y. (213) 167
Oda, M., see Ikemoto, Y. (216) 191
Oda, Y., see Kai, H. (212) 101
O'Donovan, M.C., Buckland, P.R., Spurlock, G. and McGuffin, P.
Bi-directional changes in the levels of messenger RNAs encoding γ-aminobutyric $acid_A$ receptor α subunits after flurazepam treatment (226) 335
O'Dowd, B.F., see Mihic, S.J. (218) 283
Oertel, W., see Pérez-Otaño, I. (217) 211
Ogihara, T., see Kawano, S. (211) 55
Ogino, K., Hobara, T., Ishiyama, H., Yamasaki, K., Kobayashi, H., Izumi, Y. and Oka, S.
Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats (212) 9
Ogino, K., Hobara, T., Ishiyama, H., Yamasaki, K., Kobayashi, H., Izumi, Y. and Oka, S.
Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats (219) 493
Ogino, Y. and Costa, T.
Thrombin is the major serum factor stimulating phosphoinositide turnover, but not DNA synthesis in human neuroblastoma SH-EP cells (225) 299
Ogle, C.W., see Achike, F.I. (219) 369

O'Halloran, K.P., see Mele, P.C. (218) 229
Ohara-Imaizumi, M., see Inoue, K. (215) 321
Ohashi, M., see Temma, K. (220) 63
Ohfune, Y., see Kawai, M. (211) 195
Ohhashi, K., see Notsu, T. (220) 35
Ohlstein, E.H., Arleth, A., Bryan, H., Elliott, J.D. and Sung, C.P.
The selective endothelin ET_A receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis (225) 347
Ohlstein, E.H., see Douglas, S.A. (221) 315
Ohno, M., Yamamoto, T. and Watanabe, S.
Intrahippocampal injections of benzodiazepine and muscimol impair working memory but not reference memory of rats in the three-panel runway task (219) 245
Ohrui, T., see Morikawa, M. (217) 31
Ohta, K., see Eguchi, S. (225) 79
Ohtaka, H., see Hara, H. (221) 193
Ohtsuka, T., see Kuwahara, T. (221) 99
Ohyama, M., see Kunihara, M. (214) 111
Ohzawa, N., see Shinkawa, T. (219) 217
Oka, S., see Ogino, K. (212) 9
Oka, S., see Ogino, K. (219) 493
Okada, Y., Yanagisawa, T. and Taira, N.
E4080 has a dual action, as a K^+ channel opener and a Ca^{2+} channel blocker, in canine coronary artery smooth muscle (218) 259
Okada, Y., see Sadoshima, S. (224) 109
Okajima, F., see Tada, S. (227) 25
Okajima, F., see Tomura, H. (226) 363
Okakura, K., Yamatodani, A., Mochizuki, T., Horii, A. and Wada, H.
Glutamatergic regulation of histamine release from rat hypothalamus (213) 189
Okamiya, Y., Kishimoto, T., Aoki, K., Tanabe, H. and Takeshita, T.
Relationship between tissue content of TC-81 and relaxation of rat aorta (222) 99
Okamoto, K., see Sakuta, H. (226) 199
Okamura, T., Nishikawa, M., Yoshida, K. and Toda, N.
AE0047, a new dihydropyridine Ca^{2+} entry blocker, inhibits the responses to adrenergic nerve stimulation and substance P in dog mesenteric arteries (220) 27
Okumura, K., Ichihara, K. and Nagasaka, M.
Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein (215) 253
Okumura, K., see Ujike, H. (211) 323
Okumura, T., see Tsuji, K. (210) 213
Olds, M.E. and Yuwiler, A.
Effects of acute and chronic fenfluramine on self-stimulation and its facilitation by amphetamine (216) 363
Oleggini, R., see Ghiggeri, G.M. (228) 77
Olijve, W., see Stam, N.J. (227) 153
Olivares-Reyes, A., see García-Sáinz, J.A. (227) 325
Olivares-Reyes, J.A., see García-Sáinz, J.A. (227) 239
Olivera, B.M., see Hammerland, L.G. (226) 239
Olivier, B., see Mos, J. (212) 295
Olpe, H.-R., see Andre, P. (218) 137
Omoya, H., see Yoshida, N. (216) 435
Onaya, T., see Tawata, M. (212) 87
Ong, J., Kerr, D.I.B., Berthelot, P., Vaccher, C., Flouquet, N. and Debaert, M.
Actions of thienyl analogs of baclofen in the guinea-pig isolated ileum (218) 343
Ong, J., Kerr, D.I.B., Berthelot, P., Vaccher, C., Flouquet, N. and Debaert, M.
Differing actions of β-(2-thienyl)-γ-aminobutyric acid in central and peripheral preparations (221) 145
Ono, H., see Yamazaki, J. (220) 237
Onodera, H., see Hara, H. (209) 195
Ooboshi, H., see Sadoshima, S. (224) 109
Oortgiesen, M., see Zwart, R. (228) 165
Orallo, F., see Gil-Longo, J. (221) 1
Oriowo, M.A., Bevan, R.D. and Bevan, J.A.
Vascular α-adrenoceptor affinity variation is not due to varying populations of subtypes distinguished by WB 4101 and chlorethylclonidine (216) 415
Orme, J., see Gwilt, M. (220) 231
Ortiz, J.L., see Cortijo, J. (221) 43
Orts, A., see Ballesta, J.J. (227) 349
Oset, C., see Pérez-Otaño, I. (217) 211
Osumi, Y., see Nagata, M. (223) 153
Otero Losada, M.E. and Acosta, G.B.
Effects of baclofen on amino acid release (224) 21
Otero Losada, M.E. and Rubio, M.C.
Effects of i.c.v. lithium chloride administration on monoamine concentration in rat mediobasal hypothalamus (215) 185
Otsuka, M., see Yanagisawa, M. (220) 111
Otsuka, Y., see Nakaki, T. (219) 311
Otsuki, S., see Ujike, H. (211) 323
Ott, T., see Harhammer, R. (209) 263
Ottallah, M., see Honscha, W. (226) 215
Oudenhoven, I.M.J., see Zwijsen, R.M.L. (228) 115
Overton, P., Elliott, P.J., Hagan, R.M. and Clark, D.
Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat (213) 165
Ozaki, H., see Sanagi, M. (222) 247
Ozaki, Y., see Tawata, M. (212) 87
Ozmen, V., see Mungan, Z. (214) 53

Paans, A.M.J., see Van Waarde, A. (222) 107
Paeile, C., see Miranda, H.F. (217) 137
Pageaux, J.-F., see Fayard, J.-M. (216) 127
Paiva, A.C.M., see Miasiro, N. (214) 133
Pak, H.S., see Molenaar, P. (209) 257
Pal, S.P., see Banerji, S. (219) 211
Palacios, J.M., see Pombo-Villar, E. (226) 317
Pallas, M., see Escubedo, E. (225) 15
Palmer, A.J., Zeman, S. and Lodge, D.
Methohexitone antagonises kainate and epileptiform activity in rat neocortical slices (221) 205
Palmer, R.M.J., see Gardiner, S.M. (213) 449
Pandey, G.N., Pandey, S.C., Isaac, L. and Davis, J.M.
Effect of electroconvulsive shock on 5-HT_2 and α_1-adrenoceptors and phosphoinositide signalling system in rat brain (226) 303
Pandey, S.C., see Pandey, G.N. (226) 303
Panerai, A.E., see Bianchi, M. (219) 113
Pang, C.C.Y., see Abdelrahman, A. (217) 185
Pang, C.C.Y., see Tabrizchi, R. (219) 141
Panickar, K.S. and McNaughton, N.
Comparison of the effects of buspirone and chlordiazepoxide on differential reinforcement of low rates of response (210) 307
Pantalone, D., see Gentilini, G. (217) 9
Paoletti, A.M., see Abbracchio, M.P. (227) 317
Papi, A., see Mapp, C.E. (228) 103
Parenti, P., see Masereel, B. (219) 385
Parini, A., see Tesson, F. (219) 335
Parker, R.D.R., see Hsieh, G.-C. (228) 107
Parolaro, D., see Basilico, L. (218) 75
Parolaro, D., see Basilico, L. (222) 241
Parolaro, D., see Patrini, G. (210) 259
Parratt, J., see McIntosh, M. (210) 37
Parratt, J., see McIntosh, M. (210) 45
Parratt, J.R., see Guc, M.O. (224) 63
Pascal, M., see Bârzu, T. (219) 225
Pasquale, C.P., Silva, P.M.R., Lima, M.C.R., Diaz, B.L., Rihoux, J.P., Vargaftig, B.B., Cordeiro, R.S.B. and Martins, M.A.

Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats (223) 9
Pasquale, C.P., see Martins, M.A. (220) 55
Pasternak, G.W., see Cheng, J. (226) 15
Pasternak, G.W., see Kolesnikov, Y.A. (221) 399
Pasternak, G.W., see Pick, C.G. (211) 375
Pasternak, G.W., see Pick, C.G. (220) 275
Pasternak, G.W., see Tive, L.A. (216) 249
Pasyk, E., Mao, Y.-K., Ahmad, S., Shen, S.-H. and Daniel, E.E.
An endothelial cell-line contains functional vasoactive intestinal polypeptide receptors: they control inwardly rectifying K^+ channels (212) 209
Patacchini, R., Santicioli, P., Astolfi, M., Rovero, P., Viti, G. and Maggi, C.A.
Activity of peptide and non-peptide antagonists at peripheral NK_1 receptors (215) 93
Patel, J., see Zinkand, W.C. (212) 129
Patel, S., see Freedman, S.B. (215) 135
Patrini, G., Massi, P., Rubino, T., Donin, L., Gori, E. and Parolaro, D.
Further investigations on the antipropulsive effect of centrally administered histamine and its relation with morphine (210) 259
Patrono, C., see Salvati, P. (221) 267
Paul, D., see Pick, C.G. (211) 375
Paul, D., see Tive, L.A. (216) 249
Paul, I.A., see Basile, A.S. (227) 95
Pazos, A., see González, A.M. (214) 261
Pazos, A., see González, A.M. (223) 25
Pazos, A., see Peterson, C.J. (221) 151
Pedersen, H., see Arnt, J. (218) 159
Pedigo, Jr., N.W. and Rice, M.A.
Neuropeptide modulation of muscarinic receptors and function in cerebral cortex of young and senescent rats (225) 151
Peeters, B.W.M.M., see Tonnaer, J.A.D.M. (214) 33
Peglion, J.-L., see Morain, P. (220) 11
Pelissier, T., see Miranda, H.F. (217) 137
Pellicciari, R., see Moroni, F. (218) 145
Pelloni, F., see Ferrari, F. (210) 17
Pelloni, F., see Ferrari, F. (216) 345
Penke, B., see Bidzseranova, A. (211) 411
Penn, A., Currie, J. and Snyder, C.
Inhalation of carbon monoxide does not accelerate arteriosclerosis in cockerels (228) 155
Pennefather, J.N., see Chin, J.P.F. (212) 201
Penz, W.P., see Pugsley, M.K. (212) 15
Peoples, R.W., see Giridhar, J. (213) 317
Pérez, H., Ruiz, S., Inostroza, H. and Perretta, M.
Substance P depresses bioelectrical responses evoked in the nucleus tractus solitarii: interaction with γ-aminobutyric acid-ergic neurons (213) 435
Pérez-Otaño, I., Oset, C., Herrero, M.T., Luquin, M.R., Kupsch, A., Oertel, W., Obeso, J.A. and Del Río, J.
Neurotoxic effect of prenatal exposure to MPTP on the dopaminergic systems of the marmoset brain (217) 211
Perez-Prieto, J., see Ivorra, M.D. (219) 303
Peričić, D., see Tvrdeić, A. (221) 139
Perlmutter, J.S., see Moerlein, S.M. (218) 109
Pernow, J., Modin, A. and Lundberg, J.M.
No effect of D-myo-inositol-1,2,6-triphosphate on vasoconstriction evoked by neuropeptide Y and non-adrenergic sympathetic nerve stimulation (222) 171
Perreault, C.L., see Qiu, Z. (214) 293
Perretta, M., see Pérez, H. (213) 435
Perrisoud, D., see Pretolani, M. (216) 141
Perrone, M.H., see Merkel, L.A. (216) 29
Persson, M.G. and Gustafsson, L.E.
Ethanol can inhibit nitric oxide production (224) 99
Perzborn, E., see Theis, J.G.W. (226) 149
Peskar, B.A., see Simmet, T. (211) 319
Peskar, B.A., see Sinzinger, H. (219) 129
Pessia, M., see Prisco, S. (214) 13
Peters, T., see Wermelskirchen, D. (219) 253
Peterson, C.J., Vinayak, S., Pazos, A. and Gale, K.
A rodent model of focally evoked self-sustaining status epilepticus (221) 151
Petit, J.-M., Denoroy, L. and Jouvet, M.
Effects of chronic atropine administration on regional vasoactive intestinal polypeptide concentrations in rat brain (212) 79
Petit, P., Manteghetti, M., Berdeu, D., Ribes, G. and Loubatières-Mariani, M.-M.
Effects of a peripheral-type benzodiazepine on glucose-induced insulin secretion (221) 359
Petit, P., see Bertrand, G. (214) 159
Petit-Taboué, M.C., see Abadie, P. (213) 107
Petitou, M., see Bârzu, T. (219) 225
Petrini, A., see Grignaschi, G. (211) 137
Pettinger, W.A., see Sun, L. (226) 367
Petty, M.A., Grisar, J.M. and De Jong, W.
Protective effects of an α-tocopherol analogue against myocardial reperfusion injury in rats (210) 85
Petzinger, E. and Fückel, D.
Evidence for a saturable, energy-dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes (213) 381
Petzinger, E., see Fückel, D. (213) 393
Petzinger, E., see Honscha, W. (226) 215
Pfeilschifter, J., Huwiler, A., Merriweather, C. and Briner, V.A.
Angiotensin II stimulation of phospholipase D in rat renal mesangial cells is mediated by the AT_1 receptor subtype (225) 57
Phan, T.-H., see Corley, K.C. (213) 417
Phaneuf, S., see Howard, S. (227) 123
Phelps, C.L., see Bank, P.A. (228) 85
Philippu, A., see Prast, H. (216) 139
Phillips, M.I., see Bui, J.D. (219) 147
Piccardoni, P., see Evangelista, V. (216) 401
Pick, C.G., Paul, D., Eison, M.S. and Pasternak, G.W.
Potentiation of opioid analgesia by the antidepressant nefazodone (211) 375
Pick, C.G., Roques, B., Gacel, G. and Pasternak, G.W.
Supraspinal μ_2-opioid receptors mediate spinal/supraspinal morphine synergy (220) 275
Pick, C.G., see Kolesnikov, Y.A. (221) 399
Pick, C.G., see Tive, L.A. (216) 249
Pieper, G.M., see Tseng, L.F. (212) 301
Pierce, S.K., see Reilly, T.M. (226) 179
Pietraszek, M.H., Takada, Y. and Takada, A.
Endothelins inhibit serotonin-induced platelet aggregation via a mechanism involving protein kinase C (219) 289
Pilc, A., Nowak, G. and Zak, J.
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible receptor inactivator, as a tool for measurement of α_2-adrenoceptor occupancy in vivo (212) 109
Pillar, J., see Chand, N. (211) 121
Piller, C., see Allescher, H.-D. (217) 153
Pilon, C., see Sokoloff, P. (225) 331
Pin, J.-P., see Tapia-Arancibia, L. (225) 253
Pinardi, G., see Miranda, H.F. (217) 137
Pinna, C., Caratozzolo, O. and Puglisi, L.
A possible role for urinary bladder epithelium in bradykinin-induced contraction in diabetic rats (214) 143
Pintado, A., see Aleixandre, A. (221) 129
Pinxteren, J., see Jimenez Del Rio, M. (225) 225
Piper, I., Downing, S.J. and Hollingsworth, M.
Cross tolerance between cromakalim and RP49356 in the uterus of the rat in vivo and in vitro (219) 347

Piper, P.J., see Conroy, D.M. (218) 43
Piper, P.J., see McLeod, J.D. (212) 67
Piqué, J.M., see Martinez-Cuesta, M.A. (218) 351
Pírková, J., see Maletínská, L. (222) 233
Pirotte, B., see Masereel, B. (219) 385
Pisani, T., see Kilbourn, M.R. (216) 109
Pistis, M., see Diana, M. (221) 403
Pizzi, M., Ribola, M., Valerio, A., Memo, M. and Spano, P.F.
Various Ca^{2+} entry blockers prevent glutamate-induced neurotoxicity (209) 169
Pizzi, M., see Nisoli, E. (216) 81
Plante, G.E., see Sirois, M.G. (214) 119
Plebani, M., see Crescioli, S. (228) 45
Pöch, G., see Holzmann, S. (215) 1
Pocock, J.M. and Nicholls, D.G.
A toxin (Aga-GI) from the venom of the spider *Agelenopsis aperta* inhibits the mammalian presynaptic Ca^{2+} channel coupled to glutamate exocytosis (226) 343
Poggioli, R., Rasori, E. and Bertolini, A.
Galanin inhibits sexual behavior in male rats (213) 87
Pohjalainen, T., see Lappalainen, J. (210) 195
Poiger, H., see Ahlborg, U.G. (228) 179
Polak, J.M., see Knock, G.A. (219) 415
Polak, J.M., see Rutherford, R.A.D. (212) 1
Polastron, J., Jauzac, P. and Meunier, J.-C.
The δ-opioid receptor in neuroblastoma × glioma NG 108-15 hybrid cells is strongly precoupled to a G-protein (226) 133
Pollard, C.E., see Jackson, D.M. (221) 175
Pollard, G.T., Nanry, K.P. and Howard, J.L.
Effects of tandospirone in three behavioral tests for anxiolytics (221) 297
Pollio, G., see Spreafico, E. (227) 353
Pollo, A., see Sher, E. (216) 407
Poloczek, P., see Delporte, C. (224) 183
Poloczek, P., see Delporte, C. (227) 247
Pombo-Villar, E., Wiederhold, K.-H., Mengod, G., Palacios, J.M., Supavilai, P. and Boddeke, H.W.G.M.
Stereoisomerism and muscarinic receptor agonists: synthesis and effects of the stereoisomers of 3-[5-(3-amino-1,2,4-oxadiazol)yl]-1-azabicyclo[2.2.1]heptane (226) 317
Ponchant, M., see Fajolles, C. (216) 53
Pons, F., Touvay, C., Lagente, V., Mencia-Huerta, J.M. and Braquet, P.
Involvement of a phosphoramidon-sensitive endopeptidase in the processing of big endothelin-1 in the guinea-pig (217) 65
Poole-Wilson, P.A., see Harding, S.E. (223) 39
Poole-Wilson, P.A., see Jiang, C. (211) 163
Popoli, P., see Caporali, M.G. (223) 15
Porreca, F., see Menkens, K. (219) 345
Porreca, F., see Raffa, R.B. (216) 453
Pörsti, I., see Arvola, P. (214) 289
Porter, R.H.P., Briggs, R.S.J. and Roberts, P.J.
Modulation of [^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid ([^{3}H]CPP) binding by ligands acting at the glycine and the polyamine sites of the rat brain NMDA receptor complex (227) 83
Porter, R.H.P., Cowburn, R.F., Alasuzoff, I., Briggs, R.S.J. and Roberts, P.J.
Heterogeneity of NMDA receptors labelled with [^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid ([^{3}H]CPP): receptor status in Alzheimer's disease brains (225) 195
Portoghese, P.S., Sultana, M., Nagase, H. and Takemori, A.E.
A highly selective δ_1-opioid receptor antagonist: 7-benzylidenenaltrexone (218) 195
Portoghese, P.S., see Menkens, K. (219) 345
Portoghese, P.S., see Sofuoglu, M. (210) 159
Portoghese, P.S., see Sofuoglu, M. (216) 273
Post, C., see Näsström, J. (212) 21
Postorino, A., see Mulè, F. (212) 215
Poth, M., see Mos, J. (212) 295
Potter, B.V.L., see Safrany, S.T. (226) 265
Potter, E.K., Edvinsson, L. and Gustafsson, T.
Antagonism of pre- and postjunctional responses to neuropeptide Y and sympathetic stimulation by D-myo-inositol-1,2,6-trisphosphate in the anaesthetised dog (221) 307
Potter, T., see Van Hartesveldt, C. (214) 27
Potter, W.Z., see Manji, H.K. (227) 275
Poulsson, C., see Stokke, M. (227) 379
Poverenny, A.M., see Vrána, O. (226) 5
Pozzoli, G., see Preziosi, P. (221) 343
Pranzatelli, M.R., see Trifiletti, R.R. (226) 377
Prasad, A., see Reynolds, J.N. (224) 173
Prast, H. and Philippu, A.
Nitric oxide releases acetylcholine in the basal forebrain (216) 139
Prat, A., see Hasséssian, H. (227) 103
Prenant, C., see Varastet, M. (213) 275
Pretolani, M., Lefort, J., Venco, C., Perrisoud, D. and Vargaftig, B.B.
Inhibition by azelastine of the effects of platelet-activating factor in lungs from actively sensitised guinea-pigs (216) 141
Preuss, J.M.H., Henry, P.J. and Goldie, R.G.
Influence of age on epithelium-dependent responsiveness of guinea-pig and rat tracheal smooth muscle to spasmogens (228) 3
Preuss, J.M.H., see Fernandes, L.B. (212) 187
Prezeau, L., see Manzoni, O. (225) 357
Preziosi, P., D'Amato, M., Del Carmine, R., Martire, M., Pozzoli, G. and Navarra, P.
The effects of 5-HT_3 receptor antagonists on cisplatin-induced emesis in the pigeon (221) 343
Primus, R.J. and Gallager, D.W.
$GABA_A$ receptor subunit mRNA levels are differentially influenced by chronic FG 7142 and diazepam exposure (226) 21
Prisco, S., Pessia, M., Ceci, A., Borsini, F. and Esposito, E.
Chronic treatment with DAU 6215, a new 5-HT_3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area (214) 13
Pritze, S., see Simmet, T. (211) 319
Privat, A., see Chergui, K. (219) 169
Prosdocimi, M., see Mollace, V. (222) 181
Prosdocimi, M., see Squadrito, F. (210) 107
Pruneau, D. and Bélichard, P.
Haemodynamic and humoral effects of ω-conotoxin GVIA in normotensive and spontaneously hypertensive rats (211) 329
Puech, A.J., see Martin, P. (212) 73
Puerro, M., see Aleixandre, A. (221) 129
Puglisi-Allegra, S., see Imperato, A. (212) 299
Puglisi, L., see Pinna, C. (214) 143
Pugsley, M.K., Penz, W.P., Walker, M.J.A. and Wong, T.M.
Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion (212) 15
Puig, J., see Fernández, A.G. (222) 257

Qadri, F., see Gradin, K. (218) 363
Qiu, Z., Wang, J., Perreault, C.L., Meuse, A.J., Grossman, W. and Morgan, J.P.
Effects of endothelin on intracellular Ca^{2+} and contractility in single ventricular myocytes from the ferret and human (214) 293
Quast, U., see Small, R.C. (219) 81
Quirion, R., see Aubert, I. (217) 173
Quirion, R., see Chaudieu, I. (220) 203

Rademaker, B., see Jansen, F.P. (217) 203
Raeburn, D., see Underwood, S.L. (210) 97

Raffa, R.B. and Martinez, R.P.
Morphine antinociception is mediated through a LiCl-sensitive, IP_3-restorable pathway (215) 357
Raffa, R.B., Connelly, C.D. and Martinez, R.P.
Opioid efficacy is linked to the LiCl-sensitive, inositol-1,4,5-trisphosphate-restorable pathway (217) 221
Raffa, R.B., Martinez, R.P. and Porreca, F.
Lack of antinociceptive efficacy of intracerebroventricular [D-Ala^2,Glu^4]deltorphin, but not [D-Pen^2,D-Pen^5]enkephalin, in the μ-opioid receptor deficient CXBK mouse (216) 453
Rafferty, M.F., see Stapelfeld, A. (214) 273
Rage, F., see Tapia-Arancibia, L. (225) 253
Ragheb, M.S., see Nossaman, B.D. (213) 1
Raghunathan, G., see Cruciani, R.A. (226) 287
Raiteri, M., Marchi, M., Bonanno, G., Fedele, E. and Versace, P.
Dopamine release and dopaminergic inhibition of acetylcholine release in rat striatal slices after nigro-striatal hemitransection and parenteral ganglioside administration (213) 17
Rajdev, S., see Reynolds, I.J. (226) 53
Ralevic, V., see Rubino, A. (220) 95
Ramacci, M.T., see Harsing, Jr., L.G. (218) 117
Ramage, A.G., Clement, M.E. and McCall, R.B.
8-OH-DPAT-induced inhibition of renal sympathetic nerve activity and serotonin neuronal firing (219) 165
Ramaswamy, S., Srinivasan, D. and Bapna, J.S.
Inhibition of tetrahydroisoxazolo-pyridin-3-ol and muscimol and its mechanism on gastrointestinal transit in mice (220) 147
Ramp, U., see Wölfel, C. (228) 95
Ramsay, E., see Jackson, H.C. (216) 23
Ramsey, R.L., see Macdonald, A.G. (210) 223
Rand, M.J., see Mian, M.A. (213) 47
Randle, J.C.R., Guet, T., Cordi, A. and Lepagnol, J.M.
Competitive inhibition by NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution (215) 237
Rapoport, R.M., see Bazan, E. (227) 343
Rappay, G., see Horváth, G. (225) 305
Rappe, C., see Ahlborg, U.G. (228) 179
Rasmussen, K., Stockton, M.E., Czachura, J.F. and Howbert, J.J.
Cholecystokinin (CCK) and schizophrenia: the selective CCK_B antagonist LY262691 decreases midbrain dopamine unit activity (209) 135
Rasori, E., see Poggioli, R. (213) 87
Rau, C., see Holopainen, I. (227) 225
Ravert, H.T., see Lever, J.R. (216) 459
Ravin, R.R., see Case, C.L. (218) 213
Reber, B.F.X., see Neuhaus, R. (226) 183
Récasens, M., see Tapia-Arancibia, L. (225) 253
Redegeld, F.A.M., Moison, R.M.W., Koster, A.S. and Noordhoek, J.
Depletion of ATP but not of GSH affects viability of rat hepatocytes (228) 229
Reggiani, A., see Chiamulera, C. (216) 335
Regoli, D., see Rhaleb, N.-E. (210) 115
Regoli, D., see Rollandy, I. (209) 95
Regoli, D., see Tousignant, C. (225) 235
Reid, A., see Sawynok, J. (223) 49
Reid, L.D., see Menkens, K. (219) 345
Reilly, T.M., Christ, D.D., Duncia, J.V., Pierce, S.K. and Timmermans, P.B.M.W.M.
Monoclonal antibodies to the nonpeptide angiotensin II receptor antagonist, losartan (226) 179
Reina, G., see Nisoli, E. (216) 81
Reis, D.J., see Sun, M.-K. (224) 93
Reis, D.J., see Sun, M.-k. (215) 9
Reiser, G.
Nitric oxide formation caused by Ca^{2+} release from internal stores in neuronal cell line is enhanced by cyclic AMP (227) 89
Reith, M.E.A., De Costa, B., Rice, K.C. and Jacobson, A.E.
Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter (227) 417
Remacle-Volon, G., see Damas, J. (211) 81
Remie, R., Van Rossum, J.X.M., Coppes, R.P. and Zaagsma, J.
Dysfunctional presynaptic α_2-adrenoceptors expose facilitatory β_2-adrenoceptors in the vasculature of spontaneously hypertensive rats (211) 257
Ren, K., Williams, G.M., Hylden, J.L.K., Ruda, M.A. and Dubner, R.
The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats (219) 235
Ren, L.-M., see Iwatsuki, K. (209) 63
Ren, L.-M., see Iwatsuki, K. (218) 237
Ren, L.-M., see Takei, M. (219) 15
Renesto, P., see Nahori, M.-A. (228) 213
Rengel, I., Sinowatz, F. and Schulz, R.
Opioid-controlled adenylate cyclase in the guinea-pig myenteric plexus is confined to nerve somata (227) 385
Renming, X., Ishihara, K., Sasa, M., Ujihara, H., Momiyama, T., Fujita, Y., Todo, N., Serikawa, T., Yamada, J. and Takaori, S.
Antiepileptic effects of CNK-602A, a novel thyrotropin-releasing hormone analog, on absence-like and tonic seizures of spontaneously epileptic rats (223) 185
Rensing, H., see Jackisch, R. (226) 245
Renzetti, A.R., see Brown, M.C.S. (227) 163
Repke, H., see Harhammer, R. (209) 263
Revel, L., Ferrari, F., Makovec, F., Rovati, L.C. and Impicciatore, M.
Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative (216) 217
Reverte, M., see García-Barrado, M.J. (219) 461
Reymann, K.G., see Fedorov, N.B. (228) 201
Reynolds, D.J.M., see Newberry, N.R. (221) 157
Reynolds, G.P., see Mason, S.L. (221) 397
Reynolds, I.J., Rothermund, K., Rajdev, S., Fauq, A.H. and Kozikowski, A.P.
[^{125}I]Thienylphencyclidine, a novel ligand for the NMDA receptor (226) 53
Reynolds, J.N., Prasad, A. and MacDonald, J.F.
Ethanol modulation of GABA receptor-activated Cl^- currents in neurons of the chick, rat and mouse central nervous system (224) 173
Rhaleb, N.-E., Rouissi, N., Jukic, D., Regoli, D., Henke, S., Breipohl, G. and Knolle, J.
Pharmacological characterization of a new highly potent B_2 receptor antagonist (HOE 140: D-Arg-[Hyp^3,Thi^5,D-Tic^7,Oic^8]bradykinin) (210) 115
Rhaleb, N.-E., see Tousignant, C. (225) 235
Ribes, G., see Bertrand, G. (214) 159
Ribes, G., see Hillaire-Buys, D. (218) 359
Ribes, G., see Petit, P. (221) 359
Ribola, M., see Pizzi, M. (209) 169
Ricalde, A.R., see Hammer, Jr., R.P. (209) 253
Ricci, D., Taira, C.A. and Enero, M.A.
Cardiovascular responses of sinoaortic-denervated rats to intracerebroventricular injection of α_1- and α_2-adrenoceptor agonists (212) 195
Rice, J.C., see Mungan, Z. (214) 53
Rice, K.C., see Reith, M.E.A. (227) 417
Rice, M.A., see Pedigo, Jr., N.W. (225) 151
Rice, P.J., see Abraham, S.T. (218) 243
Richards, S.J., see Challiss, R.A.J. (226) 121
Richelson, E., see Yamada, M. (226) 187
Richter, A., see Gerdes, C. (220) 91
Riddall, D.R.

A comparison of the selectivities of SCH 23390 with BW737C89 for D_1, D_2 and 5-HT_2 binding sites both in vitro and in vivo (210) 279
Riederer, P., see Gerlach, M. (226) 97
Riekkinen, Jr., P., see Jäkälä, P. (221) 351
Riekkinen, P., see Jäkälä, P. (221) 351
Riemersma, R.A., see Du, X.-J. (211) 221
Riesco, A., see Gómez-Garre, D. (224) 167
Rietjens, I.M.C.M., see Hempenius, R.A. (228) 207
Rigby, P.J., Self, G.J. and Goldie, R.G.
Eosinophil peroxidase and $^{125}I^-$ ion binding in guinea-pig trachea (228) 141
Riggle, P.C., see Walters, M.R. (213) 309
Rihoux, J.P., see Pasquale, C.P. (223) 9
Rioux, P., see Abadie, P. (213) 107
Rittenhouse, P.A., see Levy, A.D. (221) 121
Rivas, F.J., see Cambronero, J.C. (219) 75
Rivera, L.M., see Merkel, L.A. (216) 29
Rizzonelli, P., see Sigala, S. (211) 351
Roach, A.G., see Berridge, T.L. (213) 205
Roach, A.G., see Berridge, T.L. (213) 213
Roberts, D.J., see Fernández, A.G. (222) 257
Roberts, P.J., see Porter, R.H.P. (225) 195
Roberts, P.J., see Porter, R.H.P. (227) 83
Roberts, S.J., see Molenaar, P. (209) 257
Roberts, S.M., see Jackson, D.M. (221) 175
Robertson, D.W., see Cohen, M.L. (211) 43
Robertson, G.S., Hubert, G.W., Tham, C.-S. and Fibiger, H.C.
Lesions of the mesotelencephalic dopamine system enhance the effects of selective dopamine D_1 and D_2 receptor agonists on striatal acetylcholine release (219) 323
Robertson, H.A., see Chiasson, B.J. (227) 451
Robinson, N.E., see Killingsworth, C.R. (210) 231
Rodrigues, M.S., Schaffel, R. and Assreuy, J.
Comparative study on the mechanism of bradykinin potentiation induced by bradykinin-potentiating peptide 9a, enalaprilat and kinin-potentiating peptide (216) 357
Rodriguez, M., see Dubuc, I. (219) 327
Rodríguez Del Castillo, A., see Trifaró, J.-M. (225) 83
Røed, A.
Separate sites for the dantrolene-induced inhibition of contracture of the rat diaphragm preparation due to depolarization or to caffeine (209) 33
Roeder, T., see Wedemeyer, S. (223) 173
Roeske, W.R., see Henderson, A.K. (225) 175
Rogers, D.F., see Kuo, H.-P. (215) 297
Rohde, J.A.L., see Kuo, H.-P. (215) 297
Rolfsen, W., see Strömbom, J. (214) 165
Rollandy, I., Guillemain, I., Imhoff, V., Drapeau, G., Regoli, D. and Rossignol, B.
Involvement of NK_1 receptors and importance of the N-terminal sequence of substance P in the stimulation of protein secretion in rat parotid glands (209) 95
Roman, C.R., see Silbaugh, S.A. (223) 57
Romero-Avila, M.T., see García-Sáinz, J.A. (227) 239
Romero-Avila, M.T., see García-Sáinz, J.A. (227) 325
Rompré, P.-P., Bauco, P. and Gratton, A.
Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1–13) (211) 295
Rooney, S., see Chand, N. (211) 121
Roques, B., see Pick, C.G. (220) 275
Roques, B.P., see Baamonde, A. (216) 157
Roques, B.P., see Calenco-Choukroun, G. (209) 267
Roques, B.P., see Cheng, J. (226) 15
Roques, B.P., see Durieux, C. (209) 185
Roques, B.P., see Noble, F. (223) 83
Roques, B.P., see Noble, F. (223) 91
Roques, B.P., see Tive, L.A. (216) 249
Rosa, B., see Salvati, P. (221) 267
Roscetti, G., see Barbaccia, M.L. (219) 485
Roscoe, W.A., see Leung, K.H. (227) 63
Rose, S., see Taylor, M.D. (219) 183
Rosenkranz, B., see Englert, H.C. (210) 69
Ross, G., see Chyu, K.-Y. (212) 159
Ross, S.B., see Ericson, H. (226) 157
Ross, S.B., see Marcusson, J.O. (215) 191
Rosseneu, M., see Jorens, P.G. (212) 113
Rossetti, Z.L., Hmaidan, Y. and Gessa, G.L.
Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats (221) 227
Rossetti, Z.L., see Diana, M. (221) 403
Rossi, F., see Maione, S. (219) 477
Rossignol, B., see Rollandy, I. (209) 95
Rossowski, W.J., see Mungan, Z. (214) 53
Rostène, W., Boja, J.W., Scherman, D., Ivy Carroll, F. and Kuhar, M.J.
Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum (218) 175
Roth, G.S., see Villalobos-Molina, R. (226) 129
Roth, J.E., Zhang, G., Murray, T.F. and Franklin, P.H.
Dextrorotatory opioids and phencyclidine exert anticonvulsant action in prepiriform cortex (215) 293
Rothermund, K., see Reynolds, I.J. (226) 53
Rouissi, N., see Rhaleb, N.-E. (210) 115
Rourke, J.D., see Gwilt, M. (220) 231
Rousseau, A., see Filep, J.G. (219) 343
Rousseau, A., see Filep, J.G. (220) 263
Rousseau, A., see Sirois, M.G. (214) 119
Rovati, G.E., see Abbracchio, M.P. (227) 317
Rovati, L.C., see Revel, L. (216) 217
Rovero, P., see Brown, M.C.S. (227) 163
Rovero, P., see Patacchini, R. (215) 93
Rowell, P.P., see Carr, L.A. (215) 285
Roy, J.B., see Bodanszky, M. (216) 311
Roye, M., see Hillaire-Buys, D. (218) 359
Rubino, A., Ralevic, V. and Burnstock, G.
Prejunctional modulation of sensory-motor nerve mediated vasodilation of the rat mesenteric arterial bed by adenosine (220) 95
Rubino, A., Thomann, H., Henlin, J.-M., Schilling, W. and Criscione, L.
Endothelium-dependent relaxant effect of neurokinins on rabbit aorta is mediated by the NK_1 receptor (212) 237
Rubino, A., see Amerini, S. (216) 445
Rubino, A., see Mantelli, L. (213) 79
Rubino, T., see Basilico, L. (218) 75
Rubino, T., see Patrini, G. (210) 259
Rubio, E., Estañ, L.A., Morales-Olivas, F.J. and Martinez-Mir, I.
Influence of hormonal treatment on the response of the rat isolated uterus to histamine and histamine receptor agonists (212) 31
Rubio, M.C., see Otero Losada, M.E. (215) 185
Rubio, R., see Balcells, E. (210) 1
Ruch, S., Kennedy, R.H. and Seifen, E.
Aging: inotropic effects of Bay K-8644 and nifedipine on rat cardiac muscle (216) 393
Ruda, M.A., see Ren, K. (219) 235
Rüegg, J.C., see Strauss, J.D. (227) 437
Ruffolo, Jr., R.R., see Yue, T.-L. (214) 277
Ruigt, G.S.F., see Fernhout, B.J.H. (213) 313
Ruiz-Gayo, M., see Baamonde, A. (216) 157
Ruiz-Gayo, M., see Durieux, C. (209) 185
Ruiz, S., see Pérez, H. (213) 435

Rundfeldt, C. and Löscher, W.
Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats (213) 351
Russell, S.N., see Smirnov, S.V. (217) 105
Rutherford, R.A.D., Wharton, J., Gordon, L., Moscoso, G., Yacoub, M.H. and Polak, J.M.
Endocardial localization and characterization of natriuretic peptide binding sites in human fetal and adult heart (212) 1
Ryoo, H., see Murray, A.M. (227) 443

Saano, V., see Strömbom, J. (214) 165
Saavedra, H., see Miranda, H.F. (217) 137
Saavedra, J.M., see Tsutsumi, K. (226) 169
Sabouni, M.H., see Makujina, S.R. (221) 243
Sabra, R. and Branch, R.A.
Effect of amphotericin B on intracellular calcium levels in cultured glomerular mesangial cells (226) 79
Sachinidis, A., see Ko, Y. (227) 215
Sadée, W., see Lameh, J. (227) 19
Sadoshima, S., Ibayashi, S., Nakane, H., Okada, Y., Ooboshi, H. and Fujishima, M.
Attenuation of ischemic and postischemic damage to brain metabolism and circulation by a novel Ca^{2+} channel antagonist, NC-1100, in spontaneously hypertensive rats (224) 109
Sáez, J., see Ivorra, M.D. (219) 303
Safe, S.H., see Ahlborg, U.G. (228) 179
Safrany, S.T., Wilcox, R.A., Liu, C., Potter, B.V.L. and Nahorski, S.R.
3-Position modification of myo-inositol 1,4,5-trisphosphate: consequences for intracellular Ca^{2+} mobilisation and enzyme recognition (226) 265
Sahin-Erdemli, I., see Schoeffter, P. (219) 295
Said, S.I., see Bodanszky, M. (216) 311
Saigusa, T., see Kikuchi de Beltrán, K. (214) 181
Saigusa, T., see Koshikawa, N. (209) 75
Sainz, R.D., see Molenaar, P. (209) 257
Saito, H., see Watanabe, Y. (223) 179
Saito, K., see Tsujino, T. (226) 69
Saito, N., see Tsujino, T. (226) 69
Saito, Y., see Hara, H. (221) 193
Saitta, A., see Squadrito, F. (210) 107
Sakai, Y., see Sakuta, H. (226) 199
Sakamoto, T., Elwood, W., Barnes, P.J. and Chung, K.F.
Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig (213) 367
Sakata, K. and Karaki, H.
Effects of endothelin on cytosolic Ca^{2+} level and mechanical activity in rat uterine smooth muscle (221) 9
Sakatume, M., see Suzuki, S. (227) 395
Sakiyama, H., see Yoshida, M. (222) 205
Sako, K., Tsuchiya, M., Yonemasu, Y. and Asano, T.
HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats (209) 39
Sakurada, S., Watanabe, H., Sakurada, T., Kisara, K., Sasaki, Y. and Suzuki, K.
Different effects of peptidase inhibitors on dermophin- and on [D-Arg^2]dermorphin-induced antinociceptive activity (211) 75
Sakurada, T., see Sakurada, S. (211) 75
Sakuta, H., Sekiguchi, M., Okamoto, K. and Sakai, Y.
Inactivation of glibenclamide-sensitive K^+ channels in *Xenopus* oocytes by various calmodulin antagonists (226) 199
Sala, M., Braida, D., Calcaterra, P., Leone, M.P. and Gori, E.
Dose-dependent conditioned place preference produced by etonitazene and morphine (217) 37
Salama, A.I., see Zinkand, W.C. (212) 129
Salari, H., see Howard, S. (227) 123
Salel, V., see Herbert, J.M. (216) 175
Salinas, P. and Barrigón, S.
Protective effects of dazmegrel on the PAF potential of ouabain-induced cardiac arrhythmias (209) 105
Salonen, J., see Jäkälä, P. (221) 351
Salvati, P., Dho, L., Calabresi, M., Rosa, B. and Patrono, C.
Evidence for a direct vasoconstrictor effect of big endothelin-1 in the rat kidney (221) 267
Samanin, R., see Carli, M. (211) 227
Samanin, R., see Grignaschi, G. (211) 137
Samanin, R., see Grignaschi, G. (212) 287
Samhoun, M.M., see Conroy, D.M. (218) 43
Samovilova, N.N. and Vinogradov, V.A.
Subcellular distribution of (+)-[^{3}H]SKF 10,047 binding sites in rat liver (225) 69
Samsel, R.W., see Umans, J.G. (210) 343
Sanada, H., see Mizuno, K. (215) 305
Sanagi, M., Ozaki, H., Mitsui, M. and Karaki, H.
Mechanism of relaxing action of the antiasthmatic drug, azelastine, in isolated porcine tracheal smooth muscle (222) 247
Sánchez, C. and Arnt, J.
Effects on body temperature in mice differentiate between dopamine D_2 receptor agonists with high and low efficacies (211) 9
Sánchez, C., see Arnt, J. (213) 259
Sánchez-Ferrer, C.F., see Fernández-Alfonso, M.S. (221) 185
Sánchez-Medina, F., see Sánchez-Pozo, A. (228) 29
Sánchez-Pozo, A., Arenas, C. and Sánchez-Medina, F.
Antihypercholesterolemic effect of dipyridamole in chickens (228) 29
Sandell, L., see Westlind-Danielsson, A. (224) 57
Sanna, E., Cuccheddu, T., Serra, M., Concas, A. and Biggio, G.
Carbon dioxide inhalation reduces the function of $GABA_A$ receptors in the rat brain (216) 457
Sano, H., see Tsujino, T. (226) 69
Sano, T., see Morishita, Y. (225) 203
Sansom, A.J., Darlington, C.L. and Smith, P.F.
Pretreatment with MK-801 reduces spontaneous nystagmus following unilateral labyrinthectomy (220) 123
Sant'Ana, A.E.G., see Duarte, D.F.P. (215) 75
Santiago, M. and Westerink, B.H.C.
The role of GABA receptors in the control of nigrostriatal dopaminergic neurons: dual-probe microdialysis study in awake rats (219) 175
Santicioli, P., see Patacchini, R. (215) 93
Santos, I.R., see Duarte, I.D.G. (217) 225
Sanz, M.C.A., see Levy, A.D. (221) 121
Sapena, R., see Morin, D. (225) 273
Saperas, E., Kauffman, G. and Taché, Y.
Role of central prostaglandin E_2 in the regulation of gastric acid secretion in the rat (209) 1
Sarda, N., see Gharib, A. (225) 359
Saripalli, L.D., see Bidlack, J.M. (227) 257
Sarrel, P.M., see Jiang, C. (211) 163
Sarria, B., see Candenas, M.-L. (210) 291
Saruta, T., see Hishikawa, K. (215) 329
Sasa, M., see Renming, X. (223) 185
Sasaki, H., see Itabashi, S. (218) 187
Sasaki, H., see Morikawa, M. (217) 31
Sasaki, H., see Tawata, M. (212) 87
Sasaki, Y., see Sakurada, S. (211) 75
Sasamoto, S., see Kogo, H. (221) 289
Sasayama, S., see Miwa, K. (214) 127
Sato, H., see Suzuki, S. (227) 395
Sato, N., see Kawano, S. (211) 55
Sato, N., see Shimizu, H. (222) 279

Sato, N., see Shimomura, Y. (209) 15
Sato, N., see Uehara, Y. (220) 119
Sato, Y., see Itoh, H. (218) 347
Satoh, H. and Sperelakis, N.
Taurine inhibition of fast Na^+ current in embryonic chick ventricular myocytes (218) 83
Satoh, K., see Yoneyama, F. (213) 199
Satoh, M., Kojima, C. and Takayanagi, I.
Characterization of α_1-adrenoceptor subtypes labeled by [^{3}H]prazosin in single cells prepared from rabbit thoracic aorta (221) 35
Satoh, M., see Harada, J. (227) 301
Satoh, M., see Ueda, M. (219) 271
Satoh, S., see Hisa, H. (222) 265
Satoh, S., see Koga, Y. (220) 141
Satoh, S.-i., Suzuki, Y., Harada, T., Ikegaki, I., Asano, T., Shibuya, M., Sugita, K. and Hidaka, H.
Possible prophylactic potential of HA1077, a Ca^{2+} channel antagonist and vasodilator, on chronic cerebral vasospasm (220) 243
Sattler, D., see Allescher, H.-D. (217) 153
Saunders, J., see Freedman, S.B. (215) 135
Saunier, C.F., see Chergui, K. (219) 169
Sauro, M.D., Bing, B. and Zorn, N.E.
Prolactin induces growth-related gene expression in rat aortic smooth muscle in vivo (225) 351
Saussy, Jr., D.L., see Silbaugh, S.A. (223) 57
Sautter, J., see Siliprandi, R. (219) 173
Savola, J.-M., see Sjöholm, B. (215) 109
Sawutz, D.G., Faunce, D.M., Houck, W.T. and Haycock, D.
Characterization of bradykinin B_2 receptors on human IMR-90 lung fibroblasts: stimulation of $^{45}Ca^{2+}$ efflux by D-Phe^7 substituted bradykinin analogues (227) 309
Sawynok, J. and Reid, A.
Noradrenergic mediation of spinal antinociception by 5-hydroxytryptamine: characterization of receptor subtypes (223) 49
Saxena, A.K., Srivastava, P. and Baquer, N.Z.
Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and -independent tissues of diabetic rats (216) 123
Saxena, P.R., Heiligers, J.P.C., Villalón, C.M. and Ferrari, M.D.
Effects of tertatolol, a β-adrenoceptor antagonist with agonist affinity at 5-HT_{1A} receptors, in an animal model of migraine: comparison with propranolol and pindolol (220) 79
Saxena, P.R., see Dhasmana, K.M. (213) 293
Saxena, P.R., see Van Gelderen, E.M. (222) 185
Scaf, A.H.J., see Henning, R.H. (216) 73
Scapagnini, U., see Sortino, M.A. (226) 273
Scatton, B., see Claustre, Y. (225) 37
Schachter, M., see Calder, J.A. (220) 19
Schafer, A.I., see Schini, V.B. (216) 379
Schäfer, U., see Harhammer, R. (209) 263
Schaffel, R., see Rodrigues, M.S. (216) 357
Schally, A.V., see Jaworek, J. (214) 239
Schaus, J., see Gehlert, D.R. (211) 189
Scheffel, U., see Lever, J.R. (216) 459
Scheinin, M., see Sjöholm, B. (215) 109
Schenck, K., see Cohen, M.L. (211) 43
Schenk, A., see Honscha, W. (226) 215
Scherman, D., see Rostène, W. (218) 175
Schermers, H.P., see Beusenberg, F.D. (228) 57
Scherrer, E., see Jardon, B. (210) 201
Schiereck, P., see De Beer, E.L. (214) 97
Schilling, W., see Rubino, A. (212) 237
Schindler, C.W., Tella, S.R., Katz, J.L. and Goldberg, S.R.
Effects of cocaine and its quaternary derivative cocaine methiodide on cardiovascular function in squirrel monkeys (213) 99
Schingnitz, G., see Mierau, J. (215) 161
Schini, V.B., Durante, W., Elizondo, E., Scott-Burden, T., Junquero, D.C., Schafer, A.I. and Vanhoutte, P.M.
The induction of nitric oxide synthase activity is inhibited by TGF-β_1, $PDGF_{AB}$ and $PDGF_{BB}$ in vascular smooth muscle cells (216) 379
Schirgi-Degen, A., see Beubler, E. (219) 445
Schjelderup, L., see Waelbroeck, M. (227) 33
Schlegel, W., see Chiavaroli, C. (227) 173
Schmid-Schönbein, G.W., see Klee, A. (209) 223
Schmidt, A.W., McLean, S. and Heym, J.
The substance P receptor antagonist CP-96,345 interacts with Ca^{2+} channels (215) 351
Schmidt, A.W., McLean, S. and Heym, J.
The substance P receptor antagonist CP-96,345 interacts with Ca^{2+} channels (219) 490
Schmidt, C.J., Black, C.K., Taylor, V.L., Fadayel, G.M., Humphreys, T.M., Nieduzak, T.R. and Sorensen, S.M.
The 5-HT_2 receptor antagonist, MDL 28,133A, disrupts the serotonergic–dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine (220) 151
Schmidt, C.J., Fadayel, G.M., Sullivan, C.K. and Taylor, V.L.
5-HT_2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine (223) 65
Schmidt, D.E., see Kessler, R.M. (223) 105
Schmidt, H.H.H.W., see Förstermann, U. (225) 161
Schmidt, K., see Graier, W.F. (225) 43
Schmidt, W.J., see Schuster, G.M. (224) 97
Schmitt, H., see Vayssettes-Courchay, C. (211) 243
Schneider, F., Schott, C., Stoclet, J.-C. and Julou-Schaeffer, G.
L-Arginine induces relaxation of small mesenteric arteries from endotoxin-treated rats (211) 269
Schoeffter, P. and Sahin-Erdemli, I.
Further characterization of the 5-hydroxytryptamine 5-HT_1-like receptor mediating contraction of guinea-pig iliac artery (219) 295
Schoemaker, H.
Polyamines allosterically modulate [^{3}H]nitrendipine binding to the voltage-sensitive calcium channel in rat brain (225) 167
Schoepp, D.D., see McDonald, J.W. (215) 353
Schofield, G.G., see Abrahams, T.P. (227) 189
Scholey, K., see Freedman, S.B. (215) 135
Schölkens, B.A., see Englert, H.C. (210) 69
Scholz, W., see Englert, H.C. (210) 69
Schönafinger, K., see Bohn, H. (220) 71
Schott, C., see Schneider, F. (211) 269
Schotte, A., Janssen, P.F.M., Gommeren, W., Luyten, W.H.L.M. and Leysen, J.E.
Autoradiographic evidence for the occlusion of rat brain dopamine D_3 receptors *in vivo* (218) 373
Schousboe, A., see Juhász, G. (209) 131
Schrader, J., see Hartmann, M. (226) 225
Schröder, H.C., see Müller, W.E.G. (226) 209
Schroeder, H., Dumont, I., Boyet, S., Mocaër, E. and Nehlig, A.
Effects of the acute administration of a new trimethylxanthine derivative, S 9977-2, on local cerebral blood flow and glucose utilization in the rat (220) 217
Schuh, K., see Honscha, W. (226) 215
Schuijers, G.J.P.T., see Tonnaer, J.A.D.M. (214) 33
Schuller, F., Fleming, I., Stoclet, J.-C. and Gray, G.A.
Effect of endotoxin on circulating cyclic GMP in the rat (212) 93
Schulz, R., see Rengel, I. (227) 385
Schulz-Schalge, T., see Wölfel, C. (228) 95
Schunack, W., see Bungardt, E. (221) 91
Schusdziarra, V., see Allescher, H.-D. (217) 153
Schuster, G.M. and Schmidt, W.J.
D-Cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task (224) 97

Schuurkes, J.A.J., see Meulemans, A.L. (212) 51
Schwarcz, R., see Wu, H.-Q. (213) 375
Schwarting, R.K.W., see Boix, F. (216) 103
Schwartz, J.-C., see Sokoloff, P. (225) 331
Schwartz, J.E., see Minabe, Y. (209) 143
Schwartz, P.H., see Wasterlain, C.G. (212) 275
Schweri, M.M., see Deutsch, H.M. (220) 173
Schwietert, R., Wilhelm, D., Wilffert, B. and Van Zwieten, P.A.
The effect of some α-adrenoceptor antagonists on spontaneous myogenic activity in the rat portal vein and the putative involvement of ATP-sensitive K^+ channels (211) 87
Schwindt, P., see Greene, C. (226) 279
Schwinn, D.A. and Lomasney, J.W.
Pharmacologic characterization of cloned α_1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype (227) 433
Schynts, M., see Masereel, B. (219) 385
Scordamaglia, A., see Muccioli, G. (227) 293
Scorsa, A.M., see Bagetta, G. (213) 301
Scott-Burden, T., see Schini, V.B. (216) 379
Scotti de Carolis, A., see Caporali, M.G. (223) 15
Screbitsky, V.G., see Fedorov, N.B. (228) 201
Scrocco, M.G., see Imperato, A. (212) 299
Seatriz, J.V., see Hammer, Jr., R.P. (209) 253
Sebastião, A.M., see Cascalheira, J.F. (222) 49
Seeburg, P.H., see Korpi, E.R. (211) 427
Seegal, R.F., see Ahlborg, U.G. (228) 179
Seeman, P., Guan, H.-c., Civelli, O., Van Tol, H.H.M., Sunahara, R.K. and Niznik, H.B.
The cloned dopamine D_2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography (227) 139
Seeman, P., see Gehlert, D.R. (211) 189
Segal, M. and Fisher, A.
AF102B, a muscarinic M_1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices (220) 103
Seidel, A., see Wölfel, C. (228) 95
Seifen, E., see Ruch, S. (216) 393
Seiffge, D., see Klee, A. (209) 223
Sekar, M.C., see Dickinson, K.E.J. (225) 291
Sekiguchi, M., see Sakuta, H. (226) 199
Sekizawa, K., see Itabashi, S. (218) 187
Sekizawa, K., see Morikawa, M. (217) 31
Self, G.J., see Rigby, P.J. (228) 141
Selig, N., see Stier Jr., C.T. (210) 217
Selig, W. and Tocker, J.
Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea pigs (213) 331
Serikawa, T., see Renming, X. (223) 185
Serio, R., see Mulè, F. (212) 215
Serra, G., see D'Aquila, P.S. (224) 199
Serra, M., see Sanna, E. (216) 457
Sershen, H., see Harsing, Jr., L.G. (218) 117
Sette, M., see Caricati-Neto, A. (218) 51
Seutin, V., see Verbanck, P.M.P. (211) 15
Sever, P.S., see Calder, J.A. (220) 19
Sewing, K.-F., see Hennies, S. (218) 303
Sewing, K.-Fr., see Beil, W. (218) 265
Shank, R.P., see Codd, E.E. (217) 149
Shapiro, G., see Boddeke, E.W.G.M. (222) 21
Sharaf, H., see Bodanszky, M. (216) 311
Sharma, R.P., see Hsieh, G.-C. (228) 107
Sharma, R.P., see Jayasekara, S. (228) 37
Sharp, T., see Done, C. (215) 333
Sharp, T., see Gartside, S.E. (221) 27
Shaw, D., see Foster, K.A. (222) 143
Shelton, C.J., see Macdonald, A.G. (210) 223
Shen, S.-H., see Pasyk, E. (212) 209
Sheng, B.-H., see Wang, Y.-X. (222) 219
Sher, E., Biancardi, E., Pollo, A., Carbone, E., Li, G., Wollheim, C.B. and Clementi, F.
ω-Conotoxin-sensitive, voltage-operated Ca^{2+} channels in insulin-secreting cells (216) 407
Sherman, P.S., see Kilbourn, M.R. (216) 109
Shibasaki, M., Sudoh, K., Asano, M. and Murakami, K.
The effect of intravenous recombinant human renin on blood pressure in pithed spontaneously hypertensive rats (215) 271
Shibata, S., Kodama, K., Tominaga, K., Tanaka, T. and Watanabe, S.
Effect of muscarinic cholinergic drugs on ischemia-induced decreases in glucose uptake and CA1 field potentials in rat hippocampus slices (221) 113
Shibata, S., Kodama, K., Tominaga, K., Ueki, S. and Watanabe, S.
Assessment of the role of adrenoceptor function in ischemia-induced impairment of 2-deoxyglucose uptake and CA1 field potential in rat hippocampal slices (221) 255
Shibata, S., see Kagami-ishi, Y. (224) 51
Shibata, S., see Tominaga, K. (214) 79
Shibata, S., see Tominaga, K. (217) 79
Shibuya, M., see Satoh, S.-i. (220) 243
Shibuya, M., see Suzuki, Y. (219) 401
Shida, S., Nakaya, H. and Kanno, M.
Effects of Cl^- channel blockers on β-adrenoceptor-mediated decreases in resting potential and intracellular Cl^- activity in guinea-pig heart (212) 267
Shigematsu, K., see Niwa, M. (225) 281
Shigenobu, K., see Agata, N. (222) 223
Shigeri, Y., see Fujimoto, M. (215) 259
Shikada, K.-i., Yamamoto, A. and Tanaka, S.
NIP-121 and cromakalim, potassium channel openers, preferentially suppress prostanoid-induced contraction of the guinea-pig isolated trachea (209) 69
Shimamoto, H., Kwan, C.-Y. and Daniel, E.E.
Pharmacological assessment of Ca^{2+} dependence of endothelin-1-induced response in rat aorta (216) 225
Shimamoto, K., see Kawai, M. (211) 195
Shimamoto, K., see Mino, N. (221) 77
Shimizu, H., Uehara, Y., Sato, N., Shimomura, Y., Mori, M. and Kobayashi, I.
Dexamethasone attenuates altered insulin secretion elicited by interleukin-1β in HIT cells (222) 279
Shimizu, H., see Shimomura, Y. (209) 15
Shimizu, H., see Uehara, Y. (220) 119
Shimo, Y., see Kojima, S.-i. (224) 45
Shimomura, Y., Inukai, T., Kuwabara, A., Shimizu, H., Sato, N., Uehara, Y., Kobayashi, I. and Kobayashi, S.
Enhanced sensitivity to anorexia and consumption of drinking water induced by interleukin-1β in obese yellow mice (209) 15
Shimomura, Y., see Shimizu, H. (222) 279
Shimomura, Y., see Uehara, Y. (220) 119
Shimoura, K., see Shinozuka, K. (222) 113
Shingai, R., see Zaman, S.H. (225) 321
Shinji, H., see Takao, A. (217) 101
Shinkawa, T., Nakajima, H., Nishijima, K., Yamasaki, F., Kato, K., Ohzawa, N. and Mizota, M.
A novel quinolinone diuretic, M12285, and its activation mechanism through sulfate conjugation (219) 217
Shinohara, S., see Eigyo, M. (214) 149
Shinohara, S., see Eigyo, M. (219) 487
Shinozuka, K., Kobayashi, Y., Shimoura, K. and Hattori, K.
Role of nitric oxide from the endothelium on the neurogenic contractile responses of rabbit pulmonary artery (222) 113
Shintaku, H., see Eigyo, M. (214) 149
Shintaku, H., see Eigyo, M. (219) 487
Shiomi, T., see Eigyo, M. (214) 149

Shiomi, T., see Eigyo, M. (219) 487
Shiotani, T., see Hiramatsu, M. (216) 279
Shirakawa, O., see Kaneda, H. (212) 43
Shoupe, T.S., see Hogaboam, C.M. (216) 315
Showell, G.A., see Freedman, S.B. (215) 135
Shreeve, S.M. and Valliere, J.E.
The α_1-adrenoceptor is inactivated by alterations in membrane phospholipids (226) 29
Shreeve, S.M., see Valliere, J.E. (226) 191
Shukla, N., see Gill, J.K. (214) 269
Shum, A.Y.-C., see Chiou, W.-F. (215) 277
Sias, A., see D'Aquila, P.S. (224) 199
Siegel, B.W., see Boeijinga, P.H. (219) 9
Siegfried, M.R., Ma, X.-l. and Lefer, A.M.
Splanchnic vascular endothelial dysfunction in rat endotoxemia: role of superoxide radicals (212) 171
Sielczak, M.W., see Abraham, W.M. (217) 119
Sigala, S., Imperato, A., Rizzonelli, P., Casolini, P., Missale, C. and Spano, P.F.
L-α-Glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat (211) 351
Silbaugh, S.A., Stengel, P.W., Cockerham, S.L., Roman, C.R., Saussy, Jr., D.L., Spaethe, S.M., Goodson, Jr., T., Herron, D.K. and Fleisch, J.H.
Pulmonary actions of LY255283, a leukotriene B_4 receptor antagonist (223) 57
Siliprandi, R., Lipartiti, M., Fadda, E., Sautter, J. and Manev, H.
Activation of the glutamate metabotrópic receptor protects retina against N-methyl-D-aspartate toxicity (219) 173
Silva, A.R., see Castro-Faria-Neto, H.C. (213) 183
Silva, P.M.R., see Castro-Faria-Neto, H.C. (213) 183
Silva, P.M.R., see Martins, M.A. (220) 55
Silva, P.M.R., see Pasquale, C.P. (223) 9
Silver, P.J., Cumiskey, W.R. and Harris, A.L.
Vascular protein kinase C in Wistar-Kyoto and spontaneously hypertensive rats (212) 143
Silverman, P.B., Grabowski, J. and Lane, K.E.
Rotational behavior as a classically conditioned response to pentobarbital administration (212) 165
Silverstone, P., see Done, C. (215) 333
Simiand, J., Keane, P.E., Guitard, J., Langlois, X., Gonalons, N., Martin, P., Bianchetti, A., Le Fur, G. and Soubrié, P.
Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical β-adrenoceptors (219) 193
Simmet, T., Pritze, S., Thelen, K.I. and Peskar, B.A.
Release of endothelin in the oleic acid-induced respiratory distress syndrome in rats (211) 319
Simonet, S., Bonhomme, E., Laubie, M., Thurieau, C., Fauchère, J.-L. and Verbeuren, T.J.
Venous and arterial endothelial cells respond differently to thrombin and its endogenous receptor agonist (216) 135
Simonet, S., see Heuzé-Joubert, I. (220) 161
Simonnet, G., see Gicquel, S. (222) 61
Singh, V.B., see Corley, K.C. (213) 417
Sinowatz, F., see Rengel, I. (227) 385
Sinzinger, H., Virgolini, I., Keiler, A., Lupattelli, G., Gerakakis, A. and Peskar, B.A.
13,14-Dihydro-prostaglandin E_1 decreases low-density lipoprotein influx into rabbit aorta (219) 129
Sirois, M.G., Filep, J.G., Rousseau, A., Fournier, A., Plante, G.E. and Sirois, P.
Endothelin-1 enhances vascular permeability in conscious rats: role of thromboxane A_2 (214) 119
Sirois, P., see Filep, J.G. (219) 343
Sirois, P., see Filep, J.G. (220) 263
Sirois, P., see Sirois, M.G. (214) 119
Sirois, P., see Tavares de Lima, W. (213) 63
Sirviö, J., see Jäkälä, P. (221) 351
Sithers, A., see Mallard, N. (220) 1
Sjöholm, B., Voutilainen, R., Luomala, K., Savola, J.-M. and Scheinin, M.
Characterization of [^{3}H]atipamezole as a radioligand for α_2-adrenoceptors (215) 109
Skaper, S.D., see Moroni, F. (218) 145
Skolnick, P., see Boje, K.M. (212) 151
Skolnick, P., see Harris, B. (217) 215
Skolnick, P., see Von Lubitz, D.K.J.E. (219) 153
Skolnick, P., see Wong, G. (225) 63
Sladeczek, F., see Manzoni, O. (225) 357
Slaninová, J., see Maletínská, L. (222) 233
Slone, A.L., see Boeijinga, P.H. (219) 9
Small, D.L., Bolzon, B.J. and Cheung, D.W.
Endothelium-independent potentiating effects of neuropeptide Y in the rat tail artery (210) 131
Small, R.C., Berry, J.L., Foster, R.W., Blarer, S. and Quast, U.
Analysis of the relaxant action of SDZ PCO 400 in airway smooth muscle from the ox and guinea-pig (219) 81
Smart, T.G., see Xie, X. (212) 291
Smart, T.G., see Xie, X. (223) 193
Smirnov, S.V., Aaronson, P.I. and Russell, S.N.
Cromakalim does not act as a calcium antagonist in isolated human mesenteric artery cells (217) 105
Smith, C.F.C., see Berridge, T.L. (213) 205
Smith, K. and Docherty, J.R.
Are the prejunctional α_2-adrenoceptors of the rat vas deferens and submandibular gland of the α_{2A}- or α_{2D}-subtype? (219) 203
Smith, K., Connaughton, S. and Docherty, J.R.
Investigations of prejunctional α_2-adrenoceptors in rat atrium, vas deferens and submandibular gland (211) 251
Smith, P.F., see Sansom, A.J. (220) 123
Smith, R.D., see Leung, K.H. (227) 63
Smith, S.E. and Meldrum, B.S.
The glycine-site NMDA receptor antagonist, R-(+)- cis-β-methyl-3-amino-1-hydroxypyrrolid-2-one, L-687,414 is anticonvulsant in baboons (211) 109
Smith, S.E. and Meldrum, B.S.
The protein kinase C activators, phorbol 12-myristate,13-acetate and phorbol 12,13-dibutyrate, are convulsant in the pico–nanomolar range in mice (213) 133
Smits, G.J.M. and Lefebvre, R.A.
Influence of age on responsiveness of rat gastric fundus to agonists and to stimulation of intrinsic nerves (223) 97
Smits, G.J.M., see Lefebvre, R.A. (221) 235
Smits, J.F.M., see Marjorie, (217) 49
Snead, III, O.C.
Evidence for $GABA_B$-mediated mechanisms in experimental generalized absence seizures (213) 343
Sneddon, P. and McLees, A.
Purinergic and cholinergic contractions in adult and neonatal rabbit bladder (214) 7
Snyder, C., see Penn, A. (228) 155
Snyder, D.W., see Sommers, C.D. (216) 87
Snyder, S.H., see Breslow, M.J. (210) 105
Sodeyama, N., see Koga, Y. (220) 141
Sofuoglu, M., Portoghese, P.S. and Takemori, A.E.
δ-Opioid receptor binding in mouse brain: evidence for heterogeneous binding sites (216) 273
Sofuoglu, M., Portoghese, P.S. and Takemori, A.E.
Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimine (210) 159
Sokoloff, P., Andrieux, M., Besançon, R., Pilon, C., Martres, M.-P., Giros, B. and Schwartz, J.-C.
Pharmacology of human dopamine D_3 receptor expressed in a

mammalian cell line: comparison with D_2 receptor (225) 331
Solca, A.M., see Gwilt, M. (215) 137
Sommers, C.D., Bobbitt, J.L., Bemis, K.G. and Snyder, D.W.
Porcine pancreatic phospholipase A_2-induced contractions of guinea pig lung pleural strips (216) 87
Song, D.-L., see Chang, C.-H. (227) 229
Song, Z.H. and Takemori, A.E.
Stimulation by corticotropin-releasing factor of the release of immunoreactive dynorphin A from mouse spinal cords in vitro (222) 27
Sørensen, P.O., see Suzdak, P.D. (224) 189
Sorensen, S.M., see Schmidt, C.J. (220) 151
Sortino, M.A., Aleppo, G., Scapagnini, U. and Canonico, P.L.
Ipriflavone inhibits phosphoinositide hydrolysis and Ca^{2+} uptake in the osteoblast-like UMR-106 cells (226) 273
Šoskić, V. and Maelicke, A.
Synthesis and characterization of biotinylated and photoactivatable neuroleptics. Novel bifunctional probes for dopamine receptors (226) 109
Soubrié, P., see Simiand, J. (219) 193
Soudijn, W., see Van der Bent, A. (226) 327
Soustre, H., see Gauthier, C. (225) 129
Spaethe, S.M., see Silbaugh, S.A. (223) 57
Spano, P.F., see Nisoli, E. (216) 81
Spano, P.F., see Pizzi, M. (209) 169
Spano, P.F., see Sigala, S. (211) 351
Spatz-Kümbel, G., see Lambrecht, G. (217) 217
Speciale, C., Facheris, L. and Fariello, R.G.
Tetrodotoxin reveals action of spermine at presynaptic N-methyl-D-aspartate receptors (214) 107
Sperber, E., see Garant, D. (214) 75
Sperelakis, N., see Satoh, H. (218) 83
Spinazzi, A., see Crescioli, S. (228) 45
Spreafico, E., Bettini, E., Pollio, G. and Maggi, A.
Nucleotide sequence of estrogen receptor cDNA from Sprague-Dawley rat (227) 353
Spriggs, B., see Mallard, N. (220) 1
Sprosen, T.S., see Newberry, N.R. (219) 135
Spurlock, G., see O'Donovan, M.C. (226) 335
Squadrito, F., Altavilla, D., Campo, G.M., Calapai, G., Ioculano, M., Zingarelli, B., Saitta, A., Prosdocimi, M. and Caputi, A.P.
Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats (210) 107
Squadrito, F., see Zingarelli, B. (222) 13
Srinivasan, D., see Ramaswamy, S. (220) 147
Srivastava, L.K., Morency, M.A. and Mishra, R.K.
Ontogeny of dopamine D_2 receptor mRNA in rat brain (225) 143
Srivastava, P., see Saxena, A.K. (216) 123
St-Pierre, S., see T-Benchekroun, M. (216) 421
Staar, U., see Beil, W. (218) 265
Stam, N.J., Van Huizen, F., Van Alebeek, C., Brands, J., Dijkema, R., Tonnaer, J.A.D.M. and Olijve, W.
Genomic organization, coding sequence and functional expression of human 5-HT_2 and 5-HT_{1A} receptor genes (227) 153
Stamidis, H. and Young, G.A.
Naltrindole retards tolerance development to morphine-induced effects on EEG and EEG power spectra (213) 9
Stamidis, H., see Hudson, G.M. (221) 217
Stancampiano, R., see Melis, M.R. (220) 43
Stanley, E.F., see Cruciani, R.A. (226) 287
Stansby, G., see Gill, J.K. (214) 269
Stanton, J.A., see Beer, M.S. (213) 193
Stapelfeld, A., Hammond, D.L. and Rafferty, M.F.
Antinociception after intracerebroventricular administration of naltrindole in the mouse (214) 273
Starr, M.S., see Alam, A.M. (222) 227
Stauss, B., see Itoi, K. (219) 435
Steinman, M., see Andre, P. (218) 137
Stengel, P.W., see Silbaugh, S.A. (223) 57
Stephenson, J.D., see Koshikawa, N. (209) 75
Stewart-Lee, A.L., Aberdeen, J. and Burnstock, G.
The effect of atherosclerosis on neuromodulation of sympathetic neurotransmission by neuropeptide Y and calcitonin gene-related peptide in the rabbit mesenteric artery (216) 167
Stier Jr., C.T., Selig, N. and Itskovitz, H.D.
Enhanced vasodilatory responses to bradykinin in stroke-prone spontaneously hypertensive rats (210) 217
Stjernschantz, J., see Almegård, B. (211) 183
Stöcklin, K., see Waldmeier, P.C. (216) 243
Stockmeier, C.A., see Meltzer, H.Y. (216) 67
Stockton, M.E., see Rasmussen, K. (209) 135
Stoclet, J.-C., see Muller, B. (225) 263
Stoclet, J.-C., see Schneider, F. (211) 269
Stoclet, J.-C., see Schuller, F. (212) 93
Stokke, M., Hagelin, E.M., Poulsson, C. and Brørs, O.
Ca^{2+} modulates the inhibition of (+)-[^{3}H]isradipine binding by amiloride and quinacrine (227) 379
Stone, T.W., see Connick, J.H. (214) 169
Stoof, J.C., Booij, J., Drukarch, B. and Wolters, E.C.
The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way (213) 439
Strahlendorf, H.K., see Darrow, E. (209) 19
Strahlendorf, J.C., see Darrow, E. (209) 19
Strauss, J.D., Zeugner, C. and Rüegg, J.C.
The positive inotropic calcium sensitizer EMD 53998 antagonizes phosphate action on cross-bridges in cardiac skinned fibers (227) 437
Stretton, C.D., see Belvisi, M.G. (210) 221
Stretton, D., see Belvisi, M.G. (215) 341
Strohmann, C., see Waelbroeck, M. (227) 33
Strömbom, J., Jokela, R., Saano, V. and Rolfsen, W.
Binding of strychnocarpine and related β-carbolines to brain receptors in vitro (214) 165
Strosberg, A.D., see Sugasawa, T. (216) 207
Struijker-Boudier, H.A.J., see Marjorie, (217) 49
Struijker Boudier, H.A.J., Messing, M.W.J. and Van Essen, H.
Preferential small arteriolar vasodilatation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats (218) 191
Stulzaft, O., see Varastet, M. (213) 275
Sturm, B., see Noronha-Blob, L. (211) 97
Su, D.-F., Yang, Y.-C. and Xie, J.-E.
Effects of ketanserin on blood pressure and heart rate in sinoaortic denervated rats (214) 89
Suarez, J., see Balcells, E. (210) 1
Suaud-Chagny, M.F., Mermet, C., Tibiriça, E., Bousquet, P. and Gonon, F.
Does rilmenidine act in vivo on central α_2-adrenoceptors modulating noradrenaline release? (213) 305
Suda, K., see Komabayashi, T. (225) 209
Sudoh, K., see Shibasaki, M. (215) 271
Suga, H., see Takaki, M. (211) 125
Suga, O., see Fukuzaki, A. (220) 99
Suga, O., see Nagahisa, A. (217) 191
Suga, S.-i., see Himeno, A. (215) 337
Sugai, K., see Suzuki, S. (227) 395
Sugasawa, T., Matsuzaki, M., Morooka, S., Foignant, N., Blin, N. and Strosberg, A.D.
In vitro study of a novel atypical β-adrenoceptor agonist, SM-11044 (216) 207
Sugawa, M., Koide, T. and Takato, M.
BY-1949 elicits vasodilatation via preferential elevation of cyclic GMP levels within the cerebral artery: possible involvement of

endothelium-mediated mechanisms (215) 57
Sugawara, T., Kato, M., Furuhama, K., Takada, S. and Takayama, S.
Pharmacological aspects of arthritis induced by a muramyl dipeptide analogue in rats (228) 147
Sugden, D.
Effect of putative melatonin receptor antagonists on melatonin-induced pigment aggregation in isolated *Xenopus laevis* melanophores (213) 405
Sugimoto, Y., see Yamada, J. (216) 307
Sugita, K., see Satoh, S.-i. (220) 243
Sugita, K., see Suzuki, Y. (219) 401
Suh, H.H., Fujimoto, J.M. and Tseng, L.F.
Different radiant heat intensities differentiate intracerebroventricular morphine- from β-endorphin-induced inhibition of the tail-flick response in the mouse (213) 337
Suh, S.H., Chen, G., Xue, L., Zhang, G., Yamamoto, Y. and Suzuki, H.
Inhibitory actions of MCI-154 on guinea-pig femoral artery and vein preparations (219) 377
Sukamoto, T., see Hara, H. (221) 193
Sukamoto, T., see Iwamoto, T. (224) 71
Sullivan, A.F., Kalso, E.A., McQuay, H.J. and Dickenson, A.H.
The antinociceptive actions of dexmedetomidine on dorsal horn neuronal responses in the anaesthetized rat (215) 127
Sullivan, A.F., see Kalso, E.A. (216) 97
Sullivan, C.K., see Schmidt, C.J. (223) 65
Sulser, F., see Bieck, P.R. (225) 171
Sultana, M., see Portoghese, P.S. (218) 195
Sumi, T., see Ishii, Y. (221) 377
Summers, R.J., see Molenaar, P. (209) 257
Sun, L., Umemura, S., Chun, M. and Pettinger, W.A.
Northern blot and ribonuclease protection study of α_2-adrenoceptor subtypes in cultured cell lines (226) 367
Sun, M.-K., Wahlestedt, C. and Reis, D.J.
Action of externally applied ATP on rat reticulospinal vasomotor neurons (224) 93
Sun, M.-k., Wahlestedt, C. and Reis, D.J.
Inositol hexakisphosphate excites rat medullary sympathoexcitatory neurons in vivo (215) 9
Sun, X., see Mousseau, D.D. (217) 197
Sunahara, R.K., see Seeman, P. (227) 139
Sunami, A., see Nitta, J.-i. (214) 191
Sung, C.P., see Ohlstein, E.H. (225) 347
Supavilai, P., see Pombo-Villar, E. (226) 317
Surprenant, A., see Bungardt, E. (213) 53
Suthamnatpong, N., see Kanada, A. (216) 287
Suzdak, P.D., Frederiksen, K., Andersen, K.E., Sørensen, P.O., Knutsen, L.J.S. and Nielsen, E.B.
NNC-711, a novel potent and selective γ-aminobutyric acid uptake inhibitor: pharmacological characterization (224) 189
Suzdak, P.D., see Fink-Jensen, A. (220) 197
Suzdak, P.D., see Thomsen, C. (227) 361
Suzuki, A., see Hara, H. (221) 193
Suzuki, A., see Suzuki, S. (217) 97
Suzuki, H., see Hishikawa, K. (215) 329
Suzuki, H., see Suh, S.H. (219) 377
Suzuki, K., see Sakurada, S. (211) 75
Suzuki, S., Sugai, K., Sato, H., Sakatume, M. and Arakawa, M.
Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytes (227) 395
Suzuki, S., Suzuki, A., Kajikuri, J. and Itoh, T.
Endothelin-1-induced prostaglandin E_2 production: modulation of contractile response to endothelin-1 in porcine coronary artery (217) 97
Suzuki, T., Narita, M., Takahashi, Y., Misawa, M. and Nagase, H.
Effects of nor-binaltorphimine on the development of analgesic tolerance to and physical dependence on morphine (213) 91
Suzuki, Y., Tanoi, C., Shibuya, M., Sugita, K., Masuzawa-Ito, K. and Asano, M.
Different utilization of Ca^{2+} in the contractile action of endothelin-1 on cerebral, coronary and mesenteric arteries of the dog (219) 401
Suzuki, Y., see Satoh, S.-i. (220) 243
Sved, A.F., see Bagdy, G. (210) 285
Svensson, T.H., see Gradin, K. (218) 363
Svensson, T.H., see Nomikos, G.G. (216) 373
Swandulla, D., see Zeilhofer, H.U. (213) 155
Swartzwelder, H.S., see Martin, D. (219) 469
Swedberg, M.D.B., see Fink-Jensen, A. (220) 197
Syvälahti, E., see Lappalainen, J. (210) 195
Szarek, J.L., see Gruetter, C.A. (217) 109
Szemeredi, K., see Bagdy, G. (210) 285
Szewczyk, A., De Weille, J.R. and Lazdunski, M.
8-Methoxypsoralen blocks ATP-sensitive potassium channels and stimulates insulin release (216) 323
Szewczyk, A., De Weille, J.R. and Lazdunski, M.
TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate) inhibits the ATP-sensitive K^+ channel (226) 175

T-Benchekroun, M., Fournier, A., St-Pierre, S. and Cadieux, A.
Inhibitory action of neuropeptide Y on agonist-induced responses in isolated guinea pig trachea (216) 421
Tabach, R. and De Moraes, S.
Supersensitivity to morphine of the transmurally stimulated vas deferens isolated from ethanol-pretreated mice (216) 449
Tabrizchi, R., King, K.A. and Pang, C.C.Y.
Direct and indirect effects of angiotensin II on venous tone in conscious rats (219) 141
Tachado, S.D., see Abdel-Latif, A.A. (226) 351
Taché, Y., see Garrick, T. (223) 75
Taché, Y., see Saperas, E. (209) 1
Taché, Y., see Yoneda, M. (223) 197
Tachikawa, E., see Mikami, M. (210) 91
Tack, J., see Christofi, F.L. (216) 17
Tacke, R., see Bungardt, E. (213) 53
Tacke, R., see Waelbroeck, M. (227) 33
Tada, S., Okajima, F., Mitsui, Y., Kondo, Y. and Ui, M.
P_2 purinoceptor-mediated cyclic AMP accumulation in bovine vascular smooth muscle cells (227) 25
Tadipatri, S., see Dhasmana, K.M. (213) 293
Taira, C.A., see Ricci, D. (212) 195
Taira, N., see Okada, Y. (218) 259
Taira, N., see Yoneyama, F. (213) 199
Takada, A., Mitsuka, S., Diksic, M. and Yamamoto, Y.L.
Autoradiographic study of peripheral benzodiazepine receptors in animal brain tumor models and human gliomas (228) 131
Takada, A., see Pietraszek, M.H. (219) 289
Takada, S., see Sugawara, T. (228) 147
Takada, Y., see Pietraszek, M.H. (219) 289
Takagi, H., see Kawabata, A. (218) 153
Takagi, K., see Araki, N. (216) 113
Takahama, K., see Kai, H. (212) 101
Takahama, K., see Kai, H. (220) 181
Takahashi, Y., see Suzuki, T. (213) 91
Takaki, K., see Kai, H. (212) 101
Takaki, M., Nakayama, S. and Suga, H.
Possible mechanism of ruthenium red antagonism of capsaicin-induced action in the isolated guinea pig ileum (211) 125
Takamiya, M., see Kuwahara, T. (221) 99
Takanaka, A., see Inoue, K. (215) 321
Takanashi, M., see Endoh, M. (218) 355
Takanashi, M., see Endoh, M. (223) 143
Takano, M., see Takano, Y. (219) 465
Takano, Y., Takano, M. and Yaksh, T.L.

The effect of intrathecally administered imiloxan and WB4101: possible role of α_2-adrenoceptor subtypes in the spinal cord (219) 465
Takao, A., Tohru, K., Michiaki, T. and Shinji, H.
Effects of BY-1949 on evoked responses of cortical blood flow and Meynert neurons (217) 101
Takao, Y., Kamisaki, Y. and Itoh, T.
β-Adrenergic regulation of amine precursor amino acid transport across the blood-brain barrier (215) 245
Takaori, S., see Renming, X. (223) 185
Takasaki, K., see Kogo, H. (211) 69
Takasaki, K., see Kogo, H. (221) 289
Takasugi, Y., see Tsuji, K. (210) 213
Takato, M., see Sugawa, M. (215) 57
Takayama, S., see Sugawara, T. (228) 147
Takayanagi, I., see Satoh, M. (221) 35
Takeda, R., see Takeda, Y. (213) 445
Takeda, Y., Miyamori, I., Yoneda, T. and Takeda, R.
Endothelin-1 release from the mesenteric arteries of cyclosporine-treated rats (213) 445
Takei, M., Furukawa, Y., Narita, M., Ren, L.-M. and Chiba, S.
Cardiac electrical responses to catecholamines are differentially mediated by β_2-adrenoceptors in anesthetized dogs (219) 15
Takei, Y., see Kawano, S. (211) 55
Takemori, A.E., Loh, H.H. and Lee, N.M.
Suppression by dynorphin A-(1–13) of the expression of opiate withdrawal and tolerance in mice (221) 223
Takemori, A.E., see Portoghese, P.S. (218) 195
Takemori, A.E., see Sofuoglu, M. (210) 159
Takemori, A.E., see Sofuoglu, M. (216) 273
Takemori, A.E., see Song, Z.H. (222) 27
Takeo, S., see Kogo, H. (211) 69
Takeo, S., see Kogo, H. (221) 289
Takeshita, T., see Okamiya, Y. (222) 99
Takeuchi, J., see Itoh, H. (218) 347
Takeuchi, N., see Yamada, J. (216) 307
Takeuchi, S., see Moritoki, H. (210) 61
Takeuchi, T., see Kanada, A. (216) 287
Takeyama, K., see Tamaoki, J. (220) 87
Takiguchi, Y., Wada, K. and Nakashima, M.
Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma (215) 289
Takishima, T., see Itabashi, S. (218) 187
Takishima, T., see Morikawa, M. (217) 31
Takuma, K., see Nakano, Y. (219) 339
Tamaki, T., see Nishiyama, A. (218) 311
Tamaoki, J., Chiyotani, A., Takeyama, K. and Konno, K.
Effects of angiotensin II and angiotensin III on airway epithelial short-circuit current: involvement of pertussis toxin-sensitive G protein (220) 87
Tamargo, J., see Tejerina, T. (219) 279
Tamminga, C.A., see Kaneda, H. (212) 43
Tamura, K., see Kogo, H. (211) 69
Tan, Y.-H., see Wang, Y.-X. (222) 219
Tanabe, H., see Okamiya, Y. (222) 99
Tanaka, H., see Agata, N. (222) 223
Tanaka, I., see Notsu, T. (220) 35
Tanaka, M., see Yokoo, H. (222) 43
Tanaka, S., see Shikada, K.-i. (209) 69
Tanaka, T., Naganuma, A. and Imura, N.
Routes for renal transport of methylmercury in mice (228) 9
Tanaka, T., see Shibata, S. (221) 113
Tanaka, Y., see Uehara, Y. (220) 119
Tang, R.R., see Tseng, L.F. (214) 175
Tani, M., see Mizuno, K. (215) 305
Taniguchi, K., see Itoh, H. (218) 347
Taniguchi, K., see Nagahisa, A. (217) 191
Taniguchi, Y., see Tsuji, K. (210) 213
Tanimura, H., see Kawano, S. (211) 55
Taniyama, K., see Himeno, A. (215) 337
Taniyama, K., see Niwa, M. (225) 281
Tanoi, C., see Suzuki, Y. (219) 401
Tao, P.-L. and Liu, C.-F.
Chronic morphine treatment causes down-regulation of spinal adenosine A_1 receptors in rats (215) 301
Tao, R., see Hjorth, S. (209) 249
Tapia-Arancibia, L., Rage, F., Récasens, M. and Pin, J.-P.
NMDA receptor activation stimulates phospholipase A_2 and somatostatin release from rat cortical neurons in primary cultures (225) 253
Tapia, R., see Fragoso-Veloz, J. (221) 275
Tastenoy, M., see Delporte, C. (227) 247
Tastenoy, M., see Waelbroeck, M. (227) 33
Tatumi, Y., see Hara, H. (221) 193
Tavares de Lima, W., Sirois, P. and Jancar, S.
Immune-complex alveolitis in the rat: evidence for platelet activating factor and leukotrienes as mediators of the vascular lesions (213) 63
Tavernier, G., see Montastruc, P. (213) 159
Tawata, M., Aida, K., Noguchi, T., Ozaki, Y., Kume, S., Sasaki, H., Chin, M. and Onaya, T.
Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice (212) 87
Taya, K., see Kogo, H. (221) 289
Taylor, C.P. and Vartanian, M.G.
Probenecid pretreatment enhances anticonvulsant action of NBQX in mice (213) 151
Taylor, K.M., see Knock, G.A. (219) 415
Taylor, L.P., see Mansour, A. (227) 205
Taylor, M.D., De Ceballos, M.L., Rose, S., Jenner, P. and Marsden, C.D.
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia (219) 183
Taylor, S.E., see Mathis, C.A. (210) 103
Taylor, S.G., see Foster, K.A. (222) 143
Taylor, V.L., see Schmidt, C.J. (220) 151
Taylor, V.L., see Schmidt, C.J. (223) 65
Tedford, C.E., Crosby, Jr., G., Iorio, L.C. and Chipkin, R.E.
Effect of SCH 39166, a novel dopamine D_1 receptor antagonist, on [^{3}H]acetylcholine release in rat striatal slices (211) 169
Teitler, M., see Miller, K.J. (227) 99
Tejerina, T., Cauvin, C. and Tamargo, J.
Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels (219) 279
Telegdy, G., see Bidzseranova, A. (211) 411
Tella, S.R., see Schindler, C.W. (213) 99
Temma, K., Akera, T., Chugun, A., Ohashi, M., Yabuki, M. and Kondo, H.
Doxorubicin: an antagonist of muscarinic receptors in guinea pig heart (220) 63
Teng, C.-M., see Ko, F.-N. (218) 129
Teng, C.-M., see Ko, F.-N. (219) 29
Ter Laak, A.M., see Van der Bent, A. (226) 327
Tesson, F., Limon, I. and Parini, A.
Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites (219) 335
Thalody, G.P., see Wiener, H.L. (220) 131
Tham, C.-S., see Robertson, G.S. (219) 323
Theis, J.G.W., Dellweg, H., Perzborn, E. and Groß, R.
pH dependency of the binding of [^{3}H]BAY U 3405 and various non-labelled ligands to the thromboxane A_2/prostaglandin H_2 receptor of human platelet membranes (226) 149
Thelen, K.I., see Simmet, T. (211) 319

Thirstrup, S. and Nielsen-Kudsk, J.E.
Effects of K^+ channel blockers on the relaxant action of dihydralazine, cromakalim and nitroprusside in isolated rabbit femoral arteries (215) 177
Thirstrup, S., see Nielsen-Kudsk, J.E. (209) 273
Thomann, H., see Rubino, A. (212) 237
Thompson, C., see Zinkand, W.C. (212) 129
Thomsen, C., Kristensen, P., Mulvihill, E., Haldeman, B. and Suzdak, P.D.
L-2-Amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase (227) 361
Thurieau, C., see Simonet, S. (216) 135
Tibaldo-Bongiorno, M., see Walters, M.R. (213) 309
Tibiriça, E., Feldman, J., Mermet, C., Monassier, L., Gonon, F. and Bousquet, P.
Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors (209) 213
Tibiriça, E., see Suaud-Chagny, M.F. (213) 305
Tiedtke, P.I., see Bischoff, C. (213) 269
Tillement, J.-P., see Morin, D. (225) 273
Timmerman, H., see Jansen, F.P. (217) 203
Timmerman, H., see Leurs, R. (225) 137
Timmermans, P.B.M.W.M., see Leung, K.H. (227) 63
Timmermans, P.B.M.W.M., see Reilly, T.M. (226) 179
Timmermans, P.B.M.W.M., see Wong, P.C. (220) 267
Tive, L.A., Pick, C.G., Paul, D., Roques, B.P., Gacel, G.A. and Pasternak, G.W.
Analgesic potency of TRIMU-5: a mixed μ_2 opioid receptor agonist/μ_1 opioid receptor antagonist (216) 249
Tobin, J.R., see Breslow, M.J. (210) 105
Tocker, J., see Selig, W. (213) 331
Toda, N., see Okamura, T. (220) 27
Todo, N., see Renming, X. (223) 185
Tohru, K., see Takao, A. (217) 101
Tokumaru, H., Anzai, K., Abe, T. and Kirino, Y.
Purification of the cardiac 1,4-dihydropyridine receptor using immunoaffinity chromatography with a monoclonal antibody against the $\alpha_2\delta$ subunit of the skeletal muscle dihydropyridine receptor (227) 363
Tokuyama, K., see Arakawa, H. (215) 51
Toll, L., see Berzetei-Gurske, I.P. (212) 283
Tolliver, T.J., see Lesch, K.P. (227) 233
Tominaga, K., Shibata, S., Ueki, S. and Watanabe, S.
Effects of 5-HT_{1A} receptor agonists on the circadian rhythm of wheel-running activity in hamsters (214) 79
Tominaga, K., Shibata, S., Ueki, S. and Watanabe, S.
Effects of inhibitory and excitatory drugs on the metabolic rhythm of the hamster suprachiasmatic nucleus in vitro (217) 79
Tominaga, K., see Shibata, S. (221) 113
Tominaga, K., see Shibata, S. (221) 255
Tomura, H., Okajima, F. and Kondo, Y.
Discrimination between two types of P_2 purinoceptors by suramin in rat hepatocytes (226) 363
Tomura, Y., see Hisa, H. (222) 265
Tonello, C., see Nisoli, E. (216) 81
Tonnaer, J.A.D.M., Schuijers, G.J.P.T., Van Diepen, H.A. and Peeters, B.W.M.M.
Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury (214) 33
Tonnaer, J.A.D.M., see Stam, N.J. (227) 153
Törnebrandt, K., see Bodelsson, M. (219) 455
Torre, M., see Viganò, T. (219) 159
Toth, E., see Harsing, Jr., L.G. (218) 117
Tóth, G., see Bidzseranova, A. (211) 411
Totsuka, S., see Kawanami, T. (216) 385
Touret, M., see Lepetit, P. (209) 207
Tousignant, C., Regoli, D., Rhaleb, N.-E., Jukic, D. and Guillemette, G.
Characterization of a novel binding site for ^{125}I-Tyr-D-Arg-[Hyp^3,D-Phe^7,Leu^8]bradykinin on epithelial membranes of guinea pig ileum (225) 235
Touvay, C., see Pons, F. (217) 65
Toyoshi, T., Ukai, M. and Kameyama, T.
Combination of a δ opioid receptor agonist but not a μ opioid receptor agonist with the D_1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice (213) 25
Toyoshi, T., see Ukai, M. (222) 7
Trabucchi, M., see Barbaccia, M.L. (219) 485
Tramontana, M., Del Bianco, E., Cecconi, R., Maggi, C.A. and Geppetti, P.
Veratridine evokes release of calcitonin gene-related peptide from capsaicin-sensitive nerves of rat urinary bladder (212) 137
Tran, M.-A., see Montastruc, P. (213) 159
Tranchina, S., see Carli, M. (211) 227
Tranquille, N. and Emeis, J.J.
The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator from perfused rat hindlegs (213) 285
Trauner, M., see Garrick, T. (223) 75
Travère, J.M., see Abadie, P. (213) 107
Traystman, R.J., see Breslow, M.J. (210) 105
Trifaró, J.-M., Vitale, M.L. and Rodríguez Del Castillo, A.
Cytoskeleton and molecular mechanisms in neurotransmitter release by neurosecretory cells (225) 83
Trifiletti, R.R. and Pranzatelli, M.R.
ACTH binds to [^{3}H]MK-801-labelled rat hippocampal NMDA receptors (226) 377
Trifiletti, R.R.
Neuroprotective effects of N^G-nitro-L-arginine in focal stroke in the 7-day old rat (218) 197
Trivelli, A., see Ghiggeri, G.M. (228) 77
True, T.A., see Mais, D.E. (227) 267
Tsai, N., see Maguire, P. (213) 219
Tschöpe, C., see Itoi, K. (219) 435
Tschöpl, M., Harms, L., Nörenberg, W. and Illes, P.
Excitatory effects of adenosine 5′-triphosphate on rat locus coeruleus neurones (213) 71
Tseng, L.F. and Collins, K.A.
The tail-flick inhibition induced by β-endorphin administered intrathecally is mediated by activation of κ- and μ-opioid receptors in the mouse (214) 59
Tseng, L.F. and Huang, F.Y.
Release of immunoreactive [Met^5]enkephalin and cholecystokinin from the spinal cord by β-endorphin administered intraventricularly in the pentobarbital- anesthetized rat (215) 309
Tseng, L.F. and Tang, R.R.
Pentobarbital attenuates antinociception induced by i.c.v. morphine but not β-endorphin in the mouse (214) 175
Tseng, L.F., Xu, J.Y. and Pieper, G.M.
Increase of nitric oxide production by L-arginine potentiates i.c.v. administered β-endorphin-induced antinociception in the mouse (212) 301
Tseng, L.F., see Suh, H.H. (213) 337
Tsuboi, M., see Komabayashi, T. (225) 209
Tsuchiya, M., see Nagahisa, A. (217) 191
Tsuchiya, M., see Sako, K. (209) 39
Tsuda, K., Tsuda, S., Masuyama, Y. and Goldstein, M.
Effects of verapamil on [^{3}H]acetylcholine release in the striatum of spontaneously hypertensive rats (216) 319
Tsuda, S., see Tsuda, K. (216) 319
Tsuji, K., Uehara, A., Okumura, T., Taniguchi, Y., Kitamori, S.,

Takasugi, Y. and Namiki, M.
The gastric antisecretory action of lipopolysaccharide is blocked by indomethacin (210) 213
Tsuji, S., see Kawano, S. (211) 55
Tsujino, T., Sano, H., Kubota, Y., Hsieh, S.-T., Miyajima, T., Saito, K., Nakajima, M., Saito, N. and Yokoyama, M.
Expression of Fos-like immunoreactivity by yohimbine and clonidine in the rat brain (226) 69
Tsukada, M., see Chiba, S. (221) 393
Tsukamoto, G., see Hara, H. (221) 193
Tsutsumi, K., Zorad, S. and Saavedra, J.M.
The AT_2 subtype of the angiotensin II receptors has differential sensitivity to dithiothreitol in specific brain nuclei of young rats (226) 169
Tung, S.-F., see Huang, H.-C. (211) 359
Tuomisto, J., see Ahlborg, U.G. (228) 179
Turcaud, S., see Baamonde, A. (216) 157
Turcaud, S., see Noble, F. (223) 83
Tvrdeić, A. and Peričić, D.
Dihydroergotoxine modulation of the $GABA_A$ receptor-associated Cl^- ionophore in mouse brain (221) 139
Tyers, M.B., see Jones, D.N.C. (215) 63

Uchida, M.K., see Fukuzaki, A. (220) 99
Uchida, M.K., see Ishine, T. (219) 285
Uchida, Y., see Muraki, T. (226) 311
Ueda, H., see Harada, J. (227) 301
Ueda, M., Fujii, T., Kuraishi, Y. and Satoh, M.
Bifemelane enhances high K^+-evoked release of glutamate from mossy fiber synaptosomes of guinea-pig hippocampus (219) 271
Ueda, S., see Yoshida, M. (222) 205
Uehara, A., see Tsuji, K. (210) 213
Uehara, Y., Shimizu, H., Sato, N., Tanaka, Y., Shimomura, Y. and Mori, M.
Carboxyl–terminal tripeptide of α-melanocyte-stimulating hormone antagonizes interleukin-1-induced anorexia (220) 119
Uehara, Y., see Shimizu, H. (222) 279
Uehara, Y., see Shimomura, Y. (209) 15
Ueki, S., see Shibata, S. (221) 255
Ueki, S., see Tominaga, K. (214) 79
Ueki, S., see Tominaga, K. (217) 79
Ui, M., see Tada, S. (227) 25
Ujihara, H., see Renming, X. (223) 185
Ujike, H., Okumura, K., Zushi, Y., Akiyama, K. and Otsuki, S.
Persistent supersensitivity of σ receptors develops during repeated methamphetamine treatment (211) 323
Ujszászi, J., see Juhász, G. (209) 131
Ukai, M., Toyoshi, T. and Kameyama, T.
Multidimensional behavioral analyses show dynorphin A-(1–13) modulation of methamphetamine-induced behaviors in mice (222) 7
Ukai, M., see Toyoshi, T. (213) 25
Umans, J.G. and Samsel, R.W.
L-Canavanine selectively augments contraction in aortas from endotoxemic rats (210) 343
Umemura, S., see Sun, L. (226) 367
Underwood, S.L., Lewis, S.A. and Raeburn, D.
RP 59227, a novel PAF receptor antagonist: effects in guinea pig models of airway hyperreactivity (210) 97
Undie, A.S. and Friedman, E.
Selective dopaminergic mechanism of dopamine and SKF38393 stimulation of inositol phosphate formation in rat brain (226) 297
Unger, T., see Itoi, K. (219) 435
Ungerer, A., see Mathis, C. (220) 107
Ungerer, M., Obermaier-Skrobranek, B. and Lohse, M.J.
Adenosine A_1 receptor gene structure and regulation in normotensive and spontaneously hypertensive rats (226) 381
Ungerstedt, U., see Wu, H.-Q. (213) 375
Upton, C., see Maguire, P. (213) 219
Usherwood, P.N.R., see Macdonald, A.G. (210) 223
Ushijima, H., see Müller, W.E.G. (226) 209
Utagawa, A., see Inomata, H. (217) 93
Uusi-Oukari, M., see Korpi, E.R. (213) 323

Vaalburg, W., see Van Waarde, A. (222) 107
Vaccher, C., see Ong, J. (218) 343
Vaccher, C., see Ong, J. (221) 145
Vacher, P., see Chiavaroli, C. (227) 173
Valentovic, M.A., see Gruetter, C.A. (217) 109
Valerio, A., see Pizzi, M. (209) 169
Valerio, E., see Chiamulera, C. (216) 335
Valliere, J.E., DeLuca, A.W. and Shreeve, S.M.
Reconstitution of α_1-adrenoceptors having high affinity for prazosin (226) 191
Valliere, J.E., see Shreeve, S.M. (226) 29
Van Aken, H., see Mos, J. (212) 295
Van Alebeek, C., see Stam, N.J. (227) 153
Van Amsterdam, J.G.C. and Wemer, J.
Tetrahydrobiopterin induces vasodilatation via enhancement of cGMP level (215) 349
Van Amsterdam, J.G.C., see Beusenberg, F.D. (228) 57
Van Berckel, B.N.M., see Mihic, S.J. (218) 283
Van Bladeren, P.J., see Groten, J.P. (228) 23
Van Breemen, C., see Kawase, T. (214) 39
Van de Heijning, B.J.M., Koekkoek-Van den Herik, I. and Van Wimersma Greidanus, T.B.
The opioid receptor subtypes μ and κ, but not δ, are involved in the control of the vasopressin and oxytocin release in the rat (209) 199
Van de Kar, L.D., see Levy, A.D. (221) 121
Van Delden, C., see Krause, K.-H. (227) 221
Van de Meent, D., see Elliott, G.R. (214) 253
Van den Berg, M., see Ahlborg, U.G. (228) 179
Van den Buuse, M., see Buisson-Defferier, S. (223) 133
Van der Bent, A., Ter Laak, A.M., IJzerman, A.P. and Soudijn, W.
Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists (226) 327
Van der Zee, L., Nelemans, A. and Den Hertog, A.
Nucleotide receptors on DDT_1 MF-2 vas deferens cells (215) 317
Van de Velde, M.J., see Buckley, T.L. (218) 369
Van Diepen, H.A., see Tonnaer, J.A.D.M. (214) 33
Van Dijk, J., see Elliott, G.R. (214) 253
Van Eekeren, J., see Henning, R.H. (216) 73
Van Esch, B., see Folkerts, G. (228) 219
Van Essen, H., see Struijker Boudier, H.A.J. (218) 191
Van Gelderen, E.M. and Saxena, P.R.
Effect of N^G-nitro-L-arginine methyl ester on the hypotensive and hypertensive responses to 5-hydroxytryptamine in pithed rats (222) 185
Van Giersbergen, P.L.M., see Henderson, A.K. (225) 175
Van Hartesveldt, C., Cottrell, G.A., Potter, T. and Meyer, M.E.
Effects of intracerebral quinpirole on locomotion in rats (214) 27
Van Heijst, B.G.V., see De Beer, E.L. (214) 97
Van Hoestenberghe, A., De Witte, P., Geboes, K., Eyssen, H., Nijs, G. and Lemli, J.
The effect of rhein and rhein anthrone on intestinal fluid transport and on large intestine transit in germ-free rats (212) 121
Vanhoutte, P.M., see Schini, V.B. (216) 379
Van Huizen, F., see Stam, N.J. (227) 153
Vanin, A.F., see Vedernikov, Y.P. (211) 313
Vanin, A.F., see Vedernikov, Y.P. (212) 125

Van Meel, J.C.A., see Zhang, J. (218) 35
Van Oosterhout, A.J.M., Hofman, G., Woutersen-Van Nijnanten, F.M.A. and Nijkamp, F.P.
5-HT_1-like receptors mediate potentiation of cholinergic nerve-mediated contraction of isolated mouse trachea (209) 237
Van Overveld, F.J., see Jorens, P.G. (224) 7
Van Ree, J.M., see Durlach-Misteli, C. (217) 15
Van Rossum, J.X.M., see Remie, R. (211) 257
Van Tol, H.H.M., see Seeman, P. (227) 139
Van Waarde, A., Meeder, J.G., Blanksma, P.K., Brodde, O.-E., Visser, G.M., Elsinga, P.H., Paans, A.M.J., Vaalburg, W. and Lie, K.I.
Uptake of radioligands by rat heart and lung in vivo: CGP 12177 does and CGP 26505 does not reflect binding to β-adrenoceptors (222) 107
Van Wimersma Greidanus, T.B. and Maigret, C.
Neuromedin-induced excessive grooming/scratching behavior is suppressed by naloxone, neurotensin and a dopamine D_1 receptor antagonist (209) 57
Van Wimersma Greidanus, T.B., see Linthorst, A.C.E. (219) 23
Van Wimersma Greidanus, T.B., see Van de Heijning, B.J.M. (209) 199
Van Zwieten, P.A., see Schwietert, R. (211) 87
Vapaatalo, H., see Arvola, P. (214) 289
Varastet, M., Brouillet, E., Chavoix, C., Prenant, C., Crouzel, C., Stulzaft, O., Bottlaender, M., Cayla, J., Mazière, B. and Mazière, M.
In vivo visualization of central muscarinic receptors using [^{11}C]quinuclidinyl benzilate and positron emission tomography in baboons (213) 275
Varga, K. and Kunos, G.
Inhibition of baroreflex bradycardia by ethanol involves both $GABA_A$ and $GABA_B$ receptors in the brainstem of the rat (214) 223
Vargaftig, B.B., see Amorim, C.Z. (211) 29
Vargaftig, B.B., see Amorim, C.Z. (216) 429
Vargaftig, B.B., see Castro-Faria-Neto, H.C. (213) 183
Vargaftig, B.B., see Imaizumi, A. (212) 177
Vargaftig, B.B., see Nahori, M.-A. (228) 213
Vargaftig, B.B., see Pasquale, C.P. (223) 9
Vargaftig, B.B., see Pretolani, M. (216) 141
Vartanian, M.G., see Taylor, C.P. (213) 151
Vassalle, M., see Abete, P. (211) 399
Vaugeois, J.-M., Bonnet, J.-J. and Costentin, J.
In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [^{3}H]GBR 12783 (210) 77
Vauquelin, G., see Jimenez Del Rio, M. (225) 225
Vayssettes-Courchay, C., Bouysset, F., Verbeuren, T.J., Schmitt, H. and Laubie, M.
Cardiovascular effects of microinjections of quipazine into nuclei of the medulla oblongata in anaesthetized cats: comparison with L-glutamate (211) 243
Vécsei, L. and Beal, M.F.
Behavioral and pharmacological effects of centrally administered aminooxyacetic acid in rats (220) 259
Vedernikov, Y.P., Mordvintcev, P.I., Malenkova, I.V. and Vanin, A.F.
Effect of diethyldithiocarbamate on the activity of nitric oxide-releasing vasodilators (212) 125
Vedernikov, Y.P., Mordvintcev, P.I., Malenkova, I.V. and Vanin, A.F.
Similarity between the vasorelaxing activity of dinitrosyl iron cysteine complexes and endothelium-derived relaxing factor (211) 313
Veintemilla, F., Elinder, F. and Århem, P.
Mechanisms of propofol action on ion currents in the myelinated axon of *Xenopus laevis* (218) 59
Venco, C., see Pretolani, M. (216) 141
Verbanck, P.M.P., Seutin, V., Massotte, L. and Dresse, A.
Differential effects of picrotoxin and RO 15-1788 on high and low ethanol concentrations on rat locus coeruleus in vitro (211) 15
Verbeuren, T.J., see Heuzé-Joubert, I. (220) 161
Verbeuren, T.J., see Simonet, S. (216) 135
Verbeuren, T.J., see Vayssettes-Courchay, C. (211) 243
Verde, I., see Gil-Longo, J. (221) 1
Verheyen, A., see Folkerts, G. (228) 121
Verloes, R., see Gower, A.J. (222) 193
Vermeire, P.A., see Jorens, P.G. (224) 7
Versace, P., see Raiteri, M. (213) 17
Versteeg, D.H.G., see Linthorst, A.C.E. (219) 23
Vescovo, G., see Harding, S.E. (223) 39
Vetter, H., see Ko, Y. (227) 215
Viganò, T., Crivellari, M.T., Accomazzo, M.R., Monopoli, A., Belloni, P.A., Torre, M., Nicosia, S. and Folco, G.C.
Effect of SCH 37224 on anti-IgE-induced formation of sulfidopeptide leukotrienes in human lung parenchyma (219) 159
Vignon, J., see Chergui, K. (219) 169
Viitamaa, T., see Jäkälä, P. (221) 351
Vijverberg, H.P.M., see Zwart, R. (228) 165
Villalobos-Molina, R., Miyamoto, A., Kowatch, M.A. and Roth, G.S.
α_1-Adrenoceptors in parotid cells: age does not alter the ratio of α_{1A} and α_{1B} subtypes (226) 129
Villalón, C.M., see Dhasmana, K.M. (213) 293
Villalón, C.M., see Saxena, P.R. (220) 79
Villanueva, L., see Bouhassira, D. (216) 149
Villar, H.O., see Maguire, P.A. (214) 85
Villar, H.O., see Maguire, P.A. (226) 233
Vinayak, S., see Peterson, C.J. (221) 151
Vinogradov, V.A., see Samovilova, N.N. (225) 69
Virgolini, I., see Sinzinger, H. (219) 129
Virtanen, R., see Jäkälä, P. (221) 351
Visser, G.M., see Van Waarde, A. (222) 107
Vitagliano, S., see Maione, S. (219) 477
Vitale, M.L., see Trifaró, J.-M. (225) 83
Viti, G., see Eglezos, A. (209) 277
Viti, G., see Patacchini, R. (215) 93
Vittet, D., see Diochot, S. (227) 427
Vockert, E., see Bungardt, E. (213) 53
Voest, E.E., see De Beer, E.L. (214) 97
Volkova, T.M., see Davies, M.S. (227) 51
Volonté, M., Ceci, A. and Borsini, F.
Effect of haloperidol and clozapine on (+)SKF 10,047-induced dopamine release: role of 5-HT_3 receptors (213) 163
Von Euler, G. and Liu, Y.
The glutamate- and glycine-induced reduction of [^{3}H]MK-801 binding in the presence of Mg^{2+} is reversed at low pH (227) 449
Von Geldern, T., see Delporte, C. (224) 183
Von Lubitz, D.K.J.E., Lin, R.C.-S., McKenzie, R.J., Devlin, T.M., McCabe, R.T. and Skolnick, P.
A novel treatment of global cerebral ischaemia with a glycine partial agonist (219) 153
Von Lubitz, D.K.J.E., McKenzie, R.J., Kalenak, A., Lin, R.C.S. and Devlin, T.M.
Treatment of severe brain ischemia with di- and tri-Calciphor (dimer and trimer of 16,16′-dimethyl prostaglandin B_1) (216) 37
Voss, H.-P., Donnell, D. and Bast, A.
Atypical molecular pharmacology of a new long-acting β_2-adrenoceptor agonist, TA 2005 (227) 403
Votaw, J.R., see Kessler, R.M. (223) 105
Voutilainen, R., see Sjöholm, B. (215) 109
Vrána, O., Kiseleva, V.I., Poverenny, A.M. and Brabec, V.
Conversion of DNA adducts of antitumour cis-diammine-dichloroplatinum(II). Immunochemical analysis (226) 5

Vray, B., see Coquette, A. (226) 1
Vuorinen, P., see Arvola, P. (214) 289

Wachtel, H., see Lange, K.W. (212) 247
Wächter, F., see Wölfel, C. (228) 95
Wada, H., see Okakura, K. (213) 189
Wada, K., see Takiguchi, Y. (215) 289
Waddington, J.L., see Daly, S.A. (213) 251
Wadsworth, R.M., see Hay, D.W.P. (225) 313
Waelbroeck, M., Camus, J., Tastenoy, M., Mutschler, E., Strohmann, C., Tacke, R., Schjelderup, L., Aasen, A., Lambrecht, G. and Christophe, J.
Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors (227) 33
Waeldelé, F., see Da Silva, A. (212) 97
Wagner, G., see Wessler, I. (221) 371
Wagner, Jr., H.N., see Lever, J.R. (216) 459
Wahlestedt, C., see Heilig, M. (209) 27
Wahlestedt, C., see Sun, M.-K. (224) 93
Wahlestedt, C., see Sun, M.-k. (215) 9
Walczok, A., see Wessler, I. (221) 371
Waldegger, S., see Wöll, E. (212) 105
Waldmeier, P.C. and Stöcklin, K.
Displacement of in vivo binding of [^{3}H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine (216) 243
Walker, M.J.A., see Howard, P.G. (219) 1
Walker, M.J.A., see Igwemezie, L.N. (210) 271
Walker, M.J.A., see Pugsley, M.K. (212) 15
Wallace, J.L., see Hogaboam, C.M. (216) 315
Walter, J.A., see Hampson, D.R. (218) 1
Walters, M.R., Fischette, C.T., Fetzer, C., May, B., Riggle, P.C., Tibaldo-Bongiorno, M. and Christakos, S.
Specific 1,25-dihydroxyvitamin D_3 binding sites in choroid plexus (213) 309
Wang, J., see Lonart, G. (220) 271
Wang, J., see Qiu, Z. (214) 293
Wang, J.C., see Yamamoto, S. (227) 113
Wang, R.Y., see Minabe, Y. (209) 143
Wang, R.Y., see Minabe, Y. (209) 151
Wang, S., see Barr, G.A. (215) 35
Wang, Y.-X., Tan, Y.-H., Sheng, B.-H. and Chen, S.-Y.
Characteristics of depressing effect of cycloprotobuxine-A on the maximal velocity of depolarization in myocardium (222) 219
Wang, Z.-Y. and Håkanson, R.
Effect of resiniferatoxin on the isolated rabbit iris sphincter muscle: comparison with capsaicin and bradykinin (213) 235
Wang, Z.-y. and Håkanson, R.
The electrically evoked, tachykinin-mediated contractile response of the isolated rabbit iris sphincter muscle involves NK_1 receptors only (216) 327
Warburton, P., see Bryson, S.E. (225) 119
Warburton, P., see Wintersgill, H.P. (227) 283
Wasterlain, C.G., Adams, L.M., Hattori, H. and Schwartz, P.H.
Felbamate reduces hypoxic-ischemic brain damage in vivo (212) 275
Watanabe, G., see Kogo, H. (221) 289
Watanabe, H., see Sakurada, S. (211) 75
Watanabe, K., see Kikuchi de Beltrán, K. (214) 181
Watanabe, K., see Mino, N. (221) 77
Watanabe, S., see Kagami-ishi, Y. (224) 51
Watanabe, S., see Ohno, M. (219) 245
Watanabe, S., see Shibata, S. (221) 113
Watanabe, S., see Shibata, S. (221) 255
Watanabe, S., see Tominaga, K. (214) 79
Watanabe, S., see Tominaga, K. (217) 79
Watanabe, Y., Gould, E., Daniels, D.C., Cameron, H. and McEwen, B.S.
Tianeptine attenuates stress-induced morphological changes in the hippocampus (222) 157
Watanabe, Y., Saito, H. and Abe, K.
Effects of glycine and structurally related amino acids on generation of long-term potentiation in rat hippocampal slices (223) 179
Watanabe, Y., see Yamada, J. (216) 307
Watano, T., see Inoue, K. (215) 321
Watkins, C.J., see Newberry, N.R. (219) 135
Watkins, C.J., see Newberry, N.R. (221) 157
Watson, G.B., see Davies, M.S. (227) 51
Wayman, C.P., see Mabley, J. (209) 127
Wedemeyer, S., Roeder, T. and Gewecke, M.
Pharmacological characterization of a 5-HT receptor in locust nervous tissue (223) 173
Wegelius, K., see Korpi, E.R. (213) 323
Weil-Fugazza, J., see Besse, D. (223) 123
Weiss, B., see Zhou, L.-W. (218) 219
Weiss, H., see Wöll, E. (212) 105
Wellman, P.J., see Davies, B.T. (210) 11
Wells, J.W., see Hampson, D.R. (218) 1
Welsh, S., see Zhou, L.-W. (218) 219
Wemer, J., see Van Amsterdam, J.G.C. (215) 349
Weng, Y.-I., see Huang, H.-C. (218) 123
Wermelskirchen, D., Wilffert, B., Nebel, U., Leidig, A., Wirth, A. and Peters, T.
Veratridine activates a silent sodium channel in rat isolated aorta (219) 253
Wesemann, W., see Clement, H.-W. (217) 43
Wessler, I., Wagner, G. and Walczok, A.
Suppression by cholinesterase inhibition of a Ca^{2+}-independent efflux of [^{3}H]acetylcholine from the neuromuscular junction of the isolated rat diaphragm (221) 371
Westerink, B.H.C., see Santiago, M. (219) 175
Westlind-Danielsson, A., Ericsson, G., Sandell, L., Elinder, F. and Århem, P.
High concentrations of the neuroleptic remoxipride block voltage-activated Na^+ channels in central and peripheral nerve membranes (224) 57
Weyhenmeyer, J.A., see Lark, L.A. (222) 33
Wharton, J., see Knock, G.A. (219) 415
Wharton, J., see Rutherford, R.A.D. (212) 1
White, F.J., see Ackerman, J.M. (218) 171
Whiting, R.L., see Ford, A.P.D.W. (225) 105
Whitten, J.P., see Lambert, L.E. (216) 131
Whittle, B.J.R., Lopez-Belmonte, J. and Moncada, S.
Nitric oxide mediates rat mucosal vasodilatation induced by intragastric capsaicin (218) 339
Whittle, B.J.R., see Brown, J.F. (223) 103
Whittle, B.J.R., see Martinez-Cuesta, M.A. (218) 351
Wiebel, F.J., see Wölfel, C. (228) 95
Wieczorek, A.J., see Ko, Y. (227) 215
Wiederhold, K.-H., see Pombo-Villar, E. (226) 317
Wiegand, R.C., see Davies, M.S. (227) 51
Wienen, W., see Zhang, J. (218) 35
Wiener, H.L., Murray, J.M., Thalody, G.P. and Maayani, S.
Kinetics of relaxation responses to vasorelaxants in isolated rabbit aorta (220) 131
Wiesenfeld-Hallin, Z., see Xu, X.-J. (216) 337
Wijkström, A., see Ahlenius, S. (222) 69
Wilcox, C.S., see Folger, W.H. (227) 71
Wilcox, G.L., see Budai, D. (216) 441
Wilcox, R.A., see Safrany, S.T. (226) 265
Wild, K.D., see Menkens, K. (219) 345
Wilffert, B., see Schwietert, R. (211) 87
Wilffert, B., see Wermelskirchen, D. (219) 253

Wilhelm, D., see Schwietert, R. (211) 87
Williams, A.R. and Dourish, C.T.
Effects of the putative 5-HT_{1A} receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT_{1A} receptor agonist 8-OH-DPAT in the rat (219) 105
Williams, G.M., see Ren, K. (219) 235
Williams, T.J., see Lad, N. (223) 163
Wilmot, C.A., see Dunn, R.W. (214) 207
Wilson, J.F., see Mabley, J. (209) 127
Wilson, J.M., see Kish, S.J. (209) 101
Wilson, M.A. and Biscardi, R.
Effects of gender and gonadectomy on responses to chronic benzodiazepine receptor agonist exposure in rats (215) 99
Winand, J., see Delporte, C. (224) 183
Winand, J., see Delporte, C. (227) 247
Windscheif, U., see Lambrecht, G. (217) 217
Wintersgill, H.P., Warburton, P., Bryson, S.E., Ball, S.G. and Balmforth, A.J.
Characterization of the angiotensin II receptor expressed by the human hepatoma cell line, PLC-PRF-5 (227) 283
Wintersgill, H.P., see Bryson, S.E. (225) 119
Wirth, A., see Wermelskirchen, D. (219) 253
Wirth, K., see Englert, H.C. (210) 69
Wojcik, W.J., see Holopainen, I. (227) 225
Wolf, G., see Keilhoff, G. (219) 451
Wölfel, C., Heinrich-Hirsch, B., Schulz-Schalge, T., Seidel, A., Frank, H., Ramp, U., Wächter, F., Wiebel, F.J., Gonzalez, F., Greim, H. and Doehmer, J.
Genetically engineered V79 Chinese hamster cells for stable expression of human cytochrome P450IA2 (228) 95
Wöll, E., Weiss, H., Waldegger, S. and Lang, F.
Effect of calcium channel antagonists on cell membrane potential oscillations and proliferation of cells expressing the ras oncogene (212) 105
Wollheim, C.B., see Sher, E. (216) 407
Wolozin, B.L., see Lesch, K.P. (227) 109
Wolozin, B.L., see Lesch, K.P. (227) 233
Wolters, E.C., see Stoof, J.C. (213) 439
Wong, G. and Skolnick, P.
High affinity ligands for 'diazepam-insensitive' benzodiazepine receptors (225) 63
Wong, P.C., Christ, D.D. and Timmermans, P.B.M.W.M.
Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats (220) 267
Wong, T.M., see Pugsley, M.K. (212) 15
Wood, J.D., see Baidan, L.V. (225) 21
Wood, J.D., see Christofi, F.L. (216) 17
Wood, J.D., see Hanani, M. (211) 23
Wood, P.L., see Dunn, R.W. (214) 207
Woodman, O.L., see Du, Z.-Y. (211) 149
Woodman, O.L., see Du, Z.-Y. (214) 21
Woods, A.T., see Dunn, R.W. (214) 207
Woodward, J.J. and Harms, J.
The putative polyamine antagonists ifenprodil and SL 82.0715 enhance dopamine efflux from rat striatal slices independent of NMDA receptor activation (210) 265
Wooles, W.R., see Zhang, X. (222) 81
Woolverton, W.L., see Gui-Hua, C. (209) 285
Woutersen-Van Nijnanten, F.M.A., see Van Oosterhout, A.J.M. (209) 237
Wrathall, J.R., Bouzoukis, J. and Choiniere, D.
Effect of kynurenate on functional deficits resulting from traumatic spinal cord injury (218) 273
Wright, J.L.C., see Hampson, D.R. (218) 1
Wright, K.F., see Barrett, R.J. (216) 9
Wu, H.-Q., Ungerstedt, U. and Schwarcz, R.
Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats (213) 375
Wu, P.H., see Mihic, S.J. (218) 283
Wu, P.Y., see File, S.E. (218) 9
Wu, R.-T., see Huang, H.-C. (211) 359
Wu, T.-S., see Ko, F.-N. (218) 129
Wu, T.-S., see Ko, F.-N. (219) 29
Wülfert, E., see Gower, A.J. (222) 193
Wyatt, R.J., see Chrapusta, S.J. (222) 129

Xie, J.-E., see Su, D.-F. (214) 89
Xie, X. and Smart, T.G.
γ-Hydroxybutyrate depresses monosynaptic excitatory and inhibitory postsynaptic potentials in rat hippocampal slices (223) 193
Xie, X. and Smart, T.G.
γ-Hydroxybutyrate hyperpolarizes hippocampal neurones by activating $GABA_B$ receptors (212) 291
Xu, J.Y., see Tseng, L.F. (212) 301
Xu, X.-J., Dalsgaard, C.-J. and Wiesenfeld-Hallin, Z.
Intrathecal CP-96,345 blocks reflex facilitation induced in rats by substance P and C-fiber-conditioning stimulation (216) 337
Xue, L., see Suh, S.H. (219) 377

Yabuki, M., see Temma, K. (220) 63
Yacoub, M., see Belvisi, M.G. (210) 221
Yacoub, M.H., see Knock, G.A. (219) 415
Yacoub, M.H., see Rutherford, R.A.D. (212) 1
Yadid, G., Youdim, M.B.H. and Zinder, O.
Preferential release of epinephrine by glycine from adrenal chromaffin cells (221) 389
Yagasaki, O., see Kanada, A. (216) 287
Yakata, A., see Komabayashi, T. (225) 209
Yaksh, T.L., see Takano, Y. (219) 465
Yamada, H., see Yoneyama, F. (213) 199
Yamada, J., Sugimoto, Y., Kimura, I., Watanabe, Y., Takeuchi, N. and Horisaka, K.
Hyperglucagonemia induced in mice by tryptamine: involvement of the peripheral 5-HT_2 receptors (216) 307
Yamada, J., see Renming, X. (223) 185
Yamada, K., see Morishita, Y. (225) 203
Yamada, M., Yamada, M. and Richelson, E.
Block of neurotensin receptor down-regulation by an aminosteroid in N1E-115 cells (226) 187
Yamada, M., see Yamada, M. (226) 187
Yamada, N., see Martin-Iverson, M.T. (215) 119
Yamada, S., see Yokoo, H. (222) 43
Yamagata, T., see Hisa, H. (222) 265
Yamaguchi, T., see Namiki, A. (227) 339
Yamamoto, A., see Nishiyama, A. (218) 311
Yamamoto, A., see Shikada, K.-i. (209) 69
Yamamoto, S., Jiang, H., Nishikawa, K., Ishihara, M., Wang, J.C. and Kato, R.
Protein kinase C-dependent and -independent actions of a potent protein kinase C inhibitor, staurosporine (227) 113
Yamamoto, S., see Niimi, N. (221) 325
Yamamoto, T., see Ohno, M. (219) 245
Yamamoto, Y., see Suh, S.H. (219) 377
Yamamoto, Y.L., see Takada, A. (228) 131
Yamamura, H.I., see Henderson, A.K. (225) 175
Yamasaki, F., see Shinkawa, T. (219) 217
Yamasaki, K., see Ogino, K. (212) 9
Yamasaki, K., see Ogino, K. (219) 493
Yamashita, K., see Himeno, A. (215) 337
Yamashita, K., see Niwa, M. (225) 281
Yamashita, M., see Morimoto, H. (224) 1

Yamatodani, A., see Okakura, K. (213) 189
Yamauchi, T., see Morikawa, K. (213) 409
Yamazaki, J., Fukuda, H., Nagao, T. and Ono, H.
5-HT_2/5-HT_{1C} receptor-mediated facilitatory action on unit activity of ventral horn cells in rat spinal cord slices (220) 237
Yanagisawa, M., Hosoki, R. and Otsuka, M.
The isolated spinal cord–skin preparation of the newborn rat and effects of some algogenic and analgesic substances (220) 111
Yanagisawa, T., see Koga, Y. (220) 141
Yanagisawa, T., see Okada, Y. (218) 259
Yanaihara, N., see Hedlund, P.B. (224) 203
Yang, D.-C., see Moummi, C. (216) 47
Yang, H., see Garrick, T. (223) 75
Yang, Y.-C., see Su, D.-F. (214) 89
Yano, H., see Kurose, Y. (211) 39
Yano, M., see Filep, J.G. (219) 343
Yano, M., see Mino, N. (221) 77
Yao, E.F., see Bank, P.A. (228) 85
Yasukura, T., see Inoue, M. (221) 135
Yasumoto, T., see Murata, M. (227) 43
Yatabe, Y., see Kogo, H. (211) 69
Ye, M.-Q., Yuan, L.-X. and Healy, D.P.
Effects of intracerebroventricular captopril on angiotensin-converting enzyme and angiotensinogen mRNA levels in rat brain (227) 79
Yeh, S.-F., see Huang, H.-C. (221) 381
Yen, M.-H. and Lai, C.-S.
Mechanism of contractile responses to bradykinin in canine basilar arteries (221) 261
Yoburn, B.C., see Duttaroy, A. (221) 211
Yokoo, H., Yamada, S., Yoshida, M., Tanaka, M. and Nishi, S.
Attenuation of the inhibitory effect of dynorphin on dopamine release in the rat nucleus accumbens by repeated treatment with methamphetamine (222) 43
Yokoyama, M., see Tsujino, T. (226) 69
Yokoyama, T., see Arakawa, H. (215) 51
Yoneda, M., Junien, J.L. and Taché, Y.
Central action of σ receptor ligand, JO 1784, to suppress CRF-induced inhibition of gastric function in conscious rats (223) 197
Yoneda, T., see Takeda, Y. (213) 445
Yonemasu, Y., see Sako, K. (209) 39
Yoneyama, F., Yamada, H., Satoh, K. and Taira, N.
Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A_2 receptor agonist, involve the opening of glibenclamide-sensitive K^+ channels (213) 199
York, B.K., see Carr, L.A. (215) 285
Yoshida, A., see Ikemoto, Y. (216) 191
Yoshida, K., see Miura, T. (221) 333
Yoshida, K., see Okamura, T. (220) 27
Yoshida, M., Nishi, K., Machida, J., Sakiyama, H., Ikeda, K. and Ueda, S.
Effects of phorbol ester on lower urinary tract smooth muscles in rabbits (222) 205
Yoshida, M., see Yokoo, H. (222) 43
Yoshida, N., Omoya, H., Kato, S. and Ito, T.
5-HT_3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370 (216) 435
Yoshida, S., Nabeshima, T., Kinbara, K. and Kameyama, T.
Effects of NIK-247 on CO-induced impairment of passive avoidance in mice (214) 247
Yoshikami, D., see Hammerland, L.G. (226) 239
Yoshikawa, T., see Moritoki, H. (210) 61
Yoshikawa, T., see Nakano, Y. (219) 339
Yoshizaki, H., see Kuwahara, T. (221) 99
Youdim, M.B.H., see Gerlach, M. (226) 97
Youdim, M.B.H., see Yadid, G. (221) 389
Young, G.A., see Hudson, G.M. (221) 217
Young, G.A., see Stamidis, H. (213) 9
Young, R. and Glennon, R.A.
Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus (212) 117
Yousufzai, S.Y.K., see Abdel-Latif, A.A. (226) 351
Yu, X.Z., see McCaslin, P.P. (228) 73
Yu, Z.-N., see Chang, C.-H. (227) 229
Yuan, L.-X., see Ye, M.-Q. (227) 79
Yue, J.-L., see Nakamura, S. (222) 75
Yue, T.-L., McKenna, P.J., Ruffolo, Jr., R.R. and Feuerstein, G.
Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils (214) 277
Yuwiler, A., see Olds, M.E. (216) 363

Zaagsma, J., see Remie, R. (211) 257
Zafra-Polo, M.C., see Ivorra, M.D. (219) 303
Zajac, J.-M., see Gicquel, S. (222) 61
Zak, J., see Pilc, A. (212) 109
Zalkow, L.H., see Deutsch, H.M. (220) 173
Zaman, S.H., Shingai, R., Harvey, R.J., Darlison, M.G. and Barnard, E.A.
Effects of subunit types of the recombinant $GABA_A$ receptor on the response to a neurosteroid (225) 321
Zamfir, O., Broqua, P., Baudrie, V. and Chaouloff, F.
Effects of cold stress on some 5-HT_{1A}, 5-HT_{1C} and 5-HT_2 receptor-mediated responses (219) 261
Zangrossi, Jr., H., see File, S.E. (218) 9
Zarifian, E., see Abadie, P. (213) 107
Zasloff, M., see Cruciani, R.A. (226) 287
Zeilhofer, H.U., Swandulla, D., Geisslinger, G. and Brune, K.
Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons (213) 155
Zeman, S., see Palmer, A.J. (221) 205
Zeugner, C., see Strauss, J.D. (227) 437
Zhang, G., see Roth, J.E. (215) 293
Zhang, G., see Suh, S.H. (219) 377
Zhang, J., Entzeroth, M., Wienen, W. and Van Meel, J.C.A.
Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists (218) 35
Zhang, J., see Ni, H. (224) 157
Zhang, S.-P., see Zhou, L.-W. (218) 219
Zhang, X., Abdel-Rahman, A.-R.A. and Wooles, W.R.
Vasopressin receptors in the area postrema differentially modulate baroreceptor responses in rats (222) 81
Zhang, Y., see Meltzer, H.Y. (216) 67
Zharkovsky, A., see Andrews, N. (210) 247
Zharkovsky, A., see File, S.E. (218) 9
Zheng, F. and Gallagher, J.P.
Burst firing of rat septal neurons induced by 1S,3R-ACPD requires influx of extracellular calcium (211) 281
Zhou, L.-W., Zhang, S.-P., Welsh, S., Connell, T.A. and Weiss, B.
Triazolam blocks the initial rotational effects of quinpirole but permits the later developing reduction of dopamine D_2-mediated rotational behavior and dopamine D_2 receptors (218) 219
Zhu, Y.N., see Dhasmana, K.M. (213) 293
Ziegler, M.G., see Elayan, H. (212) 259
Zilletti, L., see Gentilini, G. (217) 9
Zimmerman, B.G., see Hajj-ali, A.F. (212) 279
Zinder, O., see Yadid, G. (221) 389
Zingarelli, B., Squadrito, F., Ioculano, M., Altavilla, D., Bussolino, F., Campo, G.M. and Caputi, A.P.
Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock (222) 13
Zingarelli, B., see Squadrito, F. (210) 107
Zini, R., see Morin, D. (225) 273

Zinkand, W.C., DeFeo, P.A., Thompson, C., Hargrove, H., Salama, A.I. and Patel, J.
Quisqualate neurotoxicity in rat cortical cultures: pharmacology and mechanisms (212) 129

Zongazo, M.A., Carayon, A., Masson, F., Maistre, G., Noé, E., Eurin, J., Barthelemy, C., Komajda, M. and Legrand, J.C.
Effects of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria (209) 45

Zorad, S., see Tsutsumi, K. (226) 169

Zorn, N.E., see Sauro, M.D. (225) 351

Zushi, Y., see Ujike, H. (211) 323

Zwart, R., Oortgiesen, M. and Vijverberg, H.P.M.
The nitromethylene heterocycle 1-(pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine distinguishes mammalian from insect nicotinic receptor subtypes (228) 165

Zwijsen, R.M.L., Oudenhoven, I.M.J. and De Haan, L.H.J.
Effects of cholesterol and oxysterols on gap junctional communication between human smooth muscle cells (228) 115

Key word index
volumes 209–228
1992

Master key word index to volumes 209–228

A23187
Smooth muscle; Ca^{2+}; Acetylcholine; Phasic and tonic responses; IP_3 (inositol trisphosphate) (Macara, B. (218) 27)

A69024
Chronic treatment; Dopamine D_1 receptors; Dopamine D_2 receptors; SCH 23390; SCH 39166; SK&F 38393 (Lappalainen, J. (210) 195)

Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; SCH 39166; NO 756; BW 737C (Daly, S.A. (213) 251)

AA tumor
Peripheral benzodiazepine receptors; Gliomas (human); Tumor models (rat); C6 gliomas (Takada, A. (228) 131)

A-80b
Antihypertensives; Vasodilators; Ca^{2+}; Aorta; Portal vein (Frechilla, D. (219) 409)

Abecarnil
Withdrawal seizure prone mouse (WSP); Ethanol withdrawal; Handling-induced convulsions; Diazepam; Anticonvulsant effects; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

Absence seizures
Epilepsy; $GABA_A$ receptors; $GABA_B$ receptors; γ-Hydroxybutyric acid; Pentylenetetrazole (Snead, III, O.C. (213) 343)

Abstinence syndrome
Ethanol; Morphine; Cocaine; Amphetamine; MK-801; SL 82.0715; Microdialysis (Rossetti, Z.L. (221) 227)

Accumulation
Cd^{2+}; Cadmium chloride; Cadmium-metallothionein; (Rat) (Groten, J.P. (228) 23)

Acetylcholine
WEB 1881 FU; Hippocampus; AF64A; Memory (Hashimoto, M. (209) 9)

Retina; Ethylcholine mustard arizidinium ion; Glycine; Amacrine cells; ON channels; OFF channels; (Frog) (Jardon, B. (210) 201)

Striatum (rat); Dopamine D_1 receptors; Dopamine D_2 receptors (Tedford, C.E. (211) 169)

Scopolamine; Passive avoidance; Acetylcholine release; Hippocampus; Choline precursors (Sigala, S. (211) 351)

EDRF (endothelium-derived relaxing factor); Polymorphonuclear leukocytes; Lipopolysaccharide; Mesenteric artery (superior); Nitric oxide (NO) (Siegfried, M.R. (212) 171)

Dystonia; Dopamine; Anticholinergic drugs; Haloperidol; Levodopa; Apomorphine (Löscher, W. (213) 31)

Baroreflexes; Nitroprusside; N-Nitro-L-arginine; Phenylephrine; Vasodilatation; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

cGMP; L-Cysteine; SIN-1 (3-morpholinosydnonimine); Sodium nitrite; Vascular smooth muscle relaxation (Arvola, P. (214) 289)

Smooth muscle; Ca^{2+}; A23187; Phasic and tonic responses; IP_3 (inositol trisphosphate) (Macara, B. (218) 27)

GABA (γ-aminobutyric acid); $GABA_B$ receptors; Neocortex; Quisqualate; (Rat) (Andre, P. (218) 137)

Striatum; Supersensitivity; Dopamine D_1 receptors; Dopamine D_2 receptors (Robertson, G.S. (219) 323)

AF102B; Muscarinic M_1 receptors; Hippocampus slices; Slow after-hyperpolarization (Segal, M. (220) 103)

Electrical field stimulation; Epithelium-derived acetylcholinesterase; EpDRF (epithelium-derived relaxing factor); Trachealis muscle (guinea-pig); Physostigmine (Koga, Y. (220) 141)

Nitric oxide (NO); Guanylyl cyclase; Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

Trachea (guinea-pig); Histamine; 5-HT (5-hydroxytryptamine, serotonin); Amiloride; Ouabain; K^+-free solution (Cortijo, J. (221) 43)

Neuropeptide Y (NPY); NPY receptor subtypes; Endothelium; Vasoconstriction; Vasodilatation (Grundemar, L. (221) 71)

Epilepsy; 5-HT (5-hydroxytryptamine, serotonin); GABA (γ-aminobutyric acid); Cl^- transport; Brain; (Mouse) (Inoue, M. (221) 135)

Chromaffin cells; Epinephrine; Norepinephrine; Glycine (Yadid, G. (221) 389)

Ageing; Trachea (guinea-pig and rat); Epithelium; Smooth muscle (airway); Histamine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Acetylcholine carrier
Phrenic nerve; K^+-stimulated Ca^{2+}-independent efflux of [^{3}H]acetylcholine; Cholinesterase inhibition; Vesamicol (Wessler, I. (221) 371)

Acetylcholine receptors
Doxorubicin; Adriamycin; Heart muscle preparations (isolated); Antimuscarinic actions; [^{3}H]Quinuclidinyl benzilate (QNB) binding (Temma, K. (220) 63)

Acetylcholine release
Vinpocetine; Excitatory amino acid receptors; Dopamine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Scopolamine; Passive avoidance; Acetylcholine; Hippocampus; Choline precursors (Sigala, S. (211) 351)

Nigrostriatal hemitransection; Dopamine uptake; Dopamine release; Ganglioside administration; (Recovery of function) (Raiteri, M. (213) 17)

NMDA receptors; Amantadine; Neostriatum; Dopamine release (Stoof, J.C. (213) 439)

Nitric oxide (NO); Basal forebrain (rat) (Prast, H. (216) 139)

Anticholinesterase; β-Eudesmol; Neostigmine; Neuromuscular transmission; Tetanic fade (Chiou, L.C. (216) 199)

Central nervous system (CNS); Striatum; Ca^{2+} channel antagonists; Verapamil; Spontaneously hypertensive rat (SHR) (Tsuda, K. (216) 319)

SR 95639A; Muscarinic receptor agonists (selective); Muscarinic receptor subtypes; Phosphoinositides; cAMP (Mohamed, A.S. (227) 181)

N^{α}-Acetyl-galanin-(9–29) (rat)
Galanin (rat); Galanin N-terminal fragments (rat); Galanin C-terminal fragments (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Gastric fistula (chronic); Venous cannula (chronic) (Mungan, Z. (214) 53)

Acetyl-L-carnitine
Brain dialysis; Dopamine release; Striatum (Harsing, Jr., L.G. (218) 117)

Acidosis
Alkalosis; Nifedipine; Ca^{2+} channels; Heart (rat) (Achike, F.I. (219) 369)

Acoustic startle (potentiated)
WAY100289; Light:dark box; Anxiety; 5-HT_3 receptor antagonists (Bill, D.J. (218) 327)

ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid)
Metabotropic glutamate receptor; Cerebellum; Purkinje cells; Granule cells; AP-3 ((L)-2-amino-3-phosphonopropionate) (East, S.J. (219) 395)

1S,3R-ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid)
Metabotropic glutamate receptor; Ca^{2+} (external) (Zheng, F. (211) 281)

Metabotropic receptors; Long-term potentiation (LTP) (Bortolotto, Z.A. (214) 297)

Metabotropic glutamate receptors; Excitotoxicity (Siliprandi, R. (219) 173)

t-ACPD (trans-1-aminocyclopentyl-1,3-dicarboxylic acid)
Hippocampus; Synaptic transmission (Garaschuk, O.V. (212) 305)

1S,3R-trans-ACPD
Metabotropic glutamate receptors; Hippocampal pyramidal cells (Gerber, U. (221) 401)

ACTH (adrenocorticotropic hormone)
Grooming behaviour; B-HT 920; Dopamine D_2 receptors; Stretching and yawning; Shakes (Ferrari, F. (216) 345)

Cocaine; 5-HT (5-hydroxytryptamine, serotonin); Prolactin; Oxytocin; Renin (Levy, A.D. (221) 121)

Myoclonus; Epilepsy; NMDA receptors (Trifiletti, R.R. (226) 377)

ACTH (adrenocorticotropin)
Feeding behaviour; Anorexia; B-HT 920; Immobilisation; (Rat) (Ferrari, F. (210) 17)

Histamine; Histamine H_3 receptors; AtT-20 cells (Clark, M.A. (210) 31)

Sciatic nerve crush; Org 2766; Neurotrophic factor; Regeneration; Sensorimotor function; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Penile erection; Yawning; Apomorphine; Oxytocin; Excitatory amino acid receptor antagonists (Melis, M.R. (220) 43)

ACTH release
5-HT (5-hydroxytryptamine, serotonin); Tricyclic antidepressants; Lithium; Electroconvulsive shock (Gartside, S.E. (221) 27)

Actin
Heparin derivatives; Smooth muscle cells; Proliferation; Differentiation (Bârzu, T. (219) 225)

Actin filaments
Endothelial cells; Histamine; Histamine H_1 receptors; Peripheral bands; Permeability (Niimi, N. (221) 325)

Action potentials
Cardiac hypertrophy; Depolarizations (transient); Na^+,K^+-ATPase; Ryanodine; Forskolin (Mészáros, J. (210) 325)

Ventricular papillary muscle; Contractile force; K^+ channel openers; Sulfonylurea antidiabetics; P_2 purinoceptor agonists (Bott, A. (213) 141)

Cycloprotobuxine-A; $\dot{V}$; Antiarrhythmic agents; Myocardium; (Use-dependent block) (Wang, Y.-X. (222) 219)

Ca^{2+}; Pituitary; Protein kinase A; Protein kinase C; Okadaic acid (Chiavaroli, C. (227) 173)

Addiction
Cocaine (chronic); Dopamine (Imperato, A. (212) 299)

Adenine nucleotide analogues
Skeletal muscle (innervated, frog); Ecto-enzymes; AP_5A (P^1P^5-di-(adenosine-5′)pentaphosphate); DPCPX (1,3-dipropyl-8-cyclopentylxanthine); Dipyridamole (Cascalheira, J.F. (222) 49)

Adenosine
Antianginal vasodilator; Antihypertensive vasodilator; Glibenclamide-sensitive K^+ channels; 2-(1-Octynyl)-adenosine (YT-146) (Yoneyama, F. (213) 199)

Purinoceptors; Benzodiazepine receptors (peripheral); Trachea (guinea-pig, isolated) (Devillier, P. (214) 67)

Adenosine A_1 receptors; Adenosine A_1 receptor antagonists (Barrett, R.J. (216) 9)

Enteric nervous system; Ganglia; Stomach; Synaptic transmission (Christofi, F.L. (216) 17)

Angiotensin II; Caffeine; Renal function; Hypertension (Holycross, B.J. (219) 361)

CGRP (calcitonin gene-related peptide); Sensory nerves; Mesenteric arterial bed (Rubino, A. (220) 95)

Xanthines; Seizures; Pentylenetetrazole; EEG (electroencephalogram) (Cutrufo, C. (222) 1)

Forskolin; 1,9-Dideoxyforskolin; Phosphodiesterase inhibitors; Inward calcium current-dependent phasic tension; Atrial fibres (frog) (Gauthier, C. (225) 129)

Adenosine receptors; Insulin sensitivity; Glucose transport; Amino acid transport; Skeletal muscle (Challiss, R.A.J. (226) 121)

Adenosine analogues
Adenosine receptors; Aorta (guinea-pig); 8-Phenyltheophylline (Martin, P.L. (216) 235)

Adenosine A_1 receptor antagonists
Adenosine; Adenosine A_1 receptors (Barrett, R.J. (216) 9)

Adenosine A_1 receptors
Adenosine; Adenosine A_1 receptor antagonists (Barrett, R.J. (216) 9)

Polymerase chain reaction; Spontaneously hypertensive rat (SHR) (Ungerer, M. (226) 381)

Adenosine A_2 receptors; Neuroprotection; Brain (rat); Desensitization (agonist induced) (Abbracchio, M.P. (227) 317)

Adenosine A_2 receptors
Adenosine A_1 receptors; Neuroprotection; Brain (rat); Desensitization (agonist induced) (Abbracchio, M.P. (227) 317)

Adenosine receptors
Atrium (left, dog); 8-Phenyltheophylline; DPCPX (1,3-dipropyl-8-cyclopentylxanthine); N-0861 (N^6-endonorbornan-2-yl-9-methyladenine) (Martin, P.L. (214) 199)

Morphine; Antinociception; Tolerance; (Rat) (Tao, P.-L. (215) 301)

Adenosine analogues; Aorta (guinea-pig); 8-Phenyltheophylline (Martin, P.L. (216) 235)

CGS 21680; CGS 22492; Smooth muscle (vascular); Coronary artery (human); Mammary artery (internal) (Makujina, S.R. (221) 243)

Dopamine D_1 receptors; Dopamine D_2 receptors; Perioral dyskinesia; (Rabbit) (Caporali, M.G. (223) 15)

Membrane microviscosity; Affinity states; Brain cortex (pig) (Casadó, V. (225) 7)

Pineal; AMP (Gharib, A. (225) 359)

Adenosine; Insulin sensitivity; Glucose transport; Amino acid transport; Skeletal muscle (Challiss, R.A.J. (226) 121)

Phorbol esters; Adenylyl cyclase; Gene transcription; T-lymphocytes (Kontny, E. (227) 333)

S-Adenosyl-L-methionine
Brain; Aging; Muscarinic receptors; Striatum; Hippocampus (Muccioli, G. (227) 293)

Adenylate cyclase
Cardiac hypertrophy; β-Adrenoceptors; Ca^{2+} channels (slow); Forskolin (Mészáros, J. (210) 333)

Dopamine D_1 receptors; Dopamine D_2 receptors; Circling behaviour; Stereotyped behaviour; Locomotor activity (Arnt, J. (213) 259)

δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Etorphine; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Sucrose gradients; G-proteins (Polastron, J. (226) 133)

Platelets (human); 5-HT (5-hydroxytryptamine, serotonin) (Newman, M.E. (226) 281)

Myenteric plexus (guinea-pig); μ-Opioid receptors (pre- and postsynaptic) (Rengel, I. (227) 385)

Adenylate cyclase activity
Locomotor activity; Dopamine autoreceptors; Lisuride; Tolerance; Sensitization (Nisoli, E. (216) 81)

Adenylyl cyclase
Acetylcholine; Nitric oxide (NO); Guanylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

Idazoxan; Antidepressants; β-Adrenoceptors; C6 glioma cells; Protein kinase C (Manji, H.K. (227) 275)

Phorbol esters; Adenosine receptors; Gene transcription; T-lymphocytes (Kontny, E. (227) 333)

Alveolar macrophages; cAMP; Chronic obstructive pulmonary disease; Asthma; Inflammatory mediators; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

Adenylyl cyclase inhibition
Clonidine; Norepinephrine; α_2-Adrenoceptors; Morphine; μ-Opioid receptors; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

$GABA_B$ receptors; GABA (γ-aminobuteric acid); cAMP; Baclofen; Cerebellar granule cells (Holopainen, I. (227) 225)

Adjuvant arthritis
Arthritis; MDP-Lys(L18); Cyclosporin A; (Rat) (Sugawara, T. (228) 147)

ADP-ribosyltransferase C3 *(Clostridium botulinum)*
Guanine nucleotide-binding proteins (small); rho proteins; Melittin; Mast cell degranulating peptide; Compound 48/80 (Koch, G. (226) 87)

Adrenal cortex (bovine)
Angiotensin IV; Angiotensin-(3–8); Angiotensin II; L-158,809 (Jarvis, M.F. (219) 319)

Adrenaline
Pancreas (isolated, rat); Pertussis toxin; Insulin secretion; α_2-Adrenoceptors (Hillaire-Buys, D. (218) 359)

Adrenal medulla
Gentamicin; Catecholamine level; Striatum; Hypothalamus; Vas deferens (Mikami, M. (210) 91)

Adrenergic contraction
Urethra (dog); Neurogenic response; Non-adrenergic, non-cholinergic relaxation (Hashimoto, S. (213) 117)

Adrenergic nerves
Bronchospasm; Capsaicin; Neurokinin A; Substance P; Cholinergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Dihydropyridine Ca^{2+} entry blocker; EDRF (endothelium-derived relaxing factor); Substance P; Mesenteric artery; cGMP (Okamura, T. (220) 27)

Adrenergic neurotransmission
Heart; U46619; ONO11006; Thromboxane B_2 (Mantelli, L. (213) 79)

α_2-Adrenoceptor agonists
Antinociception; Spinal cord; Dorsal horn neurons; Dexmedetomidine; Opioids (Sullivan, A.F. (215) 127)

Cough; Citric acid; GABA receptor agonists; (Conscious guinea-pig) (Callaway, J.K. (220) 187)

β-Adrenoceptor agonists
Bicarbonate secretion; β-Adrenoceptors ('atypical'); Cecum; β-Adrenoceptor antagonists (Canfield, P. (216) 293)

Alveolar macrophages; cAMP; Chronic obstructive pulmonary disease; Asthma; Adenylyl cyclase; Inflammatory mediators (Beusenberg, F.D. (228) 57)

β_2-Adrenoceptor agonists (long acting)
Ternary complex; Tight agonist binding; Tracheal smooth muscle relaxation (Voss, H.-P. (227) 403)

α-Adrenoceptor antagonists
Portal vein (rat); K^+ channels (Schwietert, R. (211) 87)

α_2-Adrenoceptors; Non-adrenergic binding sites; [^{3}H]Atipamezole; [^{3}H]Rauwolscine (Sjöholm, B. (215) 109)

5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; Desipramine; 6-Hydroxydopamine (6-OHDA); Spinal antinociception (Sawynok, J. (223) 49)

β-Adrenoceptor antagonists
Atrial effective refractory period; Atrial rate; Ventricular rate; β-Adrenoceptor blocking activity; Stereoisomers; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

Carvedilol; Free radical; Superoxide; Neutrophils; Antioxidants (Yue, T.-L. (214) 277)

Atenolol; Indenolol; Nadolol; Propranolol; Mitochondrial ATPase activity (Almotrefi, A.A. (215) 231)

Bicarbonate secretion; β-Adrenoceptors ('atypical'); Cecum; β-Adrenoceptor agonists (Canfield, P. (216) 293)

5-HT receptors; 5-HT_{1A} receptors; Migraine; Pindolol; Propranolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

α-Adrenoceptor blockade
Hypertension; 3-Methylhistidine; Terazosin; Spontaneously hypertensive rat (SHR) (Jonsson, J.R. (211) 263)

β-Adrenoceptor blocking activity
Atrial effective refractory period; Atrial rate; Ventricular rate; Stereoisomers; β-Adrenoceptor antagonists; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

α_2-Adrenoceptor mechanism
3,4-Diaminopyridine; Noradrenaline release; Hippocampus; Ca^{2+} (intracellular); (Rat); (Rabbit) (Jackisch, R. (226) 245)

β-Adrenoceptor-mediated responses
Desensitization; Lung parenchymal strips (guinea-pig); Atria (guinea-pig) (Herepath, M.L. (215) 209)

α_2-Adrenoceptor mRNA
HT29 cells; OK cells; NG108 cells (Sun, L. (226) 367)

Adrenoceptors
Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

α_{1A}-Adrenoceptors; Phosphoinositide turnover; Phosphorylase (García-Sáinz, J.A. (227) 239)

Catecholamines; Inositol phosphates (Schwinn, D.A. (227) 433)

α-Adrenoceptors
Atherosclerosis; Endothelium; Vasoconstriction; (Conscious rabbits) (Du, Z.-Y. (211) 149)

Noradrenaline; Neuronal reuptake; Presynaptic inhibition; Heart (rat) (Du, X.-J. (211) 221)

Phentolamine; Pinacidil; Cromakalim; K^+ channels; Trachea (Bang, L. (211) 235)

Baroreceptors; Clonidine; Haemorrhage; Yohimbine; (Rabbit) (Evans, R.G. (216) 265)

α_1-Adrenoceptor subtypes; WB 4101; Chlorethylclonidine; Arteries (Oriowo, M.A. (216) 415)

Vas deferens; Smooth muscle; Spontaneously hypertensive rats (SHR) (Caricati-Neto, A. (218) 51)

β-Adrenoceptors; Aorta; Jugular vein; Autoradiography; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol); [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

MCI-154; Hypotensive drugs; K^+ contracture; Vasodilatation (Suh, S.H. (219) 377)

Noradrenergic mechanisms (central); Gastric motility; Brainstem (Nagata, M. (223) 153)

Sympathetic ganglia; Catecholamine receptors; Dopamine receptors (Horn, P.T. (224) 103)

Octreotide; SMS 201-995; Somatostatin; Histamine H_3 receptors; Migraine; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

Prazosin; Receptor reconstitution; Detergent solubilization; Receptor conformation (Valliere, J.E. (226) 191)

Dopamine receptors; Inositol phosphates; Phosphoinositides; Striatum (rat); 5-HT receptors (Undie, A.S. (226) 297)

α_1-Adrenoceptors
Cirazoline; Paraventricular hypothalamus (Davies, B.T. (210) 11)

Vas deferens (rat); Protein kinase C; Phorbol esters (Abraham, S.T. (218) 243)

Vasopressin; Phosphoinositide (PI) hydrolysis; Endothelin; Nonpeptide V_1 receptor antagonists; Ventricular myocardium (rabbit) (Endoh, M. (218) 355)

Immunoreactive insulin plasma levels; β-Adrenoceptors; Ca^{2+} channel blockers; (Rabbit) (García-Barrado, M.J. (219) 461)

Thoracic aorta; (Single cell) (Satoh, M. (221) 35)

Aorta (rabbit); α_2-Adrenoceptors; BAY k 8644; Ca^{2+} channels (Aleixandre, A. (221) 129)

Membrane lipids; Phospholipases; Phospholipase C; Phospholipids; Aorta (Shreeve, S.M. (226) 29)

Amitriptyline; Xerostomia; Cytosolic free Ca^{2+}; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

Norepinephrine; Ca^{2+}; Smooth muscle (Han, C. (226) 141)

Electroconvulsive shock; Brain (rat); 5-HT_2 receptors; Phosphoinositide hydrolysis (Pandey, G.N. (226) 303)

α_{1A}-Adrenoceptors
(+)-Niguldipine; Positive inotropic effect; [^{3}H]Prazosin binding; Ventricular myocardium (rabbit) (Endoh, M. (223) 143)

Adrenoceptors; Phosphoinositide turnover; Phosphorylase (García-Sáinz, J.A. (227) 239)

α_2-Adrenoceptors
Transmitter release; K^+ channels; Aminopyridines; Tetraethylammonium (Hu, P.-S. (209) 87)

Bradykinin; Capsaicin; Nicotine; Resiniferatoxin; Bronchoconstriction (Lou, Y.-P. (210) 173)

α_{2A}-Adrenoceptors; α_{2B}-Adrenoceptors; Prazosin; ARC 239 (Smith, K. (211) 251)

EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Receptor occupancy (in vivo) (Pilc, A. (212) 109)

Rilmenidine; Clonidine; Noradrenaline release; Voltammetry (in vivo); Hypothalamus (Suaud-Chagny, M.F. (213) 305)

α-Adrenoceptor antagonists; Non-adrenergic binding sites; [^{3}H]Atipamezole; [^{3}H]Rauwolscine (Sjöholm, B. (215) 109)

Nociception; Pain (Millan, M.J. (215) 355)

Pancreas (isolated, rat); Pertussis toxin; Insulin secretion; Adrenaline (Hillaire-Buys, D. (218) 359)

Noradrenaline release; Monoamine oxidase; Antidepressant drugs; Vas deferens (rat) (Ari, G. (219) 89)

Aorta (rabbit); α_1-Adrenoceptors; BAY k 8644; Ca^{2+} channels (Aleixandre, A. (221) 129)

Atipamezole; Guanfacine; Mydriasis; Neocortical high-voltage spindles; (Rat); (Subchronic treatment) (Jäkälä, P. (221) 351)

Noradrenaline; Autoradiography; Brain imaging (Biegon, A. (224) 27)

Fos; Yohimbine; Clonidine; Guanabenz (Tsujino, T. (226) 69)

Clonidine; Norepinephrine; Morphine; μ-Opioid receptors; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

Platelets (human); Opioids (Ballesta, J.J. (227) 349)

α_{2A}-Adrenoceptors
α_2-Adrenoceptors; α_{2B}-Adrenoceptors; Prazosin; ARC 239 (Smith, K. (211) 251)

α_{2D}-Adrenoceptors; α_2-Adrenoceptors (prejunctional); Submandibular gland (rat); Vas deferens (rat); Platelets (human) (Smith, K. (219) 203)

α_{2B}-Adrenoceptors
α_2-Adrenoceptors; α_{2A}-Adrenoceptors; Prazosin; ARC 239 (Smith, K. (211) 251)

α_{2D}-Adrenoceptors
α_{2A}-Adrenoceptors; α_2-Adrenoceptors (prejunctional); Submandibular gland (rat); Vas deferens (rat); Platelets (human) (Smith, K. (219) 203)

β-Adrenoceptors
Cardiac hypertrophy; Adenylate cyclase; Ca^{2+} channels (slow); Forskolin (Mészáros, J. (210) 333)

Pulmonary surfactant; Type II pneumocyte (Kai, H. (212) 101)

Thyroxine; Portal vein; Noradrenaline; Fenoterol; Atenolol; ICI 118,551 (Chin, J.P.F. (212) 201)

α-Adrenoceptors; Aorta; Jugular vein; Autoradiography; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol); [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

Atrial effective refractory period; Atrioventricular conduction time; Ventricular effective refractory period; Sinoatrial pacemaker activity (Takei, M. (219) 15)

Immunoreactive insulin plasma levels; α_1-Adrenoceptors; Ca^{2+} channel blockers; (Rabbit) (García-Barrado, M.J. (219) 461)

Cardiac imaging; PET (positron emission tomography); CGP 12177; CGP 26505; CGP 20712A (Van Waarde, A. (222) 107)

cAMP; mRNA; Isoproterenol; C_6 glioma cells; Down-regulation (Bieck, P.R. (225) 171)

cAMP accumulation; 5-HT (5-hydroxytryptamine, serotonin) (Morin, D. (225) 273)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; Isoproterenol (Sakuta, H. (226) 199)

Idazoxan; Antidepressants; Adenylyl cyclase; C6 glioma cells; Protein kinase C (Manji, H.K. (227) 275)

β_1-Adrenoceptors
Amitriptyline; Xerostomia; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

β_2-Adrenoceptors
Amino acid transport; Blood–brain barrier; L-DOPA (L-3,4-dihydroxyphenylalanine); Isoproterenol; Salbutamol (Takao, Y. (215) 245)

β-Adrenoceptors (atypical)
Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

SM-11044; β_3-Adrenoceptors (human) (Sugasawa, T. (216) 207)

Bicarbonate secretion; Cecum; β-Adrenoceptor agonists; β-Adrenoceptor antagonists (Canfield, P. (216) 293)

Brain; Depression; Locomotor activity; Water intake (Simiand, J. (219) 193)

β_3-Adrenoceptors (human)
SM-11044; β-Adrenoceptors (atypical) (Sugasawa, T. (216) 207)

α_2-Adrenoceptors (prejunctional)
α_{2A}-Adrenoceptors; α_{2D}-Adrenoceptors; Submandibular gland (rat); Vas deferens (rat); Platelets (human) (Smith, K. (219) 203)

β-Adrenoceptors (prejunctional)
CGP 20712A; ICI 118,551; Isoprenaline; Noradrenaline release (Mian, M.A. (213) 47)

α_2-Adrenoceptors (presynaptic)
β_2-Adrenoceptors (presynaptic); Portal vein; Spontaneously hypertensive rat (SHR); Plasma catecholamines; (Freely moving rat) (Remie, R. (211) 257)

Clonidine; Aspartate; Glutamate; GABA (γ-aminobutyric acid); Brain (rat) (Kamisaki, Y. (217) 57)

β_2-Adrenoceptors (presynaptic)
Portal vein; Spontaneously hypertensive rat (SHR); α_2-Adrenoceptors (presynaptic); Plasma catecholamines; (Freely moving rat) (Remie, R. (211) 257)

α_1-Adrenoceptor subtypes
α-Adrenoceptors; WB 4101; Chlorethylclonidine; Arteries (Oriowo, M.A. (216) 415)

SDZ NVI 085; Vas deferens; Kidney; Aorta (rat) (Eltze, M. (224) 125)

Parotid cells; Aging (Villalobos-Molina, R. (226) 129)

α_2-Adrenoceptor subtypes
Rilmenidine; Oxazoline; Imidazoline; Guanidinium; Cerebral cortex (rat) (King, P.R. (218) 101)

WB4101; Imiloxan; Dexmedetomidine; Clonidine; ST-91 (Takano, Y. (219) 465)

Adriamycin
Doxorubicin; Heart muscle preparations (isolated); Acetylcholine receptors; Antimuscarinic actions; [^{3}H]Quinuclidinyl benzilate (QNB) binding (Temma, K. (220) 63)

Adverse drug reactions
Sulfotransferase; Dehydroepiandrosterone; Estrone; Liver (human) (Bamforth, K.J. (228) 15)

AF64A
WEB 1881 FU; Hippocampus; Acetylcholine; Memory (Hashimoto, M. (209) 9)

AF102B
Acetylcholine; Muscarinic M_1 receptors; Hippocampus slices; Slow after-hyperpolarization (Segal, M. (220) 103)

[^{3}H]AF-DX 384
Muscarinic receptors; Muscarinic M_2 receptor subtype; Receptor binding techniques; Autoradiography (Aubert, I. (217) 173)

Affective disorders
Phosphoinositide hydrolysis; 5-HT_2 receptors; Forced swimming test; Mianserin; Imipramine (Kawanami, T. (216) 385)

Affinity cross-linking
Opioid receptors; G-proteins; NG108-15 cells (Harada, J. (227) 301)

Affinity states
Adenosine receptors; Membrane microviscosity; Brain cortex (pig) (Casadó, V. (225) 7)

Afterdepolarization
Metabotropic receptors; Glutamate (Greene, C. (226) 279)

Aggregation
Endothelin; Polymorphonuclear leukocytes; PAF (platelet-activating factor, PAF-acether) (Gómez-Garre, D. (224) 167)

Aggression
TFMPP (1-(3-(trifluoromethyl)phenyl)piperazine hydrochloride); Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Mos, J. (212) 295)

Aging
ANP (atrial natriuretic polypeptide); Aorta (rat); Relaxation; Endothelium; cGMP; Phosphodiesterase activity (Moritoki, H. (210) 61)

Airway obstruction; Asthma; Oedema; Histamine; Plasma exudation; Substance P; Vascular permeability (Arakawa, H. (215) 51)

BAY k 8644; Ca^{2+} channel agonists; Voltage-gated Ca^{2+} channels (Khatter, J.C. (216) 351)

Cardiac muscle; Dihydropyridines; Ca^{2+} (extracellular); F344 rats; Isoproterenol (Ruch, S. (216) 393)

D-Cycloserine; Glycine; Memory; NMDA receptors; Senescence; (Mouse) (Flood, J.F. (221) 249)

Stomach (rat); Non-adrenergic, non-cholinergic (NANC); VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurons (Smits, G.J.M. (223) 97)

Cerebral cortex; Muscarinic receptors; Peptides; Phosphoinositides; (Rat) (Pedigo, Jr., N.W. (225) 151)

α_1-Adrenoceptor subtypes; Parotid cells (Villalobos-Molina, R. (226) 129)

S-Adenosyl-L-methionine; Brain; Muscarinic receptors; Striatum; Hippocampus (Muccioli, G. (227) 293)

Trachea (guinea-pig and rat); Epithelium; Smooth muscle (airway); Histamine; Acetylcholine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Aglafoline
PAF receptor antagonists; (*Aglaia elliptifolia* Merr) (Ko, F.-N. (218) 129)

Agonists
Epithelium; Kinins (characterization); Bradykinin receptor antagonists; B_2 receptor antagonist (radiolabeled) (Tousignant, C. (225) 235)

Ah (aryl-hydrocarbon)-mediated effects
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Ah receptors
TCDD(2,3,7,8-tetrachlorodibenzo-p-dioxin) (Bank, P.A. (228) 85)

Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Airway constriction
Substance P; Neurokinin A; Capsaicin; Field stimulation; Airway edema (Murai, M. (217) 23)

Airway dynamics
HOE 234; Bronchodilation; Trachea (guinea-pig); K^+ channel opening (Englert, H.C. (210) 69)

Airway edema
Substance P; Neurokinin A; Capsaicin; Field stimulation; Airway constriction (Murai, M. (217) 23)

Airway epithelium
Endothelin; Bronchus (isolated, human); Enkephalinase (Candenas, M.-L. (210) 291)

Angiotensin; Ion transport; G-protein (Tamaoki, J. (220) 87)

Airway hyperreactivity
Interleukin-1 receptor antagonists; Substance P; Bronchoalveolar lavage; Airway leukoctyes (Selig, W. (213) 331)

Airway hyperresponsiveness
5-Lipoxygenase; Leukotrienes; Asthma; Inflammation; (Late responses) (Abraham, W.M. (217) 119)

Airway leukoctyes
Interleukin-1 receptor antagonists; Airway hyperreactivity; Substance P; Bronchoalveolar lavage (Selig, W. (213) 331)

Airway microvascular leakage
Bradykinin; Bradykinin receptors; Bronchoconstriction; Hoe 140; PAF (platelet-activating factor, PAF-acether) (Sakamoto, T. (213) 367)

Airway obstruction
Aging; Asthma; Oedema; Histamine; Plasma exudation; Substance P; Vascular permeability (Arakawa, H. (215) 51)

Leukotriene B_4; Receptor binding; Parenchymal contraction; Leukotriene B_4 receptor antagonists; (Guinea-pig) (Silbaugh, S.A. (223) 57)

Airway responsiveness (in vitro)
Parainfluenza 3 virus; Inflammatory cells; Histology (Folkerts, G. (228) 121)

Airway responsiveness (in vivo)
Parainfluenza 3 virus; Inflammatory cell count; Chemiluminescence; (In vitro activation) (Folkerts, G. (228) 219)

Airways
Endothelin-1; Thromboxane A_2; Vascular permeability; Inflammation; Gastrointestinal ulceration (Sirois, M.G. (214) 119)

ω-Conotoxin GVIA; Neurotransmitter release; Cholinergic neurons; NANC (non-adrenergic, non-cholinergic) neurons; (Guinea-pig) (Boot, J.R. (219) 123)

Nitric oxide (NO); Neurogenic inflammation; NANC nerves; Plasma exudation; Vagus nerve (Kuo, H.-P. (221) 385)

Airways (guinea-pig)
Neuropeptide Y (NPY); (Inhibitory action) (T-Benchekroun, M. (216) 421)

Al^{3+}
Smooth muscle (vascular); Fluoride; G-protein; Ca^{2+} sensitivity; Protein kinase C (Kawase, T. (214) 39)

[D-Ala^2]deltorphin II
Castor-oil diarrhea; Gastrointestinal transit; Colonic bead expulsion; (I.c.v. and i.t. administration); (Rat) (Broccardo, M. (218) 69)

[D-Ala^2,Glu^4]deltorphin
δ-Opioid receptor subtypes; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); CD-1 mice; CXBK mice; Antinociception (Raffa, R.B. (216) 453)

Alanine
Glycine; Serine; Valine; Glycine modulatory site; NMDA receptors; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Alcohol sensitivity
Ro 15-4513; Cerebellar diazepam-insensitive binding; Substrate specificity; (Selected rat lines) (Korpi, E.R. (213) 323)

Aldose reductase inhibitors
Isoliquiritigenin; Anti-platelet action; Cyclooxygenase inhibitor (Tawata, M. (212) 87)

Platelet aggregation; Diabetes; (Rat) (Takiguchi, Y. (215) 289)

Aldosterone
Spontaneously hypertensive rat (SHR); MK 954 (DuP 753); Renin; Angiotensin II; (Rat) (Mizuno, K. (215) 305)

Alkalosis
Acidosis; Nifedipine; Ca^{2+} channels; Heart (rat) (Achike, F.I. (219) 369)

Allergen
Cetirizine; Leucocyte recruitment; Pleurisy (rat) (Pasquale, C.P. (223) 9)

Allergic oedema
Anaphylaxis; Anti-allergic drugs (Amorim, C.Z. (216) 429)

Allosteric regulation
Ca^{2+} channel antagonists; PN200-110; Diltiazem; Verapamil (Miwa, K. (214) 127)

Alloxan diabetes
Vanadate; Insulin mimetic effects; Liver; Kidney (Saxena, A.K. (216) 123)

Alpidem
Benzodiazepines; Spinal cord; Benzodiazepine receptor binding; (Receptor heterogeneity) (Maguire, P.A. (214) 85)

Alprazolam
Force swimming test; Desipramine; Diazepam (Flugy, A. (214) 233)

Alprenolol
β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

Alveolar macrophages
cAMP; Chronic obstructive pulmonary disease; Asthma; Adenylyl cyclase; Inflammatory mediators; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

Alzheimer's disease
[^{3}H]CPP ([^{3}H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid); NMDA receptors; Brain (rat); Cortex (human) (Porter, R.H.P. (225) 195)

Amacrine cells
Retina; Ethylcholine mustard arizidinium ion; Acetylcholine; Glycine; ON channels; OFF channels; (Frog) (Jardon, B. (210) 201)

Amantadine
NMDA receptors; Acetylcholine release; Neostriatum; Dopamine release (Stoof, J.C. (213) 439)

Amastatin
Dermorphin; [D-Arg^2]dermorphin; Captopril; Antinociceptive activity (Sakurada, S. (211) 75)

Amiloride
Myocardial ischemia; Myocardial reperfusion; Mitochondria; Arrhythmias; Ultrastructure; Na^+/H^+ exchange (Duan, J. (210) 149)

Trachea (guinea-pig); Acetylcholine; Histamine; 5-HT (5-hydroxytryptamine, serotonin); Ouabain; K^+-free solution (Cortijo, J. (221) 43)

3,4-Dichlorobenzamil; Quinacrine; Ca^{2+}; Ca^{2+} channel blockers; L-type Ca^{2+} channels (Stokke, M. (227) 379)

Amine uptake
Dopamine; Dopamine transporters; Synaptic vesicle (Rostène, W. (218) 175)

Amino acid release
Baclofen; Ca^{2+} dependence (Otero Losada, M.E. (224) 21)

Amino acids
Amitriptyline; Na^+ channels; Dopamine; Veratridine; Striatal slices (Ishii, Y. (221) 377)

Amino acid transport
Blood–brain barrier; β_2-Adrenoceptors; L-DOPA (L-3,4-dihydroxyphenylalanine); Isoproterenol; Salbutamol (Takao, Y. (215) 245)

Adenosine; Adenosine receptors; Insulin sensitivity; Glucose transport; Skeletal muscle (Challiss, R.A.J. (226) 121)

1-Aminocyclopropanecarboylic acid
Global ischaemia; Glycine receptors; NMDA receptors; (Gerbil) (Von Lubitz, D.K.J.E. (219) 153)

Aminooxyacetic acid
Excitotoxicity; Kynurenic acid; Kynurenine; Microdialysis; Neuroprotection (Wu, H.-Q. (213) 375)

GABA (γ-aminobutyric acid); Learning; Pentobarbital; Seizures; Substance P (Vécsei, L. (220) 259)

L-2-Amino-4-phosphonobutyrate (L-AP4)
Metabotropic glutamate receptors; cAMP (Thomsen, C. (227) 361)

4-Aminopyridine (4-AP)
NMDA receptors; Convulsions; Wet-dog shakes (Fragoso-Veloz, J. (221) 275)

Tetrahydroaminoacridine (THA); Tacrine; Fura-2 (fluorimetry); Drug interactions (Järlebark, L. (225) 75)

Aminopyridines
Transmitter release; K^+ channels; Tetraethylammonium; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

2-Aminopyrimidine
Isaxonine phosphate (2-isopropylaminopyrimidine); 5-Hydroxyisaxonine (Martinat, C. (228) 63)

21-Aminosteroids
Antioxidants; Lipid peroxidation; Copper; Erythrocytes; Plasma (Fernandes, A.C. (220) 211)

Amitriptyline
Na^+ channels; Dopamine; Amino acids; Veratridine; Striatal slices (Ishii, Y. (221) 377)

Xerostomia; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

Amnesia
Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Hippocampus; (Gerbil) (Eigyo, M. (214) 149)

Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Hippocampus; (Gerbil) (Eigyo, M. (219) 487)

Protein kinase C; Memory; NMDA (N-methyl-D-aspartate); (Mouse) (Mathis, C. (220) 107)

Amnesia (delayed)
Nefiracetam (DM-9384); Cholinergic system; Carbon monoxide (CO); Passive avoidance; Scopolamine; (Mouse) (Hiramatsu, M. (216) 279)

Amoxapine
Pharmacokinetics (cerebral); Dopamine; DOPAC (3,4-dihydroxyphenylacetic acid); Homovanillic acid (HVA) (Kobayashi, A. (215) 43)

AMP
Pineal; Adenosine receptors (Gharib, A. (225) 359)

cAMP
Brain slices; Glutamate; Locus coeruleus; Opiates; Withdrawal (Kogan, J.H. (211) 47)

Oesophagus (rat); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptors; Benzamides (substituted); Tropisetron (Ford, A.P.D.W. (211) 117)

Monocytes; Macrophages; Thromboxane A_2; Xanthine (Baker, A.J. (211) 157)

PACAP (pituitary adenylate cyclase-activating polypeptide); Trachea (guinea-pig); Smooth muscle (Araki, N. (216) 113)

Sensory C-fibers; Neurogenic inflammation; Substance P; Atypical adrenoceptors (Itabashi, S. (218) 187)

Okadaic acid; cGMP; Xanthine derivatives; Uterine smooth muscle (Candenas, M.-L. (219) 473)

Steroidogenesis; Brain cortical minces (Barbaccia, M.L. (219) 485)

Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

β-Adrenoceptors; mRNA; Isoproterenol; C_6 glioma cells; Down-regulation (Bieck, P.R. (225) 171)

Lithium chloride; Norepinephrine; Isoprenaline; Phenoxybenzamine; Propranolol (Mármol, F. (226) 93)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Dopamine receptors; Vascular smooth muscle (rat); Mesenteric artery; Thiol group (Hall, A.S. (226) 253)

Iris sphincter (dog); Smooth muscle; Muscarinic stimulation; Inositol trisphosphate; Ca^{2+}; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

P_2 Purinoceptors; Smooth muscle cells (vascular) (Tada, S. (227) 25)

5-HT receptors; Sumatriptan; 5-$HT_{1D\beta}$ receptors (Miller, K.J. (227) 99)

SR 95639A; Muscarinic receptor agonists (selective); Muscarinic receptor subtypes; Phosphoinositides; Acetylcholine release (Mohamed, A.S. (227) 181)

$GABA_B$ receptors; GABA (γ-aminobuteric acid); Adenylyl cyclase (inhibition); Baclofen; Cerebellar granule cells (Holopainen, I. (227) 225)

Metabotropic glutamate receptors; L-2-Amino-4-phosphonobutyrate (L-AP4) (Thomsen, C. (227) 361)

Alveolar macrophages; Chronic obstructive pulmonary disease; Asthma; Adenylyl cyclase; Inflammatory mediators; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

dbcAMP
Forskolin; Desensitisation; Myocytes; Heart failure; (Human) (Harding, S.E. (223) 39)

AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionate
Glutamate; Ca^{2+} entry blockers; Neurotoxicity (Pizzi, M. (209) 169)

Quinoxalinedione; Epilepsy; Seizure; Ataxia (Taylor, C.P. (213) 151)

NMDA (N-methyl-D-aspartate); Substance P-(1–7); Iontophoresis; Nociception; Spinal cord; (Extracellular recording) (Budai, D. (216) 441)

Domoic acid; Kainic acid; Excitatory amino acid receptor; Neurotoxin (Hampson, D.R. (218) 1)

Spider toxins; Excitatory amino acid receptors; NMDA (N-methyl-D-aspartic acid); Kainate (Davies, M.S. (227) 51)

AMPA binding
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate (Kiss, B. (209) 109)

cAMP accumulation
5-HT (5-hydroxytryptamine, serotonin); β-Adrenoceptors (Morin, D. (225) 273)

Cholecystokinin; CCK_B receptors; Synaptoneurosomes (guinea pig, cerebral cortex); Boc-[Leu^{31}]CCK-4 binding; Inositol phosphate accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

AMPA/kainate receptors
Philanthotoxin-343; Hippocampus; Glutamate; NMDA receptors; Polyamines (Fedorov, N.B. (228) 201)

Amperozide
Sexual behaviour; 5-HT_2/5-HT_{1C} receptors; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Ritanserin; Ketanserin; Mesulergine (Klint, T. (212) 241)

Dopamine D_2 receptors; 5-HT_2 receptors (Meltzer, H.Y. (216) 67)

cAMP formation
Metabotropic receptor; Striatal neurons (Manzoni, O. (225) 357)

cAMP generation
Esophagus (rat); Relaxation; 5-HT_4 receptors; Gastrointestinal motility (Moummi, C. (216) 47)

Amphetamine
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909 (Meloni, R. (209) 113)

MDMA (3,4-methylenedioxymethamphetamine); Nucleus accumbens septi; Behaviour; Locomotion (Callaway, C.W. (214) 45)

5-HT (5-hydroxytryptamine, serotonin); Dopamine; Self-stimulation; Fenfluramine (Olds, M.E. (216) 363)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT_2 receptors; Dopamine neurons (Schmidt, C.J. (220) 151)

Norepinephrine; Desipramine; Dorsal hippocampus; Locus coeruleus (Curet, O. (221) 59)

Ethanol; Morphine; Cocaine; MK-801; SL 82.0715; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Dopamine synthesis; Microdialysis; MDMA (3,4-methylenedioxymethamphetamine); 5-HT_2 receptors (Schmidt, C.J. (223) 65)

d-Amphetamine
Naloxone infusion (continuous); Locomotor activity; Opioids; Dopamine (Rat) (Jones, D.N.C. (221) 161)

Supersensitivity; Morphine; Opioid receptor regulation; Naltrexone; Analgesia; Upregulation (Duttaroy, A. (221) 211)

Dopamine transport; N-Ethylmaleimide alkylation; Cocaine; [^{3}H]Mazindol binding (Johnson, K.M. (227) 411)

Amphetamine analogues
Monoamine release; Synaptosomes; 5-HT (5-hydroxytryptamine, serotonin) (Berger, U.V. (215) 153)

Amphetamine discrimination
5-HT_3 receptor antagonists; MDL 72,222EF; MDL 73,147EF; ICS 205-930; Ondansetron (GR38032F) (Moser, P.C. (212) 271)

Amphetamines
Basal ganglia; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Dopamine; MDMA (3,4-methylenedioxymethamphetamine); Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Elayan, I. (221) 281)

Amphotericin B
Mesangial cells; Ca^{2+} (intracellular); Diltiazem; Theophylline (Sabra, R. (226) 79)

AMP-PNP (5′-adenylylimidophosphate)
Vas deferens (guinea-pig); Ca^{2+}-related inward currents; P_2 purinoceptors (Inomata, H. (217) 93)

Amrinone
Dibutyryl cAMP; Mesenteric artery; Mesenteric vein (Itoh, H. (218) 347)

Amylase
Pancreatic secretion; Bombesin; Bombesin receptor antagonists (Jaworek, J. (214) 239)

Amylase secretion
CCK-7 analogues; Receptor binding; Gall bladder contractions; Anorexia; Analgesia; Sedation (Maletínská, L. (222) 233)

Anaesthesia
Blood pressure; Ketanserin; Sinoaortic denervation (Su, D.-F. (214) 89)

Isoflurane; Stereoisomers (Harris, B. (217) 215)

Substance P; Inositol phosphates; Spinal cord; Cerebral cortex; Pentobarbital (Hasséssian, H. (227) 103)

Anaesthetics (general)
Chlormethiazole; $GABA_A$ receptors; Glycine receptors; Patch-clamp; Anticonvulsants (Hales, T.G. (210) 239)

Anaesthetics (intravenous)
Propofol; Ion channels; Myelinated nerve fibre; Voltage-clamp experiment (Veintemilla, F. (218) 59)

Analgesia
Deltorphins; δ-Opioid receptors; Locomotor activity; Social behaviour; (Rat) (Negri, L. (209) 163)

Electroacupuncture; Opioid receptors; Opioid receptor agonists; Opioid receptor antagonists; Spinal cord (Chen, X.-H. (211) 203)

Spiradoline; κ-Opioid receptor agonists; Noradrenaline uptake inhibitors; 5-HT uptake inhibitors (Kunihara, M. (214) 111)

Lithium chloride; Phosphoinositide (IP_3) (Raffa, R.B. (215) 357)

Lithium chloride; Opioids (Raffa, R.B. (217) 221)

Nitric oxide (NO); Dipyrone (Duarte, I.D.G. (217) 225)

ω-Conotoxin; Morphine; Withdrawal syndrome (Basilico, L. (218) 75)

JMV 449; Peptide bond (reduced); Pseudopeptide neurotensin analogue; Hypothermia; (Potent and long-lasting agonist) (Dubuc, I. (219) 327)

Morphine; μ-Opioid receptors (Pick, C.G. (220) 275)

Morphine; Carbachol; Nitric oxide (NO); cGMP (Duarte, I.D.G. (221) 171)

Supersensitivity; Morphine; Opioid receptor regulation; Naltrexone; d-Amphetamine; Upregulation (Duttaroy, A. (221) 211)

CRF (corticotropin-releasing factor); Dynorphin release; κ-Opioid receptors; Spinal cord (Song, Z.H. (222) 27)

CCK-7 analogues; Receptor binding; Amylase secretion; Gall bladder contractions; Anorexia; Sedation (Maletínská, L. (222) 233)

Salmon-calcitonin; Morphine (Martín, M.I. (224) 77)

Analgesic tolerance
Opioid interactions; Morphine; Physical dependence; Nor-binaltorphimine (nor-BNI) (Suzuki, T. (213) 91)

Anaphylaxis
PAF receptor antagonists; WEB 2170; Paw edema (mouse) (Amorim, C.Z. (211) 29)

Haematological alterations; Death; Azelastine (Castro-Faria-Neto, H.C. (213) 183)

Allergic oedema; Anti-allergic drugs (Amorim, C.Z. (216) 429)

A10 neurons
Phencyclidine; NMDA receptor antagonists; Ventral tegmental area (French, E.D. (217) 1)

ANF (atrial natriuretic factor)
Relaxation; Trachea (guinea-pig); Trachea (rat); Bronchus (human); Epithelium; Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

Acetylcholine; Nitric oxide (NO); Guanylyl cyclase; Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; Forskolin (Heuzé-Joubert, I. (220) 161)

Formycin A triphosphate (FTP); Guanylate cyclase; ATP; cGMP (Chang, C.-H. (227) 229)

Angiotensin
Drinking; Angiotensin AT_1 receptors; Angiotensin AT_2 receptors; DuP 753; WL 19 (Dourish, C.T. (211) 113)

Angiotensin-(3–8)
Angiotensin IV; Angiotensin II; L-158,809; Adrenal cortex (bovine) (Jarvis, M.F. (219) 319)

Ion transport; Airway epithelium; G-protein (Tamaoki, J. (220) 87)

Angiotensin AT_1 receptors; Ca^{2+}; Efficacy (Liu, Y.J. (223) 205)

Angiotensin AT_2 receptor antagonists
Angiotensin II; Monoclonal antibodies; Losartan (Reilly, T.M. (226) 179)

Angiotensin AT_1 receptors
Drinking; Angiotensin; Angiotensin AT_2 receptors; DuP 753; WL 19 (Dourish, C.T. (211) 113)

Angiotensin II; Phospholipase D; Phosphatidylcholine; Diacylglycerol; Mesangial cells (Pfeilschifter, J. (225) 57)

Angiotensin; Ca^{2+}; Efficacy (Liu, Y.J. (223) 205)

Angiotensin AT_2 receptors
Drinking; Angiotensin; Angiotensin AT_1 receptors; DuP 753; WL 19 (Dourish, C.T. (211) 113)

Angiotensin II receptor subtypes; Sulfhydryl reducing agents; Dithiothreitol; Losartan (DuP 753); Brain development (Tsutsumi, K. (226) 169)

Angiotensin-converting enzyme
Bradykinin; Smooth muscle; Phospholipase A_2; Lipoxygenase; Cyclic nucleotides (Rodrigues, M.S. (216) 357)

Converting enzyme inhibitors; Captopril; Angiotensinogen; Solution hybridization/RNase protection (Ye, M.-Q. (227) 79)

Angiotensin-converting enzyme activity
Hindlimb perfusion model; Angiotensin-converting enzyme inhibitors; Renin–angiotensin system (local) (Marjorie, (217) 49)

Angiotensin-converting enzyme inhibitors
Renal circulation; EDRF (endothelium-derived relaxing factor); Kinins; Angiotensin II receptor antagonists (Hajj-ali, A.F. (212) 279)

Cough reflex; Enalapril; Diuretics; Hydrochlorothiazide (Kamei, J. (213) 137)

Hindlimb perfusion model; Renin–angiotensin system (local); Angiotensin-converting enzyme activity (Marjorie, (217) 49)

Captopril; Dahl rat; (Intracerebroventricular administration) (Lark, L.A. (222) 33)

Angiotensin II
Jatrophone; Aorta (rat); K^+ channel blockers; Ca^{2+}; KCl; Noradrenaline (Duarte, D.F.P. (215) 75)

Estrogen; Aorta (rat); Norepinephrine; Contraction (Cheng, D.Y. (215) 171)

Angiotensin receptors; Angiotensin III; Smooth muscle cells; Protease inhibitors (Fujimoto, M. (215) 259)

Spontaneously hypertensive rat (SHR); Aldosterone; MK 954 (DuP 753); Renin; (Rat) (Mizuno, K. (215) 305)

Atrial peptides; Natriuresis; Renal perfusion pressure (Chamienia, A.L. (218) 319)

Circulatory filling pressure (mean); Sympathetic nervous system (Tabrizchi, R. (219) 141)

Losartan; DuP 753; Blood–brain barrier; Blood pressure; Thirst (Bui, J.D. (219) 147)

Angiotensin IV; Angiotensin-(3–8); L-158,809; Adrenal cortex (bovine) (Jarvis, M.F. (219) 319)

Caffeine; Adenosine; Renal function; Hypertension (Holycross, B.J. (219) 361)

ANP (atrial natriuretic peptide); Sodium nitroprusside; Renal blood flow; Norepinephrine (Hisa, H. (222) 265)

Aorta; Noradrenaline; Protein kinase C; Staurosporine; Calphostin C; Ca^{2+} uptake; Ca^{2+} efflux; (Potentiation) (Henrion, D. (224) 13)

Angiotensin AT_1 receptor; Phospholipase D; Phosphatidylcholine; Diacylglycerol; Mesangial cells (Pfeilschifter, J. (225) 57)

Angiotensin AT_2 receptor antagonists; Monoclonal antibodies; Losartan (Reilly, T.M. (226) 179)

Kidney (rat); Benzodiazepine receptors (peripheral) (Holmes, P.V. (226) 189)

Angiotensin III
Angiotensin receptors; Angiotensin II; Smooth muscle cells; Protease inhibitors (Fujimoto, M. (215) 259)

Angiotensin II receptor antagonists
Angiotensin-converting enzyme inhibitors; Renal circulation; EDRF (endothelium-derived relaxing factor); Kinins (Hajj-ali, A.F. (212) 279)

BIBS 39; BIBS 222 (Zhang, J. (218) 35)

Antihypertensive agents; Protein binding; Renin-angiotensin system (Wong, P.C. (220) 267)

Angiotensin II receptors
NG-108-15; Receptor subtypes; Radioligand binding (Bryson, S.E. (225) 119)

cGMP; Neuro-2A cells (Chaki, S. (225) 355)

PLC-PRF-5; Hepatoma cells; (Radioligand binding); (Receptor subtypes) (Wintersgill, H.P. (227) 283)

Angiotensin II receptor subtypes
AT_2 receptors; Sulfhydryl reducing agents; Dithiothreitol; Losartan (DuP 753); Brain development (Tsutsumi, K. (226) 169)

PC12W; Signal transduction pathways (Leung, K.H. (227) 63)

Angiotensin IV
Angiotensin-(3–8); Angiotensin II; L-158,809; Adrenal cortex (bovine) (Jarvis, M.F. (219) 319)

Angiotensinogen
Angiotensin-converting enzyme; Converting enzyme inhibitors; Captopril; Solution hybridization/RNase protection (Ye, M.-Q. (227) 79)

Angiotensin receptors
Angiotensin II; Angiotensin III; Smooth muscle cells; Protease inhibitors (Fujimoto, M. (215) 259)

Anion transport
Glisoxepide; Glibenclamide; Biliary elimination; Liver; Sulfonylurea; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

Annelated 1,4-diazepines
Benzodiazepine receptors; Ro 15-4513; Ro 19-4603; GABA (Wong, G. (225) 63)

Anococcygeus
Efaroxan; Idazoxan; Prazosin; Vas deferens; Glucose homeostasis; (Pithed rat) (Berridge, T.L. (213) 205)

Anorexia
Feeding behaviour; B-HT 920; ACTH (adrenocorticotropin); Immobilisation; (Rat) (Ferrari, F. (210) 17)

CCK-7 analogues; Receptor binding; Amylase secretion; Gall bladder contractions; Analgesia; Sedation (Maletínská, L. (222) 233)

ANP (atrial natriuretic polypeptide)
Aorta (rat); Relaxation; Aging; Endothelium; cGMP; Phosphodiesterase activity (Moritoki, H. (210) 61)

Apomorphine-induced stereotyped cage-climbing behavior; Apomorphine; Haloperidol (Bidzseranova, A. (211) 411)

Endotoxin; cGMP; L-Arginine/nitric oxide pathway (Schuller, F. (212) 93)

Norepinephrine; Neuromodulation; cGMP (Giridhar, J. (213) 317)

C-type natriuretic peptide (CNP); Brain natriuretic peptide (BNP); Glioma cells (rat); Receptor binding; cGMP (Eguchi, S. (225) 79)

cGMP; Endothelium; (Receptor down-regulation) (Kato, J. (225) 113)

HS-142-1; Guanylyl cyclase; ANP receptor; cGMP (antagonist) (Morishita, Y. (225) 203)

Guanylate cyclase; Ontogenesis; Aorta; Kidney; Lung (Muraki, T. (226) 311)

C-type natriuretic peptide-22; ANP receptors; Subfornical organ; Choroid plexus; (Rat) (Himeno, A. (215) 337)

Sodium nitroprusside; Renal blood flow; Norepinephrine; Angiotensin II (Hisa, H. (222) 265)

ANP receptor antagonists
ANP_A receptors; Neuroblastoma cells NB-OK-1 (human); cGMP (Delporte, C. (224) 183)

ANP receptors
C-type natriuretic peptide-22; ANP (atrial natriuretic peptide); Subfornical organ; Choroid plexus; (Rat) (Himeno, A. (215) 337)

HS-142-1; Atrial natriuretic peptide (ANP); Guanylyl cyclase; cGMP (antagonist) (Morishita, Y. (225) 203)

ANP_A receptors
ANP receptor antagonists; Neuroblastoma cells NB-OK-1 (human); cGMP (Delporte, C. (224) 183)

ANP release
Atrium (rat); Ca^{2+} influence; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

ANP-R_1 receptors
cGMP; Neutral metalloendopeptidase; Human neuroblastoma cell line NB-OK1 (Delporte, C. (227) 247)

Anterior pituitary
GH_4ZR_7 cells; Cell culture; Prolactin; Dopamine D_2 receptors; Partial agonists; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Anthracene-9-carboxylic acid (9AC)
DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid); Isoproterenol; Cardiac cells (guinea-pig); Cl^- activity (intracellular) (Shida, S. (212) 267)

Anthracyclines
Skeletal fibre (skinned); Isometric tension (De Beer, E.L. (214) 97)

Anthranoid laxative
Rhein; Rhein anthrone; (Germ-free rats) (Van Hoestenberghe, A. (212) 121)

Anthraquinones
Prostaglandins; Cathartics; Diarrhoea (Nijs, G. (218) 199)

Antiallergic drugs
Allergic oedema; Anaphylaxis (Amorim, C.Z. (216) 429)

Antianginal vasodilator
Adenosine; Antihypertensive vasodilator; Glibenclamide-sensitive K^+ channels; 2-(1-Octynyl)-adenosine (YT-146) (Yoneyama, F. (213) 199)

Antiarrhythmic actions
Mexiletine; Ischaemic arrhythmias; Convulsions; Pharmacokinetics (Igwemezie, L.N. (210) 271)

Antiarrhythmic activity
Ischaemic arrhythmias; U-50,488H; Naloxone (Pugsley, M.K. (212) 15)

Antiarrhythmics
K^+ channels; Ventricular fibrillation (Gwilt, M. (215) 137)

Development; Electrophysiologic effect (Case, C.L. (218) 213)

Quinacainol; Ischaemic arrhythmias; Electrophysiological actions (Howard, P.G. (219) 1)

Cardiac arrhythmia; K^+ channels (Gwilt, M. (220) 231)

Ibutilide fumarate; Refractory period; Conduction time; Class III activity (Cimini, M.G. (222) 93)

Cycloprotobuxine-A; Action potentials; $\dot{V}$; Myocardium; (Use-dependent block) (Wang, Y.-X. (222) 219)

Antibacterial peptide
Artificial bilayer; Ion channel reconstitution; Peptide ion channel (Cruciani, R.A. (226) 287)

Anticholinergic drugs
Dystonia; Dopamine; Acetylcholine; Haloperidol; Levodopa; Apomorphine (Löscher, W. (213) 31)

Anticholinesterase
Acetylcholine release; β-Eudesmol; Neostigmine; Neuromuscular transmission; Tetanic fade (Chiou, L.C. (216) 199)

Anticholinesterase agents
Velnacrine; Tacrine; Physostigmine; Neuromuscular junction; Twitch response; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Anticonvulsant effects
Withdrawal seizure prone mouse (WSP); Ethanol withdrawal; Handling-induced convulsions; Abecarnil; Diazepam; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

Anticonvulsants
Chlormethiazole; $GABA_A$ receptors; Glycine receptors; Patch-clamp; Anaesthetics (general) (Hales, T.G. (210) 239)

Felbamate; Cerebral ischemia; Neonate; Asphyxia neonatorum; Cerebral infarction (Wasterlain, C.G. (212) 275)

CGP 37849; CGP 39551; Kindling; NMDA receptor antagonists; Seizures (Cotterell, K.L. (214) 285)

Benzodiazepine exposure (chronic); Tolerance; Steroid hormones; Ovariectomy; GABA/benzodiazepine receptors (Wilson, M.A. (215) 99)

Epilepsy; NMDA receptor antagonists; Audiogenic seizures; Genetically epilepsy-prone rats (De Sarro, G. (215) 221)

Dextrorphan; NMDA receptor antagonists (non-competitive); Prepiriform cortex; PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride); MK-801 (Roth, J.E. (215) 293)

Microdialysis; GABA brain levels; GABA uptake inhibitor; Tiagabine; (Rat) (Fink-Jensen, A. (220) 197)

GABA uptake; NNC-711; Epilepsy (Suzdak, P.D. (224) 189)

Antidepressants
Enkephalin-degrading enzymes; RB 101 (mixed inhibitor); Naltrindole; Motility suppression (conditioned); Dopamine receptors (Baamonde, A. (216) 157)

Dopamine; Melatonin; Nucleus accumbens; Receptor supersensitivity (Durlach-Misteli, C. (217) 15)

Noradrenaline release; α_2-Adrenoceptors; Monoamine oxidase; Vas deferens (rat) (Ari, G. (219) 89)

Idazoxan; β-Adrenoceptors; Adenylyl cyclase; C6 glioma cells; Protein kinase C (Manji, H.K. (227) 275)

Antiepileptic effect
Spontaneously epileptic rat (SER); Thyrotropin-releasing hormone analogs; CNK-602A; Dopamine (Renming, X. (223) 185)

Antigen
PAF (platelet activating factor, PAF-acether); SR 27417; Skin; Oedema; Inflammation (Herbert, J.M. (216) 175)

Antigen (ovalbumin)
Bronchial hyperreactivity; PAF receptor antagonists; Inflammatory cells (Underwood, S.L. (210) 97)

Antihypertensives
A-80b; Vasodilators; Ca^{2+}; Aorta; Portal vein (Frechilla, D. (219) 409)

Angiotensin II receptor antagonists; Protein binding; Renin-angiotensin system (Wong, P.C. (220) 267)

Antihypertensive vasodilator
Adenosine; Antianginal vasodilator; Glibenclamide-sensitive K^+ channels; 2-(1-Octynyl)-adenosine (YT-146) (Yoneyama, F. (213) 199)

Anti-IL-5 monoclonal body
Bronchoalveolar eosinophilia; Asthma model (guinea pig); (Therapeutic approach) (Chand, N. (211) 121)

Antimuscarinic actions
Nicotinic receptor agonists; Olfactory cortex slice (guinea-pig); Surface field potential (N-wave); Extracellular recording (Libri, V. (212) 253)

Doxorubicin; Adriamycin; Heart muscle preparations (isolated); Acetylcholine receptors; [^{3}H]Quinuclidinyl benzilate (QNB) binding (Temma, K. (220) 63)

Antinociception
Quinpirole; Dopamine; Receptor sensitization (Kostrzewa, R.M. (209) 157)

L-Arginine; β-Endorphin (Tseng, L.F. (212) 301)

Tail-flick inhibition; β-Endorphin (intrathecal); Opioid receptors (Tseng, L.F. (214) 59)

Tail-flick inhibition; Morphine; β-Endorphin; Pentobarbital; Pain controls (descending) (Tseng, L.F. (214) 175)

Naltrindole; δ-Opioid receptors (Stapelfeld, A. (214) 273)

Development; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Morphine; Opiates (Barr, G.A. (215) 35)

Histamine; Histamine H_2 receptors; Histamine H_2 receptor antagonists; Brain; Morphine (Hough, L.B. (215) 69)

Spinal cord; Dorsal horn neurons; α_2-Adrenoceptor agonists; Dexmedetomidine; Opioids (Sullivan, A.F. (215) 127)

Morphine; Tolerance; Adenosine receptors; (Rat) (Tao, P.-L. (215) 301)

Nor-binaltorphimine (nor-BNI); Spiradoline; Morphine; κ-Opioid receptors (Jones, D.N.C. (215) 345)

Tail-flick (spinal); δ-Opioid receptors; DSTBULET (Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr); Morphine (Kalso, E.A. (216) 97)

δ-Opioid receptor subtypes; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]deltorphin; CD-1 mice; CXBK mice (Raffa, R.B. (216) 453)

Formalin test; Writhing test; Hot-plate test; Ca^{2+} channel blockers (Miranda, H.F. (217) 137)

δ-Opioid receptor subtypes binding; 7-Benzylidenenaltrexone (BNTX) (Portoghese, P.S. (218) 195)

Spinal cord; Carrageenan; Thermal hyperalgesia; NMDA (N-methyl-D-aspartate); Opioids; (Rat); (Intrathecal) (Ren, K. (219) 235)

Arthritic rats; Tramadol; Yohimbine; Idazoxan; Naloxone (Kayser, V. (224) 83)

Antinociceptive activity
Dermorphin; [D-Arg^2]dermorphin; Captopril; Amastatin (Sakurada, S. (211) 75)

Antinociceptive effect
L-Arginine; Opiodergic system; Kyotorphin; (Rat) (Kawabata, A. (218) 153)

Antinociceptive tolerance
RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Cross-tolerance (Noble, F. (223) 83)

Antioxidants
α-Tocopherol analogue; Free radical scavenger; Reperfusion injury; Vitamin E; Myocardial ischaemia/reperfusion (Petty, M.A. (210) 85)

β-Adrenoceptor antagonists; Carvedilol; Free radical; Superoxide; Neutrophils (Yue, T.-L. (214) 277)

21-Aminosteroids; Lipid peroxidation; Copper; Erythrocytes; Plasma (Fernandes, A.C. (220) 211)

Antiplatelet action
Isoliquiritigenin; Aldose reductase inhibitor; Cyclooxygenase inhibitor (Tawata, M. (212) 87)

Antiplatelet compounds
Cloricromene; Platelet aggregation; Polymorphonuclear cells (Mollace, V. (222) 181)

Antiproliferative effect
Curcumin; Mononuclear cells; Smooth muscle cells (Huang, H.-C. (221) 381)

Antipsychotics
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; Dopamine neurons; LY262691 (Rasmussen, K. (209) 135)

(+)SK&F 10,047; Dopamine release (Volonté, M. (213) 163)

DAU 6215; 5-HT_3 receptors; Dopamine neurons; Depolarization block (Prisco, S. (214) 13)

Clozapine; 5-HT_{1A} receptors (Mason, S.L. (221) 397)

Antisecretory potency
Gastric mucosa; Prostanoids; Radioligand binding; Prostaglandin receptors; Parietal cells (Hennies, S. (218) 303)

Antitumour activity
Poly(rG) · Poly(rC); Poly(rI) · Poly(rC); Interferon inducer; Liver colony assay; Survival (Jurásková, V. (221) 107)

Antitussive effects
Cough reflex; Ca^{2+} channels; Flunarizine; Nifedipine; Verapamil (Kamei, J. (212) 61)

Cough reflex; σ-Sites; (+)-SK&F 10,047; Pentazocine; DTG (1,2-di-(2-tolyl)guanidine); Dextromethorphan (Kamei, J. (224) 39)

Anxiety
WAY100289; Light:dark box; 5-HT_3 receptor antagonists; Acoustic startle (potentiated) (Bill, D.J. (218) 327)

Anxiolytics
Buspirone; Chlordiazepoxide; (Nonreward); (Rat) (Panickar, K.S. (210) 307)

5-HT receptors; Blood pressure; Dorsal raphe nucleus (Corley, K.C. (213) 417)

R-(+)-HA-966; S-(−)-HA-966; Glycine/NMDA receptor site (strychnine-insensitive); Behavioural sedation (Dunn, R.W. (214) 207)

Aversive behaviour; R(+)-Zacopride; S(−)-Zacopride; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Barnes, N.M. (218) 91)

Tandospirone; Buspirone; Ipsapirone; Azapirones; Chlordiazepoxide; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Aorta
Smooth muscle (vascular); Dibutyryl cAMP; Fura-2-Ca^{2+} signal; Forskolin; Ca^{2+} sensitivity; (Rat) (Abe, A. (211) 305)

α-Adrenoceptors; β-Adrenoceptors; Jugular vein; Autoradiography; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol); [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

Oxodipine; $^{45}Ca^{2+}$ influx; Mesenteric resistance vessels; (Rabbit) (Tejerina, T. (219) 279)

Antihypertensives; A-80b; Vasodilators; Ca^{2+}; Portal vein (Frechilla, D. (219) 409)

Ca^{2+} channel antagonists; Muscle relaxation; [^{3}H] TC-81 (distribution of) (Okamiya, Y. (222) 99)

Noradrenaline; Protein kinase C; Staurosporine; Calphostin C; Ca^{2+} uptake; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

α_1-Adrenoceptor; Membrane lipids; Phospholipases; Phospholipase C; Phospholipids (Shreeve, S.M. (226) 29)

Atrial natriuretic peptide (ANP); Guanylate cyclase; Ontogenesis; Kidney; Lung (Muraki, T. (226) 311)

Aorta (guinea-pig)
Adenosine receptors; Adenosine analogues; 8-Phenyltheophylline (Martin, P.L. (216) 235)

Ouabain; Contraction; Ca^{2+} signals; Na^+/Ca^{2+} exchangers (Iwamoto, T. (224) 71)

Aorta (rabbit)
Substance P; EDRF (endothelium-derived relaxing factor); Neurokinin A; Neurokinin B; CP-96,345 (Rubino, A. (212) 237)

13,14-Dihydroprostaglandin E_1; LDL (low density lipoprotein) influx; Atherosclerosis (experimental) (Sinzinger, H. (219) 129)

α_1-Adrenoceptors; α_2-Adrenoceptors; BAY k 8644; Ca^{2+} channels (Aleixandre, A. (221) 129)

EGF (epidermal growth factor); Endothelin; Thrombin; Hypercholesterolemia; Vasospasm; Endothelium (Merkel, L.A. (222) 175)

Aorta (rat)
ANP (atrial natriuretic polypeptide); Relaxation; Aging; Endothelium; cGMP; Phosphodiesterase activity (Moritoki, H. (210) 61)

Jatrophone; K^+ channel blockers; Ca^{2+}; KCl; Angiotensin II; Noradrenaline (Duarte, D.F.P. (215) 75)

Estrogen; Angiotensin II; Norepinephrine; Contraction (Cheng, D.Y. (215) 171)

Endothelin-1; Smooth muscle (vascular); Ca^{2+}; Cyclopiazonic acid (Shimamoto, H. (216) 225)

Diazoxide; Mechanical activity; Ionic fluxes (Antoine, M.-H. (216) 299)

Nitric oxide (NO); PDGF (platelet-derived growth factor); TGF-β (transforming growth factor-β); Interleukin-1β; Platelets (Schini, V.B. (216) 379)

5-HT (5-hydroxytryptamine, serotonin); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Na^+ channel (silent); $^{45}Ca^{2+}$ uptake; [^{14}C]Guanidinium uptake; Veratridine (Wermelskirchen, D. (219) 253)

Endothelium; BAY k 8644 enantiomers; Nifedipine; $^{45}Ca^{2+}$ influx (Gil-Longo, J. (221) 1)

Smooth muscle (vascular); Nisoldipine; Inhibitory effects (residual); Ca^{2+} levels (cytosolic); Ca^{2+} channels; (Relaxation) (Kim, B.K. (223) 157)

α_1-Adrenoceptor subtypes; SDZ NVI 085; Vas deferens; Kidney (Eltze, M. (224) 125)

Aortic segments
Diethyldithiocarbamate; Nitrovasodilators; Nitrosovasodilators (Vedernikov, Y.P. (212) 125)

AP_5A (P^1P^5-di-(adenosine-5′)pentaphosphate)
Adenine nucleotide analogues; Skeletal muscle (innervated, frog); Ecto-enzymes; DPCPX (1,3-dipropyl-8-cyclopentylxanthine); Dipyridamole (Cascalheira, J.F. (222) 49)

AP-3 ((L)-2-amino-3-phosphonopropionate)
Metabotropic glutamate receptor; ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid); Cerebellum; Purkinje cells; Granule cells (East, S.J. (219) 395)

Apomorphine
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

ANP (atrial natriuretic polypeptide); Apomorphine-induced stereotyped cage-climbing behavior; Haloperidol (Bidzseranova, A. (211) 411)

6-Hydroxydopamine (6-OHDA); Pentobarbital; Rotational behaviour; Conditioned drug effects; Drug discrimination (Silverman, P.B. (212) 165)

Dystonia; Dopamine; Acetylcholine; Anticholinergic drugs; Haloperidol; Levodopa (Löscher, W. (213) 31)

NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Stereotypies; Haloperidol (Löscher, W. (215) 199)

Corticostriatal pathways; Dopamine; Ascorbate; L-Glutamate; Scopolamine; (Rat) (Desole, M.S. (219) 67)

Penile erection; Yawning; Oxytocin; ACTH (adrenocorticotropin); Excitatory amino acid receptor antagonists (Melis, M.R. (220) 43)

Apomorphine-induced stereotyped cage-climbing behaviour
ANP (atrial natriuretic polypeptide); Apomorphine; Haloperidol (Bidzseranova, A. (211) 411)

Apoptosis
Human immunodeficiency virus type 1 (HIV-1); Cortical cells; Memantine; NMDA receptor; gp120 (Müller, W.E.G. (226) 209)

Appetitive behaviour
Interleukin-1β; Ibuprofen; (Yellow mice) (Shimomura, Y. (209) 15)

Arachidonic acid
VIP (vasoactive intestinal polypeptide); Helodermin; Leukotriene D_4; Lung (perfused, guinea-pig); Cyclo-oxygenase products (Conroy, D.M. (218) 43)

Neutrophils; PAF (platelet-activating factor, PAF-acether); Staurosporine; Phospholipase A_2 (Müller, S. (218) 251)

NMDA (N-methyl-D-aspartate); Cortical neurons; Somatostatin; Phospholipase A_2 (Tapia-Arancibia, L. (225) 253)

Muscarinic receptor subtype; T84 cell; Colonic epithelial cell; Phosphoinositides (Dickinson, K.E.J. (225) 291)

A7r5 aortic cells
2,5-Di-(tert-butyl)-1,4-benzohydroquinone; Cyclopiazonic acid; Ca^{2+} permeability (Missiaen, L. (227) 391)

ARC 239
α_2-Adrenoceptors; α_{2A}-Adrenoceptors; α_{2B}-Adrenoceptors; Prazosin (Smith, K. (211) 251)

Area postrema
[Arg^8]vasopressin; Baroreflexes; Splanchnic sympathetic efferent discharge; Vasopressin V_1 receptor antagonists; Nucleus tractus solitarii (Zhang, X. (222) 81)

[D-Arg^2]dermorphin
Dermorphin; Captopril; Amastatin; Antinociceptive activity (Sakurada, S. (211) 75)

L-Arginine
Mesentery (rat); Capsaicin; CGRP (calcitonin gene-related peptide); Saponin; N^{ω}-Nitro-L-arginine methyl ester (Li, Y. (210) 23)

β-Endorphin; Antinociception (Tseng, L.F. (212) 301)

NMDA (N-methyl-D-aspartate); Nitric oxide (NO); Nociception; Spinal cord; Facilitation; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); Endotoxic shock (Lambert, L.E. (216) 131)

Antinociceptive effect; Opiodergic system; Kyotorphin; (Rat) (Kawabata, A. (218) 153)

L-Arginine/nitric oxide pathway
Endotoxin; cGMP; ANP (atrial natriuretic polypeptide) (Schuller, F. (212) 93)

[Arg^8] vasopressin (AVP)
[Arg^8] vasotocin; Oxytocin; Prostatic contraction; Neurohypohyseal peptides; Neuropeptides (Bodanszky, M. (216) 311)

[Arg^8]vasopressin
Baroreflexes; Splanchnic sympathetic efferent discharge; Vasopressin V_1 receptor antagonists; Area postrema; Nucleus tractus solitarii (Zhang, X. (222) 81)

[Arg^8] vasotocin
Oxytocin; [Arg^8] vasopressin (AVP); Prostatic contraction; Neurohypohyseal peptides; Neuropeptides (Bodanszky, M. (216) 311)

Arrhythmias
Dromotropic effects; Coronary vascular resistance; Inotropic effects; Ventricular tachycardia; Endothelial messengers (Balcells, E. (210) 1)

Opioid receptor antagonists; Opioid receptor agonists; Ischaemia; (Rat) (McIntosh, M. (210) 37)

Amiloride; Myocardial ischemia; Myocardial reperfusion; Mitochondria; Ultrastructure; Na^+/H^+ exchange (Duan, J. (210) 149)

Arrhythmias
Coronary artery occlusion; Myocardial ischaemia; Reperfusion; Platelet aggregation; 5-HT receptor antagonists (Ellis, A.M. (219) 97)

Arterial pressure
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Vascular tone; (Rat) (Chyu, K.-Y. (212) 159)

D-Baclofen; NMDA (N-methyl-D-aspartic acid); Spinal cord; Heart rate; Sympathetic output (Hong, Y. (216) 257)

Arteries
α-Adrenoceptors; α_1-Adrenoceptor subtypes; WB 4101; Chlorethylclonidine (Oriowo, M.A. (216) 415)

Endothelin-1; Vein (Auguet, M. (224) 101)

Arteriosclerotic plaque development
Carbon monoxide (CO) (Penn, A. (228) 155)

Arthritic rats
Antinociception; Tramadol; Yohimbine; Idazoxan; Naloxone (Kayser, V. (224) 83)

Arthritis
MDP-Lys(L18); Cyclosporin A; Adjuvant arthritis; (Rat) (Sugawara, T. (228) 147)

Arthus reaction
Immune-complex alveolitis; PAF (platelet-activating factor, PAF-acether); Eicosanoids (Tavares de Lima, W. (213) 63)

Artificial bilayer
Antibacterial peptide; Ion channel reconstitution; Peptide ion channel (Cruciani, R.A. (226) 287)

Ascorbate
Corticostriatal pathways; Dopamine; L-Glutamate; Apomorphine; Scopolamine; (Rat) (Desole, M.S. (219) 67)

Aspartate
Clonidine; α_2-Adrenoceptors (presynaptic); Glutamate; GABA (γ-aminobutyric acid); Brain (rat) (Kamisaki, Y. (217) 57)

Aspartate release
Glutamate release; Ethanol; Hippocampus; GABA (γ-aminobutyric acid) (Martin, D. (219) 469)

D-Aspartate uptake
L-Glutamate; 2-(Carboxycyclopropyl)glycine; NMDA receptors; $[Ca^{2+}]_i$ increase; Neurotoxicity (Kawai, M. (211) 195)

Asphyxia neonatorum
Felbamate; Anticonvulsants; Cerebral ischemia; Neonate; Cerebral infarction (Wasterlain, C.G. (212) 275)

Aspirin ulcer
N-Phthaloyl γ-aminobutyric acid; Ethanol ulcer; Gastric acid secretion; Mucus secretion (Banerji, S. (219) 211)

Asthma
Aging; Airway obstruction; Oedema; Histamine; Plasma exudation; Substance P; Vascular permeability (Arakawa, H. (215) 51)

5-Lipoxygenase; Leukotrienes; Airway hyperresponsiveness; Inflammation; (Late responses) (Abraham, W.M. (217) 119)

Bronchial provocation test; Inflammation; Theophylline (Crescioli, S. (228) 45)

Alveolar macrophages; cAMP; Chronic obstructive pulmonary disease; Adenylyl cyclase; Inflammatory mediators; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

Asthma model (guinea pig)
Anti-IL-5 monoclonal body; Bronchoalveolar eosinophilia; (Therapeutic approach) (Chand, N. (211) 121)

Ataxia
AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionate; Quinoxalinedione; Epilepsy; Seizure (Taylor, C.P. (213) 151)

Atenolol
Thyroxine; Portal vein; β-Adrenoceptors; Noradrenaline; Fenoterol; ICI 118,551 (Chin, J.P.F. (212) 201)

β-Adrenoceptor antagonists; Indenolol; Nadolol; Propranolol; Mitochondrial ATPase activity (Almotrefi, A.A. (215) 231)

Atherosclerosis
α-Adrenoceptors; Endothelium; Vasoconstriction; (Conscious rabbits) (Du, Z.-Y. (211) 149)

Low-density lipoprotein; Nitric oxide (NO); Macrophages; Nitrite (NO_2^-) (Jorens, P.G. (212) 113)

WHHL rabbit; Mesenteric artery; Sympathetic neurotransmission; CGRP (calcitonin gene-related peptide); Neuropeptide Y (NPY) (Stewart-Lee, A.L. (216) 167)

Atherosclerosis (experimental)
13,14-Dihydroprostaglandin E_1; Aorta (rabbit); LDL (low density lipoprotein) influx (Sinzinger, H. (219) 129)

Atipamezole
α_2-Adrenoceptors; Guanfacine; Mydriasis; Neocortical high-voltage spindles; (Rat); (Subchronic treatment) (Jäkälä, P. (221) 351)

[^{3}H]Atipamezole
α_2-Adrenoceptors; α-Adrenoceptor antagonists; Non-adrenergic binding sites; [^{3}H]Rauwolscine (Sjöholm, B. (215) 109)

ATP
Physostigmine; Cerebral vasodilatation; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

Suramin; P_2 purinoceptors; Locus coeruleus neurones; Firing rate (Tschöpl, M. (213) 71)

Purinoceptors; Bladder; Neonate; Neurotransmission; Development (Sneddon, P. (214) 7)

Smooth muscle cells; DDT_1 MF-2 cells; Nucleotide receptors; UTP; K^+ currents (Van der Zee, L. (215) 317)

Ion channels; Dopamine; Dopamine receptor agonists; Dopamine receptor antagonists; Pheochromocytoma PC12 cells (Inoue, K. (215) 321)

K^+ channels; Smooth muscle (vascular); Patch clamp (Furspan, P.B. (223) 201)

Rostral ventrolateral medulla; Vasomotor neurons (Sun, M.-K. (224) 93)

Suramin; P_2 purinoceptor; Hepatocytes; (Rat) (Tomura, H. (226) 363)

Formycin A triphosphate (FTP); Guanylate cyclase; Atrial natriuretic factor (ANF); cGMP (Chang, C.-H. (227) 229)

ATP depletion
GSH depletion; Diethyl maleate; Phorone; Ethacrynic acid; Hepatocytes (Redegeld, F.A.M. (228) 229)

ATP-sensitive K^+ channel
TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); β-Cells (Szewczyk, A. (226) 175)

Calmodulin antagonist; Cromakalim; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Atrial effective refractory period
Atrial rate; Ventricular rate; β-Adrenoceptor blocking activity; Stereoisomers; β-Adrenoceptor antagonists; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

Atrioventricular conduction time; β-Adrenoceptors; Ventricular effective refractory period; Sinoatrial pacemaker activity (Takei, M. (219) 15)

Atrial fibres (frog)
Forskolin; 1,9-Dideoxyforskolin; Adenosine; Phosphodiesterase inhibitors; Inward calcium current-dependent phasic tension (Gauthier, C. (225) 129)

Atrial peptides
Natriuresis; Renal perfusion pressure; Angiotensin II (Chamienia, A.L. (218) 319)

Atrial rate
Atrial effective refractory period; Ventricular rate; β-Adrenoceptor blocking activity; Stereoisomers; β-Adrenoceptor antagonists; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

Atrioventricular conduction time
Atrial effective refractory period; β-Adrenoceptors; Ventricular effective refractory period; Sinoatrial pacemaker activity (Takei, M. (219) 15)

Atrium
Propranolol; Dopamine-β-hydroxylase (lung); Noradrenaline; Catecholamines (Elayan, H. (212) 259)

Atrium (guinea-pig)
β-Adrenoceptor-mediated responses; Desensitization; Lung parenchymal strips (guinea-pig) (Herepath, M.L. (215) 209)

Pertussis toxin; G-proteins; Capsaicin-sensitive neurones (Amerini, S. (216) 445)

Muscarinic receptor subtypes; Superior cervical ganglion; Ileum (guinea-pig); Drug discrimination (Arnt, J. (218) 159)

Atrium (left, dog)
Adenosine receptors; 8-Phenyltheophylline; DPCPX (1,3-dipropyl-8-cyclopentylxanthine); N-0861 (N^6-endonorbornan-2-yl-9-methyladenine) (Martin, P.L. (214) 199)

Atrium (rat)
ANP release; Ca^{2+} influence; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

Bepridil; Ca^{2+} channel antagonists; Ca^{2+} overload; Veratrine (Leboeuf, J. (216) 183)

Atropine
VIP (vasoactive intestinal polypeptide); Central nervous system (CNS); Chronic treatment; (Rat) (Petit, J.-M. (212) 79)

Ketanserin; p-Chlorophenylalanine; Xylamidine; MDL 72222 (Bond, E.F. (217) 127)

Raphe nuclei (medullary); Vagus; RX 77368; Thyrotropin-releasing hormone (Garrick, T. (223) 75)

AtT-20 cells
Histamine; ACTH (adrenocorticotropin); Histamine H_3 receptors (Clark, M.A. (210) 31)

Atypical adrenoceptors
Sensory C-fibers; Neurogenic inflammation; cAMP; Substance P (Itabashi, S. (218) 187)

Audiogenic seizures
Epilepsy; NMDA receptor antagonists; Anticonvulsants; Genetically epilepsy-prone rats (De Sarro, G. (215) 221)

Autonomic ganglia
Corticotropin-releasing hormone (CRH); Enteric nervous system; Synaptic transmission; Intestine (Hanani, M. (211) 23)

Sympathetic ganglia (bullfrog); Compound 48/80; Ganglionic transmission; Neuronal excitability; Spike afterhyperpolarization (Heppner, T.J. (213) 427)

Autonomic regulation
Tachykinin; Neuropeptide K; Cardiovascular responses; Catecholamines (Décarie, A. (213) 125)

Autoradiography
Basal ganglia; Dopamine D_3 receptors; Dopamine D_2 receptors; Islets of Calleja (Gehlert, D.R. (211) 189)

Heart; Endocardium; Natriuretic receptors; Natriuretic peptides (Rutherford, R.A.D. (212) 1)

ANF (atrial natriuretic factor); Relaxation; Trachea (guinea-pig); Trachea (rat); Bronchus (human); Epithelium; Smooth muscle (airway) (Fernandes, L.B. (212) 187)

Immobilization stress; Muscarinic receptors; Supersensitivity; Hippocampus; Striatum (González, A.M. (214) 261)

[^{3}H]GR65630; Brain; 5-HT$_3$ recognition sites; (Common marmoset) (Jones, D.N.C. (215) 63)

[^{3}H]AF-DX 384; Muscarinic receptors; Muscarinic M_2 receptor subtype; Receptor binding techniques (Aubert, I. (217) 173)

α-Adrenoceptors; β-Adrenoceptors; Aorta; Jugular vein; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol); [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

CGRP (calcitonin gene-related peptide); CGRP receptors; Coronary arteries; Neuropeptides (Knock, G.A. (219) 415)

Chronic stress; Muscarinic receptors; Supersensitivity; Hippocampus; Striatum (González, A.M. (223) 25)

Noradrenaline; α_2-Adrenoceptors; Brain imaging (Biegon, A. (224) 27)

Galanin-(1–15); Fragment; (Receptor) (Hedlund, P.B. (224) 203)

$^{125}I^-$ ion binding; Eosinophils; Peroxidase; Trachea (guinea-pig) (Rigby, P.J. (228) 141)

Autoradiography (quantitative)
p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis (Lepetit, P. (209) 207)

Joint inflammation; Pain (chronic); Polyarthritic rat; Opioid receptor regulation (Besse, D. (223) 123)

Autoradiography (quantitative receptor)
Endothelin receptors; ^{125}I-Endothelin-1; Spinal cord (human, pig); Chemical cross-linking (Niwa, M. (225) 281)

Aversive behaviour
R(+)-Zacopride; S(−)-Zacopride; p-Chlorophenylalanine; (Rat); (Mouse) (Barnes, N.M. (218) 15)

R(+)-Zacopride; S(−)-Zacopride; Anxiolytic agents; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Barnes, N.M. (218) 91)

Azapirones
Tandospirone; Buspirone; Ipsapirone; Chlordiazepoxide; Anxiolytics; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Azelastine
Anaphylaxis; Haematological alterations; Death (Castro-Faria-Neto, H.C. (213) 183)

Immunisation; Lung hyperresponsiveness; PAF (platelet-activating factor, PAF-acether); Leukotrienes; Histamine; (Guinea-pig) (Pretolani, M. (216) 141)

Smooth muscle (tracheal); Ca^{2+} levels (cytosolic); Relaxation; Smooth muscle (skinned) (Sanagi, M. (222) 247)

Azepexole
Rilmenidine; Clonidine; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Ba^{2+}
Nifedipine; $^{45}Ca^{2+}$ uptake; Vas deferens; $^{45}Ca^{2+}$ efflux; Verapamil; Methoxamine (Hay, D.W.P. (225) 313)

Baclofen
Prostaglandin E_2; Indomethacin; Gastric acid secretion; Vagus (Saperas, E. (209) 1)

Substantia nigra; GABA (γ-aminobutyric acid); GABA$_B$ receptors; (Rat) (Garant, D. (214) 75)

GABA (γ-aminobutyric acid); Jejunum (human); Colon (human); Intestinal motility (Gentilini, G. (217) 9)

Tyrosine hydroxylase; NMDA receptors; GABA$_B$ receptors; Dopamine synthesis; Dopaminergic transmission (Montaño, J.-A.A. (218) 335)

GABA$_B$ receptor agonists; Thienyl baclofen analogs; 2-Hydroxysaclofen; Ileum (guinea-pig, isolated) (Ong, J. (218) 343)

β-(2-Thienyl)-GABA; Ileum (guinea-pig, isolated); Neocortical slices (rat); 2-Hydroxysaclofen (Ong, J. (221) 145)

Amino acid release; Ca^{2+} dependence (Otero Losada, M.E. (224) 21)

GABA$_B$ receptors; GABA (γ-aminobuteric acid); Adenylyl cyclase (inhibition); cAMP; Cerebellar granule cells (Holopainen, I. (227) 225)

D-Baclofen
NMDA (N-methyl-D-aspartic acid); Spinal cord; Heart rate; Arterial pressure; Sympathetic output (Hong, Y. (216) 257)

Baicalein
Ear edema; Free radical; Lipid peroxidation; α-Tocopherol (Hara, H. (221) 193)

Barbiturates
Glutamate receptors; Kainate; Methohexitone; Epileptiform activity (Palmer, A.J. (221) 205)

Barbiturate sleeping
Dihydroergotoxine; [^{3}H]TBOB (t-[^{3}H]butylbicycloorthobenzoate) binding; GABA (γ-aminobutyric acid) shift; Picrotoxin-induced convulsions (Tvrdeić, A. (221) 139)

Baroreceptor reflex
S-Nitrosothiols; Excitatory amino acid; Cardiovascular regulation; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Machado, B.H. (221) 179)

Baroreceptors
α-Adrenoceptors; Clonidine; Haemorrhage; Yohimbine; (Rabbit) (Evans, R.G. (216) 265)

Baroreflexes
Acetylcholine; Nitroprusside; N-Nitro-L-arginine; Phenylephrine; Vasodilatation; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

[Arg^8]vasopressin; Splanchnic sympathetic efferent discharge; Vasopressin V_1 receptor antagonists; Area postrema; Nucleus tractus solitarii (Zhang, X. (222) 81)

Ethanol; GABA (γ-aminobutyric acid); Dorsal vagal complex (Varga, K. (214) 223)

Basal forebrain (rat)
Nitric oxide (NO); Acetylcholine release (Prast, H. (216) 139)

Basal ganglia
Dopamine uptake; Striatum; Postural asymmetry; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Dopamine D_3 receptors; Dopamine D_2 receptors; Autoradiography; Islets of Calleja (Gehlert, D.R. (211) 189)

Amphetamines; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Basilar artery
BY-1949; Cerebral blood flow; Cyclic nucleotides; Endothelial cells (Sugawa, M. (215) 57)

Basilar artery (canine)
Bradykinin; Endothelium (Yen, M.-H. (221) 261)

Basilar artery (rat)
Myograph; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor classification; Ketanserin; Ergometrine (Deckert, V. (221) 17)

BAY k 8644
Ca^{2+} channel agonists; Voltage-gated Ca^{2+} channels; Aging (Khatter, J.C. (216) 351)

Aorta (rabbit); α_1-Adrenoceptors; α_2-Adrenoceptors; Ca^{2+} channels (Aleixandre, A. (221) 129)

BAY k 8644 enantiomers
Aorta (rat); Endothelium; Nifedipine; $^{45}Ca^{2+}$ influx (Gil-Longo, J. (221) 1)

BAY U 3405
Thromboxane A_2; Thromboxane A_2 receptor antagonist; Thromboxane A_2 receptor agonist; pH dependency; Radioligand binding; Platelet membranes (human) (Theis, J.G.W. (226) 149)

B-cells
8-Methoxypsoralen; K^+ channels (ATP-sensitive); Insulin release (Szewczyk, A. (216) 323)

Behaviour
Glycine; L-687,414; NMDA (N-methyl-D-aspartate); Excitatory amino acids; Epilepsy (Smith, S.E. (211) 109)

Phorbol 12-myristate,13-acetate; Phorbol 12,13-dibutyrate; Protein kinase C; Epilepsy; Staurosporine (Smith, S.E. (213) 133)

Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Jerking; SCH 39166; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; Nucleus accumbens septi; Locomotion (Callaway, C.W. (214) 45)

Dopamine D_1 receptors; Dopamine D_2 receptors; Binding (in vivo); (Rat) (Nielsen, E.B. (219) 35)

Substance P; Neurokinin A; Senktide; Blood pressure; Heart rate; Tachykinin receptor antagonists (Itoi, K. (219) 435)

Epilepsy; NMDA (N-methyl-D-aspartate); Valproate; MK-801 (Dziki, M. (222) 273)

Behavioural desensitization
Substance P (N-terminal fragments); Substance P-(1–7); Opioid receptor antagonists (Mousseau, D.D. (217) 197)

Behavioural responses
Cold stress; 5-HT receptor subtypes; 5-HT turnover; Glucose; Corticosterone (Zamfir, O. (219) 261)

Behavioural sedation
R-(+)-HA-966; S-(−)-HA-966; Glycine/NMDA receptor site (strychnine-insensitive); Anxiolytics (Dunn, R.W. (214) 207)

Behavioural sensitization
σ Receptors; Methamphetamine; BMY 14802; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-propylpiperidine) (Ujike, H. (211) 323)

Benzamides (substituted)
Oesophagus (rat); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptors; cAMP; Tropisetron (Ford, A.P.D.W. (211) 117)

Dopamine D_2 receptors; SPECT imaging (Kessler, R.M. (223) 105)

Benzimidazolones
Oesophagus; 5-HT_4; BIMU 1; BIMU 8; DAU 6214 (Baxter, G.S. (212) 225)

Benzodiazepine antagonism
Melatonin; Convulsions; 3-Mercaptopropionic acid; (Time-dependent effects) (Golombek, D.A. (210) 253)

Benzodiazepine binding
Handling; Stress (Andrews, N. (210) 247)

Benzodiazepine exposure (chronic)
Tolerance; Steroid hormones; Ovariectomy; GABA/benzodiazepine receptors; Anticonvulsants (Wilson, M.A. (215) 99)

Benzodiazepine receptor agonists (peripheral-type)
Insulin secretion; Benzodiazepines (Petit, P. (221) 359)

Benzodiazepine receptor binding
Benzodiazepines; Spinal cord; Alpidem; (Receptor heterogeneity) (Maguire, P.A. (214) 85)

Benzodiazepine (receptor binding)
Thermodynamics; Benzodiazepine receptor (type I); Cerebellum (Maguire, P.A. (226) 233)

Benzodiazepine receptors
Flumazenil; PET (positron emission tomography) (Abadie, P. (213) 107)

Cyclopyrrolones; Body temperature; (Full and partial agonists); (Antagonists) (Jackson, H.C. (216) 23)

Circadian rhythm; Suprachiasmatic nucleus; 2-Deoxyglucose uptake; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); $GABA_A$ receptors (Tominaga, K. (217) 79)

PET (positron emission tomography); [^{18}F]FEF (5-(2′-[^{18}F]Fluoroethyl)flumazenil); Imaging; Flumazenil; Neuroreceptors (Moerlein, S.M. (218) 109)

Locomotor activity; Exploratory behaviour; Inverse agonists (Jackson, H.C. (221) 199)

Ro 15-4513; Ro 19-4603; Annelated 1,4-diazepines; GABA (Wong, G. (225) 63)

Benzodiazepine receptors (central)
Modification of receptors; [^{3}H]Ro 15-4513 binding; $GABA_A$ receptors (α subunits); Diethylpyrocarbonate; 2,3-Butanedione (Maksay, G. (227) 57)

Benzodiazepine receptors (peripheral)
Adenosine; Purinoceptors; Trachea (guinea-pig, isolated) (Devillier, P. (214) 67)

Kidney (rat); Angiotensin II (Holmes, P.V. (226) 189)

Benzodiazepine receptors (type I)
Benzodiazepine (receptor binding); Thermodynamics; Cerebellum (Maguire, P.A. (226) 233)

Benzodiazepines
α-MSH (α-melanocyte-stimulating hormone); GABA (γ-aminobutyric acid); Hypothalamus (Mabley, J. (209) 127)

Ethanol; Locus coeruleus; GABA (γ-aminobutyric acid); Picrotoxin; Ro 15-1788; Electrophysiology (Verbanck, P.M.P. (211) 15)

Spinal cord; Benzodiazepine receptor binding; Alpidem; (Receptor heterogeneity) (Maguire, P.A. (214) 85)

Strychnocarpine; β-Carbolines; 5-HT (5-hydroxytryptamine, serotonin); Tryptamine; Opiate receptors; GABA receptors (Strömbom, J. (214) 165)

GABA (γ-aminobutyric acid); 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Hippocampus; Frontal cortex (File, S.E. (218) 9)

Hippocampus; Chlordiazepoxide; Muscimol; GABA (γ-aminobutyric acid); Memory (working, reference) (Ohno, M. (219) 245)

Insulin secretion; Benzodiazepine receptor agonists (peripheral-type) (Petit, P. (221) 359)

Tolerance; $GABA_A$ receptor complex (α_1 subunit; γ_2 subunit; β_1 subunit); (Rat) (Primus, R.J. (226) 21)

Tolerance; $GABA_A$ receptor; mRNA levels; (Rat) (O'Donovan, M.C. (226) 335)

7-Benzylidenenaltrexone (BNTX)
Antinociception; δ-Opioid receptor subtypes binding (Portoghese, P.S. (218) 195)

Bepridil
Ca^{2+} channel antagonists; Ca^{2+} overload; Veratrine; Atria (rat) (Leboeuf, J. (216) 183)

Betaxolol
Methionine sulfoximine; Hypothermia; Pindolol; Propranolol; Ketanserin; ICI 118,551; $5\text{-}HT_1$ receptors (Ginefri-Gayet, M. (217) 85)

BIBS 39
Angiotensin II receptor antagonists; BIBS 222 (Zhang, J. (218) 35)

BIBS 222
Angiotensin II receptor antagonists; BIBS 39 (Zhang, J. (218) 35)

Bicarbonate secretion
β-Adrenoceptors ('atypical'); Cecum; β-Adrenoceptor agonists; β-Adrenoceptor antagonists (Canfield, P. (216) 293)

Bicuculline
Substance P; GABA (γ-aminobutyric acid); Nucleus tractus solitarii; (Evoked responses); (Rat) (Pérez, H. (213) 435)

GABA (γ-aminobutyric acid); Diazepam; Lithium chloride; Pilocarpine; Seizures (Peterson, C.J. (221) 151)

Bifemelane
Mossy fibers; Glutamate release; Protein kinase C; H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine); (Guinea-pig) (Ueda, M. (219) 271)

Big endothelin-1
Endothelin-1; Bronchoconstriction; Hypertension; Metallopeptidases (Pons, F. (217) 65)

Biliary elimination
Glisoxepide; Glibenclamide; Anion transport; Liver; Sulfonylurea; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

BIMU 1
Oesophagus; $5\text{-}HT_4$; BIMU 8; DAU 6214; Benzimidazolones (Baxter, G.S. (212) 225)

BIMU 8
Oesophagus; $5\text{-}HT_4$; BIMU 1; DAU 6214; Benzimidazolones (Baxter, G.S. (212) 225)

Binding
Neuromedin B; Bombesin; Urinary bladder (rat); Neuromedin B receptor (Bitar, K.G. (219) 117)

Binding (in vivo)
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

$5\text{-}HT_2$ receptors; 5-HT receptor antagonists; RP 62203 (Fajolles, C. (216) 53)

Dopamine D_1 receptors; Dopamine D_2 receptors; Behaviour; (Rat) (Nielsen, E.B. (219) 35)

Dopamine D_1 receptors; NNC-112; NNC-687; NNC-756 (Andersen, P.H. (219) 45)

σ Binding sites
DTG (1,3-di-(2-[5-^{3}H]tolyl)guanidine); R(+)-3-PPP (R(+)-3-(3-hydroxyphenyl)-N-(n-propyl)piperidine) (Codd, E.E. (217) 149)

Biogenic amine metabolism
N-Ethyl,N-nitrosourea; Neurotransmitters; Brain enzymes; (CD1 mouse) (Jayasekara, S. (228) 37)

Biotransformation
Glyceryl trinitrate; Rabbit aorta; Vasodilatation; Carbon monoxide (CO); Hemoprotein (Liu, Z. (211) 129)

Bisbenzyltetrahydroisoquinolines
Ca^{2+} channel antagonists; Uterus; (Rat) (Ivorra, M.D. (219) 303)

Bladder
Purinoceptors; ATP; Neonate; Neurotransmission; Development (Sneddon, P. (214) 7)

Phorbol ester; Protein kinase C; Urethra (Yoshida, M. (222) 205)

Bladder (guinea-pig)
NK receptors; Smooth muscle (Longmore, J. (222) 167)

Blood-aqueous barrier
CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

K^+ channels (ATP-sensitive); Nitric oxide (NO); Vasodilatation (Andersson, S.E. (224) 89)

Blood-brain barrier
Tryptophan; 5-HT receptors (Chaouloff, F. (214) 101)

Amino acid transport; β_2-Adrenoceptors; L-DOPA (L-3,4-dihydroxyphenylalanine); Isoproterenol; Salbutamol (Takao, Y. (215) 245)

Losartan; DuP 753; Angiotensin II; Blood pressure; Thirst (Bui, J.D. (219) 147)

Blood flow
CGRP (calcitonin gene-related peptide); Capsaicin; Skin (Hughes, S.R. (219) 481)

Blood flow (mucosal)
Nitric oxide (NO); Gastroprotection; Nocloprost (Konturek, S.J. (211) 277)

Blood pressure
Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo); Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

5-HT receptor agonists; 5-HT receptor antagonists; Plasma renin activity; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

Cocaine; Cocaine methiodide; Heart rate; Norepinephrine; (Squirrel monkey) (Schindler, C.W. (213) 99)

5-HT receptors; Anxiolytic; Dorsal raphe nucleus (Corley, K.C. (213) 417)

Endothelin-1; Cyclosporine; Hypertension; Mesenteric artery (Takeda, Y. (213) 445)

Anaesthesia; Ketanserin; Sinoaortic denervation (Su, D.-F. (214) 89)

Recombinant renin (human); Spontaneously hypertensive rat (SHR); Renin inhibitors (Shibasaki, M. (215) 271)

Substance P; Dorsal raphe nucleus; 5-HT release (Gradin, K. (218) 363)

Losartan; DuP 753; Angiotensin II; Blood–brain barrier; Thirst (Bui, J.D. (219) 147)

Substance P; Neurokinin A; Senktide; Heart rate; Behaviour; Tachykinin receptor antagonists (Itoi, K. (219) 435)

CP-96,345; Heart; NK_1 receptor antagonists; Substance P; Cigarette smoke (Delay-Goyet, P. (222) 213)

$5\text{-}HT_{1A}$ receptors; $5\text{-}HT_{1A}$ receptor agonists; $5\text{-}HT_{1A}$ receptor antagonists; Heart rate; MDL 73005EF; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

Blood vessels
Hyporesponsiveness; Endothelium; Protein synthesis; Nitric oxide (NO); Lipopolysaccharide (Nakaki, T. (219) 311)

Blood vessels (rabbit)
Purinergic nerve stimulation; Co-transmission; Ethanol (Bulloch, J.M. (211) 1)

BMY 7378
NAN-190; $5\text{-}HT_{1A}$ receptors; Partial agonists; Spare receptors; Receptor theory (Greuel, J.M. (211) 211)

$5\text{-}HT_{1A}$ receptor agonists; $5\text{-}HT_{1A}$ receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

BMY 14802
σ Receptors; Behavioral sensitization; Methamphetamine; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-propylpiperidine) (Ujike, H. (211) 323)

Boc-[Leu^{31}]CCK-4 binding
Cholecystokinin; CCK_B receptors; Synaptoneurosomes (guinea pig, cerebral cortex); Inositol phosphate accumulation; cAMP accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

Body temperature
Cyclopyrrolones; Benzodiazepine receptors; (Full and partial agonists); (Antagonists) (Jackson, H.C. (216) 23)

Morphine; Neurotensin; Pertussis toxin (Basilico, L. (222) 241)

Caffeine; Naloxone; (Mouse) (Durcan, M.J. (224) 151)

Body weight
Tumor necrosis factor; Interleukin-1; Interleukin-1 receptor antagonists; Social behaviour; (Mouse) (Bluthé, R.-M. (209) 281)

Bombesin
Pancreatic secretion; Amylase; Bombesin receptor antagonists (Jaworek, J. (214) 239)

Food intake; Satiety; Bombesin receptor agonists; Bombesin receptor antagonists; CCK receptor antagonists (Laferrère, B. (215) 23)

Neuromedin B; Binding; Urinary bladder (rat); Neuromedin B receptor (Bitar, K.G. (219) 117)

Bombesin receptor agonists
Food intake; Bombesin; Satiety; Bombesin receptor antagonists; CCK receptor antagonists (Laferrère, B. (215) 23)

Bombesin receptor antagonists
Pancreatic secretion; Amylase; Bombesin (Jaworek, J. (214) 239)

Food intake; Bombesin; Satiety; Bombesin receptor agonists; CCK receptor antagonists (Laferrère, B. (215) 23)

BQ-123
Endothelin-1; Endothelin receptor subtypes; Regional haemodynamics; Vasodilatation; (Anaesthetized rat) (Douglas, S.A. (221) 315)

Endothelin; Mitogenesis; Endothelin ET_A receptor; Endothelin ET_B receptor (Ohlstein, E.H. (225) 347)

Bradykinin
Bradykinin receptor antagonists (Rhaleb, N.-E. (210) 115)

α_2-Adrenoceptors; Capsaicin; Nicotine; Resiniferatoxin; Bronchoconstriction (Lou, Y.-P. (210) 173)

Renal vasodilatation; Spontaneously hypertensive rat, stroke prone (SHR/SP) (Stier Jr., C.T. (210) 217)

Bradykinin receptor antagonists; Carrageenan; Urate crystal; Zymosan; Scalding; Sponges (Damas, J. (211) 81)

Endopeptidase 24.15; Endopeptidase 24.11; Trachea (guinea-pig); Substance P (Da Silva, A. (212) 97)

Resiniferatoxin; Capsaicin; Tachykinins; Substance P; Iris sphincter muscle (rabbit); Tachyphylaxis (Wang, Z.-Y. (213) 235)

Airway microvascular leakage; Bradykinin receptors; Bronchoconstriction; Hoe 140; PAF (platelet-activating factor, PAF-acether) (Sakamoto, T. (213) 367)

Urinary bladder; Epithelium; Diabetes; Prostaglandins (Pinna, C. (214) 143)

Angiotensin-converting enzyme; Smooth muscle; Phospholipase A_2; Lipoxygenase; Cyclic nucleotides (Rodrigues, M.S. (216) 357)

Nociception; Spinal cord; Formalin; Prostaglandins; (Rat) (Chapman, V. (219) 427)

Desensitization; Hypersensitivity (Martins, M.A. (220) 55)

Endothelium; Basilar artery (canine) (Yen, M.-H. (221) 261)

Endothelial cells; Ca^{2+} channels; G protein; Endothelium-derived relaxing factor (EDRF); cGMP (Graier, W.F. (225) 43)

cGMP; Endothelin; EDRF (endothelium-derived relaxing factor); Forskolin; 5-HT (serotonin) (Reiser, G. (227) 89)

Bradykinin receptors; Bradykinin receptor antagonists; IMR-90 cells (Sawutz, D.G. (227) 309)

Bradykinin receptor antagonists
Bradykinin (Rhaleb, N.-E. (210) 115)

Bradykinin; Carrageenan; Urate crystal; Zymosan; Scalding; Sponges (Damas, J. (211) 81)

Smooth muscle (Griesbacher, T. (211) 393)

Histamine liberation; Pain measurement; Skin response (Kindgen-Milles, D. (218) 183)

Epithelium; Kinins (characterization); Agonists; B_2 receptor antagonist (radiolabeled) (Tousignant, C. (225) 235)

Bradykinin; Bradykinin receptors; IMR-90 cells (Sawutz, D.G. (227) 309)

Bradykinin receptors
Airway microvascular leakage; Bradykinin; Bronchoconstriction; Hoe 140; PAF (platelet-activating factor, PAF-acether) (Sakamoto, T. (213) 367)

Bradykinin; Bradykinin receptor antagonists; IMR-90 cells (Sawutz, D.G. (227) 309)

Brain
[^{3}H]GR65630; Autoradiography; 5-HT_3 recognition sites; (Common marmoset) (Jones, D.N.C. (215) 63)

Histamine; Histamine H_2 receptors; Histamine H_2 receptor antagonists; Morphine; Antinociception (Hough, L.B. (215) 69)

β-Adrenoceptor (atypical); Depression; Locomotor activity; Water intake (Simiand, J. (219) 193)

Epilepsy; 5-HT (5-hydroxytryptamine, serotonin); GABA (γ-aminobutyric acid); Acetylcholine; Cl^- transport; (Mouse) (Inoue, M. (221) 135)

Dopamine D_2 receptor; mRNA; Development (Srivastava, L.K. (225) 143)

S-Adenosyl-L-methionine; Aging; Muscarinic receptors; Striatum; Hippocampus (Muccioli, G. (227) 293)

Brain biogenic amines
Phenol; Immunotoxicology; Neurotoxicity; (Mouse) (Hsieh, G.-C. (228) 107)

Brain cortex (pig)
Adenosine receptors; Membrane microviscosity; Affinity states (Casadó, V. (225) 7)

Brain cortical minces
Steroidogenesis; cAMP (Barbaccia, M.L. (219) 485)

Brain damage
Tacrine; Seizures; LiCl; Nitric oxide (NO); L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (213) 301)

Brain development
Angiotensin II receptor subtypes; AT_2 receptors; Sulfhydryl reducing agents; Dithiothreitol; Losartan (DuP 753) (Tsutsumi, K. (226) 169)

Brain dialysis
Acetyl-L-carnitine; Dopamine release; Striatum (Harsing, Jr., L.G. (218) 117)

Brain enzymes
N-Ethyl,N-nitrosourea; Neurotransmitters; Biogenic amine metabolism; (CD1 mouse) (Jayasekara, S. (228) 37)

Brain (guinea pig)
σ Receptors; Radioreceptor assay; (+)-Pentazocine (DeHaven-Hudkins, D.L. (227) 371)

Brain (human)
5-HT_1 binding sites; 5-HT_{1D} binding sites; 5-HT_{1E} binding sites (Lowther, S. (222) 137)

Brain imaging
Noradrenaline; α_2-Adrenoceptors; Autoradiography (Biegon, A. (224) 27)

Brain ischemia
Survival; (Gerbil); (Treatment) (Von Lubitz, D.K.J.E. (216) 37)

Brain natriuretic peptide (BNP)
C-type natriuretic peptide (CNP); Atrial natriuretic peptide (ANP); Glioma cells (rat); Receptor binding; cGMP (Eguchi, S. (225) 79)

Brain protein synthesis
p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography (quantitative) (Lepetit, P. (209) 207)

Brain (rat)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis (Hjorth, S. (209) 249)

[^{3}H](R)-Zacopride; [^{3}H](S)-Zacopride; 5-HT_3 receptors; (High affinity (R)-sites) (Kidd, E. (211) 133)

[^{3}H]Paroxetine binding; 5-HT uptake inhibitors; Structure–activity relationship (Marcusson, J.O. (215) 191)

Ethanol intake; Dopamine receptors; Dopamine D_1 receptors; Dopamine D_2 receptors; (Agonist affinity) (May, T. (215) 313)

Carbon dioxide (CO_2); $GABA_A$ receptors (Sanna, E. (216) 457)

Clonidine; α_2-Adrenoceptors (presynaptic); Aspartate; Glutamate; GABA (γ-aminobutyric acid) (Kamisaki, Y. (217) 57)

[^{3}H]CPP ([^{3}H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid); NMDA receptors; Cortex (human); Alzheimer's disease (Porter, R.H.P. (225) 195)

Electroconvulsive shock; α_1-Adrenoceptors; 5-HT_2 receptors; Phosphoinositide hydrolysis (Pandey, G.N. (226) 303)

Adenosine A_1 receptors; Adenosine A_2 receptors; Neuroprotection; Desensitization (agonist induced) (Abbracchio, M.P. (227) 317)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT uptake inhibitor; 1-Piperonylpiperazine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Hashimoto, K. (228) 171)

Brain slices
NMDA (N-methyl-D-aspartate); Dopamine; Polyamines; Ifenprodil; SL 82.0715 (Woodward, J.J. (210) 265)

cAMP; Glutamate; Locus coeruleus; Opiates; Withdrawal (Kogan, J.H. (211) 47)

Brainstem
Noradrenergic mechanisms (central); α-Adrenoceptors; Gastric motility (Nagata, M. (223) 153)

Brain stimulation reward
Dopamine; Morphine; Neurotensin; Mesencephalon (ventral) (Rompré, P.-P. (211) 295)

B_2 receptor antagonist (radiolabeled)
Epithelium; Kinins (characterization); Agonists; Bradykinin receptor antagonists (Tousignant, C. (225) 235)

BRL 37344
β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

BRL 38227 (lemakalim)
Gastric fundus; Pinacidil; Non-adrenergic non-cholinergic neurostimulation; K^+ channels; (Rat) (Lefebvre, R.A. (214) 1)

Potassium channel openers; Microcirculation; Spontaneously hypertensive rat (SHR) (Struijker Boudier, H.A.J. (218) 191)

[^{3}H]Brofaromine
MAO-A (monoamine oxidase A); Brofaromine binding; Tyramine; Clorgyline; Intestine (rat) (Waldmeier, P.C. (216) 243)

Brofaromine binding
[^{3}H]Brofaromine; MAO-A (monoamine oxidase A); Tyramine; Clorgyline; Intestine (rat) (Waldmeier, P.C. (216) 243)

Bromosulfophthalein
Glisoxepide; Glibenclamide; Organic anions; Monocarboxylate transport; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide; Oleate (Fückel, D. (213) 393)

Bronchial hyperreactivity
PAF receptor antagonists; Antigen (ovalbumin); Inflammatory cells (Underwood, S.L. (210) 97)

Bronchial provocation test
Asthma; Inflammation; Theophylline (Crescioli, S. (228) 45)

Bronchoalveolar eosinophilia
Anti-IL-5 monoclonal body; Asthma model (guinea pig); (Therapeutic approach) (Chand, N. (211) 121)

Bronchoalveolar lavage
Endothelin-1; Radioimmunoassay; Respiratory distress syndrome (adult); Oleic acid; Hypoxia (Simmet, T. (211) 319)

Interleukin-1 receptor antagonists; Airway hyperreactivity; Substance P; Airway leukoctyes (Selig, W. (213) 331)

Bronchoconstriction
α_2-Adrenoceptors; Bradykinin; Capsaicin; Nicotine; Resiniferatoxin (Lou, Y.-P. (210) 173)

fMLP (formyl-L-methionyl-L-leucyl-L-phenylalanine); Histamine; Hyperreactivity; Pertussis toxin (Imaizumi, A. (212) 177)

Airway microvascular leakage; Bradykinin; Bradykinin receptors; Hoe 140; PAF (platelet-activating factor, PAF-acether) (Sakamoto, T. (213) 367)

Endothelin-1; Big endothelin-1; Hypertension; Metallopeptidases (Pons, F. (217) 65)

Bronchodilation
HOE 234; Airway dynamics; Trachea (guinea-pig); K^+ channel opening (Englert, H.C. (210) 69)

Bronchodilators
Protein kinase C; Trachealis (bovine); Smooth muscle contraction; Cholinomimetics (Langlands, J.M. (227) 131)

Bronchospasm
Capsaicin; Neurokinin A; Substance P; Cholinergic nerves; Adrenergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Bronchus (guinea-pig)
Neurokinin receptors; Electrical field stimulation; SR 48968; (±)-CP-96,345; Non-cholinergic contraction (Martin, C.A.E. (224) 137)

Bronchus (human)
ANF (atrial natriuretic factor); Relaxation; Trachea (guinea-pig); Trachea (rat); Epithelium; Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

Bronchus (isolated, human)
Endothelin; Airway epithelium; Enkephalinase (Candenas, M.-L. (210) 291)

BTCP (N[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine)
Phencyclidine; Single unit recording; Locus coeruleus; Reserpine (Chergui, K. (219) 169)

[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding; Cocaine; GBR 12935; Dopamine uptake inhibitors; Striatum (rat) (Reith, M.E.A. (227) 417)

BTS 53 554
Phosphodiesterase isoenzymes; Cardiac muscle; Smooth muscle (aortic); Flosequinan; (Guinea-pig) (Frodsham, G. (211) 383)

B type chronic lymphocytic leukemia (B-CLL)
Cytotoxicity; Cyclosporins (Larsson, R. (228) 237)

Bumetanide
Glisoxepide; Glibenclamide; Organic anions; Monocarboxylate transport; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Oleate (Fückel, D. (213) 393)

Torasemide; Cotransport; Red blood cells; Hypertension; Diuretics (loops) (Masereel, B. (219) 385)

Bumetanide transport
Loop diuretics; Photoaffinity labeling; Sinusoidal plasma membrane (rat liver); Integral plasma membrane proteins; Two-dimensional gel electrophoresis (Honscha, W. (226) 215)

Buspirone
Chlordiazepoxide; Anxiolytics; (Nonreward); (Rat) (Panickar, K.S. (210) 307)

Tandospirone; Ipsapirone; Azapirones; Chlordiazepoxide; Anxiolytics; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

2,3-Butanedione
Benzodiazepine receptors (central); Modification of receptors; [^{3}H]Ro 15-4513 binding; $GABA_A$ receptors (α subunits); Diethylpyrocarbonate (Maksay, G. (227) 57)

BW 737C
Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; SCH 39166; NO 756; A-69024 (Daly, S.A. (213) 251)

BW737C89
Dopamine D_1 receptor antagonists; SCH 23390; Tetrahydroisoquinolines; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); (Receptor binding) (Riddall, D.R. (210) 279)

BY-1949
Cerebral blood flow; Cyclic nucleotides; Basilar artery; Endothelial cells (Sugawa, M. (215) 57)

Cerebral blood flow; Nucleus basalis of Meynert; (Rat) (Takao, A. (217) 101)

Ca^{2+}
1,25-Dihydroxyvitamin D_3 binding; Choroid plexus; 1,25-Dihydroxyvitamin receptors (Walters, M.R. (213) 309)

5-HT (5-hydroxytryptamine, serotonin); Endothelium; Prostacyclin (Gill, J.K. (214) 269)

Jatrophone; Aorta (rat); K^+ channel blockers; KCl; Angiotensin II; Noradrenaline (Duarte, D.F.P. (215) 75)

Endothelin-1; Aorta (rat); Smooth muscle (vascular); Cyclopiazonic acid (Shimamoto, H. (216) 225)

Smooth muscle; Acetylcholine; A23187; Phasic and tonic responses; IP_3 (inositol trisphosphate) (Macara, B. (218) 27)

Smooth muscle; Relaxation; Uterus (Ishine, T. (219) 285)

Antihypertensives; A-80b; Vasodilators; Aorta; Portal vein (Frechilla, D. (219) 409)

Vanadate; Uterus; Smooth muscle; Ca^{2+}-free; Protein kinase C (Fukuzaki, A. (220) 99)

Endothelin; Endothelin receptor antagonists; Ischemic acute renal failure; (Rat) (Mino, N. (221) 77)

Endothelial cells; Caffeine (Chen, G. (223) 33)

Angiotensin; Angiotensin AT_1 receptors; Efficacy (Liu, Y.J. (223) 205)

Neurotransmitter release; Neurosecretory cells; Cytoskeleton; Cytoplasmic proteins; Calmodulin; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Inositol 1,4,5-trisphosphate receptors; WRK_1 cells; Inositol phosphates (Mouillac, B. (225) 179)

α_1-Adrenoceptors; Norepinephrine; Smooth muscle (Han, C. (226) 141)

Iris sphincter (dog); Smooth muscle; Muscarinic stimulation; cAMP; Inositol trisphosphate; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Action potentials; Pituitary; Protein kinase A; Protein kinase C; Okadaic acid (Chiavaroli, C. (227) 173)

Smooth muscle (vascular); Protein kinase C activity (cytosolic, particulate); Phorbol esters (Bazan, E. (227) 343)

Amiloride; 3,4-Dichlorobenzamil; Quinacrine; Ca^{2+} channel blockers; L-type Ca^{2+} channels (Stokke, M. (227) 379)

Endothelins; Megakaryoblastic cells; Inositol phosphates (Diochot, S. (227) 427)

Ca^{2+}-activated K^+ channels
Endothelins; Sarafotoxins; Intestinal relaxation (Lin, W.-W. (219) 355)

Ca^{2+}-activated K^+ currents
Pyramidal neurons (dissociated); Hippocampus (rat); Single channel recording; Trifluoperazine (Ikemoto, Y. (216) 191)

Ca^{2+} channel agonists
BAY k 8644; Voltage-gated Ca^{2+} channels; Aging (Khatter, J.C. (216) 351)

Ca^{2+} channel antagonists
Cardiac death (sudden); Ventricular fibrillation; Flunarizine (Billman, G.E. (212) 231)

PN200-110; Diltiazem; Verapamil; Allosteric regulation (Miwa, K. (214) 127)

Bepridil; Ca^{2+} overload; Veratrine; Atria (rat) (Leboeuf, J. (216) 183)

Central nervous system (CNS); Striatum; Acetylcholine release; Verapamil; Spontaneously hypertensive rat (SHR) (Tsuda, K. (216) 319)

Cardiovascular effects; ω-Conotoxin GVIA; (Guinea-pig) (Bond, A. (218) 179)

E4080; K^+ channel openers; Ca^{2+} concentration (intracellular); Vasodilators; Coronary artery (dog) (Okada, Y. (218) 259)

Bisbenzyltetrahydroisoquinolines; Uterus; (Rat) (Ivorra, M.D. (219) 303)

Ischaemia; Heart (isolated); Cardiac function (Manning, A. (220) 249)

Aorta; Muscle relaxation; [^{3}H] TC-81 (distribution of) (Okamiya, Y. (222) 99)

NC-1100; Cerebral ischemia; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (224) 109)

Ca^{2+} channel blockers
Antinociception; Formalin test; Writhing test; Hot-plate test (Miranda, H.F. (217) 137)

Immunoreactive insulin plasma levels; α_1-Adrenoceptors; β-Adrenoceptors; (Rabbit) (García-Barrado, M.J. (219) 461)

Amiloride; 3,4-Dichlorobenzamil; Quinacrine; Ca^{2+}; L-type Ca^{2+} channels (Stokke, M. (227) 379)

Ca^{2+} channel (mammalian, presynaptic)
Spider toxin; Glutamate (Pocock, J.M. (226) 343)

Ca^{2+} channels
Cough reflex; Antitussive effect; Flunarizine; Nifedipine; Verapamil (Kamei, J. (212) 61)

Nifedipine; Diltiazem; Verapamil; Cell growth; Tumor cells (Wöll, E. (212) 105)

Evodiamine; Endothelium; K^+ channels; Mesenteric artery (Chiou, W.-F. (215) 277)

CP-96,345; Substance P (Schmidt, A.W. (215) 351)

Insulin secretion; ω-Conotoxin (Sher, E. (216) 407)

Cromakalim; Vasodilators; Mesenteric artery (human); Smooth muscle (vascular) (Smirnov, S.V. (217) 105)

Acidosis; Alkalosis; Nifedipine; Heart (rat) (Achike, F.I. (219) 369)

CP-96,345; Substance P (Schmidt, A.W. (219) 490)

UMR 106 osteogenic cell line; Patch clamp; Dihydropyridines (Morain, P. (220) 11)

Vestibular compensation; MK-801 (Sansom, A.J. (220) 123)

Dihydropyridines; NMDA (N-methyl-D-aspartate); Excitatory amino acid; Dopamine; Transmitter release; Mesencephalon (Chaudieu, I. (220) 203)

Smooth muscle (uterus); Ca^{2+} levels (cytosolic); Endothelins; (Rat) (Sakata, K. (221) 9)

Aorta (rabbit); α_1-Adrenoceptors; α_2-Adrenoceptors; BAY k 8644 (Aleixandre, A. (221) 129)

Smooth muscle (vascular); Nisoldipine; Inhibitory effects (residual); Ca^{2+} levels (cytosolic); Aorta (rat); (Relaxation) (Kim, B.K. (223) 157)

Bradykinin; Endothelial cells; G protein; Endothelium-derived relaxing factor (EDRF); cGMP (Graier, W.F. (225) 43)

ω-Conotoxin; Ca^{2+} influx; Dihydropyridines; Transmitter release (Lundy, P.M. (225) 51)

Intracellular Ca^{2+}; Fura-2; Ca^{2+} ionophore; Co^{2+}; La^{3+} (Horváth, G. (225) 305)

Calmodulin; CGS 9343B; Patch clamp; Fura-2 (Neuhaus, R. (226) 183)

Maitotoxin; Cation blockers; Liposomes (Murata, M. (227) 43)

Dihydropyridine receptors; Monoclonal antibodies; Purification; Cardiac sarcolemma (Tokumaru, H. (227) 363)

Ca^{2+} channels (L-type)
Amiloride; 3,4-Dichlorobenzamil; Quinacrine; Ca^{2+}; Ca^{2+} channel blockers (Stokke, M. (227) 379)

Ca^{2+} channels (slow)
Cardiac hypertrophy; β-Adrenoceptors; Adenylate cyclase; Forskolin (Mészáros, J. (210) 333)

Ca^{2+} channels (voltage-dependent)
Endothelin-1; Cerebral arteries; Peripheral arteries; Vasoconstriction; Ca^{2+} influx; Nifedipine (Suzuki, Y. (219) 401)

Ca^{2+} concentration (intracellular)
E4080; K^+ channel openers; Ca^{2+} channel antagonists; Vasodilators; Coronary artery (dog) (Okada, Y. (218) 259)

Thromboxane A_2/prostaglandin H_2 receptors (TXA_2/PGH_2 receptors); Smooth muscle cells (vascular); Thromboxane A_2 receptor antagonist (KW-3635 and BM-13505) (Miki, I. (227) 199)

Ca^{2+} currents
Norepinephrine; Protein kinase C; 1,2-Dioctanoylglycerol; Whole-cell voltage clamp; Sympathetic ganglia (Abrahams, T.P. (227) 189)

Ca^{2+} (cytosolic)
Tetronothiodin; CCK_B receptor antagonists; GH3 cells; Fura-2; [^{125}I]CCK-8 binding (Kuwahara, T. (221) 99)

Ca^{2+} dependence
Baclofen; Amino acid release (Otero Losada, M.E. (224) 21)

Cadmium chloride
Cd^{2+}; Cadmium-metallothionein; Accumulation; (Rat) (Groten, J.P. (228) 23)

Cadmium-metallothionein
Cd^{2+}; Cadmium chloride; Accumulation; (Rat) (Groten, J.P. (228) 23)

Ca^{2+} efflux
Aorta; Noradrenaline; Protein kinase C; Staurosporine; Calphostin C; Ca^{2+} uptake; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

$^{45}Ca^{2+}$ efflux
Ba^{2+}; Nifedipine; $^{45}Ca^{2+}$ uptake; Vas deferens; Verapamil; Methoxamine (Hay, D.W.P. (225) 313)

Cholecystokinin; CCK_B receptors; Synaptoneurosomes (guinea pig, cerebral cortex); Boc-[Leu^{31}]CCK-4 binding; Inositol phosphate accumulation; cAMP accumulation (Galas, M.C. (226) 35)

Ca^{2+} entry blockers
Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Neurotoxicity (Pizzi, M. (209) 169)

Caerulein
CCK-8 (cholecystokinin octapeptide); Lorglumide; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Ca^{2+} (external)
Metabotropic glutamate receptor; 1S,3R-ACPD (1S,3R-1-amino-cyclopentane-1,3-dicarboxylic acid) (Zheng, F. (211) 281)

Ca^{2+} (extracellular)
Aging; Cardiac muscle; Dihydropyridines; F344 rats; Isoproterenol (Ruch, S. (216) 393)

Caffeine
Angiotensin II; Adenosine; Renal function; Hypertension (Holycross, B.J. (219) 361)

Endothelial cells; Ca^{2+} (Chen, G. (223) 33)

Naloxone; Body temperature; (Mouse) (Durcan, M.J. (224) 151)

Caffeine contracture
Dantrolene; Depolarization contractures; Diaphragm (rat) (Røed, A. (209) 33)

CA1 field potentials
Hypoxia/hypoglycemia; Cholinergic drugs; 2-Deoxyglucose uptake; Hippocampus; (In vitro) (Shibata, S. (221) 113)

Catecholamines; Hypoxia/hypoglycemia; 2-Deoxyglucose; Ischemia; Hippocampus; (In vitro) (Shibata, S. (221) 255)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_3$ receptors; Hypoxia/hypoglycemia; Ischemia; Hippocampus; (In vitro) (Kagami-ishi, Y. (224) 51)

Ca^{2+}-free medium
Vanadate; Uterus; Smooth muscle; Ca^{2+}; Protein kinase C (Fukuzaki, A. (220) 99)

$[Ca^{2+}]_i$ increase
L-Glutamate; 2-(Carboxycyclopropyl)glycine; NMDA receptors; D-Aspartate uptake; Neurotoxicity (Kawai, M. (211) 195)

Ca^{2+} influence
Atrium (rat); ANP release; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

Ca^{2+} influx
Progesterone; Coronary artery relaxation; Endothelium; K^+ conductance (Jiang, C. (211) 163)

Vasorelaxation (rat aorta); Osthole; cGMP; (*Angelica pubescens*) (Ko, F.-N. (219) 29)

Endothelin-1; Cerebral arteries; Peripheral arteries; Vasoconstriction; Nifedipine; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Ca^{2+} channels; ω-Conotoxin; Dihydropyridines; Transmitter release (Lundy, P.M. (225) 51)

$^{45}Ca^{2+}$ influx
Oxodipine; Aorta; Mesenteric resistance vessels; (Rabbit) (Tejerina, T. (219) 279)

Aorta (rat); Endothelium; BAY k 8644 enantiomers; Nifedipine (Gil-Longo, J. (221) 1)

Ca^{2+} (intracellular)
Endothelin-1; Cardiac myocytes; Cell shortening (Qiu, Z. (214) 293)

Amphotericin B; Mesangial cells; Diltiazem; Theophylline (Sabra, R. (226) 79)

3,4-Diaminopyridine; Noradrenaline release; Hippocampus; α_2-Adrenoceptor mechanism; (Rat); (Rabbit) (Jackisch, R. (226) 245)

Ca^{2+} ionophore
Intracellular Ca^{2+}; Fura-2; Ca^{2+} channels; Co^{2+}; La^{3+} (Horváth, G. (225) 305)

Ca^{2+} ionophore A23187
Hypertension; Prostanoids; Endothelin; Prostanoid receptor blockers (Lin, L. (220) 49)

Ca^{2+} levels (cytosolic)
Smooth muscle (uterus); Ca^{2+} channels; Endothelins; (Rat) (Sakata, K. (221) 9)

Smooth muscle (tracheal); Azelastine; Relaxation; Smooth muscle (skinned) (Sanagi, M. (222) 247)

Smooth muscle (vascular); Nisoldipine; Inhibitory effects (residual); Ca^{2+} channels; Aorta (rat); (Relaxation) (Kim, B.K. (223) 157)

Calmodulin
Neurotransmitter release; Neurosecretory cells; Cytoskeleton; Cytoplasmic proteins; Ca^{2+}; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Ca^{2+} channel; CGS 9343B; Patch clamp; Fura-2 (Neuhaus, R. (226) 183)

Calmodulin antagonist
Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Calpain inhibitor
Neuroprotection; Hypoxia; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Calphostin C
Aorta; Noradrenaline; Protein kinase C; Staurosporine; Ca^{2+} uptake; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

Ca^{2+} mobilization
Endothelin; 5-HT (5-hydroxytryptamine, serotonin); Platelet aggregation (Pietraszek, M.H. (219) 289)

Second messenger; Inositol phosphate analogues (Safrany, S.T. (226) 265)

Canavanine
Endotoxin; Nitric oxide (NO) (Umans, J.G. (210) 343)

Ca^{2+} overload
Digitalis toxicity; Na^+ activity (intracellular); Contractile force; K^+; Na^+ (Abete, P. (211) 399)

Bepridil; Ca^{2+} channel antagonists; Veratrine; Atria (rat) (Leboeuf, J. (216) 183)

Ca^{2+} permeability
2,5-Di-(tert-butyl)-1,4-benzohydroquinone; Cyclopiazonic acid; A7r5 aortic cells (Missiaen, L. (227) 391)

Capsaicin
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

Mesentery (rat); CGRP (calcitonin gene-related peptide); Saponin; L-Arginine; N^{ω}-Nitro-L-arginine methyl ester (Li, Y. (210) 23)

α_2-Adrenoceptors; Bradykinin; Nicotine; Resiniferatoxin; Bronchoconstriction (Lou, Y.-P. (210) 173)

Ileal motility; Mesenteric nerve; Neuraminidase; Sialic acid; Ruthenium red; (Guinea-pig) (Takaki, M. (211) 125)

Veratridine; CGRP (calcitonin gene-related peptide); Nifedipine; ω-Conotoxin; Sensory neurons (Tramontana, M. (212) 137)

Resiniferatoxin; Bradykinin; Tachykinins; Substance P; Iris sphincter muscle (rabbit); Tachyphylaxis (Wang, Z.-Y. (213) 235)

Bronchospasm; Neurokinin A; Substance P; Cholinergic nerves; Adrenergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Capsazepine; Non-adrenergic non-cholinergic (NANC) excitatory nerves; Electrical field stimulation; Tetrodotoxin (Belvisi, M.G. (215) 341)

Substance P; Neurokinin A; Field stimulation; Airway constriction; Airway edema (Murai, M. (217) 23)

Neurogenic inflammation; Neuropeptides (Morikawa, M. (217) 31)

Small intestine; Nitric oxide (NO); Intestinal motility; Ileum (rat) (Allescher, H.-D. (217) 153)

Neurogenic inflammation; Plasma extravasation; Substance P antagonists; Tachykinins; Pain (Nagahisa, A. (217) 191)

Nitric oxide (NO); Sensory neurons; CGRP (calcitonin gene-related peptide); L-NAME (N^G-nitro-L-arginine methyl ester); Gastric mucosa (Whittle, B.J.R. (218) 339)

CGRP (calcitonin gene-related peptide); Blood flow (Hughes, S.R. (219) 481)

Spinal cord-skin preparation; C-fibre reflex; Substance P; Spantide; CGRP (calcitonin gene-related peptide) (Yanagisawa, M. (220) 111)

Capsaicin-sensitive neurones
Pertussis toxin; G-proteins; Atrium (guinea-pig) (Amerini, S. (216) 445)

Capsazepine
Non-adrenergic non-cholinergic (NANC) excitatory nerves; Capsaicin; Electrical field stimulation; Tetrodotoxin (Belvisi, M.G. (215) 341)

CGRP (calcitonin gene-related peptide); Cardiac nerves (Franco-Cereceda, A. (221) 183)

Captopril
Dermorphin; [D-Arg^2]dermorphin; Amastatin; Antinociceptive activity (Sakurada, S. (211) 75)

Dahl rat; ACE inhibitors; (Intracerebroventricular administration) (Lark, L.A. (222) 33)

Angiotensin-converting enzyme; Converting enzyme inhibitors; Angiotensinogen; Solution hybridization/RNase protection (Ye, M.-Q. (227) 79)

Carbachol
Posterior hypothalamic nucleus; Muscarinic receptor antagonists; (Rat) (Martin, J.R. (215) 83)

Morphine; Analgesia; Nitric oxide (NO); cGMP (Duarte, I.D.G. (221) 171)

Parotid acinar cells; Diacylglycerol formation; Phosphoinositide hydrolysis; Phosphatidylcholine hydrolysis (Komabayashi, T. (225) 209)

Ageing; Trachea (guinea-pig and rat); Epithelium; Smooth muscle (airway); Histamine; Acetylcholine; K^+ (Preuss, J.M.H. (228) 3)

Carbamazepine
Glutamates; NMDA (N-methyl-D-aspartate); Quisqualate; Cerebellar granule cells; Tricyclic antidepressants (Cai, Z. (219) 53)

β-Carbolines
Strychnocarpine; 5-HT (5-hydroxytryptamine, serotonin); Benzodiazepines; Tryptamine; Opiate receptors; GABA receptors (Strömbom, J. (214) 165)

Withdrawal seizure prone mouse (WSP); Ethanol withdrawal; Handling-induced convulsions; Abecarnil; Diazepam; Anticonvulsant effects; (Genetic animal model) (Crabbe, J.C. (221) 85)

Carbon dioxide (CO_2)
$GABA_A$ receptors; Brain (rat) (Sanna, E. (216) 457)

Carbon monoxide (CO)
Glyceryl trinitrate; Biotransformation; Rabbit aorta; Vasodilatation; Hemoprotein (Liu, Z. (211) 129)

Nefiracetam (DM-9384); Cholinergic system; Amnesia (delayed); Passive avoidance; Scopolamine; (Mouse) (Hiramatsu, M. (216) 279)

Arteriosclerotic plaque development (Penn, A. (228) 155)

5-Carboxamidotryptamine
5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Endothelium; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Van Gelderen, E.M. (222) 185)

2-(Carboxycyclopropyl)glycine
L-Glutamate; NMDA receptors; D-Aspartate uptake; $[Ca^{2+}]_i$ increase; Neurotoxicity (Kawai, M. (211) 195)

Carcinogenicity
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Cardiac arrhythmia
Antiarrhythmic drugs; K^+ channels (Gwilt, M. (220) 231)

Cardiac cells (guinea-pig)
Anthracene-9-carboxylic acid (9AC); DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid); Isoproterenol; Cl^- activity (intracellular) (Shida, S. (212) 267)

Cardiac death (sudden)
Ventricular fibrillation; Ca^{2+} channel antagonists; Flunarizine (Billman, G.E. (212) 231)

Cardiac electrophysiology
Ischaemia; Opioid receptor antagonists; Purkinje fibres (McIntosh, M. (210) 45)

Cardiac function
Ca^{2+} channel antagonists; Ischaemia; Heart (isolated) (Manning, A. (220) 249)

Cardiac hypertrophy
Action potential; Depolarizations (transient); Na^+,K^+-ATPase; Ryanodine; Forskolin (Mészáros, J. (210) 325)

β-Adrenoceptors; Adenylate cyclase; Ca^{2+} channels (slow); Forskolin (Mészáros, J. (210) 333)

Cardiac imaging
β-Adrenoceptors; PET (positron emission tomography); CGP 12177; CGP 26505; CGP 20712A (Van Waarde, A. (222) 107)

Cardiac membranes
Muscarinic acetylcholine receptor; Muscarinic receptor agonists; Muscarinic receptor antagonists; G protein; GTP[S] binding; (Unliganded receptor) (Hilf, G. (225) 245)

Cardiac muscle
Phosphodiesterase isoenzymes; Smooth muscle (aortic); Flosequinan; BTS 53 554; (Guinea-pig) (Frodsham, G. (211) 383)

Aging; Dihydropyridines; Ca^{2+} (extracellular); F344 rats; Isoproterenol (Ruch, S. (216) 393)

Cardiac muscle (electrophysiology of)
Taurine; Na^+ currents (fast); Ventricular myocytes (embryonic chick); Voltage clamp (whole-cell) (Satoh, H. (218) 83)

Cardiac muscle (skinned)
Ca^{2+} sensitization; Muscle regulation; Inorganic phosphate; EMD 53998 (Strauss, J.D. (227) 437)

Cardiac myocytes
Endothelin-1; Ca^{2+} (intracellular); Cell shortening (Qiu, Z. (214) 293)

Cardiac nerves
CGRP (calcitonin gene-related peptide); Capsazepine (Franco-Cereceda, A. (221) 183)

Cardiac sarcolemma
Dihydropyridine receptors; Ca^{2+} channels; Monoclonal antibodies; Purification (Tokumaru, H. (227) 363)

Cardiac sympathetic afferents
5-HT_3 receptors; Phenylbiguanide; Spinothalamic tract; Spinoreticular tract (Blair, R.W. (216) 119)

Cardiac ventricles
Phosphodiesterase III; Phosphodiesterase IV; Cardiotonic; Rolipram; (Guinea pig) (Muller, B. (225) 263)

Cardioprotection
Pindolol; Ischemia; Reperfusion; Sympathomimetic activity (intrinsic); (Rat) (Nasa, Y. (213) 171)

Cardiotonic
Phosphodiesterase III; Phosphodiesterase IV; Cardiac ventricles; Rolipram; (Guinea pig) (Muller, B. (225) 263)

Cardiovascular effects
Ca^{2+} channel antagonists; ω-Conotoxin GVIA; (Guinea-pig) (Bond, A. (218) 179)

Cardiovascular regulation
S-Nitrosothiols; Excitatory amino acid; Baroreceptor reflex; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Machado, B.H. (221) 179)

Cardiovascular responses
Clonidine; Phenylephrine; Sinoaortic denervation; (Conscious rat); (Intracerebroventricular) (Ricci, D. (212) 195)

Tachykinin; Neuropeptide K; Catecholamines; Autonomic regulation (Décarie, A. (213) 125)

Cardiovascular system
Kinins; Spinal cord; Catecholamines; Vagal reflex; C-fibers (Lopes, P. (210) 137)

Ca^{2+}-related inward currents
Vas deferens (guinea-pig); AMP-PNP (5′-adenylylimidophosphate); P_2 purinoceptors (Inomata, H. (217) 93)

Carrageenan
Bradykinin; Bradykinin receptor antagonists; Urate crystal; Zymosan; Scalding; Sponges (Damas, J. (211) 81)

Spinal cord; Thermal hyperalgesia; Antinociception; NMDA (N-methyl-D-aspartate); Opioids; (Rat); (Intrathecal) (Ren, K. (219) 235)

Carrageenin
Dextran; Nitric oxide (NO); Oedema; Vascular permeability (Ialenti, A. (211) 177)

Carvedilol
β-Adrenoceptor antagonists; Free radical; Superoxide; Neutrophils; Antioxidants (Yue, T.-L. (214) 277)

Ca^{2+} sensitivity
Smooth muscle (vascular); Aorta; Dibutyryl cAMP; Fura-2-Ca^{2+} signal; Forskolin; (Rat) (Abe, A. (211) 305)

Smooth muscle (vascular); Fluoride; Al^{3+}; G-protein; Protein kinase C (Kawase, T. (214) 39)

Ca^{2+} sensitization
Cardiac muscle (skinned); Muscle regulation; Inorganic phosphate; EMD 53998 (Strauss, J.D. (227) 437)

Ca^{2+} signals
Ouabain; Aorta (guinea-pig); Contraction; Na^+/Ca^{2+} exchangers (Iwamoto, T. (224) 71)

Castor-oil diarrhea
[D-Ala^2]deltorphin II; Gastrointestinal transit; Colonic bead expulsion; (I.c.v. and i.t. administration); (Rat) (Broccardo, M. (218) 69)

Catecholamine level
Gentamicin; Striatum; Hypothalamus; Adrenal medulla; Vas deferens (Mikami, M. (210) 91)

Catecholamine receptors
Sympathetic ganglia; Dopamine receptors; α-Adrenoceptors (Horn, P.T. (224) 103)

Dopamine D_2 receptors; Mutagenesis; Receptor binding (Mansour, A. (227) 205)

Catecholamines
Kinins; Spinal cord; Cardiovascular system; Vagal reflex; C-fibers (Lopes, P. (210) 137)

Propranolol; Atrium; Dopamine-β-hydroxylase (lung); Noradrenaline (Elayan, H. (212) 259)

Tachykinin; Neuropeptide K; Cardiovascular responses; Autonomic regulation (Décarie, A. (213) 125)

Interleukin-1; CRF (corticotropin-releasing factor) secretion; Hypothalamic perfusion (Cambronero, J.C. (219) 75)

Hypoxia/hypoglycemia; 2-Deoxyglucose; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Shibata, S. (221) 255)

Adrenoceptors; Inositol phosphates (Schwinn, D.A. (227) 433)

Catecholamine secretion
Nitric oxide (NO); Vasodilatation (adrenal medulla) (Breslow, M.J. (210) 105)

Cathartics
Prostaglandins; Anthraquinones; Diarrhoea (Nijs, G. (218) 199)

Cathepsin G
Heparin; Platelets; Neutrophils (Evangelista, V. (216) 401)

Tracheal epithelial cells; Leukocyte elastase (human) (Nahori, M.-A. (228) 213)

Cation blockers
Maitotoxin; Ca^{2+} channels; Liposomes (Murata, M. (227) 43)

Caudal ventrolateral medulla
Quipazine; L-Glutamate; Subretrofacial nucleus; Lateral tegmental field; Nucleus tractus solitarii (Vayssettes-Courchay, C. (211) 243)

Ca^{2+} uptake
Aorta; Noradrenaline; Protein kinase C; Staurosporine; Calphostin C; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

$^{45}Ca^{2+}$ uptake
Aorta (rat); Na^+ channel (silent); [^{14}C]Guanidinium uptake; Veratridine (Wermelskirchen, D. (219) 253)

Ba^{2+}; Nifedipine; Vas deferens; $^{45}Ca^{2+}$ efflux; Verapamil; Methoxamine (Hay, D.W.P. (225) 313)

Ipriflavone; Phosphoinositides; UMR-106 cells (Sortino, M.A. (226) 273)

CCK-7 analogues
Receptor binding; Amylase secretion; Gall bladder contractions; Anorexia; Analgesia; Sedation (Maletínská, L. (222) 233)

[^{125}I]CCK-8 binding
Tetronothiodin; CCK_B receptor antagonists; GH3 cells; Ca^{2+} (cytosolic); Fura-2 (Kuwahara, T. (221) 99)

CCK-8 (cholecystokinin octapeptide)
Caerulein; Lorglumide; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK_B receptors; Tetrapeptides; (Radioligand binding) (Harhammer, R. (209) 263)

Insulin secretion; CCK_A receptors; CCK_B receptors; L-364,718; L-365,260 (Karlsson, S. (213) 145)

CCK receptor agonists
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK receptor antagonists
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

Food intake; Bombesin; Satiety; Bombesin receptor agonists; Bombesin receptor antagonists (Laferrère, B. (215) 23)

Gastrin receptor antagonists; Gastric antisecretory activity; Proglumide; Lorglumide (Revel, L. (216) 217)

CCK_A receptor antagonists
Cholecystokinin receptor; Molecular modelling; Devazepide; L-364,718 (Van der Bent, A. (226) 327)

CCK_B receptor antagonists
Tetronothiodin; GH3 cells; Ca^{2+} (cytosolic); Fura-2; [^{125}I]CCK-8 binding (Kuwahara, T. (221) 99)

CCK_A receptors
Insulin secretion; CCK-8 (cholecystokinin-8); CCK_B receptors; L-364,718; L-365,260 (Karlsson, S. (213) 145)

CCK_B receptors
Cholecystokinin (CCK); Schizophrenia; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

CCK-8 (cholecystokinin octapeptide); Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK-8 (cholecystokinin octapeptide); Tetrapeptides; (Radioligand binding) (Harhammer, R. (209) 263)

Insulin secretion; CCK-8 (cholecystokinin-8); CCK_A receptors; L-364,718; L-365,260 (Karlsson, S. (213) 145)

Cholecystokinin; Synaptoneurosomes (guinea pig, cerebral cortex); Boc-[Leu^{31}]CCK-4 binding; Inositol phosphate accumulation; cAMP accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

CCK-8s (sulfated cholecystokinin octapeptide)
β-Endorphin; [Met^5]enkephalin; Tail-flick inhibition (Tseng, L.F. (215) 309)

Cd^{2+}
Cadmium chloride; Cadmium-metallothionein; Accumulation; (Rat) (Groten, J.P. (228) 23)

[^{14}C]2-Deoxyglucose
Cerebral energy metabolism; Cerebral blood flow; Methylxanthines; [^{14}C]Iodoantipyrine (Schroeder, H. (220) 217)

CD-1 mice
δ-Opioid receptor subtypes; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]deltorphin; CXBK mice; Antinociception (Raffa, R.B. (216) 453)

Cecum
Bicarbonate secretion; β-Adrenoceptors ('atypical'); β-Adrenoceptor agonists; β-Adrenoceptor antagonists (Canfield, P. (216) 293)

Cell culture
GH_4ZR_7 cells; Anterior pituitary; Prolactin; Dopamine D_2 receptors; Partial agonists; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Ifenprodil; Neurotoxicity; NMDA receptors (Graham, D. (226) 373)

Cell growth
Nifedipine; Diltiazem; Verapamil; Tumor cells; Ca^{2+} channels (Wöll, E. (212) 105)

Cell proliferation
Tamoxifen; Phospholipase A_2; Oviduct (Fayard, J.-M. (216) 127)

β-Cells
TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); ATP-sensitive potassium channel (Szewczyk, A. (226) 175)

Cell shortening
Endothelin-1; Cardiac myocytes; Ca^{2+} (intracellular) (Qiu, Z. (214) 293)

Central nervous system (CNS)
VIP (vasoactive intestinal polypeptide); Atropine; Chronic treatment; (Rat) (Petit, J.-M. (212) 79)

Striatum; Acetylcholine release; Ca^{2+} channel antagonists; Verapamil; Spontaneously hypertensive rat (SHR) (Tsuda, K. (216) 319)

Ethanol; $GABA_A$ receptors; Cl^- currents; Modulation; (Neurons) (Reynolds, J.N. (224) 173)

Central nucleus of the amygdala
Cocaine; Extracellular single unit; Cross-correlation; Microinjection; (Cat) (Ni, H. (224) 157)

Cerebellar diazepam-insensitive binding
Ro 15-4513; Substrate specificity; Alcohol sensitivity; (Selected rat lines) (Korpi, E.R. (213) 323)

Cerebellar granule cells
Nitric oxide (NO); Excitatory amino acids; NMDA (N-methyl-D-aspartate); S-Nitroso-N-acetylpenicillamine; Neurotrophic effects (Boje, K.M. (212) 151)

Glutamates; NMDA (N-methyl-D-aspartate); Quisqualate; Tricyclic antidepressants; Carbamazepine (Cai, Z. (219) 53)

$GABA_B$ receptors; GABA (γ-aminobuteric acid); Adenylyl cyclase (inhibition); cAMP; Baclofen (Holopainen, I. (227) 225)

Cerebellum
NMDA receptors; Nitroprusside; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

Metabotropic glutamate receptor; ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid); Purkinje cells; Granule cells; AP-3 ((L)-2-amino-3-phosphonopropionate) (East, S.J. (219) 395)

Benzodiazepine (receptor binding); Thermodynamics; Benzodiazepine receptor (type I) (Maguire, P.A. (226) 233)

Cerebral arteries
Endothelin-1; Peripheral arteries; Vasoconstriction; Ca^{2+} influx; Nifedipine; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Cerebral blood flow
Cerebral glucose metabolism; Iodoantipyrine; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

BY-1949; Cyclic nucleotides; Basilar artery; Endothelial cells (Sugawa, M. (215) 57)

BY-1949; Nucleus basalis of Meynert; (Rat) (Takao, A. (217) 101)

Cerebral energy metabolism; Methylxanthines; [^{14}C]2-Deoxyglucose; [^{14}C]Iodoantipyrine (Schroeder, H. (220) 217)

HA1077; Cerebral vasospasm; Subarachnoid hemorrhage (Satoh, S.-i. (220) 243)

Cerebral cortex
Aging; Muscarinic receptors; Peptides; Phosphoinositides; (Rat) (Pedigo, Jr., N.W. (225) 151)

Substance P; Inositol phosphates; Spinal cord; Anesthesia; Pentobarbital (Hasséssian, H. (227) 103)

Cerebral cortex (rat)
Rilmenidine; Oxazoline; Imidazoline; Guanidinium; α_2-Adrenoceptor subtypes (King, P.R. (218) 101)

Polyamines; [^{3}H]Nitrendipine binding; [^{3}H]Diltiazem binding; Cooperative effects (Schoemaker, H. (225) 167)

Ouabain binding site (high affinity); Melatonin; [^{3}H]Ouabain (Acuña Castroviejo, D. (226) 59)

Cerebral energy metabolism
Cerebral blood flow; Methylxanthines; [^{14}C]2-Deoxyglucose; [^{14}C]Iodoantipyrine (Schroeder, H. (220) 217)

Cerebral glucose metabolism
Cerebral blood flow; Iodoantipyrine; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

Cerebral infarction
Felbamate; Anticonvulsants; Cerebral ischemia; Neonate; Asphyxia neonatorum (Wasterlain, C.G. (212) 275)

Cerebral ischemia
bFGF (basic fibroblast growth factor); Hippocampus; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

Felbamate; Anticonvulsants; Neonate; Asphyxia neonatorum; Cerebral infarction (Wasterlain, C.G. (212) 275)

Ceruletide; Cholecystokinin (CCK); Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (214) 149)

Excitatory amino acids; Metabotropic receptors (Chiamulera, C. (216) 335)

Ceruletide; Cholecystokinin (CCK); Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (219) 487)

Ca^{2+} channel antagonists; NC-1100; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (224) 109)

Cerebral vasodilatation
ATP; Physostigmine; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

Cerebral vasospasm
HA1077; Subarachnoid hemorrhage; Cerebral blood flow (Satoh, S.-i. (220) 243)

Ceruletide
Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (214) 149)

Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (219) 487)

Cetirizine
Allergen; Leucocyte recruitment; Pleurisy (rat) (Pasquale, C.P. (223) 9)

C-fibers
Kinins; Spinal cord; Cardiovascular system; Catecholamines; Vagal reflex (Lopes, P. (210) 137)

C-fibre reflex
Spinal cord-skin preparation; Capsaicin; Substance P; Spantide; CGRP (calcitonin gene-related peptide) (Yanagisawa, M. (220) 111)

c-fos
Ethanol; Glutamate; NMDA (N-methyl-D-aspartate); Hybridization (in situ) (Morgan, P.F. (225) 217)

c-fos expression
Muscarinic receptor subtypes; Muscarinic receptor agonists; Stereochemistry (absolute); Superior cervical ganglion (rat); Hippocampal slice (rat); Ileum (guinea pig); Hybridization (in situ) (Pombo-Villar, E. (226) 317)

[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding
Cocaine; BTCP (N[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine); GBR 12935; Dopamine uptake inhibitors; Striatum (rat) (Reith, M.E.A. (227) 417)

C6 glioma cells
β-Adrenoceptors; cAMP; mRNA; Isoproterenol; Down-regulation (Bieck, P.R. (225) 171)

Idazoxan; Antidepressants; β-Adrenoceptors; Adenylyl cyclase; Protein kinase C (Manji, H.K. (227) 275)

Peripheral benzodiazepine receptors; Gliomas (human); Tumor models (rat); AA tumor (Takada, A. (228) 131)

CGP 12177
β-Adrenoceptors; Cardiac imaging; PET (positron emission tomography); CGP 26505; CGP 20712A (Van Waarde, A. (222) 107)

CGP 20712A
β-Adrenoceptors; Cardiac imaging; PET (positron emission tomography); CGP 12177; CGP 26505 (Van Waarde, A. (222) 107)

ICI 118,551; Isoprenaline; Noradrenaline release; β-Adrenoceptors (prejunctional) (Mian, M.A. (213) 47)

CGP 26505
β-Adrenoceptors; Cardiac imaging; PET (positron emission tomography); CGP 12177; CGP 20712A (Van Waarde, A. (222) 107)

CGP 35348
γ-Hydroxybutyrate; GABA (γ-aminobutyric acid); $GABA_B$ receptors; Hippocampus; Zn^{2+} (Xie, X. (212) 291)

CGP 36742
γ-Hydroxybutyrate; $GABA_B$ receptors; EPSP (excitatory postsynaptic potential); IPSP (inhibitory postsynaptic potential); Hippocampus (Xie, X. (223) 193)

CGP 37849
NMDA receptors; CGP39551; Dizocilpine; Spatial orientation task; (Rat) (Bischoff, C. (213) 269)

CGP 39551; Kindling; Anticonvulsant drugs; NMDA receptor antagonists; Seizures (Cotterell, K.L. (214) 285)

CGP 39551
NMDA receptors; CGP37849; Dizocilpine; Spatial orientation task; (Rat) (Bischoff, C. (213) 269)

CGP 37849; Kindling; Anticonvulsant drugs; NMDA receptor antagonists; Seizures (Cotterell, K.L. (214) 285)

CGP 41251
Neutrophil; Respiratory burst; Degranulation; Protein kinase C; Staurosporin (Krause, K.-H. (227) 221)

CGRP (calcitonin gene-related peptide)
Blood-aqueous barrier; Capsaicin; Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

Mesentery (rat); Capsaicin; Saponin; L-Arginine; N^{ω}-Nitro-L-arginine methyl ester (Li, Y. (210) 23)

Endothelium-dependent vasorelaxation; Nitric oxide (NO); L-NMMA (N^{G}-monomethyl-L-arginine); L-NOARG (N^{G}-nitro-L-arginine) (Gray, D.W. (212) 37)

Veratridine; Nifedipine; ω-Conotoxin; Sensory neurons; Capsaicin (Tramontana, M. (212) 137)

Atherosclerosis; WHHL rabbit; Mesenteric artery; Sympathetic neurotransmission; Neuropeptide Y (NPY) (Stewart-Lee, A.L. (216) 167)

Circulatory filling pressure (mean); Venous tone; Noradrenaline; Ganglionic blockers (Abdelrahman, A. (217) 185)

Nitric oxide (NO); Capsaicin; Sensory neurons; L-NAME (N^{G}-nitro-L-arginine methyl ester); Gastric mucosa (Whittle, B.J.R. (218) 339)

CGRP receptors; Autoradiography; Coronary arteries; Neuropeptides (Knock, G.A. (219) 415)

Capsaicin; Skin; Blood flow (Hughes, S.R. (219) 481)

Adenosine; Sensory nerves; Mesenteric arterial bed (Rubino, A. (220) 95)

Spinal cord-skin preparation; C-fibre reflex; Capsaicin; Substance P; Spantide (Yanagisawa, M. (220) 111)

Capsazepine; Cardiac nerves (Franco-Cereceda, A. (221) 183)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

CGRP receptors
CGRP (calcitonin gene-related peptide); Autoradiography; Coronary arteries; Neuropeptides (Knock, G.A. (219) 415)

CGS 21680
Adenosine receptors; CGS 22492; Smooth muscle (vascular); Coronary artery (human); Mammary artery (internal) (Makujina, S.R. (221) 243)

CGS 22492
Adenosine receptors; CGS 21680; Smooth muscle (vascular); Coronary artery (human); Mammary artery (internal) (Makujina, S.R. (221) 243)

CGS 9343B
Ca^{2+} channel; Calmodulin; Patch clamp; Fura-2 (Neuhaus, R. (226) 183)

Channel block
Ketamine; L-Glutamate receptors; Single channels; Muscle (locust) (Macdonald, A.G. (210) 223)

CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate)
DL-Propranolol; Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); N^{G}-Nitro-L-arginine; Hindquarters (rat) (Mota-Filipe, H. (213) 227)

Characterization
Dopamine D_1 receptors; Mesangial (rat) (Bryson, S.E. (225) 1)

Chemical cross-linking
Endothelin receptors; ^{125}I-Endothelin-1; Spinal cord (human, pig); Autoradiography (quantitative receptor) (Niwa, M. (225) 281)

Chemiluminescence
Parainfluenza 3 virus; Airway responsiveness (in vivo); Inflammatory cell count; (In vitro activation) (Folkerts, G. (228) 219)

Chlordiazepoxide
Buspirone; Anxiolytics; (Nonreward); (Rat) (Panickar, K.S. (210) 307)

Hippocampus; Benzodiazepine; Muscimol; GABA (γ-aminobutyric acid); Memory (working, reference) (Ohno, M. (219) 245)

Tandospirone; Buspirone; Ipsapirone; Azapirones; Anxiolytics; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Chlorethylclonidine
α-Adrenoceptors; α_1-Adrenoceptor subtypes; WB 4101; Arteries (Oriowo, M.A. (216) 415)

Chlormethiazole
$GABA_A$ receptors; Glycine receptors; Patch-clamp; Anaesthetics (general); Anticonvulsants (Hales, T.G. (210) 239)

p-Chlorophenylalanine
L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

Ketanserin; Atropine; Xylamidine; MDL 72222 (Bond, E.F. (217) 127)

R(+)-Zacopride; S(−)-Zacopride; Aversive behaviour; (Rat); (Mouse) (Barnes, N.M. (218) 15)

Chlorpheniramine
5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Chlorpromazine
Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Cholecystokinin (CCK)
CCK_B receptors; Schizophrenia; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

Iris sphincter muscle; Lorglumide; Loxiglumide; Ciliary muscle (Almegård, B. (211) 183)

Ceruletide; Cerebral ischemia; Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (214) 149)

[Met^5]enkephalin; [Leu^5]enkephalin; Neurotensin; Substance P; 6-Hydroxydopamine (6-OHDA); L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Ceruletide; Cerebral ischemia; Neuronal cell death; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (219) 487)

Morphine; EEG power spectra (Hudson, G.M. (221) 217)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

CCK_B receptors; Synaptoneurosomes (guinea pig, cerebral cortex); Boc-[Leu^{31}]CCK-4 binding; Inositol phosphate accumulation; cAMP accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

Cholecystokinin receptor
CCK_A receptor antagonists; Molecular modelling; Devazepide; L-364,718 (Van der Bent, A. (226) 327)

Cholesterol
Oxysterol; Intercellular communication; Smooth muscle cells (Zwijsen, R.M.L. (228) 115)

Choline precursors
Scopolamine; Passive avoidance; Acetylcholine; Acetylcholine release; Hippocampus (Sigala, S. (211) 351)

Cholinergic bronchospasm (central)
(R)-α-Methylhistamine; Histamine H_1 receptors; Histamine H_3 receptors (Hey, J.A. (211) 421)

Cholinergic drugs
Hypoxia/hypoglycemia; 2-Deoxyglucose uptake; Hippocampus; CA1 field potentials; (In vitro) (Shibata, S. (221) 113)

Cholinergic nerves
Bronchospasm; Capsaicin; Neurokinin A; Substance P; Adrenergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Cholinergic neurons
ω-Conotoxin GVIA; Neurotransmitter release; NANC (non-adrenergic, non-cholinergic) neurons; Airways; (Guinea-pig) (Boot, J.R. (219) 123)

Aging; Stomach (rat); Non-adrenergic, non-cholinergic (NANC); VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Smits, G.J.M. (223) 97)

Cholinergic neurotransmission
Gastric fundus (rat); VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Lefebvre, R.A. (221) 235)

Cholinergic system
Nefiracetam (DM-9384); Carbon monoxide (CO); Amnesia (delayed); Passive avoidance; Scopolamine; (Mouse) (Hiramatsu, M. (216) 279)

Cholinesterase inhibition
Phrenic nerve; K^+-stimulated Ca^{2+}-independent efflux of [^{3}H]acetylcholine; Vesamicol; Acetylcholine carrier (Wessler, I. (221) 371)

Cholinomimetics
Protein kinase C; Trachealis (bovine); Smooth muscle contraction; Bronchodilators (Langlands, J.M. (227) 131)

Choroid plexus
1,25-Dihydroxyvitamin D_3 binding; 1,25-Dihydroxyvitamin receptors; Ca^{2+} (Walters, M.R. (213) 309)

C-type natriuretic peptide-22; ANP (atrial natriuretic peptide); ANP receptors; Subfornical organ; (Rat) (Himeno, A. (215) 337)

Chromaffin cells
Epinephrine; Norepinephrine; Acetylcholine; Glycine (Yadid, G. (221) 389)

Chronic obstructive pulmonary disease
Alveolar macrophages; cAMP; Asthma; Adenylyl cyclase; Inflammatory mediators; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

Chronic stress
Muscarinic receptors; Autoradiography; Supersensitivity; Hippocampus; Striatum (González, A.M. (223) 25)

Chronic treatment
A-69024; Dopamine D_1 receptors; Dopamine D_2 receptors; SCH 23390; SCH 39166; SK&F 38393 (Lappalainen, J. (210) 195)

VIP (vasoactive intestinal polypeptide); Atropine; Central nervous system (CNS); (Rat) (Petit, J.-M. (212) 79)

Cibenzoline
Insulin secretion; Glycemia; Imidazoline; Pancreas; (Rat) (Bertrand, G. (214) 159)

Cigarette smoke
Blood pressure; CP-96,345; Heart; NK_1 receptor antagonists; Substance P (Delay-Goyet, P. (222) 213)

Tachykinin receptor antagonists; Trachea; Plasma extravasation; (Rat) (Morimoto, H. (224) 1)

Ciliary muscle
Cholecystokinin (CCK); Iris sphincter muscle; Lorglumide; Loxiglumide (Almegård, B. (211) 183)

Cirazoline
Paraventricular hypothalamus; α_1-Adrenoceptors (Davies, B.T. (210) 11)

Circadian rhythms
5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptors; Wheel-running rhythm (Tominaga, K. (214) 79)

Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Suprachiasmatic nucleus; 2-Deoxyglucose uptake; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); $GABA_A$ receptors; Benzodiazepine receptors (Tominaga, K. (217) 79)

Circling
Dynorphin A-(1–13); Methamphetamine; Mr 2266; Rearing; (Mouse) (Ukai, M. (222) 7)

Circling behaviour
Dopamine D_1 receptors; Dopamine D_2 receptors; Adenylate cyclase; Stereotyped behaviour; Locomotor activity (Arnt, J. (213) 259)

Circulatory filling pressure (mean)
CGRP (calcitonin gene-related peptide); Venous tone; Noradrenaline; Ganglionic blockers (Abdelrahman, A. (217) 185)

Angiotensin II; Sympathetic nervous system (Tabrizchi, R. (219) 141)

Cisapride
5-HT (5-hydroxytryptamine, serotonin); 5-Methoxytryptamine (5-MeOT); ICS 205-930; $5\text{-}HT_4$ receptors (Meulemans, A.L. (212) 51)

Cisplatin
5-HT_3 receptor antagonists; Zacopride; GR38032F; Dexamethasone; Taste aversion (conditioned) (Mele, P.C. (218) 229)

5-HT receptors; 5-HT_3 receptor antagonists; 5-HT_3 receptor agonists; Emesis; (Pigeon) (Preziosi, P. (221) 343)

Pt-DNA adducts; Enzyme-linked immunosorbent assay (ELISA); Epitope; Cultured cells (Vrána, O. (226) 5)

Citalopram
5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Citric acid
Cough; α_2-Adrenoceptor agonists; GABA receptor agonists; (Conscious guinea-pig) (Callaway, J.K. (220) 187)

Cl^- activity (intracellular)
Anthracene-9-carboxylic acid (9AC); DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid); Isoproterenol; Cardiac cells (guinea-pig) (Shida, S. (212) 267)

Class III activity
Ibutilide fumarate; Antiarrhythmics; Refractory period; Conduction time (Cimini, M.G. (222) 93)

Cl^- channels
Vagus nerve; Nedocromil sodium; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulphonic acid) (Jackson, D.M. (221) 175)

Cl^- currents
Ethanol; $GABA_A$ receptors; Modulation; Central nervous system (CNS); (Neurons) (Reynolds, J.N. (224) 173)

Cl^- flux
Emotionality; GABA (γ-aminobutyric acid); Diazepam; Pentobarbital; (Mouse) (Mihic, S.J. (218) 283)

Cloned subtypes
Neurosteroid; $GABA_A$ receptor; *Xenopus* oocyte expression (Zaman, S.H. (225) 321)

Clonidine
Rilmenidine; Azepexole; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Phenylephrine; Sinoaortic denervation; Cardiovascular response; (Conscious rat); (Intracerebroventricular) (Ricci, D. (212) 195)

Rilmenidine; Noradrenaline release; Voltammetry (in vivo); α_2-Adrenoceptors; Hypothalamus (Suaud-Chagny, M.F. (213) 305)

Microdialysis; Noradrenaline; Hippocampus; Morphine withdrawal (Done, C. (215) 333)

α-Adrenoceptors; Baroreceptors; Haemorrhage; Yohimbine; (Rabbit) (Evans, R.G. (216) 265)

α_2-Adrenoceptors (presynaptic); Aspartate; Glutamate; GABA (γ-aminobutyric acid); Brain (rat) (Kamisaki, Y. (217) 57)

α_2-Adrenoceptor subtypes; WB4101; Imiloxan; Dexmedetomidine; ST-91 (Takano, Y. (219) 465)

Fos; α_2-Adrenoceptors; Yohimbine; Guanabenz (Tsujino, T. (226) 69)

Norepinephrine; α_2-Adrenoceptors; Morphine; μ-Opioid receptors; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

Cloning of receptors
G-protein-coupled receptors; Neuropeptides; Neurokinin-type receptors; Secretin-type receptors (Burbach, J.P.H. (227) 1)

Clorgyline
[^{3}H]Brofaromine; MAO-A (monoamine oxidase A); Brofaromine binding; Tyramine; Intestine (rat) (Waldmeier, P.C. (216) 243)

Cloricromene
Tumor necrosis factor (TNF-α); Endotoxin shock (Squadrito, F. (210) 107)

Platelet aggregation; Antiplatelet compounds; Polymorphonuclear cells (Mollace, V. (222) 181)

Clozapine
5-HT_{1A} receptors; Antipsychotic drugs (Mason, S.L. (221) 397)

Cl^- transport
Epilepsy; 5-HT (5-hydroxytryptamine, serotonin); GABA (γ-aminobutyric acid); Acetylcholine; Brain; (Mouse) (Inoue, M. (221) 135)

c-myc
Prolactin; Smooth muscle (vascular); Gene expression; Hypertension; Ornithine decarboxylase (Sauro, M.D. (225) 351)

CNK-602A
Spontaneously epileptic rat (SER); Thyrotropin-releasing hormone analogs; Antiepileptic effect; Dopamine (Renming, X. (223) 185)

C-type natriuretic peptide (CNP)
Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Glioma cells (rat); Receptor binding; cGMP (Eguchi, S. (225) 79)

Co^{2+}
Intracellular Ca^{2+}; Fura-2; Ca^{2+} channels; Ca^{2+} ionophore; La^{3+} (Horváth, G. (225) 305)

Cocaine
Ibogaine; Dopamine; Nucleus accumbens; Striatum; Microdialysis; Locomotor activity (Maisonneuve, I.M. (212) 263)

Cocaine methiodide; Blood pressure; Heart rate; Norepinephrine; (Squirrel monkey) (Schindler, C.W. (213) 99)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Dopamine neurons; Withdrawal; Ventral tegmental area; Electrophysiology (Ackerman, J.M. (218) 171)

Place preference; Naltrindole (Menkens, K. (219) 345)

GBR-12783; [^{3}H]Methylphenidate; Stimulants; Dopamine transporters (Deutsch, H.M. (220) 173)

5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropic hormone); Prolactin; Oxytocin; Renin (Levy, A.D. (221) 121)

Ethanol; Morphine; Amphetamine; MK-801; SL 82.0715; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Central nucleus of the amygdala; Extracellular single unit; Cross-correlation; Microinjection; (Cat) (Ni, H. (224) 157)

Dopamine transport; N-Ethylmaleimide alkylation; d-Amphetamine; [^{3}H]Mazindol binding (Johnson, K.M. (227) 411)

[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding; BTCP (N[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine); GBR 12935; Dopamine uptake inhibitors; Striatum (rat) (Reith, M.E.A. (227) 417)

Cocaine (chronic)
Dopamine; Addiction (Imperato, A. (212) 299)

Cocaine methiodide
Cocaine; Blood pressure; Heart rate; Norepinephrine; (Squirrel monkey) (Schindler, C.W. (213) 99)

Cognition enhancers
Long-term potentiation (LTP); Hippocampus; Dentate gyrus; Perforant path stimulation; (Rat); (In vivo) (Molnár, P. (215) 17)

CO-induced amnesia
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Learning; Memory; Delayed amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

Cold stress
5-HT receptor subtypes; 5-HT turnover; Behavioural responses; Glucose; Corticosterone (Zamfir, O. (219) 261)

Colon (human)
GABA (γ-aminobutyric acid); Baclofen; Jejunum (human); Intestinal motility (Gentilini, G. (217) 9)

Colonic bead expulsion
[D-Ala^2]deltorphin II; Castor-oil diarrhea; Gastrointestinal transit; (I.c.v. and i.t. administration); (Rat) (Broccardo, M. (218) 69)

Colonic epithelial cell
Muscarinic receptor subtype; T84 cell; Phosphoinositides; Arachidonic acid (Dickinson, K.E.J. (225) 291)

Colonic motility
Na^+ pump; Na^+/K^+ pump; Membrane potential; Smooth muscle (Barajas-López, C. (221) 51)

Compound 48/80
Sympathetic ganglia (bullfrog); Autonomic ganglia; Ganglionic transmission; Neuronal excitability; Spike afterhyperpolarization (Heppner, T.J. (213) 427)

Guanine nucleotide-binding proteins (small); rho proteins; ADP-ribosyltransferase C3 (*Clostridium botulinum*); Melittin; Mast cell degranulating peptide (Koch, G. (226) 87)

Conantokin
NMDA receptor; Oocytes (*Xenopus*) (Hammerland, L.G. (226) 239)

Conditioned avoidance response
Dopamine D_1 receptors; Dopamine D_2 receptors; (In vivo binding) (McQuade, R.D. (215) 29)

Conditioned drug effects
Apomorphine; 6-Hydroxydopamine (6-OHDA); Pentobarbital; Rotational behaviour; Drug discrimination (Silverman, P.B. (212) 165)

Conditioned place preference
Etonitazene; Morphine (Sala, M. (217) 37)

Conduction time
Ibutilide fumarate; Antiarrhythmics; Refractory period; Class III activity (Cimini, M.G. (222) 93)

Co-neurotransmission
Noradrenaline; Neuropeptide Y (NPY) (Montastruc, P. (213) 159)

Conflict
Tandospirone; Buspirone; Ipsapirone; Azapirones; Chlordiazepoxide; Anxiolytics; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

ω-Conotoxin
Sympathetic nerves; Hypertension; Vasodilatation (Pruneau, D. (211) 329)

Veratridine; CGRP (calcitonin gene-related peptide); Nifedipine; Sensory neurons; Capsaicin (Tramontana, M. (212) 137)

Insulin secretion; Ca^{2+} channels (Sher, E. (216) 407)

Morphine; Analgesia; Withdrawal syndrome (Basilico, L. (218) 75)

Ca^{2+} channels; Ca^{2+} influx; Dihydropyridines; Transmitter release (Lundy, P.M. (225) 51)

ω-Conotoxin GVIA
Ca^{2+} channel antagonists; Cardiovascular effects; (Guinea-pig) (Bond, A. (218) 179)

Neurotransmitter release; Cholinergic neurons; NANC (non-adrenergic, non-cholinergic) neurons; Airways; (Guinea-pig) (Boot, J.R. (219) 123)

Contractile force
Digitalis toxicity; Na^+ activity (intracellular); Ca^{2+} overload; K^+; Na^+ (Abete, P. (211) 399)

Ventricular papillary muscle; Action potentials; K^+ channel openers; Sulfonylurea antidiabetics; P_2 purinoceptor agonists (Bott, A. (213) 141)

Contractile responses
Diabetes mellitus; Mesenteric arteries; Noradrenaline; Inositol phosphates; Inositol 1,4,5-trisphosphate (Abebe, W. (225) 29)

Contraction
Estrogen; Angiotensin II; Aorta (rat); Norepinephrine (Cheng, D.Y. (215) 171)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Ouabain; Aorta (guinea-pig); Ca^{2+} signals; Na^+/Ca^{2+} exchangers (Iwamoto, T. (224) 71)

Contraction-relaxation
Iris sphincter (dog); Smooth muscle; Muscarinic stimulation; cAMP; Inositol trisphosphate; Ca^{2+}; Cross-talk (Abdel-Latif, A.A. (226) 351)

Converting enzyme inhibitors
Angiotensin-converting enzyme; Captopril; Angiotensinogen; Solution hybridization/RNase protection (Ye, M.-Q. (227) 79)

Convulsions
Melatonin; 3-Mercaptopropionic acid; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (210) 253)

Mexiletine; Antiarrhythmic actions; Ischaemic arrhythmias; Pharmacokinetics (Igwemezie, L.N. (210) 271)

4-Aminopyridine; NMDA receptors; Wet-dog shakes (Fragoso-Veloz, J. (221) 275)

ucb L059; Epileptogenesis; Petit-mal; Epilepsy (Gower, A.J. (222) 193)

Cooperative effects
Polyamines; [^{3}H]Nitrendipine binding; [^{3}H]Diltiazem binding; Cerebral cortex (rat) (Schoemaker, H. (225) 167)

Copper
21-Aminosteroids; Antioxidants; Lipid peroxidation; Erythrocytes; Plasma (Fernandes, A.C. (220) 211)

Cork gnawing
Tandospirone; Buspirone; Ipsapirone; Azapirones; Chlordiazepoxide; Anxiolytics; Conflict; Punishment; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Coronary arteries
Sulfonylureas; Glibenclamide; Cromakalim; K^+ channels; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

CGRP (calcitonin gene-related peptide); CGRP receptors; Autoradiography; Neuropeptides (Knock, G.A. (219) 415)

Coronary artery (dog)
E4080; K^+ channel openers; Ca^{2+} channel antagonists; Ca^{2+} concentration (intracellular); Vasodilators (Okada, Y. (218) 259)

Coronary artery (human)
Adenosine receptors; CGS 21680; CGS 22492; Smooth muscle (vascular); Mammary artery (internal) (Makujina, S.R. (221) 243)

Coronary artery (porcine)
Nitroglycerin; Nitroprusside; Tolerance; Zaprinast; Phosphodiesterase inhibitors (Merkel, L.A. (216) 29)

Endothelin-1; Prostaglandin E_2; Smooth muscle (vascular) (Suzuki, S. (217) 97)

Coronary artery occlusion
Arrhythmias; Myocardial ischaemia; Reperfusion; Platelet aggregation; 5-HT receptor antagonists (Ellis, A.M. (219) 97)

Coronary artery relaxation
Progesterone; Endothelium; Ca^{2+} influx; K^+ conductance (Jiang, C. (211) 163)

Coronary circulation
Endothelin-1; Vascular permeability (Filep, J.G. (219) 343)

Coronary vascular resistance
Dromotropic effects; Inotropic effects; Ventricular tachycardia; Endothelial messengers; Arrhythmias (Balcells, E. (210) 1)

Cortex (human)
[^{3}H]CPP ([^{3}H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid); NMDA receptors; Brain (rat); Alzheimer's disease (Porter, R.H.P. (225) 195)

Cortical cells
Human immunodeficiency virus type 1 (HIV-1); Apoptosis; Memantine; NMDA receptor; gp120 (Müller, W.E.G. (226) 209)

Cortical neurons
NMDA (N-methyl-D-aspartate); Arachidonic acid; Somatostatin; Phospholipase A_2 (Tapia-Arancibia, L. (225) 253)

Corticosteroids
Stress; Hippocampus; Morphology; 5-HT (5-hydroxytryptamine, serotonin); Tianeptine (Watanabe, Y. (222) 157)

Fibroblasts (lung); Nitric oxide (NO); Nitrite; Interferon-γ; Endotoxin/lipopolysaccharide; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

Corticosterone
Cold stress; 5-HT receptor subtypes; 5-HT turnover; Behavioural responses; Glucose (Zamfir, O. (219) 261)

5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sex differences; Tolerance; Hypothermia (Nakano, Y. (219) 339)

Corticostriatal pathways
Dopamine; Ascorbate; L-Glutamate; Apomorphine; Scopolamine; (Rat) (Desole, M.S. (219) 67)

Corticotropin-releasing hormone (CRH)
Autonomic ganglia; Enteric nervous system; Synaptic transmission; Intestine (Hanani, M. (211) 23)

Co-transmission
Blood vessels (rabbit); Purinergic nerve stimulation; Ethanol (Bulloch, J.M. (211) 1)

Cotransport
Torasemide; Bumetanide; Red blood cells; Hypertension; Diuretics (loops) (Masereel, B. (219) 385)

Cough
Citric acid; α_2-Adrenoceptor agonists; GABA receptor agonists; (Conscious guinea-pig) (Callaway, J.K. (220) 187)

Cough reflex
Ca^{2+} channels; Antitussive effect; Flunarizine; Nifedipine; Verapamil (Kamei, J. (212) 61)

Angiotensin-converting enzyme inhibitors; Enalapril; Diuretics; Hydrochlorothiazide (Kamei, J. (213) 137)

σ-Sites; Antitussive effects; (+)-SK&F 10,047; Pentazocine; DTG (1,2-di-(2-tolyl)guanidine); Dextromethorphan (Kamei, J. (224) 39)

CP-96,345
Substance P; EDRF (endothelium-derived relaxing factor); Neurokinin A; Neurokinin B; Aorta (rabbit) (Rubino, A. (212) 237)

NK_1 receptors; Tachykinin receptor antagonists; FR 113680; L 668,169; Spantide II (Patacchini, R. (215) 93)

Substance P; Ca^{2+} channels (Schmidt, A.W. (215) 351)

Substance P; Ca^{2+} channels (Schmidt, A.W. (219) 490)

Blood pressure; Heart; NK_1 receptor antagonists; Substance P; Cigarette smoke (Delay-Goyet, P. (222) 213)

(±)-CP-96,345
Plasma protein extravasation; Neurogenic inflammation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

Neurokinin receptors; Electrical field stimulation; SR 48968; Bronchus (guinea-pig); Non-cholinergic contraction (Martin, C.A.E. (224) 137)

m-CPP (1-3-chlorophenyl)piperazine)
5-HT receptor agonists; 5-HT receptor antagonists; Blood pressure; Plasma renin activity; Vasopressin; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

[^{3}H]CPP binding
NMDA receptors; HA-966; Glycine; Polyamines (Porter, R.H.P. (227) 83)

[^{3}H]CPP ([^{3}H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid)
NMDA receptors; Brain (rat); Cortex (human); Alzheimer's disease (Porter, R.H.P. (225) 195)

CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one)
5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

CRF (corticotropin-releasing factor) secretion
Interleukin-1; Hypothalamic perfusion; Catecholamines (Cambronero, J.C. (219) 75)

Dynorphin release; Analgesia; κ-Opioid receptors; Spinal cord (Song, Z.H. (222) 27)

σ Receptor ligands; Gastric acid secretion; Gastric emptying (Yoneda, M. (223) 197)

Cromakalim
K^+ channel opener; NIP-121; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Sulfonylureas; Glibenclamide; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Phentolamine; α-Adrenoceptors; Pinacidil; K^+ channels; Trachea (Bang, L. (211) 235)

Leukotrienes; Endothelium; Heart (isolated, guinea-pig) (McLeod, J.D. (212) 67)

Dihydralazine; Hydralazine; Nitroprusside; K^+ channels; Smooth muscle (vascular) (Thirstrup, S. (215) 177)

Calcium channels; Vasodilators; Mesenteric artery (human); Smooth muscle (vascular) (Smirnov, S.V. (217) 105)

Cross-tolerance; Uterus; RP 49356; K^+ channels (Piper, I. (219) 347)

Ion flux; K^+ channels; Rb^+; Smooth muscle relaxation (Foster, K.A. (222) 143)

Calmodulin antagonist; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Cross-correlation
Central nucleus of the amygdala; Cocaine; Extracellular single unit; Microinjection; (Cat) (Ni, H. (224) 157)

Cross-talk
Iris sphincter (dog); Smooth muscle; Muscarinic stimulation; cAMP; Inositol trisphosphate; Ca^{2+}; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Cross-tolerance
Uterus; Cromakalim; RP 49356; K^+ channels (Piper, I. (219) 347)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Antinociceptive tolerance (Noble, F. (223) 83)

CR1 receptors
Peritoneal cells (rat); Phagocytosis (bacterial); Eicosanoids; Indomethacin; Fc receptors (Coquette, A. (226) 1)

Crude oil (exposure)
Diesel-2 (exposure); DNA damage; Oil slicks; ^{32}P-Postlabeling assay (Kurelec, B. (228) 51)

5-CT (5-carboxyamidotryptamine)
5-HT (5-hydroxytryptamine, serotonin); Sumatriptan; 5-HT_{1D} binding site (Beer, M.S. (213) 193)

C-type natriuretic peptide-22
ANP (atrial natriuretic peptide); ANP receptors; Subfornical organ; Choroid plexus; (Rat) (Himeno, A. (215) 337)

Cultured cells
Cisplatin; Pt-DNA adducts; Enzyme-linked immunosorbent assay (ELISA); Epitope (Vrána, O. (226) 5)

Curcumin
Antiproliferative effect; Mononuclear cells; Smooth muscle cells (Huang, H.-C. (221) 381)

Cutaneous anaphylaxis (passive)
Cysteinyl-leukotriene; Cysteinyl-leukotriene receptor antagonists; (Rat); (Mouse) (Miura, T. (221) 333)

CXBK mice
δ-Opioid receptor subtypes; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]deltorphin; CD-1 mice; Antinociception (Raffa, R.B. (216) 453)

(−)-[^{125}I]cyanopindolol
β-Adrenoceptors (atypical); Skeletal muscle; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

Cyclic nucleotides
Gastric fundus (rat); Non-adrenergic non-cholinergic (NANC) relaxation; IBMX (3-Isobutyl-1-methylxanthine); Zaprinast (Barbier, A.J. (210) 315)

BY-1949; Cerebral blood flow; Basilar artery; Endothelial cells (Sugawa, M. (215) 57)

Bradykinin; Angiotensin-converting enzyme; Smooth muscle; Phospholipase A_2; Lipoxygenase (Rodrigues, M.S. (216) 357)

Cyclo-oxygenase inhibitor
Isoliquiritigenin; Aldose reductase inhibitor; Anti-platelet action (Tawata, M. (212) 87)

Cyclo-oxygenase products
VIP (vasoactive intestinal polypeptide); Helodermin; Leukotriene D_4; Arachidonic acid; Lung (perfused, guinea-pig) (Conroy, D.M. (218) 43)

Cyclopiazonic acid
Endothelin-1; Aorta (rat); Smooth muscle (vascular); Ca^{2+} (Shimamoto, H. (216) 225)

2,5-Di-(tert-butyl)-1,4-benzohydroquinone; Ca^{2+} permeability; A7r5 aortic cells (Missiaen, L. (227) 391)

Cycloprotobuxine-A
Action potentials; $\dot{V}$; Antiarrhythmic agents; Myocardium; (Use-dependent block) (Wang, Y.-X. (222) 219)

Cyclopyrrolones
Benzodiazepine receptors; Body temperature; (Full and partial agonists); (Antagonists) (Jackson, H.C. (216) 23)

D-Cycloserine
Aging; Glycine; Memory; NMDA receptors; Senescence; (Mouse) (Flood, J.F. (221) 249)

Quinolinic acid; Learning deficit (Schuster, G.M. (224) 97)

Cyclosporin A
Arthritis; MDP-Lys(L18); Adjuvant arthritis; (Rat) (Sugawara, T. (228) 147)

Cyclosporins
Endothelin-1; Hypertension; Mesenteric artery; Blood pressure (Takeda, Y. (213) 445)

Cytotoxicity; B type chronic lymphocytic leukemia (B-CLL) (Larsson, R. (228) 237)

CYP1A2 recombinant expression vector
Heterologous expression; Cytochrome P450IA2 (human); V79 Chinese hamster cells; P450-dependent enzymatic activity (Wölfel, C. (228) 95)

[^{125}I]CYP ([^{125}I]iodo-cyanopindolol)
α-Adrenoceptors; β-Adrenoceptors; Aorta; Jugular vein; Autoradiography; [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

Cyproheptadine
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Vas deferens (rabbit); Pizotifen; Ketotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

L-Cysteine
Acetylcholine; cGMP; SIN-1 (3-morpholinosydnonimine); Sodium nitrite; Vascular smooth muscle relaxation (Arvola, P. (214) 289)

Cysteinyl-leukotriene
Cysteinyl-leukotriene receptor antagonists; Cutaneous anaphylaxis (passive); (Rat); (Mouse) (Miura, T. (221) 333)

Cysteinyl-leukotriene receptor antagonists
Cysteinyl-leukotriene; Cutaneous anaphylaxis (passive); (Rat); (Mouse) (Miura, T. (221) 333)

Cystometrogram
Muscarinic receptor subtypes; Stereoselectivity; 3-Quinuclidinyl atrolactate stereoisomers; 3-Quinuclidinyl xanthene-9-carboxylate enantiomers (Noronha-Blob, L. (211) 97)

Cytochrome P-450
Plasminogen activator (tissue-type); Von Willebrand factor; Endothelial cell secretion; Phospholipase C; Pertussis toxin (Tranquille, N. (213) 285)

σ Receptors; Phenobarbital; 3-Methylcholanthrene (Basile, A.S. (227) 95)

Cytochrome P450IA2 (human)
Heterologous expression; CYP1A2 recombinant expression vector; V79 Chinese hamster cells; P450-dependent enzymatic activity (Wölfel, C. (228) 95)

Cytoplasmic proteins
Neurotransmitter release; Neurosecretory cells; Cytoskeleton; Ca^{2+}; Calmodulin; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Cytoskeleton
Neurotransmitter release; Neurosecretory cells; Cytoplasmic proteins; Ca^{2+}; Calmodulin; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Cytosolic-free Ca^{2+}
Amitriptyline; Xerostomia; α_1-Adrenoceptors; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

Cytostatic-induced emesis
5-HT_3 receptor antagonists; [^{3}H]GR65630 binding (Fernández, A.G. (222) 257)

Cytotoxicity
B type chronic lymphocytic leukemia (B-CLL); Cyclosporins (Larsson, R. (228) 237)

DADLE (D-Ala^2,D-Leu^5]enkephalin)
Naltriben; δ-Opioid receptor subtypes; DSLET ([D-Ser^2,Leu^5,Thr^6] enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Sofuoglu, M. (216) 273)

[^{3}H]DAGO binding
Opiates; Development; Hypothalamus (Hammer, Jr., R.P. (209) 253)

DAGO ([D-Ala^2,N-MePhe^4,Gly^5-ol]enkephalin)
Temperature; Opioid receptors; Myenteric plexus; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-50,488H (Garaulet, J.V. (223) 19)

Dahl rat
Captopril; ACE inhibitors; (Intracerebroventricular administration) (Lark, L.A. (222) 33)

DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2)
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

DAMGO ([D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin)
Opioid receptor agonist/antagonist (mixed); Nor-binaltorphimine; Ileum (guinea-pig) (Berzetei-Gurske, I.P. (212) 283)

DPLPE ([D-Pen^2,L-Pen^5]enkephalin); SKF 38393; Naltrindole; Locomotor activity; (Mouse) (Toyoshi, T. (213) 25)

Danazol
13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$; Ovarian steroids; Gonadotropin; Ovary; Uterus (Kogo, H. (211) 69)

Dantrolene
Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (209) 33)

DAT-582
5-HT_3 receptor antagonists; Granisetron; (Enantiomer) (Yoshida, N. (216) 435)

DAU 6214
Oesophagus; 5-HT_4; BIMU 1; BIMU 8; Benzimidazolones (Baxter, G.S. (212) 225)

DAU 6215
5-HT_3 receptors; Dopamine neurons; Antipsychotic drugs; Depolarization block (Prisco, S. (214) 13)

Dazmegrel
PAF (platelet-activating factor, PAF-acether); Lysine-acetylsalicylate; Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

DDT_1 MF-2 cells
Smooth muscle cells; Nucleotide receptors; ATP; UTP; K^+ currents (Van der Zee, L. (215) 317)

Death
Anaphylaxis; Haematological alterations; Azelastine (Castro-Faria-Neto, H.C. (213) 183)

Degranulation
Neutrophil; Respiratory burst; Protein kinase C; Staurosporin; cgp 41251 (Krause, K.-H. (227) 221)

Dehydroepiandrosterone
Sulfotransferase; Estrone; Liver (human); Adverse drug reactions (Bamforth, K.J. (228) 15)

Delayed amnesia
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Learning; Memory; CO-induced amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

Deltorphins
δ-Opioid receptors; Locomotor activity; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

Dentate gyrus
Long-term potentiation (LTP); Cognition enhancers; Hippocampus; Perforant path stimulation; (Rat); (In vivo) (Molnár, P. (215) 17)

2-Deoxyglucose
Cerebral blood flow; Cerebral glucose metabolism; Iodoantipyrine; HA1077 (Sako, K. (209) 39)

Catecholamines; Hypoxia/hypoglycemia; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Shibata, S. (221) 255)

2-Deoxyglucose uptake
Circadian rhythm; Suprachiasmatic nucleus; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); $GABA_A$ receptors; Benzodiazepine receptors (Tominaga, K. (217) 79)

Hypoxia/hypoglycemia; Cholinergic drugs; Hippocampus; CA1 field potentials; (In vitro) (Shibata, S. (221) 113)

Dependence
Vigabatrin; Tolerance; GABA (γ-aminobutyric acid); Glutamate; Kindling; Epilepsy (Rundfeldt, C. (213) 351)

Depolarization block
DAU 6215; 5-HT_3 receptors; Dopamine neurons; Antipsychotic drugs (Prisco, S. (214) 13)

Depolarization contractures
Dantrolene; Caffeine contracture; Diaphragm (rat) (Røed, A. (209) 33)

Depolarizations (transient)
Cardiac hypertrophy; Action potential; Na^+,K^+-ATPase; Ryanodine; Forskolin (Mészáros, J. (210) 325)

(−)-Deprenyl
2-Phenylethylamine; 2-Phenylethylamine binding sites; MAO (monoamine oxidase); MAO (monoamine oxidase) inhibitor; Pargyline (Li, X.-M. (210) 189)

L-Deprenyl
Monoamine oxidase inhibitors; Parkinson's disease; Neuroprotective mechanisms (Gerlach, M. (226) 97)

Depression
β-Adrenoceptor (atypical); Brain; Locomotor activity; Water intake (Simiand, J. (219) 193)

Dermorphin
[D-Arg^2]dermorphin; Captopril; Amastatin; Antinociceptive activity (Sakurada, S. (211) 75)

3-Desacetyl vecuronium
Neuromuscular relaxants; Vecuronium; 3,17-Desacetyl vecuronium; Metabolites (antagonism) (Khuenl-Brady, K.S. (222) 153)

3,17-Desacetyl vecuronium
Neuromuscular relaxants; Vecuronium; 3-Desacetyl vecuronium; Metabolites (antagonism) (Khuenl-Brady, K.S. (222) 153)

Descending inhibitory controls
Pain; Spinal cord; Morphine; Periaqueductal grey (Bouhassira, D. (216) 149)

Desensitization
PAF-specific; Pulmonary platelet accumulation; (Rat) (Klee, A. (209) 223)

Endothelin-3; Endothelin-1; Ileum (guinea-pig); Na^+ ions; Endothelin receptor subtypes (Miasiro, N. (214) 133)

β-Adrenoceptor-mediated responses; Lung parenchymal strips (guinea-pig); Atria (guinea-pig) (Herepath, M.L. (215) 209)

Bradykinin; Hypersensitivity (Martins, M.A. (220) 55)

Forskolin; dbcAMP; Myocytes; Heart failure; (Human) (Harding, S.E. (223) 39)

Histamine H_1 receptor; cGMP; Lung (guinea-pig); Protein kinase C (Leurs, R. (225) 137)

Desensitization (agonist induced)
Adenosine A_1 receptors; Adenosine A_2 receptors; Neuroprotection; Brain (rat) (Abbracchio, M.P. (227) 317)

Desipramine
Force swimming test; Alprazolam; Diazepam (Flugy, A. (214) 233)

Norepinephrine; Amphetamine; Dorsal hippocampus; Locus coeruleus (Curet, O. (221) 59)

5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; α-Adrenoceptor antagonists; 6-Hydroxydopamine (6-OHDA); Spinal antinociception (Sawynok, J. (223) 49)

Detergent solubilization
α-Adrenoceptors; Prazosin; Receptor reconstitution; Receptor conformation (Valliere, J.E. (226) 191)

Devazepide
Cholecystokinin receptor; CCK_A receptor antagonists; Molecular modelling; L-364,718 (Van der Bent, A. (226) 327)

Development
Opiates; [^{3}H]DAGO binding; Hypothalamus (Hammer, Jr., R.P. (209) 253)

Purinoceptors; Bladder; ATP; Neonate; Neurotransmission (Sneddon, P. (214) 7)

Antinociception; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Morphine; Opiates (Barr, G.A. (215) 35)

Antiarrhythmics; Electrophysiologic effect (Case, C.L. (218) 213)

Dopamine D_2 receptor; mRNA; Brain (Srivastava, L.K. (225) 143)

Dexamethasone
5-HT_3 receptor antagonists; Zacopride; GR38032F; Cisplatin; Taste aversion (conditioned) (Mele, P.C. (218) 229)

Interleukin; Insulin; Prostaglandin (Shimizu, H. (222) 279)

Dexmedetomidine
Antinociception; Spinal cord; Dorsal horn neurons; α_2-Adrenoceptor agonists; Opioids (Sullivan, A.F. (215) 127)

α_2-Adrenoceptor subtypes; WB4101; Imiloxan; Clonidine; ST-91 (Takano, Y. (219) 465)

Dextran
Carrageenin; Nitric oxide (NO); Oedema; Vascular permeability (Ialenti, A. (211) 177)

Dextromethorphan
Cough reflex; σ-Sites; Antitussive effects; (+)-SK&F 10,047; Pentazocine; DTG (1,2-di-(2-tolyl)guanidine) (Kamei, J. (224) 39)

Dextrorphan
NMDA receptor antagonists (non-competitive); Anticonvulsants; Prepiriform cortex; PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride); MK-801 (Roth, J.E. (215) 293)

Diabetes
Naloxone; Paradoxical analgesia; Naltrindole; (Mouse) (Kamei, J. (210) 339)

Urinary bladder; Epithelium; Prostaglandins; Bradykinin (Pinna, C. (214) 143)

Aldose reductase inhibitors; Platelet aggregation; (Rat) (Takiguchi, Y. (215) 289)

Diabetes mellitus
Mesenteric arteries; Noradrenaline; Contractile responses; Inositol phosphates; Inositol 1,4,5-trisphosphate (Abebe, W. (225) 29)

Diabetic microangiopathy
Thromboxane A_2; Prostacyclin; Streptozotocin-induced diabetes; Thromboxane synthetase inhibitors (Masumura, H. (210) 163)

Diacylglycerol
Angiotensin II; Angiotensin AT_1 receptor; Phospholipase D; Phosphatidylcholine; Mesangial cells (Pfeilschifter, J. (225) 57)

Diacylglycerol formation
Parotid acinar cells; Carbachol; Phosphoinositide hydrolysis; Phosphatidylcholine hydrolysis (Komabayashi, T. (225) 209)

3,4-Diaminopyridine
Noradrenaline release; Hippocampus; Ca^{2+} (intracellular); α_2-Adrenoceptor mechanism; (Rat); (Rabbit) (Jackisch, R. (226) 245)

Diaphragm (rat)
Dantrolene; Depolarization contractures; Caffeine contracture (Røed, A. (209) 33)

Diarrhoea
Prostaglandins; Anthraquinones; Cathartics (Nijs, G. (218) 199)

Diazepam
Force swimming test; Alprazolam; Desipramine (Flugy, A. (214) 233)

Punishment; Fixed-interval responding; Pentobarbital; Phencyclidine; Tolerance; (Pigeon) (McMillan, D.E. (215) 145)

Emotionality; GABA (γ-aminobutyric acid); Pentobarbital; Cl^- flux; (Mouse) (Mihic, S.J. (218) 283)

Withdrawal seizure prone mouse (WSP); Ethanol withdrawal; Handling-induced convulsions; Abecarnil; Anticonvulsant effects; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

GABA (γ-aminobutyric acid); Bicuculline; Lithium chloride; Pilocarpine; Seizures (Peterson, C.J. (221) 151)

Diazoxide
Aorta (rat); Mechanical activity; Ionic fluxes (Antoine, M.-H. (216) 299)

Dibutyryl cAMP
Smooth muscle (vascular); Aorta; Fura-2-Ca^{2+} signal; Forskolin; Ca^{2+} sensitivity; (Rat) (Abe, A. (211) 305)

Amrinone; Mesenteric artery; Mesenteric vein (Itoh, H. (218) 347)

3,4-Dichlorobenzamil
Amiloride; Quinacrine; Ca^{2+}; Ca^{2+} channel blockers; L-type Ca^{2+} channels (Stokke, M. (227) 379)

1,9-Dideoxyforskolin
Forskolin; Adenosine; Phosphodiesterase inhibitors; Inward calcium current-dependent phasic tension; Atrial fibres (frog) (Gauthier, C. (225) 129)

DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid)
Anthracene-9-carboxylic acid (9AC); Isoproterenol; Cardiac cells (guinea-pig); Cl^- activity (intracellular) (Shida, S. (212) 267)

Glisoxepide; Glibenclamide; Organic anions; Monocarboxylate transport; Bromosulfophthalein; Bumetanide; Oleate (Fückel, D. (213) 393)

Vagus nerve; Nedocromil sodium; Cl^- channels (Jackson, D.M. (221) 175)

Diesel-2 (exposure)
Crude oil (exposure); DNA damage; Oil slicks; ^{32}P-Postlabeling assay (Kurelec, B. (228) 51)

Diethyldithiocarbamate
Aortic segments; Nitrovasodilators; Nitrosovasodilators (Vedernikov, Y.P. (212) 125)

Diethyldithiocarbamate-induced antral ulcer
Neutrophil; Rebamipide (Ogino, K. (212) 9)

Neutrophil; Rebamipide (Ogino, K. (219) 493)

Diethyl maleate
ATP depletion; GSH depletion; Phorone; Ethacrynic acid; Hepatocytes (Redegeld, F.A.M. (228) 229)

Diethylpyrocarbonate
Benzodiazepine receptors (central); Modification of receptors; [^{3}H]Ro 15-4513 binding; $GABA_A$ receptors (α subunits); 2,3-Butanedione (Maksay, G. (227) 57)

Differentiation
Heparin derivatives; Smooth muscle cells; Proliferation; Actin (Bârzu, T. (219) 225)

α-Difluoromethylornithine
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Digitalis toxicity
Na^+ activity (intracellular); Ca^{2+} overload; Contractile force; K^+; Na^+ (Abete, P. (211) 399)

Dihydralazine
Hydralazine; Cromakalim; Nitroprusside; K^+ channels; Smooth muscle (vascular) (Thirstrup, S. (215) 177)

Dihydroergotoxine
[^{3}H]TBOB (t-[^{3}H]butylbicycloorthobenzoate) binding; GABA (γ-aminobutyric acid) shift; Barbiturate sleeping; Picrotoxin-induced convulsions (Tvrdeić, A. (221) 139)

13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$
Danazol; Ovarian steroids; Gonadotropin; Ovary; Uterus (Kogo, H. (211) 69)

13,14-Dihydroprostaglandin E_1
Aorta (rabbit); LDL (low density lipoprotein) influx; Atherosclerosis (experimental) (Sinzinger, H. (219) 129)

Dihydropyridine Ca^{2+} entry blocker
EDRF (endothelium-derived relaxing factor); Adrenergic nerve; Substance P; Mesenteric artery; cGMP (Okamura, T. (220) 27)

Dihydropyridine receptors
Ca^{2+} channels; Monoclonal antibodies; Purification; Cardiac sarcolemma (Tokumaru, H. (227) 363)

Dihydropyridines
Aging; Cardiac muscle; Ca^{2+} (extracellular); F344 rats; Isoproterenol (Ruch, S. (216) 393)

UMR 106 osteogenic cell line; Patch clamp; Ca^{2+} channels (Morain, P. (220) 11)

Ca^{2+} channels; NMDA (N-methyl-D-aspartate); Excitatory amino acid; Dopamine; Transmitter release; Mesencephalon (Chaudieu, I. (220) 203)

Ca^{2+} channels; ω-Conotoxin; Ca^{2+} influx; Transmitter release (Lundy, P.M. (225) 51)

1,25-Dihydroxyvitamin D_3 binding
Choroid plexus; 1,25-Dihydroxyvitamin receptors; Ca^{2+} (Walters, M.R. (213) 309)

1,25-Dihydroxyvitamin receptors
1,25-Dihydroxyvitamin D_3 binding; Choroid plexus; Ca^{2+} (Walters, M.R. (213) 309)

Diltiazem
Nifedipine; Verapamil; Cell growth; Tumor cells; Ca^{2+} channels (Wöll, E. (212) 105)

Ca^{2+} channel antagonists; PN200-110; Verapamil; Allosteric regulation (Miwa, K. (214) 127)

Amphotericin B; Mesangial cells; Ca^{2+} (intracellular); Theophylline (Sabra, R. (226) 79)

[^{3}H]Diltiazem binding
Polyamines; [^{3}H]Nitrendipine binding; Cerebral cortex (rat); Cooperative effects (Schoemaker, H. (225) 167)

Dinitrosyl iron complexes (with cysteine)
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Vasorelaxation (Vedernikov, Y.P. (211) 313)

1,2-Dioctanoylglycerol
Norepinephrine; Protein kinase C; Ca^{2+} current; Whole-cell voltage clamp; Sympathetic ganglia (Abrahams, T.P. (227) 189)

[^{3}H]Diprenorphine
δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Etorphine; 5'-Guanylylimidophosphate (GppNHp); Sucrose gradients; Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

Dipyridamole
Adenine nucleotide analogues; Skeletal muscle (innervated, frog); Ecto-enzymes; AP_5A (P^1P^5-di-(adenosine-5')pentaphosphate); DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Cascalheira, J.F. (222) 49)

Scavenging effects; Electron spin resonance; Hydroxyl radicals; Superoxide anions (Suzuki, S. (227) 395)

Dipyrone
Nitric oxide (NO); Analgesia (Duarte, I.D.G. (217) 225)

Distress vocalization
Development; Antinociception; Ultrasonic vocalization; Tolerance; Withdrawal; Morphine; Opiates (Barr, G.A. (215) 35)

2,5-Di-(tert-butyl)-1,4-benzohydroquinone
Cyclopiazonic acid; Ca^{2+} permeability; A7r5 aortic cells (Missiaen, L. (227) 391)

Dithiothreitol
Angiotensin II receptor subtypes; AT_2 receptors; Sulfhydryl reducing agents; Losartan (DuP 753); Brain development (Tsutsumi, K. (226) 169)

Ditolylorthoguanidine
σ Receptor ligands; DTG (1,3-di-(2-tolyl)guanidine); Hippocampus (Connick, J.H. (214) 169)

Diuretics
Cough reflex; Angiotensin-converting enzyme inhibitors; Enalapril; Hydrochlorothiazide (Kamei, J. (213) 137)

Hydrochlorothiazide; Indapamide; Resistance vessels (Calder, J.A. (220) 19)

Diuretics (loops)
Torasemide; Bumetanide; Cotransport; Red blood cells; Hypertension (Masereel, B. (219) 385)

Dizocilpine
NMDA receptors; CGP37849; CGP39551; Spatial orientation task; (Rat) (Bischoff, C. (213) 269)

Excitatory amino acids; Focal ischaemia; (Rat) (Hatfield, R.H. (216) 1)

DNA damage
Diesel-2 (exposure); Crude oil (exposure); Oil slicks; ^{32}P-Postlabeling assay (Kurelec, B. (228) 51)

DNA synthesis
Phosphoinositide turnover; α-Thrombin; Neuroblastoma (Ogino, Y. (225) 299)

Docosahexaenoic acid
Eicosapentaenoic acid; Fatty acids (omega-3, omega-6, omega-9); Fish oil (Engler, M.B. (215) 325)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
5-HT receptor agonists; 5-HT receptor antagonists; Blood pressure; Plasma renin activity; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

Sexual behaviour; 5-HT_2/5-HT_{1C} receptors; 5-HT (5-hydroxytryptamine, serotonin); Amperozide; Ritanserin; Ketanserin; Mesulergine (Klint, T. (212) 241)

5-HT_2 receptors; Glucose; Insulin; Sympathoadrenal system (Baudrie, V. (213) 41)

5-HT (5-hydroxytryptamine, serotonin); 5-Carboxamidotryptamine; Endothelium; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Van Gelderen, E.M. (222) 185)

Domoic acid
Kainic acid; AMPA; Excitatory amino acid receptor; Neurotoxin (Hampson, D.R. (218) 1)

DOPAC (3,4-dihydroxyphenylacetic acid)
Amoxapine; Pharmacokinetics (cerebral); Dopamine; Homovanillic acid (HVA) (Kobayashi, A. (215) 43)

DOPA (3,4-dihydroxyphenylalanine)
Nicotine-evoked release; Nicotinic acetylcholine receptors (tonic); Striatum; Microdialysis (Nakamura, S. (222) 75)

L-DOPA (L-3,4-dihydroxyphenylalanine)
Amino acid transport; Blood–brain barrier; β_2-Adrenoceptors; Isoproterenol; Salbutamol (Takao, Y. (215) 245)

[Met^5]enkephalin; [Leu^5]enkephalin; Neurotensin; Cholecystokinin (CCK); Substance P; 6-Hydroxydopamine (6-OHDA); Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Dopamine
Antinociception; Quinpirole; Receptor sensitization (Kostrzewa, R.M. (209) 157)

NMDA (N-methyl-D-aspartate); Brain slices; Polyamines; Ifenprodil; SL 82.0715 (Woodward, J.J. (210) 265)

Dopamine D_2 receptors; Efficacy; Hypothermia; (Full agonists); (Partial agonists); (Mouse) (Sánchez, C. (211) 9)

Brain stimulation reward; Morphine; Neurotensin; Mesencephalon (ventral) (Rompré, P.-P. (211) 295)

Ibogaine; Cocaine; Nucleus accumbens; Striatum; Microdialysis; Locomotor activity (Maisonneuve, I.M. (212) 263)

Cocaine (chronic); Addiction (Imperato, A. (212) 299)

Dystonia; Acetylcholine; Anticholinergic drugs; Haloperidol; Levodopa; Apomorphine (Löscher, W. (213) 31)

Locomotion; Dopamine D_2 receptors; Quinpirole; (Rat) (Van Hartesveldt, C. (214) 27)

Amoxapine; Pharmacokinetics (cerebral); DOPAC (3,4-dihydroxyphenylacetic acid); Homovanillic acid (HVA) (Kobayashi, A. (215) 43)

Circadian rhythms; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

ATP; Ion channels; Dopamine receptor agonists; Dopamine receptor antagonists; Pheochromocytoma PC12 cells (Inoue, K. (215) 321)

5-HT (5-hydroxytryptamine, serotonin); Self-stimulation; Fenfluramine; Amphetamine (Olds, M.E. (216) 363)

Melatonin; Nucleus accumbens; Antidepressant drugs; Receptor supersensitivity (Durlach-Misteli, C. (217) 15)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease (Pérez-Otaño, I. (217) 211)

Dopamine transporters; Synaptic vesicle; Amine uptake (Rostène, W. (218) 175)

Amphetamines; Basal ganglia; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Dopamine D_3 receptors; Neuroleptics (Schotte, A. (218) 373)

Corticostriatal pathways; Ascorbate; L-Glutamate; Apomorphine; Scopolamine; (Rat) (Desole, M.S. (219) 67)

Ca^{2+} channels; Dihydropyridines; NMDA (N-methyl-D-aspartate); Excitatory amino acid; Transmitter release; Mesencephalon (Chaudieu, I. (220) 203)

Amphetamines; MDMA (3,4-methylenedioxymethamphetamine); Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Elayan, I. (221) 281)

Amitriptyline; Na^+ channels; Amino acids; Veratridine; Striatal slices (Ishii, Y. (221) 377)

Spontaneously epileptic rat (SER); Thyrotropin-releasing hormone analogs; CNK-602A; Antiepileptic effect (Renming, X. (223) 185)

Dopamine autoreceptors
Locomotor activity; Adenylate cyclase activity; Lisuride; Tolerance; Sensitization (Nisoli, E. (216) 81)

Dopamine D_3 receptor (human); Transfected cell; Eukaryotic expression vector; Neuroleptics; Guanylnucleotide; G protein (Sokoloff, P. (225) 331)

Dopamine-β-hydroxylase (lung)
Propranolol; Atrium; Noradrenaline; Catecholamines (Elayan, H. (212) 259)

[^{3}H]Dopamine binding
Serotonin-binding proteins; Frontal cortex (bovine); [^{3}H]Serotonin binding (Jimenez Del Rio, M. (225) 225)

Dopamine cells
5-HT_3 receptor antagonists; LY 277359; Granisetron; Ventral tegmental area (Minabe, Y. (209) 143)

Extracellular recording; Neurokinin receptors (Overton, P. (213) 165)

Dopamine D_1/D_2 receptor interactions
Dopamine D_1 receptors; Dopamine D_2 receptors; Behaviour; Jerking; SCH 39166; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

Dopamine D_1 receptor agonists
Pancreas (dog); Exocrine secretion; YM435 (Iwatsuki, K. (218) 237)

Dopamine D_1 receptor antagonists
SCH 23390; BW737C89; Tetrahydroisoquinolines; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); (Receptor binding) (Riddall, D.R. (210) 279)

Dopamine D_3 receptor (human)
Transfected cell; Eukaryotic expression vector; Neuroleptics; Guanylnucleotide; G protein; Dopamine autoreceptor (Sokoloff, P. (225) 331)

Dopamine receptors
Ethanol intake; Brain (rat); Dopamine D_1 receptors; Dopamine D_2 receptors; (Agonist affinity) (May, T. (215) 313)

Enkephalin-degrading enzymes; RB 101 (mixed inhibitor); Naltrindole; Motility suppression (conditioned); Antidepressants (Baamonde, A. (216) 157)

Down-regulation; Triazolam; GABA (γ-aminobutyric acid); Quinpirole; 6-Hydroxydopamine (6-OHDA) (Zhou, L.-W. (218) 219)

Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY); Novelty-induced grooming behaviour; SCH 23390; Quinpirole (Linthorst, A.C.E. (219) 23)

Sympathetic ganglia; Catecholamine receptors; α-Adrenoceptors (Horn, P.T. (224) 103)

Imipramine (chronic); NMDA receptors; Supersensitivity (D'Aquila, P.S. (224) 199)

cAMP; Vascular smooth muscle (rat); Mesenteric artery; Thiol group (Hall, A.S. (226) 253)

Inositol phosphates; Phosphoinositides; Striatum (rat); α-Adrenoceptors; 5-HT receptors (Undie, A.S. (226) 297)

Dopamine D_1 receptors
A-69024; Chronic treatment; Dopamine D_2 receptors; SCH 23390; SCH 39166; SK&F 38393 (Lappalainen, J. (210) 195)

Striatum (rat); Dopamine D_2 receptors; Acetycholine (Tedford, C.E. (211) 169)

Vacuous chewing; Haloperidol (chronic); Tardive dyskinesia (Diana, M. (211) 415)

Dopamine D_2 receptors; Passive avoidance learning; (Mouse) (Ichihara, K. (213) 243)

Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; SCH 39166; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

Dopamine D_2 receptors; Adenylate cyclase; Circling behaviour; Stereotyped behaviour; Locomotor activity (Arnt, J. (213) 259)

Conditioned avoidance response; Dopamine D_2 receptors; (In vivo binding) (McQuade, R.D. (215) 29)

Circadian rhythms; Dopamine; Dopamine D_2 receptors; Locomotion; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Ethanol intake; Brain (rat); Dopamine receptors; Dopamine D_2 receptors; (Agonist affinity) (May, T. (215) 313)

Dopamine D_2 receptors (Šoskić, V. (226) 109)

Dopamine D_2 receptors; Binding (in vivo); Behaviour; (Rat) (Nielsen, E.B. (219) 35)

NNC-112; NNC-687; NNC-756; Binding (in vivo) (Andersen, P.H. (219) 45)

Acetylcholine; Striatum; Supersensitivity; Dopamine D_2 receptors (Robertson, G.S. (219) 323)

Dopamine D_2 receptors; Adenosine receptors; Perioral dyskinesia; (Rabbit) (Caporali, M.G. (223) 15)

Mesangial (rat); Characterization (Bryson, S.E. (225) 1)

Dopamine D_2 receptors
A-69024; Chronic treatment; Dopamine D_1 receptors; SCH 23390; SCH 39166; SK&F 38393 (Lappalainen, J. (210) 195)

Dopamine; Efficacy; Hypothermia; (Full agonists); (Partial agonists); (Mouse) (Sánchez, C. (211) 9)

Striatum (rat); Dopamine D_1 receptors; Acetycholine (Tedford, C.E. (211) 169)

Basal ganglia; Dopamine D_3 receptors; Autoradiography; Islets of Calleja (Gehlert, D.R. (211) 189)

Dopamine D_1 receptors; Passive avoidance learning; (Mouse) (Ichihara, K. (213) 243)

Dopamine D_1 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; SCH 39166; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

Dopamine D_1 receptors; Adenylate cyclase; Circling behaviour; Stereotyped behaviour; Locomotor activity (Arnt, J. (213) 259)

Dopamine; Locomotion; Quinpirole; (Rat) (Van Hartesveldt, C. (214) 27)

Conditioned avoidance response; Dopamine D_1 receptors; (In vivo binding) (McQuade, R.D. (215) 29)

Circadian rhythms; Dopamine; Dopamine D_1 receptors; Locomotion; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Ethanol intake; Brain (rat); Dopamine receptors; Dopamine D_1 receptors; (Agonist affinity) (May, T. (215) 313)

Amperozide; 5-HT_2 receptors (Meltzer, H.Y. (216) 67)

Grooming behaviour; B-HT 920; Adrenocorticotropin hormone; Stretching and yawning; Shakes (Ferrari, F. (216) 345)

GH_4ZR_7 cells; Cell culture; Anterior pituitary; Prolactin; Partial agonists; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Dopamine D_1 receptors; Binding (in vivo); Behaviour; (Rat) (Nielsen, E.B. (219) 35)

Acetylcholine; Striatum; Supersensitivity; Dopamine D_1 receptors (Robertson, G.S. (219) 323)

Dopamine D_1 receptors; Adenosine receptors; Perioral dyskinesia; (Rabbit) (Caporali, M.G. (223) 15)

Benzamide (substituted); SPECT imaging (Kessler, R.M. (223) 105)

mRNA; Brain; Development (Srivastava, L.K. (225) 143)

Dopamine D_1 receptors (Šoskić, V. (226) 109)

Dopamine receptor antagonist ligands; Positron emission tomography (human brain) (Seeman, P. (227) 139)

Mutagenesis; Receptor binding; Catecholamine receptors (Mansour, A. (227) 205)

Dopamine D_3 receptors; Striatum (Murray, A.M. (227) 443)

Dopamine D_2 receptors (mixed agonist/antagonist)
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinsonism; Terguride; (Common marmoset) (Lange, K.W. (212) 247)

Dopamine D_3 receptors
Basal ganglia; Dopamine D_2 receptors; Autoradiography; Islets of Calleja (Gehlert, D.R. (211) 189)

Dopamine; Neuroleptics (Schotte, A. (218) 373)

Dopamine D_2 receptors; Striatum (Murray, A.M. (227) 443)

Dopamine neurons
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

5-HT_3 receptors; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

DAU 6215; 5-HT_3 receptors; Antipsychotic drugs; Depolarization block (Prisco, S. (214) 13)

Cocaine; Withdrawal; Ventral tegmental area; Electrophysiology (Ackerman, J.M. (218) 171)

MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; 5-HT_2 receptors (Schmidt, C.J. (220) 151)

Ethanol; Withdrawal syndrome (Diana, M. (221) 403)

Dopamine (rat)
Naloxone infusion (continuous); D-amphetamine; Locomotor activity; Opioids (Jones, D.N.C. (221) 161)

Dopamine receptor agonists
ATP; Ion channels; Dopamine; Dopamine receptor antagonists; Pheochromocytoma PC12 cells (Inoue, K. (215) 321)

Dopamine receptor antagonist ligands
Dopamine D_2 receptors; Positron emission tomography (human brain) (Seeman, P. (227) 139)

Dopamine receptor antagonists
ATP; Ion channels; Dopamine; Dopamine receptor agonists; Pheochromocytoma PC12 cells (Inoue, K. (215) 321)

Dopamine receptors (presynaptic, postsynaptic)
Pramipexole (SND 919); (Rat); (Monkey) (Mierau, J. (215) 161)

Dopamine release
Vinpocetine; Excitatory amino acid receptors; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Nigrostriatal hemitransection; Dopamine uptake; Acetylcholine release; Ganglioside administration; (Recovery of function) (Raiteri, M. (213) 17)

(+)SK&F 10,047; Antipsychotics (Volonté, M. (213) 163)

NMDA receptors; Acetylcholine release; Amantadine; Neostriatum (Stoof, J.C. (213) 439)

Neurokinins; Neostriatum; Nucleus accumbens; Microdialysis (in vivo) (Boix, F. (216) 103)

Acetyl-L-carnitine; Brain dialysis; Striatum (Harsing, Jr., L.G. (218) 117)

Striatum; Substantia nigra; Microdialysis; $GABA_A$ receptors; $GABA_B$ receptors (Santiago, M. (219) 175)

Nucleus accumbens; Methamphetamine; Dynorphin (Yokoo, H. (222) 43)

3-Methoxytyramine; Striatum; Nucleus accumbens; Frontal cortex; (Rat) (Chrapusta, S.J. (222) 129)

Dopaminergic/cholinergic interaction
Oral movements; Striatum (dorsal); Striatum (ventral); (Rat) (Kikuchi de Beltrán, K. (214) 181)

Dopaminergic transmission
Tyrosine hydroxylase; NMDA receptors; $GABA_B$ receptors; Baclofen; Dopamine synthesis (Montaño, J.-A.A. (218) 335)

Dopamine synthesis
Tyrosine hydroxylase; NMDA receptors; $GABA_B$ receptors; Baclofen; Dopaminergic transmission (Montaño, J.-A.A. (218) 335)

Amphetamine; Microdialysis; MDMA (3,4-methylenedioxymethamphetamine); $5\text{-}HT_2$ receptors (Schmidt, C.J. (223) 65)

Dopamine transport
N-Ethylmaleimide alkylation; Cocaine; d-Amphetamine; [^{3}H]Mazindol binding (Johnson, K.M. (227) 411)

Dopamine transporters
Dopamine; Synaptic vesicle; Amine uptake (Rostène, W. (218) 175)

Cocaine; GBR-12783; [^{3}H]Methylphenidate; Stimulants (Deutsch, H.M. (220) 173)

Dopamine uptake
Striatum; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Nigrostriatal hemitransection; Dopamine release; Acetylcholine release; Ganglioside administration; (Recovery of function) (Raiteri, M. (213) 17)

MPP^+ (1-methyl-4-phenylpyridinium ion); Striatum; Nicotine; Tobacco smoke (Carr, L.A. (215) 285)

Reserpine; [^{18}F]GBR 13119 binding; (In vivo); (Mouse) (Kilbourn, M.R. (216) 109)

Dopamine uptake complex
[^{3}H]GBR 12783 binding (in vivo); Dopamine uptake inhibitors; (Mouse) (Vaugeois, J.-M. (210) 77)

Dopamine uptake inhibitors
[^{3}H]GBR 12783 binding (in vivo); Dopamine uptake complex; (Mouse) (Vaugeois, J.-M. (210) 77)

[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding; Cocaine; BTCP (N[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine); GBR 12935; Striatum (rat) (Reith, M.E.A. (227) 417)

Doppler shift technique
Kidney (isolated, perfused); Renal vascular resistance; Metalloproteases; Phosphoramidon; (Rat) (Salvati, P. (221) 267)

Dorsal hippocampus
Norepinephrine; Desipramine; Amphetamine; Locus coeruleus (Curet, O. (221) 59)

Dorsal horn neurons
Antinociception; Spinal cord; α_2-Adrenoceptor agonists; Dexmedetomidine; Opioids (Sullivan, A.F. (215) 127)

Dorsal pallidum
Sulfonylureas; K^+ channels (ATP-sensitive); Motor control (Amalric, M. (217) 71)

Dorsal raphe nucleus
5-HT receptors; Blood pressure; Anxiolytic (Corley, K.C. (213) 417)

Substance P; 5-HT release; Blood pressure (Gradin, K. (218) 363)

Dorsal vagal complex
Baroreflex; Ethanol; GABA (γ-aminobutyric acid) (Varga, K. (214) 223)

Dorsomedial nucleus accumbens
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apomorphine; Jaw movements (Koshikawa, N. (209) 75)

Down-regulation
Triazolam; GABA (γ-aminobutyric acid); Dopamine receptors; Quinpirole; 6-Hydroxydopamine (6-OHDA) (Zhou, L.-W. (218) 219)

β-Adrenoceptors; cAMP; mRNA; Isoproterenol; C_6 glioma cells (Bieck, P.R. (225) 171)

Neurotensin receptors; U-73122 (Yamada, M. (226) 187)

Doxorubicin
Adriamycin; Heart muscle preparations (isolated); Acetylcholine receptors; Antimuscarinic actions; [^{3}H]Quinuclidinyl benzilate (QNB) binding (Temma, K. (220) 63)

Nephrosis (experimental); Superoxide anion; Renal toxicity (Ghiggeri, G.M. (228) 77)

DPCPX (1,3-dipropyl-8-cyclopentylxanthine)
Atrium (left, dog); Adenosine receptors; 8-Phenyltheophylline; N-0861 (N^6-endonorbornan-2-yl-9-methyladenine) (Martin, P.L. (214) 199)

Adenine nucleotide analogues; Skeletal muscle (innervated, frog); Ecto-enzymes; AP_5A (P^1P^5-di-(adenosine-5′)pentaphosphate); Dipyridamole (Cascalheira, J.F. (222) 49)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Naltriben; δ-Opioid receptor subtypes; DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); DADLE (D-Ala^2,D-Leu^5]enkephalin) (Sofuoglu, M. (216) 273)

δ-Opioid receptor subtypes; [D-Ala^2,Glu^4]deltorphin; CD-1 mice; CXBK mice; Antinociception (Raffa, R.B. (216) 453)

Temperature; Opioid receptors; Myenteric plexus; DAGO ([D-Ala^2,N-MePhe^4,Gly^5-ol]enkephalin); U-50,488H (Garaulet, J.V. (223) 19)

DPLPE ([D-Pen^2,L-Pen^5]enkephalin)
DAMGO ([D-Ala^2,MePhe^4,Gly^5-ol]enkephalin); SKF 38393; Naltrindole; Locomotor activity; (Mouse) (Toyoshi, T. (213) 25)

Drinking
Angiotensin; Angiotensin AT_1 receptors; Angiotensin AT_2 receptors; DuP 753; WL 19 (Dourish, C.T. (211) 113)

Dromotropic effects
Coronary vascular resistance; Inotropic effects; Ventricular tachycardia; Endothelial messengers; Arrhythmias (Balcells, E. (210) 1)

Drug abuse
Amphetamines; Basal ganglia; Dopamine; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Drug discrimination
2-Methylserotonin; 5-HT_3 receptors; Zacopride isomers (Young, R. (212) 117)

Apomorphine; 6-Hydroxydopamine (6-OHDA); Pentobarbital; Rotational behaviour; Conditioned drug effects (Silverman, P.B. (212) 165)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

Muscarinic receptor subtypes; Superior cervical ganglion; Ileum (guinea-pig); Atrium (guinea-pig) (Arnt, J. (218) 159)

Ethanol; NMDA receptor antagonism; Phencyclidine; NPC 12626 (Balster, R.L. (222) 39)

Drug interactions
Tetrahydroaminoacridine (THA); Tacrine; 4-Aminopyridine (4-AP); Fura-2 (fluorimetry) (Järlebark, L. (225) 75)

DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin)
Naltriben; δ-Opioid receptor subtypes; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DADLE (D-Ala^2,D-Leu^5]enkephalin) (Sofuoglu, M. (216) 273)

DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)
Transcription factors; Locus coeruleus (Bhat, R.V. (227) 447)

DSTBULET (Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr)
Antinociception; Tail-flick (spinal); δ-Opioid receptors; Morphine (Kalso, E.A. (216) 97)

DTG (1,3-di-(2-tolyl)guanidine)
σ Receptors; Phencyclidine (PCP); SK&F 10047 (Dumont, M. (209) 245)

σ Receptor ligands; Ditolylorthoguanidine; Hippocampus (Connick, J.H. (214) 169)

Haloperidol; σ Receptors (Jansen, K.L.R. (214) 281)

σ Binding sites; R(+)-3-PPP (R(+)-3-(3-hydroxyphenyl)-N-(n-propyl)piperidine) (Codd, E.E. (217) 149)

Cough reflex; σ-Sites; Antitussive effects; (+)-SK&F 10,047; Pentazocine; Dextromethorphan (Kamei, J. (224) 39)

Duodenum
Ro 5-4864; PK 11195; Vas deferens; (Rat) (Escubedo, E. (225) 15)

Duodenum (rat)
Neurotensin; Neurotensin receptors; Non-adrenergic non-cholinergic (NANC) relaxation; Neurotensin-induced relaxation; Neurotensin-induced contraction (Mulè, F. (212) 215)

DuP 753
Drinking; Angiotensin; Angiotensin AT_1 receptors; Angiotensin AT_2 receptors; WL 19 (Dourish, C.T. (211) 113)

Semotiadil; Glomerular filtration rate; Renal blood flow; Renin–angiotensin system (Nishiyama, A. (218) 311)

Losartan; Angiotensin II; Blood–brain barrier; Blood pressure; Thirst (Bui, J.D. (219) 147)

Dynorphin
Dopamine release; Nucleus accumbens; Methamphetamine (Yokoo, H. (222) 43)

Dynorphin A
Amphetamines; Basal ganglia; Dopamine; Drug abuse; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Dynorphin A-(1–13)
Opiate withdrawal; Opiate tolerance; Morphine (Takemori, A.E. (221) 223)

Methamphetamine; Mr 2266; Circling; Rearing; (Mouse) (Ukai, M. (222) 7)

Dynorphin release
CRF (corticotropin-releasing factor); Analgesia; κ-Opioid receptors; Spinal cord (Song, Z.H. (222) 27)

Dyspnea (guinea-pig)
Neurokinin A; Substance P; Tachykinins (Kusner, E.J. (210) 299)

Dystonia
Dopamine; Acetylcholine; Anticholinergic drugs; Haloperidol; Levodopa; Apomorphine (Löscher, W. (213) 31)

E4080
K^+ channel openers; Ca^{2+} channel antagonists; Ca^{2+} concentration (intracellular); Vasodilators; Coronary artery (dog) (Okada, Y. (218) 259)

Ear edema
Baicalein; Free radical; Lipid peroxidation; α-Tocopherol (Hara, H. (221) 193)

***E. coli* enterotoxin (heat-stable)**
cGMP; 5-HT (5-hydroxytryptamine, serotonin); Indomethacin; Intestinal secretion; Ketanserin; Tropisetron (Beubler, E. (219) 445)

Ecto-enzymes
Adenine nucleotide analogues; Skeletal muscle (innervated, frog); AP_5A (P^1P^5-di-(adenosine-5′)pentaphosphate); DPCPX (1,3-dipropyl-8-cyclopentylxanthine); Dipyridamole (Cascalheira, J.F. (222) 49)

EDRF (endothelium-derived relaxing factor)
Dinitrosyl iron complexes (with cysteine); Nitric oxide (NO); Vasorelaxation (Vedernikov, Y.P. (211) 313)

Nitric oxide (NO); Vascular tone; Arterial pressure; (Rat) (Chyu, K.-Y. (212) 159)

Acetylcholine; Polymorphonuclear leukocytes; Lipopolysaccharide; Mesenteric artery (superior); Nitric oxide (NO) (Siegfried, M.R. (212) 171)

Substance P; Neurokinin A; Neurokinin B; CP-96,345; Aorta (rabbit) (Rubino, A. (212) 237)

Angiotensin-converting enzyme inhibitors; Renal circulation; Kinins; Angiotensin II receptor antagonists (Hajj-ali, A.F. (212) 279)

DL-Propranolol; Nitric oxide (NO); N^G-Nitro-L-arginine; CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate); Hindquarters (rat) (Mota-Filipe, H. (213) 227)

Nitric oxide (NO); Pressure; Endothelial cells; Mechanoreceptors; Hypertension (Hishikawa, K. (215) 329)

Nitric oxide (NO); L-Arginine; Endotoxic shock (Lambert, L.E. (216) 131)

Dihydropyridine Ca^{2+} entry blocker; Adrenergic nerve; Substance P; Mesenteric artery; cGMP (Okamura, T. (220) 27)

S-Nitrosothiols; Excitatory amino acid; Baroreceptor reflex; Cardiovascular regulation; Nitric oxide (NO) (Machado, B.H. (221) 179)

Nitric oxide (NO); Nitric oxide synthase inhibition; Vasoconstriction (Klabunde, R.E. (223) 1)

Bradykinin; Endothelial cells; Ca^{2+} channels; G protein; cGMP (Graier, W.F. (225) 43)

Bradykinin; cGMP; Endothelin; Forskolin; 5-HT (serotonin) (Reiser, G. (227) 89)

EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline)
Dopamine D_1 receptor antagonists; SCH 23390; BW737C89; Tetrahydroisoquinolines; (Receptor binding) (Riddall, D.R. (210) 279)

α_2-Adrenoceptors; Receptor occupancy (in vivo) (Pilc, A. (212) 109)

EEG (electroencephalogram)
Xanthines; Seizures; Pentylenetetrazole; Adenosine (Cutrufo, C. (222) 1)

EEG power spectra
Morphine; Naltrindole; Tolerance (Stamidis, H. (213) 9)

Cholecystokinin (CCK); Morphine (Hudson, G.M. (221) 217)

Efaroxan
Idazoxan; Prazosin; Vas deferens; Anococcygeus; Glucose homeostasis; (Pithed rat) (Berridge, T.L. (213) 205)

Glibenclamide; Plasma insulin; Plasma glucose (Berridge, T.L. (213) 213)

Efficacy
Dopamine; Dopamine D_2 receptors; Hypothermia; (Full agonists); (Partial agonists); (Mouse) (Sánchez, C. (211) 9)

Angiotensin; Angiotensin AT_1 receptors; Ca^{2+} (Liu, Y.J. (223) 205)

EGF (epidermal growth factor)
Endothelin; Thrombin; Hypercholesterolemia; Aorta (rabbit); Vasospasm; Endothelium (Merkel, L.A. (222) 175)

Eicosanoids
Immune-complex alveolitis; Arthus reaction; PAF (platelet-activating factor, PAF-acether) (Tavares de Lima, W. (213) 63)

Peritoneal cells (rat); Phagocytosis (bacterial); Indomethacin; CR1 receptors; Fc receptors (Coquette, A. (226) 1)

Eicosapentaenoic acid
Docosahexaenoic acid; Fatty acids (omega-3, omega-6, omega-9); Fish oil (Engler, M.B. (215) 325)

Electrical field stimulation
5-HT (5-hydroxytryptamine, serotonin); Trachea; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

Capsazepine; Non-adrenergic non-cholinergic (NANC) excitatory nerves; Capsaicin; Tetrodotoxin (Belvisi, M.G. (215) 341)

Acetylcholine; Epithelium-derived acetylcholinesterase; EpDRF (epithelium-derived relaxing factor); Trachealis muscle (guinea-pig); Physostigmine (Koga, Y. (220) 141)

Neurokinin receptors; SR 48968; (±)-CP-96,345; Bronchus (guinea-pig); Non-cholinergic contraction (Martin, C.A.E. (224) 137)

Electrical transmural stimulation
Pulmonary artery (rabbit); L-N^G-Nitro arginine (L-NO_2Arg); Endothelium; Nitric oxide (NO); Noradrenaline release (Shinozuka, K. (222) 113)

Electroacupuncture
Analgesia; Opioid receptors; Opioid receptor agonists; Opioid receptor antagonists; Spinal cord (Chen, X.-H. (211) 203)

Electroconvulsive shock
Hypothermia; Serotonergic neurons; 5-HT autoreceptors; 5-HT release; $5\text{-}HT_3$ receptors (Blier, P. (211) 365)

5-HT (5-hydroxytryptamine, serotonin); ACTH release; Tricyclic antidepressants; Lithium (Gartside, S.E. (221) 27)

Brain (rat); α_1-Adrenoceptors; $5\text{-}HT_2$ receptors; Phosphoinositide hydrolysis (Pandey, G.N. (226) 303)

Electron spin resonance
Dipyridamole; Scavenging effects; Hydroxyl radicals; Superoxide anions (Suzuki, S. (227) 395)

Electrophysiological actions
Quinacainol; Antiarrhythmics; Ischaemic arrhythmias (Howard, P.G. (219) 1)

Electrophysiologic effect
Antiarrhythmics; Development (Case, C.L. (218) 213)

Electrophysiology
Ethanol; Locus coeruleus; GABA (γ-aminobutyric acid); Benzodiazepine; Picrotoxin; Ro 15-1788 (Verbanck, P.M.P. (211) 15)

Cocaine; Dopamine neurons; Withdrawal; Ventral tegmental area (Ackerman, J.M. (218) 171)

Eltoprazine
Aggression; TFMPP (1-(3-(trifluoromethyl)phenyl)piperazine hydrochloride); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Mos, J. (212) 295)

$5\text{-}HT_{1A}$ receptor agonists; $5\text{-}HT_{1A}$ receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

EMD 53998
Ca^{2+} sensitization; Cardiac muscle (skinned); Muscle regulation; Inorganic phosphate (Strauss, J.D. (227) 437)

Emesis
Vagus nerve; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptors; (Ferret) (Newberry, N.R. (221) 157)

5-HT receptors; 5-HT_3 receptor antagonists; 5-HT_3 receptor agonists; Cisplatin; (Pigeon) (Preziosi, P. (221) 343)

Emodin
Immunosuppressants; Free radical (Huang, H.-C. (211) 359)

Emotionality
GABA (γ-aminobutyric acid); Diazepam; Pentobarbital; Cl^- flux; (Mouse) (Mihic, S.J. (218) 283)

Enalapril
Cough reflex; Angiotensin-converting enzyme inhibitors; Diuretics; Hydrochlorothiazide (Kamei, J. (213) 137)

Endocardium
Autoradiography; Heart; Natriuretic receptors; Natriuretic peptides (Rutherford, R.A.D. (212) 1)

Endocrine responses
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Endopeptidase 24.11
Endopeptidase 24.15; Trachea (guinea-pig); Bradykinin; Substance P (Da Silva, A. (212) 97)

Endopeptidase 24.15
Endopeptidase 24.11; Trachea (guinea-pig); Bradykinin; Substance P (Da Silva, A. (212) 97)

β-Endorphin
L-Arginine; Antinociception (Tseng, L.F. (212) 301)

Heat intensities (different); Tail-flick response; Paw-licking response; Morphine (Suh, H.H. (213) 337)

Antinociception; Tail-flick inhibition; Morphine; Pentobarbital; Pain controls (descending) (Tseng, L.F. (214) 175)

CCK-8s (sulfated cholecystokinin octapeptide); [Met^5]enkephalin; Tail-flick inhibition (Tseng, L.F. (215) 309)

Naltrexone; [Met^5]enkephalin; [Leu^5]enkephalin; Gastrointestinal content (McIntosh, C.H.S. (223) 117)

β-Endorphin (intrathecal)
Antinociception; Tail-flick inhibition; Opioid receptors (Tseng, L.F. (214) 59)

Endothelial cells
Patch-clamp; VIP receptors; VIP analogs; VIP binding sites; [4-Cl-D-Phe^6,Leu^{17}]VIP (Pasyk, E. (212) 209)

BY-1949; Cerebral blood flow; Cyclic nucleotides; Basilar artery (Sugawa, M. (215) 57)

EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pressure; Mechanoreceptors; Hypertension (Hishikawa, K. (215) 329)

Histamine; Histamine H_1 receptors; Actin filaments; Peripheral bands; Permeability (Niimi, N. (221) 325)

Caffeine; Ca^{2+} (Chen, G. (223) 33)

Bradykinin; Ca^{2+} channels; G protein; Endothelium-derived relaxing factor (EDRF); cGMP (Graier, W.F. (225) 43)

Endothelial cell secretion
Plasminogen activator (tissue-type); Von Willebrand factor; Phospholipase C; Cytochrome P-450; Pertussis toxin (Tranquille, N. (213) 285)

Endothelial cells (vascular)
Granulocyte-colony stimulating factor (G-CSF); Endothelin-1 (Namiki, A. (227) 339)

Endothelial messengers
Dromotropic effects; Coronary vascular resistance; Inotropic effects; Ventricular tachycardia; Arrhythmias (Balcells, E. (210) 1)

Endothelin
Bronchus (isolated, human); Airway epithelium; Enkephalinase (Candenas, M.-L. (210) 291)

Endothelin-1
Radioimmunoassay; Respiratory distress syndrome (adult); Oleic acid; Bronchoalveolar lavage; Hypoxia (Simmet, T. (211) 319)

Cyclosporine; Hypertension; Mesenteric artery; Blood pressure (Takeda, Y. (213) 445)

Thromboxane A_2; Vascular permeability; Airways; Inflammation; Gastrointestinal ulceration (Sirois, M.G. (214) 119)

Endothelin-3; Ileum (guinea-pig); Desensitization; Na^+ ions; Endothelin receptor subtypes (Miasiro, N. (214) 133)

Cardiac myocytes; Ca^{2+} (intracellular); Cell shortening (Qiu, Z. (214) 293)

Aorta (rat); Smooth muscle (vascular); Ca^{2+}; Cyclopiazonic acid (Shimamoto, H. (216) 225)

Big endothelin-1; Bronchoconstriction; Hypertension; Metallopeptidases (Pons, F. (217) 65)

Prostaglandin E_2; Smooth muscle (vascular); Coronary artery (porcine) (Suzuki, S. (217) 97)

Vasopressin; Phosphoinositide (PI) hydrolysis; α_1-Adrenoceptors; Nonpeptide V_1 receptor antagonists; Ventricular myocardium (rabbit) (Endoh, M. (218) 355)

5-HT (5-hydroxytryptamine, serotonin); Platelet aggregation; Ca^{2+} mobilization (Pietraszek, M.H. (219) 289)

Vascular permeability; Coronary circulation (Filep, J.G. (219) 343)

Cerebral arteries; Peripheral arteries; Vasoconstriction; Ca^{2+} influx; Nifedipine; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Hypertension; Prostanoids; Ca^{2+} ionophore A23187; Prostanoid receptor blockers (Lin, L. (220) 49)

Endothelin receptor antagonists; Ischemic acute renal failure; Ca^{2+}; (Rat) (Mino, N. (221) 77)

BQ-123; Endothelin receptor subtypes; Regional haemodynamics; Vasodilatation; (Anaesthetized rat) (Douglas, S.A. (221) 315)

EGF (epidermal growth factor); Thrombin; Hypercholesterolemia; Aorta (rabbit); Vasospasm; Endothelium (Merkel, L.A. (222) 175)

Artery; Vein (Auguet, M. (224) 101)

Aggregation; Polymorphonuclear leukocytes; PAF (platelet-activating factor, PAF-acether) (Gómez-Garre, D. (224) 167)

Mitogenesis; Endothelin ET_A receptor; Endothelin ET_B receptor; BQ123 (Ohlstein, E.H. (225) 347)

Inositol 1,4,5-trisphosphate; Protein kinase C; Flosequinan (Lang, D. (226) 259)

Bradykinin; cGMP; EDRF (endothelium-derived relaxing factor); Forskolin; 5-HT (serotonin) (Reiser, G. (227) 89)

Granulocyte-colony stimulating factor (G-CSF); Endothelial cells (vascular) (Namiki, A. (227) 339)

Endothelin-3
Endothelin-1; Ileum (guinea-pig); Desensitization; Na^+ ions; Endothelin receptor subtypes (Miasiro, N. (214) 133)

^{125}I-Endothelin-1
Endothelin receptors; Spinal cord (human, pig); Autoradiography (quantitative receptor); Chemical cross-linking (Niwa, M. (225) 281)

Endothelin-1 analogues
Endothelin receptors; Vasodilatation; Vasoconstriction (Filep, J.G. (220) 263)

Endothelin ET_A receptor
Endothelin; Mitogenesis; Endothelin ET_B receptor; BQ123 (Ohlstein, E.H. (225) 347)

Endothelin ET_B receptor
Endothelin; Mitogenesis; Endothelin ET_A receptor; BQ123 (Ohlstein, E.H. (225) 347)

Endothelin peptides
Pulmonary vascular bed; U46619; Thromboxane A_2/endoperoxide receptor-mediated responses; Sulotroban; PAF (platelet-activating factor, PAF-acether) (Nossaman, B.D. (213) 1)

Endothelin receptor antagonists
Endothelin; Ischemic acute renal failure; Ca^{2+}; (Rat) (Mino, N. (221) 77)

Endothelin receptors
Endothelin-1 analogues; Vasodilatation; Vasoconstriction (Filep, J.G. (220) 263)

^{125}I-Endothelin-1; Spinal cord (human, pig); Autoradiography (quantitative receptor); Chemical cross-linking (Niwa, M. (225) 281)

Phospholipase C; Guanine nucleotide binding proteins (Gusovsky, F. (225) 339)

Endothelin receptor subtypes
Endothelin-3; Endothelin-1; Ileum (guinea-pig); Desensitization; Na^+ ions (Miasiro, N. (214) 133)

Endothelin-1; BQ-123; Regional haemodynamics; Vasodilatation; (Anaesthetized rat) (Douglas, S.A. (221) 315)

Endothelins
Sarafotoxins; Intestinal relaxation; Ca^{2+}-activated K^+ channels (Lin, W.-W. (219) 355)

Smooth muscle (uterus); Ca^{2+} levels (cytosolic); Ca^{2+} channels; (Rat) (Sakata, K. (221) 9)

Megakaryoblastic cells; Ca^{2+}; Inositol phosphates (Diochot, S. (227) 427)

Endothelium
ANP (atrial natriuretic polypeptide); Aorta (rat); Relaxation; Aging; cGMP; Phosphodiesterase activity (Moritoki, H. (210) 61)

Neuropeptide Y (NPY); Smooth muscle (vascular) (Small, D.L. (210) 131)

α-Adrenoceptors; Atherosclerosis; Vasoconstriction; (Conscious rabbits) (Du, Z.-Y. (211) 149)

Progesterone; Coronary artery relaxation; Ca^{2+} influx; K^+ conductance (Jiang, C. (211) 163)

Leukotrienes; Cromakalim; Heart (isolated, guinea-pig) (McLeod, J.D. (212) 67)

VIP (vasoactive intestinal polypeptide); Relaxation; Glibenclamide; Mesenteric artery (rabbit) (Hattori, Y. (213) 147)

5-HT (5-hydroxytryptamine, serotonin); Ca^{2+}; Prostacyclin (Gill, J.K. (214) 269)

Evodiamine; Ca^{2+} channels; K^+ channels; Mesenteric artery (Chiou, W.-F. (215) 277)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline (Gruetter, C.A. (217) 109)

Blood vessels; Hyporesponsiveness; Protein synthesis; Nitric oxide (NO); Lipopolysaccharide (Nakaki, T. (219) 311)

Aorta (rat); BAY k 8644 enantiomers; Nifedipine; $^{45}Ca^{2+}$ influx (Gil-Longo, J. (221) 1)

Neuropeptide Y (NPY); NPY receptor subtypes; Acetylcholine; Vasoconstriction; Vasodilatation (Grundemar, L. (221) 71)

Bradykinin; Basilar artery (canine) (Yen, M.-H. (221) 261)

Pulmonary artery (rabbit); L-N^G-Nitro arginine (L-NO_2Arg); Electrical transmural stimulation; Nitric oxide (NO); Noradrenaline release (Shinozuka, K. (222) 113)

EGF (epidermal growth factor); Endothelin; Thrombin; Hypercholesterolemia; Aorta (rabbit); Vasospasm (Merkel, L.A. (222) 175)

5-HT (5-hydroxytryptamine, serotonin); 5-Carboxamidotryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Van Gelderen, E.M. (222) 185)

Atrial natriuretic peptide (ANP); cGMP; (Receptor down-regulation) (Kato, J. (225) 113)

Endothelium-dependent relaxations
Thrombin; Thrombin receptor agonist (Res 42-55) (Simonet, S. (216) 135)

Endothelium-dependent vasorelaxation
CGRP (calcitonin gene-related peptide); Nitric oxide (NO); L-NMMA (N^G-monomethyl-L-arginine); L-NOARG (N^G-nitro-L-arginine) (Gray, D.W. (212) 37)

Endotoxaemia
L-NAME (N^G-nitro-L-arginine methyl ester); Vasopressin; Nitroprusside (sodium); Sympathetic stimulation; Vascular reactivity (Guc, M.O. (224) 63)

Endotoxic shock
Nitric oxide (NO); L-Arginine; EDRF (endothelium-derived relaxing factor) (Lambert, L.E. (216) 131)

PAF (platelet-activating factor, PAF-acether); Gastrointestinal; Inflammation; Parasitic infection (Hogaboam, C.M. (216) 315)

Endotoxin
Gastric acid secretion; Immunopharmacology; Indomethacin; Interleukin-1; Lipopolysaccharide; Prostaglandin (Tsuji, K. (210) 213)

Canavanine; Nitric oxide (NO) (Umans, J.G. (210) 343)

Shock; Nitric oxide (NO); Mesenteric arteries (small) (Schneider, F. (211) 269)

cGMP; L-Arginine/nitric oxide pathway; ANP (atrial natriuretic polypeptide) (Schuller, F. (212) 93)

Gastric acid; PAF (platelet-activating factor, PAF-acether); Nitric oxide (NO); Pentagastrin (Martinez-Cuesta, M.A. (218) 351)

Endotoxin/lipopolysaccharide
Corticosteroids; Fibroblasts (lung); Nitric oxide (NO); Nitrite; Interferon-γ; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

Endotoxin shock
Cloricromene; Tumor necrosis factor (TNF-α) (Squadrito, F. (210) 107)

Endplate type nicotinic acetylcholine receptors
Nitromethylene heterocycle insecticides; 1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI); Insect neuronal type nicotinic acetylcholine receptors; Neuronal type nicotinic acetylcholine receptors; Patch clamp technique (whole-cell) (Zwart, R. (228) 165)

Enkephalinase
Endothelin; Bronchus (isolated, human); Airway epithelium (Candenas, M.-L. (210) 291)

Enkephalin-degrading enzymes
RB 101 (mixed inhibitor); Naltrindole; Motility suppression (conditioned); Dopamine receptors; Antidepressants (Baamonde, A. (216) 157)

Enteric nervous system
Corticotropin-releasing hormone (CRH); Autonomic ganglia; Synaptic transmission; Intestine (Hanani, M. (211) 23)

Ganglia; Stomach; Adenosine; Synaptic transmission (Christofi, F.L. (216) 17)

cAMP; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Environment (hot)
Propranolol; Noradrenaline; Muscimol; Food intake (Kurose, Y. (211) 39)

Enzyme-linked immunosorbent assay (ELISA)
Cisplatin; Pt-DNA adducts; Epitope; Cultured cells (Vrána, O. (226) 5)

Eosinophils
$^{125}I^-$ ion binding; Autoradiography; Peroxidase; Trachea (guinea-pig) (Rigby, P.J. (228) 141)

EpDRF (epithelium-derived relaxing factor)
Acetylcholine; Electrical field stimulation; Epithelium-derived acetylcholinesterase; Trachealis muscle (guinea-pig); Physostigmine (Koga, Y. (220) 141)

Epidermal cells (mouse)
Staurosporine; 12-O-Tetradecanoylphorbol 13-acetate; Protein kinase C; Ornithine decarboxylase; Morphological changes (Yamamoto, S. (227) 113)

Epilepsy
Glycine; L-687,414; NMDA (N-methyl-D-aspartate); Behaviour; Excitatory amino acids (Smith, S.E. (211) 109)

Phorbol 12-myristate,13-acetate; Phorbol 12,13-dibutyrate; Protein kinase C; Behaviour; Staurosporine (Smith, S.E. (213) 133)

AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionate; Quinoxalinedione; Seizure; Ataxia (Taylor, C.P. (213) 151)

Absence seizures; $GABA_A$ receptors; $GABA_B$ receptors; γ-Hydroxybutyric acid; Pentylenetetrazole (Snead, III, O.C. (213) 343)

Vigabatrin; Tolerance; Dependence; GABA (γ-aminobutyric acid); Glutamate; Kindling (Rundfeldt, C. (213) 351)

NMDA receptor antagonists; Anticonvulsants; Audiogenic seizures; Genetically epilepsy-prone rats (De Sarro, G. (215) 221)

5-HT (5-hydroxytryptamine, serotonin); GABA (γ-aminobutyric acid); Acetylcholine; Cl^- transport; Brain; (Mouse) (Inoue, M. (221) 135)

ucb L059; Convulsions; Epileptogenesis; Petit-mal (Gower, A.J. (222) 193)

NMDA (N-methyl-D-aspartate); Valproate; MK-801; Behaviour (Dziki, M. (222) 273)

GABA uptake; NNC-711; Anticonvulsants (Suzdak, P.D. (224) 189)

ACTH; Myoclonus; NMDA receptors (Trifiletti, R.R. (226) 377)

Epileptiform activity
Glutamate receptors; Kainate; Barbiturates; Methohexitone (Palmer, A.J. (221) 205)

Epileptogenesis
ucb L059; Convulsions; Petit-mal; Epilepsy (Gower, A.J. (222) 193)

Epinephrine
Glucose; Memory; Propranolol; Phenoxybenzamine; Footshock (Hall, J.L. (221) 365)

Chromaffin cells; Norepinephrine; Acetylcholine; Glycine (Yadid, G. (221) 389)

Epithelium
ANF (atrial natriuretic factor); Relaxation; Trachea (guinea-pig); Trachea (rat); Bronchus (human); Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

Urinary bladder; Diabetes; Prostaglandins; Bradykinin (Pinna, C. (214) 143)

Kinins (characterization); Agonists; Bradykinin receptor antagonists; B_2 receptor antagonist (radiolabeled) (Tousignant, C. (225) 235)

Ageing; Trachea (guinea-pig and rat); Smooth muscle (airway); Histamine; Acetylcholine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Epithelium-derived acetylcholinesterase
Acetylcholine; Electrical field stimulation; EpDRF (epithelium-derived relaxing factor); Trachealis muscle (guinea-pig); Physostigmine (Koga, Y. (220) 141)

Epitope
Cisplatin; Pt-DNA adducts; Enzyme-linked immunosorbent assay (ELISA); Cultured cells (Vrána, O. (226) 5)

EPSP (excitatory postsynaptic potential)
γ-Hydroxybutyrate; $GABA_B$ receptors; CGP 36742; IPSP (inhibitory postsynaptic potential); Hippocampus (Xie, X. (223) 193)

Ergometrine
Basilar artery (rat); Myograph; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor classification; Ketanserin (Deckert, V. (221) 17)

Erythrocytes
21-Aminosteroids; Antioxidants; Lipid peroxidation; Copper; Plasma (Fernandes, A.C. (220) 211)

Esophagus (rat)
Relaxation; cAMP generation; $5\text{-}HT_4$ receptors; Gastrointestinal motility (Moummi, C. (216) 47)

Estrogen
Angiotensin II; Aorta (rat); Norepinephrine; Contraction (Cheng, D.Y. (215) 171)

Estrogen receptors
Polymerase chain reaction; (Sprague-Dawley rat) (Spreafico, E. (227) 353)

Estrone
Sulfotransferase; Dehydroepiandrosterone; Liver (human); Adverse drug reactions (Bamforth, K.J. (228) 15)

Ethacrynic acid
ATP depletion; GSH depletion; Diethyl maleate; Phorone; Hepatocytes (Redegeld, F.A.M. (228) 229)

Ethanol
Blood vessels (rabbit); Purinergic nerve stimulation; Co-transmission (Bulloch, J.M. (211) 1)

Locus coeruleus; GABA (γ-aminobutyric acid); Benzodiazepine; Picrotoxin; Ro 15-1788; Electrophysiology (Verbanck, P.M.P. (211) 15)

Baroreflex; GABA (γ-aminobutyric acid); Dorsal vagal complex (Varga, K. (214) 223)

Aspartate release; Glutamate release; Hippocampus; GABA (γ-aminobutyric acid) (Martin, D. (219) 469)

Morphine; Cocaine; Amphetamine; MK-801; SL 82.0715; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Dopamine neurons; Withdrawal syndrome (Diana, M. (221) 403)

NMDA receptor antagonism; Phencyclidine; NPC 12626; Drug discrimination (Balster, R.L. (222) 39)

Nitric oxide (NO); Respiratory system (Persson, M.G. (224) 99)

$GABA_A$ receptors; Cl^- currents; Modulation; Central nervous system (CNS); (Neurons) (Reynolds, J.N. (224) 173)

c-fos; Glutamate; NMDA (N-methyl-D-aspartate); Hybridization (in situ) (Morgan, P.F. (225) 217)

Ethanol intake
Brain (rat); Dopamine receptors; Dopamine D_1 receptors; Dopamine D_2 receptors; (Agonist affinity) (May, T. (215) 313)

Ethanol pretreatment (chronic)
Supersensitivity; Morphine; Vas deferens (mouse); Naloxone; μ-Opioid receptors (Tabach, R. (216) 449)

Ethanol ulcer
N-Phthaloyl γ-aminobutyric acid; Aspirin ulcer; Gastric acid secretion; Mucus secretion (Banerji, S. (219) 211)

Ethanol withdrawal
Withdrawal seizure prone mouse (WSP); Handling-induced convulsions; Abecarnil; Diazepam; Anticonvulsant effects; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

Ethylcholine mustard arizidinium ion
Retina; Acetylcholine; Glycine; Amacrine cells; ON channels; OFF channels; (Frog) (Jardon, B. (210) 201)

N-Ethylmaleimide alkylation
Dopamine transport; Cocaine; d-Amphetamine; [^{3}H]Mazindol binding (Johnson, K.M. (227) 411)

N-Ethyl,N-nitrosourea
Neurotransmitters; Brain enzymes; Biogenic amine metabolism; (CD1 mouse) (Jayasekara, S. (228) 37)

Etonitazene
Morphine; Conditioned place preference (Sala, M. (217) 37)

[^{3}H]Etorphine
δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Sucrose gradients; Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

β-Eudesmol
Acetylcholine release; Anticholinesterase; Neostigmine; Neuromuscular transmission; Tetanic fade (Chiou, L.C. (216) 199)

Eudismic analysis
Muscarinic receptors; Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Pfeiffer's rule; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

Eukaryotic expression vector
Dopamine D_3 receptor (human); Transfected cell; Neuroleptics; Guanylnucleotide; G protein; Dopamine autoreceptor (Sokoloff, P. (225) 331)

Evodiamine
Endothelium; Ca^{2+} channels; K^+ channels; Mesenteric artery (Chiou, W.-F. (215) 277)

Excitability
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1C}/5-HT_2 receptors; Motoneurons; Spinal cord; (Slice) (Yamazaki, J. (220) 237)

Excitatory amino acid
Excitotoxicity; Metabotropic receptors (McDonald, J.W. (215) 353)

Ca^{2+} channels; Dihydropyridines; NMDA (N-methyl-D-aspartate); Dopamine; Transmitter release; Mesencephalon (Chaudieu, I. (220) 203)

S-Nitrosothiols; Baroreceptor reflex; Cardiovascular regulation; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Machado, B.H. (221) 179)

Excitatory amino acid receptor antagonists
Penile erection; Yawning; Apomorphine; Oxytocin; ACTH (adrenocorticotropin) (Melis, M.R. (220) 43)

Excitatory amino acid receptors
Vinpocetine; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Domoic acid; Kainic acid; AMPA; Neurotoxin (Hampson, D.R. (218) 1)

Spider toxins; NMDA (N-methyl-D-aspartic acid); Kainate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Davies, M.S. (227) 51)

Excitatory amino acids
Glycine; L-687,414; NMDA (N-methyl-D-aspartate); Behaviour; Epilepsy (Smith, S.E. (211) 109)

Spinal cord; Intrathecal; NMDA receptors; Non-NMDA receptors (Näsström, J. (212) 21)

Uptake; Toxicity (delayed) (Zinkand, W.C. (212) 129)

Nitric oxide (NO); NMDA (N-methyl-D-aspartate); Cerebellar granule cells; S-Nitroso-N-acetylpenicillamine; Neurotrophic effects (Boje, K.M. (212) 151)

Dizocilpine; Focal ischaemia; (Rat) (Hatfield, R.H. (216) 1)

Metabotropic receptors; Cerebral ischaemia (Chiamulera, C. (216) 335)

Spinal cord contusion; NMDA receptor antagonists; Non-NMDA receptor antagonists (Wrathall, J.R. (218) 273)

Proline; Hippocampus; NMDA (N-methyl-D-aspartate) (Martin, D. (219) 59)

Ischemia; Neuronal damage; Vinconate; Muscarinic receptors (presynaptic) (Iino, T. (224) 117)

Excitatory transmission
$GABA_B$ receptors (presynaptic); $GABA_B$ receptors (postsynaptic); Patch/slice recording; Inhibitory transmission (Lovinger, D.M. (211) 337)

Excitotoxicity
Aminooxyacetic acid; Kynurenic acid; Kynurenine; Microdialysis; Neuroprotection (Wu, H.-Q. (213) 375)

Excitatory amino acid; Metabotropic receptors (McDonald, J.W. (215) 353)

Glycine; NMDA receptors; Kynurenates; Thiokynurenates; Ischemia (Moroni, F. (218) 145)

1S,3R-ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid); Metabotropic glutamate receptors (Siliprandi, R. (219) 173)

Exocrine secretion
Pancreas (dog); Phosphodiesterase inhibitors; Rolipram (Iwatsuki, K. (209) 63)

Pancreas (dog); YM435; Dopamine D_1 receptor agonists (Iwatsuki, K. (218) 237)

Exploratory behaviour
Benzodiazepine receptors; Locomotor activity; Inverse agonists (Jackson, H.C. (221) 199)

Extracellular recording
Nicotinic receptor agonists; Olfactory cortex slice (guinea-pig); Surface field potential (N-wave); Antimuscarinic action (Libri, V. (212) 253)

Dopamine cells; Neurokinin receptors (Overton, P. (213) 165)

Extracellular single unit
Central nucleus of the amygdala; Cocaine; Cross-correlation; Microinjection; (Cat) (Ni, H. (224) 157)

Facilitation
NMDA (N-methyl-D-aspartate); Nitric oxide (NO); L-Arginine; Nociception; Spinal cord; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

Fatty acids (omega-3, omega-6, omega-9)
Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil (Engler, M.B. (215) 325)

Fc receptors
Peritoneal cells (rat); Phagocytosis (bacterial); Eicosanoids; Indomethacin; CR1 receptors (Coquette, A. (226) 1)

Feeding
NAN-190; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT_{1A} receptors; (Rat) (Williams, A.R. (219) 105)

Feeding behaviour
Anorexia; B-HT 920; ACTH (adrenocorticotropin); Immobilisation; (Rat) (Ferrari, F. (210) 17)

Galanin; Sexual behaviour; (Male rat) (Poggioli, R. (213) 87)

Interleukin; α-MSH (α-melanocyte-stimulating hormone) (Uehara, Y. (220) 119)

Feeding parameters
5-HT receptors; d-Fenfluramine; (Rat) (Grignaschi, G. (212) 287)

Feeding patterns
d-Fenfluramine; Sertraline; Satiety; Motor activity; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Grignaschi, G. (211) 137)

Felbamate
Anticonvulsants; Cerebral ischemia; Neonate; Asphyxia neonatorum; Cerebral infarction (Wasterlain, C.G. (212) 275)

Femoral artery (simian)
Vasopressin V_1 receptors; Vasopressin V_2 receptors; (Cannula insertion method) (Chiba, S. (221) 393)

Fenfluramine
5-HT (5-hydroxytryptamine, serotonin); Dopamine; Self-stimulation; Amphetamine (Olds, M.E. (216) 363)

d-Fenfluramine
Sertraline; Feeding patterns; Satiety; Motor activity; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Grignaschi, G. (211) 137)

5-HT receptors; Feeding parameters; (Rat) (Grignaschi, G. (212) 287)

Fenoterol
Thyroxine; Portal vein; β-Adrenoceptors; Noradrenaline; Atenolol; ICI 118,551 (Chin, J.P.F. (212) 201)

Fentanyl
Opiates; Lofentanil; Ileum; Vas deferens; (Receptor binding) (Maguire, P. (213) 219)

F8Famide
F8Famide binding sites; Peptide degradation; Morphine analgesia (Gicquel, S. (222) 61)

F8Famide binding sites
F8Famide; Peptide degradation; Morphine analgesia (Gicquel, S. (222) 61)

[^{18}F]FEF (5-(2′-[^{18}F]Fluoroethyl)flumazenil)
Benzodiazepine receptors; PET (positron emission tomography); Imaging; Flumazenil; Neuroreceptors (Moerlein, S.M. (218) 109)

bFGF (basic fibroblast growth factor)
Cerebral ischemia; Hippocampus; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

Fibroblast
Interleukin-1; Interleukin-6; Prostaglandins; 15-HETE (15-hydroxyeicosatetraenoic acid) (Elliott, G.R. (214) 253)

Fibroblasts (lung)
Corticosteroids; Nitric oxide (NO); Nitrite; Interferon-γ; Endotoxin /lipopolysaccharide; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

Field stimulation
Substance P; Neurokinin A; Capsaicin; Airway constriction; Airway edema (Murai, M. (217) 23)

Firing rate
ATP; Suramin; P_2 purinoceptors; Locus coeruleus neurones (Tschöpl, M. (213) 71)

Fish oil
Docosahexaenoic acid; Eicosapentaenoic acid; Fatty acids (omega-3, omega-6, omega-9) (Engler, M.B. (215) 325)

Fixed-interval responding
Punishment; Diazepam; Pentobarbital; Phencyclidine; Tolerance; (Pigeon) (McMillan, D.E. (215) 145)

Flecainide
Na^+ channels; Myocytes (ventricular, guinea-pig) (Nitta, J.-i. (214) 191)

Flosequinan
Phosphodiesterase isoenzymes; Cardiac muscle; Smooth muscle (aortic); BTS 53 554; (Guinea-pig) (Frodsham, G. (211) 383)

Endothelin-1; Inositol 1,4,5-trisphosphate; Protein kinase C (Lang, D. (226) 259)

Flumazenil
Benzodiazepine receptors; PET (positron emission tomography) (Abadie, P. (213) 107)

Benzodiazepine receptors; PET (positron emission tomography); [^{18}F]FEF (5-(2′-[^{18}F]Fluoroethyl)flumazenil); Imaging; Neuroreceptors (Moerlein, S.M. (218) 109)

Flunarizine
Cough reflex; Ca^{2+} channels; Antitussive effect; Nifedipine; Verapamil (Kamei, J. (212) 61)

Cardiac death (sudden); Ventricular fibrillation; Ca^{2+} channel antagonists (Billman, G.E. (212) 231)

Fluoride
Smooth muscle (vascular); Al^{3+}; G-protein; Ca^{2+} sensitivity; Protein kinase C (Kawase, T. (214) 39)

p-Fluoro-hexahydro-sila-difenidol
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Fluoxetine
5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

G proteins; Polymerase chain reaction; mRNA expression (Lesch, K.P. (227) 233)

Focal ischaemia
Dizocilpine; Excitatory amino acids; (Rat) (Hatfield, R.H. (216) 1)

Food intake
Omeprazole; Gastrin; (Chicken) (Campbell, B.J. (209) 231)

Propranolol; Noradrenaline; Muscimol; Environment (hot) (Kurose, Y. (211) 39)

Bombesin; Satiety; Bombesin receptor agonists; Bombesin receptor antagonists; CCK receptor antagonists (Laferrère, B. (215) 23)

Footshock
Epinephrine; Glucose; Memory; Propranolol; Phenoxybenzamine (Hall, J.L. (221) 365)

Forced swimming test
Alprazolam; Desipramine; Diazepam (Flugy, A. (214) 233)

Phosphoinositide hydrolysis; 5-HT_2 receptors; Mianserin; Imipramine; Affective disorders (Kawanami, T. (216) 385)

Formalin
Nociception; Spinal cord; Bradykinin; Prostaglandins; (Rat) (Chapman, V. (219) 427)

Formalin test
Antinociception; Writhing test; Hot-plate test; Ca^{2+} channel blockers (Miranda, H.F. (217) 137)

Formycin A triphosphate (FTP)
Guanylate cyclase; ATP; Atrial natriuretic factor (ANF); cGMP (Chang, C.-H. (227) 229)

Forskolin
Cardiac hypertrophy; Action potential; Depolarizations (transient); Na^+,K^+-ATPase; Ryanodine (Mészáros, J. (210) 325)

Cardiac hypertrophy; β-Adrenoceptors; Adenylate cyclase; Ca^{2+} channels (slow) (Mészáros, J. (210) 333)

Smooth muscle (vascular); Aorta; Dibutyryl cAMP; Fura-2-Ca^{2+} signal; Ca^{2+} sensitivity; (Rat) (Abe, A. (211) 305)

Acetylcholine; Nitric oxide (NO); Guanylyl cyclase; Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

dbcAMP; Desensitisation; Myocytes; Heart failure; (Human) (Harding, S.E. (223) 39)

1,9-Dideoxyforskolin; Adenosine; Phosphodiesterase inhibitors; Inward calcium current-dependent phasic tension; Atrial fibres (frog) (Gauthier, C. (225) 129)

Bradykinin; cGMP; Endothelin; EDRF (endothelium-derived relaxing factor); 5-HT (serotonin) (Reiser, G. (227) 89)

Fos
α_2-Adrenoceptors; Yohimbine; Clonidine; Guanabenz (Tsujino, T. (226) 69)

FR 113680
NK_1 receptors; Tachykinin receptor antagonists; CP-96,345; L 668,169; Spantide II (Patacchini, R. (215) 93)

Fragment
Galanin-(1–15); Autoradiography; (Receptor) (Hedlund, P.B. (224) 203)

F344 rats
Aging; Cardiac muscle; Dihydropyridines; Ca^{2+} (extracellular); Isoproterenol (Ruch, S. (216) 393)

Free radical
Immunosuppressants; Emodin (Huang, H.-C. (211) 359)

β-Adrenoceptor antagonists; Carvedilol; Superoxide; Neutrophils; Antioxidants (Yue, T.-L. (214) 277)

Baicalein; Ear edema; Lipid peroxidation; α-Tocopherol (Hara, H. (221) 193)

Free radical scavenger
α-Tocopherol analogue; Antioxidant; Reperfusion injury; Vitamin E; Myocardial ischaemia/reperfusion (Petty, M.A. (210) 85)

Vasodilator effect; Scoparone (Huang, H.-C. (218) 123)

Frontal cortex
GABA (γ-aminobutyric acid); 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Hippocampus; Benzodiazepines (File, S.E. (218) 9)

Dopamine release; 3-Methoxytyramine; Striatum; Nucleus accumbens; (Rat) (Chrapusta, S.J. (222) 129)

Frontal cortex (bovine)
Serotonin-binding proteins; [^{3}H]Serotonin binding; [^{3}H]Dopamine binding (Jimenez Del Rio, M. (225) 225)

Functional antagonism
NECA (5′-N-ethylcarboxamidoadenosine); Isoproterenol; Nitric oxide (NO); Nitroglycerin; Sodium nitroprusside (Wiener, H.L. (220) 131)

Functional selectivity
Muscarinic M_1 receptor agonists; L-687,306 (Freedman, S.B. (215) 135)

Fura-2
Tetronothiodin; CCK_B receptor antagonists; GH3 cells; Ca^{2+} (cytosolic); [^{125}I]CCK-8 binding (Kuwahara, T. (221) 99)

Intracellular Ca^{2+}; Ca^{2+} channels; Ca^{2+} ionophore; Co^{2+}; La^{3+} (Horváth, G. (225) 305)

Ca^{2+} channel; Calmodulin; CGS 9343B; Patch clamp (Neuhaus, R. (226) 183)

Fura-2-Ca^{2+} signal
Smooth muscle (vascular); Aorta; Dibutyryl cAMP; Forskolin; Ca^{2+} sensitivity; (Rat) (Abe, A. (211) 305)

Fura-2 (fluorimetry)
Tetrahydroaminoacridine (THA); Tacrine; 4-Aminopyridine (4-AP); Drug interactions (Järlebark, L. (225) 75)

GABA
Benzodiazepine receptors; Ro 15-4513; Ro 19-4603; Annelated 1,4-diazepines (Wong, G. (225) 63)

GABA/benzodiazepine receptors
Benzodiazepine exposure (chronic); Tolerance; Steroid hormones; Ovariectomy; Anticonvulsants (Wilson, M.A. (215) 99)

GABA brain levels
Microdialysis; GABA uptake inhibitor; Anticonvulsants; Tiagabine; (Rat) (Fink-Jensen, A. (220) 197)

$GABA_B$ receptors
Substantia nigra; GABA (γ-aminobutyric acid); Baclofen; (Rat) (Garant, D. (214) 75)

GABA (γ-aminobutyric acid)
α-MSH (α-melanocyte-stimulating hormone); Benzodiazepines; Hypothalamus (Mabley, J. (209) 127)

Glial uptake; Thalamus; Sleep; (Cat) (Juhász, G. (209) 131)

Ethanol; Locus coeruleus; Benzodiazepine; Picrotoxin; Ro 15-1788; Electrophysiology (Verbanck, P.M.P. (211) 15)

γ-Hydroxybutyrate; $GABA_B$ receptors; CGP35348; Hippocampus; Zn^{2+} (Xie, X. (212) 291)

Vigabatrin; Tolerance; Dependence; Glutamate; Kindling; Epilepsy (Rundfeldt, C. (213) 351)

Substance P; Bicuculline; Nucleus tractus solitarii; (Evoked responses); (Rat) (Pérez, H. (213) 435)

Substantia nigra; $GABA_B$ receptors; Baclofen; (Rat) (Garant, D. (214) 75)

Baroreflex; Ethanol; Dorsal vagal complex (Varga, K. (214) 223)

Baclofen; Jejunum (human); Colon (human); Intestinal motility (Gentilini, G. (217) 9)

Clonidine; α_2-Adrenoceptors (presynaptic); Aspartate; Glutamate; Brain (rat) (Kamisaki, Y. (217) 57)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Hippocampus; Frontal cortex; Benzodiazepines (File, S.E. (218) 9)

$GABA_B$ receptors; Neocortex; Acetylcholine; Quisqualate; (Rat) (Andre, P. (218) 137)

Down-regulation; Triazolam; Dopamine receptors; Quinpirole; 6-Hydroxydopamine (6-OHDA) (Zhou, L.-W. (218) 219)

Emotionality; Diazepam; Pentobarbital; Cl^- flux; (Mouse) (Mihic, S.J. (218) 283)

Hippocampus; Chlordiazepoxide; Benzodiazepine; Muscimol; Memory (working, reference) (Ohno, M. (219) 245)

Aspartate release; Glutamate release; Ethanol; Hippocampus (Martin, D. (219) 469)

Aminooxyacetic acid; Learning; Pentobarbital; Seizures; Substance P (Vécsei, L. (220) 259)

Epilepsy; 5-HT (5-hydroxytryptamine, serotonin); Acetylcholine; Cl^- transport; Brain; (Mouse) (Inoue, M. (221) 135)

Bicuculline; Diazepam; Lithium chloride; Pilocarpine; Seizures (Peterson, C.J. (221) 151)

$GABA_B$ receptors; Adenylyl cyclase (inhibition); cAMP; Baclofen; Cerebellar granule cells (Holopainen, I. (227) 225)

GABA (γ-aminobutyric acid) shift
Dihydroergotoxine; [^{3}H]TBOB (t-[^{3}H]butylbicycloorthobenzoate) binding; Barbiturate sleeping; Picrotoxin-induced convulsions (Tvrdeić, A. (221) 139)

GABA receptors
Strychnocarpine; β-Carbolines; 5-HT (5-hydroxytryptamine, serotonin); Benzodiazepines; Tryptamine; Opiate receptors (Strömbom, J. (214) 165)

GABA receptor agonists
Cough; Citric acid; α_2-Adrenoceptor agonists; (Conscious guinea-pig) (Callaway, J.K. (220) 187)

$GABA_B$ receptor agonists
Baclofen; Thienyl baclofen analogs; 2-Hydroxysaclofen; Ileum (guinea-pig, isolated) (Ong, J. (218) 343)

$GABA_A$ receptor antagonism
RU 5135; $GABA_A$ receptor complex; 5α-Pregnane-3α-ol-20-one (3α,5α-P); 5α-Pregnane-3α-20α-diol (5α-pregnanediol); Neurosteroid site (Cadoni, C. (227) 147)

$GABA_A$ receptor complex
RU 5135; 5α-Pregnane-3α-ol-20-one (3α,5α-P); 5α-Pregnane-3α-20α-diol (5α-pregnanediol); $GABA_A$ receptor antagonism; Neurosteroid site (Cadoni, C. (227) 147)

$GABA_A$ receptor complex (α_1 subunit; γ_2 subunit; β_1 subunit)
Benzodiazepine; Tolerance; (Rat) (Primus, R.J. (226) 21)

$GABA_A$ receptors
Chlormethiazole; Glycine receptors; Patch-clamp; Anaesthetics (general); Anticonvulsants (Hales, T.G. (210) 239)

Granule cells; TBPS (t-butylbicyclophosphorothionate) (Korpi, E.R. (211) 427)

Absence seizures; Epilepsy; $GABA_B$ receptors; γ-Hydroxybutyric acid; Pentylenetetrazole (Snead, III, O.C. (213) 343)

Carbon dioxide (CO_2); Brain (rat) (Sanna, E. (216) 457)

Circadian rhythm; Suprachiasmatic nucleus; 2-Deoxyglucose uptake; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Benzodiazepine receptors (Tominaga, K. (217) 79)

Striatum; Substantia nigra; Dopamine release; Microdialysis; $GABA_B$ receptors (Santiago, M. (219) 175)

Ethanol; Cl^- currents; Modulation; Central nervous system (CNS); (Neurons) (Reynolds, J.N. (224) 173)

Neurosteroid; Cloned subtypes; *Xenopus* oocyte expression (Zaman, S.H. (225) 321)

Benzodiazepines; Tolerance; mRNA levels; (Rat) (O'Donovan, M.C. (226) 335)

$GABA_B$ receptors
γ-Hydroxybutyrate; GABA (γ-aminobutyric acid); CGP35348; Hippocampus; Zn^{2+} (Xie, X. (212) 291)

Absence seizures; Epilepsy; $GABA_A$ receptors; γ-Hydroxybutyric acid; Pentylenetetrazole (Snead, III, O.C. (213) 343)

Inaperisone hydrochloride; Micturition reflex; Rhythmic bladder contraction; (Rat) (Morikawa, K. (213) 409)

GABA (γ-aminobutyric acid); Neocortex; Acetylcholine; Quisqualate; (Rat) (Andre, P. (218) 137)

Tyrosine hydroxylase; NMDA receptors; Baclofen; Dopamine synthesis; Dopaminergic transmission (Montaño, J.-A.A. (218) 335)

Striatum; Substantia nigra; Dopamine release; Microdialysis; $GABA_A$ receptors (Santiago, M. (219) 175)

γ-Hydroxybutyrate; CGP 36742; EPSP (excitatory postsynaptic potential); IPSP (inhibitory postsynaptic potential); Hippocampus (Xie, X. (223) 193)

GABA (γ-aminobuteric acid); Adenylyl cyclase (inhibition); cAMP; Baclofen; Cerebellar granule cells (Holopainen, I. (227) 225)

$GABA_A$ receptors (α subunits)
Benzodiazepine receptors (central); Modification of receptors; [^{3}H]Ro 15-4513 binding; Diethylpyrocarbonate; 2,3-Butanedione (Maksay, G. (227) 57)

$GABA_B$ receptors (postsynaptic)
$GABA_B$ receptors (presynaptic); Patch/slice recording; Excitatory transmission; Inhibitory transmission (Lovinger, D.M. (211) 337)

$GABA_B$ receptors (presynaptic)
$GABA_B$ receptors (postsynaptic); Patch/slice recording; Excitatory transmission; Inhibitory transmission (Lovinger, D.M. (211) 337)

GABA uptake
NNC-711; Anticonvulsants; Epilepsy (Suzdak, P.D. (224) 189)

GABA uptake inhibitor
Microdialysis; GABA brain levels; Anticonvulsants; Tiagabine; (Rat) (Fink-Jensen, A. (220) 197)

Galanin
Galanin receptor antagonists; Insulin secretion; Galantide; (Displacement) (Lindskog, S. (210) 183)

Sexual behaviour; Feeding behaviour; (Male rat) (Poggioli, R. (213) 87)

Galanin-(1–15)
Autoradiography; Fragment; (Receptor) (Hedlund, P.B. (224) 203)

Galanin C-terminal fragments (rat)
Galanin (rat); Galanin N-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Gastric fistula (chronic); Venous cannula (chronic) (Mungan, Z. (214) 53)

Galanin N-terminal fragments (rat)
Galanin (rat); Galanin C-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Gastric fistula (chronic); Venous cannula (chronic) (Mungan, Z. (214) 53)

Galanin (rat)
Galanin N-terminal fragments (rat); Galanin C-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Gastric fistula (chronic); Venous cannula (chronic) (Mungan, Z. (214) 53)

Galanin receptor antagonists
Galanin; Insulin secretion; Galantide; (Displacement) (Lindskog, S. (210) 183)

Galantide
Galanin; Galanin receptor antagonists; Insulin secretion; (Displacement) (Lindskog, S. (210) 183)

Gallamine
Muscarinic receptors; Parasympathetic nervous system; Lung resistance; Pirenzepine; (Cat) (Killingsworth, C.R. (210) 231)

Gall bladder contractions
CCK-7 analogues; Receptor binding; Amylase secretion; Anorexia; Analgesia; Sedation (Maletínská, L. (222) 233)

Ganglia
Enteric nervous system; Stomach; Adenosine; Synaptic transmission (Christofi, F.L. (216) 17)

Ganglionic blockers
CGRP (calcitonin gene-related peptide); Circulatory filling pressure (mean); Venous tone; Noradrenaline (Abdelrahman, A. (217) 185)

Ganglionic transmission
Sympathetic ganglia (bullfrog); Autonomic ganglia; Compound 48/80; Neuronal excitability; Spike afterhyperpolarization (Heppner, T.J. (213) 427)

Ganglioside administration
Nigrostriatal hemitransection; Dopamine uptake; Dopamine release; Acetylcholine release; (Recovery of function) (Raiteri, M. (213) 17)

Gastric acid
Endotoxin; PAF (platelet-activating factor, PAF-acether); Nitric oxide (NO); Pentagastrin (Martinez-Cuesta, M.A. (218) 351)

Gastric acid secretion
Prostaglandin E_2; Indomethacin; Vagus; Baclofen (Saperas, E. (209) 1)

Endotoxin; Immunopharmacology; Indomethacin; Interleukin-1; Lipopolysaccharide; Prostaglandin (Tsuji, K. (210) 213)

N-Phthaloyl γ-aminobutyric acid; Aspirin ulcer; Ethanol ulcer; Mucus secretion (Banerji, S. (219) 211)

σ Receptor ligands; CRF (corticotropin-releasing factor); Gastric emptying (Yoneda, M. (223) 197)

Gastric acid secretion (inhibition of pentagastrin-stimulated)
Galanin (rat); Galanin N-terminal fragments (rat); Galanin C-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric fistula (chronic); Venous cannula (chronic) (Mungan, Z. (214) 53)

Gastric antisecretory activity
Gastrin receptor antagonists; CCK receptor antagonists; Proglumide; Lorglumide (Revel, L. (216) 217)

Gastric emptying
σ Receptor ligands; CRF (corticotropin-releasing factor); Gastric acid secretion (Yoneda, M. (223) 197)

Gastric fistula (chronic)
Galanin (rat); Galanin N-terminal fragments (rat); Galanin C-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Venous cannula (chronic) (Mungan, Z. (214) 53)

Gastric fundus
BRL 38227 (lemakalim); Pinacidil; Non-adrenergic non-cholinergic neurostimulation; K^+ channels; (Rat) (Lefebvre, R.A. (214) 1)

Gastric fundus (rat)
Cyclic nucleotides; Non-adrenergic non-cholinergic (NANC) relaxation; IBMX (3-Isobutyl-1-methylxanthine); Zaprinast (Barbier, A.J. (210) 315)

Non-adrenergic non-cholinergic (NANC); Nitric oxide (NO); LY 83583 (Barbier, A.J.M. (219) 331)

VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurotransmission (Lefebvre, R.A. (221) 235)

Gastric motility
Noradrenergic mechanisms (central); α-Adrenoceptors; Brainstem (Nagata, M. (223) 153)

Gastric mucosa
Prostanoids; Radioligand binding; Prostaglandin receptors; Parietal cells; Antisecretory potency (Hennies, S. (218) 303)

Nitric oxide (NO); Capsaicin; Sensory neurons; CGRP (calcitonin gene-related peptide); L-NAME (N^G-nitro-L-arginine methyl ester) (Whittle, B.J.R. (218) 339)

Nitric oxide (NO); Mucus (Brown, J.F. (223) 103)

Gastric mucosa blood volume
Proton pump inhibitors; Gastric mucosa oxygenation; Reflectance spectrophotometry; Hemorrhagic shock; Omeprazole; NC-1300 (Kawano, S. (211) 55)

Gastric mucosa oxygenation
Proton pump inhibitors; Gastric mucosa blood volume; Reflectance spectrophotometry; Hemorrhagic shock; Omeprazole; NC-1300 (Kawano, S. (211) 55)

Gastrin
Omeprazole; Food intake; (Chicken) (Campbell, B.J. (209) 231)

Gastrin receptor antagonists
CCK receptor antagonists; Gastric antisecretory activity; Proglumide; Lorglumide (Revel, L. (216) 217)

Gastrin releasing peptide
cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Gastrointestinal
PAF (platelet-activating factor, PAF-acether); Inflammation; Endotoxic shock; Parasitic infection (Hogaboam, C.M. (216) 315)

Gastrointestinal content
Naltrexone; [Met^5]enkephalin; [Leu^5]enkephalin; β-Endorphin (McIntosh, C.H.S. (223) 117)

Gastrointestinal motility
Esophagus (rat); Relaxation; cAMP generation; 5-HT_4 receptors (Moummi, C. (216) 47)

Gastrointestinal transit
Opiate receptors; μ-Opioid receptors; δ-Opioid receptors; κ-Opioid receptors; Opiate lethality (Pick, C.G. (211) 375)

[D-Ala^2]deltorphin II; Castor-oil diarrhea; Colonic bead expulsion; (I.c.v. and i.t. administration); (Rat) (Broccardo, M. (218) 69)

THIP (tetrahydroisoxazolo-pyridin-3-ol); Muscimol; Neurotransmitters (Ramaswamy, S. (220) 147)

Gastrointestinal ulceration
Endothelin-1; Thromboxane A_2; Vascular permeability; Airways; Inflammation (Sirois, M.G. (214) 119)

Gastroprotection
Nitric oxide (NO); Blood flow (mucosal); Nocloprost (Konturek, S.J. (211) 277)

GBR 12909
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; Nomifensine; Amphetamine (Meloni, R. (209) 113)

GBR-12783
Cocaine; [^{3}H]Methylphenidate; Stimulants; Dopamine transporters (Deutsch, H.M. (220) 173)

[^{3}H]GBR 12783 binding (in vivo)
Dopamine uptake complex; Dopamine uptake inhibitors; (Mouse) (Vaugeois, J.-M. (210) 77)

[^{18}F]GBR 13119 binding
Dopamine uptake; Reserpine; (In vivo); (Mouse) (Kilbourn, M.R. (216) 109)

GBR 12935
[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding; Cocaine; BTCP (N-[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine); Dopamine uptake inhibitors (Reith, M.E.A. (227) 417)

Gene expression
Prolactin; Smooth muscle (vascular); Hypertension; c-myc; Ornithine decarboxylase (Sauro, M.D. (225) 351)

Genetically epilepsy-prone rats
Epilepsy; NMDA receptor antagonists; Anticonvulsants; Audiogenic seizures (De Sarro, G. (215) 221)

Gene transcription
Phorbol esters; Adenosine receptors; Adenylyl cyclase; T-lymphocytes (Kontny, E. (227) 333)

Gentamicin
Catecholamine level; Striatum; Hypothalamus; Adrenal medulla; Vas deferens (Mikami, M. (210) 91)

GH3 cells
Tetronothiodin; CCK_B receptor antagonists; Ca^{2+} (cytosolic); Fura-2; [^{125}I]CCK-8 binding (Kuwahara, T. (221) 99)

GH_4ZR_7 cells
Cell culture; Anterior pituitary; Prolactin; Dopamine D_2 receptors; Partial agonists; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Glial uptake
GABA (γ-aminobutyric acid); Thalamus; Sleep; (Cat) (Juhász, G. (209) 131)

Glibenclamide
K^+ channel opener; NIP-121; Cromakalim; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Sulfonylureas; Cromakalim; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

VIP (vasoactive intestinal polypeptide); Relaxation; Endothelium; Mesenteric artery (rabbit) (Hattori, Y. (213) 147)

Efaroxan; Plasma insulin; Plasma glucose (Berridge, T.L. (213) 213)

Glisoxepide; Biliary elimination; Anion transport; Liver; Sulfonylurea; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

Glisoxepide; Organic anions; Monocarboxylate transport; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide; Oleate (Fückel, D. (213) 393)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Glibenclamide-sensitive K^+ channels
Adenosine; Antianginal vasodilator; Antihypertensive vasodilator; 2-(1-Octynyl)-adenosine (YT-146) (Yoneyama, F. (213) 199)

Glioma cells (rat)
C-type natriuretic peptide (CNP); Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Receptor binding; cGMP (Eguchi, S. (225) 79)

Gliomas (human)
Peripheral benzodiazepine receptors; Tumor models (rat); AA tumor; C6 gliomas (Takada, A. (228) 131)

Glipizide
Somatostatin; Prolactin (Fosset, M. (220) 273)

Glisoxepide
Glibenclamide; Biliary elimination; Anion transport; Liver; Sulfonylurea; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

Glibenclamide; Organic anions; Monocarboxylate transport; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide; Oleate (Fückel, D. (213) 393)

Global ischaemia
1-Aminocyclopropanecarboylic acid; Glycine receptors; NMDA receptors; (Gerbil) (Von Lubitz, D.K.J.E. (219) 153)

Glomerular filtration rate
Semotiadil; DuP753; Renal blood flow; Renin–angiotensin system (Nishiyama, A. (218) 311)

Glomeruli
Thromboxane A_2 receptors; Platelets (radioligand binding); Inositol phosphates (Folger, W.H. (227) 71)

Glucagon
Tryptamine; 5-HT receptors; (Mouse) (Yamada, J. (216) 307)

Glucose
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 receptors; Insulin; Sympathoadrenal system (Baudrie, V. (213) 41)

Cold stress; 5-HT receptor subtypes; 5-HT turnover; Behavioural responses; Corticosterone (Zamfir, O. (219) 261)

Epinephrine; Memory; Propranolol; Phenoxybenzamine; Footshock (Hall, J.L. (221) 365)

Glucose homeostasis
Efaroxan; Idazoxan; Prazosin; Vas deferens; Anococcygeus; (Pithed rat) (Berridge, T.L. (213) 205)

Glucose transport
Adenosine; Adenosine receptors; Insulin sensitivity; Amino acid transport; Skeletal muscle (Challiss, R.A.J. (226) 121)

Glutamate
AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Ca^{2+} entry blockers; Neurotoxicity (Pizzi, M. (209) 169)

cAMP; Brain slices; Locus coeruleus; Opiates; Withdrawal (Kogan, J.H. (211) 47)

Histamine; NMDA receptors; Microdialysis; Hypothalamus (Okakura, K. (213) 189)

Vigabatrin; Tolerance; Dependence; GABA (γ-aminobutyric acid); Kindling; Epilepsy (Rundfeldt, C. (213) 351)

Clonidine; α_2-Adrenoceptors (presynaptic); Aspartate; GABA (γ-aminobutyric acid); Brain (rat) (Kamisaki, Y. (217) 57)

Ethanol; c-fos; NMDA (N-methyl-D-aspartate); Hybridization (in situ) (Morgan, P.F. (225) 217)

Metabotropic receptors; Afterdepolarization (Greene, C. (226) 279)

Spider toxin; Ca^{2+} channel (mammalian, presynaptic) (Pocock, J.M. (226) 343)

Philanthotoxin-343; Hippocampus; NMDA receptors; AMPA/kainate receptors; Polyamines (Fedorov, N.B. (228) 201)

L-Glutamate
2-(Carboxycyclopropyl)glycine; NMDA receptors; D-Aspartate uptake; $[Ca^{2+}]_i$ increase; Neurotoxicity (Kawai, M. (211) 195)

Quipazine; Subretrofacial nucleus; Caudal ventrolateral medulla; Lateral tegmental field; Nucleus tractus solitarii (Vayssettes-Courchay, C. (211) 243)

Corticostriatal pathways; Dopamine; Ascorbate; Apomorphine; Scopolamine; (Rat) (Desole, M.S. (219) 67)

Glutamate receptors
Kainate; Barbiturates; Methohexitone; Epileptiform activity (Palmer, A.J. (221) 205)

L-Glutamate receptors
Ketamine; Single channels; Channel block; Muscle (locust) (Macdonald, A.G. (210) 223)

Glutamate release
Bifemelane; Mossy fibers; Protein kinase C; H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine); (Guinea-pig) (Ueda, M. (219) 271)

Aspartate release; Ethanol; Hippocampus; GABA (γ-aminobutyric acid) (Martin, D. (219) 469)

Glutamates
NMDA (N-methyl-D-aspartate); Quisqualate; Cerebellar granule cells; Tricyclic antidepressants; Carbamazepine (Cai, Z. (219) 53)

γ-Glutamyltranspeptidase
Methylmercury; Renal uptake; Glutathione (reduced) (Tanaka, T. (228) 9)

Glutathione
Ozonides; Nucleophilic attack; Molecular orbital (Hempenius, R.A. (228) 207)

Glutathione (reduced)
Methylmercury; Renal uptake; γ-Glutamyltranspeptidase (Tanaka, T. (228) 9)

Glycemia
Cibenzoline; Insulin secretion; Imidazoline; Pancreas; (Rat) (Bertrand, G. (214) 159)

Glyceryl trinitrate
Biotransformation; Rabbit aorta; Vasodilatation; Carbon monoxide (CO); Hemoprotein (Liu, Z. (211) 129)

Glycine
Retina; Ethylcholine mustard arizidinium ion; Acetylcholine; Amacrine cells; ON channels; OFF channels; (Frog) (Jardon, B. (210) 201)

L-687,414; NMDA (N-methyl-D-aspartate); Behaviour; Excitatory amino acids; Epilepsy (Smith, S.E. (211) 109)

NMDA receptors; Kynurenates; Thiokynurenates; Ischemia; Excitotoxicity (Moroni, F. (218) 145)

Aging; D-Cycloserine; Memory; NMDA receptors; Senescence; (Mouse) (Flood, J.F. (221) 249)

Chromaffin cells; Epinephrine; Norepinephrine; Acetylcholine (Yadid, G. (221) 389)

Serine; Alanine; Valine; Glycine modulatory site; NMDA receptors; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

[^{3}H]CPP ([^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) binding; NMDA receptors; HA-966; Polyamines (Porter, R.H.P. (227) 83)

Glycine modulatory site
Glycine; Serine; Alanine; Valine; NMDA receptors; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Glycine/NMDA receptor site (strychnine-insensitive)
R-(+)-HA-966; S-(−)-HA-966; Anxiolytics; Behavioural sedation (Dunn, R.W. (214) 207)

Glycine receptors
Chlormethiazole; $GABA_A$ receptors; Patch-clamp; Anaesthetics (general); Anticonvulsants (Hales, T.G. (210) 239)

Global ischaemia; 1-Aminocyclopropanecarboylic acid; NMDA receptors; (Gerbil) (Von Lubitz, D.K.J.E. (219) 153)

cGMP
Cerebellum; NMDA receptors; Nitroprusside; Nitric oxide (NO) (East, S.J. (209) 119)

ANP (atrial natriuretic polypeptide); Aorta (rat); Relaxation; Aging; Endothelium; Phosphodiesterase activity (Moritoki, H. (210) 61)

Endotoxin; L-Arginine/nitric oxide pathway; ANP (atrial natriuretic polypeptide) (Schuller, F. (212) 93)

ANP (atrial natriuretic polypeptide); Norepinephrine; Neuromodulation (Giridhar, J. (213) 317)

Acetylcholine; L-Cysteine; SIN-1 (3-morpholinosydnonimine); Sodium nitrite; Vascular smooth muscle relaxation (Arvola, P. (214) 289)

Nicorandil; Hyperpolarization; K^+ channels (ATP-dependent); Methylene blue (Holzmann, S. (215) 1)

Nitric oxide (NO); Non-adrenergic non-cholinergic (NANC) inhibition; Ileum (rat) (Kanada, A. (216) 287)

Vasorelaxation (rat aorta); Osthole; Ca^{2+} influx; (*Angelica pubescens*) (Ko, F.-N. (219) 29)

E. coli enterotoxin (heat-stable); 5-HT (5-hydroxytryptamine, serotonin); Indomethacin; Intestinal secretion; Ketanserin; Tropisetron (Beubler, E. (219) 445)

Okadaic acid; cAMP; Xanthine derivatives; Uterine smooth muscle (Candenas, M.-L. (219) 473)

Dihydropyridine Ca^{2+} entry blocker; EDRF (endothelium-derived relaxing factor); Adrenergic nerve; Substance P; Mesenteric artery (Okamura, T. (220) 27)

Morphine; Carbachol; Analgesia; Nitric oxide (NO) (Duarte, I.D.G. (221) 171)

ANP_A receptors; ANP receptor antagonists; Neuroblastoma cells NB-OK-1 (human) (Delporte, C. (224) 183)

Bradykinin; Endothelial cells; Ca^{2+} channels; G protein; Endothelium-derived relaxing factor (EDRF) (Graier, W.F. (225) 43)

C-type natriuretic peptide (CNP); Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Glioma cells (rat); Receptor binding (Eguchi, S. (225) 79)

Atrial natriuretic peptide (ANP); Endothelium; (Receptor down-regulation) (Kato, J. (225) 113)

Histamine H_1 receptor; Desensitization; Lung (guinea-pig); Protein kinase C (Leurs, R. (225) 137)

Lipopolysaccharides; Interferon-γ; N^G-Methyl-L-arginine; N^G-Nitro-L-arginine (Förstermann, U. (225) 161)

Angiotensin II receptor; Neuro-2A cells (Chaki, S. (225) 355)

Bradykinin; Endothelin; EDRF (endothelium-derived relaxing factor); Forskolin; 5-HT (serotonin) (Reiser, G. (227) 89)

Formycin A triphosphate (FTP); Guanylate cyclase; ATP; Atrial natriuretic factor (ANF) (Chang, C.-H. (227) 229)

$ANP\text{-}R_1$ receptors; Neutral metalloendopeptidase; Human neuroblastoma cell line NB-OK1 (Delporte, C. (227) 247)

cGMP (antagonist)
HS-142-1; Atrial natriuretic peptide (ANP); Guanylyl cyclase; ANP receptor (Morishita, Y. (225) 203)

Goblet cell secretion
K^+ channel activators (Kuo, H.-P. (215) 297)

Gonadotrophin
Inhibin; Oestradiol-17β; Indomethacin; Prostaglandin $F_{2\alpha}$; PMSG-primed immature rat; Ovary (Kogo, H. (221) 289)

Gonadotropin
Danazol; 13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$; Ovarian steroids; Ovary; Uterus (Kogo, H. (211) 69)

gp120
Human immunodeficiency virus type 1 (HIV-1); Apoptosis; Cortical cells; Memantine; NMDA receptor (Müller, W.E.G. (226) 209)

G-protein-coupled receptors
Cloning of receptors; Neuropeptides; Neurokinin-type receptors; Secretin-type receptors (Burbach, J.P.H. (227) 1)

G-protein coupling
5-HT_2 receptors (human); 5-HT_{1A} receptors (human); Ketanserin; (±)-8-Hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) (Stam, N.J. (227) 153)

G-proteins
Smooth muscle (vascular); Fluoride; Al^{3+}; Ca^{2+} sensitivity; Protein kinase C (Kawase, T. (214) 39)

Pertussis toxin; Capsaicin-sensitive neurones; Atrium (guinea-pig) (Amerini, S. (216) 445)

Angiotensin; Ion transport; Airway epithelium (Tamaoki, J. (220) 87)

Bradykinin; Endothelial cells; Ca^{2+} channels; Endothelium-derived relaxing factor (EDRF); cGMP (Graier, W.F. (225) 43)

Neurotransmitter release; Neurosecretory cells; Cytoskeleton; Cytoplasmic proteins; Ca^{2+}; Calmodulin; Protein kinase C (Trifaró, J.-M. (225) 83)

Muscarinic acetylcholine receptor; Muscarinic receptor agonists; Muscarinic receptor antagonists; GTP[S] binding; Cardiac membranes; (Unliganded receptor) (Hilf, G. (225) 245)

Na^+-K^+-ATPase (renal); Streptozotocin diabetes; Protein kinase C (Chen, C.-C. (225) 275)

Dopamine D_3 receptor (human); Transfected cell; Eukaryotic expression vector; Neuroleptics; Guanylnucleotide; Dopamine autoreceptor (Sokoloff, P. (225) 331)

δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Etorphine; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Sucrose gradients; Adenylate cyclase (Polastron, J. (226) 133)

Leukotrienes; Smooth muscles; Pulmonary system; Inositol phosphates; Protein kinase C (Howard, S. (227) 123)

Polymerase chain reaction; mRNA expression; Fluoxetine (Lesch, K.P. (227) 233)

Opioid receptors; Affinity cross-linking; NG108-15 cells (Harada, J. (227) 301)

Granisetron
5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

5-HT_3 receptor antagonists; DAT-582; (Enantiomer) (Yoshida, N. (216) 435)

Granule cells
$GABA_A$ receptors; TBPS (t-butylbicyclophosphorothionate) (Korpi, E.R. (211) 427)

Metabotropic glutamate receptor; ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid); Cerebellum; Purkinje cells; AP-3 ((L)-2-amino-3-phosphonopropionate) (East, S.J. (219) 395)

Granulocyte-colony stimulating factor (G-CSF)
Endothelin-1; Endothelial cells (vascular) (Namiki, A. (227) 339)

GR38032F
5-HT_3 receptor antagonists; Zacopride; Dexamethasone; Cisplatin; Taste aversion (conditioned) (Mele, P.C. (218) 229)

[^{3}H]GR65630
Brain; Autoradiography; 5-HT_3 recognition sites; (Common marmoset) (Jones, D.N.C. (215) 63)

[^{3}H]GR65630 binding
5-HT_3 receptor antagonists; Cytostatic-induced emesis (Fernández, A.G. (222) 257)

Grooming behaviour
B-HT 920; Adrenocorticotropin hormone; Dopamine D_2 receptors; Stretching and yawning; Shakes (Ferrari, F. (216) 345)

Grooming/scratching behaviour
Neuromedin B; Neuromedin C (Van Wimersma Greidanus, T.B. (209) 57)

GSH depletion
ATP depletion; Diethyl maleate; Phorone; Ethacrynic acid; Hepatocytes (Redegeld, F.A.M. (228) 229)

GTP[S] binding
Muscarinic acetylcholine receptor; Muscarinic receptor agonists; Muscarinic receptor antagonists; G protein; Cardiac membranes; (Unliganded receptor) (Hilf, G. (225) 245)

Guanabenz
Fos; α_2-Adrenoceptors; Yohimbine; Clonidine (Tsujino, T. (226) 69)

Guanfacine
α_2-Adrenoceptors; Atipamezole; Mydriasis; Neocortical high-voltage spindles; (Rat); (Subchronic treatment) (Jäkälä, P. (221) 351)

Guanidinium
Rilmenidine; Oxazoline; Imidazoline; α_2-Adrenoceptor subtypes; Cerebral cortex (rat) (King, P.R. (218) 101)

[^{14}C]Guanidinium uptake
Aorta (rat); Na^+ channel (silent); $^{45}Ca^{2+}$ uptake; Veratridine (Wermelskirchen, D. (219) 253)

Guanine nucleotide binding proteins
Endothelin receptors; Phospholipase C (Gusovsky, F. (225) 339)

Guanine nucleotide-binding proteins (small)
rho proteins; ADP-ribosyltransferase C3 (*Clostridium botulinum*); Melittin; Mast cell degranulating peptide; Compound 48/80 (Koch, G. (226) 87)

Guanylate cyclase
Atrial natriuretic peptide (ANP); Ontogenesis; Aorta; Kidney; Lung (Muraki, T. (226) 311)

Formycin A triphosphate (FTP); ATP; Atrial natriuretic factor (ANF); cGMP (Chang, C.-H. (227) 229)

Guanylnucleotide
Dopamine D_3 receptor (human); Transfected cell; Eukaryotic expression vector; Neuroleptics; G protein; Dopamine autoreceptor (Sokoloff, P. (225) 331)

Guanylyl cyclase
Acetylcholine; Nitric oxide (NO); Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

HS-142-1; Atrial natriuretic peptide (ANP); ANP receptor; cGMP (antagonist) (Morishita, Y. (225) 203)

5′-Guanylylimidophosphate (GppNHp)
δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Etorphine; [^{3}H]Diprenorphine; Sucrose gradients; Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

H^+
NMDA channels; Mg^+ (Von Euler, G. (227) 449)

HA1077
Cerebral blood flow; Cerebral glucose metabolism; Iodoantipyrine; 2-Deoxyglucose (Sako, K. (209) 39)

Cerebral vasospasm; Subarachnoid hemorrhage; Cerebral blood flow (Satoh, S.-i. (220) 243)

HA-966
[^{3}H]CPP ([^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) binding; NMDA receptors; Glycine; Polyamines (Porter, R.H.P. (227) 83)

R-(+)-HA-966
S-(−)-HA-966; Glycine/NMDA receptor site (strychnine-insensitive); Anxiolytics; Behavioural sedation (Dunn, R.W. (214) 207)

S-(−)-HA-966
R-(+)-HA-966; Glycine/NMDA receptor site (strychnine-insensitive); Anxiolytics; Behavioural sedation (Dunn, R.W. (214) 207)

Haematological alterations
Anaphylaxis; Death; Azelastine (Castro-Faria-Neto, H.C. (213) 183)

Haemodynamics
L-NMMA (N^G-monomethyl-L-arginine; L-NAME (N^G-nitro-L-arginine methyl ester); Hypertension; (Brattleboro rat) (Gardiner, S.M. (213) 449)

Haemorrhage
α-Adrenoceptors; Baroreceptors; Clonidine; Yohimbine; (Rabbit) (Evans, R.G. (216) 265)

Haloperidol
ANP (atrial natriuretic polypeptide); Apomorphine-induced stereotyped cage-climbing behavior; Apomorphine (Bidzseranova, A. (211) 411)

Dystonia; Dopamine; Acetylcholine; Anticholinergic drugs; Levodopa; Apomorphine (Löscher, W. (213) 31)

DTG (1,3-di-(2-tolyl)guanidine); σ Receptors (Jansen, K.L.R. (214) 281)

NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Stereotypies; Apomorphine (Löscher, W. (215) 199)

Remoxipride; σ Recognition sites (Ericson, H. (226) 157)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Haloperidol (chronic)
Vacuous chewing; Tardive dyskinesia; Dopamine D_1 receptors (Diana, M. (211) 415)

Tardive dyskinesia; Vacuous chewing movements; Progabide (Kaneda, H. (212) 43)

Hand (human)
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Smooth muscle; Vein (Bodelsson, M. (219) 455)

Handling
Benzodiazepine binding; Stress (Andrews, N. (210) 247)

Strychnine; Seizures; NMDA receptor antagonists; (Mouse) (McAllister, K.H. (211) 105)

Handling-induced convulsions
Withdrawal seizure prone mouse (WSP); Ethanol withdrawal; Abecarnil; Diazepam; Anticonvulsant effects; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

Head-twitch response
Naftidrofuryl oxalate (LS-121); Quantitative autoradiography; 5-HT_2 receptors; 5-Hydroxytryptophan (5-HTP); (Mouse) (Nabeshima, T. (223) 109)

Heart
Autoradiography; Endocardium; Natriuretic receptors; Natriuretic peptides (Rutherford, R.A.D. (212) 1)

Adrenergic neurotransmission; U46619; ONO11006; Thromboxane B_2 (Mantelli, L. (213) 79)

Blood pressure; CP-96,345; NK_1 receptor antagonists; Substance P; Cigarette smoke (Delay-Goyet, P. (222) 213)

Protein kinase C; Protein (15 kDa); Phospholamban (Hartmann, M. (226) 225)

Heart failure
Forskolin; dbcAMP; Desensitisation; Myocytes; (Human) (Harding, S.E. (223) 39)

Heart (guinea pig)
Muscarinic receptors; Inositol phosphates; Receptor coupling (Ford, A.P.D.W. (225) 105)

Heart (isolated)
Ca^{2+} channel antagonists; Ischaemia; Cardiac function (Manning, A. (220) 249)

Heart (isolated, guinea-pig)
Leukotrienes; Endothelium; Cromakalim (McLeod, J.D. (212) 67)

Heart muscle preparations (isolated)
Doxorubicin; Adriamycin; Acetylcholine receptors; Antimuscarinic actions; [^{3}H]Quinuclidinyl benzilate (QNB) binding (Temma, K. (220) 63)

Heart (rat)
Noradrenaline; Neuronal reuptake; Presynaptic inhibition; α-Adrenoceptors (Du, X.-J. (211) 221)

Acidosis; Alkalosis; Nifedipine; Ca^{2+} channels (Achike, F.I. (219) 369)

Heart rate
Cocaine; Cocaine methiodide; Blood pressure; Norepinephrine; (Squirrel monkey) (Schindler, C.W. (213) 99)

D-Baclofen; NMDA (N-methyl-D-aspartic acid); Spinal cord; Arterial pressure; Sympathetic output (Hong, Y. (216) 257)

Substance P; Neurokinin A; Senktide; Blood pressure; Behaviour; Tachykinin receptor antagonists (Itoi, K. (219) 435)

5-HT_{1A} receptors; 5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; Blood pressure; MDL 73005EF; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

[^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone)
α-Adrenoceptors; β-Adrenoceptors; Aorta; Jugular vein; Autoradiography; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol) (Killam, A.L. (218) 295)

Heat intensities (different)
Tail-flick response; Paw-licking response; β-Endorphin; Morphine (Suh, H.H. (213) 337)

Helodermin
VIP (vasoactive intestinal polypeptide); Leukotriene D_4; Arachidonic acid; Lung (perfused, guinea-pig); Cyclo-oxygenase products (Conroy, D.M. (218) 43)

Hemodynamics
Pirsidomine; IS-5-MN (isosorbide-5-mononitrate); Tolerance; (Dog) (Bohn, H. (220) 71)

Hemoprotein
Glyceryl trinitrate; Biotransformation; Rabbit aorta; Vasodilatation; Carbon monoxide (CO) (Liu, Z. (211) 129)

Hemorrhagic shock
Proton pump inhibitors; Gastric mucosa blood volume; Gastric mucosa oxygenation; Reflectance spectrophotometry; Omeprazole; NC-1300 (Kawano, S. (211) 55)

Heparin
Platelets; Neutrophils; Cathepsin G (Evangelista, V. (216) 401)

Heparin derivatives
Smooth muscle cells; Proliferation; Differentiation; Actin (Bârzu, T. (219) 225)

Hepatocytes
Suramin; ATP; P_2 purinoceptor; (Rat) (Tomura, H. (226) 363)

ATP depletion; GSH depletion; Diethyl maleate; Phorone; Ethacrynic acid (Redegeld, F.A.M. (228) 229)

Hepatocytes
Histamine H_1 receptors (García-Sáinz, J.A. (227) 325)

Hepatoma cells
PLC-PRF-5; Angiotensin II receptors; (Radioligand binding); (Receptor subtypes) (Wintersgill, H.P. (227) 283)

15-HETE (15-hydroxyeicosatetraenoic acid)
Interleukin-1; Interleukin-6; Prostaglandins; Fibroblast (Elliott, G.R. (214) 253)

Heterologous expression
Cytochrome P450IA2 (human); CYP1A2 recombinant expression vector; V79 Chinese hamster cells; P450-dependent enzymatic activity (Wölfel, C. (228) 95)

Hexahydro-difenidol
Muscarinic receptors; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Pfeiffer's rule; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

Hexbutinol
Muscarinic receptors; Hexahydro-difenidol; Oxyphencyclimine; Eudismic analysis; Pfeiffer's rule; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

Hindlimb perfusion model
Angiotensin-converting enzyme inhibitors; Renin–angiotensin system (local); Angiotensin-converting enzyme activity (Marjorie, (217) 49)

Hindquarters (rat)
DL-Propranolol; Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); N^G-Nitro-L-arginine; CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate) (Mota-Filipe, H. (213) 227)

Hippocampal pyramidal cells
Metabotropic glutamate receptors; 1S,3R-trans-ACPD (Gerber, U. (221) 401)

Hippocampal slices
Neuroprotection; Calpain inhibitor; Hypoxia; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Xenopus oocytes (rat cortex mRNA-injected); Quinoxalinediones (Randle, J.C.R. (215) 237)

Hippocampal slices (rat)
Glycine; Serine; Alanine; Valine; Glycine modulatory site; NMDA receptors; Long-term potentiation (Watanabe, Y. (223) 179)

Muscarinic receptor subtypes; Muscarinic receptor agonists; Stereochemistry (absolute); Superior cervical ganglion (rat); Ileum (guinea pig); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

Hippocampus
WEB 1881 FU; Acetylcholine; AF64A; Memory (Hashimoto, M. (209) 9)

bFGF (basic fibroblast growth factor); Cerebral ischemia; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

Scopolamine; Passive avoidance; Acetylcholine; Acetylcholine release; Choline precursors (Sigala, S. (211) 351)

γ-Hydroxybutyrate; GABA (γ-aminobutyric acid); $GABA_B$ receptors; CGP35348; Zn^{2+} (Xie, X. (212) 291)

t-ACPD (trans-1-aminocyclopentyl-1,3-dicarboxylic acid); Synaptic transmission (Garaschuk, O.V. (212) 305)

Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Amnesia; (Gerbil) (Eigyo, M. (214) 149)

σ Receptor ligands; DTG (1,3-di-(2-tolyl)guanidine); Ditolylorthoguanidine (Connick, J.H. (214) 169)

Immobilization stress; Muscarinic receptors; Autoradiography; Supersensitivity; Striatum (González, A.M. (214) 261)

Long-term potentiation (LTP); Cognition enhancers; Dentate gyrus; Perforant path stimulation; (Rat); (In vivo) (Molnár, P. (215) 17)

Microdialysis; Noradrenaline; Morphine withdrawal; Clonidine (Done, C. (215) 333)

Nitric oxide (NO); Neurotoxicity (Loiacono, R.E. (216) 331)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; (S)-UH-301; Microdialysis; (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) (Nomikos, G.G. (216) 373)

GABA (γ-aminobutyric acid); 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Frontal cortex; Benzodiazepines (File, S.E. (218) 9)

Proline; NMDA (N-methyl-D-aspartate); Excitatory amino acids (Martin, D. (219) 59)

Chlordiazepoxide; Benzodiazepine; Muscimol; GABA (γ-aminobutyric acid); Memory (working, reference) (Ohno, M. (219) 245)

Memantine; Quinolinic acid; Neurodegeneration (Keilhoff, G. (219) 451)

Aspartate release; Glutamate release; Ethanol; GABA (γ-aminobutyric acid) (Martin, D. (219) 469)

Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Neuronal cell death; Amnesia; (Gerbil) (Eigyo, M. (219) 487)

Hypoxia/hypoglycemia; Cholinergic drugs; 2-Deoxyglucose uptake; CA1 field potentials; (In vitro) (Shibata, S. (221) 113)

Catecholamines; Hypoxia/hypoglycemia; 2-Deoxyglucose; Ischemia; CA1 field potential; (In vitro) (Shibata, S. (221) 255)

Stress; Morphology; 5-HT (5-hydroxytryptamine, serotonin); Corticosteroids; Tianeptine (Watanabe, Y. (222) 157)

SK&F 38393; SCH 23390; Pilocarpine; Motor seizures (Alam, A.M. (222) 227)

Chronic stress; Muscarinic receptors; Autoradiography; Supersensitivity; Striatum (González, A.M. (223) 25)

γ-Hydroxybutyrate; $GABA_B$ receptors; CGP 36742; EPSP (excitatory postsynaptic potential); IPSP (inhibitory postsynaptic potential) (Xie, X. (223) 193)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptors; Hypoxia/hypoglycemia; Ischemia; CA1 field potential; (In vitro) (Kagami-ishi, Y. (224) 51)

3,4-Diaminopyridine; Noradrenaline release; Ca^{2+} (intracellular); α_2-Adrenoceptor mechanism; (Rat); (Rabbit) (Jackisch, R. (226) 245)

S-Adenosyl-L-methionine; Brain; Aging; Muscarinic receptors; Striatum (Muccioli, G. (227) 293)

Philanthotoxin-343; Glutamate; NMDA receptors; AMPA/kainate receptors; Polyamines (Fedorov, N.B. (228) 201)

Hippocampus (immature rat)
5-HT receptors; Phosphoinositide turnover (Claustre, Y. (225) 37)

Hippocampus (rat)
Ca^{2+}-activated K^+ currents; Pyramidal neurons (dissociated); Single channel recording; Trifluoperazine (Ikemoto, Y. (216) 191)

Hippocampus slices
AF102B; Acetylcholine; Muscarinic M_1 receptors; Slow after-hyperpolarization (Segal, M. (220) 103)

[^{125}I]His-NKA
NK_2 receptors; Small intestine smooth muscle (rat); NK receptor subtypes; Radioligand binding (Brown, M.C.S. (227) 163)

H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine)
Bifemelane; Mossy fibers; Glutamate release; Protein kinase C; (Guinea-pig) (Ueda, M. (219) 271)

Histamine
ACTH (adrenocorticotropin); Histamine H_3 receptors; AtT-20 cells (Clark, M.A. (210) 31)

Morphine; Intestinal motility (Patrini, G. (210) 259)

Bronchoconstriction; fMLP (formyl-L-methionyl-L-leucyl-L-phenylalanine); Hyperreactivity; Pertussis toxin (Imaizumi, A. (212) 177)

Glutamate; NMDA receptors; Microdialysis; Hypothalamus (Okakura, K. (213) 189)

Aging; Airway obstruction; Asthma; Oedema; Plasma exudation; Substance P; Vascular permeability (Arakawa, H. (215) 51)

Histamine H_2 receptors; Histamine H_2 receptor antagonists; Brain; Morphine; Antinociception (Hough, L.B. (215) 69)

Azelastine; Immunisation; Lung hyperresponsiveness; PAF (platelet-activating factor, PAF-acether); Leukotrienes; (Guinea-pig) (Pretolani, M. (216) 141)

Trachea (guinea-pig); Acetylcholine; 5-HT (5-hydroxytryptamine, serotonin); Amiloride; Ouabain; K^+-free solution (Cortijo, J. (221) 43)

Endothelial cells; Histamine H_1 receptors; Actin filaments; Peripheral bands; Permeability (Niimi, N. (221) 325)

Ageing; Trachea (guinea-pig and rat); Epithelium; Smooth muscle (airway); Acetylcholine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Histamine H_3 receptor antagonist (radiolabeled)
Histamine H_3 receptors; [^{125}I]Iodophenpropit binding (Jansen, F.P. (217) 203)

Histamine H_2 receptor antagonists
Histamine; Histamine H_2 receptors; Brain; Morphine; Antinociception (Hough, L.B. (215) 69)

Histamine H_1 receptors
Cholinergic bronchospasm (central); (R)-α-Methylhistamine; Histamine H_3 receptors (Hey, J.A. (211) 421)

Endothelial cells; Histamine; Actin filaments; Peripheral bands; Permeability (Niimi, N. (221) 325)

Desensitization; cGMP; Lung (guinea-pig); Protein kinase C (Leurs, R. (225) 137)

Hepatocytes; Inositol phosphates (García-Sáinz, J.A. (227) 325)

Histamine H_2 receptors
Histamine; Histamine H_2 receptor antagonists; Brain; Morphine; Antinociception (Hough, L.B. (215) 69)

Histamine H_3 receptors
Histamine; ACTH (adrenocorticotropin); AtT-20 cells (Clark, M.A. (210) 31)

Cholinergic bronchospasm (central); (R)-α-Methylhistamine; Histamine H_1 receptors (Hey, J.A. (211) 421)

Histamine H_3 receptor antagonist (radiolabeled); [^{125}I]Iodophenpropit binding (Jansen, F.P. (217) 203)

Octreotide; SMS 201-995; Somatostatin; α-Adrenoceptors; Migraine; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

Histamine liberation
Bradykinin receptor antagonists; Pain measurement; Skin response (Kindgen-Milles, D. (218) 183)

Histamine receptor agonists (H_1- and H_2-selective)
Histamine receptor subtypes; Impromidine; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Adrenoceptors; Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

Histamine receptors
Uterus (rat); Progesterone; Ovarian steroids; Oestrogen (Rubio, E. (212) 31)

Histamine receptor subtypes
Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Adrenoceptors; Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

Histology
Parainfluenza 3 virus; Airway responsiveness (in vitro); Inflammatory cells (Folkerts, G. (228) 121)

H^+,K^+-ATPase
Omeprazole; Pantoprazole (Beil, W. (218) 265)

13-HODE (13-hydroxyoctadecadienoic acid)
Oedema formation; Leukotriene B_4; Skin (rabbit) (Buckley, T.L. (218) 369)

HOE 140
Airway microvascular leakage; Bradykinin; Bradykinin receptors; Bronchoconstriction; PAF (platelet-activating factor, PAF-acether) (Sakamoto, T. (213) 367)

HOE 234
Bronchodilation; Airway dynamics; Trachea (guinea-pig); K^+ channel opening (Englert, H.C. (210) 69)

Homovanillic acid (HVA)
Amoxapine; Pharmacokinetics (cerebral); Dopamine; DOPAC (3,4-dihydroxyphenylacetic acid) (Kobayashi, A. (215) 43)

Hot-plate test
Antinociception; Formalin test; Writhing test; Ca^{2+} channel blockers (Miranda, H.F. (217) 137)

Monoamine oxidase-A inhibitors; Nociception; Tail-flick test; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (219) 113)

HS-142-1
Atrial natriuretic peptide (ANP); Guanylyl cyclase; ANP receptor; cGMP (antagonist) (Morishita, Y. (225) 203)

5-HT_4
Oesophagus; BIMU 1; BIMU 8; DAU 6214; Benzimidazolones (Baxter, G.S. (212) 225)

B-HT 920
Feeding behaviour; Anorexia; ACTH (adrenocorticotropin); Immobilisation; (Rat) (Ferrari, F. (210) 17)

Grooming behaviour; Adrenocorticotropin hormone; Dopamine D_2 receptors; Stretching and yawning; Shakes (Ferrari, F. (216) 345)

5-HT autoreceptors
Electroconvulsive shocks; Hypothermia; Serotonergic neurons; 5-HT release; 5-HT_3 receptors (Blier, P. (211) 365)

5-HT_1 binding sites
5-HT_{1D} binding sites; 5-HT_{1E} binding sites; Brain (human) (Lowther, S. (222) 137)

5-HT_{1D} binding sites
5-HT (5-hydroxytryptamine, serotonin); 5-CT (5-carboxyamidotryptamine); Sumatriptan (Beer, M.S. (213) 193)

5-HT_1 binding sites; 5-HT_{1E} binding sites; Brain (human) (Lowther, S. (222) 137)

5-HT_{1E} binding sites
5-HT_1 binding sites; 5-HT_{1D} binding sites; Brain (human) (Lowther, S. (222) 137)

HT29 cells
α_2-Adrenoceptor mRNA; OK cells; NG108 cells (Sun, L. (226) 367)

5-$HT_{1D\beta}$ receptors
5-HT receptors; cAMP; Sumatriptan (Miller, K.J. (227) 99)

5-HT_2 /5-HT_{1C} receptors
Sexual behaviour; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ritanserin; Ketanserin; Mesulergine (Klint, T. (212) 241)

5-HT_{1C} /5-HT_2 receptors
5-HT (5-hydroxytryptamine, serotonin); Motoneurons; Excitability; Spinal cord; (Slice) (Yamazaki, J. (220) 237)

5-HT (5-hydroxytryptamine, serotonin)
Purkinje neurons; Microiontophoresis; 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

p-Chlorophenylalanine; L-5-Hydroxytryptophan; Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

Electrical field stimulation; Trachea; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol (Molenaar, P. (209) 257)

Saphenous veins (canine); Sumatriptan; 5-HT_{1D} receptors (Cohen, M.L. (211) 43)

Oesophagus (rat); 5-HT_4 receptors; cAMP; Benzamides (substituted); Tropisetron (Ford, A.P.D.W. (211) 117)

d-Fenfluramine; Sertraline; Feeding patterns; Satiety; Motor activity; (Rat) (Grignaschi, G. (211) 137)

Cisapride; 5-Methoxytryptamine (5-MeOT); ICS 205-930; 5-HT_4 receptors (Meulemans, A.L. (212) 51)

Sexual behaviour; 5-HT_2 /5-HT_{1C} receptors; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ritanserin; Ketanserin; Mesulergine (Klint, T. (212) 241)

5-CT (5-carboxyamidotryptamine); Sumatriptan; 5-HT_{1D} binding site (Beer, M.S. (213) 193)

5-HT_1-like receptors; Intragastric pressure; 5-HT receptor antagonists; (Rat) (Dhasmana, K.M. (213) 293)

5-HT_{1A} receptors; Circadian rhythm; Wheel-running rhythm (Tominaga, K. (214) 79)

Strychnocarpine; β-Carbolines; Benzodiazepines; Tryptamine; Opiate receptors; GABA receptors (Strömbom, J. (214) 165)

Ca^{2+}; Endothelium; Prostacyclin (Gill, J.K. (214) 269)

Amphetamine analogues; Monoamine release; Synaptosomes (Berger, U.V. (215) 153)

NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; Ipsapirone; Schizophrenia; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

Dopamine; Self-stimulation; Fenfluramine; Amphetamine (Olds, M.E. (216) 363)

5-HT_{1A} receptors; (S)-UH-301; Hippocampus; Microdialysis; (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) (Nomikos, G.G. (216) 373)

Norepinephrine; Nucleus raphe dorsalis; Locus coeruleus; Voltammetry (in vivo); (Rat) (Clement, H.-W. (217) 43)

Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

GABA (γ-aminobutyric acid); 5-HT release; Hippocampus; Frontal cortex; Benzodiazepines (File, S.E. (218) 9)

Aversive behaviour; R(+)-Zacopride; S(−)-Zacopride; Anxiolytic agents; (Mouse) (Barnes, N.M. (218) 91)

Amphetamines; Basal ganglia; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Monoamine oxidase-A inhibitors; Nociception; Tail-flick test; Hot-plate test (Bianchi, M. (219) 113)

Endothelin; Platelet aggregation; Ca^{2+} mobilization (Pietraszek, M.H. (219) 289)

5-HT_1-like receptors; 5-HT_{1D} receptor subtype; Iliac artery (guinea-pig); Smooth muscle (vascular) (Schoeffter, P. (219) 295)

cGMP; *E. coli* enterotoxin (heat-stable); Indomethacin; Intestinal secretion; Ketanserin; Tropisetron (Beubler, E. (219) 445)

Hand (human); 5-HT receptors; Smooth muscle; Vein (Bodelsson, M. (219) 455)

Skeletal muscles; (Swine) (Gerdes, C. (220) 91)

Acetylcholine; Nitric oxide (NO); Guanylyl cyclase; Adenylyl cyclase; Prostacyclin; Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

5-HT_{1C} /5-HT_2 receptors; Motoneurons; Excitability; Spinal cord; (Slice) (Yamazaki, J. (220) 237)

Basilar artery (rat); Myograph; 5-HT receptor classification; Ketanserin; Ergometrine (Deckert, V. (221) 17)

ACTH release; Tricyclic antidepressants; Lithium; Electroconvulsive shock (Gartside, S.E. (221) 27)

Trachea (guinea-pig); Acetylcholine; Histamine; Amiloride; Ouabain; K^+-free solution (Cortijo, J. (221) 43)

Cocaine; ACTH (adrenocorticotropic hormone); Prolactin; Oxytocin; Renin (Levy, A.D. (221) 121)

Epilepsy; GABA (γ-aminobutyric acid); Acetylcholine; Cl^- transport; Brain; (Mouse) (Inoue, M. (221) 135)

Vagus nerve; 5-HT_3 receptors; Emesis; (Ferret) (Newberry, N.R. (221) 157)

Placental vein (human); Na^+,K^+-ATPase; $^{86}Rb^+$ uptake (Fernández-Alfonso, M.S. (221) 185)

Amphetamines; Dopamine; MDMA (3,4-methylenedioxymethamphetamine); Norepinephrine; Neurotoxicity (Elayan, I. (221) 281)

(−)-Penbutolol; 5-HT_{1A} receptor antagonism; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Synthesis and turnover; 5-HT-like behaviour; Hypothermia (Hjorth, S. (222) 121)

Stress; Hippocampus; Morphology; Corticosteroids; Tianeptine (Watanabe, Y. (222) 157)

5-Carboxamidotryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Endothelium; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Van Gelderen, E.M. (222) 185)

Noradrenaline; α-Adrenoceptor antagonists; Desipramine; 6-Hydroxydopamine (6-OHDA); Spinal antinociception (Sawynok, J. (223) 49)

5-HT_1-like receptors; Stomach fundus (guinea-pig) (Kojima, S.-i. (224) 45)

5-HT_3 receptors; Hypoxia/hypoglycemia; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Kagami-ishi, Y. (224) 51)

cAMP accumulation; β-Adrenoceptors (Morin, D. (225) 273)

Adenylate cyclase; Platelets (human) (Newman, M.E. (226) 281)

Bradykinin; cGMP; Endothelin; EDRF (endothelium-derived relaxing factor); Forskolin (Reiser, G. (227) 89)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT uptake inhibitor; 1-Piperonylpiperazine; Neurotoxicity; Brain (rat) (Hashimoto, K. (228) 171)

5-HT-like behaviour
(−)-Penbutolol; 5-HT_{1A} receptor antagonism; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Synthesis and turnover; Hypothermia (Hjorth, S. (222) 121)

5-HT_1-like receptors
5-HT (5-hydroxytryptamine, serotonin); Intragastric pressure; 5-HT receptor antagonists; (Rat) (Dhasmana, K.M. (213) 293)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor subtype; Iliac artery (guinea-pig); Smooth muscle (vascular) (Schoeffter, P. (219) 295)

5-HT (5-hydroxytryptamine, serotonin); Stomach fundus (guinea-pig) (Kojima, S.-i. (224) 45)

5-HT receptor agonists
5-HT receptor antagonists; Blood pressure; Plasma renin activity; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

5-HT_{1A} receptor agonists
5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

5-HT_{1A} receptors; 5-HT_{1A} receptor antagonists; Blood pressure; Heart rate; MDL 73005EF; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

5-HT_{1B} receptor agonists
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

5-HT_3 receptor agonists
5-HT receptors; 5-HT_3 receptor antagonists; Cisplatin; Emesis; (Pigeon) (Preziosi, P. (221) 343)

5-HT_{1A} receptor antagonism
(−)-Penbutolol; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Synthesis and turnover; 5-HT-like behaviour; Hypothermia (Hjorth, S. (222) 121)

5-HT receptor antagonists
5-HT receptor agonists; Blood pressure; Plasma renin activity; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors; Intragastric pressure; (Rat) (Dhasmana, K.M. (213) 293)

5-HT_2 receptors; Binding (in vivo); RP 62203 (Fajolles, C. (216) 53)

Arrhythmias; Coronary artery occlusion; Myocardial ischaemia; Reperfusion; Platelet aggregation (Ellis, A.M. (219) 97)

5-HT_{1A} receptor antagonists
5-HT_{1A} receptor agonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

5-HT_{1A} receptors; 5-HT_{1A} receptor agonists; Blood pressure; Heart rate; MDL 73005EF; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

5-HT_3 receptor antagonists
LY 277359; Granisetron; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; 5-HT_3 receptors; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

Learned helplessness paradigm; (Rat) (Martin, P. (212) 73)

Amphetamine discrimination; MDL 72,222EF; MDL 73,147EF; ICS 205-930; Ondansetron (GR38032F) (Moser, P.C. (212) 271)

DAT-582; Granisetron; (Enantiomer) (Yoshida, N. (216) 435)

Zacopride; GR38032F; Dexamethasone; Cisplatin; Taste aversion (conditioned) (Mele, P.C. (218) 229)

WAY100289; Light:dark box; Anxiety; Acoustic startle (potentiated) (Bill, D.J. (218) 327)

5-HT receptors; 5-HT_3 receptor agonists; Cisplatin; Emesis; (Pigeon) (Preziosi, P. (221) 343)

Cytostatic-induced emesis; [^{3}H]GR65630 binding (Fernández, A.G. (222) 257)

5-HT_{1B} receptor binding sites
Trigeminal ganglia (rat); 5-HT_{1B} receptor messenger RNA (Bruinvels, A.T. (227) 357)

5-HT receptor classification
Basilar artery (rat); Myograph; 5-HT (5-hydroxytryptamine, serotonin); Ketanserin; Ergometrine (Deckert, V. (221) 17)

5-HT_{1B} receptor messenger RNA
Trigeminal ganglia (rat); 5-HT_{1B} receptor binding sites (Bruinvels, A.T. (227) 357)

5-HT receptors
Hypothalamus; K^+ channels; 5-HT_{1A} receptors; K^+ (Newberry, N.R. (210) 209)

d-Fenfluramine; Feeding parameters; (Rat) (Grignaschi, G. (212) 287)

Blood pressure; Anxiolytic; Dorsal raphe nucleus (Corley, K.C. (213) 417)

Tryptophan; Blood–brain barrier (Chaouloff, F. (214) 101)

Tryptamine; Glucagon; (Mouse) (Yamada, J. (216) 307)

5-HT_3 receptors; Vagus; Tubocurarine (Newberry, N.R. (219) 135)

Hand (human); 5-HT (5-hydroxytryptamine, serotonin); Smooth muscle; Vein (Bodelsson, M. (219) 455)

β-Adrenoceptor antagonists; 5-HT_{1A} receptors; Migraine; Pindolol; Propranolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

5-HT_3 receptor antagonists; 5-HT_3 receptor agonists; Cisplatin; Emesis; (Pigeon) (Preziosi, P. (221) 343)

LSD (lysergic acid diethylamide); Learning; (Locust) (Wedemeyer, S. (223) 173)

Phosphoinositide turnover; Hippocampus (immature rat) (Claustre, Y. (225) 37)

Dopamine receptors; Inositol phosphates; Phosphoinositides; Striatum (rat); α-Adrenoceptors (Undie, A.S. (226) 297)

cAMP; Sumatriptan; 5-$HT_{1D\beta}$ receptors (Miller, K.J. (227) 99)

5-HT_1 receptors
Methionine sulfoximine; Hypothermia; Pindolol; Propranolol; Ketanserin; Betaxolol; ICI 118,551 (Ginefri-Gayet, M. (217) 85)

5-HT_{1A} receptors
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Sexual behaviour (male); Nucleus accumbens; Nucleus raphe; Medial preoptic area; 5-$HT_{1B/C}$ receptors (Fernández-Guasti, A. (210) 121)

Hypothalamus; 5-HT receptors; K^+ channels; K^+ (Newberry, N.R. (210) 209)

NAN-190; BMY 7378; Partial agonists; Spare receptors; Receptor theory (Greuel, J.M. (211) 211)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Passive avoidance; Memory (Carli, M. (211) 227)

5-HT (5-hydroxytryptamine, serotonin); Circadian rhythm; Wheel-running rhythm (Tominaga, K. (214) 79)

5-HT (5-hydroxytryptamine, serotonin); (S)-UH-301; Hippocampus; Microdialysis; (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) (Nomikos, G.G. (216) 373)

NAN-190; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Feeding; (Rat) (Williams, A.R. (219) 105)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Renal nerve activity; Medullary 5-HT neurons (Ramage, A.G. (219) 165)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sex differences; Tolerance; Corticosterone; Hypothermia (Nakano, Y. (219) 339)

β-Adrenoceptor antagonists; 5-HT receptors; Migraine; Pindolol; Propranolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

Clozapine; Antipsychotic drugs (Mason, S.L. (221) 397)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; Blood pressure; Heart rate; MDL 73005EF; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

5-$HT_{1B/C}$ receptors
Sexual behaviour (male); 5-HT_{1A} receptors; Nucleus accumbens; Nucleus raphe; Medial preoptic area (Fernández-Guasti, A. (210) 121)

5-HT_{1D} receptors
Saphenous veins (canine); Sumatriptan; 5-HT (5-hydroxytryptamine, serotonin) (Cohen, M.L. (211) 43)

5-HT_2 receptors
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Glucose; Insulin; Sympathoadrenal system (Baudrie, V. (213) 41)

Binding (in vivo); 5-HT receptor antagonists; RP 62203 (Fajolles, C. (216) 53)

Amperozide; Dopamine D_2 receptors (Meltzer, H.Y. (216) 67)

Phosphoinositide hydrolysis; Forced swimming test; Mianserin; Imipramine; Affective disorders (Kawanami, T. (216) 385)

MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; Dopamine neurons (Schmidt, C.J. (220) 151)

Amphetamine; Dopamine synthesis; Microdialysis; MDMA (3,4-methylenedioxymethamphetamine) (Schmidt, C.J. (223) 65)

Naftidrofuryl oxalate (LS-121); Quantitative autoradiography; 5-Hydroxytryptophan (5-HTP); Head-twitch response; (Mouse) (Nabeshima, T. (223) 109)

Electroconvulsive shock; Brain (rat); α_1-Adrenoceptors; Phosphoinositide hydrolysis (Pandey, G.N. (226) 303)

5-HT_3 receptors
Dopamine neurons; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

[^{3}H](R)-Zacopride; [^{3}H](S)-Zacopride; Brain (rat); (High affinity (R)-sites) (Kidd, E. (211) 133)

Electroconvulsive shocks; Hypothermia; Serotonergic neurons; 5-HT autoreceptors; 5-HT release (Blier, P. (211) 365)

2-Methylserotonin; Drug discrimination; Zacopride isomers (Young, R. (212) 117)

DAU 6215; Dopamine neurons; Antipsychotic drugs; Depolarization block (Prisco, S. (214) 13)

Cardiac sympathetic afferents; Phenylbiguanide; Spinothalamic tract; Spinoreticular tract (Blair, R.W. (216) 119)

NG108-15; MDL 73147EF; MDL 74156; ICS 205-930 (Boeijinga, P.H. (219) 9)

5-HT receptors; Vagus; Tubocurarine (Newberry, N.R. (219) 135)

Vagus nerve; 5-HT (5-hydroxytryptamine, serotonin); Emesis; (Ferret) (Newberry, N.R. (221) 157)

5-HT (5-hydroxytryptamine, serotonin); Hypoxia/hypoglycemia; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Kagami-ishi, Y. (224) 51)

5-HT_4 receptors
Oesophagus (rat); 5-HT (5-hydroxytryptamine, serotonin); cAMP; Benzamides (substituted); Tropisetron (Ford, A.P.D.W. (211) 117)

Cisapride; 5-HT (5-hydroxytryptamine, serotonin); 5-Methoxytryptamine (5-MeOT); ICS 205-930 (Meulemans, A.L. (212) 51)

Esophagus (rat); Relaxation; cAMP generation; Gastrointestinal motility (Moummi, C. (216) 47)

5-HT_{1A} receptors (human)
5-HT_2 receptors (human); G-protein coupling; Ketanserin; (±)-8-Hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) (Stam, N.J. (227) 153)

5-HT_2 receptors (human)
5-HT_{1A} receptors (human); G-protein coupling; Ketanserin; (±)-8-Hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) (Stam, N.J. (227) 153)

5-HT receptor subtypes
Cold stress; 5-HT turnover; Behavioural responses; Glucose; Corticosterone (Zamfir, O. (219) 261)

5-HT_{1D} receptor subtypes
5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors; Iliac artery (guinea-pig); Smooth muscle (vascular) (Schoeffter, P. (219) 295)

5-HT_3 recognition sites
[^{3}H]GR65630; Brain; Autoradiography; (Common marmoset) (Jones, D.N.C. (215) 63)

5-HT release
Electroconvulsive shocks; Hypothermia; Serotonergic neurons; 5-HT autoreceptors; 5-HT_3 receptors (Blier, P. (211) 365)

GABA (γ-aminobutyric acid); 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; Frontal cortex; Benzodiazepines (File, S.E. (218) 9)

Substance P; Dorsal raphe nucleus; Blood pressure (Gradin, K. (218) 363)

5-HT release (in vivo)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

5-HT turnover
Cold stress; 5-HT receptor subtypes; Behavioural responses; Glucose; Corticosterone (Zamfir, O. (219) 261)

5-HT uptake
[^{125}I]5-Iodo-6-nitroquipazine (Mathis, C.A. (210) 103)

5-HT uptake inhibitors
Spiradoline; κ-Opioid receptor agonists; Analgesia; Noradrenaline uptake inhibitors (Kunihara, M. (214) 111)

[^{3}H]Paroxetine binding; Structure–activity relationship; Brain (rat) (Marcusson, J.O. (215) 191)

MDMA (3,4-methylenedioxymethamphetamine); 1-Piperonylpiperazine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain (rat) (Hashimoto, K. (228) 171)

Human immunodeficiency virus type 1 (HIV-1)
Apoptosis; Cortical cells; Memantine; NMDA receptor; gp120 (Müller, W.E.G. (226) 209)

Human neuroblastoma cell line NB-OK1
ANP-R_1 receptors; cGMP; Neutral metalloendopeptidase (Delporte, C. (227) 247)

Hybridization (in situ)
Ethanol; c-fos; Glutamate; NMDA (N-methyl-D-aspartate) (Morgan, P.F. (225) 217)

Muscarinic receptor subtypes; Muscarinic receptor agonists; Stereochemistry (absolute); Superior cervical ganglion (rat); Hippocampal slice (rat); Ileum (guinea pig); c-fos expression (Pombo-Villar, E. (226) 317)

Hydralazine
Dihydralazine; Cromakalim; Nitroprusside; K^+ channels; Smooth muscle (vascular) (Thirstrup, S. (215) 177)

Hydrochlorothiazide
Cough reflex; Angiotensin-converting enzyme inhibitors; Enalapril; Diuretics (Kamei, J. (213) 137)

Diuretics; Indapamide; Resistance vessels (Calder, J.A. (220) 19)

γ-Hydroxybutyrate
GABA (γ-aminobutyric acid); $GABA_B$ receptors; CGP35348; Hippocampus; Zn^{2+} (Xie, X. (212) 291)

$GABA_B$ receptors; CGP 36742; EPSP (excitatory postsynaptic potential); IPSP (inhibitory postsynaptic potential); Hippocampus (Xie, X. (223) 193)

γ-Hydroxybutyric acid
Absence seizures; Epilepsy; $GABA_A$ receptors; $GABA_B$ receptors; Pentylenetetrazole (Snead, III, O.C. (213) 343)

5-Hydroxydecanoate
Ischemia; Metabolic changes; Patch clamp; Ventricular cells (Notsu, T. (220) 35)

6-Hydroxydopamine (6-OHDA)
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Apomorphine; Pentobarbital; Rotational behaviour; Conditioned drug effects; Drug discrimination (Silverman, P.B. (212) 165)

Down-regulation; Triazolam; GABA (γ-aminobutyric acid); Dopamine receptors; Quinpirole (Zhou, L.-W. (218) 219)

[Met^5]enkephalin; [Leu^5]enkephalin; Neurotensin; Cholecystokinin (CCK); Substance P; L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; α-Adrenoceptor antagonists; Desipramine; Spinal antinociception (Sawynok, J. (223) 49)

5-Hydroxyisaxonine
Isaxonine phosphate (2-isopropylaminopyrimidine); 2-Aminopyrimidine (Martinat, C. (228) 63)

Hydroxylamine
Sodium nitroprusside; Neurotransmitter release (Lonart, G. (220) 271)

Hydroxyl radicals
Dipyridamole; Scavenging effects; Electron spin resonance; Superoxide anions (Suzuki, S. (227) 395)

2-Hydroxysaclofen
Baclofen; $GABA_B$ receptor agonists; Thienyl baclofen analogs; Ileum (guinea-pig, isolated) (Ong, J. (218) 343)

β-(2-Thienyl)-GABA; Baclofen; Ileum (guinea-pig, isolated); Neocortical slices (rat) (Ong, J. (221) 145)

L-5-Hydroxytryptophan
p-Chlorophenylalanine; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

5-Hydroxytryptophan (5-HTP)
Naftidrofuryl oxalate (LS-121); Quantitative autoradiography; 5-HT_2 receptors; Head-twitch response; (Mouse) (Nabeshima, T. (223) 109)

Hyperalgesia
NMDA (N-methyl-D-aspartate); Nitric oxide (NO); L-Arginine; Nociception; Spinal cord; Facilitation; Pain; (Rat) (Meller, S.T. (214) 93)

Nitric oxide (NO); Neurogenic oedema (Ferreira, S.H. (217) 207)

Hypercholesterolemia
EGF (epidermal growth factor); Endothelin; Thrombin; Aorta (rabbit); Vasospasm; Endothelium (Merkel, L.A. (222) 175)

Hyperpolarization
Nicorandil; K^+ channels (ATP-dependent); cGMP; Methylene blue (Holzmann, S. (215) 1)

Hyperreactivity
Bronchoconstriction; fMLP (formyl-L-methionyl-L-leucyl-L-phenylalanine); Histamine; Pertussis toxin (Imaizumi, A. (212) 177)

Hypersensitivity
Bradykinin; Desensitization (Martins, M.A. (220) 55)

Hypertension
3-Methylhistidine; Terazosin; α-Adrenoceptor blockade; Spontaneously hypertensive rat (SHR) (Jonsson, J.R. (211) 263)

ω-Conotoxin; Sympathetic nerves; Vasodilatation (Pruneau, D. (211) 329)

Endothelin-1; Cyclosporine; Mesenteric artery; Blood pressure (Takeda, Y. (213) 445)

L-NMMA (N^G-monomethyl-L-arginine; L-NAME (N^G-nitro-L-arginine methyl ester); Haemodynamics; (Brattleboro rat) (Gardiner, S.M. (213) 449)

EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pressure; Endothelial cells; Mechanoreceptors (Hishikawa, K. (215) 329)

Endothelin-1; Big endothelin-1; Bronchoconstriction; Metallopeptidases (Pons, F. (217) 65)

Angiotensin II; Caffeine; Adenosine; Renal function (Holycross, B.J. (219) 361)

Torasemide; Bumetanide; Cotransport; Red blood cells; Diuretics (loops) (Masereel, B. (219) 385)

Prostanoids; Ca^{2+} ionophore A23187; Endothelin; Prostanoid receptor blockers (Lin, L. (220) 49)

Prolactin; Smooth muscle (vascular); Gene expression; c-myc; Ornithine decarboxylase (Sauro, M.D. (225) 351)

Hypertrophy
Smooth muscle cells; Losartan; Phosphoinositide signalling system (Ko, Y. (227) 215)

Hyporesponsiveness
Blood vessels; Endothelium; Protein synthesis; Nitric oxide (NO); Lipopolysaccharide (Nakaki, T. (219) 311)

Hypotensive drugs
MCI-154; α-Adrenoceptors; K^+ contracture; Vasodilatation (Suh, S.H. (219) 377)

Hypothalamic perfusion
Interleukin-1; CRF (corticotropin-releasing factor) secretion; Catecholamines (Cambronero, J.C. (219) 75)

Hypothalamic stimulation
Sympatho-inhibition; Prazosin; Rauwolscine; Phenoxybenzamine; Nerve stimulation (peripheral) (Koss, M.C. (211) 61)

Hypothalamus
α-MSH (α-melanocyte-stimulating hormone); GABA (γ-aminobutyric acid); Benzodiazepines (Mabley, J. (209) 127)

Opiates; [^{3}H]DAGO binding; Development (Hammer, Jr., R.P. (209) 253)

Gentamicin; Catecholamine level; Striatum; Adrenal medulla; Vas deferens (Mikami, M. (210) 91)

5-HT receptors; K^+ channels; 5-HT_{1A} receptors; K^+ (Newberry, N.R. (210) 209)

Histamine; Glutamate; NMDA receptors; Microdialysis (Okakura, K. (213) 189)

Rilmenidine; Clonidine; Noradrenaline release; Voltammetry (in vivo); α_2-Adrenoceptors (Suaud-Chagny, M.F. (213) 305)

Lithium chloride; Monoamines; (i.c.v.) (Otero Losada, M.E. (215) 185)

Hypothermia
Dopamine; Dopamine D_2 receptors; Efficacy; (Full agonists); (Partial agonists); (Mouse) (Sánchez, C. (211) 9)

Electroconvulsive shocks; Serotonergic neurons; 5-HT autoreceptors; 5-HT release; 5-HT_3 receptors (Blier, P. (211) 365)

Methionine sulfoximine; Pindolol; Propranolol; Ketanserin; Betaxolol; ICI 118,551; 5-HT_1 receptors (Ginefri-Gayet, M. (217) 85)

JMV 449; Peptide bond (reduced); Pseudopeptide neurotensin analogue; Analgesia; (Potent and long-lasting agonist) (Dubuc, I. (219) 327)

5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sex differences; Tolerance; Corticosterone (Nakano, Y. (219) 339)

(−)-Penbutolol; 5-HT_{1A} receptor antagonism; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Synthesis and turnover; 5-HT-like behaviour (Hjorth, S. (222) 121)

Hypoxia
Neuroprotection; Calpain inhibitor; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Endothelin-1; Radioimmunoassay; Respiratory distress syndrome (adult); Oleic acid; Bronchoalveolar lavage (Simmet, T. (211) 319)

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Learning; Memory; CO-induced amnesia; Delayed amnesia; Passive avoidance task (Yoshida, S. (214) 247)

Hypoxia/hypoglycemia
Cholinergic drugs; 2-Deoxyglucose uptake; Hippocampus; CA1 field potentials; (In vitro) (Shibata, S. (221) 113)

Catecholamines; 2-Deoxyglucose; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Shibata, S. (221) 255)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptors; Ischemia; CA1 field potential; Hippocampus; (In vitro) (Kagami-ishi, Y. (224) 51)

IBMX (3-isobutyl-1-methylxanthine)
Gastric fundus (rat); Cyclic nucleotides; Non-adrenergic non-cholinergic (NANC) relaxation; Zaprinast (Barbier, A.J. (210) 315)

Ibogaine
Cocaine; Dopamine; Nucleus accumbens; Striatum; Microdialysis; Locomotor activity (Maisonneuve, I.M. (212) 263)

Ibuprofen
Interleukin-1β; Appetitive behaviour; (Yellow mice) (Shimomura, Y. (209) 15)

Ibutilide fumarate
Antiarrhythmics; Refractory period; Conduction time; Class III activity (Cimini, M.G. (222) 93)

ICI 118,551
Thyroxine; Portal vein; β-Adrenoceptors; Noradrenaline; Fenoterol; Atenolol (Chin, J.P.F. (212) 201)

CGP 20712A; Isoprenaline; Noradrenaline release; β-Adrenoceptors (prejunctional) (Mian, M.A. (213) 47)

Methionine sulfoximine; Hypothermia; Pindolol; Propranolol; Ketanserin; Betaxolol; 5-HT_1 receptors (Ginefri-Gayet, M. (217) 85)

ICS 205-930
Cisapride; 5-HT (5-hydroxytryptamine, serotonin); 5-Methoxytryptamine (5-MeOT); 5-HT_4 receptors (Meulemans, A.L. (212) 51)

Amphetamine discrimination; 5-HT_3 receptor antagonists; MDL 72,222EF; MDL 73,147EF; Ondansetron (GR38032F) (Moser, P.C. (212) 271)

5-HT_3 receptors; NG108-15; MDL 73147EF; MDL 74156 (Boeijinga, P.H. (219) 9)

Idazoxan
Efaroxan; Prazosin; Vas deferens; Anococcygeus; Glucose homeostasis; (Pithed rat) (Berridge, T.L. (213) 205)

Mitochondria; (Rabbit); (Human) (Tesson, F. (219) 335)

Antinociception; Arthritic rats; Tramadol; Yohimbine; Naloxone (Kayser, V. (224) 83)

Antidepressants; β-Adrenoceptors; Adenylyl cyclase; C6 glioma cells; Protein kinase C (Manji, H.K. (227) 275)

Ifenprodil
NMDA (N-methyl-D-aspartate); Dopamine; Brain slices; Polyamines; SL 82.0715 (Woodward, J.J. (210) 265)

Neurotoxicity; Cell culture; NMDA receptors (Graham, D. (226) 373)

[^{125}I]5-Iodo-6-nitroquipazine
5-HT uptake (Mathis, C.A. (210) 103)

$^{125}I^-$ ion binding
Autoradiography; Eosinophils; Peroxidase; Trachea (guinea-pig) (Rigby, P.J. (228) 141)

Ileal motility
Capsaicin; Mesenteric nerve; Neuraminidase; Sialic acid; Ruthenium red; (Guinea-pig) (Takaki, M. (211) 125)

Ileum
Opiates; Fentanyl; Lofentanil; Vas deferens; (Receptor binding) (Maguire, P. (213) 219)

Ileum (guinea-pig)
Opioid receptor agonist/antagonist (mixed); DAMGO ([D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin); Nor-binaltorphimine (Berzetei-Gurske, I.P. (212) 283)

Endothelin-3; Endothelin-1; Desensitization; Na^+ ions; Endothelin receptor subtypes (Miasiro, N. (214) 133)

Muscarinic receptor subtypes; Superior cervical ganglion; Atrium (guinea-pig); Drug discrimination (Arnt, J. (218) 159)

Muscarinic receptor subtypes; Muscarinic receptor agonists; Stereochemistry (absolute); Superior cervical ganglion (rat); Hippocampal slice (rat); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

Ileum (guinea-pig, isolated)
Baclofen; $GABA_B$ receptor agonists; Thienyl baclofen analogs; 2-Hydroxysaclofen (Ong, J. (218) 343)

β-(2-Thienyl)-GABA; Baclofen; Neocortical slices (rat); 2-Hydroxysaclofen (Ong, J. (221) 145)

Ileum (rat)
Nitric oxide (NO); cGMP; Non-adrenergic non-cholinergic (NANC) inhibition (Kanada, A. (216) 287)

Small intestine; Capsaicin; Nitric oxide (NO); Intestinal motility (Allescher, H.-D. (217) 153)

Iliac artery (guinea-pig)
5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors; 5-HT_{1D} receptor subtype; Smooth muscle (vascular) (Schoeffter, P. (219) 295)

Imaging
Benzodiazepine receptors; PET (positron emission tomography); [^{18}F]FEF (5-(2′-[^{18}F]Fluoroethyl)flumazenil); Flumazenil; Neuroreceptors (Moerlein, S.M. (218) 109)

Imidazoline
Cibenzoline; Insulin secretion; Glycemia; Pancreas; (Rat) (Bertrand, G. (214) 159)

Nicorandil; Portal vein (rat); K^+ channels (Okumura, K. (215) 253)

Rilmenidine; Oxazoline; Guanidinium; α_2-Adrenoceptor subtypes; Cerebral cortex (rat) (King, P.R. (218) 101)

Imidazoline-preferring receptors
Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo); Blood pressure (Tibiriça, E. (209) 213)

Imiloxan
α_2-Adrenoceptor subtypes; WB4101; Dexmedetomidine; Clonidine; ST-91 (Takano, Y. (219) 465)

Imipramine
Phosphoinositide hydrolysis; 5-HT_2 receptors; Forced swimming test; Mianserin; Affective disorders (Kawanami, T. (216) 385)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Imipramine (chronic)
NMDA receptors; Dopamine receptors; Supersensitivity (D'Aquila, P.S. (224) 199)

Immediate-early genes
Striatum; Phosphorothioate (Chiasson, B.J. (227) 451)

Immobilization
Feeding behaviour; Anorexia; B-HT 920; ACTH (adrenocorticotropin); (Rat) (Ferrari, F. (210) 17)

Immobilization stress
Muscarinic receptors; Autoradiography; Supersensitivity; Hippocampus; Striatum (González, A.M. (214) 261)

Immune-complex alveolitis
Arthus reaction; PAF (platelet-activating factor, PAF-acether); Eicosanoids (Tavares de Lima, W. (213) 63)

Immunisation
Azelastine; Lung hyperresponsiveness; PAF (platelet-activating factor, PAF-acether); Leukotrienes; Histamine; (Guinea-pig) (Pretolani, M. (216) 141)

Immunopharmacology
Endotoxin; Gastric acid secretion; Indomethacin; Interleukin-1; Lipopolysaccharide; Prostaglandin (Tsuji, K. (210) 213)

Immunoreactive insulin plasma levels
α_1-Adrenoceptors; β-Adrenoceptors; Ca^{2+} channel blockers; (Rabbit) (García-Barrado, M.J. (219) 461)

Immunosuppressants
Emodin; Free radical (Huang, H.-C. (211) 359)

Scoparone; Tyrosine kinase inhibitor (Huang, H.-C. (217) 143)

Immunotoxicology
Phenol; Neurotoxicity; Brain biogenic amines; (Mouse) (Hsieh, G.-C. (228) 107)

Impromidine
Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Adrenoceptors; Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

IMR-90 cells
Bradykinin; Bradykinin receptors; Bradykinin receptor antagonists (Sawutz, D.G. (227) 309)

Inaperisone hydrochloride
Micturition reflex; Rhythmic bladder contraction; $GABA_B$ receptors; (Rat) (Morikawa, K. (213) 409)

Indapamide
Diuretics; Hydrochlorothiazide; Resistance vessels (Calder, J.A. (220) 19)

Indenolol
β-Adrenoceptor antagonists; Atenolol; Nadolol; Propranolol; Mitochondrial ATPase activity (Almotrefi, A.A. (215) 231)

Indomethacin
Prostaglandin E_2; Gastric acid secretion; Vagus; Baclofen (Saperas, E. (209) 1)

Endotoxin; Gastric acid secretion; Immunopharmacology; Interleukin-1; Lipopolysaccharide; Prostaglandin (Tsuji, K. (210) 213)

cGMP; *E. coli* enterotoxin (heat-stable); 5-HT (5-hydroxytryptamine, serotonin); Intestinal secretion; Ketanserin; Tropisetron (Beubler, E. (219) 445)

Inhibin; Oestradiol-17β; Gonadotrophin; Prostaglandin $F_{2\alpha}$; PMSG-primed immature rat; Ovary (Kogo, H. (221) 289)

Peritoneal cells (rat); Phagocytosis (bacterial); Eicosanoids; CR1 receptors; Fc receptors (Coquette, A. (226) 1)

Inflammation
Endothelin-1; Thromboxane A_2; Vascular permeability; Airways; Gastrointestinal ulceration (Sirois, M.G. (214) 119)

PAF (platelet activating factor, PAF-acether); SR 27417; Antigen; Skin; Oedema (Herbert, J.M. (216) 175)

PAF (platelet-activating factor, PAF-acether); Gastrointestinal; Endotoxic shock; Parasitic infection (Hogaboam, C.M. (216) 315)

5-Lipoxygenase; Leukotrienes; Asthma; Airway hyperresponsiveness; (Late responses) (Abraham, W.M. (217) 119)

Asthma; Bronchial provocation test; Theophylline (Crescioli, S. (228) 45)

Inflammatory cell count
Parainfluenza 3 virus; Airway responsiveness (in vivo); Chemiluminescence; (In vitro activation) (Folkerts, G. (228) 219)

Inflammatory cells
Bronchial hyperreactivity; PAF receptor antagonists; Antigen (ovalbumin) (Underwood, S.L. (210) 97)

Parainfluenza 3 virus; Airway responsiveness (in vitro); Histology (Folkerts, G. (228) 121)

Inflammatory mediators
Alveolar macrophages; cAMP; Chronic obstructive pulmonary disease; Asthma; Adenylyl cyclase; β-Adrenoceptor agonists (Beusenberg, F.D. (228) 57)

Inhibin
Oestradiol-17β; Indomethacin; Gonadotrophin; Prostaglandin $F_{2\alpha}$; PMSG-primed immature rat; Ovary (Kogo, H. (221) 289)

Inhibitory effects (residual)
Smooth muscle (vascular); Nisoldipine; Ca^{2+} levels (cytosolic); Ca^{2+} channels; Aorta (rat); (Relaxation) (Kim, B.K. (223) 157)

Inhibitory transmission
$GABA_B$ receptors (presynaptic); $GABA_B$ receptors (postsynaptic); Patch/slice recording; Excitatory transmission (Lovinger, D.M. (211) 337)

Inorganic phosphate
Ca^{2+} sensitization; Cardiac muscle (skinned); Muscle regulation; EMD 53998 (Strauss, J.D. (227) 437)

Inositol hexakisphosphate
Vasomotor neurons; Medulla (rostral ventrolateral); Phytic acid (Sun, M.-k. (215) 9)

Inositol phosphate accumulation
Cholecystokinin; CCK_B receptors; Synaptoneurosomes (guinea pig, cerebral cortex); Boc-[Leu^{31}]CCK-4 binding; cAMP accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

Inositol phosphate analogues
Second messenger; Ca^{2+} mobilization (Safrany, S.T. (226) 265)

Inositol phosphates
Diabetes mellitus; Mesenteric arteries; Noradrenaline; Contractile responses; Inositol 1,4,5-trisphosphate (Abebe, W. (225) 29)

Muscarinic receptors; Heart (guinea pig); Receptor coupling (Ford, A.P.D.W. (225) 105)

Ca^{2+}; Inositol 1,4,5-trisphosphate receptors; WRK_1 cells (Mouillac, B. (225) 179)

Dopamine receptors; Phosphoinositides; Striatum (rat); α-Adrenoceptors; 5-HT receptors (Undie, A.S. (226) 297)

Thromboxane A_2 receptors; Glomeruli; Platelets (radioligand binding) (Folger, W.H. (227) 71)

Substance P; Spinal cord; Cerebral cortex; Anesthesia; Pentobarbital (Hasséssian, H. (227) 103)

Leukotrienes; Smooth muscles; Pulmonary system; Protein kinase C; G-Protein (Howard, S. (227) 123)

Hepatocytes; Histamine H_1 receptors (García-Sáinz, J.A. (227) 325)

Endothelins; Megakaryoblastic cells; Ca^{2+} (Diochot, S. (227) 427)

Adrenoceptors; Catecholamines (Schwinn, D.A. (227) 433)

D-myo-Inositol-1,2,6-triphosphate (PP56)
Neuropeptide Y; Vasoconstriction; Non-adrenergic sympathetic nerve stimulation (Pernow, J. (222) 171)

Inositol 1,4,5-trisphosphate
Diabetes mellitus; Mesenteric arteries; Noradrenaline; Contractile responses; Inositol phosphates (Abebe, W. (225) 29)

Endothelin-1; Protein kinase C; Flosequinan (Lang, D. (226) 259)

Inositol trisphosphate
Iris sphincter (dog); Smooth muscle; Muscarinic stimulation; cAMP; Ca^{2+}; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Inositol 1,4,5-trisphosphate receptors
Ca^{2+}; WRK_1 cells; Inositol phosphates (Mouillac, B. (225) 179)

Inotropic effects
Dromotropic effects; Coronary vascular resistance; Ventricular tachycardia; Endothelial messengers; Arrhythmias (Balcells, E. (210) 1)

Inotropism
Mn^{2+}; Ryanodine; Nicardipine; Myocardium; (Rat) (Agata, N. (222) 223)

Insect neuronal type nicotinic acetylcholine receptors
Nitromethylene heterocycle insecticides; 1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI); Endplate type nicotinic acetylcholine receptors; Neuronal type nicotinic acetylcholine receptors; Patch clamp technique (whole-cell) (Zwart, R. (228) 165)

Insulin
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); $5\text{-}HT_2$ receptors; Glucose; Sympathoadrenal system (Baudrie, V. (213) 41)

Interleukin; Prostaglandin; Dexamethasone (Shimizu, H. (222) 279)

Insulin mimetic effects
Vanadate; Alloxan diabetes; Liver; Kidney (Saxena, A.K. (216) 123)

Insulin release
8-Methoxypsoralen; K^+ channels (ATP-sensitive); B-cells (Szewczyk, A. (216) 323)

Insulin secretion
Galanin; Galanin receptor antagonists; Galantide; (Displacement) (Lindskog, S. (210) 183)

CCK-8 (cholecystokinin-8); CCK_A receptors; CCK_B receptors; L-364,718; L-365,260 (Karlsson, S. (213) 145)

Cibenzoline; Glycemia; Imidazoline; Pancreas; (Rat) (Bertrand, G. (214) 159)

Ca^{2+} channels; ω-Conotoxin (Sher, E. (216) 407)

Pancreas (isolated, rat); Pertussis toxin; Adrenaline; α_2-Adrenoceptors (Hillaire-Buys, D. (218) 359)

Benzodiazepines; Benzodiazepine receptor agonists (peripheral-type) (Petit, P. (221) 359)

Insulin sensitivity
Adenosine; Adenosine receptors; Glucose transport; Amino acid transport; Skeletal muscle (Challiss, R.A.J. (226) 121)

Integral plasma membrane proteins
Bumetanide transport; Loop diuretics; Photoaffinity labeling; Sinusoidal plasma membrane (rat liver); Two-dimensional gel electrophoresis (Honscha, W. (226) 215)

Intercellular communication
Cholesterol; Oxysterol; Smooth muscle cells (Zwijsen, R.M.L. (228) 115)

Interferon-γ
Corticosteroids; Fibroblasts (lung); Nitric oxide (NO); Nitrite; Endotoxin/lipopolysaccharide; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

Lipopolysaccharides; N^G-Methyl-L-arginine; N^G-Nitro-L-arginine; cGMP (Förstermann, U. (225) 161)

Interferon inducer
Poly(rG)·Poly(rC); Poly(rI)·Poly(rC); Antitumour activity; Liver colony assay; Survival (Jurásková, V. (221) 107)

Interleukin-1
Tumor necrosis factor; Interleukin-1 receptor antagonists; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Endotoxin; Gastric acid secretion; Immunopharmacology; Indomethacin; Lipopolysaccharide; Prostaglandin (Tsuji, K. (210) 213)

Interleukin-6; Prostaglandins; 15-HETE (15-hydroxyeicosatetraenoic acid); Fibroblast (Elliott, G.R. (214) 253)

CRF (corticotropin-releasing factor) secretion; Hypothalamic perfusion; Catecholamines (Cambronero, J.C. (219) 75)

α-MSH (α-melanocyte-stimulating hormone); Feeding behaviour (Uehara, Y. (220) 119)

Insulin; Prostaglandin; Dexamethasone (Shimizu, H. (222) 279)

Interleukin-1β
Appetitive behaviour; Ibuprofen; (Yellow mice) (Shimomura, Y. (209) 15)

Nitric oxide (NO); PDGF (platelet-derived growth factor); TGF-β (transforming growth factor-β); Platelets; Aorta (rat) (Schini, V.B. (216) 379)

Corticosteroids; Fibroblasts (lung); Nitric oxide (NO); Nitrite; Interferon-γ; Endotoxin/lipopolysaccharide; (Rat) (Jorens, P.G. (224) 7)

Interleukin-1 receptor antagonists
Tumor necrosis factor; Interleukin-1; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Airway hyperreactivity; Substance P; Bronchoalveolar lavage; Airway leukoctyes (Selig, W. (213) 331)

Interleukin-6
Interleukin-1; Prostaglandins; 15-HETE (15-hydroxyeicosatetraenoic acid); Fibroblast (Elliott, G.R. (214) 253)

Intestinal motility
Histamine; Morphine (Patrini, G. (210) 259)

Mucosal transport; Mebeverine; (Ferret) (Greenwood, B. (211) 143)

GABA (γ-aminobutyric acid); Baclofen; Jejunum (human); Colon (human) (Gentilini, G. (217) 9)

Small intestine; Capsaicin; Nitric oxide (NO); Ileum (rat) (Allescher, H.-D. (217) 153)

Intestinal relaxation
Endothelins; Sarafotoxins; Ca^{2+}-activated K^+ channels (Lin, W.-W. (219) 355)

Intestinal secretion
cGMP; *E. coli* enterotoxin (heat-stable); 5-HT (5-hydroxytryptamine, serotonin); Indomethacin; Ketanserin; Tropisetron (Beubler, E. (219) 445)

Intestine
Corticotropin-releasing hormone (CRH); Autonomic ganglia; Enteric nervous system; Synaptic transmission (Hanani, M. (211) 23)

cAMP; Enteric nervous system; Myenteric neurons; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Intestine (rat)
[^{3}H]Brofaromine; MAO-A (monoamine oxidase A); Brofaromine binding; Tyramine; Clorgyline (Waldmeier, P.C. (216) 243)

Intracellular Ca^{2+}
Fura-2; Ca^{2+} channels; Ca^{2+} ionophore; Co^{2+}; La^{3+} (Horváth, G. (225) 305)

Intragastric pressure
5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors; 5-HT receptor antagonists; (Rat) (Dhasmana, K.M. (213) 293)

Intrathecal
Excitatory amino acids; Spinal cord; NMDA receptors; Non-NMDA receptors (Näsström, J. (212) 21)

Inverse agonists
Benzodiazepine receptors; Locomotor activity; Exploratory behaviour (Jackson, H.C. (221) 199)

Inward calcium current-dependent phasic tension
Forskolin; 1,9-Dideoxyforskolin; Adenosine; Phosphodiesterase inhibitors; Atrial fibres (frog) (Gauthier, C. (225) 129)

Iodoantipyrine
Cerebral blood flow; Cerebral glucose metabolism; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

[^{14}C]Iodoantipyrine
Cerebral energy metabolism; Cerebral blood flow; Methylxanthines; [^{14}C]2-Deoxyglucose (Schroeder, H. (220) 217)

[^{125}I]Iodophenpropit binding
Histamine H_3 receptors; Histamine H_3 receptor antagonist (radiolabeled) (Jansen, F.P. (217) 203)

Ion channel reconstitution
Antibacterial peptide; Artificial bilayer; Peptide ion channel (Cruciani, R.A. (226) 287)

Ion channels
ATP; Dopamine; Dopamine receptor agonists; Dopamine receptor antagonists; Pheochromocytoma PC12 cells (Inoue, K. (215) 321)

Propofol; Myelinated nerve fibre; Voltage-clamp experiment; Anaesthetics (intravenous) (Veintemilla, F. (218) 59)

Ion flux
Cromakalim; K^+ channels; Rb^+; Smooth muscle relaxation (Foster, K.A. (222) 143)

Ionic channels
Ketamine; NMDA (N-methyl-D-aspartate); (Enantiomer) (Zeilhofer, H.U. (213) 155)

Ionic fluxes
Aorta (rat); Diazoxide; Mechanical activity (Antoine, M.-H. (216) 299)

Iontophoresis
NMDA (N-methyl-D-aspartate); AMPA; Substance P-(1–7); Nociception; Spinal cord; (Extracellular recording) (Budai, D. (216) 441)

Ion transport
Angiotensin; Airway epithelium; G-protein (Tamaoki, J. (220) 87)

IP_3 (inositol trisphosphate)
Neuropeptide Y (NPY); Locomotion; (Feeding); (Receptors) (Heilig, M. (209) 27)

Smooth muscle; Ca^{2+}; Acetylcholine; A23187; Phasic and tonic responses (Macara, B. (218) 27)

Ipriflavone
Phosphoinositides; UMR-106 cells; $^{45}Ca^{2+}$ uptake (Sortino, M.A. (226) 273)

Ipsapirone
NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Schizophrenia; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

Tandospirone; Buspirone; Azapirones; Chlordiazepoxide; Anxiolytics; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

IPSP (inhibitory postsynaptic potential)
γ-Hydroxybutyrate; $GABA_B$ receptors; CGP 36742; EPSP (excitatory postsynaptic potential); Hippocampus (Xie, X. (223) 193)

Iris (rabbit)
Tachykinins; NK_1 receptors; Tachykinin receptor antagonists (selective) (Wang, Z.-y. (216) 327)

Iris sphincter (dog)
Smooth muscle; Muscarinic stimulation; cAMP; Inositol trisphosphate; Ca^{2+}; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Iris sphincter muscle
Cholecystokinin (CCK); Lorglumide; Loxiglumide; Ciliary muscle (Almegård, B. (211) 183)

Iris sphincter muscle (rabbit)
Resiniferatoxin; Capsaicin; Bradykinin; Tachykinins; Substance P; Tachyphylaxis (Wang, Z.-Y. (213) 235)

Isaxonine phosphate (2-isopropylaminopyrimidine)
5-Hydroxyisaxonine; 2-Aminopyrimidine (Martinat, C. (228) 63)

Ischaemia
Opioid receptor antagonists; Opioid receptor agonists; Arrhythmias; (Rat) (McIntosh, M. (210) 37)

Cardiac electrophysiology; Opioid receptor antagonists; Purkinje fibres (McIntosh, M. (210) 45)

Pindolol; Reperfusion; Cardioprotection; Sympathomimetic activity (intrinsic); (Rat) (Nasa, Y. (213) 171)

Glycine; NMDA receptors; Kynurenates; Thiokynurenates; Excitotoxicity (Moroni, F. (218) 145)

Metabolic changes; Patch clamp; Ventricular cells; 5-Hydroxydecanoate (Notsu, T. (220) 35)

Ca^{2+} channel antagonists; Heart (isolated); Cardiac function (Manning, A. (220) 249)

Catecholamines; Hypoxia/hypoglycemia; 2-Deoxyglucose; CA1 field potential; Hippocampus; (In vitro) (Shibata, S. (221) 255)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_3$ receptors; Hypoxia/hypoglycemia; CA1 field potential; Hippocampus; (In vitro) (Kagamiishi, Y. (224) 51)

Excitatory amino acids; Neuronal damage; Vinconate; Muscarinic receptors (presynaptic) (Iino, T. (224) 117)

Ischaemic acute renal failure
Endothelin; Endothelin receptor antagonists; Ca^{2+}; (Rat) (Mino, N. (221) 77)

Ischaemic arrhythmias
Mexiletine; Antiarrhythmic actions; Convulsions; Pharmacokinetics (Igwemezie, L.N. (210) 271)

Antiarrhythmic activity; U-50,488H; Naloxone (Pugsley, M.K. (212) 15)

Quinacainol; Antiarrhythmics; Electrophysiological actions (Howard, P.G. (219) 1)

Islets of Calleja
Basal ganglia; Dopamine D_3 receptors; Dopamine D_2 receptors; Autoradiography (Gehlert, D.R. (211) 189)

IS-5-MN (isosorbide-5-mononitrate)
Pirsidomine; Hemodynamics; Tolerance; (Dog) (Bohn, H. (220) 71)

Isocyanate hydrolysis
Toluene diisocyanate; Bronchial smooth muscle (guinea-pig) (Mapp, C.E. (228) 103)

Isoflurane
Anesthesia; Stereoisomers (Harris, B. (217) 215)

Isoliquiritigenin
Aldose reductase inhibitor; Anti-platelet action; Cyclooxygenase inhibitor (Tawata, M. (212) 87)

Isometric tension
Skeletal fibre (skinned); Anthracyclines (De Beer, E.L. (214) 97)

Isoprenaline
CGP 20712A; ICI 118,551; Noradrenaline release; β-Adrenoceptors (prejunctional) (Mian, M.A. (213) 47)

Lithium chloride; cAMP; Norepinephrine; Phenoxybenzamine; Propranolol (Mármol, F. (226) 93)

Isoproterenol
Anthracene-9-carboxylic acid (9AC); DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid); Cardiac cells (guinea-pig); Cl^- activity (intracellular) (Shida, S. (212) 267)

Amino acid transport; Blood–brain barrier; β_2-Adrenoceptors; L-DOPA (L-3,4-dihydroxyphenylalanine); Salbutamol (Takao, Y. (215) 245)

Aging; Cardiac muscle; Dihydropyridines; Ca^{2+} (extracellular); F344 rats (Ruch, S. (216) 393)

NECA (5′-N-ethylcarboxamidoadenosine); Functional antagonism; Nitric oxide (NO); Nitroglycerin; Sodium nitroprusside (Wiener, H.L. (220) 131)

β-Adrenoceptors; cAMP; mRNA; C_6 glioma cells; Down-regulation (Bieck, P.R. (225) 171)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor (Sakuta, H. (226) 199)

Jatrophone
Aorta (rat); K^+ channel blockers; Ca^{2+}; KCl; Angiotensin II; Noradrenaline (Duarte, D.F.P. (215) 75)

Jaw movements
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apomorphine; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Jejunum (human)
GABA (γ-aminobutyric acid); Baclofen; Colon (human); Intestinal motility (Gentilini, G. (217) 9)

Jerking
Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; SCH 39166; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

JMV 449
Peptide bond (reduced); Pseudopeptide neurotensin analogue; Hypothermia; Analgesia; (Potent and long-lasting agonist) (Dubuc, I. (219) 327)

Joint inflammation
Pain (chronic); Polyarthritic rat; Autoradiography (quantitative); Opioid receptor regulation (Besse, D. (223) 123)

Jugular vein
α-Adrenoceptors; β-Adrenoceptors; Aorta; Autoradiography; [^{125}I]CYP ([^{125}I]iodo-cyanopindolol); [^{125}I]HEAT ([^{125}I][β-(4-hydroxy-3-iodophenyl)-ethyl-aminomethyl]-tetralone) (Killam, A.L. (218) 295)

K^+
Hypothalamus; 5-HT receptors; K^+ channels; 5-HT_{1A} receptors (Newberry, N.R. (210) 209)

Digitalis toxicity; Na^+ activity (intracellular); Ca^{2+} overload; Contractile force; Na^+ (Abete, P. (211) 399)

Ageing; Trachea (guinea-pig and rat); Epithelium; Smooth muscle (airway); Histamine; Acetylcholine; Carbachol (Preuss, J.M.H. (228) 3)

Kainate
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; AMPA binding (Kiss, B. (209) 109)

Glutamate receptors; Barbiturates; Methohexitone; Epileptiform activity (Palmer, A.J. (221) 205)

Spider toxins; Excitatory amino acid receptors; NMDA (N-methyl-D-aspartic acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Davies, M.S. (227) 51)

Kainic acid
Domoic acid; AMPA; Excitatory amino acid receptor; Neurotoxin (Hampson, D.R. (218) 1)

Kava extract
Methysticin; Memantine; Middle cerebral artery occlusion; (Rat); (Mouse) (Backhauß, C. (215) 265)

K^+-stimulated Ca^{2+}-independent efflux of [^{3}H]acetylcholine
Phrenic nerve; Cholinesterase inhibition; Vesamicol; Acetylcholine carrier (Wessler, I. (221) 371)

K^+ channel activators
Goblet cell secretion (Kuo, H.-P. (215) 297)

K^+ channel blockers
Jatrophone; Aorta (rat); Ca^{2+}; KCl; Angiotensin II; Noradrenaline (Duarte, D.F.P. (215) 75)

K^+ channel inhibitors
SDZ PCO 400; Trachealis (guinea-pig and bovine); K^+-rich media; $^{86}Rb^+$ efflux; (Electrophysiology) (Small, R.C. (219) 81)

K^+ channel openers
NIP-121; Cromakalim; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Ventricular papillary muscle; Contractile force; Action potentials; Sulfonylurea antidiabetics; P_2 purinoceptor agonists (Bott, A. (213) 141)

BRL 38227; Microcirculation; Spontaneously hypertensive rat (SHR) (Struijker Boudier, H.A.J. (218) 191)

E4080; Ca^{2+} channel antagonists; Ca^{2+} concentration (intracellular); Vasodilators; Coronary artery (dog) (Okada, Y. (218) 259)

K^+ channel opening
HOE 234; Bronchodilation; Airway dynamics; Trachea (guinea-pig) (Englert, H.C. (210) 69)

K^+ channels
Transmitter release; Aminopyridines; Tetraethylammonium; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

Sulfonylureas; Glibenclamide; Cromakalim; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Hypothalamus; 5-HT receptors; 5-HT_{1A} receptors; K^+ (Newberry, N.R. (210) 209)

α-Adrenoceptor antagonists; Portal vein (rat) (Schwietert, R. (211) 87)

Phentolamine; α-Adrenoceptors; Pinacidil; Cromakalim; Trachea (Bang, L. (211) 235)

Gastric fundus; BRL 38227 (lemakalim); Pinacidil; Non-adrenergic non-cholinergic neurostimulation; (Rat) (Lefebvre, R.A. (214) 1)

Antiarrhythmic agents; Ventricular fibrillation (Gwilt, M. (215) 137)

Dihydralazine; Hydralazine; Cromakalim; Nitroprusside; Smooth muscle (vascular) (Thirstrup, S. (215) 177)

Nicorandil; Imidazoline; Portal vein (rat) (Okumura, K. (215) 253)

Evodiamine; Endothelium; Ca^{2+} channels; Mesenteric artery (Chiou, W.-F. (215) 277)

Cross-tolerance; Uterus; Cromakalim; RP 49356 (Piper, I. (219) 347)

Cardiac arrhythmia; Antiarrhythmic drugs (Gwilt, M. (220) 231)

Cromakalim; Ion flux; Rb^+; Smooth muscle relaxation (Foster, K.A. (222) 143)

ATP; Smooth muscle (vascular); Patch clamp (Furspan, P.B. (223) 201)

$^{86}Rb^+$ efflux; Na^+ channels; Remoxipride; Neuroleptics; Voltage clamp (Westlind-Danielsson, A. (224) 57)

K^+ channels (ATP-dependent)
Glisoxepide; Glibenclamide; Biliary elimination; Anion transport; Liver; Sulfonylurea (Petzinger, E. (213) 381)

Nicorandil; Hyperpolarization; cGMP; Methylene blue (Holzmann, S. (215) 1)

K^+ channels (ATP-sensitive)
8-Methoxypsoralen; Insulin release; B-cells (Szewczyk, A. (216) 323)

Sulfonylureas; Motor control; Dorsal pallidum (Amalric, M. (217) 71)

Blood-aqueous barrier; Nitric oxide (NO); Vasodilatation (Andersson, S.E. (224) 89)

KCl
Jatrophone; Aorta (rat); K^+ channel blockers; Ca^{2+}; Angiotensin II; Noradrenaline (Duarte, D.F.P. (215) 75)

K^+ conductance
Progesterone; Coronary artery relaxation; Endothelium; Ca^{2+} influx (Jiang, C. (211) 163)

K^+ contracture
MCI-154; Hypotensive drugs; α-Adrenoceptors; Vasodilatation (Suh, S.H. (219) 377)

K^+ currents
Smooth muscle cells; DDT_1 MF-2 cells; Nucleotide receptors; ATP; UTP (Van der Zee, L. (215) 317)

Kelatorphan
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Ketamine
L-Glutamate receptors; Single channels; Channel block; Muscle (locust) (Macdonald, A.G. (210) 223)

NMDA (N-methyl-D-aspartate); Ionic channels; (Enantiomer) (Zeilhofer, H.U. (213) 155)

Ketanserin
Sexual behaviour; $5\text{-}HT_2/5\text{-}HT_{1C}$ receptors; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ritanserin; Mesulergine (Klint, T. (212) 241)

Anaesthesia; Blood pressure; Sinoaortic denervation (Su, D.-F. (214) 89)

Methionine sulfoximine; Hypothermia; Pindolol; Propranolol; Betaxolol; ICI 118,551; $5\text{-}HT_1$ receptors (Ginefri-Gayet, M. (217) 85)

p-Chlorophenylalanine; Atropine; Xylamidine; MDL 72222 (Bond, E.F. (217) 127)

cGMP; *E. coli* enterotoxin (heat-stable); 5-HT (5-hydroxytryptamine, serotonin); Indomethacin; Intestinal secretion; Tropisetron (Beubler, E. (219) 445)

Basilar artery (rat); Myograph; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor classification; Ergometrine (Deckert, V. (221) 17)

$5\text{-}HT_2$ receptors (human); $5\text{-}HT_{1A}$ receptors (human); G-protein coupling; (±)-8-Hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) (Stam, N.J. (227) 153)

Ketotifen
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Vas deferens (rabbit); Cyproheptadine; Pizotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

K^+-free solution
Trachea (guinea-pig); Acetylcholine; Histamine; 5-HT (5-hydroxytryptamine, serotonin); Amiloride; Ouabain (Cortijo, J. (221) 43)

Kidney
Vanadate; Alloxan diabetes; Insulin mimetic effects; Liver (Saxena, A.K. (216) 123)

α_1-Adrenoceptor subtypes; SDZ NVI 085; Vas deferens; Aorta (rat) (Eltze, M. (224) 125)

Atrial natriuretic peptide (ANP); Guanylate cyclase; Ontogenesis; Aorta; Lung (Muraki, T. (226) 311)

Kidney (isolated, perfused)
Doppler shift technique; Renal vascular resistance; Metalloproteases; Phosphoramidon; (Rat) (Salvati, P. (221) 267)

Kidney (rat)
Benzodiazepine receptors (peripheral); Angiotensin II (Holmes, P.V. (226) 189)

Kindling
Vigabatrin; Tolerance; Dependence; GABA (γ-aminobutyric acid); Glutamate; Epilepsy (Rundfeldt, C. (213) 351)

CGP 37849; CGP 39551; Anticonvulsant drugs; NMDA receptor antagonists; Seizures (Cotterell, K.L. (214) 285)

Kinetics
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Kinins
Spinal cord; Cardiovascular system; Catecholamines; Vagal reflex; C-fibers (Lopes, P. (210) 137)

Angiotensin-converting enzyme inhibitors; Renal circulation; EDRF (endothelium-derived relaxing factor); Angiotensin II receptor antagonists (Hajj-ali, A.F. (212) 279)

Kinins (characterization)
Epithelium; Agonists; Bradykinin receptor antagonists; B_2 receptor antagonist (radiolabeled) (Tousignant, C. (225) 235)

K^+-rich media
SDZ PCO 400; Trachealis (guinea-pig and bovine); K^+ channel inhibitors; $^{86}Rb^+$ efflux; (Electrophysiology) (Small, R.C. (219) 81)

Kynurenates
Glycine; NMDA receptors; Thiokynurenates; Ischemia; Excitotoxicity (Moroni, F. (218) 145)

Kynurenic acid
Aminooxyacetic acid; Excitotoxicity; Kynurenine; Microdialysis; Neuroprotection (Wu, H.-Q. (213) 375)

Kynurenine
Aminooxyacetic acid; Excitotoxicity; Kynurenic acid; Microdialysis; Neuroprotection (Wu, H.-Q. (213) 375)

Kyotorphin
L-Arginine; Antinociceptive effect; Opiodergic system; (Rat) (Kawabata, A. (218) 153)

L-158,809
Angiotensin IV; Angiotensin-(3–8); Angiotensin II; Adrenal cortex (bovine) (Jarvis, M.F. (219) 319)

L-364,718
Insulin secretion; CCK-8 (cholecystokinin-8); CCK_A receptors; CCK_B receptors; L-365,260 (Karlsson, S. (213) 145)

Cholecystokinin receptor; CCK_A receptor antagonists; Molecular modelling; Devazepide (Van der Bent, A. (226) 327)

L-365,260
Insulin secretion; CCK-8 (cholecystokinin-8); CCK_A receptors; CCK_B receptors; L-364,718 (Karlsson, S. (213) 145)

L-659,989
Splanchnic artery occlusion shock; PAF (platelet-activating factor, PAF-acether); TNF-α (tumor necrosis factor); Myocardial depressant factor (Zingarelli, B. (222) 13)

L 668,169
NK_1 receptors; Tachykinin receptor antagonists; CP-96,345; FR 113680; Spantide II (Patacchini, R. (215) 93)

L-687,306
Muscarinic M_1 receptor agonists; Functional selectivity (Freedman, S.B. (215) 135)

L-687,414
Glycine; NMDA (N-methyl-D-aspartate); Behaviour; Excitatory amino acids; Epilepsy (Smith, S.E. (211) 109)

La^{3+}
Intracellular Ca^{2+}; Fura-2; Ca^{2+} channels; Ca^{2+} ionophore; Co^{2+} (Horváth, G. (225) 305)

Lateral tegmental field
Quipazine; L-Glutamate; Subretrofacial nucleus; Caudal ventrolateral medulla; Nucleus tractus solitarii (Vayssettes-Courchay, C. (211) 243)

Learned helplessness paradigm
5-HT_3 receptor antagonists; (Rat) (Martin, P. (212) 73)

Learning
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Memory; CO-induced amnesia; Delayed amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

Aminooxyacetic acid; GABA (γ-aminobutyric acid); Pentobarbital; Seizures; Substance P (Vécsei, L. (220) 259)

5-HT receptors; LSD (lysergic acid diethylamide); (Locust) (Wedemeyer, S. (223) 173)

Learning deficit
Quinolinic acid; D-Cycloserine (Schuster, G.M. (224) 97)

Leucocyte recruitment
Cetirizine; Allergen; Pleurisy (rat) (Pasquale, C.P. (223) 9)

[Leu^5]enkephalin
[Met^5]enkephalin; Neurotensin; Cholecystokinin (CCK); Substance P; 6-Hydroxydopamine (6-OHDA); L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Naltrexone; [Met^5]enkephalin; β-Endorphin; Gastrointestinal content (McIntosh, C.H.S. (223) 117)

Leukocyte elastase (human)
Tracheal epithelial cells; Cathepsin G (Nahori, M.-A. (228) 213)

Leukotriene B_4
13-HODE (13-hydroxyoctadecadienoic acid); Oedema formation; Skin (rabbit) (Buckley, T.L. (218) 369)

Receptor binding; Parenchymal contraction; Airway obstruction; Leukotriene B_4 receptor antagonists; (Guinea-pig) (Silbaugh, S.A. (223) 57)

Leukotriene binding
SCH 37224; Sulfidopeptide leukotrienes; Lung parenchyma (human) (Viganò, T. (219) 159)

Leukotriene B_4 receptor antagonists
Leukotriene B_4; Receptor binding; Parenchymal contraction; Airway obstruction; (Guinea-pig) (Silbaugh, S.A. (223) 57)

Leukotriene D_4
VIP (vasoactive intestinal polypeptide); Helodermin; Arachidonic acid; Lung (perfused, guinea-pig); Cyclo-oxygenase products (Conroy, D.M. (218) 43)

Leukotrienes
Endothelium; Cromakalim; Heart (isolated, guinea-pig) (McLeod, J.D. (212) 67)

Azelastine; Immunisation; Lung hyperresponsiveness; PAF (platelet-activating factor, PAF-acether); Histamine; (Guinea-pig) (Pretolani, M. (216) 141)

5-Lipoxygenase; Asthma; Airway hyperresponsiveness; Inflammation; (Late responses) (Abraham, W.M. (217) 119)

Smooth muscles; Pulmonary system; Inositol phosphates; Protein kinase C; G-Protein (Howard, S. (227) 123)

Levodopa
Dystonia; Dopamine; Acetylcholine; Anticholinergic drugs; Haloperidol; Apomorphine (Löscher, W. (213) 31)

Light : dark box
WAY100289; Anxiety; 5-HT_3 receptor antagonists; Acoustic startle (potentiated) (Bill, D.J. (218) 327)

Lipid peroxidation
21-Aminosteroids; Antioxidants; Copper; Erythrocytes; Plasma (Fernandes, A.C. (220) 211)

Baicalein; Ear edema; Free radical; α-Tocopherol (Hara, H. (221) 193)

Lipopolysaccharides
Endotoxin; Gastric acid secretion; Immunopharmacology; Indomethacin; Interleukin-1; Prostaglandin (Tsuji, K. (210) 213)

Acetylcholine; EDRF (endothelium-derived relaxing factor); Polymorphonuclear leukocytes; Mesenteric artery (superior); Nitric oxide (NO) (Siegfried, M.R. (212) 171)

Blood vessels; Hyporesponsiveness; Endothelium; Protein synthesis; Nitric oxide (NO) (Nakaki, T. (219) 311)

Interferon-γ; N^G-Methyl-L-arginine; N^G-Nitro-L-arginine; cGMP (Förstermann, U. (225) 161)

Liposomes
Maitotoxin; Ca^{2+} channels; Cation blockers (Murata, M. (227) 43)

Lipoxygenase
Bradykinin; Angiotensin-converting enzyme; Smooth muscle; Phospholipase A_2; Cyclic nucleotides (Rodrigues, M.S. (216) 357)

5-Lipoxygenase
Leukotrienes; Asthma; Airway hyperresponsiveness; Inflammation; (Late responses) (Abraham, W.M. (217) 119)

Lisuride
Locomotor activity; Adenylate cyclase activity; Dopamine autoreceptors; Tolerance; Sensitization (Nisoli, E. (216) 81)

Lithium
5-HT (5-hydroxytryptamine, serotonin); ACTH release; Tricyclic antidepressants; Electroconvulsive shock (Gartside, S.E. (221) 27)

Lithium chloride
Tacrine; Seizures; Brain damage; Nitric oxide (NO); L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (213) 301)

Monoamines; Hypothalamus; (i.c.v.) (Otero Losada, M.E. (215) 185)

Phosphoinositide (IP_3); Analgesia (Raffa, R.B. (215) 357)

Analgesia; Opioids (Raffa, R.B. (217) 221)

GABA (γ-aminobutyric acid); Bicuculline; Diazepam; Pilocarpine; Seizures (Peterson, C.J. (221) 151)

cAMP; Norepinephrine; Isoprenaline; Phenoxybenzamine; Propranolol (Mármol, F. (226) 93)

Liver
Glisoxepide; Glibenclamide; Biliary elimination; Anion transport; Sulfonylurea; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

Vanadate; Alloxan diabetes; Insulin mimetic effects; Kidney (Saxena, A.K. (216) 123)

Liver colony assay
Poly(rG)·Poly(rC); Poly(rI)·Poly(rC); Interferon inducer; Antitumour activity; Survival (Jurásková, V. (221) 107)

Liver (human)
Sulfotransferase; Dehydroepiandrosterone; Estrone; Adverse drug reactions (Bamforth, K.J. (228) 15)

Liver (rat)
(+)-[^{3}H]SKF 10,047; σ Receptors; Subcellular distribution (Samovilova, N.N. (225) 69)

Locomotion
Neuropeptide Y (NPY); IP_3; (Feeding); (Receptors) (Heilig, M. (209) 27)

Dopamine; Dopamine D_2 receptors; Quinpirole; (Rat) (Van Hartesveldt, C. (214) 27)

MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; Nucleus accumbens septi; Behaviour (Callaway, C.W. (214) 45)

Circadian rhythms; Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Locomotor activity
Deltorphins; δ-Opioid receptors; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens (Calenco-Choukroun, G. (209) 267)

Ibogaine; Cocaine; Dopamine; Nucleus accumbens; Striatum; Microdialysis (Maisonneuve, I.M. (212) 263)

DAMGO ([D-Ala^2,MePhe^4,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); SKF 38393; Naltrindole; (Mouse) (Toyoshi, T. (213) 25)

Dopamine D_1 receptors; Dopamine D_2 receptors; Adenylate cyclase; Circling behaviour; Stereotyped behaviour (Arnt, J. (213) 259)

Adenylate cyclase activity; Dopamine autoreceptors; Lisuride; Tolerance; Sensitization (Nisoli, E. (216) 81)

β-Adrenoceptor (atypical); Brain; Depression; Water intake (Simiand, J. (219) 193)

Naloxone infusion (continuous); D-amphetamine; Opioids; Dopamine (Rat) (Jones, D.N.C. (221) 161)

Benzodiazepine receptors; Exploratory behaviour; Inverse agonists (Jackson, H.C. (221) 199)

Locomotor behaviour
Monoamines; Monoamine synthesis; Monoamine receptors; Umespirone; (Rat) (Ahlenius, S. (222) 69)

Locus coeruleus
Ethanol; GABA (γ-aminobutyric acid); Benzodiazepine; Picrotoxin; Ro 15-1788; Electrophysiology (Verbanck, P.M.P. (211) 15)

cAMP; Brain slices; Glutamate; Opiates; Withdrawal (Kogan, J.H. (211) 47)

5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Nucleus raphe dorsalis; Voltammetry (in vivo); (Rat) (Clement, H.-W. (217) 43)

Phencyclidine; BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine; Single unit recording; Reserpine (Chergui, K. (219) 169)

Norepinephrine; Desipramine; Amphetamine; Dorsal hippocampus (Curet, O. (221) 59)

Transcription factors; DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) (Bhat, R.V. (227) 447)

Locus coeruleus neurones
ATP; Suramin; P_2 purinoceptors; Firing rate (Tschöpl, M. (213) 71)

Lofentanil
Opiates; Fentanyl; Ileum; Vas deferens; (Receptor binding) (Maguire, P. (213) 219)

Long-term potentiation
1S,3R-ACPD (1S,3R-aminocyclopentane dicarboxylate); Metabotropic receptors (Bortolotto, Z.A. (214) 297)

Cognition enhancers; Hippocampus; Dentate gyrus; Perforant path stimulation; (Rat); (In vivo) (Molnár, P. (215) 17)

SDZ ENS 163; Muscarinic M_1 receptor agonists (Boddeke, E.W.G.M. (222) 21)

Glycine; Serine; Alanine; Valine; Glycine modulatory site; NMDA receptors; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Loop diuretics
M12285; Sulfate conjugation; Quinolinone oxime sulfonic acids (Shinkawa, T. (219) 217)

Bumetanide transport; Photoaffinity labeling; Sinusoidal plasma membrane (rat liver); Integral plasma membrane proteins; Two-dimensional gel electrophoresis (Honscha, W. (226) 215)

Lorglumide
CCK-8 (cholecystokinin octapeptide); Caerulein; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Cholecystokinin (CCK); Iris sphincter muscle; Loxiglumide; Ciliary muscle (Almegård, B. (211) 183)

Gastrin receptor antagonists; CCK receptor antagonists; Gastric antisecretory activity; Proglumide (Revel, L. (216) 217)

Losartan
DuP 753; Angiotensin II; Blood–brain barrier; Blood pressure; Thirst (Bui, J.D. (219) 147)

Angiotensin II; Angiotensin AT_2 receptor antagonists; Monoclonal antibodies (Reilly, T.M. (226) 179)

Smooth muscle cells; Hypertrophy; Phosphoinositide signalling system (Ko, Y. (227) 215)

Losartan (DuP 753)
Angiotensin II receptor subtypes; AT_2 receptors; Sulfhydryl reducing agents; Dithiothreitol; Brain development (Tsutsumi, K. (226) 169)

Low-density lipoprotein
Atherosclerosis; Nitric oxide (NO); Macrophages; Nitrite (NO_2^-) (Jorens, P.G. (212) 113)

Low density lipoprotein influx
13,14-Dihydroprostaglandin E_1; Aorta (rabbit); Atherosclerosis (experimental) (Sinzinger, H. (219) 129)

Loxiglumide
Cholecystokinin (CCK); Iris sphincter muscle; Lorglumide; Ciliary muscle (Almegård, B. (211) 183)

LSD (lysergic acid diethylamide)
5-HT receptors; Learning; (Locust) (Wedemeyer, S. (223) 173)

Lung
Atrial natriuretic peptide (ANP); Guanylate cyclase; Ontogenesis; Aorta; Kidney (Muraki, T. (226) 311)

Lung (guinea-pig)
Neuraminidase; Muscarinic receptor agonists (binding) (Haddad, E.-B. (211) 273)

Phospholipase A_2; Pancreatic phospholipase A_2 (porcine) (Sommers, C.D. (216) 87)

Histamine H_1 receptor; Desensitization; cGMP; Protein kinase C (Leurs, R. (225) 137)

Lung hyperresponsiveness
Azelastine; Immunisation; PAF (platelet-activating factor, PAF-acether); Leukotrienes; Histamine; (Guinea-pig) (Pretolani, M. (216) 141)

Lung parenchyma (human)
SCH 37224; Sulfidopeptide leukotrienes; Leukotriene binding (Viganò, T. (219) 159)

Lung parenchymal strips (guinea-pig)
β-Adrenoceptor-mediated responses; Desensitization; Atria (guinea-pig) (Herepath, M.L. (215) 209)

Lung (perfused, guinea-pig)
VIP (vasoactive intestinal polypeptide); Helodermin; Leukotriene D_4; Arachidonic acid; Cyclo-oxygenase products (Conroy, D.M. (218) 43)

Lung resistance
Muscarinic receptors; Parasympathetic nervous system; Gallamine; Pirenzepine; (Cat) (Killingsworth, C.R. (210) 231)

Luzindole
Melatonin; Melatonin receptor antagonists; *Xenopus* melanophores; Pigment aggregation (Sugden, D. (213) 405)

LY 262691
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; Dopamine neurons; Antipsychotic drugs (Rasmussen, K. (209) 135)

LY 277359
5-HT_3 receptor antagonists; Granisetron; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; 5-HT_3 receptors; 5-HT_3 receptor antagonists; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

LY 83583
Gastric fundus (rat); Non-adrenergic non-cholinergic (NANC); Nitric oxide (NO) (Barbier, A.J.M. (219) 331)

Lysine-acetylsalicylate
Dazmegrel; PAF (platelet-activating factor, PAF-acether); Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

Lysophosphatidic acid
Oocytes *Xenopus laevis* (Fernhout, B.J.H. (213) 313)

M12285
Loop diuretics; Sulfate conjugation; Quinolinone oxime sulfonic acids (Shinkawa, T. (219) 217)

Macrophages
Monocytes; Thromboxane A_2; Xanthine; cAMP (Baker, A.J. (211) 157)

Atherosclerosis; Low-density lipoprotein; Nitric oxide (NO); Nitrite (NO_2^-) (Jorens, P.G. (212) 113)

Maitotoxin
Ca^{2+} channels; Cation blockers; Liposomes (Murata, M. (227) 43)

Mammary artery (internal)
Adenosine receptors; CGS 21680; CGS 22492; Smooth muscle (vascular); Coronary artery (human) (Makujina, S.R. (221) 243)

Mast cell degranulating peptide
Guanine nucleotide-binding proteins (small); rho proteins; ADP-ribosyltransferase C3 (*Clostridium botulinum*); Melittin; Compound 48/80 (Koch, G. (226) 87)

[^{3}H]Mazindol binding
Dopamine transport; N-Ethylmaleimide alkylation; Cocaine; d-Amphetamine (Johnson, K.M. (227) 411)

MCI-154
Hypotensive drugs; α-Adrenoceptors; K^+ contracture; Vasodilatation (Suh, S.H. (219) 377)

MDL 72,222
Ketanserin; p-Chlorophenylalanine; Atropine; Xylamidine (Bond, E.F. (217) 127)

MDL 72,222EF
Amphetamine discrimination; 5-HT_3 receptor antagonists; MDL 73,147EF; ICS 205-930; Ondansetron (GR38032F) (Moser, P.C. (212) 271)

MDL 73,005EF
5-HT_{1A} receptors; 5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; Blood pressure; Heart rate; Spontaneously hypertensive rat (SHR) (Buisson-Defferier, S. (223) 133)

MDL 73,147EF
Amphetamine discrimination; 5-HT_3 receptor antagonists; MDL 72,222EF; ICS 205-930; Ondansetron (GR38032F) (Moser, P.C. (212) 271)

5-HT_3 receptors; NG108-15; MDL 74156; ICS 205-930 (Boeijinga, P.H. (219) 9)

MDL 74,156
5-HT_3 receptors; NG108-15; MDL 73147EF; ICS 205-930 (Boeijinga, P.H. (219) 9)

MDMA (3,4-methylenedioxymethamphetamine)
Amphetamine; Nucleus accumbens septi; Behaviour; Locomotion (Callaway, C.W. (214) 45)

Amphetamine; 5-HT_2 receptors; Dopamine neurons (Schmidt, C.J. (220) 151)

Amphetamines; Dopamine; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Elayan, I. (221) 281)

Amphetamine; Dopamine synthesis; Microdialysis; 5-HT_2 receptors (Schmidt, C.J. (223) 65)

5-HT uptake inhibitor; 1-Piperonylpiperazine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain (rat) (Hashimoto, K. (228) 171)

MDP-Lys(L18)
Arthritis; Cyclosporin A; Adjuvant arthritis; (Rat) (Sugawara, T. (228) 147)

Mebeverine
Intestinal motility; Mucosal transport; (Ferret) (Greenwood, B. (211) 143)

Mechanical activity
Aorta (rat); Diazoxide; Ionic fluxes (Antoine, M.-H. (216) 299)

Mechanoreceptors
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pressure; Endothelial cells; Hypertension (Hishikawa, K. (215) 329)

Medial preoptic area
Sexual behaviour (male); 5-HT_{1A} receptors; Nucleus accumbens; Nucleus raphe; 5-$HT_{1B/C}$ receptors (Fernández-Guasti, A. (210) 121)

Medulla (rostral ventrolateral)
Vasomotor neurons; Inositol hexakisphosphate; Phytic acid (Sun, M.-k. (215) 9)

Medullary 5-HT neurons
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Renal nerve activity (Ramage, A.G. (219) 165)

Megakaryoblastic cells
Endothelins; Ca^{2+}; Inositol phosphates (Diochot, S. (227) 427)

Melatonin
Convulsions; 3-Mercaptopropionic acid; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (210) 253)

Melatonin receptor antagonists; *Xenopus* melanophores; Pigment aggregation; Luzindole (Sugden, D. (213) 405)

Dopamine; Nucleus accumbens; Antidepressant drugs; Receptor supersensitivity (Durlach-Misteli, C. (217) 15)

Ouabain binding site (high affinity); [^{3}H]Ouabain; Cerebral cortex (rat) (Acuña Castroviejo, D. (226) 59)

Melatonin receptor antagonists
Melatonin; *Xenopus* melanophores; Pigment aggregation; Luzindole (Sugden, D. (213) 405)

Melittin
Guanine nucleotide-binding proteins (small); rho proteins; ADP-ribosyltransferase C3 (*Clostridium botulinum*); Mast cell degranulating peptide; Compound 48/80 (Koch, G. (226) 87)

Memantine
Kava extract; Methysticin; Middle cerebral artery occlusion; (Rat); (Mouse) (Backhauß, C. (215) 265)

Quinolinic acid; Neurodegeneration; Hippocampus (Keilhoff, G. (219) 451)

Human immunodeficiency virus type 1 (HIV-1); Apoptosis; Cortical cells; NMDA receptor; gp120 (Müller, W.E.G. (226) 209)

Membrane lipids
α_1-Adrenoceptor; Phospholipases; Phospholipase C; Phospholipids; Aorta (Shreeve, S.M. (226) 29)

Membrane microviscosity
Adenosine receptors; Affinity states; Brain cortex (pig) (Casadó, V. (225) 7)

Membrane potential
Na^+ pump; Na^+/K^+ pump; Colonic motility; Smooth muscle (Barajas-López, C. (221) 51)

Memory
WEB 1881 FU; Hippocampus; Acetylcholine; AF64A (Hashimoto, M. (209) 9)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT_{1A} receptors; Passive avoidance (Carli, M. (211) 227)

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Learning; CO-induced amnesia; Delayed amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

Protein kinase C: Amnesia; NMDA (N-methyl-D-aspartate); (Mouse) (Mathis, C. (220) 107)

Aging; D-Cycloserine; Glycine; NMDA receptors; Senescence; (Mouse) (Flood, J.F. (221) 249)

Epinephrine; Glucose; Propranolol; Phenoxybenzamine; Footshock (Hall, J.L. (221) 365)

Memory (working, reference)
Hippocampus; Chlordiazepoxide; Benzodiazepine; Muscimol; GABA (γ-aminobutyric acid) (Ohno, M. (219) 245)

MEN 10207
MEN 10208; NK_2 receptor subtype; Neurokinin A (NKA) (Henderson, A.K. (225) 175)

MEN 10208
MEN 10207; NK_2 receptor subtype; Neurokinin A (NKA) (Henderson, A.K. (225) 175)

3-Mercaptopropionic acid
Melatonin; Convulsions; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (210) 253)

Mesangial cells
Angiotensin II; Angiotensin AT_1 receptor; Phospholipase D; Phosphatidylcholine; Diacylglycerol (Pfeilschifter, J. (225) 57)

Amphotericin B; Ca^{2+} (intracellular); Diltiazem; Theophylline (Sabra, R. (226) 79)

Mesangial (rat)
Dopamine D_1 receptors; Characterization (Bryson, S.E. (225) 1)

Mesencephalon
Ca^{2+} channels; Dihydropyridines; NMDA (N-methyl-D-aspartate); Excitatory amino acid; Dopamine; Transmitter release (Chaudieu, I. (220) 203)

Mesencephalon (ventral)
Brain stimulation reward; Dopamine; Morphine; Neurotensin (Rompré, P.-P. (211) 295)

Mesenteric arterial bed
Adenosine; CGRP (calcitonin gene-related peptide); Sensory nerves (Rubino, A. (220) 95)

Mesenteric arteries (small)
Shock; Endotoxin; Nitric oxide (NO) (Schneider, F. (211) 269)

Mesenteric artery
Endothelin-1; Cyclosporine; Hypertension; Blood pressure (Takeda, Y. (213) 445)

Evodiamine; Endothelium; Ca^{2+} channels; K^+ channels (Chiou, W.-F. (215) 277)

Atherosclerosis; WHHL rabbit; Sympathetic neurotransmission; CGRP (calcitonin gene-related peptide); Neuropeptide Y (NPY) (Stewart-Lee, A.L. (216) 167)

Amrinone; Dibutyryl cAMP; Mesenteric vein (Itoh, H. (218) 347)

Dihydropyridine Ca^{2+} entry blocker; EDRF (endothelium-derived relaxing factor); Adrenergic nerve; Substance P; cGMP (Okamura, T. (220) 27)

Diabetes mellitus; Noradrenaline; Contractile responses; Inositol phosphates; Inositol 1,4,5-trisphosphate (Abebe, W. (225) 29)

cAMP; Dopamine receptors; Vascular smooth muscle (rat); Thiol group (Hall, A.S. (226) 253)

Mesenteric artery (human)
Calcium channels; Cromakalim; Vasodilators; Smooth muscle (vascular) (Smirnov, S.V. (217) 105)

Mesenteric artery (rabbit)
VIP (vasoactive intestinal polypeptide); Relaxation; Endothelium; Glibenclamide (Hattori, Y. (213) 147)

Mesenteric artery (superior)
Acetylcholine; EDRF (endothelium-derived relaxing factor); Polymorphonuclear leukocytes; Lipopolysaccharide; Nitric oxide (NO) (Siegfried, M.R. (212) 171)

Mesenteric nerve
Capsaicin; Ileal motility; Neuraminidase; Sialic acid; Ruthenium red; (Guinea-pig) (Takaki, M. (211) 125)

Mesenteric resistance vessels
Oxodipine; Aorta; $^{45}Ca^{2+}$ influx; (Rabbit) (Tejerina, T. (219) 279)

Mesenteric vein
Amrinone; Dibutyryl cAMP; Mesenteric artery (Itoh, H. (218) 347)

Mesentery (rat)
Capsaicin; CGRP (calcitonin gene-related peptide); Saponin; L-Arginine; N^{ω}-Nitro-L-arginine methyl ester (Li, Y. (210) 23)

Mesulergine
Sexual behaviour; 5-HT_2/5-HT_{1C} receptors; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ritanserin; Ketanserin (Klint, T. (212) 241)

Metabolic changes
Ischemia; Patch clamp; Ventricular cells; 5-Hydroxydecanoate (Notsu, T. (220) 35)

Metabolism
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Species differences (Ahlborg, U.G. (228) 179)

Metabolites (antagonism)
Neuromuscular relaxants; Vecuronium; 3-Desacetyl vecuronium; 3,17-Desacetyl vecuronium (Khuenl-Brady, K.S. (222) 153)

Metabotropic glutamate receptors
Ca^{2+} (external); 1S,3R-ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid) (Zheng, F. (211) 281)

1S,3R-ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitotoxicity (Siliprandi, R. (219) 173)

ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid); Cerebellum; Purkinje cells; Granule cells; AP-3 ((L)-2-amino-3-phosphonopropionate) (East, S.J. (219) 395)

1S,3R-trans-ACPD; Hippocampal pyramidal cells (Gerber, U. (221) 401)

L-2-Amino-4-phosphonobutyrate (L-AP4); cAMP (Thomsen, C. (227) 361)

Metabotropic receptors
1S,3R-ACPD (1S,3R-aminocyclopentane dicarboxylate); Long-term potentiation (LTP) (Bortolotto, Z.A. (214) 297)

Excitotoxicity; Excitatory amino acid (McDonald, J.W. (215) 353)

Excitatory amino acids; Cerebral ischaemia (Chiamulera, C. (216) 335)

cAMP formation; Striatal neurons (Manzoni, O. (225) 357)

Glutamate; Afterdepolarization (Greene, C. (226) 279)

Metallopeptidases
Endothelin-1; Big endothelin-1; Bronchoconstriction; Hypertension (Pons, F. (217) 65)

Metalloproteases
Doppler shift technique; Kidney (isolated, perfused); Renal vascular resistance; Phosphoramidon; (Rat) (Salvati, P. (221) 267)

[Met^5]enkephalin
β-Endorphin; CCK-8s (sulfated cholecystokinin octapeptide); Tail-flick inhibition (Tseng, L.F. (215) 309)

[Leu^5]enkephalin; Neurotensin; Cholecystokinin (CCK); Substance P; 6-Hydroxydopamine (6-OHDA); L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Naltrexone; [Leu^5]enkephalin; β-Endorphin; Gastrointestinal content (McIntosh, C.H.S. (223) 117)

Methamphetamine
σ Receptors; Behavioral sensitization; BMY 14802; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-propylpiperidine) (Ujike, H. (211) 323)

Dynorphin A-(1–13); Mr 2266; Circling; Rearing; (Mouse) (Ukai, M. (222) 7)

Dopamine release; Nucleus accumbens; Dynorphin (Yokoo, H. (222) 43)

Methionine sulfoximine
Hypothermia; Pindolol; Propranolol; Ketanserin; Betaxolol; ICI 118,551; 5-HT_1 receptors (Ginefri-Gayet, M. (217) 85)

Methiothepin
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

Methohexitone
Glutamate receptors; Kainate; Barbiturates; Epileptiform activity (Palmer, A.J. (221) 205)

Methoxamine
Ba^{2+}; Nifedipine; $^{45}Ca^{2+}$ uptake; Vas deferens; $^{45}Ca^{2+}$ efflux; Verapamil (Hay, D.W.P. (225) 313)

8-Methoxypsoralen
K^+ channels (ATP-sensitive); Insulin release; B-cells (Szewczyk, A. (216) 323)

5-Methoxytryptamine
Cisapride; 5-HT (5-hydroxytryptamine, serotonin); ICS 205-930; 5-HT_4 receptors (Meulemans, A.L. (212) 51)

3-Methoxytyramine
Dopamine release; Striatum; Nucleus accumbens; Frontal cortex; (Rat) (Chrapusta, S.J. (222) 129)

4-Methylaminorex
Amphetamines; Basal ganglia; Dopamine; Drug abuse; Dynorphin A; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

3-Methylcholanthrene
Cytochrome P-450; σ Receptors; Phenobarbital (Basile, A.S. (227) 95)

[^{3}H]α,β-Methylene ATP
P_{2X} purinoceptors; Urinary bladder; Urethra (Bo, X. (216) 59)

Methylene blue
Nicorandil; Hyperpolarization; K^+ channels (ATP-dependent); cGMP (Holzmann, S. (215) 1)

(R)-α-Methylhistamine
Cholinergic bronchospasm (central); Histamine H_1 receptors; Histamine H_3 receptors (Hey, J.A. (211) 421)

3-Methylhistidine
Hypertension; Terazosin; α-Adrenoceptor blockade; Spontaneously hypertensive rat (SHR) (Jonsson, J.R. (211) 263)

N^G-Methyl-L-arginine
Lipopolysaccharides; Interferon-γ; N^G-Nitro-L-arginine; cGMP (Förstermann, U. (225) 161)

Methylmercury
Renal uptake; Glutathione (reduced); γ-Glutamyltranspeptidase (Tanaka, T. (228) 9)

[^{3}H]Methylphenidate
Cocaine; GBR-12783; Stimulants; Dopamine transporters (Deutsch, H.M. (220) 173)

2-Methylserotonin
5-HT_3 receptors; Drug discrimination; Zacopride isomers (Young, R. (212) 117)

Methylxanthines
Cerebral energy metabolism; Cerebral blood flow; [^{14}C]2-Deoxyglucose; [^{14}C]Iodoantipyrine (Schroeder, H. (220) 217)

Methysergide
Micturition; Phentolamine; Prazosin; (Cat) (Espey, M.J. (221) 167)

Methysticin
Kava extract; Memantine; Middle cerebral artery occlusion; (Rat); (Mouse) (Backhauß, C. (215) 265)

Mexiletine
Antiarrhythmic actions; Ischaemic arrhythmias; Convulsions; Pharmacokinetics (Igwemezie, L.N. (210) 271)

Mg^{2+}
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Mg^+
NMDA channels; H^+ (Von Euler, G. (227) 449)

Mianserin
Phosphoinositide hydrolysis; 5-HT_2 receptors; Forced swimming test; Imipramine; Affective disorders (Kawanami, T. (216) 385)

Microcirculation
BRL 38227; Potassium channel openers; Spontaneously hypertensive rat (SHR) (Struijker Boudier, H.A.J. (218) 191)

Microdialysis
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Brain (rat) (Hjorth, S. (209) 249)

Ibogaine; Cocaine; Dopamine; Nucleus accumbens; Striatum; Locomotor activity (Maisonneuve, I.M. (212) 263)

Histamine; Glutamate; NMDA receptors; Hypothalamus (Okakura, K. (213) 189)

Aminooxyacetic acid; Excitotoxicity; Kynurenic acid; Kynurenine; Neuroprotection (Wu, H.-Q. (213) 375)

Noradrenaline; Hippocampus; Morphine withdrawal; Clonidine (Done, C. (215) 333)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; (S)-UH-301; Hippocampus; (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) (Nomikos, G.G. (216) 373)

Striatum; Substantia nigra; Dopamine release; $GABA_A$ receptors; $GABA_B$ receptors (Santiago, M. (219) 175)

GABA brain levels; GABA uptake inhibitor; Anticonvulsants; Tiagabine; (Rat) (Fink-Jensen, A. (220) 197)

Ethanol; Morphine; Cocaine; Amphetamine; MK-801; SL 82.0715; Abstinence syndrome (Rossetti, Z.L. (221) 227)

DOPA (3,4-dihydroxyphenylalanine); Nicotine-evoked release; Nicotinic acetylcholine receptors (tonic); Striatum (Nakamura, S. (222) 75)

Amphetamine; Dopamine synthesis; MDMA (3,4-methylenedioxymethamphetamine); 5-HT_2 receptors (Schmidt, C.J. (223) 65)

Microdialysis (in vivo)
Neurokinins; Dopamine release; Neostriatum; Nucleus accumbens (Boix, F. (216) 103)

Microinjection
Central nucleus of the amygdala; Cocaine; Extracellular single unit; Cross-correlation; (Cat) (Ni, H. (224) 157)

Microiontophoresis
Purkinje neurons; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Retinal ganglion cell; NMDA receptors; Spontaneous firing; MK-801 (Ikeda, H. (210) 53)

Micturition
Methysergide; Phentolamine; Prazosin; (Cat) (Espey, M.J. (221) 167)

Micturition reflex
Inaperisone hydrochloride; Rhythmic bladder contraction; $GABA_B$ receptors; (Rat) (Morikawa, K. (213) 409)

Middle cerebral artery occlusion
Kava extract; Methysticin; Memantine; (Rat); (Mouse) (Backhauß, C. (215) 265)

Migraine
β-Adrenoceptor antagonists; 5-HT receptors; 5-HT_{1A} receptors; Pindolol; Propranolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

Octreotide; SMS 201-995; Somatostatin; α-Adrenoceptors; Histamine H_3 receptors; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

Miosis
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

Mitochondria
Amiloride; Myocardial ischemia; Myocardial reperfusion; Arrhythmias; Ultrastructure; Na^+/H^+ exchange (Duan, J. (210) 149)

Idazoxan; (Rabbit); (Human) (Tesson, F. (219) 335)

Mitochondrial ATPase activity
β-Adrenoceptor antagonists; Atenolol; Indenolol; Nadolol; Propranolol (Almotrefi, A.A. (215) 231)

Mitogenesis
Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; BQ123 (Ohlstein, E.H. (225) 347)

MK-801 (dizocilpine)
Retinal ganglion cell; NMDA receptors; Spontaneous firing; Microiontophoresis (Ikeda, H. (210) 53)

NMDA (N-methyl-D-aspartate); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

Dextrorphan; NMDA receptor antagonists (non-competitive); Anticonvulsants; Prepiriform cortex; PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride) (Roth, J.E. (215) 293)

Vestibular compensation; Ca^{2+} channels (Sansom, A.J. (220) 123)

Ethanol; Morphine; Cocaine; Amphetamine; SL 82.0715; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Epilepsy; NMDA (N-methyl-D-aspartate); Valproate; Behaviour (Dziki, M. (222) 273)

MK 954 (DuP 753)
Spontaneously hypertensive rat (SHR); Aldosterone; Renin; Angiotensin II; (Rat) (Mizuno, K. (215) 305)

fMLP (formyl-L-methionyl-L-leucyl-L-phenylalanine)
Bronchoconstriction; Histamine; Hyperreactivity; Pertussis toxin (Imaizumi, A. (212) 177)

Mn^{2+}
Ryanodine; Nicardipine; Myocardium; Inotropism; (Rat) (Agata, N. (222) 223)

Modification of receptors
Benzodiazepine receptors (central); [^{3}H]Ro 15-4513 binding; $GABA_A$ receptors (α subunits); Diethylpyrocarbonate; 2,3-Butanedione (Maksay, G. (227) 57)

Modulation
Ethanol; $GABA_A$ receptors; Cl^- currents; Central nervous system (CNS); (Neurons) (Reynolds, J.N. (224) 173)

Molecular modelling
Cholecystokinin receptor; CCK_A receptor antagonists; Devazepide; L-364,718 (Van der Bent, A. (226) 327)

Molecular orbital
Ozonides; Glutathione; Nucleophilic attack (Hempenius, R.A. (228) 207)

Monoamine oxidase
2-Phenylethylamine; 2-Phenylethylamine binding sites; MAO (monoamine oxidase) inhibitor; Pargyline; (−)-Deprenyl (Li, X.-M. (210) 189)

Noradrenaline release; α_2-Adrenoceptors; Antidepressant drugs; Vas deferens (rat) (Ari, G. (219) 89)

[^{3}H]Brofaromine; Brofaromine binding; Tyramine; Clorgyline; Intestine (rat) (Waldmeier, P.C. (216) 243)

Monoamine oxidase-A inhibitors
Nociception; Tail-flick test; Hot-plate test; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (219) 113)

Monoamine oxidase inhibitors
2-Phenylethylamine; 2-Phenylethylamine binding sites; MAO (monoamine oxidase); Pargyline; (−)-Deprenyl (Li, X.-M. (210) 189)

Parkinson's disease; L-Deprenyl; Neuroprotective mechanisms (Gerlach, M. (226) 97)

Monoamine receptors
Locomotor behaviour; Monoamines; Monoamine synthesis; Umespirone; (Rat) (Ahlenius, S. (222) 69)

Monoamine release
Amphetamine analogues; Synaptosomes; 5-HT (5-hydroxytryptamine, serotonin) (Berger, U.V. (215) 153)

Monoamines
Lithium chloride; Hypothalamus; (i.c.v.) (Otero Losada, M.E. (215) 185)

Locomotor behaviour; Monoamine synthesis; Monoamine receptors; Umespirone; (Rat) (Ahlenius, S. (222) 69)

Monoamine synthesis
Locomotor behaviour; Monoamines; Monoamine receptors; Umespirone; (Rat) (Ahlenius, S. (222) 69)

Monocarboxylate transport
Glisoxepide; Glibenclamide; Organic anions; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide; Oleate (Fückel, D. (213) 393)

Monoclonal antibodies
Angiotensin II; Angiotensin AT_2 receptor antagonists; Losartan (Reilly, T.M. (226) 179)

Dihydropyridine receptors; Ca^{2+} channels; Purification; Cardiac sarcolemma (Tokumaru, H. (227) 363)

Monocytes
Macrophages; Thromboxane A_2; Xanthine; cAMP (Baker, A.J. (211) 157)

Mononuclear cells
Curcumin; Antiproliferative effect; Smooth muscle cells (Huang, H.-C. (221) 381)

Morphine
Opioid tolerance; Norbinaltorphimine; κ-Opioid receptors (Sofuoglu, M. (210) 159)

Histamine; Intestinal motility (Patrini, G. (210) 259)

Brain stimulation reward; Dopamine; Neurotensin; Mesencephalon (ventral) (Rompré, P.-P. (211) 295)

Naltrindole; Tolerance; EEG power spectra (Stamidis, H. (213) 9)

Opioid interactions; Analgesic tolerance; Physical dependence; Norbinaltorphimine (nor-BNI) (Suzuki, T. (213) 91)

Heat intensities (different); Tail-flick response; Paw-licking response; β-Endorphin (Suh, H.H. (213) 337)

Antinociception; Tail-flick inhibition; β-Endorphin; Pentobarbital; Pain controls (descending) (Tseng, L.F. (214) 175)

Development; Antinociception; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Opiates (Barr, G.A. (215) 35)

Histamine; Histamine H_2 receptors; Histamine H_2 receptor antagonists; Brain; Antinociception (Hough, L.B. (215) 69)

Antinociception; Tolerance; Adenosine receptors; (Rat) (Tao, P.-L. (215) 301)

Nor-binaltorphimine (nor-BNI); Spiradoline; Antinociception; κ-Opioid receptors (Jones, D.N.C. (215) 345)

Antinociception; Tail-flick (spinal); δ-Opioid receptors; DSTBULET (Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr) (Kalso, E.A. (216) 97)

Pain; Spinal cord; Descending inhibitory controls; Periaqueductal grey (Bouhassira, D. (216) 149)

Supersensitivity; Ethanol pretreatment (chronic); Vas deferens (mouse); Naloxone; μ-Opioid receptors (Tabach, R. (216) 449)

Etonitazene; Conditioned place preference (Sala, M. (217) 37)

ω-Conotoxin; Analgesia; Withdrawal syndrome (Basilico, L. (218) 75)

Analgesia; μ-Opioid receptors (Pick, C.G. (220) 275)

Carbachol; Analgesia; Nitric oxide (NO); cGMP (Duarte, I.D.G. (221) 171)

Supersensitivity; Opioid receptor regulation; Naltrexone; d-Amphetamine; Analgesia; Upregulation (Duttaroy, A. (221) 211)

Cholecystokinin (CCK); EEG power spectra (Hudson, G.M. (221) 217)

Dynorphin A-(1–13); Opiate withdrawal; Opiate tolerance (Takemori, A.E. (221) 223)

Ethanol; Cocaine; Amphetamine; MK-801; SL 82.0715; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Neurotensin; Body temperature; Pertussis toxin (Basilico, L. (222) 241)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Antinociceptive tolerance; Cross-tolerance (Noble, F. (223) 83)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Naloxone; Physical dependence; (Systemic administration) (Noble, F. (223) 91)

Salmon-calcitonin; Analgesia (Martín, M.I. (224) 77)

κ-Opioid receptor; Naloxone benzoylhydrazone (Cheng, J. (226) 15)

Clonidine; Norepinephrine; α_2-Adrenoceptors; μ-Opioid receptors; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

Morphine analgesia
Morphine dependence; Yohimbine (Iglesias, V. (211) 35)

F8Famide; F8Famide binding sites; Peptide degradation (Gicquel, S. (222) 61)

Morphine dependence
Morphine analgesia; Yohimbine (Iglesias, V. (211) 35)

Morphine withdrawal
Microdialysis; Noradrenaline; Hippocampus; Clonidine (Done, C. (215) 333)

Morphological changes
Staurosporine; 12-O-Tetradecanoylphorbol 13-acetate; Protein kinase C; Ornithine decarboxylase; Epidermal cells (mouse) (Yamamoto, S. (227) 113)

Morphology
Stress; Hippocampus; 5-HT (5-hydroxytryptamine, serotonin); Corticosteroids; Tianeptine (Watanabe, Y. (222) 157)

Mossy fibers
Bifemelane; Glutamate release; Protein kinase C; H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine); (Guinea-pig) (Ueda, M. (219) 271)

Motility suppression (conditioned)
Enkephalin-degrading enzymes; RB 101 (mixed inhibitor); Naltrindole; Dopamine receptors; Antidepressants (Baamonde, A. (216) 157)

Motoneurons
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1C}/5-HT_2 receptors; Excitability; Spinal cord; (Slice) (Yamazaki, J. (220) 237)

Motor activity
d-Fenfluramine; Sertraline; Feeding patterns; Satiety; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Grignaschi, G. (211) 137)

Motor control
Sulfonylureas; K^+ channels (ATP-sensitive); Dorsal pallidum (Amalric, M. (217) 71)

Motor seizures
Hippocampus; SK&F 38393; SCH 23390; Pilocarpine (Alam, A.M. (222) 227)

MPP^+ (1-methyl-4-phenylpyridinium ion)
Striatum; Dopamine uptake; Nicotine; Tobacco smoke (Carr, L.A. (215) 285)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Parkinsonism; Terguride; Dopamine D_2 receptors (mixed agonist/antagonist); (Common marmoset) (Lange, K.W. (212) 247)

Dopamine; Parkinson's disease (Pérez-Otaño, I. (217) 211)

Mr 2266
Dynorphin A-(1–13); Methamphetamine; Circling; Rearing; (Mouse) (Ukai, M. (222) 7)

α-MSH (α-melanocyte-stimulating hormone)
GABA (γ-aminobutyric acid); Benzodiazepines; Hypothalamus (Mabley, J. (209) 127)

Interleukin; Feeding behaviour (Uehara, Y. (220) 119)

Mucosal transport
Intestinal motility; Mebeverine; (Ferret) (Greenwood, B. (211) 143)

Mucus
Nitric oxide (NO); Gastric mucosa (Brown, J.F. (223) 103)

Mucus secretion
N-Phthaloyl γ-aminobutyric acid; Aspirin ulcer; Ethanol ulcer; Gastric acid secretion (Banerji, S. (219) 211)

Muscarinic acetylcholine receptors
Muscarinic receptor agonists; Muscarinic receptor antagonists; G protein; GTP[S] binding; Cardiac membranes; (Unliganded receptor) (Hilf, G. (225) 245)

Amitriptyline; Xerostomia; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; β_1-Adrenoceptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

Muscarinic M_1 receptor agonists
Functional selectivity; L-687,306 (Freedman, S.B. (215) 135)

SDZ ENS 163; Long-term potentiation (Boddeke, E.W.G.M. (222) 21)

Muscarinic M_1 receptors
AF102B; Acetylcholine; Hippocampus slices; Slow after-hyperpolarization (Segal, M. (220) 103)

Muscarinic M_2 receptor subtype
[^{3}H]AF-DX 384; Muscarinic receptors; Receptor binding techniques; Autoradiography (Aubert, I. (217) 173)

Muscarinic receptor agonists
Muscarinic acetylcholine receptor; Muscarinic receptor antagonists; G protein; GTP[S] binding; Cardiac membranes; (Unliganded receptor) (Hilf, G. (225) 245)

Muscarinic receptor subtypes; Stereochemistry (absolute); Superior cervical ganglion (rat); Hippocampal slice (rat); Ileum (guinea pig); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

Muscarinic receptor agonists (binding)
Neuraminidase; Lung (guinea-pig) (Haddad, E.-B. (211) 273)

Muscarinic receptor agonists (M_1-selective)
Muscarinic receptor subtypes; Muscarinic receptor antagonists (M_3-selective); p-Fluoro-hexahydro-sila-difenidol; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Muscarinic receptor agonists (selective)
SR 95639A; Muscarinic receptor subtypes; Phosphoinositides; cAMP; Acetylcholine release (Mohamed, A.S. (227) 181)

Muscarinic receptor antagonists
Posterior hypothalamic nucleus; Carbachol; (Rat) (Martin, J.R. (215) 83)

Muscarinic acetylcholine receptor; Muscarinic receptor agonists; G protein; GTP[S] binding; Cardiac membranes; (Unliganded receptor) (Hilf, G. (225) 245)

Muscarinic receptor antagonists (M_3-selective)
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); p-Fluoro-hexahydro-sila-difenidol; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Muscarinic receptors
Parasympathetic nervous system; Lung resistance; Gallamine; Pirenzepine; (Cat) (Killingsworth, C.R. (210) 231)

Immobilization stress; Autoradiography; Supersensitivity; Hippocampus; Striatum (González, A.M. (214) 261)

[^{3}H]AF-DX 384; Muscarinic M_2 receptor subtype; Receptor binding techniques; Autoradiography (Aubert, I. (217) 173)

Chronic stress; Autoradiography; Supersensitivity; Hippocampus; Striatum (González, A.M. (223) 25)

Inositol phosphates; Heart (guinea pig); Receptor coupling (Ford, A.P.D.W. (225) 105)

Aging; Cerebral cortex; Peptides; Phosphoinositides; (Rat) (Pedigo, Jr., N.W. (225) 151)

Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Pfeiffer's rule; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

S-Adenosyl-L-methionine; Brain; Aging; Striatum; Hippocampus (Muccioli, G. (227) 293)

Muscarinic receptors (central)
[^{11}C]Quinuclidinyl benzilate ([^{11}C]QNB); PET (positron emission tomography); (Baboon) (Varastet, M. (213) 275)

Muscarinic receptors (presynaptic)
Ischemia; Excitatory amino acids; Neuronal damage; Vinconate (Iino, T. (224) 117)

Muscarinic receptor subtypes
Stereoselectivity; 3-Quinuclidinyl atrolactate stereoisomers; 3-Quinuclidinyl xanthene-9-carboxylate enantiomers; Cystometrogram (Noronha-Blob, L. (211) 97)

Tricyclic antimuscarinics; Vas deferens (rabbit); Cyproheptadine; Pizotifen; Ketotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); p-Fluoro-hexahydro-sila-difenidol; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Superior cervical ganglion; Ileum (guinea-pig); Atrium (guinea-pig); Drug discrimination (Arnt, J. (218) 159)

T84 cell; Colonic epithelial cell; Phosphoinositides; Arachidonic acid (Dickinson, K.E.J. (225) 291)

Muscarinic receptor agonists; Stereochemistry (absolute); Superior cervical ganglion (rat); Hippocampal slice (rat); Ileum (guinea pig); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

SR 95639A; Muscarinic receptor agonists (selective); Phosphoinositides; cAMP; Acetylcholine release (Mohamed, A.S. (227) 181)

Muscarinic stimulation
Iris sphincter (dog); Smooth muscle; cAMP; Inositol trisphosphate; Ca^{2+}; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Muscimol
Propranolol; Noradrenaline; Food intake; Environment (hot) (Kurose, Y. (211) 39)

Hippocampus; Chlordiazepoxide; Benzodiazepine; GABA (γ-aminobutyric acid); Memory (working, reference) (Ohno, M. (219) 245)

Gastrointestinal transit; THIP (tetrahydroisoxazolo-pyridin-3-ol); Neurotransmitters (Ramaswamy, S. (220) 147)

Muscle (locust)
Ketamine; L-Glutamate receptors; Single channels; Channel block (Macdonald, A.G. (210) 223)

Muscle regulation
Ca^{2+} sensitization; Cardiac muscle (skinned); Inorganic phosphate; EMD 53998 (Strauss, J.D. (227) 437)

Muscle relaxation
Aorta; Ca^{2+} channel antagonists; [^{3}H] TC-81 (distribution of) (Okamiya, Y. (222) 99)

Mutagenesis
Dopamine D_2 receptors; Receptor binding; Catecholamine receptors (Mansour, A. (227) 205)

Mydriasis
α_2-Adrenoceptors; Atipamezole; Guanfacine; Neocortical high-voltage spindles; (Rat); (Subchronic treatment) (Jäkälä, P. (221) 351)

Myelinated nerve fibre
Propofol; Ion channels; Voltage-clamp experiment; Anaesthetics (intravenous) (Veintemilla, F. (218) 59)

Myeloperoxidase
Neutrophil-endothelial cell interaction; Myocardium (rabbit); Reperfusion injury (Lad, N. (223) 163)

Myenteric neurons
cAMP; Enteric nervous system; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Myenteric plexus
Temperature; Opioid receptors; DAGO ([D-Ala^2,N-MePhe^4,Gly^5-ol]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-50,488H (Garaulet, J.V. (223) 19)

Myenteric plexus (guinea-pig)
Adenylate cyclase; μ-Opioid receptors (pre- and postsynaptic) (Rengel, I. (227) 385)

Myocardial depressant factor
Splanchnic artery occlusion shock; PAF (platelet-activating factor, PAF-acether); TNF-α (tumor necrosis factor); L-659,989 (Zingarelli, B. (222) 13)

Myocardial ischaemia
Arrhythmias, Coronary artery occlusion; Reperfusion; Platelet aggregation; 5-HT receptor antagonists (Ellis, A.M. (219) 97)

Myocardial ischaemia
Amiloride; Myocardial reperfusion; Mitochondria; Arrhythmias; Ultrastructure; Na^+/H^+ exchange (Duan, J. (210) 149)

Myocardial ischaemia/reperfusion
α-Tocopherol analogue; Free radical scavenger; Antioxidant; Reperfusion injury; Vitamin E (Petty, M.A. (210) 85)

Myocardial reperfusion
Amiloride; Myocardial ischemia; Mitochondria; Arrhythmias; Ultrastructure; Na^+/H^+ exchange (Duan, J. (210) 149)

Myocardium
Cycloprotobuxine-A; Action potentials; $\dot{V}$; Antiarrhythmic agents; (Use-dependent block) (Wang, Y.-X. (222) 219)

Mn^{2+}; Ryanodine; Nicardipine; Inotropism; (Rat) (Agata, N. (222) 223)

Myocardium (rabbit)
Neutrophil-endothelial cell interaction; Reperfusion injury; Myeloperoxidase (Lad, N. (223) 163)

Myoclonus
ACTH; Epilepsy; NMDA receptors (Trifiletti, R.R. (226) 377)

Myocytes
Forskolin; dbcAMP; Desensitisation; Heart failure; (Human) (Harding, S.E. (223) 39)

Myocytes (ventricular, guinea-pig)
Flecainide; Na^+ channels (Nitta, J.-i. (214) 191)

Myograph
Basilar artery (rat); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor classification; Ketanserin; Ergometrine (Deckert, V. (221) 17)

D-Myo-inositol-1,2,6-trisphosphate
Neuropeptide Y; Vagal stimulation; (Sympathetic) (Potter, E.K. (221) 307)

Na^+
Digitalis toxicity; Na^+ activity (intracellular); Ca^{2+} overload; Contractile force; K^+ (Abete, P. (211) 399)

Na^+ activity (intracellular)
Digitalis toxicity; Ca^{2+} overload; Contractile force; K^+; Na^+ (Abete, P. (211) 399)

Na^+/Ca^{2+} exchangers
Ouabain; Aorta (guinea-pig); Contraction; Ca^{2+} signals (Iwamoto, T. (224) 71)

Na^+ channels
Flecainide; Myocytes (ventricular, guinea-pig) (Nitta, J.-i. (214) 191)

Amitriptyline; Dopamine; Amino acids; Veratridine; Striatal slices (Ishii, Y. (221) 377)

$^{86}Rb^+$ efflux; K^+ channels; Remoxipride; Neuroleptics; Voltage clamp (Westlind-Danielsson, A. (224) 57)

Na^+ channel (silent)
Aorta (rat); $^{45}Ca^{2+}$ uptake; [^{14}C]Guanidinium uptake; Veratridine (Wermelskirchen, D. (219) 253)

Na^+ currents (fast)
Taurine; Ventricular myocytes (embryonic chick); Voltage clamp (whole-cell); Cardiac muscle (electrophysiology of) (Satoh, H. (218) 83)

Nadolol
β-Adrenoceptor antagonists; Atenolol; Indenolol; Propranolol; Mitochondrial ATPase activity (Almotrefi, A.A. (215) 231)

Naftidrofuryl oxalate (LS-121)
Quantitative autoradiography; 5-HT_2 receptors; 5-Hydroxytryptophan (5-HTP); Head-twitch response; (Mouse) (Nabeshima, T. (223) 109)

Na^+/H^+ exchange
Amiloride; Myocardial ischemia; Myocardial reperfusion; Mitochondria; Arrhythmias; Ultrastructure (Duan, J. (210) 149)

Na^+ ions
Endothelin-3; Endothelin-1; Ileum (guinea-pig); Desensitization; Endothelin receptor subtypes (Miasiro, N. (214) 133)

Na^+,K^+-ATPase
Cardiac hypertrophy; Action potential; Depolarizations (transient); Ryanodine; Forskolin (Mészáros, J. (210) 325)

Placental vein (human); 5-HT (5-hydroxytryptamine, serotonin) (Fernández-Alfonso, M.S. (221) 185)

Na^+-K^+-ATPase (renal)
Streptozotocin diabetes; G-proteins; Protein kinase C (Chen, C.-C. (225) 275)

Na^+/K^+ pump
Na^+ pump; Colonic motility; Membrane potential; Smooth muscle (Barajas-López, C. (221) 51)

Naloxone
Vasopressin; Oxytocin; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Diabetes; Paradoxical analgesia; Naltrindole; (Mouse) (Kamei, J. (210) 339)

Antiarrhythmic activity; Ischaemic arrhythmias; U-50,488H (Pugsley, M.K. (212) 15)

Supersensitivity; Ethanol pretreatment (chronic); Morphine; Vas deferens (mouse); μ-Opioid receptors (Tabach, R. (216) 449)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Physical dependence; (Systemic administration) (Noble, F. (223) 91)

Antinociception; Arthritic rats; Tramadol; Yohimbine; Idazoxan (Kayser, V. (224) 83)

Caffeine; Body temperature; (Mouse) (Durcan, M.J. (224) 151)

Naloxone benzoylhydrazone
κ-Opioid receptor; Morphine (Cheng, J. (226) 15)

Naloxone infusion (continuous)
D-amphetamine; Locomotor activity; Opioids; Dopamine (Rat) (Jones, D.N.C. (221) 161)

Naltrexone
Supersensitivity; Morphine; Opioid receptor regulation; d-Amphetamine; Analgesia; Upregulation (Duttaroy, A. (221) 211)

[Met^5]enkephalin; [Leu^5]enkephalin; β-Endorphin; Gastrointestinal content (McIntosh, C.H.S. (223) 117)

Naltriben
δ-Opioid receptor subtypes; DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DADLE (D-Ala^2,D-Leu^5]enkephalin) (Sofuoglu, M. (216) 273)

Naltrindole
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Diabetes; Naloxone; Paradoxical analgesia; (Mouse) (Kamei, J. (210) 339)

Morphine; Tolerance; EEG power spectra (Stamidis, H. (213) 9)

DAMGO ([D-Ala^2,$MePhe^4$,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); SKF 38393; Locomotor activity; (Mouse) (Toyoshi, T. (213) 25)

Antinociception; δ-Opioid receptors (Stapelfeld, A. (214) 273)

Enkephalin-degrading enzymes; RB 101 (mixed inhibitor); Motility suppression (conditioned); Dopamine receptors; Antidepressants (Baamonde, A. (216) 157)

δ-Opioid receptors; PET (positron emmission tomography) (Lever, J.R. (216) 459)

Cocaine; Place preference (Menkens, K. (219) 345)

L-NAME (N^G-nitro-L-arginine methyl ester)
Mesentery (rat); Capsaicin; CGRP (calcitonin gene-related peptide); Saponin; L-Arginine (Li, Y. (210) 23)

Tacrine; Seizures; Brain damage; LiCl; Nitric oxide (NO) (Bagetta, G. (213) 301)

L-NMMA (N^G-monomethyl-L-arginine; Hypertension; Haemodynamics; (Brattleboro rat) (Gardiner, S.M. (213) 449)

Nitric oxide (NO); Capsaicin; Sensory neurons; CGRP (calcitonin gene-related peptide); Gastric mucosa (Whittle, B.J.R. (218) 339)

5-HT (5-hydroxytryptamine, serotonin); 5-Carboxamidotryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Endothelium; Nitric oxide (NO) (Van Gelderen, E.M. (222) 185)

Vasopressin; Nitroprusside (sodium); Endotoxaemia; Sympathetic stimulation; Vascular reactivity (Guc, M.O. (224) 63)

NAN-190
BMY 7378; 5-HT_{1A} receptors; Partial agonists; Spare receptors; Receptor theory (Greuel, J.M. (211) 211)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Feeding; 5-HT_{1A} receptors; (Rat) (Williams, A.R. (219) 105)

NANC nerves
Nitric oxide (NO); Neurogenic inflammation; Plasma exudation; Vagus nerve; Airways (Kuo, H.-P. (221) 385)

NANC (non-adrenergic, non-cholinergic)
Bronchospasm; Capsaicin; Neurokinin A; Substance P; Cholinergic nerves; Adrenergic nerves (Ballati, L. (214) 215)

Aging; Stomach (rat); VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurons (Smits, G.J.M. (223) 97)

NANC excitatory nerves
Capsazepine; Capsaicin; Electrical field stimulation; Tetrodotoxin (Belvisi, M.G. (215) 341)

NANC inhibition
Nitric oxide (NO); cGMP; Ileum (rat) (Kanada, A. (216) 287)

Gastric fundus (rat); Nitric oxide (NO); LY 83583 (Barbier, A.J.M. (219) 331)

NANC relaxation
Gastric fundus (rat); Cyclic nucleotides; IBMX (3-Isobutyl-1-methylxanthine); Zaprinast (Barbier, A.J. (210) 315)

Neurotensin; Neurotensin receptors; Duodenum (rat); Neurotensin-induced relaxation; Neurotensin-induced contraction (Mulè, F. (212) 215)

Urethra (dog); Neurogenic response; Adrenergic contraction (Hashimoto, S. (213) 117)

i-NANC nerves
Nitric oxide (NO); Trachea (human) (Belvisi, M.G. (210) 221)

NANC neurons
ω-Conotoxin GVIA; Neurotransmitter release; Cholinergic neurons; Airways; (Guinea-pig) (Boot, J.R. (219) 123)

NANC neurostimulation
Gastric fundus; BRL 38227 (lemakalim); Pinacidil; K^+ channels; (Rat) (Lefebvre, R.A. (214) 1)

Na^+ pump
Na^+/K^+ pump; Colonic motility; Membrane potential; Smooth muscle (Barajas-López, C. (221) 51)

Natriuresis
Atrial peptides; Renal perfusion pressure; Angiotensin II (Chamienia, A.L. (218) 319)

Natriuretic peptides
Autoradiography; Heart; Endocardium; Natriuretic receptors (Rutherford, R.A.D. (212) 1)

Natriuretic receptors
Autoradiography; Heart; Endocardium; Natriuretic peptides (Rutherford, R.A.D. (212) 1)

NC-1100
Ca^{2+} channel antagonists; Cerebral ischemia; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (224) 109)

NC-1300
Proton pump inhibitors; Gastric mucosa blood volume; Gastric mucosa oxygenation; Reflectance spectrophotometry; Hemorrhagic shock; Omeprazole (Kawano, S. (211) 55)

NECA (5'-N-ethylcarboxamidoadenosine)
Functional antagonism; Isoproterenol; Nitric oxide (NO); Nitroglycerin; Sodium nitroprusside (Wiener, H.L. (220) 131)

Nedocromil sodium
Vagus nerve; Cl^- channels; DIDS (4,4'-diisothiocyanostilbene-2,2'-disulphonic acid) (Jackson, D.M. (221) 175)

Nefiracetam (DM-9384)
Cholinergic system; Carbon monoxide (CO); Amnesia (delayed); Passive avoidance; Scopolamine; (Mouse) (Hiramatsu, M. (216) 279)

Neocortex
GABA (γ-aminobutyric acid); $GABA_B$ receptors; Acetylcholine; Quisqualate; (Rat) (Andre, P. (218) 137)

Neocortical high-voltage spindles
α_2-Adrenoceptors; Atipamezole; Guanfacine; Mydriasis; (Rat); (Subchronic treatment) (Jäkälä, P. (221) 351)

Neocortical slices (rat)
β-(2-Thienyl)-GABA; Baclofen; Ileum (guinea-pig, isolated); 2-Hydroxysaclofen (Ong, J. (221) 145)

Neonate
Felbamate; Anticonvulsants; Cerebral ischemia; Asphyxia neonatorum; Cerebral infarction (Wasterlain, C.G. (212) 275)

Purinoceptors; Bladder; ATP; Neurotransmission; Development (Sneddon, P. (214) 7)

Neostigmine
Acetylcholine release; Anticholinesterase; β-Eudesmol; Neuromuscular transmission; Tetanic fade (Chiou, L.C. (216) 199)

Neostriatum
NMDA receptors; Acetylcholine release; Amantadine; Dopamine release (Stoof, J.C. (213) 439)

Neurokinins; Dopamine release; Nucleus accumbens; Microdialysis (in vivo) (Boix, F. (216) 103)

Nephrosis (experimental)
Doxorubicin; Superoxide anion; Renal toxicity (Ghiggeri, G.M. (228) 77)

Nerve stimulation (peripheral)
Sympatho-inhibition; Prazosin; Rauwolscine; Phenoxybenzamine; Hypothalamic stimulation (Koss, M.C. (211) 61)

Neuraminidase
Capsaicin; Ileal motility; Mesenteric nerve; Sialic acid; Ruthenium red; (Guinea-pig) (Takaki, M. (211) 125)

Muscarinic receptor agonists (binding); Lung (guinea-pig) (Haddad, E.-B. (211) 273)

Sialic acid; Tracheal contraction (Kai, H. (220) 181)

Neuro-2A cells
Angiotensin II receptor; cGMP (Chaki, S. (225) 355)

Neurobehavioural responses
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Neuroblastoma
Phosphoinositide turnover; DNA synthesis; α-Thrombin (Ogino, Y. (225) 299)

Neuroblastoma cells NB-OK-1 (human)
ANP_A receptors; ANP receptor antagonists; cGMP (Delporte, C. (224) 183)

Neuroblastoma SH-SY5Y cells
Clonidine; Norepinephrine; α_2-Adrenoceptors; Morphine; μ-Opioid receptors; Adenylyl cyclase inhibition; Retinoic acid (Lameh, J. (227) 19)

Neurodegeneration
Memantine; Quinolinic acid; Hippocampus (Keilhoff, G. (219) 451)

Neurogenic inflammation
(±)-CP-96,345; Plasma protein extravasation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

Neuropeptides; Capsaicin (Morikawa, M. (217) 31)

Plasma extravasation; Substance P antagonists; Tachykinins; Capsaicin; Pain (Nagahisa, A. (217) 191)

Sensory C-fibers; cAMP; Substance P; Atypical adrenoceptors (Itabashi, S. (218) 187)

Nitric oxide (NO); NANC nerves; Plasma exudation; Vagus nerve; Airways (Kuo, H.-P. (221) 385)

Octreotide; SMS 201-995; Somatostatin; α-Adrenoceptors; Histamine H_3 receptors; Migraine; Substance P (Matsubara, T. (224) 145)

Neurogenic oedema
Nitric oxide (NO); Hyperalgesia (Ferreira, S.H. (217) 207)

Neurogenic response
Urethra (dog); Adrenergic contraction; Non-adrenergic, non-cholinergic relaxation (Hashimoto, S. (213) 117)

Neurohypophyseal peptides
[Arg^8] vasotocin; Oxytocin; [Arg^8] vasopressin (AVP); Prostatic contraction; Neuropeptides (Bodanszky, M. (216) 311)

Neurokinin A
Substance P; Tachykinins; Dyspnea (guinea-pig) (Kusner, E.J. (210) 299)

Substance P; EDRF (endothelium-derived relaxing factor); Neurokinin B; CP-96,345; Aorta (rabbit) (Rubino, A. (212) 237)

Bronchospasm; Capsaicin; Substance P; Cholinergic nerves; Adrenergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Substance P; Capsaicin; Field stimulation; Airway constriction; Airway edema (Murai, M. (217) 23)

Substance P; Senktide; Blood pressure; Heart rate; Behaviour; Tachykinin receptor antagonists (Itoi, K. (219) 435)

MEN 10207; MEN 10208; NK_2 receptor subtype (Henderson, A.K. (225) 175)

Neurokinin B
Substance P; EDRF (endothelium-derived relaxing factor); Neurokinin A; CP-96,345; Aorta (rabbit) (Rubino, A. (212) 237)

Neurokinin receptors
Dopamine cells; Extracellular recording (Overton, P. (213) 165)

Electrical field stimulation; SR 48968; (±)-CP-96,345; Bronchus (guinea-pig); Non-cholinergic contraction (Martin, C.A.E. (224) 137)

Neurokinins
Dopamine release; Neostriatum; Nucleus accumbens; Microdialysis (in vivo) (Boix, F. (216) 103)

Neurokinin-type receptors
Cloning of receptors; G-protein-coupled receptors; Neuropeptides; Secretin-type receptors (Burbach, J.P.H. (227) 1)

Neuroleptics
Dopamine; Dopamine D_3 receptors (Schotte, A. (218) 373)

$^{86}Rb^+$ efflux; Na^+ channels; K^+ channels; Remoxipride; Voltage clamp (Westlind-Danielsson, A. (224) 57)

Dopamine D_3 receptor (human); Transfected cell; Eukaryotic expression vector; Guanylnucleotide; G protein; Dopamine autoreceptor (Sokoloff, P. (225) 331)

Neuromedin B
Neuromedin C; Grooming/scratching behaviour (Van Wimersma Greidanus, T.B. (209) 57)

Bombesin; Binding; Urinary bladder (rat); Neuromedin B receptor (Bitar, K.G. (219) 117)

Neuromedin B receptor
Neuromedin B; Bombesin; Binding; Urinary bladder (rat) (Bitar, K.G. (219) 117)

Neuromedin C
Neuromedin B; Grooming/scratching behaviour (Van Wimersma Greidanus, T.B. (209) 57)

Neuromodulation
ANP (atrial natriuretic polypeptide); Norepinephrine; cGMP (Giridhar, J. (213) 317)

Neuromuscular blocking agents (non-depolarizing)
Suramin; Succinylcholine; Purinoceptors; Neuromuscular junction (rat); Striated muscle (Henning, R.H. (216) 73)

Neuromuscular junction
Velnacrine; Tacrine; Physostigmine; Anticholinesterase agents; Twitch response; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Neuromuscular junction (rat)
Suramin; Neuromuscular blocking agents (non-depolarizing); Succinylcholine; Purinoceptors; Striated muscle (Henning, R.H. (216) 73)

Neuromuscular relaxants
Vecuronium; 3-Desacetyl vecuronium; 3,17-Desacetyl vecuronium; Metabolites (antagonism) (Khuenl-Brady, K.S. (222) 153)

Neuromuscular transmission
Acetylcholine release; Anticholinesterase; β-Eudesmol; Neostigmine; Tetanic fade (Chiou, L.C. (216) 199)

Neuronal cell death
Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (214) 149)

Ceruletide; Cholecystokinin (CCK); Cerebral ischemia; Amnesia; Hippocampus; (Gerbil) (Eigyo, M. (219) 487)

Neuronal damage
Ischemia; Excitatory amino acids; Vinconate; Muscarinic receptors (presynaptic) (Iino, T. (224) 117)

Neuronal excitability
Sympathetic ganglia (bullfrog); Autonomic ganglia; Compound 48/80; Ganglionic transmission; Spike afterhyperpolarization (Heppner, T.J. (213) 427)

Neuronal reuptake
Noradrenaline; Presynaptic inhibition; α-Adrenoceptors; Heart (rat) (Du, X.-J. (211) 221)

Neuronal type nicotinic acetylcholine receptors
Nitromethylene heterocycle insecticides; 1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI); Insect neuronal type nicotinic acetylcholine receptors; Endplate type nicotinic acetylcholine receptors; Patch clamp technique (whole-cell) (Zwart, R. (228) 165)

Neuropeptide K
Tachykinin; Cardiovascular responses; Catecholamines; Autonomic regulation (Décarie, A. (213) 125)

Neuropeptides
[Arg^8] vasotocin; Oxytocin; [Arg^8] vasopressin (AVP); Prostatic contraction; Neurohypohyseal peptides (Bodanszky, M. (216) 311)

Neurogenic inflammation; Capsaicin (Morikawa, M. (217) 31)

CGRP (calcitonin gene-related peptide); CGRP receptors; Autoradiography; Coronary arteries (Knock, G.A. (219) 415)

Cloning of receptors; G-protein-coupled receptors; Neurokinin-type receptors; Secretin-type receptors (Burbach, J.P.H. (227) 1)

IP_3; Locomotion; (Feeding); (Receptors) (Heilig, M. (209) 27)

Endothelium; Smooth muscle (vascular) (Small, D.L. (210) 131)

Noradrenaline; Co-neurotransmission (Montastruc, P. (213) 159)

Atherosclerosis; WHHL rabbit; Mesenteric artery; Sympathetic neurotransmission; CGRP (calcitonin gene-related peptide) (Stewart-Lee, A.L. (216) 167)

Airways (guinea-pig); (Inhibitory action) (T-Benchekroun, M. (216) 421)

NPY receptor subtypes; Acetylcholine; Endothelium; Vasoconstriction; Vasodilatation (Grundemar, L. (221) 71)

Neuropeptide Y
Vagal stimulation; D-Myo-inositol-1,2,6-trisphosphate; (Sympathetic) (Potter, E.K. (221) 307)

Vasoconstriction; Non-adrenergic sympathetic nerve stimulation; D-myo-Inositol-1,2,6-triphosphate (PP56) (Pernow, J. (222) 171)

Neuroprotection
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase (Kish, S.J. (209) 101)

Calpain inhibitor; Hypoxia; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Aminooxyacetic acid; Excitotoxicity; Kynurenic acid; Kynurenine; Microdialysis (Wu, H.-Q. (213) 375)

Nitric oxide (NO); Stroke (Trifiletti, R.R. (218) 197)

Adenosine A_1 receptors; Adenosine A_2 receptors; Brain (rat); Desensitization (agonist induced) (Abbracchio, M.P. (227) 317)

Neuroprotective mechanisms
Monoamine oxidase inhibitors; Parkinson's disease; L-Deprenyl (Gerlach, M. (226) 97)

Neuroreceptors
Benzodiazepine receptors; PET (positron emission tomography); [^{18}F]FEF (5-(2'-[^{18}F]Fluoroethyl)flumazenil); Imaging; Flumazenil (Moerlein, S.M. (218) 109)

Neurosecretory cells
Neurotransmitter release; Cytoskeleton; Cytoplasmic proteins; Ca^{2+}; Calmodulin; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Neurosteroid
$GABA_A$ receptor; Cloned subtypes; *Xenopus* oocyte expression (Zaman, S.H. (225) 321)

Neurosteroid site
RU 5135; $GABA_A$ receptor complex; 5α-Pregnane-3α-ol-20-one (3α,5α-P); 5α-Pregnane-3α-20α-diol (5α-pregnanediol); $GABA_A$ receptor antagonism (Cadoni, C. (227) 147)

Neurotensin
Brain stimulation reward; Dopamine; Morphine; Mesencephalon (ventral) (Rompré, P.-P. (211) 295)

Neurotensin receptors; Non-adrenergic non-cholinergic (NANC) relaxation; Duodenum (rat); Neurotensin-induced relaxation; Neurotensin-induced contraction (Mulè, F. (212) 215)

Amphetamines; Basal ganglia; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Tryptophan hydroxylase (Hanson, G.R. (218) 287)

[Met^5]enkephalin; [Leu^5]enkephalin; Cholecystokinin (CCK); Substance P; 6-Hydroxydopamine (6-OHDA); L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Morphine; Body temperature; Pertussis toxin (Basilico, L. (222) 241)

Neurotensin-induced contraction
Neurotensin; Neurotensin receptors; Non-adrenergic non-cholinergic (NANC) relaxation; Duodenum (rat); Neurotensin-induced relaxation (Mulè, F. (212) 215)

Neurotensin-induced relaxation
Neurotensin; Neurotensin receptors; Non-adrenergic non-cholinergic (NANC) relaxation; Duodenum (rat); Neurotensin-induced contraction (Mulè, F. (212) 215)

Neurotensin receptors
Neurotensin; Non-adrenergic non-cholinergic (NANC) relaxation; Duodenum (rat); Neurotensin-induced relaxation; Neurotensin-induced contraction (Mulè, F. (212) 215)

Down-regulation; U-73122 (Yamada, M. (226) 187)

Neurotoxicity
Polyamine; NMDA (N-methyl-D-aspartate); α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Ca^{2+} entry blockers (Pizzi, M. (209) 169)

L-Glutamate; 2-(Carboxycyclopropyl)glycine; NMDA receptors; D-Aspartate uptake; $[Ca^{2+}]_i$ increase (Kawai, M. (211) 195)

Nitric oxide (NO); Hippocampus (Loiacono, R.E. (216) 331)

Amphetamines; Dopamine; MDMA (3,4-methylenedioxymethamphetamine); Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin) (Elayan, I. (221) 281)

Ifenprodil; Cell culture; NMDA receptors (Graham, D. (226) 373)

Phenol; Immunotoxicology; Brain biogenic amines; (Mouse) (Hsieh, G.-C. (228) 107)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT uptake inhibitor; 1-Piperonylpiperazine; 5-HT (5-hydroxytryptamine, serotonin); Brain (rat) (Hashimoto, K. (228) 171)

Neurotoxin
Domoic acid; Kainic acid; AMPA; Excitatory amino acid receptor (Hampson, D.R. (218) 1)

Neurotransmission
Purinoceptors; Bladder; ATP; Neonate; Development (Sneddon, P. (214) 7)

Neurotransmitter release
ω-Conotoxin GVIA; Cholinergic neurons; NANC (non-adrenergic, non-cholinergic) neurons; Airways; (Guinea-pig) (Boot, J.R. (219) 123)

Hydroxylamine; Sodium nitroprusside (Lonart, G. (220) 271)

Neurosecretory cells; Cytoskeleton; Cytoplasmic proteins; Ca^{2+}; Calmodulin; G-proteins; Protein kinase C (Trifaró, J.-M. (225) 83)

Neurotransmitters
Gastrointestinal transit; THIP (tetrahydroisoxazolo-pyridin-3-ol); Muscimol (Ramaswamy, S. (220) 147)

N-Ethyl,N-nitrosourea; Brain enzymes; Biogenic amine metabolism; (CD1 mouse) (Jayasekara, S. (228) 37)

Neurotrophic effects
Nitric oxide (NO); Excitatory amino acids; NMDA (N-methyl-D-aspartate); Cerebellar granule cells; S-Nitroso-N-acetylpenicillamine (Boje, K.M. (212) 151)

Neurotrophic factor
Sciatic nerve crush; Org 2766; ACTH (adrenocorticotropin); Regeneration; Sensorimotor function; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Neutral metalloendopeptidase
ANP-R_1 receptors; cGMP; Human neuroblastoma cell line NB-OK1 (Delporte, C. (227) 247)

Neutrophil
Diethyldithiocarbamate-induced antral ulcer; Rebamipide (Ogino, K. (212) 9)

Diethyldithiocarbamate-induced antral ulcer; Rebamipide (Ogino, K. (219) 493)

Respiratory burst; Degranulation; Protein kinase C; Staurosporin; cgp 41251 (Krause, K.-H. (227) 221)

Neutrophil-endothelial cell interaction
Myocardium (rabbit); Reperfusion injury; Myeloperoxidase (Lad, N. (223) 163)

Neutrophils
β-Adrenoceptor antagonists; Carvedilol; Free radical; Superoxide; Antioxidants (Yue, T.-L. (214) 277)

Heparin; Platelets; Cathepsin G (Evangelista, V. (216) 401)

Arachidonic acid; PAF (platelet-activating factor, PAF-acether); Staurosporine; Phospholipase A_2 (Müller, S. (218) 251)

NG108-15
5-HT_3 receptors; MDL 73147EF; MDL 74156; ICS 205-930 (Boeijinga, P.H. (219) 9)

Angiotensin II receptors; Receptor subtypes; Radioligand binding (Bryson, S.E. (225) 119)

NG108 cells
α_2-Adrenoceptor mRNA; HT29 cells; OK cells (Sun, L. (226) 367)

NG108-15 cells
Opioid receptors; G-proteins; Affinity cross-linking (Harada, J. (227) 301)

NG 108-15 hybrid cell
δ-Opioid receptors; [^{3}H]Etorphine; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Sucrose gradients; Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

Nicardipine
Mn^{2+}; Ryanodine; Myocardium; Inotropism; (Rat) (Agata, N. (222) 223)

Nicorandil
Hyperpolarization; K^+ channels (ATP-dependent); cGMP; Methylene blue (Holzmann, S. (215) 1)

Imidazoline; Portal vein (rat); K^+ channels (Okumura, K. (215) 253)

Nicotine
α_2-Adrenoceptors; Bradykinin; Capsaicin; Resiniferatoxin; Bronchoconstriction (Lou, Y.-P. (210) 173)

MPP^+ (1-methyl-4-phenylpyridinium ion); Striatum; Dopamine uptake; Tobacco smoke (Carr, L.A. (215) 285)

Nicotine-evoked release
DOPA (3,4-dihydroxyphenylalanine); Nicotinic acetylcholine receptors (tonic); Striatum; Microdialysis (Nakamura, S. (222) 75)

Nicotinic acetylcholine receptors (tonic)
DOPA (3,4-dihydroxyphenylalanine); Nicotine-evoked release; Striatum; Microdialysis (Nakamura, S. (222) 75)

Nicotinic receptor agonists
Olfactory cortex slice (guinea-pig); Surface field potential (N-wave); Extracellular recording; Antimuscarinic action (Libri, V. (212) 253)

Nifedipine
Cough reflex; Ca^{2+} channels; Antitussive effect; Flunarizine; Verapamil (Kamei, J. (212) 61)

Diltiazem; Verapamil; Cell growth; Tumor cells; Ca^{2+} channels (Wöll, E. (212) 105)

Veratridine; CGRP (calcitonin gene-related peptide); ω-Conotoxin; Sensory neurons; Capsaicin (Tramontana, M. (212) 137)

Acidosis; Alkalosis; Ca^{2+} channels; Heart (rat) (Achike, F.I. (219) 369)

Endothelin-1; Cerebral arteries; Peripheral arteries; Vasoconstriction; Ca^{2+} influx; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Aorta (rat); Endothelium; BAY k 8644 enantiomers; $^{45}Ca^{2+}$ influx (Gil-Longo, J. (221) 1)

Ba^{2+}; $^{45}Ca^{2+}$ uptake; Vas deferens; $^{45}Ca^{2+}$ efflux; Verapamil; Methoxamine (Hay, D.W.P. (225) 313)

Nigrostriatal hemitransection
Dopamine uptake; Dopamine release; Acetylcholine release; Ganglioside administration; (Recovery of function) (Raiteri, M. (213) 17)

(+)-Niguldipine
α_{1A}-Adrenoceptors; Positive inotropic effect; [^{3}H]Prazosin binding; Ventricular myocardium (rabbit) (Endoh, M. (223) 143)

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride)
Tacrine; Learning; Memory; CO-induced amnesia; Delayed amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

NIP-121
K^+ channel opener; Cromakalim; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Nisoldipine
Smooth muscle (vascular); Inhibitory effects (residual); Ca^{2+} levels (cytosolic); Ca^{2+} channels; Aorta (rat); (Relaxation) (Kim, B.K. (223) 157)

[^{3}H]Nitrendipine binding
Polyamines; [^{3}H]Diltiazem binding; Cerebral cortex (rat); Cooperative effects (Schoemaker, H. (225) 167)

Nitric oxide (NO)
Cerebellum; NMDA receptors; Nitroprusside; cGMP (East, S.J. (209) 119)

Catecholamine secretion; Vasodilatation (adrenal medulla) (Breslow, M.J. (210) 105)

Non-adrenergic non-cholinergic inhibitory (i-NANC) nerves; Trachea (human) (Belvisi, M.G. (210) 221)

Canavanine; Endotoxin (Umans, J.G. (210) 343)

Carrageenin; Dextran; Oedema; Vascular permeability (Ialenti, A. (211) 177)

Shock; Endotoxin; Mesenteric arteries (small) (Schneider, F. (211) 269)

Gastroprotection; Blood flow (mucosal); Nocloprost (Konturek, S.J. (211) 277)

Dinitrosyl iron complexes (with cysteine); EDRF (endothelium-derived relaxing factor); Vasorelaxation (Vedernikov, Y.P. (211) 313)

CGRP (calcitonin gene-related peptide); Endothelium-dependent vasorelaxation; L-NMMA (N^G-monomethyl-L-arginine); L-NOARG (N^G-nitro-L-arginine) (Gray, D.W. (212) 37)

Atherosclerosis; Low-density lipoprotein; Macrophages; Nitrite (NO_2^-) (Jorens, P.G. (212) 113)

Excitatory amino acids; NMDA (N-methyl-D-aspartate); Cerebellar granule cells; S-Nitroso-N-acetylpenicillamine; Neurotrophic effects (Boje, K.M. (212) 151)

EDRF (endothelium-derived relaxing factor); Vascular tone; Arterial pressure; (Rat) (Chyu, K.-Y. (212) 159)

Acetylcholine; EDRF (endothelium-derived relaxing factor); Polymorphonuclear leukocytes; Lipopolysaccharide; Mesenteric artery (superior) (Siegfried, M.R. (212) 171)

DL-Propranolol; EDRF (endothelium-derived relaxing factor); N^G-Nitro-L-arginine; CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate); Hindquarters (rat) (Mota-Filipe, H. (213) 227)

Tacrine; Seizures; Brain damage; LiCl; L-NAME (N^ω-nitro-L-arginine methyl ester) (Bagetta, G. (213) 301)

NMDA (N-methyl-D-aspartate); L-Arginine; Nociception; Spinal cord; Facilitation; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

EDRF (endothelium-derived relaxing factor); Pressure; Endothelial cells; Mechanoreceptors; Hypertension (Hishikawa, K. (215) 329)

L-Arginine; EDRF (endothelium-derived relaxing factor); Endotoxic shock (Lambert, L.E. (216) 131)

Acetylcholine release; Basal forebrain (rat) (Prast, H. (216) 139)

cGMP; Non-adrenergic non-cholinergic (NANC) inhibition; Ileum (rat) (Kanada, A. (216) 287)

Hippocampus; Neurotoxicity (Loiacono, R.E. (216) 331)

PDGF (platelet-derived growth factor); TGF-β (transforming growth factor-β); Interleukin-1β; Platelets; Aorta (rat) (Schini, V.B. (216) 379)

Small intestine; Capsaicin; Intestinal motility; Ileum (rat) (Allescher, H.-D. (217) 153)

Hyperalgesia; Neurogenic oedema (Ferreira, S.H. (217) 207)

Analgesia; Dipyrone (Duarte, I.D.G. (217) 225)

Stroke; Neuroprotection (Trifiletti, R.R. (218) 197)

Capsaicin; Sensory neurons; CGRP (calcitonin gene-related peptide); L-NAME (N^G-nitro-L-arginine methyl ester); Gastric mucosa (Whittle, B.J.R. (218) 339)

Gastric acid; Endotoxin; PAF (platelet-activating factor, PAF-acether); Pentagastrin (Martinez-Cuesta, M.A. (218) 351)

Blood vessels; Hyporesponsiveness; Endothelium; Protein synthesis; Lipopolysaccharide (Nakaki, T. (219) 311)

Gastric fundus (rat); Non-adrenergic non-cholinergic (NANC); LY 83583 (Barbier, A.J.M. (219) 331)

NECA (5′-N-ethylcarboxamidoadenosine); Functional antagonism; Isoproterenol; Nitroglycerin; Sodium nitroprusside (Wiener, H.L. (220) 131)

Acetylcholine; Guanylyl cyclase; Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Prostacyclin; Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

Morphine; Carbachol; Analgesia; cGMP (Duarte, I.D.G. (221) 171)

S-Nitrosothiols; Excitatory amino acid; Baroreceptor reflex; Cardiovascular regulation; EDRF (endothelium-derived relaxing factor) (Machado, B.H. (221) 179)

Gastric fundus (rat); VIP (vasoactive intestinal polypeptide); Cholinergic neurotransmission (Lefebvre, R.A. (221) 235)

Neurogenic inflammation; NANC nerves; Plasma exudation; Vagus nerve; Airways (Kuo, H.-P. (221) 385)

NMDA receptor antagonists; NO synthase (Kolesnikov, Y.A. (221) 399)

Pulmonary artery (rabbit); L-N^G-Nitro arginine (L-NO_2Arg); Endothelium; Electrical transmural stimulation; Noradrenaline release (Shinozuka, K. (222) 113)

5-HT (5-hydroxytryptamine, serotonin); 5-Carboxamidotryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Endothelium; L-NAME (N^G-nitro-L-arginine methyl ester) (Van Gelderen, E.M. (222) 185)

EDRF (endothelium-derived relaxing factor); Nitric oxide synthase inhibition; Vasoconstriction (Klabunde, R.E. (223) 1)

Aging; Stomach (rat); Non-adrenergic, non-cholinergic (NANC); VIP (vasoactive intestinal polypeptide); Cholinergic neurons (Smits, G.J.M. (223) 97)

Mucus; Gastric mucosa (Brown, J.F. (223) 103)

Corticosteroids; Fibroblasts (lung); Nitrite; Interferon-γ; Endotoxin/lipopolysaccharide; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

K^+ channels (ATP-sensitive); Blood-aqueous barrier; Vasodilatation (Andersson, S.E. (224) 89)

Ethanol; Respiratory system (Persson, M.G. (224) 99)

Nitric oxide synthase
Tetrahydrobiopterin; Vasodilatation (Van Amsterdam, J.G.C. (215) 349)

Nitric oxide synthase inhibition
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Vasoconstriction (Klabunde, R.E. (223) 1)

Nitrite
Corticosteroids; Fibroblasts (lung); Nitric oxide (NO); Interferon-γ; Endotoxin/lipopolysaccharide; Interleukin-1β; (Rat) (Jorens, P.G. (224) 7)

Nitrite (NO_2^-)
Atherosclerosis; Low-density lipoprotein; Nitric oxide (NO); Macrophages (Jorens, P.G. (212) 113)

L-N^G-Nitro-arginine (L-NO_2Arg)
Pulmonary artery (rabbit); Endothelium; Electrical transmural stimulation; Nitric oxide (NO); Noradrenaline release (Shinozuka, K. (222) 113)

Nitroglycerin
Nitroprusside; Tolerance; Coronary artery (porcine); Zaprinast; Phosphodiesterase inhibitors (Merkel, L.A. (216) 29)

NECA (5′-N-ethylcarboxamidoadenosine); Functional antagonism; Isoproterenol; Nitric oxide (NO); Sodium nitroprusside (Wiener, H.L. (220) 131)

N^G-Nitro-L-arginine
DL-Propranolol; Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate); Hindquarters (rat) (Mota-Filipe, H. (213) 227)

Acetylcholine; Baroreflexes; Nitroprusside; Phenylephrine; Vasodilatation; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

Lipopolysaccharides; Interferon-γ; N^G-Methyl-L-arginine; cGMP (Förstermann, U. (225) 161)

Nitromethylene heterocycle insecticides
1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI); Insect neuronal type nicotinic acetylcholine receptors; Endplate type nicotinic acetylcholine receptors; Neuronal type nicotinic acetylcholine receptors; Patch clamp technique (whole-cell) (Zwart, R. (228) 165)

Nitroprusside
Cerebellum; NMDA receptors; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

Acetylcholine; Baroreflexes; N-Nitro-L-arginine; Phenylephrine; Vasodilatation; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

Dihydralazine; Hydralazine; Cromakalim; K^+ channels; Smooth muscle (vascular) (Thirstrup, S. (215) 177)

Nitroglycerin; Tolerance; Coronary artery (porcine); Zaprinast; Phosphodiesterase inhibitors (Merkel, L.A. (216) 29)

Nitroprusside (sodium)
L-NAME (N^G-nitro-L-arginine methyl ester); Vasopressin; Endotoxaemia; Sympathetic stimulation; Vascular reactivity (Guc, M.O. (224) 63)

S-Nitroso-N-acetylpenicillamine
Nitric oxide (NO); Excitatory amino acids; NMDA (N-methyl-D-aspartate); Cerebellar granule cells; Neurotrophic effects (Boje, K.M. (212) 151)

S-Nitrosothiols
Excitatory amino acid; Baroreceptor reflex; Cardiovascular regulation; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Machado, B.H. (221) 179)

Nitrosovasodilators
Aortic segments; Diethyldithiocarbamate; Nitrovasodilators (Vedernikov, Y.P. (212) 125)

Nitrovasodilators
Aortic segments; Diethyldithiocarbamate; Nitrosovasodilators (Vedernikov, Y.P. (212) 125)

NK_1 receptor antagonists
Blood pressure; CP-96,345; Heart; Substance P; Cigarette smoke (Delay-Goyet, P. (222) 213)

NK_1 receptors
Tachykinin receptor antagonists; CP-96,345; FR 113680; L 668,169; Spantide II (Patacchini, R. (215) 93)

Iris (rabbit); Tachykinins; Tachykinin receptor antagonists (selective) (Wang, Z.-y. (216) 327)

NK receptors
Smooth muscle; Bladder (guinea-pig) (Longmore, J. (222) 167)

NK_2 receptors
Small intestine smooth muscle (rat); NK receptor subtypes; Radioligand binding; [^{125}I]His-NKA (Brown, M.C.S. (227) 163)

NK_2 receptor subtype
MEN 10207; MEN 10208; Neurokinin A (NKA) (Henderson, A.K. (225) 175)

NK receptor subtypes
NK_2 receptors; Small intestine smooth muscle (rat); Radioligand binding; [^{125}I]His-NKA (Brown, M.C.S. (227) 163)

NMDA channels
H^+; Mg^+ (Von Euler, G. (227) 449)

NMDA (N-methyl-D-aspartate)
Polyamine; Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Dopamine; Brain slices; Polyamines; Ifenprodil; SL 82.0715 (Woodward, J.J. (210) 265)

Glycine; L-687,414; Behaviour; Excitatory amino acids; Epilepsy (Smith, S.E. (211) 109)

Nitric oxide (NO); Excitatory amino acids; Cerebellar granule cells; S-Nitroso-N-acetylpenicillamine; Neurotrophic effects (Boje, K.M. (212) 151)

Ketamine; Ionic channels; (Enantiomer) (Zeilhofer, H.U. (213) 155)

Nitric oxide (NO); L-Arginine; Nociception; Spinal cord; Facilitation; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

Spermine; Tetrodotoxin (Speciale, C. (214) 107)

MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

AMPA; Substance P-(1–7); Iontophoresis; Nociception; Spinal cord; (Extracellular recording) (Budai, D. (216) 441)

Glutamates; Quisqualate; Cerebellar granule cells; Tricyclic antidepressants; Carbamazepine (Cai, Z. (219) 53)

Proline; Hippocampus; Excitatory amino acids (Martin, D. (219) 59)

Spinal cord; Carrageenan; Thermal hyperalgesia; Antinociception; Opioids; (Rat); (Intrathecal) (Ren, K. (219) 235)

Pentylenetetrazole; Pregnenolone sulfate; Seizure; (Mouse) (Maione, S. (219) 477)

Protein kinase C: Amnesia; Memory; (Mouse) (Mathis, C. (220) 107)

Ca^{2+} channels; Dihydropyridines; Excitatory amino acid; Dopamine; Transmitter release; Mesencephalon (Chaudieu, I. (220) 203)

Epilepsy; Valproate; MK-801; Behaviour (Dziki, M. (222) 273)

Ethanol; c-fos; Glutamate; Hybridization (in situ) (Morgan, P.F. (225) 217)

Cortical neurons; Arachidonic acid; Somatostatin; Phospholipase A_2 (Tapia-Arancibia, L. (225) 253)

NMDA (N-methyl-D-aspartic acid)
D-Baclofen; Spinal cord; Heart rate; Arterial pressure; Sympathetic output (Hong, Y. (216) 257)

Spider toxins; Excitatory amino acid receptors; Kainate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Davies, M.S. (227) 51)

NMDA receptor antagonism
Ethanol; Phencyclidine; NPC 12626; Drug discrimination (Balster, R.L. (222) 39)

NMDA receptor antagonists
Strychnine; Handling; Seizures; (Mouse) (McAllister, K.H. (211) 105)

CGP 37849; CGP 39551; Kindling; Anticonvulsant drugs; Seizures (Cotterell, K.L. (214) 285)

Epilepsy; Anticonvulsants; Audiogenic seizures; Genetically epilepsy-prone rats (De Sarro, G. (215) 221)

Phencyclidine; Ventral tegmental area; A10 neurons (French, E.D. (217) 1)

Spinal cord contusion; Non-NMDA receptor antagonists; Excitatory amino acids (Wrathall, J.R. (218) 273)

Nitric oxide (NO); NO synthase (Kolesnikov, Y.A. (221) 399)

NMDA receptor mRNA; Polymerase chain reaction (Lesch, K.P. (227) 109)

NMDA receptor antagonists (non-competitive)
Dextrorphan; Anticonvulsants; Prepiriform cortex; PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride); MK-801 (Roth, J.E. (215) 293)

NMDA receptor mRNA
NMDA receptor antagonists; Polymerase chain reaction (Lesch, K.P. (227) 109)

NMDA receptors
Cerebellum; Nitroprusside; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

Retinal ganglion cell; Spontaneous firing; Microiontophoresis; MK-801 (Ikeda, H. (210) 53)

L-Glutamate; 2-(Carboxycyclopropyl)glycine; D-Aspartate uptake; $[Ca^{2+}]_i$ increase; Neurotoxicity (Kawai, M. (211) 195)

Excitatory amino acids; Spinal cord; Intrathecal; Non-NMDA receptors (Näsström, J. (212) 21)

Histamine; Glutamate; Microdialysis; Hypothalamus (Okakura, K. (213) 189)

CGP37849; CGP39551; Dizocilpine; Spatial orientation task; (Rat) (Bischoff, C. (213) 269)

Acetylcholine release; Amantadine; Neostriatum; Dopamine release (Stoof, J.C. (213) 439)

Glycine; Kynurenates; Thiokynurenates; Ischemia; Excitotoxicity (Moroni, F. (218) 145)

Tyrosine hydroxylase; $GABA_B$ receptors; Baclofen; Dopamine synthesis; Dopaminergic transmission (Montaño, J.-A.A. (218) 335)

Global ischaemia; 1-Aminocyclopropanecarboylic acid; Glycine receptors; (Gerbil) (Von Lubitz, D.K.J.E. (219) 153)

Aging; D-Cycloserine; Glycine; Memory; Senescence; (Mouse) (Flood, J.F. (221) 249)

4-Aminopyridine; Convulsions; Wet-dog shakes (Fragoso-Veloz, J. (221) 275)

Glycine; Serine; Alanine; Valine; Glycine modulatory site; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Imipramine (chronic); Dopamine receptors; Supersensitivity (D'Aquila, P.S. (224) 199)

[^{3}H]CPP ([^{3}H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid); Brain (rat); Cortex (human); Alzheimer's disease (Porter, R.H.P. (225) 195)

[^{125}I]Thienylphencyclidine; Polyamines (Reynolds, I.J. (226) 53)

Human immunodeficiency virus type 1 (HIV-1); Apoptosis; Cortical cells; Memantine; gp120 (Müller, W.E.G. (226) 209)

Oocytes (*Xenopus*); Conantokin (Hammerland, L.G. (226) 239)

Ifenprodil; Neurotoxicity; Cell culture (Graham, D. (226) 373)

ACTH; Myoclonus; Epilepsy (Trifiletti, R.R. (226) 377)

[^{3}H]CPP ([^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) binding; HA-966; Glycine; Polyamines (Porter, R.H.P. (227) 83)

Philanthotoxin-343; Hippocampus; Glutamate; AMPA/kainate receptors; Polyamines (Fedorov, N.B. (228) 201)

L-NMMA (N^G-monomethyl-L-arginine)
CGRP (calcitonin gene-related peptide); Endothelium-dependent vasorelaxation; Nitric oxide (NO); L-NOARG (N^G-nitro-L-arginine) (Gray, D.W. (212) 37)

L-NAME (N^G-nitro-L-arginine methyl ester); Hypertension; Haemodynamics; (Brattleboro rat) (Gardiner, S.M. (213) 449)

NNC-112
Dopamine D_1 receptors; NNC-687; NNC-756; Binding (in vivo) (Andersen, P.H. (219) 45)

NNC-687
Dopamine D_1 receptors; NNC-112; NNC-756; Binding (in vivo) (Andersen, P.H. (219) 45)

NNC-711
GABA uptake; Anticonvulsants; Epilepsy (Suzdak, P.D. (224) 189)

NNC-756
Dopamine D_1 receptors; NNC-112; NNC-687; Binding (in vivo) (Andersen, P.H. (219) 45)

N-0861 (N^6-endonorbornan-2-yl-9-methyladenine)
Atrium (left, dog); Adenosine receptors; 8-Phenyltheophylline; DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Martin, P.L. (214) 199)

NO 756
Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; SCH 39166; A-69024; BW 737C (Daly, S.A. (213) 251)

L-NOARG (N^G-nitro-L-arginine)
CGRP (calcitonin gene-related peptide); Endothelium-dependent vasorelaxation; Nitric oxide (NO); L-NMMA (N^G-monomethyl-L-arginine) (Gray, D.W. (212) 37)

Nociception
NMDA (N-methyl-D-aspartate); Nitric oxide (NO); L-Arginine; Spinal cord; Facilitation; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

α_2-Adrenoceptors; Pain (Millan, M.J. (215) 355)

Substance P; Tachykinins; Pain; Spinal cord (Xu, X.-J. (216) 337)

NMDA (N-methyl-D-aspartate); AMPA; Substance P-(1–7); Iontophoresis; Spinal cord; (Extracellular recording) (Budai, D. (216) 441)

Monoamine oxidase-A inhibitors; Tail-flick test; Hot-plate test; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (219) 113)

Spinal cord; Formalin; Bradykinin; Prostaglandins; (Rat) (Chapman, V. (219) 427)

Nocloprost
Nitric oxide (NO); Gastroprotection; Blood flow (mucosal) (Konturek, S.J. (211) 277)

Nomifensine
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Non-adrenergic binding sites
α_2-Adrenoceptors; α-Adrenoceptor antagonists; [^{3}H]Atipamezole; [^{3}H]Rauwolscine (Sjöholm, B. (215) 109)

Non-adrenergic sympathetic nerve stimulation
Neuropeptide Y; Vasoconstriction; D-myo-Inositol-1,2,6-triphosphate (PP56) (Pernow, J. (222) 171)

Non-Ah (aryl-hydrocarbon)-mediated effects
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Non-cholinergic contraction
Neurokinin receptors; Electrical field stimulation; SR 48968; (±)-CP-96,345; Bronchus (guinea-pig) (Martin, C.A.E. (224) 137)

Non-NMDA receptor antagonists
Spinal cord contusion; NMDA receptor antagonists; Excitatory amino acids (Wrathall, J.R. (218) 273)

Non-NMDA receptors
Excitatory amino acids; Spinal cord; Intrathecal; NMDA receptors (Näsström, J. (212) 21)

Nonpeptide V_1 receptor antagonists
Vasopressin; Phosphoinositide (PI) hydrolysis; α_1-Adrenoceptors; Endothelin; Ventricular myocardium (rabbit) (Endoh, M. (218) 355)

Noradrenaline
Propranolol; Muscimol; Food intake; Environment (hot) (Kurose, Y. (211) 39)

Neuronal reuptake; Presynaptic inhibition; α-Adrenoceptors; Heart (rat) (Du, X.-J. (211) 221)

Thyroxine; Portal vein; β-Adrenoceptors; Fenoterol; Atenolol; ICI 118,551 (Chin, J.P.F. (212) 201)

Propranolol; Atrium; Dopamine-β-hydroxylase (lung); Catecholamines (Elayan, H. (212) 259)

Neuropeptide Y (NPY); Co-neurotransmission (Montastruc, P. (213) 159)

Jatrophone; Aorta (rat); K^+ channel blockers; Ca^{2+}; KCl; Angiotensin II (Duarte, D.F.P. (215) 75)

Microdialysis; Hippocampus; Morphine withdrawal; Clonidine (Done, C. (215) 333)

CGRP (calcitonin gene-related peptide); Circulatory filling pressure (mean); Venous tone; Ganglionic blockers (Abdelrahman, A. (217) 185)

5-HT (5-hydroxytryptamine, serotonin); α-Adrenoceptor antagonists; Desipramine; 6-Hydroxydopamine (6-OHDA); Spinal antinociception (Sawynok, J. (223) 49)

Aorta; Protein kinase C; Staurosporine; Calphostin C; Ca^{2+} uptake; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

α_2-Adrenoceptors; Autoradiography; Brain imaging (Biegon, A. (224) 27)

Diabetes mellitus; Mesenteric arteries; Contractile responses; Inositol phosphates; Inositol 1,4,5-trisphosphate (Abebe, W. (225) 29)

Noradrenaline release
CGP 20712A; ICI 118,551; Isoprenaline; β-Adrenoceptors (prejunctional) (Mian, M.A. (213) 47)

Rilmenidine; Clonidine; Voltammetry (in vivo); α_2-Adrenoceptors; Hypothalamus (Suaud-Chagny, M.F. (213) 305)

α_2-Adrenoceptors; Monoamine oxidase; Antidepressant drugs; Vas deferens (rat) (Ari, G. (219) 89)

Pulmonary artery (rabbit); L-N^G-Nitro arginine (L-NO_2Arg); Endothelium; Electrical transmural stimulation; Nitric oxide (NO) (Shinozuka, K. (222) 113)

3,4-Diaminopyridine; Hippocampus; Ca^{2+} (intracellular); α_2-Adrenoceptor mechanism; (Rat); (Rabbit) (Jackisch, R. (226) 245)

Noradrenaline uptake inhibitors
Spiradoline; κ-Opioid receptor agonists; Analgesia; 5-HT uptake inhibitors (Kunihara, M. (214) 111)

Noradrenergic mechanisms (central)
α-Adrenoceptors; Gastric motility; Brainstem (Nagata, M. (223) 153)

Nor-binaltorphimine (nor-BNI)
Vasopressin; Oxytocin; Naloxone; Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Opioid tolerance; Morphine; κ-Opioid receptors (Sofuoglu, M. (210) 159)

Opioid receptor agonist/antagonist (mixed); DAMGO ([D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin); Ileum (guinea-pig) (Berzetei-Gurske, I.P. (212) 283)

Opioid interactions; Morphine; Analgesic tolerance; Physical dependence (Suzuki, T. (213) 91)

Spiradoline; Antinociception; Morphine; κ-Opioid receptors (Jones, D.N.C. (215) 345)

Norepinephrine
Cocaine; Cocaine methiodide; Blood pressure; Heart rate; (Squirrel monkey) (Schindler, C.W. (213) 99)

ANP (atrial natriuretic polypeptide); Neuromodulation; cGMP (Giridhar, J. (213) 317)

Estrogen; Angiotensin II; Aorta (rat); Contraction (Cheng, D.Y. (215) 171)

5-HT (5-hydroxytryptamine, serotonin); Nucleus raphe dorsalis; Locus coeruleus; Voltammetry (in vivo); (Rat) (Clement, H.-W. (217) 43)

Desipramine; Amphetamine; Dorsal hippocampus; Locus coeruleus (Curet, O. (221) 59)

Amphetamines; Dopamine; MDMA (3,4-methylenedioxymethamphetamine); 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Elayan, I. (221) 281)

Chromaffin cells; Epinephrine; Acetylcholine; Glycine (Yadid, G. (221) 389)

ANP (atrial natriuretic peptide); Sodium nitroprusside; Renal blood flow; Angiotensin II (Hisa, H. (222) 265)

Lithium chloride; cAMP; Isoprenaline; Phenoxybenzamine; Propranolol (Mármol, F. (226) 93)

α_1-Adrenoceptors; Ca^{2+}; Smooth muscle (Han, C. (226) 141)

Clonidine; α_2-Adrenoceptors; Morphine; μ-Opioid receptors; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

Protein kinase C; 1,2-Dioctanoylglycerol; Ca^{2+} current; Whole-cell voltage clamp; Sympathetic ganglia (Abrahams, T.P. (227) 189)

NO synthase
NMDA receptor antagonists; Nitric oxide (NO) (Kolesnikov, Y.A. (221) 399)

Novelty-induced grooming behaviour
Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY); SCH 23390; Quinpirole; Dopamine receptors (Linthorst, A.C.E. (219) 23)

NPC 12626
Ethanol; NMDA receptor antagonism; Phencyclidine; Drug discrimination (Balster, R.L. (222) 39)

NPY receptor subtypes
Neuropeptide Y (NPY); Acetylcholine; Endothelium; Vasoconstriction; Vasodilatation (Grundemar, L. (221) 71)

N-terminal part
Tachykinins; Protein secretion; Substance P; Parotid glands (Rollandy, I. (209) 95)

Nucleophilic attack
Ozonides; Glutathione; Molecular orbital (Hempenius, R.A. (228) 207)

Nucleotide receptors
Smooth muscle cells; DDT_1 MF-2 cells; ATP; UTP; K^+ currents (Van der Zee, L. (215) 317)

Nucleus accumbens
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Sexual behaviour (male); 5-HT_{1A} receptors; Nucleus raphe; Medial preoptic area; 5-$HT_{1B/C}$ receptors (Fernández-Guasti, A. (210) 121)

Ibogaine; Cocaine; Dopamine; Striatum; Microdialysis; Locomotor activity (Maisonneuve, I.M. (212) 263)

Neurokinins; Dopamine release; Neostriatum; Microdialysis (in vivo) (Boix, F. (216) 103)

Dopamine; Melatonin; Antidepressant drugs; Receptor supersensitivity (Durlach-Misteli, C. (217) 15)

Dopamine release; Methamphetamine; Dynorphin (Yokoo, H. (222) 43)

Dopamine release; 3-Methoxytyramine; Striatum; Frontal cortex; (Rat) (Chrapusta, S.J. (222) 129)

Nucleus accumbens septi
MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; Behaviour; Locomotion (Callaway, C.W. (214) 45)

Nucleus basalis of Meynert
BY-1949; Cerebral blood flow; (Rat) (Takao, A. (217) 101)

Nucleus raphe
Sexual behaviour (male); 5-HT_{1A} receptors; Nucleus accumbens; Medial preoptic area; 5-$HT_{1B/C}$ receptors (Fernández-Guasti, A. (210) 121)

Nucleus raphe dorsalis
5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Locus coeruleus; Voltammetry (in vivo); (Rat) (Clement, H.-W. (217) 43)

Nucleus tractus solitarii
Quipazine; L-Glutamate; Subretrofacial nucleus; Caudal ventrolateral medulla; Lateral tegmental field (Vayssettes-Courchay, C. (211) 243)

Substance P; GABA (γ-aminobutyric acid); Bicuculline; (Evoked responses); (Rat) (Pérez, H. (213) 435)

[Arg^8]vasopressin; Baroreflexes; Splanchnic sympathetic efferent discharge; Vasopressin V_1 receptor antagonists; Area postrema (Zhang, X. (222) 81)

Nuvenzepine
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Vas deferens (rabbit); Cyproheptadine; Pizotifen; Ketotifen; Thiazinamium (Eltze, M. (211) 283)

Octreotide
SMS 201-995; Somatostatin; α-Adrenoceptors; Histamine H_3 receptors; Migraine; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

2-(1-Octynyl)-adenosine (YT-146)
Adenosine; Antianginal vasodilator; Antihypertensive vasodilator; Glibenclamide-sensitive K^+ channels (Yoneyama, F. (213) 199)

Oedema
Carrageenin; Dextran; Nitric oxide (NO); Vascular permeability (Ialenti, A. (211) 177)

Aging; Airway obstruction; Asthma; Histamine; Plasma exudation; Substance P; Vascular permeability (Arakawa, H. (215) 51)

PAF (platelet activating factor, PAF-acether); SR 27417; Antigen; Skin; Inflammation (Herbert, J.M. (216) 175)

Oedema formation
13-HODE (13-hydroxyoctadecadienoic acid); Leukotriene B_4; Skin (rabbit) (Buckley, T.L. (218) 369)

Oesophagus
5-HT_4; BIMU 1; BIMU 8; DAU 6214; Benzimidazolones (Baxter, G.S. (212) 225)

Oesophagus (rat)
5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptors; cAMP; Benzamides (substituted); Tropisetron (Ford, A.P.D.W. (211) 117)

Oestradiol-17β
Inhibin; Indomethacin; Gonadotrophin; Prostaglandin $F_{2\alpha}$; PMSG-primed immature rat; Ovary (Kogo, H. (221) 289)

Oestrogen
Histamine receptors; Uterus (rat); Progesterone; Ovarian steroids (Rubio, E. (212) 31)

OFF channels
Retina; Ethylcholine mustard arizidinium ion; Acetylcholine; Glycine; Amacrine cells; ON channels; (Frog) (Jardon, B. (210) 201)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

5-HT receptor agonists; 5-HT receptor antagonists; Blood pressure; Plasma renin activity; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (210) 285)

5-HT_{1A} receptors; Passive avoidance; Memory (Carli, M. (211) 227)

Aggression; TFMPP (1-(3-(trifluoromethyl)phenyl)piperazine hydrochloride); Eltoprazine; (Rat) (Mos, J. (212) 295)

Circadian rhythm; Suprachiasmatic nucleus; 2-Deoxyglucose uptake; $GABA_A$ receptors; Benzodiazepine receptors (Tominaga, K. (217) 79)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

NAN-190; Feeding; 5-HT_{1A} receptors; (Rat) (Williams, A.R. (219) 105)

5-HT_{1A} receptors; Renal nerve activity; Medullary 5-HT neurons (Ramage, A.G. (219) 165)

5-HT_{1A} receptors; Sex differences; Tolerance; Corticosterone; Hypothermia (Nakano, Y. (219) 339)

(−)-Penbutolol; 5-HT_{1A} receptor antagonism; 5-HT (5-hydroxytryptamine, serotonin); Synthesis and turnover; 5-HT-like behaviour; Hypothermia (Hjorth, S. (222) 121)

Oil slicks
Diesel-2 (exposure); Crude oil (exposure); DNA damage; ^{32}P-Post-labeling assay (Kurelec, B. (228) 51)

Okadaic acid
cAMP; cGMP; Xanthine derivatives; Uterine smooth muscle (Candenas, M.-L. (219) 473)

Ca^{2+}; Action potentials; Pituitary; Protein kinase A; Protein kinase C (Chiavaroli, C. (227) 173)

OK cells
α_2-Adrenoceptor mRNA; HT29 cells; NG108 cells (Sun, L. (226) 367)

Oleate
Glisoxepide; Glibenclamide; Organic anions; Monocarboxylate transport; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide (Fückel, D. (213) 393)

Oleic acid
Endothelin-1; Radioimmunoassay; Respiratory distress syndrome (adult); Bronchoalveolar lavage; Hypoxia (Simmet, T. (211) 319)

Olfactory cortex slice (guinea-pig)
Nicotinic receptor agonists; Surface field potential (N-wave); Extracellular recording; Antimuscarinic action (Libri, V. (212) 253)

Trans-ACPD (trans-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); Slow inward tail current (I_{ADP}) (Constanti, A. (214) 105)

Omeprazole
Gastrin; Food intake; (Chicken) (Campbell, B.J. (209) 231)

Proton pump inhibitors; Gastric mucosa blood volume; Gastric mucosa oxygenation; Reflectance spectrophotometry; Hemorrhagic shock; NC-1300 (Kawano, S. (211) 55)

H^+,K^+-ATPase; Pantoprazole (Beil, W. (218) 265)

ON channels
Retina; Ethylcholine mustard arizidinium ion; Acetylcholine; Glycine; Amacrine cells; OFF channels; (Frog) (Jardon, B. (210) 201)

Ondansetron (GR38032F)
Amphetamine discrimination; 5-HT_3 receptor antagonists; MDL 72,222EF; MDL 73,147EF; ICS 205-930 (Moser, P.C. (212) 271)

ONO11006
Heart; Adrenergic neurotransmission; U46619; Thromboxane B_2 (Mantelli, L. (213) 79)

Ontogenesis
Atrial natriuretic peptide (ANP); Guanylate cyclase; Aorta; Kidney; Lung (Muraki, T. (226) 311)

Oocytes *(Xenopus laevis)*
Lysophosphatidic acid (Fernhout, B.J.H. (213) 313)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

NMDA receptor; Conantokin (Hammerland, L.G. (226) 239)

Opiate analgesia
μ-Opioid receptors; Opioid receptors (mixed agonist/antagonist) (Tive, L.A. (216) 249)

Opiate lethality
Opiate receptors; μ-Opioid receptors; δ-Opioid receptors; κ-Opioid receptors; Gastrointestinal transit (Pick, C.G. (211) 375)

Opiate receptors
μ-Opioid receptors; δ-Opioid receptors; κ-Opioid receptors; Opiate lethality; Gastrointestinal transit (Pick, C.G. (211) 375)

Strychnocarpine; β-Carbolines; 5-HT (5-hydroxytryptamine, serotonin); Benzodiazepines; Tryptamine; GABA receptors (Strömbom, J. (214) 165)

Opiates
[^{3}H]DAGO binding; Development; Hypothalamus (Hammer, Jr., R.P. (209) 253)

cAMP; Brain slices; Glutamate; Locus coeruleus; Withdrawal (Kogan, J.H. (211) 47)

Fentanyl; Lofentanil; Ileum; Vas deferens; (Receptor binding) (Maguire, P. (213) 219)

Development; Antinociception; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Morphine (Barr, G.A. (215) 35)

Opiate tolerance
Dynorphin A-(1–13); Opiate withdrawal; Morphine (Takemori, A.E. (221) 223)

Opiate withdrawal
Dynorphin A-(1–13); Opiate tolerance; Morphine (Takemori, A.E. (221) 223)

Opiodergic system
L-Arginine; Antinociceptive effect; Kyotorphin; (Rat) (Kawabata, A. (218) 153)

κ-Opioid binding sites
Opioid receptors; R1.1 lymphoma cell line; [^{3}H]U69,593 (Bidlack, J.M. (227) 257)

Opioid interactions
Morphine; Analgesic tolerance; Physical dependence; Nor-binaltorphimine (nor-BNI) (Suzuki, T. (213) 91)

Opioid receptor agonist/antagonist (mixed)
DAMGO ([D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin); Nor-binaltorphimine; Ileum (guinea-pig) (Berzetei-Gurske, I.P. (212) 283)

Opioid receptor agonists
Opioid receptor antagonists; Arrhythmias; Ischaemia; (Rat) (McIntosh, M. (210) 37)

Electroacupuncture; Analgesia; Opioid receptors; Opioid receptor antagonists; Spinal cord (Chen, X.-H. (211) 203)

κ-Opioid receptor agonists
Spiradoline; Analgesia; Noradrenaline uptake inhibitors; 5-HT uptake inhibitors (Kunihara, M. (214) 111)

δ-Opioid receptor agonists (selective)
μ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

μ-Opioid receptor agonists (selective)
δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Opioid receptor antagonists
Opioid receptor agonists; Arrhythmias; Ischaemia; (Rat) (McIntosh, M. (210) 37)

Cardiac electrophysiology; Ischaemia; Purkinje fibres (McIntosh, M. (210) 45)

Electroacupuncture; Analgesia; Opioid receptors; Opioid receptor agonists; Spinal cord (Chen, X.-H. (211) 203)

Substance P (N-terminal fragments); Substance P-(1–7); Behavioural desensitization (Mousseau, D.D. (217) 197)

Opioid receptor regulation
Supersensitivity; Morphine; Naltrexone; d-Amphetamine; Analgesia; Upregulation (Duttaroy, A. (221) 211)

Joint inflammation; Pain (chronic); Polyarthritic rat; Autoradiography (quantitative) (Besse, D. (223) 123)

Opioid receptors
Electroacupuncture; Analgesia; Opioid receptor agonists; Opioid receptor antagonists; Spinal cord (Chen, X.-H. (211) 203)

Antinociception; Tail-flick inhibition; β-Endorphin (intrathecal) (Tseng, L.F. (214) 59)

Temperature; Myenteric plexus; DAGO ([D-Ala^2,N-MePhe^4,Gly^5-ol]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-50,488H (Garaulet, J.V. (223) 19)

R1.1 lymphoma cell line; κ-Opioid binding sites; [^{3}H]U69,593 (Bidlack, J.M. (227) 257)

G-proteins; Affinity cross-linking; NG108-15 cells (Harada, J. (227) 301)

δ-Opioid receptors
Deltorphins; Locomotor activity; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

Opiate receptors; μ-Opioid receptors; κ-Opioid receptors; Opiate lethality; Gastrointestinal transit (Pick, C.G. (211) 375)

Naltrindole; Antinociception (Stapelfeld, A. (214) 273)

Antinociception; Tail-flick (spinal); DSTBULET (Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr); Morphine (Kalso, E.A. (216) 97)

Naltrindole; PET (positron emmission tomography) (Lever, J.R. (216) 459)

NG 108-15 hybrid cell; [^{3}H]Etorphine; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Sucrose gradients; Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

κ-Opioid receptors
Opioid tolerance; Morphine; Norbinaltorphimine (Sofuoglu, M. (210) 159)

Opiate receptors; μ-Opioid receptors; δ-Opioid receptors; Opiate lethality; Gastrointestinal transit (Pick, C.G. (211) 375)

Nor-binaltorphimine (nor-BNI); Spiradoline; Antinociception; Morphine (Jones, D.N.C. (215) 345)

CRF (corticotropin-releasing factor); Dynorphin release; Analgesia; Spinal cord (Song, Z.H. (222) 27)

Naloxone benzoylhydrazone; Morphine (Cheng, J. (226) 15)

μ-Opioid receptors
Opiate receptors; δ-Opioid receptors; κ-Opioid receptors; Opiate lethality; Gastrointestinal transit (Pick, C.G. (211) 375)

Opiate analgesia; Opioid receptors (mixed agonist/antagonist) (Tive, L.A. (216) 249)

Supersensitivity; Ethanol pretreatment (chronic); Morphine; Vas deferens (mouse); Naloxone (Tabach, R. (216) 449)

Morphine; Analgesia (Pick, C.G. (220) 275)

Clonidine; Norepinephrine; α_2-Adrenoceptors; Morphine; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells; Retinoic acid (Lameh, J. (227) 19)

Opioid receptors (mixed agonist/antagonist)
Opiate analgesia; μ-Opioid receptors (Tive, L.A. (216) 249)

μ-Opioid receptors (pre- and postsynaptic)
Myenteric plexus (guinea-pig); Adenylate cyclase (Rengel, I. (227) 385)

δ-Opioid receptor subtypes
Naltriben; DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DADLE (D-Ala^2,D-Leu^5]enkephalin) (Sofuoglu, M. (216) 273)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]deltorphin; CD-1 mice; CXBK mice; Antinociception (Raffa, R.B. (216) 453)

δ-Opioid receptor subtypes binding
Antinociception; 7-Benzylidenenaltrexone (BNTX) (Portoghese, P.S. (218) 195)

Opioids
Antinociception; Spinal cord; Dorsal horn neurons; α_2-Adrenoceptor agonists; Dexmedetomidine (Sullivan, A.F. (215) 127)

Lithium chloride; Analgesia (Raffa, R.B. (217) 221)

Spinal cord; Carrageenan; Thermal hyperalgesia; Antinociception; NMDA (N-methyl-D-aspartate); (Rat); (Intrathecal) (Ren, K. (219) 235)

Naloxone infusion (continuous); D-amphetamine; Locomotor activity; Dopamine (Rat) (Jones, D.N.C. (221) 161)

Platelets (human); α_2-Adrenoceptors (Ballesta, J.J. (227) 349)

Opioid tolerance
Morphine; Norbinaltorphimine; κ-Opioid receptors (Sofuoglu, M. (210) 159)

Oral movements
Dopaminergic/cholinergic interaction; Striatum (dorsal); Striatum (ventral); (Rat) (Kikuchi de Beltrán, K. (214) 181)

Org 2766
Sciatic nerve crush; ACTH (adrenocorticotropin); Neurotrophic factor; Regeneration; Sensorimotor function; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Organic anions
Glisoxepide; Glibenclamide; Monocarboxylate transport; Bromosulfophthalein; DIDS (4,4-diisothiocyano-2,2′-stilbenedisulfonate); Bumetanide; Oleate (Fückel, D. (213) 393)

Ornithine decarboxylase
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Neuroprotection (Kish, S.J. (209) 101)

Prolactin; Smooth muscle (vascular); Gene expression; Hypertension; c-myc (Sauro, M.D. (225) 351)

Staurosporine; 12-O-Tetradecanoylphorbol 13-acetate; Protein kinase C; Epidermal cells (mouse); Morphological changes (Yamamoto, S. (227) 113)

Osmolarity
Atrium (rat); ANP release; Ca^{2+} influence; V_1 receptor antagonists (Zongazo, M.A. (209) 45)

Osthole
Vasorelaxation (rat aorta); Ca^{2+} influx; cGMP; (*Angelica pubescens*) (Ko, F.-N. (219) 29)

Ouabain
Trachea (guinea-pig); Acetylcholine; Histamine; 5-HT (5-hydroxytryptamine, serotonin); Amiloride; K^+-free solution (Cortijo, J. (221) 43)

Aorta (guinea-pig); Contraction; Ca^{2+} signals; Na^+/Ca^{2+} exchangers (Iwamoto, T. (224) 71)

[^{3}H]Ouabain
Ouabain binding site (high affinity); Melatonin; Cerebral cortex (rat) (Acuña Castroviejo, D. (226) 59)

Ouabain binding site (high affinity)
Melatonin; [^{3}H]Ouabain; Cerebral cortex (rat) (Acuña Castroviejo, D. (226) 59)

Ouabain-induced arrhythmia
Dazmegrel; PAF (platelet-activating factor, PAF-acether); Lysine-acetylsalicylate; (Guinea-pig) (Salinas, P. (209) 105)

Ovarian steroids
Danazol; 13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$; Gonadotropin; Ovary; Uterus (Kogo, H. (211) 69)

Histamine receptors; Uterus (rat); Progesterone; Oestrogen (Rubio, E. (212) 31)

Ovariectomy
Benzodiazepine exposure (chronic); Tolerance; Steroid hormones; GABA/benzodiazepine receptors; Anticonvulsants (Wilson, M.A. (215) 99)

Ovary
Danazol; 13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$; Ovarian steroids; Gonadotropin; Uterus (Kogo, H. (211) 69)

Inhibin; Oestradiol-17β; Indomethacin; Gonadotrophin; Prostaglandin $F_{2\alpha}$; PMSG-primed immature rat (Kogo, H. (221) 289)

Oviduct
Tamoxifen; Phospholipase A_2; Cell proliferation (Fayard, J.-M. (216) 127)

Oxazoline
Rilmenidine; Imidazoline; Guanidinium; α_2-Adrenoceptor subtypes; Cerebral cortex (rat) (King, P.R. (218) 101)

Oxodipine
Aorta; $^{45}Ca^{2+}$ influx; Mesenteric resistance vessels; (Rabbit) (Tejerina, T. (219) 279)

Oxyphencyclimine
Muscarinic receptors; Hexahydro-difenidol; Hexbutinol; Eudismic analysis; Pfeiffer's rule; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

Oxysterol
Cholesterol; Intercellular communication; Smooth muscle cells (Zwijsen, R.M.L. (228) 115)

Oxytocin
Vasopressin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

[Arg^8] vasotocin; [Arg^8] vasopressin (AVP); Prostatic contraction; Neurohypophyseal peptides; Neuropeptides (Bodanszky, M. (216) 311)

Penile erection; Yawning; Apomorphine; ACTH (adrenocorticotropin); Excitatory amino acid receptor antagonists (Melis, M.R. (220) 43)

Cocaine; 5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropic hormone); Prolactin; Renin (Levy, A.D. (221) 121)

Ozonides
Glutathione; Nucleophilic attack; Molecular orbital (Hempenius, R.A. (228) 207)

PACAP (pituitary adenylate cyclase-activating polypeptide)
Trachea (guinea-pig); Smooth muscle; cAMP (Araki, N. (216) 113)

PAF (platelet-activating factor, PAF-acether)
Dazmegrel; Lysine-acetylsalicylate; Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

Pulmonary vascular bed; U46619; Thromboxane A_2/endoperoxide receptor-mediated responses; Sulotroban; Endothelin peptides (Nossaman, B.D. (213) 1)

Immune-complex alveolitis; Arthus reaction; Eicosanoids (Tavares de Lima, W. (213) 63)

Airway microvascular leakage; Bradykinin; Bradykinin receptors; Bronchoconstriction; Hoe 140 (Sakamoto, T. (213) 367)

Azelastine; Immunisation; Lung hyperresponsiveness; Leukotrienes; Histamine; (Guinea-pig) (Pretolani, M. (216) 141)

SR 27417; Antigen; Skin; Oedema; Inflammation (Herbert, J.M. (216) 175)

Gastrointestinal; Inflammation; Endotoxic shock; Parasitic infection (Hogaboam, C.M. (216) 315)

Neutrophils; Arachidonic acid; Staurosporine; Phospholipase A_2 (Müller, S. (218) 251)

Gastric acid; Endotoxin; Nitric oxide (NO); Pentagastrin (Martinez-Cuesta, M.A. (218) 351)

Splanchnic artery occlusion shock; TNF-α (tumor necrosis factor); Myocardial depressant factor; L-659,989 (Zingarelli, B. (222) 13)

Endothelin; Aggregation; Polymorphonuclear leukocytes (Gómez-Garre, D. (224) 167)

PAF receptor antagonists
Bronchial hyperreactivity; Antigen (ovalbumin); Inflammatory cells (Underwood, S.L. (210) 97)

WEB 2170; Paw edema (mouse); Anaphylaxis (Amorim, C.Z. (211) 29)

Aglafoline; (*Aglaia elliptifolia* Merr) (Ko, F.-N. (218) 129)

PAF-specific
Pulmonary platelet accumulation; Desensitization; (Rat) (Klee, A. (209) 223)

Pain
NMDA (N-methyl-D-aspartate); Nitric oxide (NO); L-Arginine; Nociception; Spinal cord; Facilitation; Hyperalgesia; (Rat) (Meller, S.T. (214) 93)

α_2-Adrenoceptors; Nociception (Millan, M.J. (215) 355)

Spinal cord; Morphine; Descending inhibitory controls; Periaqueductal grey (Bouhassira, D. (216) 149)

Substance P; Tachykinins; Nociception; Spinal cord (Xu, X.-J. (216) 337)

Neurogenic inflammation; Plasma extravasation; Substance P antagonists; Tachykinins; Capsaicin (Nagahisa, A. (217) 191)

Pain (chronic)
Joint inflammation; Polyarthritic rat; Autoradiography (quantitative); Opioid receptor regulation (Besse, D. (223) 123)

Pain controls (descending)
Antinociception; Tail-flick inhibition; Morphine; β-Endorphin; Pentobarbital (Tseng, L.F. (214) 175)

Pain measurement
Bradykinin receptor antagonists; Histamine liberation; Skin response (Kindgen-Milles, D. (218) 183)

Pancreas
Cibenzoline; Insulin secretion; Glycemia; Imidazoline; (Rat) (Bertrand, G. (214) 159)

Pancreas (dog)
Exocrine secretion; Phosphodiesterase inhibitors; Rolipram (Iwatsuki, K. (209) 63)

Exocrine secretion; YM435; Dopamine D_1 receptor agonists (Iwatsuki, K. (218) 237)

Pancreas (isolated, rat)
Pertussis toxin; Insulin secretion; Adrenaline; α_2-Adrenoceptors (Hillaire-Buys, D. (218) 359)

Pancreatic phospholipase A_2 (porcine)
Phospholipase A_2; Lung (guinea-pig) (Sommers, C.D. (216) 87)

Pancreatic secretion
Amylase; Bombesin; Bombesin receptor antagonists (Jaworek, J. (214) 239)

Pantoprazole
H^+,K^+-ATPase; Omeprazole (Beil, W. (218) 265)

Paradoxical analgesia
Diabetes; Naloxone; Naltrindole; (Mouse) (Kamei, J. (210) 339)

Parainfluenza 3 virus
Airway responsiveness (in vitro); Inflammatory cells; Histology (Folkerts, G. (228) 121)

Airway responsiveness (in vivo); Inflammatory cell count; Chemiluminescence; (In vitro activation) (Folkerts, G. (228) 219)

Parasitic infection
PAF (platelet-activating factor, PAF-acether); Gastrointestinal; Inflammation; Endotoxic shock (Hogaboam, C.M. (216) 315)

Parasympathetic nervous system
Muscarinic receptors; Lung resistance; Gallamine; Pirenzepine; (Cat) (Killingsworth, C.R. (210) 231)

Paraventricular hypothalamus
Cirazoline; α_1-Adrenoceptors (Davies, B.T. (210) 11)

Parenchymal contraction
Leukotriene B_4; Receptor binding; Airway obstruction; Leukotriene B_4 receptor antagonists; (Guinea-pig) (Silbaugh, S.A. (223) 57)

Pargyline
2-Phenylethylamine; 2-Phenylethylamine binding sites; MAO (monoamine oxidase); MAO (monoamine oxidase) inhibitor; (−)-Deprenyl (Li, X.-M. (210) 189)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Uptake; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Endothelium (Gruetter, C.A. (217) 109)

Parietal cells
Gastric mucosa; Prostanoids; Radioligand binding; Prostaglandin receptors; Antisecretory potency (Hennies, S. (218) 303)

Parkinsonism
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Terguride; Dopamine D_2 receptors (mixed agonist/antagonist); (Common marmoset) (Lange, K.W. (212) 247)

Parkinson's disease
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopamine (Pérez-Otaño, I. (217) 211)

[Met^5]enkephalin; [Leu^5]enkephalin; Neurotensin; Cholecystokinin (CCK); Substance P; 6-Hydroxydopamine (6-OHDA); L-DOPA; (Prolonged treatment) (Taylor, M.D. (219) 183)

Monoamine oxidase inhibitors; L-Deprenyl; Neuroprotective mechanisms (Gerlach, M. (226) 97)

Parotid acinar cells
Carbachol; Diacylglycerol formation; Phosphoinositide hydrolysis; Phosphatidylcholine hydrolysis (Komabayashi, T. (225) 209)

Parotid cells
α_1-Adrenoceptor subtypes; Aging (Villalobos-Molina, R. (226) 129)

Parotid gland
Amitriptyline; Xerostomia; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Salivary glands (Glenert, U. (226) 43)

Parotid glands
Tachykinins; Protein secretion; Substance P; N-terminal part (Rollandy, I. (209) 95)

[^{3}H]Paroxetine binding
5-HT uptake inhibitors; Structure–activity relationship; Brain (rat) (Marcusson, J.O. (215) 191)

Partial agonists
NAN-190; BMY 7378; 5-HT_{1A} receptors; Spare receptors; Receptor theory (Greuel, J.M. (211) 211)

GH_4ZR_7 cells; Cell culture; Anterior pituitary; Prolactin; Dopamine D_2 receptors; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Passive avoidance
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT_{1A} receptors; Memory (Carli, M. (211) 227)

Scopolamine; Acetylcholine; Acetylcholine release; Hippocampus; Choline precursors (Sigala, S. (211) 351)

Nefiracetam (DM-9384); Cholinergic system; Carbon monoxide (CO); Amnesia (delayed); Scopolamine; (Mouse) (Hiramatsu, M. (216) 279)

Passive avoidance learning
Dopamine D_1 receptors; Dopamine D_2 receptors; (Mouse) (Ichihara, K. (213) 243)

Passive avoidance task
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Tacrine; Learning; Memory; CO-induced amnesia; Delayed amnesia; Hypoxia (Yoshida, S. (214) 247)

Patch-clamp
Chlormethiazole; $GABA_A$ receptors; Glycine receptors; Anaesthetics (general); Anticonvulsants (Hales, T.G. (210) 239)

Endothelial cells; VIP receptors; VIP analogs; VIP binding sites; [4-Cl-D-Phe^6,Leu^{17}]VIP (Pasyk, E. (212) 209)

Patch clamp
UMR 106 osteogenic cell line; Ca^{2+} channels; Dihydropyridines (Morain, P. (220) 11)

Ischemia; Metabolic changes; Ventricular cells; 5-Hydroxydecanoate (Notsu, T. (220) 35)

K^+ channels; ATP; Smooth muscle (vascular) (Furspan, P.B. (223) 201)

Ca^{2+} channel; Calmodulin; CGS 9343B; Fura-2 (Neuhaus, R. (226) 183)

Patch clamp technique (whole-cell)
Nitromethylene heterocycle insecticides; 1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI); Insect neuronal type nicotinic acetylcholine receptors; Endplate type nicotinic acetylcholine receptors; Neuronal type nicotinic acetylcholine receptors (Zwart, R. (228) 165)

Patch/slice recording
$GABA_B$ receptors (presynaptic); $GABA_B$ receptors (postsynaptic); Excitatory transmission; Inhibitory transmission (Lovinger, D.M. (211) 337)

Paw edema (mouse)
PAF receptor antagonists; WEB 2170; Anaphylaxis (Amorim, C.Z. (211) 29)

Paw-licking response
Heat intensities (different); Tail-flick response; β-Endorphin; Morphine (Suh, H.H. (213) 337)

[^{3}H]pBC 264
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; (Mouse) (Durieux, C. (209) 185)

PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride)
Dextrorphan; NMDA receptor antagonists (non-competitive); Anticonvulsants; Prepiriform cortex; MK-801 (Roth, J.E. (215) 293)

PC12W
Angiotensin II receptor subtypes; Signal transduction pathways (Leung, K.H. (227) 63)

P450-dependent enzymatic activity
Heterologous expression; Cytochrome P450IA2 (human); CYP1A2 recombinant expression vector; V79 Chinese hamster cells (Wölfel, C. (228) 95)

PDGF (platelet-derived growth factor)
Nitric oxide (NO); TGF-β (transforming growth factor-β); Interleukin-1β; Platelets; Aorta (rat) (Schini, V.B. (216) 379)

(−)-Penbutolol
5-HT_{1A} receptor antagonism; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Synthesis and turnover; 5-HT-like behaviour; Hypothermia (Hjorth, S. (222) 121)

Penile erection
Yawning; Apomorphine; Oxytocin; ACTH (adrenocorticotropin); Excitatory amino acid receptor antagonists (Melis, M.R. (220) 43)

Pentagastrin
Gastric acid; Endotoxin; PAF (platelet-activating factor, PAF-acether); Nitric oxide (NO) (Martinez-Cuesta, M.A. (218) 351)

Pentazocine
Cough reflex; σ-Sites; Antitussive effects; (+)-SK&F 10,047; DTG (1,2-di-(2-tolyl)guanidine); Dextromethorphan (Kamei, J. (224) 39)

(+)-Pentazocine
σ Receptors; Brain (guinea pig); Radioreceptor assay (DeHaven-Hudkins, D.L. (227) 371)

Pentobarbital
Apomorphine; 6-Hydroxydopamine (6-OHDA); Rotational behaviour; Conditioned drug effects; Drug discrimination (Silverman, P.B. (212) 165)

Antinociception; Tail-flick inhibition; Morphine; β-Endorphin; Pain controls (descending) (Tseng, L.F. (214) 175)

Punishment; Fixed-interval responding; Diazepam; Phencyclidine; Tolerance; (Pigeon) (McMillan, D.E. (215) 145)

Emotionality; GABA (γ-aminobutyric acid); Diazepam; Cl^- flux; (Mouse) (Mihic, S.J. (218) 283)

Aminooxyacetic acid; GABA (γ-aminobutyric acid); Learning; Seizures; Substance P (Vécsei, L. (220) 259)

Substance P; Inositol phosphates; Spinal cord; Cerebral cortex; Anesthesia (Hasséssian, H. (227) 103)

Pentylenetetrazole
Absence seizures; Epilepsy; $GABA_A$ receptors; $GABA_B$ receptors; γ-Hydroxybutyric acid (Snead, III, O.C. (213) 343)

NMDA (N-methyl-D-aspartate); Pregnenolone sulfate; Seizure; (Mouse) (Maione, S. (219) 477)

Xanthines; Seizures; EEG (electroencephalogram); Adenosine (Cutrufo, C. (222) 1)

Peptidase inhibitors
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

Peptide bond (reduced)
JMV 449; Pseudopeptide neurotensin analogue; Hypothermia; Analgesia; (Potent and long-lasting agonist) (Dubuc, I. (219) 327)

Peptide degradation
F8Famide; F8Famide binding sites; Morphine analgesia (Gicquel, S. (222) 61)

Peptide ion channel
Antibacterial peptide; Artificial bilayer; Ion channel reconstitution (Cruciani, R.A. (226) 287)

Peptides
Aging; Cerebral cortex; Muscarinic receptors; Phosphoinositides; (Rat) (Pedigo, Jr., N.W. (225) 151)

Perforant path stimulation
Long-term potentiation (LTP); Cognition enhancers; Hippocampus; Dentate gyrus; (Rat); (In vivo) (Molnár, P. (215) 17)

Periaqueductal grey
Pain; Spinal cord; Morphine; Descending inhibitory controls (Bouhassira, D. (216) 149)

Perioral dyskinesia
Dopamine D_1 receptors; Dopamine D_2 receptors; Adenosine receptors; (Rabbit) (Caporali, M.G. (223) 15)

Peripheral arteries
Endothelin-1; Cerebral arteries; Vasoconstriction; Ca^{2+} influx; Nifedipine; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Peripheral bands
Endothelial cells; Histamine; Histamine H_1 receptors; Actin filaments; Permeability (Niimi, N. (221) 325)

Peripheral benzodiazepine receptors
Gliomas (human); Tumor models (rat); AA tumor; C6 gliomas (Takada, A. (228) 131)

Peritoneal cells (rat)
Phagocytosis (bacterial); Eicosanoids; Indomethacin; CR1 receptors; Fc receptors (Coquette, A. (226) 1)

Permeability
Endothelial cells; Histamine; Histamine H_1 receptors; Actin filaments; Peripheral bands (Niimi, N. (221) 325)

Peroxidase
$^{125}I^-$ ion binding; Autoradiography; Eosinophils; Trachea (guinea-pig) (Rigby, P.J. (228) 141)

Pertussis toxin
Bronchoconstriction; fMLP (formyl-L-methionyl-L-leucyl-L-phenylalanine); Histamine; Hyperreactivity (Imaizumi, A. (212) 177)

Plasminogen activator (tissue-type); Von Willebrand factor; Endothelial cell secretion; Phospholipase C; Cytochrome P-450 (Tranquille, N. (213) 285)

G-proteins; Capsaicin-sensitive neurones; Atrium (guinea-pig) (Amerini, S. (216) 445)

Pancreas (isolated, rat); Insulin secretion; Adrenaline; α_2-Adrenoceptors (Hillaire-Buys, D. (218) 359)

Morphine; Neurotensin; Body temperature (Basilico, L. (222) 241)

Petit-mal
ucb L059; Convulsions; Epileptogenesis; Epilepsy (Gower, A.J. (222) 193)

PET (human brain)
Dopamine D_2 receptors; Dopamine receptor antagonist ligands (Seeman, P. (227) 139)

PET (positron emission tomography)
Benzodiazepine receptors; Flumazenil (Abadie, P. (213) 107)

Muscarinic receptors (central); [^{11}C]Quinuclidinyl benzilate ([^{11}C] QNB); (Baboon) (Varastet, M. (213) 275)

Benzodiazepine receptors; [^{18}F]FEF (5-(2′-[^{18}F]Fluoroethyl)flumazenil); Imaging; Flumazenil; Neuroreceptors (Moerlein, S.M. (218) 109)

β-Adrenoceptors; Cardiac imaging; CGP 12177; CGP 26505; CGP 20712A (Van Waarde, A. (222) 107)

δ-Opioid receptors; Naltrindole (Lever, J.R. (216) 459)

Pfeiffer's rule
Muscarinic receptors; Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Stereoselectivity; Receptor interaction (Waelbroeck, M. (227) 33)

Phagocytosis (bacterial)
Peritoneal cells (rat); Eicosanoids; Indomethacin; CR1 receptors; Fc receptors (Coquette, A. (226) 1)

Pharmacokinetics
Mexiletine; Antiarrhythmic actions; Ischaemic arrhythmias; Convulsions (Igwemezie, L.N. (210) 271)

Pharmacokinetics (cerebral)
Amoxapine; Dopamine; DOPAC (3,4-dihydroxyphenylacetic acid); Homovanillic acid (HVA) (Kobayashi, A. (215) 43)

Phasic and tonic responses
Smooth muscle; Ca^{2+}; Acetylcholine; A23187; IP_3 (inositol trisphosphate) (Macara, B. (218) 27)

pH dependency
Thromboxane A_2; Thromboxane A_2 receptor antagonist; Thromboxane A_2 receptor agonist; Radioligand binding; Platelet membranes (human); BAY U 3405 (Theis, J.G.W. (226) 149)

Phencyclidine
σ Receptors; DTG (1,3-di(2-tolyl)guanidine); SK&F 10047 (Dumont, M. (209) 245)

Punishment; Fixed-interval responding; Diazepam; Pentobarbital; Tolerance; (Pigeon) (McMillan, D.E. (215) 145)

NMDA receptor antagonists; Ventral tegmental area; A10 neurons (French, E.D. (217) 1)

BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine; Single unit recording; Locus coeruleus; Reserpine (Chergui, K. (219) 169)

Ethanol; NMDA receptor antagonism; NPC 12626; Drug discrimination (Balster, R.L. (222) 39)

Phenobarbital
Cytochrome P-450; σ Receptors; 3-Methylcholanthrene (Basile, A.S. (227) 95)

Phenol
Immunotoxicology; Neurotoxicity; Brain biogenic amines; (Mouse) (Hsieh, G.-C. (228) 107)

Phenothiazines
Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Phenoxybenzamine
Sympatho-inhibition; Prazosin; Rauwolscine; Nerve stimulation (peripheral); Hypothalamic stimulation (Koss, M.C. (211) 61)

Epinephrine; Glucose; Memory; Propranolol; Footshock (Hall, J.L. (221) 365)

Lithium chloride; cAMP; Norepinephrine; Isoprenaline; Propranolol (Mármol, F. (226) 93)

Phentolamine
α-Adrenoceptors; Pinacidil; Cromakalim; K^+ channels; Trachea (Bang, L. (211) 235)

Micturition; Methysergide; Prazosin; (Cat) (Espey, M.J. (221) 167)

Phenylbiguanide
Cardiac sympathetic afferents; 5-HT_3 receptors; Spinothalamic tract; Spinoreticular tract (Blair, R.W. (216) 119)

Phenylephrine
Clonidine; Sinoaortic denervation; Cardiovascular response; (Conscious rat); (Intracerebroventricular) (Ricci, D. (212) 195)

Acetylcholine; Baroreflexes; Nitroprusside; N-Nitro-L-arginine; Vasodilatation; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

2-Phenylethylamine
2-Phenylethylamine binding sites; MAO (monoamine oxidase); MAO (monoamine oxidase) inhibitor; Pargyline; (−)-Deprenyl (Li, X.-M. (210) 189)

2-Phenylethylamine binding sites
2-Phenylethylamine; MAO (monoamine oxidase); MAO (monoamine oxidase) inhibitor; Pargyline; (−)-Deprenyl (Li, X.-M. (210) 189)

8-Phenyltheophylline
Atrium (left, dog); Adenosine receptors; DPCPX (1,3-dipropyl-8-cyclopentylxanthine); N-0861 (N^6-endonorbornan-2-yl-9-methyladenine) (Martin, P.L. (214) 199)

Adenosine receptors; Adenosine analogues; Aorta (guinea-pig) (Martin, P.L. (216) 235)

Pheochromocytoma PC12 cells
ATP; Ion channels; Dopamine; Dopamine receptor agonists; Dopamine receptor antagonists (Inoue, K. (215) 321)

Philanthotoxin-343
Hippocampus; Glutamate; NMDA receptors; AMPA/kainate receptors; Polyamines (Fedorov, N.B. (228) 201)

PHNO ((+)-4-propyl-9-hydroxynaphthoxazine)
Circadian rhythms; Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Sensitization; Tolerance; SKF 38393 (Martin-Iverson, M.T. (215) 119)

Phorbol 12,13-dibutyrate
Phorbol 12-myristate,13-acetate; Protein kinase C; Epilepsy; Behaviour; Staurosporine (Smith, S.E. (213) 133)

Phorbol esters
Vas deferens (rat); Protein kinase C; α_1-Adrenoceptors (Abraham, S.T. (218) 243)

Protein kinase C; Bladder; Urethra (Yoshida, M. (222) 205)

Adenosine receptors; Adenylyl cyclase; Gene transcription; T-lymphocytes (Kontny, E. (227) 333)

Smooth muscle (vascular); Ca^{2+}; Protein kinase C activity (cytosolic, particulate) (Bazan, E. (227) 343)

Phorbol 12-myristate,13-acetate
Phorbol 12,13-dibutyrate; Protein kinase C; Epilepsy; Behaviour; Staurosporine (Smith, S.E. (213) 133)

Phorone
ATP depletion; GSH depletion; Diethyl maleate; Ethacrynic acid; Hepatocytes (Redegeld, F.A.M. (228) 229)

Phosphatidylcholine
Angiotensin II; Angiotensin AT_1 receptor; Phospholipase D; Diacylglycerol; Mesangial cells (Pfeilschifter, J. (225) 57)

Phosphatidylcholine hydrolysis
Parotid acinar cells; Carbachol; Diacylglycerol formation; Phosphoinositide hydrolysis (Komabayashi, T. (225) 209)

Phosphodiesterase activity
ANP (atrial natriuretic polypeptide); Aorta (rat); Relaxation; Aging; Endothelium; cGMP (Moritoki, H. (210) 61)

Phosphodiesterase III
Phosphodiesterase IV; Cardiac ventricles; Cardiotonic; Rolipram; (Guinea pig) (Muller, B. (225) 263)

Phosphodiesterase inhibitors
Pancreas (dog); Exocrine secretion; Rolipram (Iwatsuki, K. (209) 63)

Nitroglycerin; Nitroprusside; Tolerance; Coronary artery (porcine); Zaprinast (Merkel, L.A. (216) 29)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide (Baidan, L.V. (225) 21)

Forskolin; 1,9-Dideoxyforskolin; Adenosine; Inward calcium current-dependent phasic tension; Atrial fibres (frog) (Gauthier, C. (225) 129)

Phosphodiesterase isoenzymes
Cardiac muscle; Smooth muscle (aortic); Flosequinan; BTS 53 554; (Guinea-pig) (Frodsham, G. (211) 383)

Phosphodiesterase IV
Phosphodiesterase III; Cardiac ventricles; Cardiotonic; Rolipram; (Guinea pig) (Muller, B. (225) 263)

Phosphoinositide hydrolysis
$5\text{-}HT_2$ receptors; Forced swimming test; Mianserin; Imipramine; Affective disorders (Kawanami, T. (216) 385)

Parotid acinar cells; Carbachol; Diacylglycerol formation; Phosphatidylcholine hydrolysis (Komabayashi, T. (225) 209)

Electroconvulsive shock; Brain (rat); α_1-Adrenoceptors; $5\text{-}HT_2$ receptors (Pandey, G.N. (226) 303)

Phosphoinositide (IP_3)
Lithium chloride; Analgesia (Raffa, R.B. (215) 357)

Phosphoinositide (PI) hydrolysis
Vasopressin; α_1-Adrenoceptors; Endothelin; Nonpeptide V_1 receptor antagonists; Ventricular myocardium (rabbit) (Endoh, M. (218) 355)

Phosphoinositides
Aging; Cerebral cortex; Muscarinic receptors; Peptides; (Rat) (Pedigo, Jr., N.W. (225) 151)

Muscarinic receptor subtype; T84 cell; Colonic epithelial cell; Arachidonic acid (Dickinson, K.E.J. (225) 291)

Ipriflavone; UMR-106 cells; $^{45}Ca^{2+}$ uptake (Sortino, M.A. (226) 273)

Dopamine receptors; Inositol phosphates; Striatum (rat); α-Adrenoceptors; 5-HT receptors (Undie, A.S. (226) 297)

SR 95639A; Muscarinic receptor agonists (selective); Muscarinic receptor subtypes; cAMP; Acetylcholine release (Mohamed, A.S. (227) 181)

Phosphoinositide signalling system
Smooth muscle cells; Losartan; Hypertrophy (Ko, Y. (227) 215)

Phosphoinositide turnover
5-HT receptors; Hippocampus (immature rat) (Claustre, Y. (225) 37)

DNA synthesis; α-Thrombin; Neuroblastoma (Ogino, Y. (225) 299)

Adrenoceptors; α_{1A}-Adrenoceptors; Phosphorylase (García-Sáinz, J.A. (227) 239)

Phospholamban
Protein kinase C; Heart; Protein (15 kDa) (Hartmann, M. (226) 225)

Phospholipase A_2
Lung (guinea-pig); Pancreatic phospholipase A_2 (porcine) (Sommers, C.D. (216) 87)

Tamoxifen; Oviduct; Cell proliferation (Fayard, J.-M. (216) 127)

Bradykinin; Angiotensin-converting enzyme; Smooth muscle; Lipoxygenase; Cyclic nucleotides (Rodrigues, M.S. (216) 357)

Neutrophils; Arachidonic acid; PAF (platelet-activating factor, PAF-acether); Staurosporine (Müller, S. (218) 251)

NMDA (N-methyl-D-aspartate); Cortical neurons; Arachidonic acid; Somatostatin (Tapia-Arancibia, L. (225) 253)

Phospholipase C
Plasminogen activator (tissue-type); Von Willebrand factor; Endothelial cell secretion; Cytochrome P-450; Pertussis toxin (Tranquille, N. (213) 285)

Endothelin receptors; Guanine nucleotide binding proteins (Gusovsky, F. (225) 339)

α_1-Adrenoceptor; Membrane lipids; Phospholipases; Phospholipids; Aorta (Shreeve, S.M. (226) 29)

Phospholipase D
Angiotensin II; Angiotensin AT_1 receptor; Phosphatidylcholine; Diacylglycerol; Mesangial cells (Pfeilschifter, J. (225) 57)

Phospholipases
α_1-Adrenoceptor; Membrane lipids; Phospholipase C; Phospholipids; Aorta (Shreeve, S.M. (226) 29)

Phospholipids
α_1-Adrenoceptor; Membrane lipids; Phospholipases; Phospholipase C; Aorta (Shreeve, S.M. (226) 29)

Phosphoramidon
Doppler shift technique; Kidney (isolated, perfused); Renal vascular resistance; Metalloproteases; (Rat) (Salvati, P. (221) 267)

Phosphorothioate
Striatum; Immediate-early genes (Chiasson, B.J. (227) 451)

Phosphorylase
Adrenoceptors; α_{1A}-Adrenoceptors; Phosphoinositide turnover (García-Sáinz, J.A. (227) 239)

Photoaffinity labelling
Bumetanide transport; Loop diuretics; Sinusoidal plasma membrane (rat liver); Integral plasma membrane proteins; Two-dimensional gel electrophoresis (Honscha, W. (226) 215)

Thromboxane A_2 receptors; Receptors (Mais, D.E. (227) 267)

Phrenic nerve
K^+-stimulated Ca^{2+}-independent efflux of [^{3}H]acetylcholine; Cholinesterase inhibition; Vesamicol; Acetylcholine carrier (Wessler, I. (221) 371)

N-Phthaloyl γ-aminobutyric acid
Aspirin ulcer; Ethanol ulcer; Gastric acid secretion; Mucus secretion (Banerji, S. (219) 211)

Physical dependence
Opioid interactions; Morphine; Analgesic tolerance; Nor-binaltorphimine (nor-BNI) (Suzuki, T. (213) 91)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Naloxone; (Systemic administration) (Noble, F. (223) 91)

Physostigmine
ATP; Cerebral vasodilatation; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

Acetylcholine; Electrical field stimulation; Epithelium-derived acetylcholinesterase; EpDRF (epithelium-derived relaxing factor); Trachealis muscle (guinea-pig) (Koga, Y. (220) 141)

Velnacrine; Tacrine; Anticholinesterase agents; Neuromuscular junction; Twitch response; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Phytic acid
Vasomotor neurons; Inositol hexakisphosphate; Medulla (rostral ventrolateral) (Sun, M.-k. (215) 9)

Picrotoxin
Ethanol; Locus coeruleus; GABA (γ-aminobutyric acid); Benzodiazepine; Ro 15-1788; Electrophysiology (Verbanck, P.M.P. (211) 15)

Picrotoxin-induced convulsions
Dihydroergotoxine; [^{3}H]TBOB (t-[^{3}H]butylbicycloorthobenzoate) binding; GABA (γ-aminobutyric acid) shift; Barbiturate sleeping (Tvrdeić, A. (221) 139)

Pigment aggregation
Melatonin; Melatonin receptor antagonists; *Xenopus* melanophores; Luzindole (Sugden, D. (213) 405)

Pilocarpine
GABA (γ-aminobutyric acid); Bicuculline; Diazepam; Lithium chloride; Seizures (Peterson, C.J. (221) 151)

Hippocampus; SK&F 38393; SCH 23390; Motor seizures (Alam, A.M. (222) 227)

Pinacidil
Phentolamine; α-Adrenoceptors; Cromakalim; K^+ channels; Trachea (Bang, L. (211) 235)

Gastric fundus; BRL 38227 (lemakalim); Non-adrenergic non-cholinergic neurostimulation; K^+ channels; (Rat) (Lefebvre, R.A. (214) 1)

Pindolol
Ischemia; Reperfusion; Cardioprotection; Sympathomimetic activity (intrinsic); (Rat) (Nasa, Y. (213) 171)

Methionine sulfoximine; Hypothermia; Propranolol; Ketanserin; Betaxolol; ICI 118,551; 5-HT_1 receptors (Ginefri-Gayet, M. (217) 85)

β-Adrenoceptor antagonists; 5-HT receptors; 5-HT_{1A} receptors; Migraine; Propranolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

(±)-Pindolol
5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; Prazosin; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

Pineal
Adenosine receptors; AMP (Gharib, A. (225) 359)

1-Piperonylpiperazine
MDMA (3,4-methylenedioxymethamphetamine); 5-HT uptake inhibitor; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain (rat) (Hashimoto, K. (228) 171)

Pirenzepine
Muscarinic receptors; Parasympathetic nervous system; Lung resistance; Gallamine; (Cat) (Killingsworth, C.R. (210) 231)

Pirsidomine
IS-5-MN (isosorbide-5-mononitrate); Hemodynamics; Tolerance; (Dog) (Bohn, H. (220) 71)

Pituitary
Ca^{2+}; Action potentials; Protein kinase A; Protein kinase C; Okadaic acid (Chiavaroli, C. (227) 173)

Pizotifen
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Vas deferens (rabbit); Cyproheptadine; Ketotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

PK 11195
Ro 5-4864; Duodenum; Vas deferens; (Rat) (Escubedo, E. (225) 15)

Placental vein (human)
5-HT (5-hydroxytryptamine, serotonin); Na^+,K^+-ATPase; $^{86}Rb^+$ uptake (Fernández-Alfonso, M.S. (221) 185)

Place preference
Cocaine; Naltrindole (Menkens, K. (219) 345)

Plasma
21-Aminosteroids; Antioxidants; Lipid peroxidation; Copper; Erythrocytes (Fernandes, A.C. (220) 211)

Plasma catecholamines
β_2-Adrenoceptors (presynaptic); Portal vein; Spontaneously hypertensive rat (SHR); α_2-Adrenoceptors (presynaptic); (Freely moving rat) (Remie, R. (211) 257)

Plasma extravasation
Neurogenic inflammation; Substance P antagonists; Tachykinins; Capsaicin; Pain (Nagahisa, A. (217) 191)

Cigarette smoke; Tachykinin receptor antagonists; Trachea; (Rat) (Morimoto, H. (224) 1)

Plasma exudation
Aging; Airway obstruction; Asthma; Oedema; Histamine; Substance P; Vascular permeability (Arakawa, H. (215) 51)

Nitric oxide (NO); Neurogenic inflammation; NANC nerves; Vagus nerve; Airways (Kuo, H.-P. (221) 385)

Plasma glucose
Efaroxan; Glibenclamide; Plasma insulin (Berridge, T.L. (213) 213)

Plasma insulin
Efaroxan; Glibenclamide; Plasma glucose (Berridge, T.L. (213) 213)

Plasma protein extravasation
(±)-CP-96,345; Neurogenic inflammation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

Plasma renin activity
5-HT receptor agonists; 5-HT receptor antagonists; Blood pressure; Vasopressin; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

Plasminogen activator (tissue-type)
Von Willebrand factor; Endothelial cell secretion; Phospholipase C; Cytochrome P-450; Pertussis toxin (Tranquille, N. (213) 285)

Platelet aggregation
Aldose reductase inhibitors; Diabetes; (Rat) (Takiguchi, Y. (215) 289)

Arrhythmias, Coronary artery occlusion; Myocardial ischaemia; Reperfusion; 5-HT receptor antagonists (Ellis, A.M. (219) 97)

Endothelin; 5-HT (5-hydroxytryptamine, serotonin); Ca^{2+} mobilization (Pietraszek, M.H. (219) 289)

Cloricromene; Antiplatelet compounds; Polymorphonuclear cells (Mollace, V. (222) 181)

Platelet membranes (human)
Thromboxane A_2; Thromboxane A_2 receptor antagonist; Thromboxane A_2 receptor agonist; pH dependency; Radioligand binding; BAY U 3405 (Theis, J.G.W. (226) 149)

Platelets
Nitric oxide (NO); PDGF (platelet-derived growth factor); TGF-β (transforming growth factor-β); Interleukin-1β; Aorta (rat) (Schini, V.B. (216) 379)

Heparin; Neutrophils; Cathepsin G (Evangelista, V. (216) 401)

Platelets (human)
α_{2A}-Adrenoceptors; α_{2D}-Adrenoceptors; α_2-Adrenoceptors (prejunctional); Submandibular gland (rat); Vas deferens (rat) (Smith, K. (219) 203)

Adenylate cyclase; 5-HT (5-hydroxytryptamine, serotonin) (Newman, M.E. (226) 281)

Platelets (human)
Opioids; α_2-Adrenoceptors (Ballesta, J.J. (227) 349)

Platelets (radioligand binding)
Thromboxane A_2 receptors; Glomeruli; Inositol phosphates (Folger, W.H. (227) 71)

PLC-PRF-5
Angiotensin II receptors; Hepatoma cells; (Radioligand binding); (Receptor subtypes) (Wintersgill, H.P. (227) 283)

Pleurisy (rat)
Cetirizine; Allergen; Leucocyte recruitment (Pasquale, C.P. (223) 9)

PMSG-primed immature rat
Inhibin; Oestradiol-17β; Indomethacin; Gonadotrophin; Prostaglandin $F_{2\alpha}$; Ovary (Kogo, H. (221) 289)

PN200-110
Ca^{2+} channel antagonists; Diltiazem; Verapamil; Allosteric regulation (Miwa, K. (214) 127)

Polyamines
NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

NMDA (N-methyl-D-aspartate); Dopamine; Brain slices; Ifenprodil; SL 82.0715 (Woodward, J.J. (210) 265)

[^{3}H]Nitrendipine binding; [^{3}H]Diltiazem binding; Cerebral cortex (rat); Cooperative effects (Schoemaker, H. (225) 167)

NMDA receptor; [^{125}I]Thienylphencyclidine (Reynolds, I.J. (226) 53)

[^{3}H]CPP ([^{3}H]3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) binding; NMDA receptors; HA-966; Glycine (Porter, R.H.P. (227) 83)

Philanthotoxin-343; Hippocampus; Glutamate; NMDA receptors; AMPA/kainate receptors (Fedorov, N.B. (228) 201)

Polyarthritic rat
Joint inflammation; Pain (chronic); Autoradiography (quantitative); Opioid receptor regulation (Besse, D. (223) 123)

Polychlorinated biphenyls (PCBs)
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Polychlorinated dibenzofurans (PCDFs)
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Polychlorinated dibenzo-p-dioxins (PCDDs)
Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Polymerase chain reaction
Adenosine A_1 receptors; Spontaneously hypertensive rat (SHR) (Ungerer, M. (226) 381)

NMDA receptor mRNA; NMDA receptor antagonists (Lesch, K.P. (227) 109)

G proteins; mRNA expression; Fluoxetine (Lesch, K.P. (227) 233)

Estrogen receptors; (Sprague-Dawley rat) (Spreafico, E. (227) 353)

Polymorphonuclear cells
Cloricromene; Platelet aggregation; Antiplatelet compounds (Mollace, V. (222) 181)

Polymorphonuclear leukocytes
Acetylcholine; EDRF (endothelium-derived relaxing factor); Lipopolysaccharide; Mesenteric artery (superior); Nitric oxide (NO) (Siegfried, M.R. (212) 171)

Endothelin; Aggregation; PAF (platelet-activating factor, PAF-acether) (Gómez-Garre, D. (224) 167)

Poly(rG)·Poly(rC)
Poly(rI)·Poly(rC); Interferon inducer; Antitumour activity; Liver colony assay; Survival (Jurásková, V. (221) 107)

Poly(rI)·Poly(rC)
Poly(rG)·Poly(rC); Interferon inducer; Antitumour activity; Liver colony assay; Survival (Jurásková, V. (221) 107)

Portal vein
β_2-Adrenoceptors (presynaptic); Spontaneously hypertensive rat (SHR); α_2-Adrenoceptors (presynaptic); Plasma catecholamines; (Freely moving rat) (Remie, R. (211) 257)

Thyroxine; β-Adrenoceptors; Noradrenaline; Fenoterol; Atenolol; ICI 118,551 (Chin, J.P.F. (212) 201)

Antihypertensives; A-80b; Vasodilators; Ca^{2+}; Aorta (Frechilla, D. (219) 409)

Portal vein (rat)
α-Adrenoceptor antagonists; K^+ channels (Schwietert, R. (211) 87)

Nicorandil; Imidazoline; K^+ channels (Okumura, K. (215) 253)

Positive inotropic effect
(+)-Niguldipine; α_{1A}-Adrenoceptors; [^{3}H]Prazosin binding; Ventricular myocardium (rabbit) (Endoh, M. (223) 143)

Posterior hypothalamic nucleus
Carbachol; Muscarinic receptor antagonists; (Rat) (Martin, J.R. (215) 83)

^{32}P-Postlabeling assay
Diesel-2 (exposure); Crude oil (exposure); DNA damage; Oil slicks (Kurelec, B. (228) 51)

Postural asymmetry
Dopamine uptake; Striatum; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid)
P_2 purinoceptors (antagonists); Vas deferens (rabbit) (Lambrecht, G. (217) 217)

R(+)-3-PPP (R(+)-3-(3-hydroxyphenyl)-N-(n-propyl)piperidine)
σ Binding sites; DTG (1,3-di-(2-[5-^{3}H]tolyl)guanidine) (Codd, E.E. (217) 149)

P_2 purinoceptor agonists
Ventricular papillary muscle; Contractile force; Action potentials; K^+ channel openers; Sulfonylurea antidiabetics (Bott, A. (213) 141)

P_2 purinoceptors
ATP; Suramin; Locus coeruleus neurones; Firing rate (Tschöpl, M. (213) 71)

Vas deferens (guinea-pig); Ca^{2+}-related inward currents; AMP-PNP (5′-adenylylimidophosphate) (Inomata, H. (217) 93)

Vas deferens; Suramin; Purinergic neurotransmission (Mallard, N. (220) 1)

Suramin; ATP; Hepatocytes; (Rat) (Tomura, H. (226) 363)

cAMP; Smooth muscle cells (vascular) (Tada, S. (227) 25)

P_{2X} purinoceptors
[^{3}H]α,β-Methylene ATP; Urinary bladder; Urethra (Bo, X. (216) 59)

P_2 purinoceptors (antagonists)
PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid); Vas deferens (rabbit) (Lambrecht, G. (217) 217)

Pramipexole (SND 919)
Dopamine receptors (presynaptic, postsynaptic); (Rat); (Monkey) (Mierau, J. (215) 161)

Prazosin
Sympatho-inhibition; Rauwolscine; Phenoxybenzamine; Nerve stimulation (peripheral); Hypothalamic stimulation (Koss, M.C. (211) 61)

α_2-Adrenoceptors; α_{2A}-Adrenoceptors; α_{2B}-Adrenoceptors; ARC 239 (Smith, K. (211) 251)

Efaroxan; Idazoxan; Vas deferens; Anococcygeus; Glucose homeostasis; (Pithed rat) (Berridge, T.L. (213) 205)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Eltoprazine; RU 24969; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

Micturition; Methysergide; Phentolamine; (Cat) (Espey, M.J. (221) 167)

α-Adrenoceptors; Receptor reconstitution; Detergent solubilization; Receptor conformation (Valliere, J.E. (226) 191)

[^{3}H]Prazosin binding
(+)-Niguldipine; α_{1A}-Adrenoceptors; Positive inotropic effect; Ventricular myocardium (rabbit) (Endoh, M. (223) 143)

5α-Pregnane-3α-20α-diol (5α-pregnanediol)
RU 5135; $GABA_A$ receptor complex; 5α-Pregnane-3α-ol-20-one (3α,5α-P); $GABA_A$ receptor antagonism; Neurosteroid site (Cadoni, C. (227) 147)

5α-Pregnane-3α-ol-20-one (3α,5α-P)
RU 5135; $GABA_A$ receptor complex; 5α-Pregnane-3α-20α-diol (5α-pregnanediol); $GABA_A$ receptor antagonism; Neurosteroid site (Cadoni, C. (227) 147)

Pregnenolone sulfate
NMDA (N-methyl-D-aspartate); Pentylenetetrazole; Seizure; (Mouse) (Maione, S. (219) 477)

Prepiriform cortex
Dextrorphan; NMDA receptor antagonists (non-competitive); Anticonvulsants; PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride); MK-801 (Roth, J.E. (215) 293)

Pressure
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Endothelial cells; Mechanoreceptors; Hypertension (Hishikawa, K. (215) 329)

Presynaptic inhibition
Noradrenaline; Neuronal reuptake; α-Adrenoceptors; Heart (rat) (Du, X.-J. (211) 221)

Progabide
Tardive dyskinesia; Vacuous chewing movements; Haloperidol (chronic) (Kaneda, H. (212) 43)

Progesterone
Coronary artery relaxation; Endothelium; Ca^{2+} influx; K^+ conductance (Jiang, C. (211) 163)

Histamine receptors; Uterus (rat); Ovarian steroids; Oestrogen (Rubio, E. (212) 31)

Proglumide
Gastrin receptor antagonists; CCK receptor antagonists; Gastric antisecretory activity; Lorglumide (Revel, L. (216) 217)

Prolactin
GH_4ZR_7 cells; Cell culture; Anterior pituitary; Dopamine D_2 receptors; Partial agonists; Transdihydrolisuride; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Glipizide; Somatostatin (Fosset, M. (220) 273)

Cocaine; 5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropic hormone); Oxytocin; Renin (Levy, A.D. (221) 121)

Smooth muscle (vascular); Gene expression; Hypertension; c-myc; Ornithine decarboxylase (Sauro, M.D. (225) 351)

Proliferation
Heparin derivatives; Smooth muscle cells; Differentiation; Actin (Bârzu, T. (219) 225)

Proline
Hippocampus; NMDA (N-methyl-D-aspartate); Excitatory amino acids (Martin, D. (219) 59)

Propofol
Ion channels; Myelinated nerve fibre; Voltage-clamp experiment; Anaesthetics (intravenous) (Veintemilla, F. (218) 59)

Propranolol
Noradrenaline; Muscimol; Food intake; Environment (hot) (Kurose, Y. (211) 39)

Atrium; Dopamine-β-hydroxylase (lung); Noradrenaline; Catecholamines (Elayan, H. (212) 259)

β-Adrenoceptor antagonists; Atenolol; Indenolol; Nadolol; Mitochondrial ATPase activity (Almotrefi, A.A. (215) 231)

Methionine sulfoximine; Hypothermia; Pindolol; Ketanserin; Betaxolol; ICI 118,551; $5\text{-}HT_1$ receptors (Ginefri-Gayet, M. (217) 85)

β-Adrenoceptor antagonists; 5-HT receptors; $5\text{-}HT_{1A}$ receptors; Migraine; Pindolol; Tertatolol; (Pig) (Saxena, P.R. (220) 79)

Epinephrine; Glucose; Memory; Phenoxybenzamine; Footshock (Hall, J.L. (221) 365)

Lithium chloride; cAMP; Norepinephrine; Isoprenaline; Phenoxybenzamine (Mármol, F. (226) 93)

DL-Propranolol
Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); N^G-Nitro-L-arginine; CHAPS (3-3 cholamidopropyl dimethylammonium 1-propane sulphonate); Hindquarters (rat) (Mota-Filipe, H. (213) 227)

Prostacyclin
Thromboxane A_2; Streptozotocin-induced diabetes; Diabetic microangiopathy; Thromboxane synthetase inhibitors (Masumura, H. (210) 163)

5-HT (5-hydroxytryptamine, serotonin); Ca^{2+}; Endothelium (Gill, J.K. (214) 269)

Acetylcholine; Nitric oxide (NO); Guanylyl cyclase; Adenylyl cyclase; 5-HT (5-hydroxytryptamine, serotonin); Forskolin; ANF (atrial natriuretic factor) (Heuzé-Joubert, I. (220) 161)

Prostaglandin
K^+ channel opener; NIP-121; Cromakalim; Glibenclamide; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Endotoxin; Gastric acid secretion; Immunopharmacology; Indomethacin; Interleukin-1; Lipopolysaccharide (Tsuji, K. (210) 213)

Interleukin; Insulin; Dexamethasone (Shimizu, H. (222) 279)

Prostaglandin E_2
Indomethacin; Gastric acid secretion; Vagus; Baclofen (Saperas, E. (209) 1)

Endothelin-1; Smooth muscle (vascular); Coronary artery (porcine) (Suzuki, S. (217) 97)

Prostaglandin $F_{2\alpha}$
Inhibin; Oestradiol-17β; Indomethacin; Gonadotrophin; PMSG-primed immature rat; Ovary (Kogo, H. (221) 289)

6-keto-Prostaglandin $F_{1\alpha}$ (immunoreactive)
Y-20811; Thromboxane A_2 synthetase inhibitor; Thrombosis (coronary); Thromboxane B_2 (immunoreactive) (Matsumoto, Y. (213) 167)

Prostaglandin receptors
Gastric mucosa; Prostanoids; Radioligand binding; Parietal cells; Antisecretory potency (Hennies, S. (218) 303)

Prostaglandins
Urinary bladder; Epithelium; Diabetes; Bradykinin (Pinna, C. (214) 143)

Interleukin-1; Interleukin-6; 15-HETE (15-hydroxyeicosatetraenoic acid); Fibroblast (Elliott, G.R. (214) 253)

Anthraquinones; Cathartics; Diarrhoea (Nijs, G. (218) 199)

Nociception; Spinal cord; Formalin; Bradykinin; (Rat) (Chapman, V. (219) 427)

Prostanoid receptor blockers
Hypertension; Prostanoids; Ca^{2+} ionophore A23187; Endothelin (Lin, L. (220) 49)

Prostanoids
Gastric mucosa; Radioligand binding; Prostaglandin receptors; Parietal cells; Antisecretory potency (Hennies, S. (218) 303)

Hypertension; Ca^{2+} ionophore A23187; Endothelin; Prostanoid receptor blockers (Lin, L. (220) 49)

Prostatic contraction
[Arg^8] vasotocin; Oxytocin; [Arg^8] vasopressin (AVP); Neurohypophyseal peptides; Neuropeptides (Bodanszky, M. (216) 311)

Protease inhibitors
Angiotensin receptors; Angiotensin II; Angiotensin III; Smooth muscle cells (Fujimoto, M. (215) 259)

Protein (15 kDa)
Protein kinase C; Heart; Phospholamban (Hartmann, M. (226) 225)

Protein binding
Angiotensin II receptor antagonists; Antihypertensive agents; Renin-angiotensin system (Wong, P.C. (220) 267)

Protein kinase A
Ca^{2+}; Action potentials; Pituitary; Protein kinase C; Okadaic acid (Chiavaroli, C. (227) 173)

Protein kinase C
Spontaneously hypertensive rat (SHR); Smooth muscle (vascular) (Silver, P.J. (212) 143)

Phorbol 12-myristate,13-acetate; Phorbol 12,13-dibutyrate; Epilepsy; Behaviour; Staurosporine (Smith, S.E. (213) 133)

Smooth muscle (vascular); Fluoride; Al^{3+}; G-protein; Ca^{2+} sensitivity (Kawase, T. (214) 39)

Vas deferens (rat); Phorbol esters; α_1-Adrenoceptors (Abraham, S.T. (218) 243)

Bifemelane; Mossy fibers; Glutamate release; H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine); (Guinea-pig) (Ueda, M. (219) 271)

Vanadate; Uterus; Smooth muscle; Ca^{2+}; Ca^{2+}-free (Fukuzaki, A. (220) 99)

Phorbol ester; Bladder; Urethra (Yoshida, M. (222) 205)

Aorta; Noradrenaline; Staurosporine; Calphostin C; Ca^{2+} uptake; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

Neurotransmitter release; Neurosecretory cells; Cytoskeleton; Cytoplasmic proteins; Ca^{2+}; Calmodulin; G-proteins (Trifaró, J.-M. (225) 83)

Histamine H_1 receptor; Desensitization; cGMP; Lung (guinea-pig) (Leurs, R. (225) 137)

Na^+-K^+-ATPase (renal); Streptozotocin diabetes; G-proteins (Chen, C.-C. (225) 275)

Heart; Protein (15 kDa); Phospholamban (Hartmann, M. (226) 225)

Endothelin-1; Inositol 1,4,5-trisphosphate; Flosequinan (Lang, D. (226) 259)

Staurosporine; 12-O-Tetradecanoylphorbol 13-acetate; Ornithine decarboxylase; Epidermal cells (mouse); Morphological changes (Yamamoto, S. (227) 113)

Leukotrienes; Smooth muscles; Pulmonary system; Inositol phosphates; G-Protein (Howard, S. (227) 123)

Trachealis (bovine); Smooth muscle contraction; Cholinomimetics; Bronchodilators (Langlands, J.M. (227) 131)

Ca^{2+}; Action potentials; Pituitary; Protein kinase A; Okadaic acid (Chiavaroli, C. (227) 173)

Norepinephrine; 1,2-Dioctanoylglycerol; Ca^{2+} current; Whole-cell voltage clamp; Sympathetic ganglia (Abrahams, T.P. (227) 189)

Neutrophil; Respiratory burst; Degranulation; Staurosporin; cgp 41251 (Krause, K.-H. (227) 221)

Idazoxan; Antidepressants; β-Adrenoceptors; Adenylyl cyclase; C6 glioma cells (Manji, H.K. (227) 275)

Protein kinase C activity (cytosolic, particulate)
Smooth muscle (vascular); Ca^{2+}; Phorbol esters (Bazan, E. (227) 343)

Protein kinase C
Amnesia; Memory; NMDA (N-methyl-D-aspartate); (Mouse) (Mathis, C. (220) 107)

Protein secretion
Tachykinins; Substance P; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Protein synthesis
Blood vessels; Hyporesponsiveness; Endothelium; Nitric oxide (NO); Lipopolysaccharide (Nakaki, T. (219) 311)

Proteolysis
Neuroprotection; Calpain inhibitor; Hypoxia; Hippocampal slice; (Rat) (Arlinghaus, L. (209) 123)

Proton pump inhibitors
Gastric mucosa blood volume; Gastric mucosa oxygenation; Reflectance spectrophotometry; Hemorrhagic shock; Omeprazole; NC-1300 (Kawano, S. (211) 55)

Pseudopeptide neurotensin analogue
JMV 449; Peptide bond (reduced); Hypothermia; Analgesia; (Potent and long-lasting agonist) (Dubuc, I. (219) 327)

Pt-DNA adducts
Cisplatin; Enzyme-linked immunosorbent assay (ELISA); Epitope; Cultured cells (Vrána, O. (226) 5)

Pulmonary artery (rabbit)
L-N^G-Nitro arginine (L-NO_2Arg); Endothelium; Electrical transmural stimulation; Nitric oxide (NO); Noradrenaline release (Shinozuka, K. (222) 113)

Pulmonary platelet accumulation
PAF-specific; Desensitization; (Rat) (Klee, A. (209) 223)

Pulmonary surfactant
β-Adrenoceptors; Type II pneumocyte (Kai, H. (212) 101)

Pulmonary system
Leukotrienes; Smooth muscles; Inositol phosphates; Protein kinase C; G-Protein (Howard, S. (227) 123)

Pulmonary vascular bed
U46619; Thromboxane A_2/endoperoxide receptor-mediated responses; Sulotroban; Endothelin peptides; PAF (platelet-activating factor, PAF-acether) (Nossaman, B.D. (213) 1)

Punishment
Fixed-interval responding; Diazepam; Pentobarbital; Phencyclidine; Tolerance; (Pigeon) (McMillan, D.E. (215) 145)

Tandospirone; Buspirone; Ipsapirone; Azapirones; Chlordiazepoxide; Anxiolytics; Conflict; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Purification
Dihydropyridine receptors; Ca^{2+} channels; Monoclonal antibodies; Cardiac sarcolemma (Tokumaru, H. (227) 363)

Purinergic nerve stimulation
Blood vessels (rabbit); Co-transmission; Ethanol (Bulloch, J.M. (211) 1)

Purinergic neurotransmission
Vas deferens; Suramin; P_2 purinoceptors (Mallard, N. (220) 1)

Purinoceptors
Bladder; ATP; Neonate; Neurotransmission; Development (Sneddon, P. (214) 7)

Adenosine; Benzodiazepine receptors (peripheral); Trachea (guinea-pig, isolated) (Devillier, P. (214) 67)

Suramin; Neuromuscular blocking agents (non-depolarizing); Succinylcholine; Neuromuscular junction (rat); Striated muscle (Henning, R.H. (216) 73)

Purkinje cells
Metabotropic glutamate receptor; ACPD (1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid); Cerebellum; Granule cells; AP-3 ((L)-2-amino-3-phosphonopropionate) (East, S.J. (219) 395)

Purkinje fibres
Cardiac electrophysiology; Ischaemia; Opioid receptor antagonists (McIntosh, M. (210) 45)

Purkinje neurons
Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Pyramidal neurons (dissociated)
Ca^{2+}-activated K^+ currents; Hippocampus (rat); Single channel recording; Trifluoperazine (Ikemoto, Y. (216) 191)

1-(Pyridin-3-yl-methyl)-2-nitromethylene-imidazolidine (PMNI)
Nitromethylene heterocycle insecticides; Insect neuronal type nicotinic acetylcholine receptors; Endplate type nicotinic acetylcholine receptors; Neuronal type nicotinic acetylcholine receptors; Patch clamp technique (whole-cell) (Zwart, R. (228) 165)

Quantitative autoradiography
Naftidrofuryl oxalate (LS-121); $5\text{-}HT_2$ receptors; 5-Hydroxytryptophan (5-HTP); Head-twitch response; (Mouse) (Nabeshima, T. (223) 109)

Quinacainol
Antiarrhythmics; Ischaemic arrhythmias; Electrophysiological actions (Howard, P.G. (219) 1)

Quinacrine
Amiloride; 3,4-Dichlorobenzamil; Ca^{2+}; Ca^{2+} channel blockers; L-type Ca^{2+} channels (Stokke, M. (227) 379)

Quinolinic acid
Memantine; Neurodegeneration; Hippocampus (Keilhoff, G. (219) 451)

Learning deficit; D-Cycloserine (Schuster, G.M. (224) 97)

Quinolinone oxime sulfonic acids
M12285; Loop diuretics; Sulfate conjugation (Shinkawa, T. (219) 217)

Quinoxalinedione
AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionate; Epilepsy; Seizure; Ataxia (Taylor, C.P. (213) 151)

Quinoxalinediones
Xenopus oocytes (rat cortex mRNA-injected); Hippocampal slices (Randle, J.C.R. (215) 237)

Quinpirole
Antinociception; Dopamine; Receptor sensitization (Kostrzewa, R.M. (209) 157)

Dopamine; Locomotion; Dopamine D_2 receptors; (Rat) (Van Hartesveldt, C. (214) 27)

Down-regulation; Triazolam; GABA (γ-aminobutyric acid); Dopamine receptors; 6-Hydroxydopamine (6-OHDA) (Zhou, L.-W. (218) 219)

Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY); Novelty-induced grooming behaviour; SCH 23390; Dopamine receptors (Linthorst, A.C.E. (219) 23)

3-Quinuclidinyl atrolactate stereoisomers
Muscarinic receptor subtypes; Stereoselectivity; 3-Quinuclidinyl xanthene-9-carboxylate enantiomers; Cystometrogram (Noronha-Blob, L. (211) 97)

[^{11}C]Quinuclidinyl benzilate
Muscarinic receptors (central); PET (positron emission tomography); (Baboon) (Varastet, M. (213) 275)

[^{3}H]Quinuclidinyl benzilate binding
Doxorubicin; Adriamycin; Heart muscle preparations (isolated); Acetylcholine receptors; Antimuscarinic actions (Temma, K. (220) 63)

3-Quinuclidinyl xanthene-9-carboxylate enantiomers
Muscarinic receptor subtypes; Stereoselectivity; 3-Quinuclidinyl atrolactate stereoisomers; Cystometrogram (Noronha-Blob, L. (211) 97)

Quipazine
L-Glutamate; Subretrofacial nucleus; Caudal ventrolateral medulla; Lateral tegmental field; Nucleus tractus solitarii (Vayssettes-Courchay, C. (211) 243)

Quisqualate
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Kainate; AMPA binding (Kiss, B. (209) 109)

GABA (γ-aminobutyric acid); $GABA_B$ receptors; Neocortex; Acetylcholine; (Rat) (Andre, P. (218) 137)

Glutamates; NMDA (N-methyl-D-aspartate); Cerebellar granule cells; Tricyclic antidepressants; Carbamazepine (Cai, Z. (219) 53)

Rabbit aorta
Glyceryl trinitrate; Biotransformation; Vasodilatation; Carbon monoxide (CO); Hemoprotein (Liu, Z. (211) 129)

Radioimmunoassay
Endothelin-1; Respiratory distress syndrome (adult); Oleic acid; Bronchoalveolar lavage; Hypoxia (Simmet, T. (211) 319)

Radioligand binding
Gastric mucosa; Prostanoids; Prostaglandin receptors; Parietal cells; Antisecretory potency (Hennies, S. (218) 303)

NG-108-15; Angiotensin II receptors; Receptor subtypes (Bryson, S.E. (225) 119)

Thromboxane A_2; Thromboxane A_2 receptor antagonist; Thromboxane A_2 receptor agonist; pH dependency; Platelet membranes (human); BAY U 3405 (Theis, J.G.W. (226) 149)

NK_2 receptors; Small intestine smooth muscle (rat); NK receptor subtypes; [^{125}I]His-NKA (Brown, M.C.S. (227) 163)

Radioreceptor assay
σ Receptors; Brain (guinea pig); (+)-Pentazocine (DeHaven-Hudkins, D.L. (227) 371)

Raphe nuclei (medullary)
Vagus; Atropine; RX 77368; Thyrotropin-releasing hormone (Garrick, T. (223) 75)

Rauwolscine
Sympatho-inhibition; Prazosin; Phenoxybenzamine; Nerve stimulation (peripheral); Hypothalamic stimulation (Koss, M.C. (211) 61)

[^{3}H]Rauwolscine
α_2-Adrenoceptors; α-Adrenoceptor antagonists; Non-adrenergic binding sites; [^{3}H]Atipamezole (Sjöholm, B. (215) 109)

Rb^+
Cromakalim; Ion flux; K^+ channels; Smooth muscle relaxation (Foster, K.A. (222) 143)

$^{86}Rb^+$ efflux
SDZ PCO 400; Trachealis (guinea-pig and bovine); K^+-rich media; K^+ channel inhibitors; (Electrophysiology) (Small, R.C. (219) 81)

Na^+ channels; K^+ channels; Remoxipride; Neuroleptics; Voltage clamp (Westlind-Danielsson, A. (224) 57)

$^{86}Rb^+$ uptake
Placental vein (human); 5-HT (5-hydroxytryptamine, serotonin); Na^+,K^+-ATPase (Fernández-Alfonso, M.S. (221) 185)

RB 101 (mixed inhibitor)
Enkephalin-degrading enzymes; Naltrindole; Motility suppression (conditioned); Dopamine receptors; Antidepressants (Baamonde, A. (216) 157)

RB101 (mixed inhibitor of enkephalin-degrading enzymes)
Morphine; Antinociceptive tolerance; Cross-tolerance (Noble, F. (223) 83)

Morphine; Naloxone; Physical dependence; (Systemic administration) (Noble, F. (223) 91)

Rearing
Dynorphin A-(1–13); Methamphetamine; Mr 2266; Circling; (Mouse) (Ukai, M. (222) 7)

Rebamipide
Diethyldithiocarbamate-induced antral ulcer; Neutrophil (Ogino, K. (212) 9)

Diethyldithiocarbamate-induced antral ulcer; Neutrophil (Ogino, K. (219) 493)

Receptor binding
CCK-7 analogues; Amylase secretion; Gall bladder contractions; Anorexia; Analgesia; Sedation (Maletínská, L. (222) 233)

Leukotriene B_4; Parenchymal contraction; Airway obstruction; Leukotriene B_4 receptor antagonists; (Guinea-pig) (Silbaugh, S.A. (223) 57)

C-type natriuretic peptide (CNP); Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Glioma cells (rat); cGMP (Eguchi, S. (225) 79)

Dopamine D_2 receptors; Mutagenesis; Catecholamine receptors (Mansour, A. (227) 205)

Receptor binding techniques
[^{3}H]AF-DX 384; Muscarinic receptors; Muscarinic M_2 receptor subtype; Autoradiography (Aubert, I. (217) 173)

Receptor conformation
α-Adrenoceptors; Prazosin; Receptor reconstitution; Detergent solubilization (Valliere, J.E. (226) 191)

Receptor coupling
Muscarinic receptors; Inositol phosphates; Heart (guinea pig) (Ford, A.P.D.W. (225) 105)

Receptor interaction
Muscarinic receptors; Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Pfeiffer's rule; Stereoselectivity (Waelbroeck, M. (227) 33)

σ Receptor ligands
DTG (1,3-di-(2-tolyl)guanidine); Ditolylorthoguanidine; Hippocampus (Connick, J.H. (214) 169)

CRF (corticotropin-releasing factor); Gastric acid secretion; Gastric emptying (Yoneda, M. (223) 197)

Receptor occupancy (in vivo)
α_2-Adrenoceptors; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Pilc, A. (212) 109)

Receptor reconstitution
α-Adrenoceptors; Prazosin; Detergent solubilization; Receptor conformation (Valliere, J.E. (226) 191)

Receptors
Thromboxane A_2 receptors; Photoaffinity labelling (Mais, D.E. (227) 267)

σ Receptors
DTG (1,3-di(2-tolyl)guanidine); Phencyclidine (PCP); SK&F 10047 (Dumont, M. (209) 245)

Behavioral sensitization; Methamphetamine; BMY 14802; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-propylpiperidine) (Ujike, H. (211) 323)

DTG (1,3-di-(2-tolyl)guanidine); Haloperidol (Jansen, K.L.R. (214) 281)

Liver (rat); (+)-[^{3}H]SKF 10,047; Subcellular distribution (Samovilova, N.N. (225) 69)

Cytochrome P-450; Phenobarbital; 3-Methylcholanthrene (Basile, A.S. (227) 95)

Brain (guinea pig); Radioreceptor assay; (+)-Pentazocine (De-Haven-Hudkins, D.L. (227) 371)

Receptor sensitization
Antinociception; Quinpirole; Dopamine (Kostrzewa, R.M. (209) 157)

Receptor subtypes
NG-108-15; Angiotensin II receptors; Radioligand binding (Bryson, S.E. (225) 119)

Receptor supersensitivity
Dopamine; Melatonin; Nucleus accumbens; Antidepressant drugs (Durlach-Misteli, C. (217) 15)

Receptor theory
NAN-190; BMY 7378; 5-HT_{1A} receptors; Partial agonists; Spare receptors (Greuel, J.M. (211) 211)

σ Recognition sites
Haloperidol; Remoxipride (Ericson, H. (226) 157)

Recombinant renin (human)
Spontaneously hypertensive rat (SHR); Blood pressure; Renin inhibitors (Shibasaki, M. (215) 271)

Red blood cells
Torasemide; Bumetanide; Cotransport; Hypertension; Diuretics (loops) (Masereel, B. (219) 385)

Reflectance spectrophotometry
Proton pump inhibitors; Gastric mucosa blood volume; Gastric mucosa oxygenation; Hemorrhagic shock; Omeprazole; NC-1300 (Kawano, S. (211) 55)

Refractory period
Ibutilide fumarate; Antiarrhythmics; Conduction time; Class III activity (Cimini, M.G. (222) 93)

Regeneration
Sciatic nerve crush; Org 2766; ACTH (adrenocorticotropin); Neurotrophic factor; Sensorimotor function; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Regional haemodynamics
Endothelin-1; BQ-123; Endothelin receptor subtypes; Vasodilatation; (Anaesthetized rat) (Douglas, S.A. (221) 315)

Relaxation
ANP (atrial natriuretic polypeptide); Aorta (rat); Aging; Endothelium; cGMP; Phosphodiesterase activity (Moritoki, H. (210) 61)

ANF (atrial natriuretic factor); Trachea (guinea-pig); Trachea (rat); Bronchus (human); Epithelium; Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

VIP (vasoactive intestinal polypeptide); Endothelium; Glibenclamide; Mesenteric artery (rabbit) (Hattori, Y. (213) 147)

Esophagus (rat); cAMP generation; 5-HT_4 receptors; Gastrointestinal motility (Moummi, C. (216) 47)

Ca^{2+}; Smooth muscle; Uterus (Ishine, T. (219) 285)

Smooth muscle (tracheal); Azelastine; Ca^{2+} levels (cytosolic); Smooth muscle (skinned) (Sanagi, M. (222) 247)

Remoxipride
$^{86}Rb^+$ efflux; Na^+ channels; K^+ channels; Neuroleptics; Voltage clamp (Westlind-Danielsson, A. (224) 57)

Haloperidol; σ Recognition sites (Ericson, H. (226) 157)

Renal blood flow
Semotiadil; DuP753; Glomerular filtration rate; Renin–angiotensin system (Nishiyama, A. (218) 311)

ANP (atrial natriuretic peptide); Sodium nitroprusside; Norepinephrine; Angiotensin II (Hisa, H. (222) 265)

Renal circulation
Angiotensin-converting enzyme inhibitors; EDRF (endothelium-derived relaxing factor); Kinins; Angiotensin II receptor antagonists (Hajj-ali, A.F. (212) 279)

Renal function
Angiotensin II; Caffeine; Adenosine; Hypertension (Holycross, B.J. (219) 361)

Renal nerve activity
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Medullary 5-HT neurons (Ramage, A.G. (219) 165)

Renal perfusion pressure
Atrial peptides; Natriuresis; Angiotensin II (Chamienia, A.L. (218) 319)

Renal toxicity
Doxorubicin; Nephrosis (experimental); Superoxide anion (Ghiggeri, G.M. (228) 77)

Renal uptake
Methylmercury; Glutathione (reduced); γ-Glutamyltranspeptidase (Tanaka, T. (228) 9)

Renal vascular resistance
Doppler shift technique; Kidney (isolated, perfused); Metalloproteases; Phosphoramidon; (Rat) (Salvati, P. (221) 267)

Renal vasodilatation
Bradykinin; Spontaneously hypertensive rat, stroke prone (SHR/SP) (Stier Jr., C.T. (210) 217)

Renin
Spontaneously hypertensive rat (SHR); Aldosterone; MK 954 (DuP 753); Angiotensin II; (Rat) (Mizuno, K. (215) 305)

Cocaine; 5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropic hormone); Prolactin; Oxytocin (Levy, A.D. (221) 121)

Renin–angiotensin system
Semotiadil; DuP753; Glomerular filtration rate; Renal blood flow (Nishiyama, A. (218) 311)

Angiotensin II receptor antagonists; Antihypertensive agents; Protein binding (Wong, P.C. (220) 267)

Renin–angiotensin system (local)
Hindlimb perfusion model; Angiotensin-converting enzyme inhibitors; Angiotensin-converting enzyme activity (Marjorie, (217) 49)

Renin inhibitors
Recombinant renin (human); Spontaneously hypertensive rat (SHR); Blood pressure (Shibasaki, M. (215) 271)

Reperfusion
Pindolol; Ischemia; Cardioprotection; Sympathomimetic activity (intrinsic); (Rat) (Nasa, Y. (213) 171)

Arrhythmias, Coronary artery occlusion; Myocardial ischaemia; Platelet aggregation; 5-HT receptor antagonists (Ellis, A.M. (219) 97)

Reperfusion injury
α-Tocopherol analogue; Free radical scavenger; Antioxidant; Vitamin E; Myocardial ischaemia/reperfusion (Petty, M.A. (210) 85)

Neutrophil-endothelial cell interaction; Myocardium (rabbit); Myeloperoxidase (Lad, N. (223) 163)

Reserpine
Dopamine uptake; [^{18}F]GBR 13119 binding; (In vivo); (Mouse) (Kilbourn, M.R. (216) 109)

Phencyclidine; BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine; Single unit recording; Locus coeruleus (Chergui, K. (219) 169)

Resiniferatoxin
α_2-Adrenoceptors; Bradykinin; Capsaicin; Nicotine; Bronchoconstriction (Lou, Y.-P. (210) 173)

Capsaicin; Bradykinin; Tachykinins; Substance P; Iris sphincter muscle (rabbit); Tachyphylaxis (Wang, Z.-Y. (213) 235)

Resistance vessels
Diuretics; Hydrochlorothiazide; Indapamide (Calder, J.A. (220) 19)

Respiratory airways
5-HT (5-hydroxytryptamine, serotonin); Electrical field stimulation; Trachea (Van Oosterhout, A.J.M. (209) 237)

Respiratory burst
Neutrophil; Degranulation; Protein kinase C; Staurosporin; cgp 41251 (Krause, K.-H. (227) 221)

Respiratory distress syndrome (adult)
Endothelin-1; Radioimmunoassay; Oleic acid; Bronchoalveolar lavage; Hypoxia (Simmet, T. (211) 319)

Respiratory system
Nitric oxide (NO); Ethanol (Persson, M.G. (224) 99)

Retina
Ethylcholine mustard arizidinium ion; Acetylcholine; Glycine; Amacrine cells; ON channels; OFF channels; (Frog) (Jardon, B. (210) 201)

Retinal ganglion cell
NMDA receptors; Spontaneous firing; Microiontophoresis; MK-801 (Ikeda, H. (210) 53)

Retinoic acid
Clonidine; Norepinephrine; α_2-Adrenoceptors; Morphine; μ-Opioid receptors; Adenylyl cyclase inhibition; Neuroblastoma SH-SY5Y cells (Lameh, J. (227) 19)

Rhein
Anthranoid laxative; Rhein anthrone; (Germ-free rats) (Van Hoestenberghe, A. (212) 121)

Rhein anthrone
Anthranoid laxative; Rhein; (Germ-free rats) (Van Hoestenberghe, A. (212) 121)

rho proteins
Guanine nucleotide-binding proteins (small); ADP-ribosyltransferase C3 (*Clostridium botulinum*); Melittin; Mast cell degranulating peptide; Compound 48/80 (Koch, G. (226) 87)

Rhythmic bladder contraction
Inaperisone hydrochloride; Micturition reflex; $GABA_B$ receptors; (Rat) (Morikawa, K. (213) 409)

Rilmenidine
Azepexole; Clonidine; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Clonidine; Noradrenaline release; Voltammetry (in vivo); α_2-Adrenoceptors; Hypothalamus (Suaud-Chagny, M.F. (213) 305)

Oxazoline; Imidazoline; Guanidinium; α_2-Adrenoceptor subtypes; Cerebral cortex (rat) (King, P.R. (218) 101)

Risk management
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Ritanserin
Sexual behaviour; $5\text{-}HT_2/5\text{-}HT_{1C}$ receptors; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ketanserin; Mesulergine (Klint, T. (212) 241)

R1.1 lymphoma cell line
Opioid receptors; κ-Opioid binding sites; [^{3}H]U69,593 (Bidlack, J.M. (227) 257)

mRNA
Dopamine D_2 receptor; Brain; Development (Srivastava, L.K. (225) 143)

β-Adrenoceptors; cAMP; Isoproterenol; C_6 glioma cells; Down-regulation (Bieck, P.R. (225) 171)

mRNA expression
G proteins; Polymerase chain reaction; Fluoxetine (Lesch, K.P. (227) 233)

mRNA levels
Benzodiazepines; Tolerance; $GABA_A$ receptor; (Rat) (O'Donovan, M.C. (226) 335)

Ro 5-4864
PK 11195; Duodenum; Vas deferens; (Rat) (Escubedo, E. (225) 15)

Ro 15-1788
Ethanol; Locus coeruleus; GABA (γ-aminobutyric acid); Benzodiazepine; Picrotoxin; Electrophysiology (Verbanck, P.M.P. (211) 15)

Ro 15-4513
Cerebellar diazepam-insensitive binding; Substrate specificity; Alcohol sensitivity; (Selected rat lines) (Korpi, E.R. (213) 323)

Benzodiazepine receptors; Ro 19-4603; Annelated 1,4-diazepines; GABA (Wong, G. (225) 63)

Ro 19-4603
Benzodiazepine receptors; Ro 15-4513; Annelated 1,4-diazepines; GABA (Wong, G. (225) 63)

[^{3}H]Ro 15-4513 binding
Benzodiazepine receptors (central); Modification of receptors; $GABA_A$ receptors (α subunits); Diethylpyrocarbonate; 2,3-Butanedione (Maksay, G. (227) 57)

Rolipram
Pancreas (dog); Exocrine secretion; Phosphodiesterase inhibitors (Iwatsuki, K. (209) 63)

Phosphodiesterase III; Phosphodiesterase IV; Cardiac ventricles; Cardiotonic; (Guinea pig) (Muller, B. (225) 263)

Rostral ventrolateral medulla
ATP; Vasomotor neurons (Sun, M.-K. (224) 93)

Rotational behaviour
Apomorphine; 6-Hydroxydopamine (6-OHDA); Pentobarbital; Conditioned drug effects; Drug discrimination (Silverman, P.B. (212) 165)

RP 49356
Cross-tolerance; Uterus; Cromakalim; K^+ channels (Piper, I. (219) 347)

RP 62203
$5\text{-}HT_2$ receptors; Binding (in vivo); 5-HT receptor antagonists (Fajolles, C. (216) 53)

RU 5135
$GABA_A$ receptor complex; 5α-Pregnane-3α-ol-20-one (3α,5α-P); 5α-Pregnane-3α-20α-diol (5α-pregnanediol); $GABA_A$ receptor antagonism; Neurosteroid site (Cadoni, C. (227) 147)

RU 24969
$5\text{-}HT_{1A}$ receptor agonists; $5\text{-}HT_{1A}$ receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); (Pigeon) (Barrett, J.E. (217) 163)

RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); $5\text{-}HT_{1B}$ receptor agonists; Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

Ruthenium red
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Substance P (Andersson, S.E. (209) 175)

Capsaicin; Ileal motility; Mesenteric nerve; Neuraminidase; Sialic acid; (Guinea-pig) (Takaki, M. (211) 125)

RX 77368
Raphe nuclei (medullary); Vagus; Atropine; Thyrotropin-releasing hormone (Garrick, T. (223) 75)

Ryanodine
Cardiac hypertrophy; Action potential; Depolarizations (transient); Na^+,K^+-ATPase; Forskolin (Mészáros, J. (210) 325)

Mn^{2+}; Nicardipine; Myocardium; Inotropism; (Rat) (Agata, N. (222) 223)

Salbutamol
Amino acid transport; Blood–brain barrier; β_2-Adrenoceptors; L-DOPA (L-3,4-dihydroxyphenylalanine); Isoproterenol (Takao, Y. (215) 245)

Salivary glands
Amitriptyline; Xerostomia; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland (Glenert, U. (226) 43)

Salmon-calcitonin
Morphine; Analgesia (Martín, M.I. (224) 77)

Saphenous veins (canine)
Sumatriptan; $5\text{-}HT_{1D}$ receptors; 5-HT (5-hydroxytryptamine, serotonin) (Cohen, M.L. (211) 43)

Saponin
Mesentery (rat); Capsaicin; CGRP (calcitonin gene-related peptide); L-Arginine; N^{ω}-Nitro-L-arginine methyl ester (Li, Y. (210) 23)

Sarafotoxins
Endothelins; Intestinal relaxation; Ca^{2+}-activated K^+ channels (Lin, W.-W. (219) 355)

Satiety
d-Fenfluramine; Sertraline; Feeding patterns; Motor activity; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Grignaschi, G. (211) 137)

Food intake; Bombesin; Bombesin receptor agonists; Bombesin receptor antagonists; CCK receptor antagonists (Laferrère, B. (215) 23)

Scalding
Bradykinin; Bradykinin receptor antagonists; Carrageenan; Urate crystal; Zymosan; Sponges (Damas, J. (211) 81)

Scavenging effects
Dipyridamole; Electron spin resonance; Hydroxyl radicals; Superoxide anions (Suzuki, S. (227) 395)

SCH 23390
A-69024; Chronic treatment; Dopamine D_1 receptors; Dopamine D_2 receptors; SCH 39166; SK&F 38393 (Lappalainen, J. (210) 195)

Dopamine D_1 receptor antagonists; BW737C89; Tetrahydroisoquinolines; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); (Receptor binding) (Riddall, D.R. (210) 279)

Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY); Novelty-induced grooming behaviour; Quinpirole; Dopamine receptors (Linthorst, A.C.E. (219) 23)

Hippocampus; SK&F 38393; Pilocarpine; Motor seizures (Alam, A.M. (222) 227)

SCH 37224
Sulfidopeptide leukotrienes; Lung parenchyma (human); Leukotriene binding (Viganò, T. (219) 159)

SCH 39166
A-69024; Chronic treatment; Dopamine D_1 receptors; Dopamine D_2 receptors; SCH 23390; SK&F 38393 (Lappalainen, J. (210) 195)

Dopamine D_1 receptors; Dopamine D_2 receptors; Dopamine D_1/D_2 receptor interactions; Behaviour; Jerking; NO 756; A-69024; BW 737C (Daly, S.A. (213) 251)

Schizophrenia
Cholecystokinin (CCK); CCK_B receptors; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Stereotypies; Haloperidol; Apomorphine (Löscher, W. (215) 199)

Sciatic nerve crush
Org 2766; ACTH (adrenocorticotropin); Neurotrophic factor; Regeneration; Sensorimotor function; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Scoparone
Immunosuppressants; Tyrosine kinase inhibitor (Huang, H.-C. (217) 143)

Vasodilator effect; Free radical scavenger (Huang, H.-C. (218) 123)

Scopolamine
Passive avoidance; Acetylcholine; Acetylcholine release; Hippocampus; Choline precursors (Sigala, S. (211) 351)

Nefiracetam (DM-9384); Cholinergic system; Carbon monoxide (CO); Amnesia (delayed); Passive avoidance; (Mouse) (Hiramatsu, M. (216) 279)

Corticostriatal pathways; Dopamine; Ascorbate; L-Glutamate; Apomorphine; (Rat) (Desole, M.S. (219) 67)

SDZ ENS 163
Muscarinic M_1 receptor agonists; Long-term potentiation (Boddeke, E.W.G.M. (222) 21)

SDZ NVI 085
α_1-Adrenoceptor subtypes; Vas deferens; Kidney; Aorta (rat) (Eltze, M. (224) 125)

SDZ PCO 400
Trachealis (guinea-pig and bovine); K^+-rich media; K^+ channel inhibitors; $^{86}Rb^+$ efflux; (Electrophysiology) (Small, R.C. (219) 81)

Second messenger
Inositol phosphate analogues; Ca^{2+} mobilization (Safrany, S.T. (226) 265)

Secretin-type receptors
Cloning of receptors; G-protein-coupled receptors; Neuropeptides; Neurokinin-type receptors (Burbach, J.P.H. (227) 1)

Sedation
CCK-7 analogues; Receptor binding; Amylase secretion; Gall bladder contractions; Anorexia; Analgesia (Maletínská, L. (222) 233)

Seizures
Strychnine; Handling; NMDA receptor antagonists; (Mouse) (McAllister, K.H. (211) 105)

AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionate; Quinoxalinedione; Epilepsy; Ataxia (Taylor, C.P. (213) 151)

Tacrine; Brain damage; LiCl; Nitric oxide (NO); L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (213) 301)

CGP 37849; CGP 39551; Kindling; Anticonvulsant drugs; NMDA receptor antagonists (Cotterell, K.L. (214) 285)

NMDA (N-methyl-D-aspartate); Pentylenetetrazole; Pregnenolone sulfate; (Mouse) (Maione, S. (219) 477)

Aminooxyacetic acid; GABA (γ-aminobutyric acid); Learning; Pentobarbital; Substance P (Vécsei, L. (220) 259)

GABA (γ-aminobutyric acid); Bicuculline; Diazepam; Lithium chloride; Pilocarpine (Peterson, C.J. (221) 151)

Xanthines; Pentylenetetrazole; EEG (electroencephalogram); Adenosine (Cutrufo, C. (222) 1)

Self-stimulation
5-HT (5-hydroxytryptamine, serotonin); Dopamine; Fenfluramine; Amphetamine (Olds, M.E. (216) 363)

Semotiadil
DuP753; Glomerular filtration rate; Renal blood flow; Renin–angiotensin system (Nishiyama, A. (218) 311)

Senescence
Aging; D-Cycloserine; Glycine; Memory; NMDA receptors; (Mouse) (Flood, J.F. (221) 249)

Senktide
Substance P; Neurokinin A; Blood pressure; Heart rate; Behaviour; Tachykinin receptor antagonists (Itoi, K. (219) 435)

Sensitization
Circadian rhythms; Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Locomotor activity; Adenylate cyclase activity; Dopamine autoreceptors; Lisuride; Tolerance (Nisoli, E. (216) 81)

Sensorimotor function
Sciatic nerve crush; Org 2766; ACTH (adrenocorticotropin); Neurotrophic factor; Regeneration; (Histology) (Tonnaer, J.A.D.M. (214) 33)

Sensory C-fibers
Neurogenic inflammation; cAMP; Substance P; Atypical adrenoceptors (Itabashi, S. (218) 187)

Sensory nerves
Adenosine; CGRP (calcitonin gene-related peptide); Mesenteric arterial bed (Rubino, A. (220) 95)

Sensory neurons
Veratridine; CGRP (calcitonin gene-related peptide); Nifedipine; ω-Conotoxin; Capsaicin (Tramontana, M. (212) 137)

Nitric oxide (NO); Capsaicin; CGRP (calcitonin gene-related peptide); L-NAME (N^G-nitro-L-arginine methyl ester); Gastric mucosa (Whittle, B.J.R. (218) 339)

Serine
Glycine; Alanine; Valine; Glycine modulatory site; NMDA receptors; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Serotonergic neurons
Electroconvulsive shocks; Hypothermia; 5-HT autoreceptors; 5-HT release; 5-HT_3 receptors (Blier, P. (211) 365)

[^{3}H]Serotonin binding
Serotonin-binding proteins; Frontal cortex (bovine); [^{3}H]Dopamine binding (Jimenez Del Rio, M. (225) 225)

Serotonin-binding proteins
Frontal cortex (bovine); [^{3}H]Serotonin binding; [^{3}H]Dopamine binding (Jimenez Del Rio, M. (225) 225)

Sertraline
d-Fenfluramine; Feeding patterns; Satiety; Motor activity; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Grignaschi, G. (211) 137)

Sex differences
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin); Tolerance; Corticosterone; Hypothermia (Nakano, Y. (219) 339)

Sexual behaviour
5-HT_2/5-HT_{1C} receptors; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amperozide; Ritanserin; Ketanserin; Mesulergine (Klint, T. (212) 241)

Galanin; Feeding behaviour; (Male rat) (Poggioli, R. (213) 87)

Sexual behaviour (male)
5-HT_{1A} receptors; Nucleus accumbens; Nucleus raphe; Medial preoptic area; 5-$HT_{1B/C}$ receptors (Fernández-Guasti, A. (210) 121)

Shakes
Grooming behaviour; B-HT 920; Adrenocorticotropin hormone; Dopamine D_2 receptors; Stretching and yawning (Ferrari, F. (216) 345)

Shock
Endotoxin; Nitric oxide (NO); Mesenteric arteries (small) (Schneider, F. (211) 269)

Sialic acid
Capsaicin; Ileal motility; Mesenteric nerve; Neuraminidase; Ruthenium red; (Guinea-pig) (Takaki, M. (211) 125)

Neuraminidase; Tracheal contraction (Kai, H. (220) 181)

Signal transduction pathways
PC12W; Angiotensin II receptor subtypes (Leung, K.H. (227) 63)

Single channel recording
Ca^{2+}-activated K^+ currents; Pyramidal neurons (dissociated); Hippocampus (rat); Trifluoperazine (Ikemoto, Y. (216) 191)

Single channels
Ketamine; L-Glutamate receptors; Channel block; Muscle (locust) (Macdonald, A.G. (210) 223)

Single unit recording
Phencyclidine; BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine; Locus coeruleus; Reserpine (Chergui, K. (219) 169)

SIN-1 (3-morpholinosydnonimine)
Acetylcholine; cGMP; L-Cysteine; Sodium nitrite; Vascular smooth muscle relaxation (Arvola, P. (214) 289)

Sinoaortic denervation
Clonidine; Phenylephrine; Cardiovascular response; (Conscious rat); (Intracerebroventricular) (Ricci, D. (212) 195)

Anaesthesia; Blood pressure; Ketanserin (Su, D.-F. (214) 89)

Sinoatrial pacemaker activity
Atrial effective refractory period; Atrioventricular conduction time; β-Adrenoceptors; Ventricular effective refractory period (Takei, M. (219) 15)

Sinusoidal plasma membrane (rat liver)
Bumetanide transport; Loop diuretics; Photoaffinity labeling; Integral plasma membrane proteins; Two-dimensional gel electrophoresis (Honscha, W. (226) 215)

σ-Sites
Cough reflex; Antitussive effects; (+)-SK&F 10,047; Pentazocine; DTG (1,2-di-(2-tolyl)guanidine); Dextromethorphan (Kamei, J. (224) 39)

Skeletal fibre (skinned)
Isometric tension; Anthracyclines (De Beer, E.L. (214) 97)

Skeletal muscle
β-Adrenoceptors (atypical); (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

5-HT (5-hydroxytryptamine, serotonin); (Swine) (Gerdes, C. (220) 91)

Adenosine; Adenosine receptors; Insulin sensitivity; Glucose transport; Amino acid transport (Challiss, R.A.J. (226) 121)

Skeletal muscle (innervated, frog)
Adenine nucleotide analogues; Ecto-enzymes; AP_5A (P^1P^5-di-(adenosine-5′)pentaphosphate); DPCPX (1,3-dipropyl-8-cyclopentylxanthine); Dipyridamole (Cascalheira, J.F. (222) 49)

SK&F 10047
σ Receptors; DTG (1,3-di(2-tolyl)guanidine); Phencyclidine (PCP) (Dumont, M. (209) 245)

(+)-SK&F 10,047
Dopamine release; Antipsychotics (Volonté, M. (213) 163)

Cough reflex; σ-Sites; Antitussive effects; Pentazocine; DTG (1,2-di-(2-tolyl)guanidine); Dextromethorphan (Kamei, J. (224) 39)

SK&F 38393
A-69024; Chronic treatment; Dopamine D_1 receptors; Dopamine D_2 receptors; SCH 23390; SCH 39166 (Lappalainen, J. (210) 195)

DAMGO ([D-Ala^2,MePhe^4,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); Naltrindole; Locomotor activity; (Mouse) (Toyoshi, T. (213) 25)

Circadian rhythms; Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Sensitization; Tolerance; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Martin-Iverson, M.T. (215) 119)

Hippocampus; SCH 23390; Pilocarpine; Motor seizures (Alam, A.M. (222) 227)

(+)-[^{3}H]SKF 10,047
Liver (rat); σ Receptors; Subcellular distribution (Samovilova, N.N. (225) 69)

Skin
PAF (platelet activating factor, PAF-acether); SR 27417; Antigen; Oedema; Inflammation (Herbert, J.M. (216) 175)

Skin (rabbit)
13-HODE (13-hydroxyoctadecadienoic acid); Oedema formation; Leukotriene B_4 (Buckley, T.L. (218) 369)

Skin response
Bradykinin receptor antagonists; Histamine liberation; Pain measurement (Kindgen-Milles, D. (218) 183)

SL 82.0715
NMDA (N-methyl-D-aspartate); Dopamine; Brain slices; Polyamines; Ifenprodil (Woodward, J.J. (210) 265)

Ethanol; Morphine; Cocaine; Amphetamine; MK-801; Microdialysis; Abstinence syndrome (Rossetti, Z.L. (221) 227)

Sleep
GABA (γ-aminobutyric acid); Glial uptake; Thalamus; (Cat) (Juhász, G. (209) 131)

Slow after-hyperpolarization
AF102B; Acetylcholine; Muscarinic M_1 receptors; Hippocampus slices (Segal, M. (220) 103)

Slow inward tail current (I_{ADP})
Trans-ACPD (trans-($\pm$)-1-amino-1,3-cyclopentanedicarboxylic acid); Olfactory cortex slice (guinea-pig) (Constanti, A. (214) 105)

SM-11044
β-Adrenoceptors (atypical); β_3-Adrenoceptors (human) (Sugasawa, T. (216) 207)

Small intestine
Capsaicin; Nitric oxide (NO); Intestinal motility; Ileum (rat) (Allescher, H.-D. (217) 153)

Small intestine smooth muscle (rat)
NK_2 receptors; NK receptor subtypes; Radioligand binding; [^{125}I]His-NKA (Brown, M.C.S. (227) 163)

Smooth muscle
Sulfonylureas; Glibenclamide; Cromakalim; K^+ channels; Coronary aretery (Nielsen-Kudsk, J.E. (209) 273)

Bradykinin receptor antagonists (Griesbacher, T. (211) 393)

PACAP (pituitary adenylate cyclase-activating polypeptide); Trachea (guinea-pig); cAMP (Araki, N. (216) 113)

Bradykinin; Angiotensin-converting enzyme; Phospholipase A_2; Lipoxygenase; Cyclic nucleotides (Rodrigues, M.S. (216) 357)

Ca^{2+}; Acetylcholine; A23187; Phasic and tonic responses; IP_3 (inositol trisphosphate) (Macara, B. (218) 27)

Vas deferens; α-Adrenoceptors; Spontaneously hypertensive rats (SHR) (Caricati-Neto, A. (218) 51)

Ca^{2+}; Relaxation; Uterus (Ishine, T. (219) 285)

Hand (human); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Vein (Bodelsson, M. (219) 455)

Vanadate; Uterus; Ca^{2+}; Ca^{2+}-free; Protein kinase C (Fukuzaki, A. (220) 99)

Na^+ pump; Na^+/K^+ pump; Colonic motility; Membrane potential (Barajas-López, C. (221) 51)

NK receptors; Bladder (guinea-pig) (Longmore, J. (222) 167)

α_1-Adrenoceptors; Norepinephrine; Ca^{2+} (Han, C. (226) 141)

Iris sphincter (dog); Muscarinic stimulation; cAMP; Inositol trisphosphate; Ca^{2+}; Cross-talk; Contraction-relaxation (Abdel-Latif, A.A. (226) 351)

Leukotrienes; Pulmonary system; Inositol phosphates; Protein kinase C; G-Protein (Howard, S. (227) 123)

Smooth muscle (airway)
ANF (atrial natriuretic factor); Relaxation; Trachea (guinea-pig); Trachea (rat); Bronchus (human); Epithelium; Autoradiography (Fernandes, L.B. (212) 187)

Ageing; Trachea (guinea-pig and rat); Epithelium; Histamine; Acetylcholine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Smooth muscle (aortic)
Phosphodiesterase isoenzymes; Cardiac muscle; Flosequinan; BTS 53 554; (Guinea-pig) (Frodsham, G. (211) 383)

Smooth muscle (arteriolar)
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); p-Fluorohexahydro-sila-difenidol; Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Submucosal plexus (guinea-pig); Adrenoceptors; Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

Smooth muscle (branchial, guinea-pig)
Toluene diisocyanate; Isocyanate hydrolysis (Mapp, C.E. (228) 103)

Smooth muscle cells
Angiotensin receptors; Angiotensin II; Angiotensin III; Protease inhibitors (Fujimoto, M. (215) 259)

DDT_1 MF-2 cells; Nucleotide receptors; ATP; UTP; K^+ currents (Van der Zee, L. (215) 317)

Heparin derivatives; Proliferation; Differentiation; Actin (Bârzu, T. (219) 225)

Curcumin; Antiproliferative effect; Mononuclear cells (Huang, H.-C. (221) 381)

Losartan; Hypertrophy; Phosphoinositide signalling system (Ko, Y. (227) 215)

Cholesterol; Oxysterol; Intercellular communication (Zwijsen, R.M.L. (228) 115)

Smooth muscle cells (vascular)
P_2 Purinoceptors; cAMP (Tada, S. (227) 25)

Thromboxane A_2/prostaglandin H_2 receptors (TXA_2/PGH_2 receptors); Ca^{2+} concentrations (intracellular); Thromboxane A_2 receptor antagonist (KW-3635 and BM-13505) (Miki, I. (227) 199)

Smooth muscle contraction
Protein kinase C; Trachealis (bovine); Cholinomimetics; Bronchodilators (Langlands, J.M. (227) 131)

Smooth muscle relaxation
Cromakalim; Ion flux; K^+ channels; Rb^+ (Foster, K.A. (222) 143)

Smooth muscle (skinned)
Smooth muscle (tracheal); Azelastine; Ca^{2+} levels (cytosolic); Relaxation (Sanagi, M. (222) 247)

Smooth muscle (tracheal)
Azelastine; Ca^{2+} levels (cytosolic); Relaxation; Smooth muscle (skinned) (Sanagi, M. (222) 247)

Smooth muscle (uterus)
Ca^{2+} levels (cytosolic); Ca^{2+} channels; Endothelins; (Rat) (Sakata, K. (221) 9)

Smooth muscle (vascular)
Neuropeptide Y (NPY); Endothelium (Small, D.L. (210) 131)

Aorta; Dibutyryl cAMP; Fura-2-Ca^{2+} signal; Forskolin; Ca^{2+} sensitivity; (Rat) (Abe, A. (211) 305)

Protein kinase C; Spontaneously hypertensive rat (SHR) (Silver, P.J. (212) 143)

Fluoride; Al^{3+}; G-protein; Ca^{2+} sensitivity; Protein kinase C (Kawase, T. (214) 39)

Dihydralazine; Hydralazine; Cromakalim; Nitroprusside; K^+ channels (Thirstrup, S. (215) 177)

Endothelin-1; Aorta (rat); Ca^{2+}; Cyclopiazonic acid (Shimamoto, H. (216) 225)

Endothelin-1; Prostaglandin E_2; Coronary artery (porcine) (Suzuki, S. (217) 97)

Calcium channels; Cromakalim; Vasodilators; Mesenteric artery (human) (Smirnov, S.V. (217) 105)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors; 5-HT_{1D} receptor subtype; Iliac artery (guinea-pig) (Schoeffter, P. (219) 295)

Adenosine receptors; CGS 21680; CGS 22492; Coronary artery (human); Mammary artery (internal) (Makujina, S.R. (221) 243)

Nisoldipine; Inhibitory effects (residual); Ca^{2+} levels (cytosolic); Ca^{2+} channels; Aorta (rat); (Relaxation) (Kim, B.K. (223) 157)

K^+ channels; ATP; Patch clamp (Furspan, P.B. (223) 201)

Prolactin; Gene expression; Hypertension; c-myc; Ornithine decarboxylase (Sauro, M.D. (225) 351)

Ca^{2+}; Protein kinase C activity (cytosolic, particulate); Phorbol esters (Bazan, E. (227) 343)

SMS 201-995
Octreotide; Somatostatin; α-Adrenoceptors; Histamine H_3 receptors; Migraine; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

Social behaviour
Deltorphins; δ-Opioid receptors; Locomotor activity; Analgesia; (Rat) (Negri, L. (209) 163)

Tumor necrosis factor; Interleukin-1; Interleukin-1 receptor antagonists; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Sodium nitrite
Acetylcholine; cGMP; L-Cysteine; SIN-1 (3-morpholinosydnonimine); Vascular smooth muscle relaxation (Arvola, P. (214) 289)

Sodium nitroprusside
NECA (5′-N-ethylcarboxamidoadenosine); Functional antagonism; Isoproterenol; Nitric oxide (NO); Nitroglycerin (Wiener, H.L. (220) 131)

Hydroxylamine; Neurotransmitter release (Lonart, G. (220) 271)

ANP (atrial natriuretic peptide); Renal blood flow; Norepinephrine; Angiotensin II (Hisa, H. (222) 265)

Solution hybridization/RNase protection
Angiotensin-converting enzyme; Converting enzyme inhibitors; Captopril; Angiotensinogen (Ye, M.-Q. (227) 79)

Somatostatin
Glipizide; Prolactin (Fosset, M. (220) 273)

Octreotide; SMS 201-995; α-Adrenoceptors; Histamine H_3 receptors; Migraine; Neurogenic inflammation; Substance P (Matsubara, T. (224) 145)

NMDA (N-methyl-D-aspartate); Cortical neurons; Arachidonic acid; Phospholipase A_2 (Tapia-Arancibia, L. (225) 253)

Spantide
Spinal cord-skin preparation; C-fibre reflex; Capsaicin; Substance P; CGRP (calcitonin gene-related peptide) (Yanagisawa, M. (220) 111)

Spantide II
NK_1 receptors; Tachykinin receptor antagonists; CP-96,345; FR 113680; L 668,169 (Patacchini, R. (215) 93)

Spare receptors
NAN-190; BMY 7378; 5-HT_{1A} receptors; Partial agonists; Receptor theory (Greuel, J.M. (211) 211)

Spatial orientation task
NMDA receptors; CGP37849; CGP39551; Dizocilpine; (Rat) (Bischoff, C. (213) 269)

Species differences
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Toxic equivalency factor (TEF); Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism (Ahlborg, U.G. (228) 179)

SPECT imaging
Dopamine D_2 receptors; Benzamide (substituted) (Kessler, R.M. (223) 105)

Spermine
NMDA (N-methyl-D-aspartate); Tetrodotoxin (Speciale, C. (214) 107)

Spider toxins
Ca^{2+} channel (mammalian, presynaptic); Glutamate (Pocock, J.M. (226) 343)

Excitatory amino acid receptors; NMDA (N-methyl-D-aspartic acid); Kainate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Davies, M.S. (227) 51)

Spike afterhyperpolarization
Sympathetic ganglia (bullfrog); Autonomic ganglia; Compound 48/80; Ganglionic transmission; Neuronal excitability (Heppner, T.J. (213) 427)

Spinal antinociception
5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; α-Adrenoceptor antagonists; Desipramine; 6-Hydroxydopamine (6-OHDA) (Sawynok, J. (223) 49)

Spinal cord
Kinins; Cardiovascular system; Catecholamines; Vagal reflex; C-fibers (Lopes, P. (210) 137)

Electroacupuncture; Analgesia; Opioid receptors; Opioid receptor agonists; Opioid receptor antagonists (Chen, X.-H. (211) 203)

Excitatory amino acids; Intrathecal; NMDA receptors; Non-NMDA receptors (Näsström, J. (212) 21)

Benzodiazepines; Benzodiazepine receptor binding; Alpidem; (Receptor heterogeneity) (Maguire, P.A. (214) 85)

NMDA (N-methyl-D-aspartate); Nitric oxide (NO); L-Arginine; Nociception; Facilitation; Hyperalgesia; Pain; (Rat) (Meller, S.T. (214) 93)

Antinociception; Dorsal horn neurons; α_2-Adrenoceptor agonists; Dexmedetomidine; Opioids (Sullivan, A.F. (215) 127)

Pain; Morphine; Descending inhibitory controls; Periaqueductal grey (Bouhassira, D. (216) 149)

D-Baclofen; NMDA (N-methyl-D-aspartic acid); Heart rate; Arterial pressure; Sympathetic output (Hong, Y. (216) 257)

Substance P; Tachykinins; Pain; Nociception (Xu, X.-J. (216) 337)

NMDA (N-methyl-D-aspartate); AMPA; Substance P-(1–7); Iontophoresis; Nociception; (Extracellular recording) (Budai, D. (216) 441)

Carrageenan; Thermal hyperalgesia; Antinociception; NMDA (N-methyl-D-aspartate); Opioids; (Rat); (Intrathecal) (Ren, K. (219) 235)

Nociception; Formalin; Bradykinin; Prostaglandins; (Rat) (Chapman, V. (219) 427)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1C}/5-HT_2 receptors; Motoneurons; Excitability; (Slice) (Yamazaki, J. (220) 237)

CRF (corticotropin-releasing factor); Dynorphin release; Analgesia; κ-Opioid receptors (Song, Z.H. (222) 27)

Substance P; Inositol phosphates; Cerebral cortex; Anesthesia; Pentobarbital (Hasséssian, H. (227) 103)

Spinal cord contusion
NMDA receptor antagonists; Non-NMDA receptor antagonists; Excitatory amino acids (Wrathall, J.R. (218) 273)

Spinal cord (human, pig)
Endothelin receptors; ^{125}I-Endothelin-1; Autoradiography (quantitative receptor); Chemical cross-linking (Niwa, M. (225) 281)

Spinal cord-skin preparation
C-fibre reflex; Capsaicin; Substance P; Spantide; CGRP (calcitonin gene-related peptide) (Yanagisawa, M. (220) 111)

Spinoreticular tract
Cardiac sympathetic afferents; 5-HT_3 receptors; Phenylbiguanide; Spinothalamic tract (Blair, R.W. (216) 119)

Spinothalamic tract
Cardiac sympathetic afferents; 5-HT_3 receptors; Phenylbiguanide; Spinoreticular tract (Blair, R.W. (216) 119)

Spiradoline
κ-Opioid receptor agonists; Analgesia; Noradrenaline uptake inhibitors; 5-HT uptake inhibitors (Kunihara, M. (214) 111)

Nor-binaltorphimine (nor-BNI); Antinociception; Morphine; κ-Opioid receptors (Jones, D.N.C. (215) 345)

Splanchnic artery occlusion shock
PAF (platelet-activating factor, PAF-acether); TNF-α (tumor necrosis factor); Myocardial depressant factor; L-659,989 (Zingarelli, B. (222) 13)

Splanchnic sympathetic efferent discharge
[Arg^8]vasopressin; Baroreflexes; Vasopressin V_1 receptor antagonists; Area postrema; Nucleus tractus solitarii (Zhang, X. (222) 81)

Sponges
Bradykinin; Bradykinin receptor antagonists; Carrageenan; Urate crystal; Zymosan; Scalding (Damas, J. (211) 81)

Spontaneous firing
Retinal ganglion cell; NMDA receptors; Microiontophoresis; MK-801 (Ikeda, H. (210) 53)

Spontaneously epileptic rat (SER)
Thyrotropin-releasing hormone analogs; CNK-602A; Antiepileptic effect; Dopamine (Renming, X. (223) 185)

Spontaneously hypertensive rat (SHR)
β_2-Adrenoceptors (presynaptic); Portal vein; α_2-Adrenoceptors (presynaptic); Plasma catecholamines; (Freely moving rat) (Remie, R. (211) 257)

Hypertension; 3-Methylhistidine; Terazosin; α-Adrenoceptor blockade (Jonsson, J.R. (211) 263)

Protein kinase C; Smooth muscle (vascular) (Silver, P.J. (212) 143)

Recombinant renin (human); Blood pressure; Renin inhibitors (Shibasaki, M. (215) 271)

Aldosterone; MK 954 (DuP 753); Renin; Angiotensin II; (Rat) (Mizuno, K. (215) 305)

Central nervous system (CNS); Striatum; Acetylcholine release; Ca^{2+} channel antagonists; Verapamil (Tsuda, K. (216) 319)

Vas deferens; Smooth muscle; α-Adrenoceptors (Caricati-Neto, A. (218) 51)

BRL 38227; Potassium channel openers; Microcirculation (Struijker Boudier, H.A.J. (218) 191)

Wistar-Kyoto rat (WKY); Novelty-induced grooming behaviour; SCH 23390; Quinpirole; Dopamine receptors (Linthorst, A.C.E. (219) 23)

5-HT_{1A} receptors; 5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; Blood pressure; Heart rate; MDL 73005EF (Buisson-Defferier, S. (223) 133)

Ca^{2+} channel antagonists; NC-1100; Cerebral ischemia (Sadoshima, S. (224) 109)

Adenosine A_1 receptors; Polymerase chain reaction (Ungerer, M. (226) 381)

Spontaneously hypertensive rat, stroke prone (SHR/SP)
Bradykinin; Renal vasodilatation (Stier Jr., C.T. (210) 217)

SR 27417
PAF (platelet activating factor, PAF-acether); Antigen; Skin; Oedema; Inflammation (Herbert, J.M. (216) 175)

SR 48968
Neurokinin receptors; Electrical field stimulation; (±)-CP-96,345; Bronchus (guinea-pig); Non-cholinergic contraction (Martin, C.A.E. (224) 137)

SR 95639A
Muscarinic receptor agonists (selective); Muscarinic receptor subtypes; Phosphoinositides; cAMP; Acetylcholine release (Mohamed, A.S. (227) 181)

ST-91
α_2-Adrenoceptor subtypes; WB4101; Imiloxan; Dexmedetomidine; Clonidine (Takano, Y. (219) 465)

Staurosporine
Phorbol 12-myristate,13-acetate; Phorbol 12,13-dibutyrate; Protein kinase C; Epilepsy; Behaviour (Smith, S.E. (213) 133)

Neutrophils; Arachidonic acid; PAF (platelet-activating factor, PAF-acether); Phospholipase A_2 (Müller, S. (218) 251)

Aorta; Noradrenaline; Protein kinase C; Calphostin C; Ca^{2+} uptake; Ca^{2+} efflux; Angiotensin II; (Potentiation) (Henrion, D. (224) 13)

12-O-Tetradecanoylphorbol 13-acetate; Protein kinase C; Ornithine decarboxylase; Epidermal cells (mouse); Morphological changes (Yamamoto, S. (227) 113)

Neutrophil; Respiratory burst; Degranulation; Protein kinase C; cgp 41251 (Krause, K.-H. (227) 221)

Stereochemistry (absolute)
Muscarinic receptor subtypes; Muscarinic receptor agonists; Superior cervical ganglion (rat); Hippocampal slice (rat); Ileum (guinea pig); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

Stereoisomers
Atrial effective refractory period; Atrial rate; Ventricular rate; β-Adrenoceptor blocking activity; β-Adrenoceptor antagonists; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

Isoflurane; Anesthesia (Harris, B. (217) 215)

Stereoselectivity
Muscarinic receptor subtypes; 3-Quinuclidinyl atrolactate stereoisomers; 3-Quinuclidinyl xanthene-9-carboxylate enantiomers; Cystometrogram (Noronha-Blob, L. (211) 97)

Muscarinic receptors; Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Pfeiffer's rule; Receptor interaction (Waelbroeck, M. (227) 33)

Stereoselectivity (at muscarinic receptors)
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); p-Fluorohexahydro-sila-difenidol; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Videomicroscopy (Bungardt, E. (213) 53)

Stereotyped behaviour
Dopamine D_1 receptors; Dopamine D_2 receptors; Adenylate cyclase; Circling behaviour; Locomotor activity (Arnt, J. (213) 259)

Stereotypies
NMDA (N-methyl-D-aspartate); MK-801 (dizocilpine); Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; Schizophrenia; Haloperidol; Apomorphine (Löscher, W. (215) 199)

Steroid hormones
Benzodiazepine exposure (chronic); Tolerance; Ovariectomy; GABA/benzodiazepine receptors; Anticonvulsants (Wilson, M.A. (215) 99)

Steroidogenesis
cAMP; Brain cortical minces (Barbaccia, M.L. (219) 485)

Stimulants
Cocaine; GBR-12783; [^{3}H]Methylphenidate; Dopamine transporters (Deutsch, H.M. (220) 173)

Stomach
Enteric nervous system; Ganglia; Adenosine; Synaptic transmission (Christofi, F.L. (216) 17)

Stomach fundus (guinea-pig)
5-HT (5-hydroxytryptamine, serotonin); 5-HT_1-like receptors (Kojima, S.-i. (224) 45)

Stomach (rat)
Aging; Non-adrenergic, non-cholinergic (NANC); VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurons (Smits, G.J.M. (223) 97)

Streptozotocin-induced diabetes
Thromboxane A_2; Prostacyclin; Diabetic microangiopathy; Thromboxane synthetase inhibitors (Masumura, H. (210) 163)

Na^+-K^+-ATPase (renal); G-proteins; Protein kinase C (Chen, C.-C. (225) 275)

Stress
Benzodiazepine binding; Handling (Andrews, N. (210) 247)

Hippocampus; Morphology; 5-HT (5-hydroxytryptamine, serotonin); Corticosteroids; Tianeptine (Watanabe, Y. (222) 157)

Stretching and yawning
Grooming behaviour; B-HT 920; Adrenocorticotropin hormone; Dopamine D_2 receptors; Shakes (Ferrari, F. (216) 345)

Striatal neurons
Metabotropic receptor; cAMP formation (Manzoni, O. (225) 357)

Striatal slices
Amitriptyline; Na^+ channels; Dopamine; Amino acids; Veratridine (Ishii, Y. (221) 377)

Striated muscle
Suramin; Neuromuscular blocking agents (non-depolarizing); Succinylcholine; Purinoceptors; Neuromuscular junction (rat) (Henning, R.H. (216) 73)

Striatum
Dopamine uptake; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Gentamicin; Catecholamine level; Hypothalamus; Adrenal medulla; Vas deferens (Mikami, M. (210) 91)

Ibogaine; Cocaine; Dopamine; Nucleus accumbens; Microdialysis; Locomotor activity (Maisonneuve, I.M. (212) 263)

Immobilization stress; Muscarinic receptors; Autoradiography; Supersensitivity; Hippocampus (González, A.M. (214) 261)

MPP^+ (1-methyl-4-phenylpyridinium ion); Dopamine uptake; Nicotine; Tobacco smoke (Carr, L.A. (215) 285)

Central nervous system (CNS); Acetylcholine release; Ca^{2+} channel antagonists; Verapamil; Spontaneously hypertensive rat (SHR) (Tsuda, K. (216) 319)

Acetyl-L-carnitine; Brain dialysis; Dopamine release (Harsing, Jr., L.G. (218) 117)

Substantia nigra; Dopamine release; Microdialysis; $GABA_A$ receptors; $GABA_B$ receptors (Santiago, M. (219) 175)

Acetylcholine; Supersensitivity; Dopamine D_1 receptors; Dopamine D_2 receptors (Robertson, G.S. (219) 323)

DOPA (3,4-dihydroxyphenylalanine); Nicotine-evoked release; Nicotinic acetylcholine receptors (tonic); Microdialysis (Nakamura, S. (222) 75)

Dopamine release; 3-Methoxytyramine; Nucleus accumbens; Frontal cortex; (Rat) (Chrapusta, S.J. (222) 129)

Chronic stress; Muscarinic receptors; Autoradiography; Supersensitivity; Hippocampus (González, A.M. (223) 25)

S-Adenosyl-L-methionine; Brain; Aging; Muscarinic receptors; Hippocampus (Muccioli, G. (227) 293)

Dopamine D_2 receptors; Dopamine D_3 receptors (Murray, A.M. (227) 443)

Phosphorothioate; Immediate-early genes (Chiasson, B.J. (227) 451)

Striatum (dorsal)
Oral movements; Dopaminergic/cholinergic interaction; Striatum (ventral); (Rat) (Kikuchi de Beltrán, K. (214) 181)

Striatum (rat)
Dopamine D_1 receptors; Dopamine D_2 receptors; Acetycholine (Tedford, C.E. (211) 169)

Dopamine receptors; Inositol phosphates; Phosphoinositides; α-Adrenoceptors; 5-HT receptors (Undie, A.S. (226) 297)

[^{3}H]CFT (2β-carbomethoxy-3β-(4-fluorophenyl)-tropane) binding; Cocaine; BTCP (N[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine); GBR 12935; Dopamine uptake inhibitors (Reith, M.E.A. (227) 417)

Striatum (ventral)
Oral movements; Dopaminergic/cholinergic interaction; Striatum (dorsal); (Rat) (Kikuchi de Beltrán, K. (214) 181)

Stroke
Nitric oxide (NO); Neuroprotection (Trifiletti, R.R. (218) 197)

Structure–activity relationship
[^{3}H]Paroxetine binding; 5-HT uptake inhibitors; Brain (rat) (Marcusson, J.O. (215) 191)

Strychnine
Handling; Seizures; NMDA receptor antagonists; (Mouse) (McAllister, K.H. (211) 105)

Strychnocarpine
β-Carbolines; 5-HT (5-hydroxytryptamine, serotonin); Benzodiazepines; Tryptamine; Opiate receptors; GABA receptors (Strömbom, J. (214) 165)

Subarachnoid hemorrhage
HA1077; Cerebral vasospasm; Cerebral blood flow (Satoh, S.-i. (220) 243)

Subcellular distribution
Liver (rat); (+)-[^{3}H]SKF 10,047; σ Receptors (Samovilova, N.N. (225) 69)

Subfornical organ
C-type natriuretic peptide-22; ANP (atrial natriuretic peptide); ANP receptors; Choroid plexus; (Rat) (Himeno, A. (215) 337)

Submandibular gland (rat)
α_{2A}-Adrenoceptors; α_{2D}-Adrenoceptors; α_2-Adrenoceptors (prejunctional); Vas deferens (rat); Platelets (human) (Smith, K. (219) 203)

Submucosal plexus (guinea-pig)
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); p-Fluorohexahydro-sila-difenidol; Smooth muscle (arteriolar); Stereoselectivity (at muscarinic receptors); Videomicroscopy (Bungardt, E. (213) 53)

Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Smooth muscle (arteriolar); Adrenoceptors; Videomicroscopy; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

Subretrofacial nucleus
Quipazine; L-Glutamate; Caudal ventrolateral medulla; Lateral tegmental field; Nucleus tractus solitarii (Vayssettes-Courchay, C. (211) 243)

Substance P
Tachykinins; Protein secretion; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Ruthenium red (Andersson, S.E. (209) 175)

Neurokinin A; Tachykinins; Dyspnea (guinea-pig) (Kusner, E.J. (210) 299)

Endopeptidase 24.15; Endopeptidase 24.11; Trachea (guinea-pig); Bradykinin (Da Silva, A. (212) 97)

EDRF (endothelium-derived relaxing factor); Neurokinin A; Neurokinin B; CP-96,345; Aorta (rabbit) (Rubino, A. (212) 237)

Resiniferatoxin; Capsaicin; Bradykinin; Tachykinins; Iris sphincter muscle (rabbit); Tachyphylaxis (Wang, Z.-Y. (213) 235)

Interleukin-1 receptor antagonists; Airway hyperreactivity; Bronchoalveolar lavage; Airway leukoctyes (Selig, W. (213) 331)

GABA (γ-aminobutyric acid); Bicuculline; Nucleus tractus solitarii; (Evoked responses); (Rat) (Pérez, H. (213) 435)

Bronchospasm; Capsaicin; Neurokinin A; Cholinergic nerves; Adrenergic nerves; NANC (non-adrenergic, non-cholinergic) (Ballati, L. (214) 215)

Aging; Airway obstruction; Asthma; Oedema; Histamine; Plasma exudation; Vascular permeability (Arakawa, H. (215) 51)

CP-96,345; Ca^{2+} channels (Schmidt, A.W. (215) 351)

Tachykinins; Pain; Nociception; Spinal cord (Xu, X.-J. (216) 337)

Substance P-(1–7)
NMDA (N-methyl-D-aspartate); AMPA; Iontophoresis; Nociception; Spinal cord; (Extracellular recording) (Budai, D. (216) 441)

Neurokinin A; Capsaicin; Field stimulation; Airway constriction; Airway edema (Murai, M. (217) 23)

Substance P (N-terminal fragments); Opioid receptor antagonists; Behavioural desensitization (Mousseau, D.D. (217) 197)

Sensory C-fibers; Neurogenic inflammation; cAMP; Atypical adrenoceptors (Itabashi, S. (218) 187)

Amphetamines; Basal ganglia; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Tryptophan hydroxylase (Hanson, G.R. (218) 287)

Dorsal raphe nucleus; 5-HT release; Blood pressure (Gradin, K. (218) 363)

[Met^5]enkephalin; [Leu^5]enkephalin; Neurotensin; Cholecystokinin (CCK); 6-Hydroxydopamine (6-OHDA); L-DOPA; Parkinson's disease; (Prolonged treatment) (Taylor, M.D. (219) 183)

Neurokinin A; Senktide; Blood pressure; Heart rate; Behaviour; Tachykinin receptor antagonists (Itoi, K. (219) 435)

CP-96,345; Ca^{2+} channels (Schmidt, A.W. (219) 490)

Dihydropyridine Ca^{2+} entry blocker; EDRF (endothelium-derived relaxing factor); Adrenergic nerve; Mesenteric artery; cGMP (Okamura, T. (220) 27)

Spinal cord-skin preparation; C-fibre reflex; Capsaicin; Spantide; CGRP (calcitonin gene-related peptide) (Yanagisawa, M. (220) 111)

Aminooxyacetic acid; GABA (γ-aminobutyric acid); Learning; Pentobarbital; Seizures (Vécsei, L. (220) 259)

Blood pressure; CP-96,345; Heart; NK_1 receptor antagonists; Cigarette smoke (Delay-Goyet, P. (222) 213)

Octreotide; SMS 201-995; Somatostatin; α-Adrenoceptors; Histamine H_3 receptors; Migraine; Neurogenic inflammation (Matsubara, T. (224) 145)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Inositol phosphates; Spinal cord; Cerebral cortex; Anesthesia; Pentobarbital (Hasséssian, H. (227) 103)

Substance P antagonists
Neurogenic inflammation; Plasma extravasation; Tachykinins; Capsaicin; Pain (Nagahisa, A. (217) 191)

Substance P (N-terminal fragments)
Substance P-(1–7); Opioid receptor antagonists; Behavioural desensitization (Mousseau, D.D. (217) 197)

Substantia nigra
GABA (γ-aminobutyric acid); $GABA_B$ receptors; Baclofen; (Rat) (Garant, D. (214) 75)

Striatum; Dopamine release; Microdialysis; $GABA_A$ receptors; $GABA_B$ receptors (Santiago, M. (219) 175)

Substantia nigra pars compacta
Dopamine neurons; 5-HT_3 receptors; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area (Minabe, Y. (209) 151)

Substrate specificity
Ro 15-4513; Cerebellar diazepam-insensitive binding; Alcohol sensitivity; (Selected rat lines) (Korpi, E.R. (213) 323)

Succinylcholine
Suramin; Neuromuscular blocking agents (non-depolarizing); Purinoceptors; Neuromuscular junction (rat); Striated muscle (Henning, R.H. (216) 73)

Sucrose gradients
δ-Opioid receptors; NG 108-15 hybrid cell; [^{3}H]Etorphine; [^{3}H]Diprenorphine; 5′-Guanylylimidophosphate (GppNHp); Adenylate cyclase; G-proteins (Polastron, J. (226) 133)

Sulfate conjugation
M12285; Loop diuretics; Quinolinone oxime sulfonic acids (Shinkawa, T. (219) 217)

Sulfhydryl reducing agents
Angiotensin II receptor subtypes; AT_2 receptors; Dithiothreitol; Losartan (DuP 753); Brain development (Tsutsumi, K. (226) 169)

Sulfidopeptide leukotrienes
SCH 37224; Lung parenchyma (human); Leukotriene binding (Viganò, T. (219) 159)

Sulfonylurea antidiabetics
Ventricular papillary muscle; Contractile force; Action potentials; K^+ channel openers; P_2 purinoceptor agonists (Bott, A. (213) 141)

Sulfonylureas
Glibenclamide; Cromakalim; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Glisoxepide; Glibenclamide; Biliary elimination; Anion transport; Liver; K^+ channel (ATP-dependent) (Petzinger, E. (213) 381)

K^+ channels (ATP-sensitive); Motor control; Dorsal pallidum (Amalric, M. (217) 71)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Sulfotransferase
Dehydroepiandrosterone; Estrone; Liver (human); Adverse drug reactions (Bamforth, K.J. (228) 15)

Sulotroban
Pulmonary vascular bed; U46619; Thromboxane A_2/endoperoxide receptor-mediated responses; Endothelin peptides; PAF (platelet-activating factor, PAF-acether) (Nossaman, B.D. (213) 1)

Sumatriptan
Saphenous veins (canine); 5-HT_{1D} receptors; 5-HT (5-hydroxytryptamine, serotonin) (Cohen, M.L. (211) 43)

5-HT (5-hydroxytryptamine, serotonin); 5-CT (5-carboxyamidotryptamine); 5-HT_{1D} binding site (Beer, M.S. (213) 193)

5-HT receptors; cAMP; 5-$HT_{1D\beta}$ receptors (Miller, K.J. (227) 99)

Superior cervical ganglion
Muscarinic receptor subtypes; Ileum (guinea-pig); Atrium (guinea-pig); Drug discrimination (Arnt, J. (218) 159)

Superior cervical ganglion (rat)
Muscarinic receptor subtypes; Muscarinic receptor agonists; Stereochemistry (absolute); Hippocampal slice (rat); Ileum (guinea pig); c-fos expression; Hybridization (in situ) (Pombo-Villar, E. (226) 317)

Superoxide
β-Adrenoceptor antagonists; Carvedilol; Free radical; Neutrophils; Antioxidants (Yue, T.-L. (214) 277)

Superoxide anions
Dipyridamole; Scavenging effects; Electron spin resonance; Hydroxyl radicals (Suzuki, S. (227) 395)

Doxorubicin; Nephrosis (experimental); Renal toxicity (Ghiggeri, G.M. (228) 77)

Supersensitivity
Immobilization stress; Muscarinic receptors; Autoradiography; Hippocampus; Striatum (González, A.M. (214) 261)

Ethanol pretreatment (chronic); Morphine; Vas deferens (mouse); Naloxone; μ-Opioid receptors (Tabach, R. (216) 449)

Acetylcholine; Striatum; Dopamine D_1 receptors; Dopamine D_2 receptors (Robertson, G.S. (219) 323)

Morphine; Opioid receptor regulation; Naltrexone; d-Amphetamine; Analgesia; Upregulation (Duttaroy, A. (221) 211)

Chronic stress; Muscarinic receptors; Autoradiography; Hippocampus; Striatum (González, A.M. (223) 25)

Imipramine (chronic); NMDA receptors; Dopamine receptors (D'Aquila, P.S. (224) 199)

Suprachiasmatic nucleus
Circadian rhythm; 2-Deoxyglucose uptake; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); $GABA_A$ receptors; Benzodiazepine receptors (Tominaga, K. (217) 79)

Suramin
ATP; P_2 purinoceptors; Locus coeruleus neurones; Firing rate (Tschöpl, M. (213) 71)

Neuromuscular blocking agents (non-depolarizing); Succinylcholine; Purinoceptors; Neuromuscular junction (rat); Striated muscle (Henning, R.H. (216) 73)

Vas deferens; Purinergic neurotransmission; P_2 purinoceptors (Mallard, N. (220) 1)

ATP; P_2 purinoceptor; Hepatocytes; (Rat) (Tomura, H. (226) 363)

Surface field potential (N-wave)
Nicotinic receptor agonists; Olfactory cortex slice (guinea-pig); Extracellular recording; Antimuscarinic action (Libri, V. (212) 253)

Survival
Brain ischemia; (Gerbil); (Treatment) (Von Lubitz, D.K.J.E. (216) 37)

Poly(rG)·Poly(rC); Poly(rI)·Poly(rC); Interferon inducer; Antitumour activity; Liver colony assay (Jurásková, V. (221) 107)

Sympathetic ganglia
Catecholamine receptors; Dopamine receptors; α-Adrenoceptors (Horn, P.T. (224) 103)

Norepinephrine; Protein kinase C; 1,2-Dioctanoylglycerol; Ca^{2+} current; Whole-cell voltage clamp (Abrahams, T.P. (227) 189)

Sympathetic ganglia (bullfrog)
Autonomic ganglia; Compound 48/80; Ganglionic transmission; Neuronal excitability; Spike afterhyperpolarization (Heppner, T.J. (213) 427)

Sympathetic nerves
ω-Conotoxin; Hypertension; Vasodilatation (Pruneau, D. (211) 329)

Sympathetic nervous system
Circulatory filling pressure (mean); Angiotensin II (Tabrizchi, R. (219) 141)

Sympathetic neurotransmission
Atherosclerosis; WHHL rabbit; Mesenteric artery; CGRP (calcitonin gene-related peptide); Neuropeptide Y (NPY) (Stewart-Lee, A.L. (216) 167)

Sympathetic output
D-Baclofen; NMDA (N-methyl-D-aspartic acid); Spinal cord; Heart rate; Arterial pressure (Hong, Y. (216) 257)

Sympathetic stimulation
L-NAME (N^G-nitro-L-arginine methyl ester); Vasopressin; Nitroprusside (sodium); Endotoxaemia; Vascular reactivity (Guc, M.O. (224) 63)

Sympathoadrenal system
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 receptors; Glucose; Insulin (Baudrie, V. (213) 41)

Sympatho-inhibition
Prazosin; Rauwolscine; Phenoxybenzamine; Nerve stimulation (peripheral); Hypothalamic stimulation (Koss, M.C. (211) 61)

Sympathomimetic activity (intrinsic)
Pindolol; Ischemia; Reperfusion; Cardioprotection; (Rat) (Nasa, Y. (213) 171)

Synaptic transmission
Corticotropin-releasing hormone (CRH); Autonomic ganglia; Enteric nervous system; Intestine (Hanani, M. (211) 23)

t-ACPD (trans-1-aminocyclopentyl-1,3-dicarboxylic acid); Hippocampus (Garaschuk, O.V. (212) 305)

Enteric nervous system; Ganglia; Stomach; Adenosine (Christofi, F.L. (216) 17)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Substance P; Calcitonin gene-related peptide (CGRP); Vasoactive intestinal peptide (VIP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Synaptic vesicle
Dopamine; Dopamine transporters; Amine uptake (Rostène, W. (218) 175)

Synaptoneurosomes (guinea pig, cerebral cortex)
Cholecystokinin; CCK_B receptors; Boc-[Leu^{31}]CCK-4 binding; Inositol phosphate accumulation; cAMP accumulation; $^{45}Ca^{2+}$ efflux (Galas, M.C. (226) 35)

Synaptosomes
Amphetamine analogues; Monoamine release; 5-HT (5-hydroxytryptamine, serotonin) (Berger, U.V. (215) 153)

Synthesis and turnover
(−)-Penbutolol; 5-HT_{1A} receptor antagonism; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); 5-HT-like behaviour; Hypothermia (Hjorth, S. (222) 121)

Tachykinin
Neuropeptide K; Cardiovascular responses; Catecholamines; Autonomic regulation (Décarie, A. (213) 125)

Tachykinin NK_1 receptors
(±)-CP-96,345; Plasma protein extravasation; Neurogenic inflammation (Eglezos, A. (209) 277)

Tachykinin receptor antagonists
NK_1 receptors; CP-96,345; FR 113680; L 668,169; Spantide II (Patacchini, R. (215) 93)

Substance P; Neurokinin A; Senktide; Blood pressure; Heart rate; Behaviour (Itoi, K. (219) 435)

Cigarette smoke; Trachea; Plasma extravasation; (Rat) (Morimoto, H. (224) 1)

Tachykinin receptor antagonists (selective)
Iris (rabbit); Tachykinins; NK_1 receptors (Wang, Z.-y. (216) 327)

Tachykinins
Protein secretion; Substance P; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Neurokinin A; Substance P; Dyspnea (guinea-pig) (Kusner, E.J. (210) 299)

Resiniferatoxin; Capsaicin; Bradykinin; Substance P; Iris sphincter muscle (rabbit); Tachyphylaxis (Wang, Z.-Y. (213) 235)

Iris (rabbit); NK_1 receptors; Tachykinin receptor antagonists (selective) (Wang, Z.-y. (216) 327)

Substance P; Pain; Nociception; Spinal cord (Xu, X.-J. (216) 337)

Neurogenic inflammation; Plasma extravasation; Substance P antagonists; Capsaicin; Pain (Nagahisa, A. (217) 191)

Tachyphylaxis
Resiniferatoxin; Capsaicin; Bradykinin; Tachykinins; Substance P; Iris sphincter muscle (rabbit) (Wang, Z.-Y. (213) 235)

Tacrine
Seizures; Brain damage; LiCl; Nitric oxide (NO); L-NAME (N^ω-nitro-L-arginine methyl ester) (Bagetta, G. (213) 301)

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate hydrochloride); Learning; Memory; CO-induced amnesia; Delayed amnesia; Hypoxia; Passive avoidance task (Yoshida, S. (214) 247)

Velnacrine; Physostigmine; Anticholinesterase agents; Neuromuscular junction; Twitch response; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Tetrahydroaminoacridine (THA); 4-Aminopyridine (4-AP); Fura-2 (fluorimetry); Drug interactions (Järlebark, L. (225) 75)

Tail-flick inhibition
Antinociception; β-Endorphin (intrathecal); Opioid receptors (Tseng, L.F. (214) 59)

Antinociception; Morphine; β-Endorphin; Pentobarbital; Pain controls (descending) (Tseng, L.F. (214) 175)

β-Endorphin; CCK-8s (sulfated cholecystokinin octapeptide); [Met^5]enkephalin (Tseng, L.F. (215) 309)

Tail-flick response
Heat intensities (different); Paw-licking response; β-Endorphin; Morphine (Suh, H.H. (213) 337)

Tail-flick (spinal)
Antinociception; δ-Opioid receptors; DSTBULET (Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr); Morphine (Kalso, E.A. (216) 97)

Tail-flick test
Monoamine oxidase-A inhibitors; Nociception; Hot-plate test; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (219) 113)

Tamoxifen
Phospholipase A_2; Oviduct; Cell proliferation (Fayard, J.-M. (216) 127)

Tandospirone
Buspirone; Ipsapirone; Azapirones; Chlordiazepoxide; Anxiolytics; Conflict; Punishment; Cork gnawing; (Pigeon); (Rat) (Pollard, G.T. (221) 297)

Tardive dyskinesia
Vacuous chewing; Haloperidol (chronic); Dopamine D_1 receptors (Diana, M. (211) 415)

Vacuous chewing movements; Haloperidol (chronic); Progabide (Kaneda, H. (212) 43)

Taste aversion (conditioned)
5-HT_3 receptor antagonists; Zacopride; GR38032F; Dexamethasone; Cisplatin (Mele, P.C. (218) 229)

Taurine
Na^+ currents (fast); Ventricular myocytes (embryonic chick); Voltage clamp (whole-cell); Cardiac muscle (electrophysiology of) (Satoh, H. (218) 83)

[^{3}H]TBOB (t-[^{3}H]butylbicycloorthobenzoate) binding
Dihydroergotoxine; GABA (γ-aminobutyric acid) shift; Barbiturate sleeping; Picrotoxin-induced convulsions (Tvrdeić, A. (221) 139)

TBPS (t-butylbicyclophosphorothionate)
Granule cells; $GABA_A$ receptors (Korpi, E.R. (211) 427)

TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)
Ah receptor (Bank, P.A. (228) 85)

[^{3}H]TC-81 (distribution of)
Aorta; Ca^{2+} channel antagonists; Muscle relaxation (Okamiya, Y. (222) 99)

T84 cell
Muscarinic receptor subtype; Colonic epithelial cell; Phosphoinositides; Arachidonic acid (Dickinson, K.E.J. (225) 291)

Temperature
Opioid receptors; Myenteric plexus; DAGO ([D-Ala^2,N-MePhe^4, Gly^5-ol]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-50,488H (Garaulet, J.V. (223) 19)

Terazosin
Hypertension; 3-Methylhistidine; α-Adrenoceptor blockade; Spontaneously hypertensive rat (SHR) (Jonsson, J.R. (211) 263)

Terguride
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinsonism; Dopamine D_2 receptors (mixed agonist/antagonist); (Common marmoset) (Lange, K.W. (212) 247)

Ternary complex
β_2-Adrenoceptor agonists (long acting); Tight agonist binding; Tracheal smooth muscle relaxation (Voss, H.-P. (227) 403)

Tertatolol
β-Adrenoceptor antagonists; 5-HT receptors; 5-HT_{1A} receptors; Migraine; Pindolol; Propranolol; (Pig) (Saxena, P.R. (220) 79)

Tetanic fade
Acetylcholine release; Anticholinesterase; β-Eudesmol; Neostigmine; Neuromuscular transmission (Chiou, L.C. (216) 199)

Tetanic stimulation
Velnacrine; Tacrine; Physostigmine; Anticholinesterase agents; Neuromuscular junction; Twitch response; (Rat) (Bosch, F. (222) 163)

12-O-Tetradecanoylphorbol 13-acetate
Staurosporine; Protein kinase C; Ornithine decarboxylase; Epidermal cells (mouse); Morphological changes (Yamamoto, S. (227) 113)

Tetraethylammonium
Transmitter release; K^+ channels; Aminopyridines; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

Tetrahydroaminoacridine (THA)
Tacrine; 4-Aminopyridine (4-AP); Fura-2 (fluorimetry); Drug interactions (Järlebark, L. (225) 75)

Tetrahydrobiopterin
Vasodilatation; Nitric oxide synthase (Van Amsterdam, J.G.C. (215) 349)

Tetrahydroisoquinolines
Dopamine D_1 receptor antagonists; SCH 23390; BW737C89; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); (Receptor binding) (Riddall, D.R. (210) 279)

Tetrapeptides
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; (Radioligand binding) (Harhammer, R. (209) 263)

Tetrodotoxin
Spermine; NMDA (N-methyl-D-aspartate) (Speciale, C. (214) 107)

Capsazepine; Non-adrenergic non-cholinergic (NANC) excitatory nerves; Capsaicin; Electrical field stimulation (Belvisi, M.G. (215) 341)

Tetronothiodin
CCK_B receptor antagonists; GH3 cells; Ca^{2+} (cytosolic); Fura-2; [^{125}I]CCK-8 binding (Kuwahara, T. (221) 99)

TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine)
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Darrow, E. (209) 19)

Aggression; Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Mos, J. (212) 295)

5-HT_{1A} receptor agonists; 5-HT_{1A} receptor antagonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); NAN-190; BMY 7378; Drug discrimination; (±)-Pindolol; Prazosin; Eltoprazine; RU 24969; (Pigeon) (Barrett, J.E. (217) 163)

TGF-β (transforming growth factor-β)
Nitric oxide (NO); PDGF (platelet-derived growth factor); Interleukin-1β; Platelets; Aorta (rat) (Schini, V.B. (216) 379)

Thalamus
GABA (γ-aminobutyric acid); Glial uptake; Sleep; (Cat) (Juhász, G. (209) 131)

Theophylline
Amphotericin B; Mesangial cells; Ca^{2+} (intracellular); Diltiazem (Sabra, R. (226) 79)

Asthma; Bronchial provocation test; Inflammation (Crescioli, S. (228) 45)

Thermal hyperalgesia
Spinal cord; Carrageenan; Antinociception; NMDA (N-methyl-D-aspartate); Opioids; (Rat); (Intrathecal) (Ren, K. (219) 235)

Thermodynamics
Benzodiazepine (receptor binding); Benzodiazepine receptor (type I); Cerebellum (Maguire, P.A. (226) 233)

Thiazinamium
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Vas deferens (rabbit); Cyproheptadine; Pizotifen; Ketotifen; Nuvenzepine (Eltze, M. (211) 283)

Thienyl baclofen analogs
Baclofen; $GABA_B$ receptor agonists; 2-Hydroxysaclofen; Ileum (guinea-pig, isolated) (Ong, J. (218) 343)

β-(2-Thienyl)-GABA
Baclofen; Ileum (guinea-pig, isolated); Neocortical slices (rat); 2-Hydroxysaclofen (Ong, J. (221) 145)

[^{125}I]Thienylphencyclidine
NMDA receptor; Polyamines (Reynolds, I.J. (226) 53)

Thiokynurenates
Glycine; NMDA receptors; Kynurenates; Ischemia; Excitotoxicity (Moroni, F. (218) 145)

Thiol group
cAMP; Dopamine receptors; Vascular smooth muscle (rat); Mesenteric artery (Hall, A.S. (226) 253)

THIP (tetrahydroisoxazolo-pyridin-3-ol)
Gastrointestinal transit; Muscimol; Neurotransmitters (Ramaswamy, S. (220) 147)

Thirst
Losartan; DuP 753; Angiotensin II; Blood–brain barrier; Blood pressure (Bui, J.D. (219) 147)

Thoracic aorta
α_1-Adrenoceptors; (Single cell) (Satoh, M. (221) 35)

Thrombin
Endothelium-dependent relaxations; Thrombin receptor agonist (Res 42-55) (Simonet, S. (216) 135)

EGF (epidermal growth factor); Endothelin; Hypercholesterolemia; Aorta (rabbit); Vasospasm; Endothelium (Merkel, L.A. (222) 175)

α-Thrombin
Phosphoinositide turnover; DNA synthesis; Neuroblastoma (Ogino, Y. (225) 299)

Thrombin receptor agonist (Res 42-55)
Endothelium-dependent relaxations; Thrombin (Simonet, S. (216) 135)

Thrombosis (coronary)
Y-20811; Thromboxane A_2 synthetase inhibitor; Thromboxane B_2 (immunoreactive); 6-keto-Prostaglandin $F_{1\alpha}$ (immunoreactive) (Matsumoto, Y. (213) 167)

Thromboxane A_2
Prostacyclin; Streptozotocin-induced diabetes; Diabetic microangiopathy; Thromboxane synthetase inhibitors (Masumura, H. (210) 163)

Monocytes; Macrophages; Xanthine; cAMP (Baker, A.J. (211) 157)

Endothelin-1; Vascular permeability; Airways; Inflammation; Gastrointestinal ulceration (Sirois, M.G. (214) 119)

Thromboxane A_2 receptor antagonist; Thromboxane A_2 receptor agonist; pH dependency; Radioligand binding; Platelet membranes (human); BAY U 3405 (Theis, J.G.W. (226) 149)

Thromboxane A_2/endoperoxide receptor-mediated responses
Pulmonary vascular bed; U46619; Sulotroban; Endothelin peptides; PAF (platelet-activating factor, PAF-acether) (Nossaman, B.D. (213) 1)

Thromboxane A_2/prostaglandin H_2 receptors (TXA_2/PGH_2 receptors)
Smooth muscle cells (vascular); Ca^{2+} concentrations (intracellular); Thromboxane A_2 receptor antagonist (KW-3635 and BM-13505) (Miki, I. (227) 199)

Thromboxane A_2 receptor agonist
Thromboxane A_2; Thromboxane A_2 receptor antagonist; pH dependency; Radioligand binding; Platelet membranes (human); BAY U 3405 (Theis, J.G.W. (226) 149)

Thromboxane A_2 receptor antagonist
Thromboxane A_2; Thromboxane A_2 receptor agonist; pH dependency; Radioligand binding; Platelet membranes (human); BAY U 3405 (Theis, J.G.W. (226) 149)

Thromboxane A_2 receptor antagonist (KW-3635 and BM-13505)
Thromboxane A_2/prostaglandin H_2 receptors (TXA_2/PGH_2 receptors); Smooth muscle cells (vascular); Ca^{2+} concentrations (intracellular) (Miki, I. (227) 199)

Thromboxane A_2 receptors
Glomeruli; Platelets (radioligand binding); Inositol phosphates (Folger, W.H. (227) 71)

Photoaffinity labelling; Receptors (Mais, D.E. (227) 267)

Thromboxane A_2 synthetase inhibitor
Y-20811; Thrombosis (coronary); Thromboxane B_2 (immunoreactive); 6-keto-Prostaglandin $F_{1\alpha}$ (immunoreactive) (Matsumoto, Y. (213) 167)

Thromboxane B_2
Heart; Adrenergic neurotransmission; U46619; ONO11006 (Mantelli, L. (213) 79)

Thromboxane B_2 (immunoreactive)
Y-20811; Thromboxane A_2 synthetase inhibitor; Thrombosis (coronary); 6-keto-Prostaglandin $F_{1\alpha}$ (immunoreactive) (Matsumoto, Y. (213) 167)

Thromboxane synthetase inhibitors
Thromboxane A_2; Prostacyclin; Streptozotocin-induced diabetes; Diabetic microangiopathy (Masumura, H. (210) 163)

Thyrotropin-releasing hormone
Raphe nuclei (medullary); Vagus; Atropine; RX 77368 (Garrick, T. (223) 75)

Thyrotropin-releasing hormone analogs
Spontaneously epileptic rat (SER); CNK-602A; Antiepileptic effect; Dopamine (Renming, X. (223) 185)

Thyroxine
Portal vein; β-Adrenoceptors; Noradrenaline; Fenoterol; Atenolol; ICI 118,551 (Chin, J.P.F. (212) 201)

Tiagabine
Microdialysis; GABA brain levels; GABA uptake inhibitor; Anticonvulsants; (Rat) (Fink-Jensen, A. (220) 197)

Tianeptine
Stress; Hippocampus; Morphology; 5-HT (5-hydroxytryptamine, serotonin); Corticosteroids (Watanabe, Y. (222) 157)

Tight agonist binding
β_2-Adrenoceptor agonists (long acting); Ternary complex; Tracheal smooth muscle relaxation (Voss, H.-P. (227) 403)

T-lymphocytes
Phorbol esters; Adenosine receptors; Adenylyl cyclase; Gene transcription (Kontny, E. (227) 333)

TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate)
ATP-sensitive potassium channel; β-Cells (Szewczyk, A. (226) 175)

TNF-α (tumor necrosis factor)
Splanchnic artery occlusion shock; PAF (platelet-activating factor, PAF-acether); Myocardial depressant factor; L-659,989 (Zingarelli, B. (222) 13)

Tobacco smoke
MPP^+ (1-methyl-4-phenylpyridinium ion); Striatum; Dopamine uptake; Nicotine (Carr, L.A. (215) 285)

α-Tocopherol
Baicalein; Ear edema; Free radical; Lipid peroxidation (Hara, H. (221) 193)

α-Tocopherol analogue
Free radical scavenger; Antioxidant; Reperfusion injury; Vitamin E; Myocardial ischaemia/reperfusion (Petty, M.A. (210) 85)

Tolerance
Morphine; Naltrindole; EEG power spectra (Stamidis, H. (213) 9)

Vigabatrin; Dependence; GABA (γ-aminobutyric acid); Glutamate; Kindling; Epilepsy (Rundfeldt, C. (213) 351)

Development; Antinociception; Distress vocalization; Ultrasonic vocalization; Withdrawal; Morphine; Opiates (Barr, G.A. (215) 35)

Benzodiazepine exposure (chronic); Steroid hormones; Ovariectomy; GABA/benzodiazepine receptors; Anticonvulsants (Wilson, M.A. (215) 99)

Circadian rhythms; Dopamine; Dopamine D_1 receptors; Dopamine D_2 receptors; Locomotion; Sensitization; PHNO ((+)-4-propyl-9-hydroxynaphthoxazine); SKF 38393 (Martin-Iverson, M.T. (215) 119)

Punishment; Fixed-interval responding; Diazepam; Pentobarbital; Phencyclidine; (Pigeon) (McMillan, D.E. (215) 145)

Morphine; Antinociception; Adenosine receptors; (Rat) (Tao, P.-L. (215) 301)

Nitroglycerin; Nitroprusside; Coronary artery (porcine); Zaprinast; Phosphodiesterase inhibitors (Merkel, L.A. (216) 29)

Locomotor activity; Adenylate cyclase activity; Dopamine autoreceptors; Lisuride; Sensitization (Nisoli, E. (216) 81)

$5\text{-}HT_{1A}$ receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sex differences; Corticosterone; Hypothermia (Nakano, Y. (219) 339)

Pirsidomine; IS-5-MN (isosorbide-5-mononitrate); Hemodynamics; (Dog) (Bohn, H. (220) 71)

Benzodiazepine; $GABA_A$ receptor complex (α_1 subunit; γ_2 subunit; β_1 subunit); (Rat) (Primus, R.J. (226) 21)

Benzodiazepines; $GABA_A$ receptor; mRNA levels; (Rat) (O'Donovan, M.C. (226) 335)

Toluene diisocyanate
Isocyanate hydrolysis; Bronchial smooth muscle (guinea-pig) (Mapp, C.E. (228) 103)

Torasemide
Bumetanide; Cotransport; Red blood cells; Hypertension; Diuretics (loops) (Masereel, B. (219) 385)

Toxic equivalency factor (TEF)
Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); Ah receptors; Ah (aryl-hydrocarbon)-mediated effects; Non-Ah (aryl-hydrocarbon)-mediated effects; Risk management; Neurobehavioural responses; Carcinogenicity; Endocrine responses; Kinetics; Metabolism; Species differences (Ahlborg, U.G. (228) 179)

Toxicity (delayed)
Excitatory amino acids; Uptake (Zinkand, W.C. (212) 129)

Trachea
5-HT (5-hydroxytryptamine, serotonin); Electrical field stimulation; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

Phentolamine; α-Adrenoceptors; Pinacidil; Cromakalim; K^+ channels (Bang, L. (211) 235)

Cigarette smoke; Tachykinin receptor antagonists; Plasma extravasation; (Rat) (Morimoto, H. (224) 1)

Trachea (guinea-pig)
HOE 234; Bronchodilation; Airway dynamics; K^+ channel opening (Englert, H.C. (210) 69)

Endopeptidase 24.15; Endopeptidase 24.11; Bradykinin; Substance P (Da Silva, A. (212) 97)

ANF (atrial natriuretic factor); Relaxation; Trachea (rat); Bronchus (human); Epithelium; Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

PACAP (pituitary adenylate cyclase-activating polypeptide); Smooth muscle; cAMP (Araki, N. (216) 113)

Acetylcholine; Histamine; 5-HT (5-hydroxytryptamine, serotonin); Amiloride; Ouabain; K^+-free solution (Cortijo, J. (221) 43)

$^{125}I^-$ ion binding; Autoradiography; Eosinophils; Peroxidase (Rigby, P.J. (228) 141)

Trachea (guinea-pig and rat)
Ageing; Epithelium; Smooth muscle (airway); Histamine; Acetylcholine; Carbachol; K^+ (Preuss, J.M.H. (228) 3)

Trachea (guinea-pig, isolated)
K^+ channel opener; NIP-121; Cromakalim; Glibenclamide; Prostaglandin (Shikada, K.-i. (209) 69)

Adenosine; Purinoceptors; Benzodiazepine receptors (peripheral) (Devillier, P. (214) 67)

Trachea (human)
Nitric oxide (NO); Non-adrenergic non-cholinergic inhibitory (i-NANC) nerves (Belvisi, M.G. (210) 221)

Tracheal contraction
Neuraminidase; Sialic acid (Kai, H. (220) 181)

Tracheal epithelial cells
Leukocyte elastase (human); Cathepsin G (Nahori, M.-A. (228) 213)

Trachealis (bovine)
Protein kinase C; Smooth muscle contraction; Cholinomimetics; Bronchodilators (Langlands, J.M. (227) 131)

Trachealis (guinea-pig and bovine)
SDZ PCO 400; K^+-rich media; K^+ channel inhibitors; $^{86}Rb^+$ efflux; (Electrophysiology) (Small, R.C. (219) 81)

Trachealis muscle (guinea-pig)
Acetylcholine; Electrical field stimulation; Epithelium-derived acetylcholinesterase; EpDRF (epithelium-derived relaxing factor); Physostigmine (Koga, Y. (220) 141)

Tracheal smooth muscle relaxation
β_2-Adrenoceptor agonists (long acting); Ternary complex; Tight agonist binding (Voss, H.-P. (227) 403)

Trachea (rat)
ANF (atrial natriuretic factor); Relaxation; Trachea (guinea-pig); Bronchus (human); Epithelium; Smooth muscle (airway); Autoradiography (Fernandes, L.B. (212) 187)

Tramadol
Antinociception; Arthritic rats; Yohimbine; Idazoxan; Naloxone (Kayser, V. (224) 83)

Trans-ACPD (trans-(±)-1-amino-1,3-cyclopentanedicarboxylic acid)
Slow inward tail current (I_{ADP}); Olfactory cortex slice (guinea-pig) (Constanti, A. (214) 105)

Transcription factors
Locus coeruleus; DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) (Bhat, R.V. (227) 447)

Transdihydrolisuride
GH_4ZR_7 cells; Cell culture; Anterior pituitary; Prolactin; Dopamine D_2 receptors; Partial agonists; (±)3-PPP ((±)-3-(3-hydroxyphenyl)-N-n-propylpiperidine); (In vitro) (Nilsson, C. (218) 205)

Transfected cell
Dopamine D_3 receptor (human); Eukaryotic expression vector; Neuroleptics; Guanylnucleotide; G protein; Dopamine autoreceptor (Sokoloff, P. (225) 331)

Transmitter release
Ca^{2+} channels; Dihydropyridines; NMDA (N-methyl-D-aspartate); Excitatory amino acid; Dopamine; Mesencephalon (Chaudieu, I. (220) 203)

Ca^{2+} channels; ω-Conotoxin; Ca^{2+} influx; Dihydropyridines (Lundy, P.M. (225) 51)

Transmitter release
Aminopyridines; Tetraethylammonium; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

Triazolam
Down-regulation; GABA (γ-aminobutyric acid); Dopamine receptors; Quinpirole; 6-Hydroxydopamine (6-OHDA) (Zhou, L.-W. (218) 219)

Tricyclic antidepressants
Glutamates; NMDA (N-methyl-D-aspartate); Quisqualate; Cerebellar granule cells; Carbamazepine (Cai, Z. (219) 53)

5-HT (5-hydroxytryptamine, serotonin); ACTH release; Lithium; Electroconvulsive shock (Gartside, S.E. (221) 27)

Tricyclic antimuscarinics
Muscarinic receptor subtypes; Vas deferens (rabbit); Cyproheptadine; Pizotifen; Ketotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

Trifluoperazine
Ca^{2+}-activated K^+ currents; Pyramidal neurons (dissociated); Hippocampus (rat); Single channel recording (Ikemoto, Y. (216) 191)

Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; W-5; Phenothiazines; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Trigeminal ganglia (rat)
5-HT_{1B} receptor messenger RNA; 5-HT_{1B} receptor binding sites (Bruinvels, A.T. (227) 357)

Tropisetron
Oesophagus (rat); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptors; cAMP; Benzamides (substituted) (Ford, A.P.D.W. (211) 117)

cGMP; *E. coli* enterotoxin (heat-stable); 5-HT (5-hydroxytryptamine, serotonin); Indomethacin; Intestinal secretion; Ketanserin (Beubler, E. (219) 445)

Tryptamine
Strychnocarpine; β-Carbolines; 5-HT (5-hydroxytryptamine, serotonin); Benzodiazepines; Opiate receptors; GABA receptors (Strömbom, J. (214) 165)

Glucagon; 5-HT receptors; (Mouse) (Yamada, J. (216) 307)

Tryptophan
5-HT receptors; Blood–brain barrier (Chaouloff, F. (214) 101)

Tryptophan hydroxylase
Amphetamines; Basal ganglia; Dopamine; Drug abuse; Dynorphin A; 4-Methylaminorex; Neurotensin; 5-HT (5-hydroxytryptamine, serotonin); Substance P (Hanson, G.R. (218) 287)

Tubocurarine
5-HT receptors; 5-HT_3 receptors; Vagus (Newberry, N.R. (219) 135)

Tumor cells
Nifedipine; Diltiazem; Verapamil; Cell growth; Ca^{2+} channels (Wöll, E. (212) 105)

Tumor models (rat)
Peripheral benzodiazepine receptors; Gliomas (human); AA tumor; C6 gliomas (Takada, A. (228) 131)

Tumor necrosis factor
Interleukin-1; Interleukin-1 receptor antagonists; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Tumor necrosis factor (TNF-α)
Cloricromene; Endotoxin shock (Squadrito, F. (210) 107)

Twitch response
Velnacrine; Tacrine; Physostigmine; Anticholinesterase agents; Neuromuscular junction; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Two-dimensional gel electrophoresis
Bumetanide transport; Loop diuretics; Photoaffinity labeling; Sinusoidal plasma membrane (rat liver); Integral plasma membrane proteins (Honscha, W. (226) 215)

Type II pneumocyte
β-Adrenoceptors; Pulmonary surfactant (Kai, H. (212) 101)

Tyramine
[^{3}H]Brofaromine; MAO-A (monoamine oxidase A); Brofaromine binding; Clorgyline; Intestine (rat) (Waldmeier, P.C. (216) 243)

Tyrosine hydroxylase
NMDA receptors; $GABA_B$ receptors; Baclofen; Dopamine synthesis; Dopaminergic transmission (Montaño, J.-A.A. (218) 335)

Tyrosine kinase inhibitor
Immunosuppressants; Scoparone (Huang, H.-C. (217) 143)

U-69,593
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Van de Heijning, B.J.M. (209) 199)

U46,619
Pulmonary vascular bed; Thromboxane A_2/endoperoxide receptor-mediated responses; Sulotroban; Endothelin peptides; PAF (platelet-activating factor, PAF-acether) (Nossaman, B.D. (213) 1)

Heart; Adrenergic neurotransmission; ONO11006; Thromboxane B_2 (Mantelli, L. (213) 79)

U-73,122
Neurotensin receptors; Down-regulation (Yamada, M. (226) 187)

U-50,488H
Antiarrhythmic activity; Ischaemic arrhythmias; Naloxone (Pugsley, M.K. (212) 15)

Temperature; Opioid receptors; Myenteric plexus; DAGO ([D-Ala^2,N-MePhe^4,Gly^5-ol]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Garaulet, J.V. (223) 19)

[^{3}H]U69,593
Opioid receptors; R1.1 lymphoma cell line; κ-Opioid binding sites (Bidlack, J.M. (227) 257)

ucb L059
Convulsions; Epileptogenesis; Petit-mal; Epilepsy (Gower, A.J. (222) 193)

(S)-UH-301
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Hippocampus; Microdialysis; (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) (Nomikos, G.G. (216) 373)

Ultrasonic vocalization
Development; Antinociception; Distress vocalization; Tolerance; Withdrawal; Morphine; Opiates (Barr, G.A. (215) 35)

Ultrastructure
Amiloride; Myocardial ischemia; Myocardial reperfusion; Mitochondria; Arrhythmias; Na^+/H^+ exchange (Duan, J. (210) 149)

Umespirone
Locomotor behaviour; Monoamines; Monoamine synthesis; Monoamine receptors; (Rat) (Ahlenius, S. (222) 69)

UMR-106 cells
Ipriflavone; Phosphoinositides; $^{45}Ca^{2+}$ uptake (Sortino, M.A. (226) 273)

UMR-106 osteogenic cell line
Patch clamp; Ca^{2+} channels; Dihydropyridines (Morain, P. (220) 11)

Upregulation
Supersensitivity; Morphine; Opioid receptor regulation; Naltrexone; d-Amphetamine; Analgesia (Duttaroy, A. (221) 211)

Uptake
Excitatory amino acids; Toxicity (delayed) (Zinkand, W.C. (212) 129)

5-HT (5-hydroxytryptamine, serotonin); Aorta (rat); Contraction; Imipramine; Chlorpheniramine; Citalopram; Fluoxetine; Cocaine; Pargyline; Endothelium (Gruetter, C.A. (217) 109)

Urate crystal
Bradykinin; Bradykinin receptor antagonists; Carrageenan; Zymosan; Scalding; Sponges (Damas, J. (211) 81)

Urethra
P_{2X} purinoceptors; [^{3}H]α,β-Methylene ATP; Urinary bladder (Bo, X. (216) 59)

Phorbol ester; Protein kinase C; Bladder (Yoshida, M. (222) 205)

Urethra (dog)
Neurogenic response; Adrenergic contraction; Non-adrenergic, non-cholinergic relaxation (Hashimoto, S. (213) 117)

Urinary bladder
Epithelium; Diabetes; Prostaglandins; Bradykinin (Pinna, C. (214) 143)

P_{2X} purinoceptors; [^{3}H]α,β-Methylene ATP; Urethra (Bo, X. (216) 59)

Urinary bladder (rat)
Neuromedin B; Bombesin; Binding; Neuromedin B receptor (Bitar, K.G. (219) 117)

Uterine smooth muscle
Okadaic acid; cAMP; cGMP; Xanthine derivatives (Candenas, M.-L. (219) 473)

Uterus
Danazol; 13,14-Dihydro-15-keto-prostaglandin $F_{2\alpha}$; Ovarian steroids; Gonadotropin; Ovary (Kogo, H. (211) 69)

Ca^{2+}; Smooth muscle; Relaxation (Ishine, T. (219) 285)

Bisbenzyltetrahydroisoquinolines; Ca^{2+} channel antagonists; (Rat) (Ivorra, M.D. (219) 303)

Cross-tolerance; Cromakalim; RP 49356; K^+ channels (Piper, I. (219) 347)

Vanadate; Smooth muscle; Ca^{2+}; Ca^{2+}-free; Protein kinase C (Fukuzaki, A. (220) 99)

Uterus (rat)
Histamine receptors; Progesterone; Ovarian steroids; Oestrogen (Rubio, E. (212) 31)

UTP
Smooth muscle cells; DDT_1 MF-2 cells; Nucleotide receptors; ATP; K^+ currents (Van der Zee, L. (215) 317)

$\dot{V}$
Cycloprotobuxine-A; Action potentials; Antiarrhythmic agents; Myocardium; (Use-dependent block) (Wang, Y.-X. (222) 219)

Vacuous chewing
Haloperidol (chronic); Tardive dyskinesia; Dopamine D_1 receptors (Diana, M. (211) 415)

Vacuous chewing movements
Tardive dyskinesia; Haloperidol (chronic); Progabide (Kaneda, H. (212) 43)

Vagal reflex
Kinins; Spinal cord; Cardiovascular system; Catecholamines; C-fibers (Lopes, P. (210) 137)

Vagal stimulation
Neuropeptide Y; D-Myo-inositol-1,2,6-trisphosphate; (Sympathetic) (Potter, E.K. (221) 307)

Vagus
Prostaglandin E_2; Indomethacin; Gastric acid secretion; Baclofen (Saperas, E. (209) 1)

5-HT receptors; 5-HT_3 receptors; Tubocurarine (Newberry, N.R. (219) 135)

Raphe nuclei (medullary); Atropine; RX 77368; Thyrotropin-releasing hormone (Garrick, T. (223) 75)

Vagus nerve
5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptors; Emesis; (Ferret) (Newberry, N.R. (221) 157)

Nedocromil sodium; Cl^- channels; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulphonic acid) (Jackson, D.M. (221) 175)

Nitric oxide (NO); Neurogenic inflammation; NANC nerves; Plasma exudation; Airways (Kuo, H.-P. (221) 385)

Valine
Glycine; Serine; Alanine; Glycine modulatory site; NMDA receptors; Long-term potentiation; Hippocampal slices (rat) (Watanabe, Y. (223) 179)

Valproate
Epilepsy; NMDA (N-methyl-D-aspartate); MK-801; Behaviour (Dziki, M. (222) 273)

Vanadate
Alloxan diabetes; Insulin mimetic effects; Liver; Kidney (Saxena, A.K. (216) 123)

Uterus; Smooth muscle; Ca^{2+}; Ca^{2+}-free; Protein kinase C (Fukuzaki, A. (220) 99)

Vascular permeability
Carrageenin; Dextran; Nitric oxide (NO); Oedema (Ialenti, A. (211) 177)

Endothelin-1; Thromboxane A_2; Airways; Inflammation; Gastrointestinal ulceration (Sirois, M.G. (214) 119)

Aging; Airway obstruction; Asthma; Oedema; Histamine; Plasma exudation; Substance P (Arakawa, H. (215) 51)

Endothelin-1; Coronary circulation (Filep, J.G. (219) 343)

Vascular reactivity
L-NAME (N^G-nitro-L-arginine methyl ester); Vasopressin; Nitroprusside (sodium); Endotoxaemia; Sympathetic stimulation (Guc, M.O. (224) 63)

Vascular smooth muscle (rat)
cAMP; Dopamine receptors; Mesenteric artery; Thiol group (Hall, A.S. (226) 253)

Vascular smooth muscle relaxation
Acetylcholine; cGMP; L-Cysteine; SIN-1 (3-morpholinosydnonimine); Sodium nitrite (Arvola, P. (214) 289)

Vascular tone
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Arterial pressure; (Rat) (Chyu, K.-Y. (212) 159)

Vas deferens
Gentamicin; Catecholamine level; Striatum; Hypothalamus; Adrenal medulla (Mikami, M. (210) 91)

Efaroxan; Idazoxan; Prazosin; Anococcygeus; Glucose homeostasis; (Pithed rat) (Berridge, T.L. (213) 205)

Opiates; Fentanyl; Lofentanil; Ileum; (Receptor binding) (Maguire, P. (213) 219)

Smooth muscle; α-Adrenoceptors; Spontaneously hypertensive rats (SHR) (Caricati-Neto, A. (218) 51)

Suramin; Purinergic neurotransmission; P_2 purinoceptors (Mallard, N. (220) 1)

α_1-Adrenoceptor subtypes; SDZ NVI 085; Kidney; Aorta (rat) (Eltze, M. (224) 125)

Ro 5-4864; PK 11195; Duodenum; (Rat) (Escubedo, E. (225) 15)

Ba^{2+}; Nifedipine; $^{45}Ca^{2+}$ uptake; $^{45}Ca^{2+}$ efflux; Verapamil; Methoxamine (Hay, D.W.P. (225) 313)

Vas deferens (guinea-pig)
Ca^{2+}-related inward currents; AMP-PNP (5′-adenylylimidophosphate); P_2 purinoceptors (Inomata, H. (217) 93)

Vas deferens (mouse)
Supersensitivity; Ethanol pretreatment (chronic); Morphine; Naloxone; μ-Opioid receptors (Tabach, R. (216) 449)

Vas deferens (rabbit)
Muscarinic receptor subtypes; Tricyclic antimuscarinics; Cyproheptadine; Pizotifen; Ketotifen; Thiazinamium; Nuvenzepine (Eltze, M. (211) 283)

PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid); P_2 purinoceptors (antagonists) (Lambrecht, G. (217) 217)

Vas deferens (rat)
Protein kinase C; Phorbol esters; α_1-Adrenoceptors (Abraham, S.T. (218) 243)

Noradrenaline release; α_2-Adrenoceptors; Monoamine oxidase; Antidepressant drugs (Ari, G. (219) 89)

α_{2A}-Adrenoceptors; α_{2D}-Adrenoceptors; α_2-Adrenoceptors (prejunctional); Submandibular gland (rat); Platelets (human) (Smith, K. (219) 203)

Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Adrenoceptors; Videomicroscopy; (Spontaneous activity) (Bungardt, E. (221) 91)

Vasoconstriction
α-Adrenoceptors; Atherosclerosis; Endothelium; (Conscious rabbits) (Du, Z.-Y. (211) 149)

Acetylcholine; Baroreflexes; Nitroprusside; N-Nitro-L-arginine; Phenylephrine; Vasodilatation; (Conscious rabbit) (Du, Z.-Y. (214) 21)

Endothelin-1; Cerebral arteries; Peripheral arteries; Ca^{2+} influx; Nifedipine; Ca^{2+} channels (voltage-dependent) (Suzuki, Y. (219) 401)

Endothelin-1 analogues; Endothelin receptors; Vasodilatation (Filep, J.G. (220) 263)

Neuropeptide Y (NPY); NPY receptor subtypes; Acetylcholine; Endothelium; Vasodilatation (Grundemar, L. (221) 71)

Neuropeptide Y; Non-adrenergic sympathetic nerve stimulation; D-myo-Inositol-1,2,6-triphosphate (PP56) (Pernow, J. (222) 171)

EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Nitric oxide synthase inhibition (Klabunde, R.E. (223) 1)

Vasodilatation
Glyceryl trinitrate; Biotransformation; Rabbit aorta; Carbon monoxide (CO); Hemoprotein (Liu, Z. (211) 129)

ω-Conotoxin; Sympathetic nerves; Hypertension (Pruneau, D. (211) 329)

Acetylcholine; Baroreflexes; Nitroprusside; N-Nitro-L-arginine; Phenylephrine; Vasoconstriction; (Conscious rabbit) (Du, Z.-Y. (214) 21)

Tetrahydrobiopterin; Nitric oxide synthase (Van Amsterdam, J.G.C. (215) 349)

MCI-154; Hypotensive drugs; α-Adrenoceptors; K^+ contracture (Suh, S.H. (219) 377)

Endothelin-1 analogues; Endothelin receptors; Vasoconstriction (Filep, J.G. (220) 263)

Neuropeptide Y (NPY); NPY receptor subtypes; Acetylcholine; Endothelium; Vasoconstriction (Grundemar, L. (221) 71)

Endothelin-1; BQ-123; Endothelin receptor subtypes; Regional haemodynamics; (Anaesthetized rat) (Douglas, S.A. (221) 315)

K^+ channels (ATP-sensitive); Blood-aqueous barrier; Nitric oxide (NO) (Andersson, S.E. (224) 89)

Vasodilatation (adrenal medulla)
Nitric oxide (NO); Catecholamine secretion (Breslow, M.J. (210) 105)

Vasodilator effect
Scoparone; Free radical scavenger (Huang, H.-C. (218) 123)

Vasodilators
Calcium channels; Cromakalim; Mesenteric artery (human); Smooth muscle (vascular) (Smirnov, S.V. (217) 105)

E4080; K^+ channel openers; Ca^{2+} channel antagonists; Ca^{2+} concentration (intracellular); Coronary artery (dog) (Okada, Y. (218) 259)

Antihypertensives; A-80b; Ca^{2+}; Aorta; Portal vein (Frechilla, D. (219) 409)

Vasomotor neurons
Inositol hexakisphosphate; Medulla (rostral ventrolateral); Phytic acid (Sun, M.-k. (215) 9)

ATP; Rostral ventrolateral medulla (Sun, M.-K. (224) 93)

Vasopressin
Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

5-HT receptor agonists; 5-HT receptor antagonists; Blood pressure; Plasma renin activity; m-CPP (1-3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Bagdy, G. (210) 285)

Phosphoinositide (PI) hydrolysis; α_1-Adrenoceptors; Endothelin; Nonpeptide V_1 receptor antagonists; Ventricular myocardium (rabbit) (Endoh, M. (218) 355)

L-NAME (N^G-nitro-L-arginine methyl ester); Nitroprusside (sodium); Endotoxaemia; Sympathetic stimulation; Vascular reactivity (Guc, M.O. (224) 63)

Vasopressin V_1 receptor antagonists
[Arg^8]vasopressin; Baroreflexes; Splanchnic sympathetic efferent discharge; Area postrema; Nucleus tractus solitarii (Zhang, X. (222) 81)

Vasopressin V_1 receptors
Femoral artery (simian); Vasopressin V_2 receptors; (Cannula insertion method) (Chiba, S. (221) 393)

Vasopressin V_2 receptors
Femoral artery (simian); Vasopressin V_1 receptors; (Cannula insertion method) (Chiba, S. (221) 393)

Vasorelaxation
Dinitrosyl iron complexes (with cysteine); EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Vedernikov, Y.P. (211) 313)

Vasorelaxation (rat aorta)
Osthole; Ca^{2+} influx; cGMP; (*Angelica pubescens*) (Ko, F.-N. (219) 29)

Vasospasm
EGF (epidermal growth factor); Endothelin; Thrombin; Hypercholesterolemia; Aorta (rabbit); Endothelium (Merkel, L.A. (222) 175)

V79 Chinese hamster cells
Heterologous expression; Cytochrome P450IA2 (human); CYP1A2 recombinant expression vector; P450-dependent enzymatic activity (Wölfel, C. (228) 95)

Vecuronium
Neuromuscular relaxants; 3-Desacetyl vecuronium; 3,17-Desacetyl vecuronium; Metabolites (antagonism) (Khuenl-Brady, K.S. (222) 153)

Vein
Hand (human); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptors; Smooth muscle (Bodelsson, M. (219) 455)

Endothelin-1; Artery (Auguet, M. (224) 101)

Velnacrine
Tacrine; Physostigmine; Anticholinesterase agents; Neuromuscular junction; Twitch response; Tetanic stimulation; (Rat) (Bosch, F. (222) 163)

Venous cannula (chronic)
Galanin (rat); Galanin N-terminal fragments (rat); Galanin C-terminal fragments (rat); N^{α}-Acetyl-galanin-(9–29) (rat); Gastric acid secretion (inhibition of pentagastrin-stimulated); Gastric fistula (chronic) (Mungan, Z. (214) 53)

Venous tone
CGRP (calcitonin gene-related peptide); Circulatory filling pressure (mean); Noradrenaline; Ganglionic blockers (Abdelrahman, A. (217) 185)

Ventral tegmental area
$5\text{-}HT_3$ receptor antagonists; LY 277359; Granisetron; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; $5\text{-}HT_3$ receptors; $5\text{-}HT_3$ receptor antagonists; LY 277359; Substantia nigra pars compacta (Minabe, Y. (209) 151)

μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Phencyclidine; NMDA receptor antagonists; A10 neurons (French, E.D. (217) 1)

Cocaine; Dopamine neurons; Withdrawal; Electrophysiology (Ackerman, J.M. (218) 171)

Ventricular cells
Ischemia; Metabolic changes; Patch clamp; 5-Hydroxydecanoate (Notsu, T. (220) 35)

Ventricular effective refractory period
Atrial effective refractory period; Atrioventricular conduction time; β-Adrenoceptors; Sinoatrial pacemaker activity (Takei, M. (219) 15)

Ventricular fibrillation
Cardiac death (sudden); Ca^{2+} channel antagonists; Flunarizine (Billman, G.E. (212) 231)

Antiarrhythmic agents; K^+ channels (Gwilt, M. (215) 137)

Ventricular myocardium (rabbit)
Vasopressin; Phosphoinositide (PI) hydrolysis; α_1-Adrenoceptors; Endothelin; Nonpeptide V_1 receptor antagonists (Endoh, M. (218) 355)

(+)-Niguldipine; α_{1A}-Adrenoceptors; Positive inotropic effect; [^{3}H]Prazosin binding (Endoh, M. (223) 143)

Ventricular myocytes (embryonic chick)
Taurine; Na^+ currents (fast); Voltage clamp (whole-cell); Cardiac muscle (electrophysiology of) (Satoh, H. (218) 83)

Ventricular papillary muscle
Contractile force; Action potentials; K^+ channel openers; Sulfonylurea antidiabetics; P_2 purinoceptor agonists (Bott, A. (213) 141)

Ventricular rate
Atrial effective refractory period; Atrial rate; β-Adrenoceptor blocking activity; Stereoisomers; β-Adrenoceptor antagonists; (Conscious A-V blocked dogs) (Boucher, M. (211) 343)

Ventricular tachycardia
Dromotropic effects; Coronary vascular resistance; Inotropic effects; Endothelial messengers; Arrhythmias (Balcells, E. (210) 1)

Verapamil
Cough reflex; Ca^{2+} channels; Antitussive effect; Flunarizine; Nifedipine (Kamei, J. (212) 61)

Nifedipine; Diltiazem; Cell growth; Tumor cells; Ca^{2+} channels (Wöll, E. (212) 105)

Ca^{2+} channel antagonists; PN200-110; Diltiazem; Allosteric regulation (Miwa, K. (214) 127)

Central nervous system (CNS); Striatum; Acetylcholine release; Ca^{2+} channel antagonists; Spontaneously hypertensive rat (SHR) (Tsuda, K. (216) 319)

Ba^{2+}; Nifedipine; $^{45}Ca^{2+}$ uptake; Vas deferens; $^{45}Ca^{2+}$ efflux; Methoxamine (Hay, D.W.P. (225) 313)

Veratridine
CGRP (calcitonin gene-related peptide); Nifedipine; ω-Conotoxin; Sensory neurons; Capsaicin (Tramontana, M. (212) 137)

Aorta (rat); Na^+ channel (silent); $^{45}Ca^{2+}$ uptake; [^{14}C]Guanidinium uptake (Wermelskirchen, D. (219) 253)

Amitriptyline; Na^+ channels; Dopamine; Amino acids; Striatal slices (Ishii, Y. (221) 377)

Veratrine
Bepridil; Ca^{2+} channel antagonists; Ca^{2+} overload; Atria (rat) (Leboeuf, J. (216) 183)

Vesamicol
Phrenic nerve; K^+-stimulated Ca^{2+}-independent efflux of [^{3}H]acetylcholine; Cholinesterase inhibition; Acetylcholine carrier (Wessler, I. (221) 371)

Vestibular compensation
MK-801; Ca^{2+} channels (Sansom, A.J. (220) 123)

Videomicroscopy
Muscarinic receptor subtypes; Muscarinic receptor agonists (M_1-selective); Muscarinic receptor antagonists (M_3-selective); p-Fluorohexahydro-sila-difenidol; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Stereoselectivity (at muscarinic receptors) (Bungardt, E. (213) 53)

Histamine receptor subtypes; Histamine receptor agonists (H_1- and H_2-selective); Impromidine; Smooth muscle (arteriolar); Submucosal plexus (guinea-pig); Adrenoceptors; Vas deferens (rat); (Spontaneous activity) (Bungardt, E. (221) 91)

Vigabatrin
Tolerance; Dependence; GABA (γ-aminobutyric acid); Glutamate; Kindling; Epilepsy (Rundfeldt, C. (213) 351)

Vinconate
Ischemia; Excitatory amino acids; Neuronal damage; Muscarinic receptors (presynaptic) (Iino, T. (224) 117)

Vinpocetine
Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

VIP analogs
Endothelial cells; Patch-clamp; VIP receptors; VIP binding sites; [4-Cl-D-Phe^6,Leu^{17}]VIP (Pasyk, E. (212) 209)

VIP binding sites
Endothelial cells; Patch-clamp; VIP receptors; VIP analogs; [4-Cl-D-Phe^6,Leu^{17}]VIP (Pasyk, E. (212) 209)

[4-Cl-D-Phe^6,Leu^{17}]VIP
Endothelial cells; Patch-clamp; VIP receptors; VIP analogs; VIP binding sites (Pasyk, E. (212) 209)

VIP receptors
Endothelial cells; Patch-clamp; VIP analogs; VIP binding sites; [4-Cl-D-Phe^6,Leu^{17}]VIP (Pasyk, E. (212) 209)

VIP (vasoactive intestinal polypeptide)
Atropine; Central nervous system (CNS); Chronic treatment; (Rat) (Petit, J.-M. (212) 79)

Relaxation; Endothelium; Glibenclamide; Mesenteric artery (rabbit) (Hattori, Y. (213) 147)

Helodermin; Leukotriene D_4; Arachidonic acid; Lung (perfused, guinea-pig); Cyclo-oxygenase products (Conroy, D.M. (218) 43)

Gastric fundus (rat); Nitric oxide (NO); Cholinergic neurotransmission (Lefebvre, R.A. (221) 235)

Aging; Stomach (rat); Non-adrenergic, non-cholinergic (NANC); Nitric oxide (NO); Cholinergic neurons (Smits, G.J.M. (223) 97)

cAMP; Enteric nervous system; Myenteric neurons; Intestine; Synaptic transmission; Substance P; Calcitonin gene-related peptide (CGRP); Cholecystokinin; Gastrin releasing peptide; Phosphodiesterase inhibitors (Baidan, L.V. (225) 21)

Vitamin E
α-Tocopherol analogue; Free radical scavenger; Antioxidant; Reperfusion injury; Myocardial ischaemia/reperfusion (Petty, M.A. (210) 85)

Voltage clamp
$^{86}Rb^+$ efflux; Na^+ channels; K^+ channels; Remoxipride; Neuroleptics (Westlind-Danielsson, A. (224) 57)

Voltage-clamp experiment
Propofol; Ion channels; Myelinated nerve fibre; Anaesthetics (intravenous) (Veintemilla, F. (218) 59)

Voltage clamp (whole-cell)
Taurine; Na^+ currents (fast); Ventricular myocytes (embryonic chick); Cardiac muscle (electrophysiology of) (Satoh, H. (218) 83)

Voltage-gated Ca^{2+} channels
BAY k 8644; Ca^{2+} channel agonists; Aging (Khatter, J.C. (216) 351)

Voltammetry (in vivo)
Rilmenidine; Azepexole; Clonidine; Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Rilmenidine; Clonidine; Noradrenaline release; α_2-Adrenoceptors; Hypothalamus (Suaud-Chagny, M.F. (213) 305)

5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Nucleus raphe dorsalis; Locus coeruleus; (Rat) (Clement, H.-W. (217) 43)

Von Willebrand factor
Plasminogen activator (tissue-type); Endothelial cell secretion; Phospholipase C; Cytochrome P-450; Pertussis toxin (Tranquille, N. (213) 285)

V_1 receptor antagonists
Atrium (rat); ANP release; Ca^{2+} influence; Osmolarity (Zongazo, M.A. (209) 45)

Vulnerability (selective)
bFGF (basic fibroblast growth factor); Cerebral ischemia; Hippocampus; (Rat) (Hara, H. (209) 195)

W-5
Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-7; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

W-7
Calmodulin antagonist; Cromakalim; ATP-sensitive K^+ channel; Oocyte (*Xenopus laevis*); W-5; Phenothiazines; Trifluoperazine; Chlorpromazine; Haloperidol; Sulfonylurea; Glibenclamide; cAMP; β-Adrenoceptor; Isoproterenol (Sakuta, H. (226) 199)

Water intake
β-Adrenoceptor (atypical); Brain; Depression; Locomotor activity (Simiand, J. (219) 193)

WAY100289
Light:dark box; Anxiety; 5-HT_3 receptor antagonists; Acoustic startle (potentiated) (Bill, D.J. (218) 327)

WB 4101
α-Adrenoceptors; α_1-Adrenoceptor subtypes; Chlorethylclonidine; Arteries (Oriowo, M.A. (216) 415)

α_2-Adrenoceptor subtypes; Imiloxan; Dexmedetomidine; Clonidine; ST-91 (Takano, Y. (219) 465)

WEB 2170
PAF receptor antagonists; Paw edema (mouse); Anaphylaxis (Amorim, C.Z. (211) 29)

WEB 1881 FU
Hippocampus; Acetylcholine; AF64A; Memory (Hashimoto, M. (209) 9)

Wet-dog shakes
4-Aminopyridine; NMDA receptors; Convulsions (Fragoso-Veloz, J. (221) 275)

Wheel-running rhythm
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Circadian rhythm (Tominaga, K. (214) 79)

WHHL rabbit
Atherosclerosis; Mesenteric artery; Sympathetic neurotransmission; CGRP (calcitonin gene-related peptide); Neuropeptide Y (NPY) (Stewart-Lee, A.L. (216) 167)

Whole-cell voltage clamp
Norepinephrine; Protein kinase C; 1,2-Dioctanoylglycerol; Ca^{2+} current; Sympathetic ganglia (Abrahams, T.P. (227) 189)

Wistar-Kyoto rat (WKY)
Spontaneously hypertensive rat (SHR); Novelty-induced grooming behaviour; SCH 23390; Quinpirole; Dopamine receptors (Linthorst, A.C.E. (219) 23)

Withdrawal
cAMP; Brain slices; Glutamate; Locus coeruleus; Opiates (Kogan, J.H. (211) 47)

Development; Antinociception; Distress vocalization; Ultrasonic vocalization; Tolerance; Morphine; Opiates (Barr, G.A. (215) 35)

Cocaine; Dopamine neurons; Ventral tegmental area; Electrophysiology (Ackerman, J.M. (218) 171)

Withdrawal seizure prone mouse (WSP)
Ethanol withdrawal; Handling-induced convulsions; Abecarnil; Diazepam; Anticonvulsant effects; β-Carbolines; (Genetic animal model) (Crabbe, J.C. (221) 85)

Withdrawal syndrome
ω-Conotoxin; Morphine; Analgesia (Basilico, L. (218) 75)

Dopamine neurons; Ethanol (Diana, M. (221) 403)

WL 19
Drinking; Angiotensin; Angiotensin AT_1 receptors; Angiotensin AT_2 receptors; DuP 753 (Dourish, C.T. (211) 113)

Writhing test
Antinociception; Formalin test; Hot-plate test; Ca^{2+} channel blockers (Miranda, H.F. (217) 137)

WRK_1 cells
Ca^{2+}; Inositol 1,4,5-trisphosphate receptors; Inositol phosphates (Mouillac, B. (225) 179)

Xanthine derivatives
Okadaic acid; cAMP; cGMP; Uterine smooth muscle (Candenas, M.-L. (219) 473)

Xanthines
Monocytes; Macrophages; Thromboxane A_2; cAMP (Baker, A.J. (211) 157)

Seizures; Pentylenetetrazole; EEG (electroencephalogram); Adenosine (Cutrufo, C. (222) 1)

***Xenopus* melanophores**
Melatonin; Melatonin receptor antagonists; Pigment aggregation; Luzindole (Sugden, D. (213) 405)

***Xenopus* oocyte expression**
Neurosteroid; $GABA_A$ receptor; Cloned subtypes (Zaman, S.H. (225) 321)

***Xenopus* oocytes (rat cortex mRNA-injected)**
Hippocampal slices; Quinoxalinediones (Randle, J.C.R. (215) 237)

Xerostomia
Amitriptyline; Cytosolic free Ca^{2+}; α_1-Adrenoceptors; β_1-Adrenoceptors; Muscarinic acetylcholine receptors; Parotid gland; Salivary glands (Glenert, U. (226) 43)

Xylamidine
Ketanserin; p-Chlorophenylalanine; Atropine; MDL 72222 (Bond, E.F. (217) 127)

Y-20811
Thromboxane A_2 synthetase inhibitor; Thrombosis (coronary); Thromboxane B_2 (immunoreactive); 6-keto-Prostaglandin $F_{1\alpha}$ (immunoreactive) (Matsumoto, Y. (213) 167)

Yawning
Penile erection; Apomorphine; Oxytocin; ACTH (adrenocorticotropin); Excitatory amino acid receptor antagonists (Melis, M.R. (220) 43)

YM435
Pancreas (dog); Exocrine secretion; Dopamine D_1 receptor agonists (Iwatsuki, K. (218) 237)

Yohimbine
Morphine analgesia; Morphine dependence (Iglesias, V. (211) 35)

α-Adrenoceptors; Baroreceptors; Clonidine; Haemorrhage; (Rabbit) (Evans, R.G. (216) 265)

Antinociception; Arthritic rats; Tramadol; Idazoxan; Naloxone (Kayser, V. (224) 83)

Fos; α_2-Adrenoceptors; Clonidine; Guanabenz (Tsujino, T. (226) 69)

Zacopride
5-HT_3 receptor antagonists; GR38032F; Dexamethasone; Cisplatin; Taste aversion (conditioned) (Mele, P.C. (218) 229)

[^{3}H](R)-Zacopride
[^{3}H](S)-Zacopride; 5-HT_3 receptors; Brain (rat); (High affinity (R)-sites) (Kidd, E. (211) 133)

[^{3}H](S)-Zacopride
[^{3}H](R)-Zacopride; 5-HT_3 receptors; Brain (rat); (High affinity (R)-sites) (Kidd, E. (211) 133)

R(+)-Zacopride
S(−)-Zacopride; p-Chlorophenylalanine; Aversive behaviour; (Rat); (Mouse) (Barnes, N.M. (218) 15)

Aversive behaviour; S(−)-Zacopride; Anxiolytic agents; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Barnes, N.M. (218) 91)

S(−)-Zacopride
R(+)-Zacopride; p-Chlorophenylalanine; Aversive behaviour; (Rat); (Mouse) (Barnes, N.M. (218) 15)

S(−)-Zacopride
Aversive behaviour; R(+)-Zacopride; Anxiolytic agents; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Barnes, N.M. (218) 91)

Zacopride isomers
2-Methylserotonin; 5-HT_3 receptors; Drug discrimination (Young, R. (212) 117)

Zaprinast
Gastric fundus (rat); Cyclic nucleotides; Non-adrenergic non-cholinergic (NANC) relaxation; IBMX (3-Isobutyl-1-methylxanthine) (Barbier, A.J. (210) 315)

Nitroglycerin; Nitroprusside; Tolerance; Coronary artery (porcine); Phosphodiesterase inhibitors (Merkel, L.A. (216) 29)

Zn^{2+}
γ-Hydroxybutyrate; GABA (γ-aminobutyric acid); $GABA_B$ receptors; CGP35348; Hippocampus (Xie, X. (212) 291)

Zymosan
Bradykinin; Bradykinin receptor antagonists; Carrageenan; Urate crystal; Scalding; Sponges (Damas, J. (211) 81)

CONTENTS

Master author index to volumes 209–228 1

Master key word index to volumes 209–228 55

0014-2999(1992)209/228*;1-P